[
    {
        "page_content": "<!-- image -->\n\n## ANNUAL REPORT 2022",
        "metadata": {
            "page": 1
        },
        "id": "2669e20e-cf62-4376-a664-571433f191c6"
    },
    {
        "page_content": "## Safe harbor\n\nThis letter contains forward-looking statements relating to: our strategy and plans; potential of, and expectations for, our commercial business and pipeline programs; capital allocation and investment strategy; clinical development programs, clinical trials, and data readouts and presentations; regulatory discussions, submissions, /filings and approvals; the potential bene/fits, safety, and ef/ficacy of our and our collaboration partners' products and investigational therapies; the anticipated bene/fits and potential of investments, cost-saving initiatives, actions to improve risk pro/file and productivity of R&D pipeline, collaborations and business development activities; and our future /financial and operating results. These forward-looking statements may be accompanied by such words as 'aim,' 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'intend,' 'may,' 'plan,' 'potential,' 'possible,' 'prospect,' 'will,' 'would,' and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later-stage or larger-scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements.\n\nThese statements involve risks and uncertainties that could cause actual results to differ materially from those re/flected in such statements, including: our dependence on sales from our products; uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; failure to compete effectively due to signi/ficant product competition in the markets for our products; failure to successfully execute or realize the anticipated bene/fits of our strategic and growth initiatives; dif/ficulties in obtaining and maintaining adequate coverage, pricing and reimbursement for our products; our dependence on collaborators, joint venture partners and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; the potential impact of the con/flict in Ukraine; risks associated with current and potential future healthcare reforms; risks related to commercialization of\n\nbiosimilars; failure to obtain, protect and enforce our data, intellectual property, and other proprietary rights and the risks and uncertainties relating to intellectual property claims and challenges; the risk that positive results in a clinical trial may not be replicated in subsequent or con/firmatory trials or success in early-stage clinical trials may not be predictive of results in later-stage or large-scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, the risk that regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use of our products, or product liability claims; risks relating to technology failures or breaches; problems with our manufacturing processes; risks relating to management and personnel changes, including attracting and retaining personnel; failure to comply with legal and regulatory requirements; the risks of doing business internationally, including currency exchange rate /fluctuations; risks relating to investment in our manufacturing capacity; the direct and indirect impacts of the ongoing COVID-19 pandemic on our business; risks relating to the distribution and sale by third parties of counterfeit or un/fit versions of our products; risks relating to the use of social media for our business; results of operations and /financial condition; /fluctuations in our operating results; risks related to investment in properties; the market, interest, and credit risks associated with our investment portfolio; risks relating to share repurchase programs; risks relating to access to capital and credit markets; risks related to indebtedness; change in control provisions in certain of our collaboration agreements; /fluctuations in our effective tax rate; environmental risks; and any other risks and uncertainties that are described in other reports we have /filed with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this letter. We do not undertake any obligation to publicly update any forward-looking statements.",
        "metadata": {
            "page": 2
        },
        "id": "f9fbfdaa-d785-4490-9cd1-502adbc8f24e"
    },
    {
        "page_content": "## CEO Letter\n\n<!-- image -->\n\n-\n\nFor more than 40 years, Biogen has been driven by its heritage of innovation. As we write the next chapter in our story, I see substantial opportunity to build on that strong legacy as we execute on clear priorities to put the company back on a sustainable growth trajectory.\n\nChristopher A. Viehbacher\n\nPresident and Chief Executive Of/ficer\n\n-\n\n## My fellow stockholders,\n\nI am honored to write you as Biogen's new President and Chief Executive Of/ficer and to have joined a team that is pioneering important new medicines to address some of the most dif/ficult and challenging conditions in healthcare. For more than 40 years, Biogen has been driven by its heritage of innovation. As we write the next chapter in our story, I see substantial opportunity to build on that strong legacy as we execute on clear priorities to put the company back on a sustainable growth trajectory.\n\nIn 2022, Biogen continued to advance therapeutic breakthroughs for patients and achieved /financial performance in line with expectations, while adversely affected by increased competition in our multiple sclerosis (MS) portfolio. I step into this role with the clear understanding that we are operating in a much more competitive environment, with a cost base higher than industry benchmarks, and therefore need to transform the business to build an even stronger company for the bene/fit of patients, investors and other stakeholders.\n\nWe are starting that journey with some clear advantages, including being in the remarkable position of having developed two potentially transformative medicines that we believe would give us signi/ficant potential future opportunity. The /first would treat Alzheimer's disease (AD), and a second, pending U.S. Food and Drug Administration (FDA) approval, would treat depression in a new way. In 2023, we are focused on executing on these and other opportunities, while also reducing our cost base, as we build on our 2022 results.\n\nWe maintained a strong /financial position last year, giving us the opportunity to invest prudently in our business. We generated more than $10.1 billion in revenue, while reducing overall expenses through our cost reduction measures.\n\nWe ended the year with approximately $5.6 billion in total cash, cash equivalents and marketable securities. Allocating that capital will be a primary focus for Biogen in 2023 as we look to rationalize our cost base and achieve a meaningful return on investment where we do invest.\n\nI would like to thank you for your continued support of and investment in Biogen. I outline below how in 2023 we intend to execute against several priorities.\n\n## Bringing two breakthrough medicines to market\n\nIn January 2023, the FDA granted accelerated approval to LEQEMBI (lecanemab-irmb), a treatment for early AD developed in collaboration with Eisai Co., Ltd (Eisai). The accelerated approval was based on phase 2 data that demonstrated LEQEMBI reduced the accumulation of amyloid-beta (A \u0215 ) plaque in the brain, a de/fining feature of AD. The data from the phase 3 CLARITY AD study provide clear evidence that reducing plaque burden slows cognitive decline. After decades of research, we can now see the promise of potential disease modi/fication.\n\nWith potential traditional approval - the Prescription Drug User Fee Act (PDUFA) date is planned for July 6, 2023 - broader access could be within reach of more patients. The Centers for Medicare",
        "metadata": {
            "page": 3
        },
        "id": "49a6e42f-0744-48ec-b7a1-f377dffed4d7"
    },
    {
        "page_content": "& Medicaid Services (CMS) announced its intent to provide broader coverage on the same day within the Coverage with Evidence Development framework.\n\nWe believe LEQEMBI represents a catalyst for further innovation and is an incredible opportunity to build upon as we invest in advancing the care of patients suffering with AD. We continue to see progress in the development of blood-based and digital biomarkers. We imagine a world where early detection, before the onset of symptoms, will have the potential to allow treatment much earlier in the disease course to potentially delay or even prevent AD. Biogen is committed to continuing research in AD, including investigation into a promising molecule in our pipeline which could reduce tau, another de/fining pathology of AD.\n\nIn collaboration with Sage Therapeutics Inc. (Sage), we have advanced zuranolone, a potential treatment for major depressive disorder (MDD) and postpartum depression (PPD). If approved, zuranolone could be an important new treatment option in an area with high unmet need.\n\nWe have all seen the surge in mental illness the last few years, and we know the current standard-ofcare antidepressants may not work for everyone or may take up to six to eight weeks to reach maximal ef/ficacy when they do.\n\nZuranolone is currently under priority review at the FDA as a potential 14-day, rapid-acting, once-daily, oral medication to treat MDD and PPD following promising phase 3 clinical trial results. Its novel mechanism of action targets brain networks responsible for functions such as mood, arousal, behavior and cognition and could provide bene/fit as early as day three. With a PDUFA date set for August 5, 2023, we are anticipating a potential launch toward the end of the year in the United States, and we are building our commercial infrastructure and capabilities to enter this market.\n\n## Strengthening our portfolio and our pipeline, and improving operational ef/ficiency\n\nWe believe our return to a sustainable growth trajectory will also require thoughtful portfolio and pipeline optimization, external growth initiatives and diligent cost management across the enterprise.\n\nIn our core business, we are working to deliver on further growth opportunities in spinal muscular atrophy (SMA) and improving our pro/fitability in MS.\n\nWe have started a review of our strategic options for our biosimilars business.\n\nOur research and development pipeline and balance sheet are strong, and we believe our pipeline will be able to deliver signi/ficant growth over the medium and long term. But there is still more we must do to optimize our existing portfolio and diversify into new therapeutic areas such as neuropsychiatry, specialized immunology and rare diseases. We are closely examining new paths to balancing and de-risking our pipeline in a systemic and data-driven way, while sharpening our focus on value generation in the areas in which we have the most con/fidence, as compared to the achievement of operational milestones alone.\n\nThrough internal research and development, thoughtful business development, and disciplined capital allocation, I believe we will create new opportunities for growth.\n\nWe also have the goal of bringing our cost base in line with our revenue expectations while, at the same time, investing in upcoming launches and potential future growth drivers. We remain on track to achieve our previously announced $1.0 billion in cost-saving initiatives, and we will continue to seek new ways to create shareholder value and achieve greater operational ef/ficiency.\n\n## Building on our heritage of innovation\n\nAs we approach the 45 th anniversary of Biogen, it is a privilege to lead such an established, purpose-driven and diverse organization. I was drawn to join Biogen not only for its reputation as a biotechnology pioneer, but also by its dynamic team, which is as committed to advancing health equity as it is to pioneering patient breakthroughs. I have had the pleasure of getting to know many talented employees over the past several months and have witnessed /firsthand their incredible expertise, tenacity and passion for our mission. I look forward to executing against our key milestones in 2023, with the support of the accomplished team at Biogen, our strong partnerships with collaborators like Eisai and Sage, and the continued support of our shareholders.\n\nSincerely,\n\n<!-- image -->\n\nChristopher A. Viehbacher President and Chief Executive Of/ficer",
        "metadata": {
            "page": 4
        },
        "id": "75c55672-14c9-42e4-a2a3-a8bf516637a4"
    },
    {
        "page_content": "## ,% +glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* *glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>,) + glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=28,font=/PIIBCD+FranklinGothic-Book>/glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=31,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book> glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&$$ ** &%\n\n.3E:;@9FA@glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=18,font=/PIIBCD+FranklinGothic-Book>glyph<c=17,font=/PIIBCD+FranklinGothic-Book>glyph<c=22,font=/PIIBCD+FranklinGothic-Book>\n\n## glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD? glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=10,font=/PIIBCD+FranklinGothic-Book>\"\n\n<!-- image -->\n\nglyph<c=2,font=/PIIBDD+ArialUnicodeMS> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%%,glyph<c=24,font=/PIIBCD+FranklinGothic-Book># )glyph<c=28,font=/PIIBCD+FranklinGothic-Book>'&)+ ',)*,glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%+ +& *glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>+ &% glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=16,font=/PIIBCD+FranklinGothic-Book> &) glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=18,font=/PIIBCD+FranklinGothic-Book>glyph<c=6,font=/PIIBCD+FranklinGothic-Book>6glyph<c=7,font=/PIIBCD+FranklinGothic-Book> &glyph<c=29,font=/PIIBCD+FranklinGothic-Book> +glyph<c=31,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book> *glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>,) + glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* glyph<c=28,font=/PIIBCD+FranklinGothic-Book>/glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=31,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book> + &glyph<c=29,font=/PIIBCD+FranklinGothic-Book> glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=22,font=/PIIBCD+FranklinGothic-Book>glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=17,font=/PIIBCD+FranklinGothic-Book>\n\nglyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 8;E53> K73D 7@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>\n\nAD\n\nglyph<c=1,font=/PIIBDD+ArialUnicodeMS> +)glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%* + &% )glyph<c=28,font=/PIIBCD+FranklinGothic-Book>'&)+ ',)*,glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%+ +& *glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>+ &% glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=16,font=/PIIBCD+FranklinGothic-Book> &) glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=18,font=/PIIBCD+FranklinGothic-Book>glyph<c=6,font=/PIIBCD+FranklinGothic-Book>6glyph<c=7,font=/PIIBCD+FranklinGothic-Book> &glyph<c=29,font=/PIIBCD+FranklinGothic-Book> +glyph<c=31,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book> *glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>,) + glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* glyph<c=28,font=/PIIBCD+FranklinGothic-Book>/glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=31,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>+ &glyph<c=29,font=/PIIBCD+FranklinGothic-Book> glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=22,font=/PIIBCD+FranklinGothic-Book>glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=17,font=/PIIBCD+FranklinGothic-Book>\n\nglyph<c=26,font=/PIIBCD+FranklinGothic-Book>A??;EE;A@ 8;>7 @G?47Dglyph<c=23,font=/PIIBCD+FranklinGothic-Book>\n\nglyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=10,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=22,font=/PIIBCD+FranklinGothic-Book>glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>\n\n## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book>\n\nglyph<c=5,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>F/1B </;3 =4 @357AB@/<B /A A>3174732 7< 7BA 16/@B3@glyph<c=6,font=/PIIBDE+FranklinGothic-BookItal>\n\nglyph<c=27,font=/PIIBCD+FranklinGothic-Book>7>3I3D7\n\nglyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=10,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=19,font=/PIIBCD+FranklinGothic-Book>glyph<c=17,font=/PIIBCD+FranklinGothic-Book>glyph<c=17,font=/PIIBCD+FranklinGothic-Book>\n\nglyph<c=5,font=/PIIBDE+FranklinGothic-BookItal>'B/B3 =@ =B63@ 8C@7A271B7=< =4 7<1=@>=@/B7=< =@ =@5/<7H/B7=<glyph<c=6,font=/PIIBDE+FranklinGothic-BookItal>\n\nglyph<c=5,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal>&glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal>'glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>;>:=G3@ glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>23<B7471/B7=< \"=glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=6,font=/PIIBDE+FranklinGothic-BookItal>\n\nglyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=18,font=/PIIBCD+FranklinGothic-Book> glyph<c=25,font=/PIIBCD+FranklinGothic-Book>;@@7K *FD77Fglyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=26,font=/PIIBCD+FranklinGothic-Book>3?4D;697glyph<c=9,font=/PIIBCD+FranklinGothic-Book> $glyph<c=24,font=/PIIBCD+FranklinGothic-Book> glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=17,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>\n\nglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=19,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=20,font=/PIIBCD+FranklinGothic-Book>glyph<c=7,font=/PIIBCD+FranklinGothic-Book> glyph<c=19,font=/PIIBCD+FranklinGothic-Book>glyph<c=20,font=/PIIBCD+FranklinGothic-Book>glyph<c=22,font=/PIIBCD+FranklinGothic-Book>glyph<c=10,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>\n\nglyph<c=5,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>22@3AAglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> 7<1:C27<5 H7> 1=23glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> /<2 B3:3>6=<3 <C;03@glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> 7<1:C27<5 /@3/ 1=23glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> =4 &357AB@/<BMA >@7<17>/: 3F31CB7D3 =44713Aglyph<c=6,font=/PIIBDE+FranklinGothic-BookItal>\n\nglyph<c=19,font=/PIIBDF+FranklinGothic-Medium>glyph<c=27,font=/PIIBDF+FranklinGothic-Medium>glyph<c=25,font=/PIIBDF+FranklinGothic-Medium>&#glyph<c=31,font=/PIIBDF+FranklinGothic-Medium>%glyph<c=31,font=/PIIBDF+FranklinGothic-Medium>glyph<c=27,font=/PIIBDF+FranklinGothic-Medium>$ #glyph<c=27,font=/PIIBDF+FranklinGothic-Medium>glyph<c=29,font=/PIIBDF+FranklinGothic-Medium>glyph<c=31,font=/PIIBDF+FranklinGothic-Medium>$%glyph<c=27,font=/PIIBDF+FranklinGothic-Medium>#glyph<c=27,font=/PIIBDF+FranklinGothic-Medium>glyph<c=26,font=/PIIBDF+FranklinGothic-Medium> \"&#$&glyph<c=23,font=/PIIBDF+FranklinGothic-Medium> % %! glyph<c=19,font=/PIIBDF+FranklinGothic-Medium>glyph<c=27,font=/PIIBDF+FranklinGothic-Medium>glyph<c=25,font=/PIIBDF+FranklinGothic-Medium>%glyph<c=31,font=/PIIBDF+FranklinGothic-Medium>! glyph<c=4,font=/PIIBDF+FranklinGothic-Medium>glyph<c=5,font=/PIIBDF+FranklinGothic-Medium>glyph<c=2,font=/PIIBDF+FranklinGothic-Medium>glyph<c=24,font=/PIIBDF+FranklinGothic-Medium>glyph<c=3,font=/PIIBDF+FranklinGothic-Medium> !glyph<c=28,font=/PIIBDF+FranklinGothic-Medium> %glyph<c=30,font=/PIIBDF+FranklinGothic-Medium>glyph<c=27,font=/PIIBDF+FranklinGothic-Medium> glyph<c=7,font=/PIIBDF+FranklinGothic-Medium>glyph<c=25,font=/PIIBDF+FranklinGothic-Medium>%glyph<c=6,font=/PIIBDF+FranklinGothic-Medium>\n\n+;F>7 A8 glyph<c=28,font=/PIIBCD+FranklinGothic-Book>35: glyph<c=26,font=/PIIBCD+FranklinGothic-Book>>3EE\n\n+D36;@9 *K?4A>glyph<c=6,font=/PIIBCD+FranklinGothic-Book>Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\n%3?7 A8 glyph<c=28,font=/PIIBCD+FranklinGothic-Book>35: glyph<c=28,font=/PIIBCD+FranklinGothic-Book>J5:3@97 A@ .:;5: )79;EF7D76\n\nglyph<c=26,font=/PIIBCD+FranklinGothic-Book>A??A@ *FA5=glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=3,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=18,font=/PIIBCD+FranklinGothic-Book> B3D H3>G7\n\nglyph<c=25,font=/PIIBCD+FranklinGothic-Book>  glyph<c=25,font=/PIIBCD+FranklinGothic-Book>\n\n+:7 %3E63C glyph<c=30,font=/PIIBCD+FranklinGothic-Book>>A43> *7>75F $3D=7F\n\nglyph<c=19,font=/PIIBDF+FranklinGothic-Medium>glyph<c=27,font=/PIIBDF+FranklinGothic-Medium>glyph<c=25,font=/PIIBDF+FranklinGothic-Medium>&#glyph<c=31,font=/PIIBDF+FranklinGothic-Medium>%glyph<c=31,font=/PIIBDF+FranklinGothic-Medium>glyph<c=27,font=/PIIBDF+FranklinGothic-Medium>$ #glyph<c=27,font=/PIIBDF+FranklinGothic-Medium>glyph<c=29,font=/PIIBDF+FranklinGothic-Medium>glyph<c=31,font=/PIIBDF+FranklinGothic-Medium>$%glyph<c=27,font=/PIIBDF+FranklinGothic-Medium>#glyph<c=27,font=/PIIBDF+FranklinGothic-Medium>glyph<c=26,font=/PIIBDF+FranklinGothic-Medium> \"&#$&glyph<c=23,font=/PIIBDF+FranklinGothic-Medium> % %! glyph<c=19,font=/PIIBDF+FranklinGothic-Medium>glyph<c=27,font=/PIIBDF+FranklinGothic-Medium>glyph<c=25,font=/PIIBDF+FranklinGothic-Medium>%glyph<c=31,font=/PIIBDF+FranklinGothic-Medium>! glyph<c=4,font=/PIIBDF+FranklinGothic-Medium>glyph<c=5,font=/PIIBDF+FranklinGothic-Medium>glyph<c=2,font=/PIIBDF+FranklinGothic-Medium>glyph<c=29,font=/PIIBDF+FranklinGothic-Medium>glyph<c=3,font=/PIIBDF+FranklinGothic-Medium> !glyph<c=28,font=/PIIBDF+FranklinGothic-Medium> %glyph<c=30,font=/PIIBDF+FranklinGothic-Medium>glyph<c=27,font=/PIIBDF+FranklinGothic-Medium> glyph<c=7,font=/PIIBDF+FranklinGothic-Medium>glyph<c=25,font=/PIIBDF+FranklinGothic-Medium>%glyph<c=6,font=/PIIBDF+FranklinGothic-Medium> %A@7\n\n$D:?97J; 8O 9>;9A C7HA ?< J>; H;=?IJH7DJ ?I 7 M;BBglyph<c=13,font=/PIIBEG+FranklinGothic-Book>ADEMD I;7IED;: ?IIK;Hglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7I :;<?D;: ?D -KB; glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book> E< J>; .;9KH?J?;I glyph<c=28,font=/PIIBEG+FranklinGothic-Book>9Jglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 4;I glyph<c=1,font=/PIIBFH+Wingdings-Regular> )E glyph<c=3,font=/PIIBFH+Wingdings-Regular>\n\n$D:?97J; 8O 9>;9A C7HA ?< J>; H;=?IJH7DJ ?I DEJ H;GK?H;: JE <?B; H;FEHJI FKHIK7DJ JE .;9J?ED glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book> EH .;9J?ED glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=8,font=/PIIBEG+FranklinGothic-Book>:glyph<c=9,font=/PIIBEG+FranklinGothic-Book> E< J>; glyph<c=28,font=/PIIBEG+FranklinGothic-Book>9Jglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 4;I glyph<c=3,font=/PIIBFH+Wingdings-Regular> )E glyph<c=1,font=/PIIBFH+Wingdings-Regular>\n\n$D:?97J; 8O 9>;9A C7HA M>;J>;H J>; H;=?IJH7DJ glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book> >7I <?B;: 7BB H;FEHJI H;GK?H;:JE8;<?B;:8O.;9J?EDglyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>EHglyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=8,font=/PIIBEG+FranklinGothic-Book>:glyph<c=9,font=/PIIBEG+FranklinGothic-Book>E< J>; .;9KH?J?;I  N9>7D=; glyph<c=28,font=/PIIBEG+FranklinGothic-Book>9J E< glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book> :KH?D= J>; FH;9;:?D= glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> CEDJ>I glyph<c=8,font=/PIIBEG+FranklinGothic-Book>EH <EH IK9> I>EHJ;H F;H?E: J>7J J>; H;=?IJH7DJ M7I H;GK?H;: JE <?B; IK9> H;FEHJIglyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book> >7I 8;;D IK8@;9J JE IK9> <?B?D= H;GK?H;C;DJI <EH J>; F7IJ\n\nglyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>\n\n:7OIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n4;I glyph<c=1,font=/PIIBFH+Wingdings-Regular>\n\n)E glyph<c=3,font=/PIIBFH+Wingdings-Regular>\n\n$D:?97J; 8O 9>;9A C7HA M>;J>;H J>; H;=?IJH7DJ >7I IK8C?JJ;: ;B;9JHED?97BBO ;L;HO $DJ;H79J?L; glyph<c=31,font=/PIIBEG+FranklinGothic-Book>7J7 !?B; H;GK?H;: JE 8; IK8C?JJ;: FKHIK7DJ JE -KB; glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book> E< -;=KB7J?ED .glyph<c=13,font=/PIIBEG+FranklinGothic-Book>/ glyph<c=8,font=/PIIBEG+FranklinGothic-Book>S glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book> E< J>?I 9>7FJ;Hglyph<c=9,font=/PIIBEG+FranklinGothic-Book> :KH?D= J>; FH;9;:?D= glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> CEDJ>I glyph<c=8,font=/PIIBEG+FranklinGothic-Book>EH <EH IK9> I>EHJ;H F;H?E: J>7J J>; H;=?IJH7DJ M7I H;GK?H;: JE IK8C?J IK9> <?B;Iglyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 4;I glyph<c=1,font=/PIIBFH+Wingdings-Regular> )E glyph<c=3,font=/PIIBFH+Wingdings-Regular>\n\n$D:?97J; 8O 9>;9A C7HA M>;J>;H J>; H;=?IJH7DJ ?I 7 B7H=; 799;B;H7J;: <?B;Hglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D 799;B;H7J;: <?B;Hglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 DEDglyph<c=13,font=/PIIBEG+FranklinGothic-Book>799;B;H7J;: <?B;Hglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 IC7BB;H H;FEHJ?D= 9ECF7DOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> EH 7D ;C;H=?D= =HEMJ> 9ECF7DOglyph<c=14,font=/PIIBEG+FranklinGothic-Book> .;; J>; :;<?D?J?EDI E< [B7H=; 799;B;H7J;: <?B;Hglyph<c=12,font=/PIIBEG+FranklinGothic-Book>\\ [799;B;H7J;: <?B;Hglyph<c=12,font=/PIIBEG+FranklinGothic-Book>\\ [IC7BB;H H;FEHJ?D= 9ECF7DO\\ 7D: glyph<c=2,font=/PIIBEG+FranklinGothic-Book>;C;H=?D= =HEMJ> 9ECF7DOglyph<c=2,font=/PIIBEG+FranklinGothic-Book> ?D -KB; glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>8glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> E< J>;  N9>7D=; glyph<c=28,font=/PIIBEG+FranklinGothic-Book>9Jglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=1,font=/PIIBFH+Wingdings-Regular>\n\n'7H=; 799;B;H7J;: <?B;H\n\nglyph<c=1,font=/PIIBFH+Wingdings-Regular>\n\nglyph<c=28,font=/PIIBEG+FranklinGothic-Book>99;B;H7J;: <?B;H glyph<c=1,font=/PIIBDD+ArialUnicodeMS>\n\n)EDglyph<c=13,font=/PIIBEG+FranklinGothic-Book>799;B;H7J;: <?B;H\n\nglyph<c=1,font=/PIIBDD+ArialUnicodeMS>\n\n.C7BB;H H;FEHJ?D= 9ECF7DO glyph<c=1,font=/PIIBDD+ArialUnicodeMS>\n\nC;H=?D= =HEMJ> 9ECF7DO glyph<c=1,font=/PIIBDD+ArialUnicodeMS>\n\n$< 7D ;C;H=?D= =HEMJ> 9ECF7DOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D:?97J; 8O 9>;9A C7HA ?< J>; H;=?IJH7DJ >7I ;B;9J;: DEJ JE KI; J>; ;NJ;D:;: JH7DI?J?ED F;H?E: <EH 9ECFBO?D= M?J> 7DO D;M EH H;L?I;: <?D7D9?7B 799EKDJ?D= IJ7D:7H:I FHEL?:;: FKHIK7DJ JE .;9J?ED glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=8,font=/PIIBEG+FranklinGothic-Book>7glyph<c=9,font=/PIIBEG+FranklinGothic-Book> E< J>;  N9>7D=; glyph<c=28,font=/PIIBEG+FranklinGothic-Book>9Jglyph<c=14,font=/PIIBEG+FranklinGothic-Book> J\n\n$D:?97J; 8O 9>;9A C7HA M>;J>;H J>; H;=?IJH7DJ >7I <?B;: 7 H;FEHJ ED 7D: 7JJ;IJ7J?ED JE ?JI C7D7=;C;DJglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I 7II;IIC;DJ E< J>; ;<<;9J?L;D;II E< ?JI ?DJ;HD7B 9EDJHEB EL;H <?D7D9?7B H;FEHJ?D= KD:;H .;9J?ED glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=8,font=/PIIBEG+FranklinGothic-Book>8glyph<c=9,font=/PIIBEG+FranklinGothic-Book> E< J>; .7H87D;Iglyph<c=13,font=/PIIBEG+FranklinGothic-Book>*NB;O glyph<c=28,font=/PIIBEG+FranklinGothic-Book>9J glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book> 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=8,font=/PIIBEG+FranklinGothic-Book>8glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book> 8O J>; H;=?IJ;H;: FK8B?9 799EKDJ?D= <?HC J>7J FH;F7H;: EH ?IIK;: ?JI 7K:?J H;FEHJglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=1,font=/PIIBFH+Wingdings-Regular>\n\n$D:?97J; 8O 9>;9A C7HA M>;J>;H J>; H;=?IJH7DJ ?I 7 I>;BB 9ECF7DO glyph<c=8,font=/PIIBEG+FranklinGothic-Book>7I :;<?D;:?D-KB;glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>8glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>E<J>; glyph<c=1,font=/PIIBDD+ArialUnicodeMS> )E glyph<c=1,font=/PIIBFH+Wingdings-Regular>\n\nglyph<c=28,font=/PIIBEG+FranklinGothic-Book>9Jglyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 4;I\n\n/>; 7==H;=7J; C7HA;J L7BK; E< J>; H;=?IJH7DJ^I 9ECCED IJE9A >;B: 8O DEDglyph<c=13,font=/PIIBEG+FranklinGothic-Book>7<<?B?7J;I E< J>; H;=?IJH7DJ glyph<c=8,font=/PIIBEG+FranklinGothic-Book>M?J>EKJ 7:C?JJ?D= J>7J 7DO F;HIED M>EI; I>7H;I 7H; DEJ ?D9BK:;: ?D IK9> 97B9KB7J?ED ?I 7D 7<<?B?7J;glyph<c=9,font=/PIIBEG+FranklinGothic-Book> 9ECFKJ;: 8O H;<;H;D9; JE J>; FH?9; 7J M>?9> J>; 9ECCED IJE9A M7I B7IJ IEB: 7I E< J>; B7IJ 8KI?D;II :7O E< J>; H;=?IJH7DJ^I CEIJ H;9;DJBO 9ECFB;J;: I;9ED: <?I97B GK7HJ;H M7I glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=28,font=/PIIBEG+FranklinGothic-Book>I E< !;8HK7HO glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; H;=?IJH7DJ >7: glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book> I>7H;I E< 9ECCED IJE9Aglyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book> F7H L7BK;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> EKJIJ7D:?D=glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=10,font=/PIIBDF+FranklinGothic-Medium>glyph<c=16,font=/PIIBDF+FranklinGothic-Medium>glyph<c=9,font=/PIIBDF+FranklinGothic-Medium>glyph<c=21,font=/PIIBDF+FranklinGothic-Medium>glyph<c=14,font=/PIIBDF+FranklinGothic-Medium>glyph<c=11,font=/PIIBDF+FranklinGothic-Medium>glyph<c=15,font=/PIIBDF+FranklinGothic-Medium>glyph<c=20,font=/PIIBDF+FranklinGothic-Medium>glyph<c=19,font=/PIIBDF+FranklinGothic-Medium> glyph<c=13,font=/PIIBDF+FranklinGothic-Medium>glyph<c=15,font=/PIIBDF+FranklinGothic-Medium>glyph<c=9,font=/PIIBDF+FranklinGothic-Medium>glyph<c=16,font=/PIIBDF+FranklinGothic-Medium>glyph<c=18,font=/PIIBDF+FranklinGothic-Medium>glyph<c=17,font=/PIIBDF+FranklinGothic-Medium>glyph<c=16,font=/PIIBDF+FranklinGothic-Medium>glyph<c=18,font=/PIIBDF+FranklinGothic-Medium>glyph<c=7,font=/PIIBDF+FranklinGothic-Medium>glyph<c=20,font=/PIIBDF+FranklinGothic-Medium>glyph<c=11,font=/PIIBDF+FranklinGothic-Medium>glyph<c=10,font=/PIIBDF+FranklinGothic-Medium> glyph<c=8,font=/PIIBDF+FranklinGothic-Medium>glyph<c=22,font=/PIIBDF+FranklinGothic-Medium> glyph<c=18,font=/PIIBDF+FranklinGothic-Medium>glyph<c=11,font=/PIIBDF+FranklinGothic-Medium>glyph<c=12,font=/PIIBDF+FranklinGothic-Medium>glyph<c=11,font=/PIIBDF+FranklinGothic-Medium>glyph<c=18,font=/PIIBDF+FranklinGothic-Medium>glyph<c=11,font=/PIIBDF+FranklinGothic-Medium>glyph<c=15,font=/PIIBDF+FranklinGothic-Medium>glyph<c=9,font=/PIIBDF+FranklinGothic-Medium>glyph<c=11,font=/PIIBDF+FranklinGothic-Medium>\n\n+EHJ?EDI E< J>; :;<?D?J?L; FHENO IJ7J;C;DJ <EH EKH glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>DDK7B (;;J?D= E< .JE9A>EB:;HI 7H; ?D9EHFEH7J;: 8O H;<;H;D9; ?DJE +7HJ $$$ E< J>?I H;FEHJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>",
        "metadata": {
            "page": 5
        },
        "id": "2890747c-df09-4294-b52e-f9afe6842687"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book>\n\n## glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%%,glyph<c=24,font=/PIIBCD+FranklinGothic-Book># )glyph<c=28,font=/PIIBCD+FranklinGothic-Book>'&)+ &% glyph<c=29,font=/PIIBCD+FranklinGothic-Book>&)$ glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=10,font=/PIIBCD+FranklinGothic-Book>\" glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073D glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>\n\n## +glyph<c=24,font=/PIIBCD+FranklinGothic-Book>glyph<c=25,font=/PIIBCD+FranklinGothic-Book>#glyph<c=28,font=/PIIBCD+FranklinGothic-Book> &glyph<c=29,font=/PIIBCD+FranklinGothic-Book> glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+*\n\n|                                                                                                                                           |                                                                                                                                                                                                                                                                                                             | '397                                                                                       |\n|-------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|\n| 'glyph<c=24,font=/PIIBCD+FranklinGothic-Book>)+                                                                                           | 'glyph<c=24,font=/PIIBCD+FranklinGothic-Book>)+                                                                                                                                                                                                                                                             | 'glyph<c=24,font=/PIIBCD+FranklinGothic-Book>)+                                            |\n| $J;C glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                             | glyph<c=29,font=/PIIBEG+FranklinGothic-Book>KI?D;II                                                                                                                                                                                                                                                         | glyph<c=17,font=/PIIBEG+FranklinGothic-Book>                                               |\n| $J;C glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> | -?IA !79JEHI                                                                                                                                                                                                                                                                                                | glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>   |\n| $J;C glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=29,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> | 0DH;IEBL;: .J7<< glyph<c=30,font=/PIIBEG+FranklinGothic-Book>ECC;DJI                                                                                                                                                                                                                                        | glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>   |\n| $J;C glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                             | +HEF;HJ?;I                                                                                                                                                                                                                                                                                                  | glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>   |\n| $J;C glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                             | ';=7B +HE9;;:?D=I                                                                                                                                                                                                                                                                                           | glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>   |\n| $J;C glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                             | (?D; .7<;JO glyph<c=31,font=/PIIBEG+FranklinGothic-Book>?I9BEIKH;I                                                                                                                                                                                                                                          | glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>   |\n| 'glyph<c=24,font=/PIIBCD+FranklinGothic-Book>)+                                                                                           | 'glyph<c=24,font=/PIIBCD+FranklinGothic-Book>)+                                                                                                                                                                                                                                                             | 'glyph<c=24,font=/PIIBCD+FranklinGothic-Book>)+                                            |\n| $J;C glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                             | (7HA;J <EH -;=?IJH7DJ^I glyph<c=30,font=/PIIBEG+FranklinGothic-Book>ECCED  GK?JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> -;B7J;: .JE9A>EB:;H (7JJ;HI 7D: $IIK;H +KH9>7I;I E<  GK?JO .;9KH?J?;I                                                                                                          | glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>   |\n| $J;C glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                             | -;I;HL;:                                                                                                                                                                                                                                                                                                    | glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>   |\n| $J;C glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                             | (7D7=;C;DJ^I glyph<c=31,font=/PIIBEG+FranklinGothic-Book>?I9KII?ED 7D: glyph<c=28,font=/PIIBEG+FranklinGothic-Book>D7BOI?I E< !?D7D9?7B glyph<c=30,font=/PIIBEG+FranklinGothic-Book>ED:?J?ED 7D: -;IKBJI E< *F;H7J?EDI                                                                                      | glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>   |\n| $J;C glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> | ,K7DJ?J7J?L; 7D: ,K7B?J7J?L; glyph<c=31,font=/PIIBEG+FranklinGothic-Book>?I9BEIKH;I glyph<c=28,font=/PIIBEG+FranklinGothic-Book>8EKJ (7HA;J -?IA                                                                                                                                                            | glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>   |\n| $J;C glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                             | !?D7D9?7B .J7J;C;DJI 7D: .KFFB;C;DJ7HO glyph<c=31,font=/PIIBEG+FranklinGothic-Book>7J7                                                                                                                                                                                                                      | glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>   |\n| $J;C glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                             | glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>7D=;I ?D 7D: glyph<c=31,font=/PIIBEG+FranklinGothic-Book>?I7=H;;C;DJI M?J> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>99EKDJ7DJI ED glyph<c=28,font=/PIIBEG+FranklinGothic-Book>99EKDJ?D= 7D: !?D7D9?7B glyph<c=31,font=/PIIBEG+FranklinGothic-Book>?I9BEIKH; | glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>   |\n| $J;C glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> | glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EDJHEBI 7D: +HE9;:KH;I                                                                                                                                                                                                                                          | glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>   |\n| $J;C glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=29,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> | *J>;H $D<EHC7J?ED                                                                                                                                                                                                                                                                                           | glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>   |\n| $J;C glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> | glyph<c=31,font=/PIIBEG+FranklinGothic-Book>?I9BEIKH; -;=7H:?D= !EH;?=D %KH?I:?9J?EDI J>7J +H;L;DJ $DIF;9J?EDI                                                                                                                                                                                              | glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>   |\n| 'glyph<c=24,font=/PIIBCD+FranklinGothic-Book>)+                                                                                           | 'glyph<c=24,font=/PIIBCD+FranklinGothic-Book>)+                                                                                                                                                                                                                                                             | 'glyph<c=24,font=/PIIBCD+FranklinGothic-Book>)+                                            |\n| $J;C glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> | glyph<c=31,font=/PIIBEG+FranklinGothic-Book>?H;9JEHIglyph<c=12,font=/PIIBEG+FranklinGothic-Book>  N;9KJ?L; *<<?9;HI 7D: glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EHFEH7J; \"EL;HD7D9;                                                                                                                     | glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>   |\n| $J;C glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> | N;9KJ?L; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>ECF;DI7J?ED                                                                                                                                                                                                                                            | glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>   |\n| $J;C glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> | .;9KH?JO *MD;HI>?F E< glyph<c=30,font=/PIIBEG+FranklinGothic-Book>;HJ7?D glyph<c=29,font=/PIIBEG+FranklinGothic-Book>;D;<?9?7B *MD;HI 7D: (7D7=;C;DJ 7D: -;B7J;: .JE9A>EB:;H (7JJ;HI                                                                                                                        | glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>   |\n| $J;C glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> | glyph<c=30,font=/PIIBEG+FranklinGothic-Book>;HJ7?D -;B7J?EDI>?FI 7D: -;B7J;: /H7DI79J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: glyph<c=31,font=/PIIBEG+FranklinGothic-Book>?H;9JEH $D:;F;D:;D9;                                                                                                  | glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>   |\n| $J;C glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> | +H?D9?F7B glyph<c=28,font=/PIIBEG+FranklinGothic-Book>99EKDJ7DJ !;;I 7D: .;HL?9;I                                                                                                                                                                                                                           | glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>   |\n| 'glyph<c=24,font=/PIIBCD+FranklinGothic-Book>)+  -                                                                                        | 'glyph<c=24,font=/PIIBCD+FranklinGothic-Book>)+  -                                                                                                                                                                                                                                                          | 'glyph<c=24,font=/PIIBCD+FranklinGothic-Book>)+  -                                         |\n| $J;C glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> | N>?8?JI 7D: !?D7D9?7B .J7J;C;DJ .9>;:KB;I                                                                                                                                                                                                                                                                   | glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>   |\n| $J;C glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> | !EHC glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=13,font=/PIIBEG+FranklinGothic-Book>& .KCC7HO                                                                                                                                                          | glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>   |\n| .?=D7JKH;I                                                                                                                                | .?=D7JKH;I                                                                                                                                                                                                                                                                                                  | glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>   |\n| glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EDIEB?:7J;: !?D7D9?7B .J7J;C;DJI                                                              | glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EDIEB?:7J;: !?D7D9?7B .J7J;C;DJI                                                                                                                                                                                                                                | !glyph<c=13,font=/PIIBEG+FranklinGothic-Book> glyph<c=17,font=/PIIBEG+FranklinGothic-Book> |",
        "metadata": {
            "page": 6
        },
        "id": "4d9f86ef-f4f3-477c-8913-b7174d95fbeb"
    },
    {
        "page_content": "## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book> )glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>)glyph<c=27,font=/PIIBCD+FranklinGothic-Book> %glyph<c=30,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book>&).glyph<c=24,font=/PIIBCD+FranklinGothic-Book>)glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=10,font=/PIIBCD+FranklinGothic-Book>#&&\" %glyph<c=30,font=/PIIBCD+FranklinGothic-Book> *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+*\n\n/>?I H;FEHJ 9EDJ7?DI <EHM7H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>BEEA?D= IJ7J;C;DJI J>7J 7H; 8;?D= C7:; FKHIK7DJ JE J>; FHEL?I?EDI E< J>; +H?L7J; .;9KH?J?;I '?J?=7J?ED -;<EHC glyph<c=28,font=/PIIBEG+FranklinGothic-Book>9J E< glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book>J>; glyph<c=28,font=/PIIBEG+FranklinGothic-Book>9Jglyph<c=9,font=/PIIBEG+FranklinGothic-Book> M?J> J>; ?DJ;DJ?ED E< E8J7?D?D= J>; 8;D;<?JI E< J>; [.7<; #7H8EH\\ FHEL?I?EDI E< J>; glyph<c=28,font=/PIIBEG+FranklinGothic-Book>9Jglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />;I; <EHM7H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>BEEA?D= IJ7J;C;DJI C7O 8; 799ECF7D?;: 8O IK9> MEH:I 7I [7?Cglyph<c=12,font=/PIIBEG+FranklinGothic-Book>\\ [7DJ?9?F7J;glyph<c=12,font=/PIIBEG+FranklinGothic-Book>\\ [8;B?;L;glyph<c=12,font=/PIIBEG+FranklinGothic-Book>\\ [9EKB:glyph<c=12,font=/PIIBEG+FranklinGothic-Book>\\ [;IJ?C7J;glyph<c=12,font=/PIIBEG+FranklinGothic-Book>\\ [;NF;9Jglyph<c=12,font=/PIIBEG+FranklinGothic-Book>\\ [<EH;97IJglyph<c=12,font=/PIIBEG+FranklinGothic-Book>\\ glyph<c=2,font=/PIIBEG+FranklinGothic-Book>=E7Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=2,font=/PIIBEG+FranklinGothic-Book> [?DJ;D:glyph<c=12,font=/PIIBEG+FranklinGothic-Book>\\ [C7Oglyph<c=12,font=/PIIBEG+FranklinGothic-Book>\\ [FB7Dglyph<c=12,font=/PIIBEG+FranklinGothic-Book>\\ [FEJ;DJ?7Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book>\\ [FEII?8B;glyph<c=12,font=/PIIBEG+FranklinGothic-Book>\\ [M?BBglyph<c=12,font=/PIIBEG+FranklinGothic-Book>\\ [MEKB:\\ 7D: EJ>;H MEH:I 7D: J;HCI E< I?C?B7H C;7D?D=glyph<c=14,font=/PIIBEG+FranklinGothic-Book> -;<;H;D9; ?I C7:; ?D F7HJ?9KB7H JE <EHM7H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>BEEA?D= IJ7J;C;DJI H;=7H:?D=glyph<c=26,font=/PIIBEG+FranklinGothic-Book>\n\n- T J>; 7DJ?9?F7J;: 7CEKDJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J?C?D= 7D: 799EKDJ?D= E< H;L;DK;glyph<c=27,font=/PIIBEG+FranklinGothic-Book> 9EDJ?D=;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> C?B;IJED;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> HEO7BJO 7D: EJ>;H F7OC;DJI KD:;H B?9;DI?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9EBB78EH7J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 79GK?I?J?ED EH :?L;IJ?JKH; 7=H;;C;DJIglyph<c=27,font=/PIIBEG+FranklinGothic-Book> J7N FEI?J?EDI 7D: 9EDJ?D=;D9?;Iglyph<c=27,font=/PIIBEG+FranklinGothic-Book> 9EBB;9J78?B?JO E< H;9;?L78B;Iglyph<c=27,font=/PIIBEG+FranklinGothic-Book> FH;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>7FFHEL7B ?DL;DJEHOglyph<c=27,font=/PIIBEG+FranklinGothic-Book> 9EIJ E< I7B;Iglyph<c=27,font=/PIIBEG+FranklinGothic-Book> H;I;7H9> 7D: :;L;BEFC;DJ 9EIJIglyph<c=27,font=/PIIBEG+FranklinGothic-Book> 9ECF;DI7J?ED 7D: EJ>;H I;BB?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> =;D;H7B 7D: 7:C?D?IJH7J?L; ;NF;DI;glyph<c=27,font=/PIIBEG+FranklinGothic-Book> 7CEHJ?P7J?ED E< ?DJ7D=?8B; 7II;JIglyph<c=27,font=/PIIBEG+FranklinGothic-Book> <EH;?=D 9KHH;D9O ;N9>7D=; H?IAglyph<c=27,font=/PIIBEG+FranklinGothic-Book> ;IJ?C7J;: <7?H L7BK; E< 7II;JI 7D: B?78?B?J?;Iglyph<c=27,font=/PIIBEG+FranklinGothic-Book> 7D: ?CF7?HC;DJ 7II;IIC;DJIglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T ;NF;9J7J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FB7DI 7D: FHEIF;9JI H;B7J?D= JE I7B;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FH?9?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> =HEMJ>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;?C8KHI;C;DJ 7D: B7KD9> E< EKH C7HA;J;: 7D: F?F;B?D; FHE:K9JIglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T J>; FEJ;DJ?7B ?CF79J E< ?D9H;7I;: FHE:K9J 9ECF;J?J?ED ?D J>; C7HA;JI ?D M>?9> M; 9ECF;J;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= ?D9H;7I;: 9ECF;J?J?ED <HEC D;M EH?=?D7JEH J>;H7F?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> =;D;H?9Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FHE:HK=I 7D: 8?EI?C?B7HI E< ;N?IJ?D= FHE:K9JI 7D: FHE:K9JI 7FFHEL;: KD:;H 788H;L?7J;: H;=KB7JEHO F7J>M7OIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= =;D;H?9 EH 8?EI?C?B7H L;HI?EDI E< EKH FHE:K9JI EH 9ECF;J?D= FHE:K9JIglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T F7J;DJ J;HCIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> F7J;DJ J;HC ;NJ;DI?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> F7J;DJ E<<?9; 79J?EDI 7D: ;NF;9J;: 7L7?B78?B?JO 7D: F;H?E: E< H;=KB7JEHO ;N9BKI?L?JOglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T EKH FB7DI 7D: ?DL;IJC;DJI ?D EKH FEHJ<EB?E 7I M;BB 7I ?CFB;C;DJ7J?ED E< EKH 9EHFEH7J; IJH7J;=Oglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T J>; :H?L;HI <EH =HEM?D= EKH 8KI?D;IIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= EKH FB7DI 7D: ?DJ;DJ?ED JE 9ECC?J H;IEKH9;I H;B7J?D= JE :?I9EL;HOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;I;7H9> 7D: :;L;BEFC;DJ FHE=H7CI 7D: 8KI?D;II :;L;BEFC;DJ EFFEHJKD?J?;I 7I M;BB 7I J>; FEJ;DJ?7B 8;D;<?JI 7D: H;IKBJI E<glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: J>; 7DJ?9?F7J;: 9ECFB;J?ED E<glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9;HJ7?D 8KI?D;II :;L;BEFC;DJ JH7DI79J?EDI 7D: 9EIJglyph<c=13,font=/PIIBEG+FranklinGothic-Book>H;:K9J?ED C;7IKH;Iglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T J>; ;NF;9J7J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> :;L;BEFC;DJ FB7DI 7D: 7DJ?9?F7J;: J?C;B?D;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= 9EIJI 7D: J?C?D= E< FEJ;DJ?7B 9B?D?97B JH?7BIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> <?B?D=I 7D: 7FFHEL7BIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> E< EKH FHE:K9JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> :HK= 97D:?:7J;I 7D: F?F;B?D; FHE=H7CIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= 9EBB78EH7J?EDI M?J> J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJ?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7I M;BB 7I J>; FEJ;DJ?7B J>;H7F;KJ?9 I9EF; E< J>; :;L;BEFC;DJ 7D: 9ECC;H9?7B?P7J?ED E< EKH 7D: EKH 9EBB78EH7JEHI^ F?F;B?D; FHE:K9JIglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T J>; J?C?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> EKJ9EC; 7D: ?CF79J E< 7:C?D?IJH7J?L;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;=KB7JEHOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> B;=7B 7D: EJ>;H FHE9;;:?D=I H;B7J;: JE EKH F7J;DJI 7D: EJ>;H FHEFH?;J7HO 7D: ?DJ;BB;9JK7B FHEF;HJO H?=>JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J7N 7K:?JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7II;IIC;DJI 7D: I;JJB;C;DJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FH?9?D= C7JJ;HIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> I7B;I 7D: FHECEJ?ED7B FH79J?9;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FHE:K9J B?78?B?JO 7D: EJ>;H C7JJ;HIglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T EKH 78?B?JO JE <?D7D9; EKH EF;H7J?EDI 7D: 8KI?D;II ?D?J?7J?L;I 7D: E8J7?D <KD:?D= <EH IK9> 79J?L?J?;Iglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T 7:L;HI; I7<;JO ;L;DJI ?DLEBL?D= EKH C7HA;J;: FHE:K9JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> =;D;H?9 EH 8?EI?C?B7H L;HI?EDI E< EKH C7HA;J;: FHE:K9JI EH 7DO EJ>;H FHE:K9JI <HEC J>; I7C; 9B7II 7I ED; E< EKH FHE:K9JIglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T J>; :?H;9J 7D: ?D:?H;9J ?CF79J E< J>; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>*1$glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book> F7D:;C?9 7D: EJ>;H =BE87B >;7BJ> EKJ8H;7AI ED EKH 8KI?D;II 7D: EF;H7J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= I7B;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ;NF;DI;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;I;HL;I 7D: 7BBEM7D9;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; IKFFBO 9>7?Dglyph<c=12,font=/PIIBEG+FranklinGothic-Book> C7DK<79JKH?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9O8;Hglyph<c=13,font=/PIIBEG+FranklinGothic-Book>7JJ79AI EH EJ>;H FH?L79O EH :7J7 I;9KH?JO ?D9?:;DJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;I;7H9> 7D: :;L;BEFC;DJ 9EIJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9B?D?97B JH?7BI 7D: ;CFBEO;;Iglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T J>; 9KHH;DJ 7D: FEJ;DJ?7B ?CF79JI E< J>; 9ED<B?9J ?D 0AH7?D;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= ?CF79JI ED EKH EF;H7J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> I7B;I 7D: J>; FEII?8B; :?IHKFJ?EDI EH :;B7OI ?D EKH FB7DI JE 9ED:K9J 9B?D?97B JH?7B 79J?L?J?;I ?D 7<<;9J;: H;=?EDIglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T J>; FEJ;DJ?7B ?CF79J E< >;7BJ>97H; H;<EHC ?D J>; 0D?J;: .J7J;I glyph<c=8,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= J>; $D<B7J?ED -;:K9J?ED glyph<c=28,font=/PIIBEG+FranklinGothic-Book>9J E< glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book>$-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: C;7IKH;I 8;?D= J7A;D MEHB:M?:; :;I?=D;: JE H;:K9; >;7BJ>97H; 9EIJI 7D: B?C?J J>; EL;H7BB B;L;B E< =EL;HDC;DJ ;NF;D:?JKH;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= J>; ?CF79J E< FH?9?D= 79J?EDI 7D: H;:K9;: H;?C8KHI;C;DJ <EH EKH FHE:K9JIglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T EKH C7DK<79JKH?D= 97F79?JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> KI; E< J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJO 9EDJH79J C7DK<79JKH?D= EH=7D?P7J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FB7DI 7D: J?C?D= H;B7J?D= JE 9>7D=;I ?D EKH C7DK<79JKH?D= 97F78?B?J?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 79J?L?J?;I ?D D;M EH ;N?IJ?D= C7DK<79JKH?D= <79?B?J?;I 7D: J>; ;NF;9J;: J?C;B?D; <EH J>; H;C7?D?D= FEHJ?ED E< J>; .EBEJ>KHD C7DK<79JKH?D= <79?B?JO JE 8;=?D C7DK<79JKH?D= FHE:K9JI EH FHE:K9J 97D:?:7J;I 7D: <EH J>; =;D; J>;H7FO C7DK<79JKH?D= <79?B?JO ?D -;I;7H9> /H?7D=B; +7HA glyph<c=8,font=/PIIBEG+FranklinGothic-Book>-/+glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> )glyph<c=30,font=/PIIBEG+FranklinGothic-Book> JE 8; EF;H7J?ED7Bglyph<c=27,font=/PIIBEG+FranklinGothic-Book>",
        "metadata": {
            "page": 7
        },
        "id": "5b10a9b4-79b8-457e-8eb2-f19fd08b7dbd"
    },
    {
        "page_content": "- T J>; ?CF79J E< J>; 9EDJ?DK;: KD9;HJ7?DJO E< J>; 9H;:?J 7D: ;9EDEC?9 9ED:?J?EDI ?D 9;HJ7?D 9EKDJH?;I 7D: EKH 9EBB;9J?ED E< 799EKDJI H;9;?L78B; ?D IK9> 9EKDJH?;Iglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T B;7I; 9ECC?JC;DJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FKH9>7I; E8B?=7J?EDI 7D: J>; J?C?D= 7D: I7J?I<79J?ED E< EJ>;H 9EDJH79JK7B E8B?=7J?EDIglyph<c=27,font=/PIIBEG+FranklinGothic-Book> 7D:\n- T J>; ?CF79J E< D;M B7MI glyph<c=8,font=/PIIBEG+FranklinGothic-Book>?D9BK:?D= J7Nglyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;=KB7JEHO H;GK?H;C;DJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> @K:?9?7B :;9?I?EDI 7D: 799EKDJ?D= IJ7D:7H:Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n/>;I; <EHM7H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>BEEA?D= IJ7J;C;DJI ?DLEBL; H?IAI 7D: KD9;HJ7?DJ?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= J>EI; J>7J 7H; :;I9H?8;: ?D glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>B3; glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal> &7A9 glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>/1B=@A ?D9BK:;: ?D J>?I H;FEHJ 7D: ;BI;M>;H; ?D J>?I H;FEHJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>7J 9EKB: 97KI; 79JK7B H;IKBJI JE :?<<;H C7J;H?7BBO <HEC J>EI; H;<B;9J;: ?D IK9> IJ7J;C;DJIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 4EK I>EKB: DEJ FB79; KD:K; H;B?7D9; ED J>;I; IJ7J;C;DJIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> !EHM7H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>BEEA?D= IJ7J;C;DJI IF;7A EDBO 7I E< J>; :7J; E< J>?I H;FEHJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>  N9;FJ 7I H;GK?H;: 8O B7Mglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; :E DEJ KD:;HJ7A; 7DO E8B?=7J?ED JE FK8B?9BO KF:7J; 7DO <EHM7H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>BEEA?D= IJ7J;C;DJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>;J>;H 7I 7 H;IKBJ E< D;M ?D<EHC7J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> <KJKH; :;L;BEFC;DJI EH EJ>;HM?I;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book> )glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>)glyph<c=27,font=/PIIBCD+FranklinGothic-Book> %glyph<c=30,font=/PIIBCD+FranklinGothic-Book> glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&$'glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%0 glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> ')&glyph<c=27,font=/PIIBCD+FranklinGothic-Book>,glyph<c=26,font=/PIIBCD+FranklinGothic-Book>+ )glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=29,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>)glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n-;<;H;D9;I ?D J>?I H;FEHJ JEglyph<c=26,font=/PIIBEG+FranklinGothic-Book>\n\n- T [glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E=;Dglyph<c=12,font=/PIIBEG+FranklinGothic-Book>\\ J>; [9ECF7DOglyph<c=12,font=/PIIBEG+FranklinGothic-Book>\\ [M;glyph<c=12,font=/PIIBEG+FranklinGothic-Book>\\ [KI\\ 7D: [EKH\\ H;<;H JE glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E=;D $D9glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 7D: ?JI 9EDIEB?:7J;: IK8I?:?7H?;Iglyph<c=27,font=/PIIBEG+FranklinGothic-Book> 7D:\n- T [-$/03glyph<c=28,font=/PIIBEG+FranklinGothic-Book>)\\ H;<;HI JE 8EJ> -$/03glyph<c=28,font=/PIIBEG+FranklinGothic-Book>) glyph<c=8,font=/PIIBEG+FranklinGothic-Book>J>; JH7:; D7C; <EH H?JKN?C78 ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>7D7:7 7D: %7F7Dglyph<c=9,font=/PIIBEG+FranklinGothic-Book> 7D: (78/>;H7 glyph<c=8,font=/PIIBEG+FranklinGothic-Book>J>; JH7:; D7C; <EH H?JKN?C78 EKJI?:; J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>7D7:7 7D: %7F7Dglyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book> )glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>)glyph<c=27,font=/PIIBCD+FranklinGothic-Book> %glyph<c=30,font=/PIIBCD+FranklinGothic-Book> +)glyph<c=24,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=24,font=/PIIBCD+FranklinGothic-Book>)\"*\n\nglyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>0# '( U glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>1*) 3 U glyph<c=12,font=/PIIBEG+FranklinGothic-Book>+' \"-$glyph<c=31,font=/PIIBEG+FranklinGothic-Book>4 U glyph<c=12,font=/PIIBEG+FranklinGothic-Book> -$/03glyph<c=28,font=/PIIBEG+FranklinGothic-Book>) U glyph<c=12,font=/PIIBEG+FranklinGothic-Book> -$/03glyph<c=28,font=/PIIBEG+FranklinGothic-Book>) #4glyph<c=30,font=/PIIBEG+FranklinGothic-Book> 'glyph<c=28,font=/PIIBEG+FranklinGothic-Book> U glyph<c=12,font=/PIIBEG+FranklinGothic-Book> .+$)-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>5glyph<c=28,font=/PIIBEG+FranklinGothic-Book> U glyph<c=12,font=/PIIBEG+FranklinGothic-Book> / glyph<c=30,font=/PIIBEG+FranklinGothic-Book>!$glyph<c=31,font=/PIIBEG+FranklinGothic-Book> -glyph<c=28,font=/PIIBEG+FranklinGothic-Book> U glyph<c=12,font=/PIIBEG+FranklinGothic-Book> /4.glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=29,font=/PIIBEG+FranklinGothic-Book>-$ U 7D: 10( -$/4 U 7H; H;=?IJ;H;: JH7:;C7HAI E< glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E=;Dglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=29,font=/PIIBEG+FranklinGothic-Book> ) +glyph<c=28,font=/PIIBEG+FranklinGothic-Book>'$ V glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>4**1$5 V glyph<c=12,font=/PIIBEG+FranklinGothic-Book> !'$3glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$ V glyph<c=12,font=/PIIBEG+FranklinGothic-Book> !0(glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book> -( V glyph<c=12,font=/PIIBEG+FranklinGothic-Book> $(-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>'glyph<c=31,font=/PIIBEG+FranklinGothic-Book>$ V 7D: #;7BJ>O glyph<c=30,font=/PIIBEG+FranklinGothic-Book>B?C7J;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> #;7BJ>O '?L;I V 7H; JH7:;C7HAI E< glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E=;Dglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=30,font=/PIIBEG+FranklinGothic-Book>/ (-glyph<c=28,font=/PIIBEG+FranklinGothic-Book> U glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>$(5$glyph<c=28,font=/PIIBEG+FranklinGothic-Book> U glyph<c=12,font=/PIIBEG+FranklinGothic-Book> )glyph<c=29,font=/PIIBEG+FranklinGothic-Book>- ' U glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 4' glyph<c=28,font=/PIIBEG+FranklinGothic-Book> U glyph<c=12,font=/PIIBEG+FranklinGothic-Book> !glyph<c=28,font=/PIIBEG+FranklinGothic-Book>(+4-glyph<c=28,font=/PIIBEG+FranklinGothic-Book> V glyph<c=12,font=/PIIBEG+FranklinGothic-Book> \"glyph<c=28,font=/PIIBEG+FranklinGothic-Book>541glyph<c=28,font=/PIIBEG+FranklinGothic-Book> U glyph<c=12,font=/PIIBEG+FranklinGothic-Book> #0($-glyph<c=28,font=/PIIBEG+FranklinGothic-Book> U glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ' , (glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$ V glyph<c=12,font=/PIIBEG+FranklinGothic-Book> '0glyph<c=30,font=/PIIBEG+FranklinGothic-Book> )/$. U glyph<c=12,font=/PIIBEG+FranklinGothic-Book> '0).0($* V glyph<c=12,font=/PIIBEG+FranklinGothic-Book> *glyph<c=30,font=/PIIBEG+FranklinGothic-Book>- 10. U glyph<c=12,font=/PIIBEG+FranklinGothic-Book> - ($glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book> U 7D: EJ>;H JH7:;C7HAI H;<;H;D9;: ?D J>?I H;FEHJ 7H; J>; FHEF;HJO E< J>;?H H;IF;9J?L; EMD;HIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>",
        "metadata": {
            "page": 8
        },
        "id": "32321211-26cb-471b-92fc-9dacc77a2e08"
    },
    {
        "page_content": "## +glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$ glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=25,font=/PIIBCD+FranklinGothic-Book>,* %glyph<c=28,font=/PIIBCD+FranklinGothic-Book>**\n\n## &H7DH;7I\n\nglyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E=;D ?I 7 =BE87B 8?EF>7HC79;KJ?97B 9ECF7DO <E9KI;: ED :?I9EL;H?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> :;L;BEF?D= 7D: :;B?L;H?D= ?DDEL7J?L; J>;H7F?;I <EH F;EFB; B?L?D= M?J> I;H?EKI 7D: 9ECFB;N :?I;7I;I MEHB:M?:;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; >7L; 7 8HE7: FEHJ<EB?E E< C;:?9?D;I JE JH;7J CKBJ?FB; I9B;HEI?I glyph<c=8,font=/PIIBEG+FranklinGothic-Book>(.glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> >7L; ?DJHE:K9;: J>; <?HIJ 7FFHEL;: JH;7JC;DJ <EH IF?D7B CKI9KB7H 7JHEF>O glyph<c=8,font=/PIIBEG+FranklinGothic-Book>.(glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book> 7D: 9Eglyph<c=13,font=/PIIBEG+FranklinGothic-Book> :;L;BEF;: JME JH;7JC;DJI JE 7::H;II 7 :;<?D?D= F7J>EBE=O E< glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BP>;?C;H^I :?I;7I;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; 7H; <E9KI;: ED 7:L7D9?D= EKH F?F;B?D; ?D D;KHEBE=Oglyph<c=12,font=/PIIBEG+FranklinGothic-Book> D;KHEFIO9>?7JHOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> IF;9?7B?P;: ?CCKDEBE=O 7D: H7H; :?I;7I;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; IKFFEHJ EKH :HK= :?I9EL;HO 7D: :;L;BEFC;DJ ;<<EHJI J>HEK=> ?DJ;HD7B H;I;7H9> 7D: :;L;BEFC;DJ FHE=H7CI 7D: ;NJ;HD7B 9EBB78EH7J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n*KH C7HA;J;: FHE:K9JI ?D9BK:; / glyph<c=30,font=/PIIBEG+FranklinGothic-Book>!$glyph<c=31,font=/PIIBEG+FranklinGothic-Book> -glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 10( -$/4glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>1*) 3glyph<c=12,font=/PIIBEG+FranklinGothic-Book> +' \"-$glyph<c=31,font=/PIIBEG+FranklinGothic-Book>4glyph<c=12,font=/PIIBEG+FranklinGothic-Book> /4.glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=29,font=/PIIBEG+FranklinGothic-Book>-$ 7D: !glyph<c=28,font=/PIIBEG+FranklinGothic-Book>(+4-glyph<c=28,font=/PIIBEG+FranklinGothic-Book> <EH J>; JH;7JC;DJ E< (.glyph<c=27,font=/PIIBEG+FranklinGothic-Book> .+$)-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>5glyph<c=28,font=/PIIBEG+FranklinGothic-Book> <EH J>; JH;7JC;DJ E< .(glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=27,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>0# '( <EH J>; JH;7JC;DJ E< glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BP>;?C;Hglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I :?I;7I;glyph<c=27,font=/PIIBEG+FranklinGothic-Book> 7D: !0(glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book> -( <EH J>; JH;7JC;DJ E< I;L;H; FB7GK; FIEH?7I?Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; 7BIE 9EBB78EH7J; M?J>  ?I7? glyph<c=30,font=/PIIBEG+FranklinGothic-Book>Eglyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 'J:glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book> ?I7?glyph<c=9,font=/PIIBEG+FranklinGothic-Book> ED J>; 9ECC;H9?7B?P7J?ED E< ' , (glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$ <EH J>; JH;7JC;DJ E< glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BP>;?C;Hglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I :?I;7I;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> M7I =H7DJ;: 799;B;H7J;: 7FFHEL7B 8O J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> !EE: 7D: glyph<c=31,font=/PIIBEG+FranklinGothic-Book>HK= glyph<c=28,font=/PIIBEG+FranklinGothic-Book>:C?D?IJH7J?ED glyph<c=8,font=/PIIBEG+FranklinGothic-Book>!glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book> ?D %7DK7HO glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; >7L; 9;HJ7?D 8KI?D;II 7D: <?D7D9?7B H?=>JI M?J> H;IF;9J JE -$/03glyph<c=28,font=/PIIBEG+FranklinGothic-Book>) <EH J>; JH;7JC;DJ E< DEDglyph<c=13,font=/PIIBEG+FranklinGothic-Book>#E:=A?Dglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I BOCF>EC7glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9>HED?9 BOCF>E9OJ?9 B;KA;C?7 glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=30,font=/PIIBEG+FranklinGothic-Book>''glyph<c=9,font=/PIIBEG+FranklinGothic-Book> 7D: EJ>;H 9ED:?J?EDIglyph<c=27,font=/PIIBEG+FranklinGothic-Book> -$/03glyph<c=28,font=/PIIBEG+FranklinGothic-Book>) #4glyph<c=30,font=/PIIBEG+FranklinGothic-Book> 'glyph<c=28,font=/PIIBEG+FranklinGothic-Book> <EH J>; JH;7JC;DJ E< DEDglyph<c=13,font=/PIIBEG+FranklinGothic-Book>#E:=A?Dglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I BOCF>EC7 7D: glyph<c=30,font=/PIIBEG+FranklinGothic-Book>''glyph<c=27,font=/PIIBEG+FranklinGothic-Book> \"glyph<c=28,font=/PIIBEG+FranklinGothic-Book>541glyph<c=28,font=/PIIBEG+FranklinGothic-Book> <EH J>; JH;7JC;DJ E< glyph<c=30,font=/PIIBEG+FranklinGothic-Book>'' 7D: <EBB?9KB7H BOCF>EC7glyph<c=27,font=/PIIBEG+FranklinGothic-Book> *glyph<c=30,font=/PIIBEG+FranklinGothic-Book>- 10. <EH J>; JH;7JC;DJ E< FH?C7HO FHE=H;II?L; (. glyph<c=8,font=/PIIBEG+FranklinGothic-Book>++(.glyph<c=9,font=/PIIBEG+FranklinGothic-Book> 7D: H;B7FI?D= (. glyph<c=8,font=/PIIBEG+FranklinGothic-Book>-(.glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=27,font=/PIIBEG+FranklinGothic-Book> '0).0($* glyph<c=8,font=/PIIBEG+FranklinGothic-Book>CEIKD;JKPKC78glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> M7I =H7DJ;: 799;B;H7J;: 7FFHEL7B ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> :KH?D= J>; <EKHJ> GK7HJ;H E< glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> <EH J>; JH;7JC;DJ E< H;B7FI;: EH H;<H79JEHO <EBB?9KB7H BOCF>EC7glyph<c=27,font=/PIIBEG+FranklinGothic-Book> =BE<?J7C78glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D ?DL;IJ?=7J?ED7B 8?IF;9?<?9 7DJ?8E:O <EH J>; FEJ;DJ?7B JH;7JC;DJ E< DEDglyph<c=13,font=/PIIBEG+FranklinGothic-Book>#E:=A?Dglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I BOCF>EC7glyph<c=27,font=/PIIBEG+FranklinGothic-Book> 7D: >7L; J>; EFJ?ED JE 7:: EJ>;H FEJ;DJ?7B 7DJ?glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> J>;H7F?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FKHIK7DJ JE EKH 9EBB78EH7J?ED 7HH7D=;C;DJI M?J> \";D;DJ;9>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> $D9glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book>\";D;DJ;9>glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 M>EBBOglyph<c=13,font=/PIIBEG+FranklinGothic-Book>EMD;: C;C8;H E< J>; -E9>; \"HEKFglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n$D 7::?J?ED JE 9EDJ?DK?D= JE ?DL;IJ ?D D;M FEJ;DJ?7B ?DDEL7J?ED ?D (. 7D: .(glyph<c=28,font=/PIIBEG+FranklinGothic-Book> M; 7H; 7:L7D9?D= EKH C?:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>JEglyph<c=13,font=/PIIBEG+FranklinGothic-Book>B7J; IJ7=; FHE=H7CI ?D9BK:?D= PKH7DEBED; <EH C7@EH :;FH;II?L; :?IEH:;H glyph<c=8,font=/PIIBEG+FranklinGothic-Book>(glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book> 7D: FEIJF7HJKC :;FH;II?ED glyph<c=8,font=/PIIBEG+FranklinGothic-Book>++glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$$glyph<c=29,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> <EH glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BP>;?C;Hglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I :?I;7I;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> JE<;HI;D <EH 7COEJHEF>?9 B7J;H7B I9B;HEI?I glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>'.glyph<c=9,font=/PIIBEG+FranklinGothic-Book> 7D: 8EJ> B?J?<?B?C78 7D: :7F?HEB?PKC78 F;=EB <EH 9;HJ7?D <EHCI E< BKFKIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n2; 7BIE 9ECC;H9?7B?P; 8?EI?C?B7HI E< 7:L7D9;: 8?EBE=?9I ?D9BK:?D= glyph<c=29,font=/PIIBEG+FranklinGothic-Book> ) +glyph<c=28,font=/PIIBEG+FranklinGothic-Book>'$glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D ;J7D;H9;FJ 8?EI?C?B7H H;<;H;D9?D=  )glyph<c=29,font=/PIIBEG+FranklinGothic-Book>- 'glyph<c=12,font=/PIIBEG+FranklinGothic-Book> $(-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>'glyph<c=31,font=/PIIBEG+FranklinGothic-Book>$glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D 7:7B?CKC78 8?EI?C?B7H H;<;H;D9?D= #0($-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: !'$3glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D ?D<B?N?C78 8?EI?C?B7H H;<;H;D9?D= - ($glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book> glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D 9;HJ7?D 9EKDJH?;I ?D  KHEF;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7I M;BB 7I glyph<c=29,font=/PIIBEG+FranklinGothic-Book>4**1$5glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 H7D?8?PKC78 8?EI?C?B7H H;<;H;D9?D= '0glyph<c=30,font=/PIIBEG+FranklinGothic-Book> )/$.glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; 9EDJ?DK; JE :;L;BEF FEJ;DJ?7B 8?EI?C?B7H FHE:K9JI ?D9BK:?D= glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$$glyph<c=29,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 FHEFEI;: JE9?B?PKC78 8?EI?C?B7H H;<;H;D9?D= glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=30,font=/PIIBEG+FranklinGothic-Book>/ (-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: .glyph<c=29,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 FHEFEI;: 7<B?8;H9;FJ 8?EI?C?B7H H;<;H;D9?D=  4' glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n!EH 7::?J?ED7B ?D<EHC7J?ED ED EKH 9EBB78EH7J?ED 7HH7D=;C;DJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FB;7I; H;7: \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>A glyph<c=12,font=/PIIBEG+FranklinGothic-Book> JE EKH 9EDIEB?:7J;: <?D7D9?7B IJ7J;C;DJI ?D9BK:;: ?D J>?I H;FEHJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## \"7K glyph<c=25,font=/PIIBCD+FranklinGothic-Book>GE;@7EE glyph<c=27,font=/PIIBCD+FranklinGothic-Book>7H7>AB?7@FE\n\n/>; <EBBEM?D= ?I 7 IKCC7HO E< A;O :;L;BEFC;DJI 7<<;9J?D= EKH 8KI?D;II I?D9; J>; 8;=?DD?D= E< glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n!EH 7::?J?ED7B ?D<EHC7J?ED ED EKH 9EBB78EH7J?L; 7D: EJ>;H H;B7J?EDI>?FI :?I9KII;: 8;BEMglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FB;7I; H;7: \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>Aglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> JE EKH 9EDIEB?:7J;: <?D7D9?7B IJ7J;C;DJI ?D9BK:;: ?D J>?I H;FEHJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>3D3:=>;3<BA 7< glyph<c=31,font=/PIIBDE+FranklinGothic-BookItal>3G glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 &3:/B7=<A67>A\n\n## glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>7A/7 glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7=< glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>5@33;3<BA\n\n## glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>%glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>!glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=5,font=/PIIBDE+FranklinGothic-BookItal>:31/<3;/0glyph<c=6,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7=< glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>5@33;3<B\n\n$D %7DK7HO glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book> M; 7D:  ?I7? 7DDEKD9;: J>7J J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> =H7DJ;: 799;B;H7J;: 7FFHEL7B E< ' , (glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D 7DJ?glyph<c=13,font=/PIIBEG+FranklinGothic-Book> 7COBE?: 7DJ?8E:O <EH J>; JH;7JC;DJ E< glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BP>;?C;Hglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I :?I;7I;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>::?J?ED7BBOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D %7DK7HO glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book> M; 7D:  ?I7? 7DDEKD9;: J>; 9ECFB;J;: IK8C?II?ED E< 7 IKFFB;C;DJ7B glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?EBE=?9I '?9;DI; glyph<c=28,font=/PIIBEG+FranklinGothic-Book>FFB?97J?ED glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=29,font=/PIIBEG+FranklinGothic-Book>'glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book> JE J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> <EH JH7:?J?ED7B 7FFHEL7B E< ' , (glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n$D %7DK7HO glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book> J>;  KHEF;7D (;:?9?D;I glyph<c=28,font=/PIIBEG+FranklinGothic-Book>=;D9O glyph<c=8,font=/PIIBEG+FranklinGothic-Book> (glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book> 799;FJ;: <EH H;L?;M J>; (7HA;J?D= glyph<c=28,font=/PIIBEG+FranklinGothic-Book>KJ>EH?P7J?ED glyph<c=28,font=/PIIBEG+FranklinGothic-Book>FFB?97J?ED glyph<c=8,font=/PIIBEG+FranklinGothic-Book>(glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book> <EH B;97D;C78glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n$D %7DK7HO glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book> ?I7? 9ECFB;J;: J>; IK8C?II?ED E< 7 (glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> JE J>; +>7HC79;KJ?97BI 7D: (;:?97B glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;L?9;I glyph<c=28,font=/PIIBEG+FranklinGothic-Book>=;D9O glyph<c=8,font=/PIIBEG+FranklinGothic-Book>+(glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book> ?D %7F7D <EH B;97D;C78glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: M7I =H7DJ;: +H?EH?JO -;L?;M 8O J>; %7F7D;I; (?D?IJHO E< #;7BJ>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> '78EH 7D: 2;B<7H;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## 'glyph<c=24,font=/PIIBCD+FranklinGothic-Book>)+",
        "metadata": {
            "page": 9
        },
        "id": "fcbf3ff6-77e2-4923-9d33-ea8e96215098"
    },
    {
        "page_content": "$D glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> ?I7? ?D?J?7J;: 7 HEBB?D= IK8C?II?ED E< 7 glyph<c=29,font=/PIIBEG+FranklinGothic-Book>'glyph<c=28,font=/PIIBEG+FranklinGothic-Book> JE J>; )7J?ED7B (;:?9?D7B +HE:K9JI glyph<c=28,font=/PIIBEG+FranklinGothic-Book>:C?D?IJH7J?ED glyph<c=8,font=/PIIBEG+FranklinGothic-Book>)(+glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book> E< glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>?D7 <EH J>; 7FFHEL7B E< B;97D;C78glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n$D (7H9> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> M; ;NJ;D:;: EKH IKFFBO 7=H;;C;DJ M?J>  ?I7? H;B7J;: JE ' , (glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$ <HEC <?L; O;7HI JE J;D O;7HI <EH J>; C7DK<79JKH; E< ' , (glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$ :HK= IK8IJ7D9;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>)glyph<c=28,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal> ! glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7=< glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>5@33;3<B\n\n*D (7H9> glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 7C;D:;: EKH glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>0# '( glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EBB78EH7J?ED glyph<c=28,font=/PIIBEG+FranklinGothic-Book>=H;;C;DJ M?J>  ?I7?glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>I E< J>; 7C;D:C;DJ :7J;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; >7L; IEB; :;9?I?ED C7A?D= 7D: 9ECC;H9?7B?P7J?ED H?=>JI MEHB:M?:; ED glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>0# '(glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: 8;=?DD?D= %7DK7HO glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?I7? H;9;?L;I EDBO 7 J?;H;: HEO7BJO 87I;: ED D;J I7B;I E< glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>0# '(glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: DE BED=;H F7HJ?9?F7J;I ?D I>7H?D= glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>0# '(glyph<c=7,font=/PIIBEG+FranklinGothic-Book>I =BE87B FHE<?JI 7D: BEII;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> ?I7?glyph<c=7,font=/PIIBEG+FranklinGothic-Book>I I>7H; E< :;L;BEFC;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9ECC;H9?7B?P7J?ED 7D: C7DK<79JKH?D= ;NF;DI; M7I B?C?J;: JE glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> C?BB?ED <EH J>; F;H?E: <HEC %7DK7HO glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> JE glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> M7I 79>?;L;: 7I E< glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> *D9; J>?I B?C?J M7I 79>?;L;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 8;97C; H;IFEDI?8B; <EH 7BB glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>0# '( H;B7J;: 9EIJIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n!EH 7::?J?ED7B ?D<EHC7J?ED ED EKH 9EBB78EH7J?ED 7HH7D=;C;DJI M?J>  ?I7?glyph<c=12,font=/PIIBEG+FranklinGothic-Book> FB;7I; H;7: \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>Aglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> JE EKH 9EDIEB?:7J;: <?D7D9?7B IJ7J;C;DJI ?D9BK:;: ?D J>?I H;FEHJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## .C@/<=:=<3 glyph<c=5,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=15,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=6,font=/PIIBDE+FranklinGothic-BookItal>\n\n$D %KD; glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> M; 7D: EKH 9EBB78EH7J?ED F7HJD;H .7=; />;H7F;KJ?9Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> $D9glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book>.7=;glyph<c=9,font=/PIIBEG+FranklinGothic-Book> 7DDEKD9;: J>7J J>; +>7I; glyph<c=19,font=/PIIBEG+FranklinGothic-Book> .&4'glyph<c=28,font=/PIIBEG+FranklinGothic-Book>-& IJK:O E< PKH7DEBED;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> <EH J>; FEJ;DJ?7B JH;7JC;DJ E< (glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book> 7D: ++glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> C;J ?JI FH?C7HO 7D: 7BB A;O I;9ED:7HO ;D:FE?DJIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n$D glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> M; 7D: .7=; 9ECFB;J;: J>; HEBB?D= IK8C?II?ED E< 7 );M glyph<c=31,font=/PIIBEG+FranklinGothic-Book>HK= glyph<c=28,font=/PIIBEG+FranklinGothic-Book>FFB?97J?ED glyph<c=8,font=/PIIBEG+FranklinGothic-Book>)glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book> JE J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> <EH J>; 7FFHEL7B E< PKH7DEBED; <EH J>; FEJ;DJ?7B JH;7JC;DJ E< (glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book> 7D: ++glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />?I IK8C?II?ED 9ECFB;J;I J>; )glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> <?B?D= ?D?J?7J;: ;7HB?;H ?D glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n$D !;8HK7HO glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book> J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 799;FJ;: J>; )glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 7D: =H7DJ;: +H?EH?JO -;L?;M <EH PKH7DEBED;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M?J> 7 +H;I9H?FJ?ED glyph<c=31,font=/PIIBEG+FranklinGothic-Book>HK= 0I;H !;; glyph<c=28,font=/PIIBEG+FranklinGothic-Book>9J glyph<c=8,font=/PIIBEG+FranklinGothic-Book>+glyph<c=31,font=/PIIBEG+FranklinGothic-Book>0!glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book> 79J?ED :7J; E< glyph<c=28,font=/PIIBEG+FranklinGothic-Book>K=KIJ glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n!EH 7::?J?ED7B ?D<EHC7J?ED ED EKH 9EBB78EH7J?ED 7HH7D=;C;DJ M?J> .7=;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> FB;7I; H;7: \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>A glyph<c=12,font=/PIIBEG+FranklinGothic-Book> JE EKH 9EDIEB?:7J;: <?D7D9?7B IJ7J;C;DJI ?D9BK:;: ?D J>?I H;FEHJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>3<3<B316\n\n## )\"')!glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal># glyph<c=5,font=/PIIBDE+FranklinGothic-BookItal>;=AC<3BCHC;/0glyph<c=6,font=/PIIBDE+FranklinGothic-BookItal>\n\n$D %7DK7HO glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> M; ;N;H9?I;: EKH EFJ?ED M?J> \";D;DJ;9> JE F7HJ?9?F7J; ?D J>; @E?DJ :;L;BEFC;DJ 7D: 9ECC;H9?7B?P7J?ED E< '0).0($* glyph<c=8,font=/PIIBEG+FranklinGothic-Book>CEIKD;JKPKC78glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 8?IF;9?<?9 7DJ?8E:O <EH J>; JH;7JC;DJ E< H;B7FI;: EH H;<H79JEHO <EBB?9KB7H BOCF>EC7glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D 9EDD;9J?ED M?J> J>?I ;N;H9?I;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; H;9EH:;: 7 glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> C?BB?ED EFJ?ED ;N;H9?I; <;; F7O78B; JE \";D;DJ;9> ?D glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n$D glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> \";D;DJ;9> 7DDEKD9;: J>7J J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> =H7DJ;: 799;B;H7J;: 7FFHEL7B E< '0).0($*glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> M7I 7BIE 7FFHEL;: 8O J>;  KHEF;7D glyph<c=30,font=/PIIBEG+FranklinGothic-Book>ECC?II?ED glyph<c=8,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book> ?D %KD; glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>:=47B/;/0\n\n$D glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> M; H;79>;: 7D 7=H;;C;DJ M?J> \";D;DJ;9> H;B7J;: JE J>; 9ECC;H9?7B?P7J?ED 7D: I>7H?D= E< ;9EDEC?9I <EH =BE<?J7C78glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D ?DL;IJ?=7J?ED7B /glyph<c=13,font=/PIIBEG+FranklinGothic-Book>9;BB ;D=7=?D= 8?IF;9?<?9 7DJ?8E:O J7H=;J?D= glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> 7D: glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book> <EH J>; FEJ;DJ?7B JH;7JC;DJ E< glyph<c=29,font=/PIIBEG+FranklinGothic-Book>glyph<c=13,font=/PIIBEG+FranklinGothic-Book>9;BB DEDglyph<c=13,font=/PIIBEG+FranklinGothic-Book>#E:=A?Dglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I BOCF>EC7glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n!EH 7::?J?ED7B ?D<EHC7J?ED ED EKH 9EBB78EH7J?ED 7HH7D=;C;DJI M?J> \";D;DJ;9>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> FB;7I; H;7: \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>A glyph<c=12,font=/PIIBEG+FranklinGothic-Book> JE EKH 9EDIEB?:7J;: <?D7D9?7B IJ7J;C;DJI ?D9BK:;: ?D J>?I H;FEHJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>",
        "metadata": {
            "page": 10
        },
        "id": "8b5cc9ec-3d3b-437a-8bbe-8acad2eb9949"
    },
    {
        "page_content": "## #B63@ glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 &3:/B7=<A67>A\n\n## glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>:1G=<3 (63@/>3CB71A\n\n$D glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> M; ;DJ;H;: ?DJE 7 B?9;DI; 7D: 9EBB78EH7J?ED 7=H;;C;DJ M?J> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>B9OED; />;H7F;KJ?9I glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>B9OED;glyph<c=9,font=/PIIBEG+FranklinGothic-Book> JE @E?DJBO :;L;BEF J>; />;97!B;N glyph<c=31,font=/PIIBEG+FranklinGothic-Book>-NV .OIJ;Cglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D ?CFB7DJ78B; C;:?97B :;L?9; ?DJ;D:;: <EH IK89KJ7D;EKI :;B?L;HO E< 7DJ?I;DI; EB?=EDK9B;EJ?:; glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>.*glyph<c=9,font=/PIIBEG+FranklinGothic-Book> J>;H7F?;I M?J> 7 =E7B E< ?CFHEL?D= J>; F7J?;DJ JH;7JC;DJ ;NF;H?;D9; 7D: 799;II?8?B?JO <EH F;EFB; IK<<;H?D= <HEC D;KHEBE=?97B :?IEH:;HIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> IK9> 7I .(glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 7D: glyph<c=28,font=/PIIBEG+FranklinGothic-Book>'.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 0D:;H J>; J;HCI E< J>?I 9EBB78EH7J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 7D: glyph<c=28,font=/PIIBEG+FranklinGothic-Book>B9OED; M?BB @E?DJBO :;L;BEF J>; />;97!B;N glyph<c=31,font=/PIIBEG+FranklinGothic-Book>-NV .OIJ;C 7D: glyph<c=28,font=/PIIBEG+FranklinGothic-Book>B9OED; M?BB 8; IEB;BO H;IFEDI?8B; <EH ?JI C7DK<79JKH; 7D: 9ECC;H9?7B?P7J?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D 9EDD;9J?ED M?J> J>?I JH7DI79J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; C7:; 7D KF<HEDJ F7OC;DJ E< glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> C?BB?ED JE glyph<c=28,font=/PIIBEG+FranklinGothic-Book>B9OED;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=@>=@/B3 !/BB3@A\n\n## '/;AC<5 glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>7=3>7A glyph<c=8,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>7=53<glyph<c=4,font=/PIIBDE+FranklinGothic-BookItal>A glyph<c=30,font=/PIIBDE+FranklinGothic-BookItal>=7<B *3<BC@3 E7B6 '/;AC<5 glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>7= =571A\n\n$D glyph<c=28,font=/PIIBEG+FranklinGothic-Book>FH?B glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> M; 9ECFB;J;: J>; I7B; E< EKH glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=5,font=/PIIBEG+FranklinGothic-Book> ;GK?JO ?DJ;H;IJ ?D .7CIKD= glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E;F?I JE .7CIKD= glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E'E=?9I glyph<c=30,font=/PIIBEG+FranklinGothic-Book>Eglyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 'J:glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book>.7CIKD= glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E'E=?9Iglyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 0D:;H J>; J;HCI E< J>?I JH7DI79J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; H;9;?L;: 7FFHEN?C7J;BO glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> 8?BB?ED ?D 97I> 7J 9BEI?D= 7D: ;NF;9J JE H;9;?L; 7FFHEN?C7J;BO glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book> 8?BB?ED ?D 97I> JE 8; :;<;HH;: EL;H JME F7OC;DJI E< 7FFHEN?C7J;BO glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book> C?BB?ED :K; 7J J>; <?HIJ 7DD?L;HI7HO 7D: 7FFHEN?C7J;BO glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book> C?BB?ED :K; 7J J>; I;9ED: 7DD?L;HI7HO E< J>; 9BEI?D= E< J>?I JH7DI79J?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=28,font=/PIIBEG+FranklinGothic-Book>I F7HJ E< J>?I JH7DI79J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 7H; 7BIE ;B?=?8B; JE H;9;?L; KF JE 7D 7::?J?ED7B glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> C?BB?ED KFED J>; 79>?;L;C;DJ E< 9;HJ7?D 9ECC;H9?7B C?B;IJED;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> *KH FEB?9O <EH 9EDJ?D=;DJ F7OC;DJI E< J>?I D7JKH; ?I JE H;9E=D?P; J>; F7OC;DJI ?D J>; F;H?E: J>7J J>;O 8;9EC; H;7B?P78B;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> ?I =;D;H7BBO J>; I7C; F;H?E: ?D M>?9> J>; F7OC;DJI 7H; ;7HD;:glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n!EH 7::?J?ED7B ?D<EHC7J?ED ED J>; I7B; E< EKH ;GK?JO ?DJ;H;IJ ?D .7CIKD= glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E;F?Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FB;7I; H;7: \"=B3 glyph<c=13,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>7A>=A7B7=<Aglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> JE EKH 9EDIEB?:7J;: <?D7D9?7B IJ7J;C;DJI ?D9BK:;: ?D J>?I H;FEHJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=10,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=AB '/D7<5 glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><7B7/B7D3A\n\n$D glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book> 7D: (7O glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> M; 7DDEKD9;: EKH FB7DI JE ?CFB;C;DJ 7 I;H?;I E< 9EIJglyph<c=13,font=/PIIBEG+FranklinGothic-Book>H;:K9J?ED C;7IKH;I J>7J M>;D 9ECFB;J;: M; ;NF;9J C7O O?;B: 7FFHEN?C7J;BO glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> 8?BB?ED ?D ;NF;DI; I7L?D=Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />;I; I7L?D=I 7H; 8;?D= 79>?;L;: J>HEK=> 7 DKC8;H E< ?D?J?7J?L;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= H;:K9J?EDI JE EKH MEHA<EH9;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; IK8IJ7DJ?7B ;B?C?D7J?ED E< EKH 9ECC;H9?7B glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>0# '( ?D<H7IJHK9JKH;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; 9EDIEB?:7J?ED E< 9;HJ7?D H;7B ;IJ7J; BE97J?EDI 7D: EF;H7J?D= ;<<?9?;D9O =7?DI 79HEII EKH I;BB?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> =;D;H7B 7D: 7:C?D?IJH7J?L; 7D: H;I;7H9> 7D: :;L;BEFC;DJ <KD9J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n0D:;H J>;I; ?D?J?7J?L;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; ;IJ?C7J; M; M?BB ?D9KH JEJ7B H;IJHK9JKH?D= 9>7H=;I E< 7FFHEN?C7J;BO glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> C?BB?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FH?C7H?BO H;B7J;: JE I;L;H7D9;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />;I; 7CEKDJI M;H; IK8IJ7DJ?7BBO ?D9KHH;: :KH?D= glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>I E< glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7FFHEN?C7J;BO glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book> C?BB?ED H;C7?D;: ?D EKH H;IJHK9JKH?D= H;I;HL; 7D: F7OC;DJI 7H; ;NF;9J;: JE 8; C7:; J>HEK=> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n!EH 7::?J?ED7B ?D<EHC7J?ED ED EKH glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> 9EIJ I7L?D= ?D?J?7J?L;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FB;7I; H;7: \"=B3 glyph<c=14,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> &3AB@C1BC@7<5 glyph<c=12,font=/PIIBEG+FranklinGothic-Book> JE EKH 9EDIEB?:7J;: <?D7D9?7B IJ7J;C;DJI ?D9BK:;: ?D J>?I H;FEHJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=15,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>@=/2E/G '/:3 /<2  3/A30/19 (@/<A/1B7=<\n\n$D .;FJ;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> M; 9ECFB;J;: J>; I7B; E< EKH 8K?B:?D= 7D: B7D: F7H9;B BE97J;: 7J glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>HE7:M7Oglyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>7C8H?:=;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> (glyph<c=28,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>HE7:M7Oglyph<c=9,font=/PIIBEG+FranklinGothic-Book> <EH 7D 7==H;=7J; I7B;I FH?9; E< 7FFHEN?C7J;BO glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> C?BB?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> ?I ?D9BKI?L; E< 7 glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book> C?BB?ED J;D7DJ 7BBEM7D9;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> .?CKBJ7D;EKIBOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M?J> J>; 9BEI; E< J>?I JH7DI79J?ED M; B;7I;: 879A J>; 8K?B:?D= <EH 7 J;HC E< 7FFHEN?C7J;BO glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book> O;7HIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n!EH 7::?J?ED7B ?D<EHC7J?ED ED EKH glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>HE7:M7O I7B; 7D: B;7I;879A JH7DI79J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FB;7I; H;7: \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> $@=>3@BGglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> $:/<B /<2 glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>?C7>;3<B 7D: \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> 3/A3A glyph<c=12,font=/PIIBEG+FranklinGothic-Book> JE EKH 9EDIEB?:7J;: <?D7D9?7B IJ7J;C;DJI ?D9BK:;: ?D J>?I H;FEHJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## !/</53;3<B glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>6/<53A\n\n- T $D )EL;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> M; 7DDEKD9;: J>; 7FFE?DJC;DJ E< glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>H?IJEF>;H glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 1?;>879>;H 7I +H;I?:;DJ 7D: glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>?;< N;9KJ?L; *<<?9;Hglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- T $D !;8HK7HO glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> M; 7DDEKD9;: J>; 7FFE?DJC;DJ E< )?9EB; (KHF>O 7I  N;9KJ?L; 1?9; +H;I?:;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> +>7HC79;KJ?97B *F;H7J?EDI 7D: /;9>DEBE=Oglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- T $D %7DK7HO glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book> M; 7DDEKD9;: J>; 7FFE?DJC;DJ E< +H?O7 .?D=>7B 7I  N;9KJ?L; 1?9; +H;I?:;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> #;7: E< glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;L;BEFC;DJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>",
        "metadata": {
            "page": 11
        },
        "id": "822cda7f-d080-4dff-b44f-665195bfa15a"
    },
    {
        "page_content": "## glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>=/@2 =4 glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>7@31B=@A )>2/B3\n\n- T $D %KD; glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> )7D9O ';7C?D= 7D: glyph<c=29,font=/PIIBEG+FranklinGothic-Book>H?7D +EID;H H;J?H;: <HEC EKH glyph<c=29,font=/PIIBEG+FranklinGothic-Book>E7H: E< glyph<c=31,font=/PIIBEG+FranklinGothic-Book>?H;9JEHIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- T $D )EL;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>H?IJEF>;H glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 1?;>879>;H @E?D;: EKH glyph<c=29,font=/PIIBEG+FranklinGothic-Book>E7H: E< glyph<c=31,font=/PIIBEG+FranklinGothic-Book>?H;9JEHIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n!EH 7::?J?ED7B ?D<EHC7J?ED ED EKH ;N;9KJ?L; E<<?9;HIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FB;7I; H;7: J>; IK8I;9J?ED ;DJ?JB;: glyph<c=2,font=/PIIBEG+FranklinGothic-Book>$D<EHC7J?ED 78EKJ EKH N;9KJ?L; *<<?9;HIglyph<c=2,font=/PIIBEG+FranklinGothic-Book> ?D9BK:;: ?D J>?I H;FEHJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## 'DA6G5F 3@6 ';B7>;@7 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>7H7>AB?7@FE\n\n!C:B7>:3 '1:3@=A7A /<2 \"3C@=7;;C<=:=5G\n\n## (glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>&glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=5,font=/PIIBDE+FranklinGothic-BookItal>27;3B6G: 4C;3@/B3glyph<c=6,font=/PIIBDE+FranklinGothic-BookItal>\n\n- I $D %KD; glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> J>;  KHEF;7D +7J;DJ *<<?9; glyph<c=8,font=/PIIBEG+FranklinGothic-Book> +*glyph<c=9,font=/PIIBEG+FranklinGothic-Book> =H7DJ;: 7 F7J;DJ J>7J ;NF?H;I ?D !;8HK7HO glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book> H;B7J;: JE / glyph<c=30,font=/PIIBEG+FranklinGothic-Book>!$glyph<c=31,font=/PIIBEG+FranklinGothic-Book> -glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- T $D *9JE8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> J>; glyph<c=28,font=/PIIBEG+FranklinGothic-Book>:LE97J; \";D;H7B E< J>; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EKHJ E< %KIJ?9; E< J>;  KHEF;7D 0D?ED glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=30,font=/PIIBEG+FranklinGothic-Book>% 0glyph<c=9,font=/PIIBEG+FranklinGothic-Book> ?IIK;: 7 DED8?D:?D= 7:L?IEHO EF?D?ED ?D glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E=;Dglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I <7LEH H;B7J?D= JE H;=KB7JEHO :7J7 FHEJ;9J?ED <EH / glyph<c=30,font=/PIIBEG+FranklinGothic-Book>!$glyph<c=31,font=/PIIBEG+FranklinGothic-Book> -glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />?I EF?D?ED H;9ECC;D:I J>7J J>; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>% 0 I;J 7I?:; J>; ;7HB?;H @K:=;C;DJ E< J>;  KHEF;7D \";D;H7B glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EKHJ 7DDKBB?D= J>;  (glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=7,font=/PIIBEG+FranklinGothic-Book>I :;9?I?ED DEJ JE L7B?:7J; 7D 7FFB?97J?ED JE C7HA;J 7 =;D;H?9 L;HI?ED E< / glyph<c=30,font=/PIIBEG+FranklinGothic-Book>!$glyph<c=31,font=/PIIBEG+FranklinGothic-Book> -glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>:H637;3@glyph<c=4,font=/PIIBDE+FranklinGothic-BookItal>A glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>7A3/A3 /<2 glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>3;3<B7/\n\n## glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>%glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>!glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=5,font=/PIIBDE+FranklinGothic-BookItal>:31/<3;/0glyph<c=6,font=/PIIBDE+FranklinGothic-BookItal>\n\n- I $D %7DK7HO glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book> M; 7D:  ?I7? 7DDEKD9;: J>7J J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> =H7DJ;: 799;B;H7J;: 7FFHEL7B E< ' , (glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D 7DJ?glyph<c=13,font=/PIIBEG+FranklinGothic-Book> 7COBE?: 7DJ?8E:O <EH J>; JH;7JC;DJ E< glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BP>;?C;Hglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I :?I;7I;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>::?J?ED7BBOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D %7DK7HO glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book> M; 7D:  ?I7? 7DDEKD9;: J>; 9ECFB;J;: IK8C?II?ED E< 7 IKFFB;C;DJ7B glyph<c=29,font=/PIIBEG+FranklinGothic-Book>'glyph<c=28,font=/PIIBEG+FranklinGothic-Book> JE J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> <EH JH7:?J?ED7B 7FFHEL7B E< ' , (glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- T $D .;FJ;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> M; 7D:  ?I7? 7DDEKD9;: FEI?J?L; JEFB?D; H;IKBJI <HEC J>; 9ED<?HC7JEHO +>7I; glyph<c=19,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>'glyph<c=28,font=/PIIBEG+FranklinGothic-Book>-$/4 glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BP>;?C;Hglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I :?I;7I; IJK:O E< ' , (glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$glyph<c=14,font=/PIIBEG+FranklinGothic-Book> ' , (glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$ C;J J>; FH?C7HO ;D:FE?DJ 7D: 7BB A;O I;9ED:7HO ;D:FE?DJI M?J> >?=>BO IJ7J?IJ?97BBO I?=D?<?97DJ H;IKBJIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- T $D )EL;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> ?I7? FH;I;DJ;: <KBB H;IKBJI <HEC J>; 9ED<?HC7JEHO +>7I; glyph<c=19,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>'glyph<c=28,font=/PIIBEG+FranklinGothic-Book>-$/4 glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BP>;?C;Hglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I :?I;7I; IJK:O E< ' , (glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$ 7J J>; glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>B?D?97B /H?7BI ED glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BP>;?C;Hglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I glyph<c=31,font=/PIIBEG+FranklinGothic-Book>?I;7I; 9ED<;H;D9;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- T $D )EL;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> (63 \"3E glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal><5:/<2 glyph<c=30,font=/PIIBDE+FranklinGothic-BookItal>=C@</: =4 !32717<3 FK8B?I>;: <KBB H;IKBJI <HEC J>; 9ED<?HC7JEHO +>7I; glyph<c=19,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>'glyph<c=28,font=/PIIBEG+FranklinGothic-Book>-$/4 glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BP>;?C;Hglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I :?I;7I; IJK:O E< ' , (glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>)glyph<c=28,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal> ! glyph<c=5,font=/PIIBDE+FranklinGothic-BookItal>/2C1/<C;/0glyph<c=6,font=/PIIBDE+FranklinGothic-BookItal>\n\n- T $D (7H9> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> M; 7DDEKD9;: D;M :7J7 I>EM?D= J>7J 7<J;H D;7HBO JME 7D: 7 >7B< O;7HI E< JH;7JC;DJ glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book> M;;AIglyph<c=9,font=/PIIBEG+FranklinGothic-Book> M?J> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>0# '( ?D@;9J?ED glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> C=glyph<c=15,font=/PIIBEG+FranklinGothic-Book>C' <EH ?DJH7L;DEKI KI;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> F7J?;DJI ?D J>; BED=glyph<c=13,font=/PIIBEG+FranklinGothic-Book>J;HC ;NJ;DI?ED F>7I; E< J>; +>7I; glyph<c=19,font=/PIIBEG+FranklinGothic-Book> JH?7BI 9EDJ?DK;: JE ;NF;H?;D9; I?=D?<?97DJ H;:K9J?EDI ?D JME A;O glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BP>;?C;Hglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I :?I;7I; F7J>EBE=?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7COBE?: 8;J7 FB7GK;I 7D: FB7IC7 Fglyph<c=13,font=/PIIBEG+FranklinGothic-Book>J7Kglyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- T $D (7H9> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> (63 glyph<c=30,font=/PIIBDE+FranklinGothic-BookItal>=C@</: =4 $@3D3<B7=< =4 glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>:H637;3@glyph<c=4,font=/PIIBDE+FranklinGothic-BookItal>A glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>7A3/A3 FK8B?I>;: 7 F;;Hglyph<c=13,font=/PIIBEG+FranklinGothic-Book>H;L?;M;: C7DKI9H?FJ :;J7?B?D= :7J7 <HEC J>; F?LEJ7B +>7I; glyph<c=19,font=/PIIBEG+FranklinGothic-Book>  ( -\"  7D:  )\"glyph<c=28,font=/PIIBEG+FranklinGothic-Book>\" IJK:?;I E< glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>0# '( glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> C=glyph<c=15,font=/PIIBEG+FranklinGothic-Book>C' ?D@;9J?ED <EH ?DJH7L;DEKI KI; ?D ;7HBO glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BP>;?C;Hglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I :?I;7I;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; FK8B?97J?ED ?D9BK:;I H;IKBJI <HEC J>; FH?C7HOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> I;9ED:7HO 7D: J;HJ?7HO ;D:FE?DJI ?D J>; JH?7BIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7I M;BB 7I I7<;JO :7J7 7D: 8?EC7HA;H IK8glyph<c=13,font=/PIIBEG+FranklinGothic-Book>IJK:?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- T $D (7H9> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> M; IK8C?JJ;: J>; <?D7B IJK:O FHEJE9EB <EH J>; 9ED<?HC7JEHO +>7I; glyph<c=20,font=/PIIBEG+FranklinGothic-Book>  )1$.$*) IJK:O E< glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>0# '( JE J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> <EH H;L?;M 7D: 7FFHEL7Bglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- T $D glyph<c=28,font=/PIIBEG+FranklinGothic-Book>FH?B glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> J>; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>;DJ;HI <EH (;:?97H; 7D: (;:?97?: .;HL?9;I glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=30,font=/PIIBEG+FranklinGothic-Book>(.glyph<c=9,font=/PIIBEG+FranklinGothic-Book> H;B;7I;: 7 <?D7B )glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book> <EH J>; 9B7II E< 7DJ?glyph<c=13,font=/PIIBEG+FranklinGothic-Book>7COBE?: JH;7JC;DJI ?D glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BP>;?C;Hglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I :?I;7I;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>0# '(glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; <?D7B )glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book> 9ED<?HC;: 9EL;H7=; M?J> ;L?:;D9; :;L;BEFC;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D M>?9> F7J?;DJI M?J> (;:?97H; 97D EDBO 799;II JH;7JC;DJ ?< J>;O 7H; F7HJ E< 7D 7FFHEL;: 9B?D?97B JH?7Bglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />?I :;9?I?ED ;<<;9J?L;BO H;IKBJ;: ?D :;DO?D= 7BB (;:?97H; 8;D;<?9?7H?;I 799;II JE glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>0# '(glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- T $D glyph<c=28,font=/PIIBEG+FranklinGothic-Book>FH?B glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> M; 7DDEKD9;: EKH FB7DI JE E<<;H 7 9EDJ?DK?JO E< 97H; FB7D <EH 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> F7J?;DJI 9KHH;DJBO JH;7J;: M?J> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>0# '(glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7I 7 H;IKBJ E< J>; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>(. :;9?I?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book>",
        "metadata": {
            "page": 12
        },
        "id": "1a453d25-0d77-4f22-81b3-779d042dfec1"
    },
    {
        "page_content": "## \"3C@=>AG167/B@G\n\n## .C@/<=:=<3 glyph<c=5,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=15,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=6,font=/PIIBDE+FranklinGothic-BookItal>\n\n- T $D !;8HK7HO glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> M; 7D: .7=; 7DDEKD9;: J>; +>7I; glyph<c=19,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>*-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>' IJK:O E< PKH7DEBED; ?D F;EFB; M?J> (glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book> C;J J>; JH?7B E8@;9J?L;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> :;CEDIJH7J?D= 7 H7F?: 7D: IJ7J?IJ?97BBO I?=D?<?97DJ H;:K9J?ED ?D :;FH;II?L; IOCFJECI 7J glyph<c=31,font=/PIIBEG+FranklinGothic-Book>7O glyph<c=19,font=/PIIBEG+FranklinGothic-Book> 7D: EL;H J>; glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=13,font=/PIIBEG+FranklinGothic-Book>M;;A JH;7JC;DJ F;H?E:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 79>?;L?D= J>; FH?C7HO 7D: A;O I;9ED:7HO ;D:FE?DJIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- T $D %KD; glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> M; 7D: .7=; 7DDEKD9;: J>7J J>; +>7I; glyph<c=19,font=/PIIBEG+FranklinGothic-Book> .&4'glyph<c=28,font=/PIIBEG+FranklinGothic-Book>-& IJK:O E< PKH7D7BED; ?D MEC;D M?J> ++glyph<c=31,font=/PIIBEG+FranklinGothic-Book> C;J ?JI FH?C7HO 7D: 7BB A;O I;9ED:7HO ;D:FE?DJIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- T $D *9JE8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> M; 7D: .7=; FH;I;DJ;: 7::?J?ED7B :7J7 <HEC J>; +>7I; glyph<c=19,font=/PIIBEG+FranklinGothic-Book> .&4'glyph<c=28,font=/PIIBEG+FranklinGothic-Book>-& IJK:O E< PKH7D7BED; ?D MEC;D M?J> ++glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />?I :7J7 M7I FH;I;DJ;: 7J J>;  KHEF;7D glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EBB;=; E< );KHEFIO9>EF>7HC79EBE=O glyph<c=8,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>)+glyph<c=9,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>ED=H;IIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- T $D glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> M; 7D: .7=; 9ECFB;J;: J>; HEBB?D= IK8C?II?ED E< 7 )glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> JE J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> <EH J>; 7FFHEL7B E< PKH7DEBED; <EH J>; FEJ;DJ?7B JH;7JC;DJ E< (glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book> 7D: ++glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />?I IK8C?II?ED 9ECFB;J;I J>; )glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> <?B?D= ?D?J?7J;: ;7HB?;H ?D glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- I $D !;8HK7HO glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book> J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 799;FJ;: J>; )glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 7D: =H7DJ;: +H?EH?JO -;L?;M <EH PKH7DEBED;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M?J> 7 +glyph<c=31,font=/PIIBEG+FranklinGothic-Book>0!glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 79J?ED :7J; E< glyph<c=28,font=/PIIBEG+FranklinGothic-Book>K=KIJ glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## \"3C@=;CA1C:/@ glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>7A=@23@A\n\n## '$glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>\"&glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>.glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=5,font=/PIIBDE+FranklinGothic-BookItal><CA7<3@A3<glyph<c=6,font=/PIIBDE+FranklinGothic-BookItal>\n\n- I $D (7H9> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> M; 7DDEKD9;: J>; <?HIJ F7J?;DJ M7I JH;7J;: ?D J>; =BE87B +>7I; glyph<c=19,font=/PIIBEG+FranklinGothic-Book>8 glyph<c=28,font=/PIIBEG+FranklinGothic-Book>.glyph<c=30,font=/PIIBEG+FranklinGothic-Book> )glyph<c=31,font=/PIIBEG+FranklinGothic-Book> IJK:Oglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> ?I :;I?=D;: JE ;L7BK7J; J>; 9B?D?97B EKJ9EC;I 7D: 7II;II J>; I7<;JO E< 7 >?=>;H :EI; E< .+$)-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>5glyph<c=28,font=/PIIBEG+FranklinGothic-Book> ?D 9>?B:H;Dglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J;;DI 7D: 7:KBJI M?J> B7J;Hglyph<c=13,font=/PIIBEG+FranklinGothic-Book>EDI;J .(glyph<c=28,font=/PIIBEG+FranklinGothic-Book> M>E M;H; FH;L?EKIBO JH;7J;: M?J>  LHOI:?glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=15,font=/PIIBDE+FranklinGothic-BookItal>\n\n- T $D *9JE8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> J>; <?HIJ F7J?;DJ ?D J>; +>7I; glyph<c=17,font=/PIIBEG+FranklinGothic-Book> IJK:O E< glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$$glyph<c=29,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D ?DL;IJ?=7J?ED7B glyph<c=28,font=/PIIBEG+FranklinGothic-Book>.* ?D :;L;BEFC;DJ <EH .(glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M7I :EI;:glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## (=43@A3< glyph<c=5,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=10,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=16,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=17,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=6,font=/PIIBDE+FranklinGothic-BookItal>\n\n- I $D %KD; glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> M; 7DDEKD9;: D;M glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=13,font=/PIIBEG+FranklinGothic-Book>CEDJ> :7J7 <EH JE<;HI;D :;CEDIJH7J?D= J>7J ;7HB?;H ?D?J?7J?ED E< JE<;HI;D 9ECF7H;: JE :;B7O;: ?D?J?7J?ED glyph<c=8,font=/PIIBEG+FranklinGothic-Book>I?N CEDJ>I B7J;H ?D J>; EF;Dglyph<c=13,font=/PIIBEG+FranklinGothic-Book>B78;B ;NJ;DI?ED IJK:Oglyph<c=9,font=/PIIBEG+FranklinGothic-Book> IBEM;: :;9B?D;I ?D 9B?D?97B <KD9J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;IF?H7JEHO <KD9J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> CKI9B; IJH;D=J> 7D: GK7B?JO E< B?<;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- I $D %KBO glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 799;FJ;: J>; )glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 7D: =H7DJ;: +H?EH?JO -;L?;M <EH JE<;HI;Dglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D ?DL;IJ?=7J?ED7B 7DJ?I;DI; :HK= 8;?D= ;L7BK7J;: <EH F;EFB; M?J> IKF;HEN?:; :?ICKJ7I; glyph<c=17,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book>.*glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>'.glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> 9KHH;DJBO >7I 7 +glyph<c=31,font=/PIIBEG+FranklinGothic-Book>0!glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 79J?ED :7J; E< glyph<c=28,font=/PIIBEG+FranklinGothic-Book>FH?B glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- T $D .;FJ;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> (63 \"3E glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal><5:/<2 glyph<c=30,font=/PIIBDE+FranklinGothic-BookItal>=C@</: =4 !32717<3 FK8B?I>;: :;J7?B;: H;IKBJI <HEC J>; +>7I; glyph<c=19,font=/PIIBEG+FranklinGothic-Book> 1glyph<c=28,font=/PIIBEG+FranklinGothic-Book>'*IJK:O E< JE<;HI;Dglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= J>; 9EC8?D;: 7D7BOI?I E< J>; +>7I; glyph<c=19,font=/PIIBEG+FranklinGothic-Book> 1glyph<c=28,font=/PIIBEG+FranklinGothic-Book>'*IJK:O 7D: ?JI EF;Dglyph<c=13,font=/PIIBEG+FranklinGothic-Book>B78;B ;NJ;DI?ED IJK:O ;L7BK7J?D= JE<;HI;D <EH J>; FEJ;DJ?7B JH;7JC;DJ E< .*glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>'.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- T $D glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> J>;  (glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 799;FJ;: <EH H;L?;M J>; (glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> <EH JE<;HI;Dglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## !=D3;3<B glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>7A=@23@A\n\n## glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=5,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>\" glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=15,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=6,font=/PIIBDE+FranklinGothic-BookItal>\n\n- T $D (7O glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> :EI?D= 9ECC;D9;: ?D J>; +>7I; glyph<c=18,font=/PIIBEG+FranklinGothic-Book>8 '0(glyph<c=28,font=/PIIBEG+FranklinGothic-Book> IJK:O E< glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$$glyph<c=29,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 IC7BB CEB;9KB; ?D>?8?JEH E< B;K9?D;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>H?9> H;F;7J A?D7I; glyph<c=18,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book>'--&glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ;L7BK7J?D= J>; ;<<?979O 7D: I7<;JO E< glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$$glyph<c=29,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> 9ECF7H;: JE FB79;8E ?D 7FFHEN?C7J;BO glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> F7J?;DJI M?J> ;7HBO IJ7=; +7HA?DIEDglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I :?I;7I;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- T $D *9JE8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> M; 7D: EKH 9EBB78EH7J?ED F7HJD;H glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;D7B? />;H7F;KJ?9I $D9glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;D7B?glyph<c=9,font=/PIIBEG+FranklinGothic-Book> 7DDEKD9;: J>; ?D?J?7J?ED E< J>; +>7I; glyph<c=19,font=/PIIBEG+FranklinGothic-Book> '$\"#/#*0.  IJK:O E< glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$$glyph<c=29,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> ?D F7J?;DJI M?J> +7HA?DIEDglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I :?I;7I; 7D: 7 9ED<?HC;: F7J>E=;D?9 CKJ7J?ED ?D J>; '--&glyph<c=18,font=/PIIBEG+FranklinGothic-Book> =;D;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal> #glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=18,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>\n\n- I $D %KD; glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> M; ;DJ;H;: ?DJE 7 9EBB78EH7J?ED 7D: B?9;DI; 7=H;;C;DJ M?J> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>B;9JEI />;H7F;KJ?9I $D9glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>B;9JEIglyph<c=9,font=/PIIBEG+FranklinGothic-Book> JE :;L;BEF 7D: 9ECC;H9?7B?P; glyph<c=28,font=/PIIBEG+FranklinGothic-Book>'*glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 DEL;B FH;9B?D?97B I;B;9J?L; \"glyph<c=29,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> ?D>?8?JEHglyph<c=12,font=/PIIBEG+FranklinGothic-Book> <EH J>; FEJ;DJ?7B EH7B :?I;7I; CE:?<O?D= JH;7JC;DJ <EH F7J?;DJI M?J> +7HA?DIEDglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I :?I;7I;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>",
        "metadata": {
            "page": 13
        },
        "id": "4ca188fb-8e9a-4c99-ab98-c2ed96d1e23c"
    },
    {
        "page_content": "## glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>;;C<=:=5G\n\n## 7B747:7;/0 glyph<c=5,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=10,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=15,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=6,font=/PIIBDE+FranklinGothic-BookItal>\n\n- T $D %KBO glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> (63 \"3E glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal><5:/<2 glyph<c=30,font=/PIIBDE+FranklinGothic-BookItal>=C@</: =4 !32717<3 FK8B?I>;: FEI?J?L; H;IKBJI <HEC J>; 9KJ7D;EKI BKFKI ;HOJ>;C7JEIKI glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=30,font=/PIIBEG+FranklinGothic-Book>' glyph<c=9,font=/PIIBEG+FranklinGothic-Book> FEHJ?ED E< J>; JMEglyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJ +>7I; glyph<c=18,font=/PIIBEG+FranklinGothic-Book> '$'glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=30,font=/PIIBEG+FranklinGothic-Book> IJK:O glyph<c=8,font=/PIIBEG+FranklinGothic-Book>+7HJ glyph<c=29,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book> ;L7BK7J?D= B?J?<?B?C78glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D ?DL;IJ?=7J?ED7B :HK= <EH J>; JH;7JC;DJ E< BKFKIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; IJK:O C;J ?JI FH?C7HO ;D:FE?DJ 8O :;CEDIJH7J?D= J>; ;D>7D9;: ;<<?979O E< B?J?<?B?C78 9ECF7H;: JE FB79;8E ?D H;:K9?D= IA?D :?I;7I; 79J?L?JOglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- T $D .;FJ;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> (63 \"3E glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal><5:/<2 glyph<c=30,font=/PIIBDE+FranklinGothic-BookItal>=C@</: =4 !32717<3 FK8B?I>;: 7 I;9ED: C7DKI9H?FJ :;J7?B?D= FEI?J?L; H;IKBJI <HEC J>; IOIJ;C?9 BKFKI ;HOJ>;C7JEIKI glyph<c=8,font=/PIIBEG+FranklinGothic-Book>.' glyph<c=9,font=/PIIBEG+FranklinGothic-Book> FEHJ?ED E< J>; JMEglyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJ +>7I; glyph<c=18,font=/PIIBEG+FranklinGothic-Book> '$'glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=30,font=/PIIBEG+FranklinGothic-Book> IJK:O glyph<c=8,font=/PIIBEG+FranklinGothic-Book>+7HJ glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book> ;L7BK7J?D= B?J?<?B?C78glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; IJK:O C;J ?JI FH?C7HO ;D:FE?DJ 8O :;CEDIJH7J?D= J>7J B?J?<?B?C78 M7I 7IIE9?7J;: M?J> 7 IJ7J?IJ?97BBO I?=D?<?97DJ H;:K9J?ED ?D JEJ7B 79J?L; @E?DJ 9EKDJ 9ECF7H;: JE FB79;8Eglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- T $D *9JE8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> J>; <?HIJ F7J?;DJ M7I :EI;: ?D J>; +>7I; glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=15,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>( /#4./ IJK:O E< B?J?<?B?C78glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ;L7BK7J?D= J>; ;<<?979O 7D: I7<;JO E< B?J?<?B?C78 9ECF7H;: JE FB79;8E ?D F7J?;DJI M?J> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>' glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>7=A7;7:/@A\n\n## glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=18,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=10,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=5,font=/PIIBDE+FranklinGothic-BookItal>@343@3<17<5 glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>!.glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=6,font=/PIIBDE+FranklinGothic-BookItal>\n\n- I $D !;8HK7HO glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> M; ;DJ;H;: ?DJE 7 9ECC;H9?7B?P7J?ED 7D: B?9;DI; 7=H;;C;DJ M?J> 38H7D; glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?EF>7HC7 glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=29,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book>38H7D;glyph<c=9,font=/PIIBEG+FranklinGothic-Book> JE :;L;BEFglyph<c=12,font=/PIIBEG+FranklinGothic-Book> C7DK<79JKH; 7D: 9ECC;H9?7B?P; glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$$glyph<c=29,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 FHEFEI;: 9;HJEB?PKC78 F;=EB 8?EI?C?B7H H;<;H;D9?D= glyph<c=30,font=/PIIBEG+FranklinGothic-Book>$(5$glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>-##*glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>. glyph<c=5,font=/PIIBDE+FranklinGothic-BookItal>@343@3<17<5 )glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>\"(glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>'glyph<c=6,font=/PIIBDE+FranklinGothic-BookItal>\n\n- T $D %KD; glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> M; 7D: .7CIKD= glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E;F?I 7DDEKD9;: J>7J glyph<c=29,font=/PIIBEG+FranklinGothic-Book>4**1$5glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 H7D?8?PKC78 8?EI?C?B7H H;<;H;D9?D= '0glyph<c=30,font=/PIIBEG+FranklinGothic-Book> )/$.glyph<c=12,font=/PIIBEG+FranklinGothic-Book> B7KD9>;: ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=18,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=10,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=10,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=5,font=/PIIBDE+FranklinGothic-BookItal>@343@3<17<5 glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>(glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>!&glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=6,font=/PIIBDE+FranklinGothic-BookItal>\n\n- I $D %KD; glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> M; 7D: EKH 9EBB78EH7J?ED F7HJD;H glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?Eglyph<c=13,font=/PIIBEG+FranklinGothic-Book>/>;H7 .EBKJ?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 'J:glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?Eglyph<c=13,font=/PIIBEG+FranklinGothic-Book>/>;H7glyph<c=9,font=/PIIBEG+FranklinGothic-Book> FH;I;DJ;: FEI?J?L; H;IKBJI <HEC J>; +>7I; glyph<c=19,font=/PIIBEG+FranklinGothic-Book> IJK:O E< glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$$glyph<c=29,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 FHEFEI;: JE9?B?PKC78 8?EI?C?B7H H;<;H;D9?D= glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=30,font=/PIIBEG+FranklinGothic-Book>/ (-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D 7DJ?glyph<c=13,font=/PIIBEG+FranklinGothic-Book>?DJ;HB;KA?Dglyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book> H;9;FJEH CEDE9BED7B 7DJ?8E:Oglyph<c=12,font=/PIIBEG+FranklinGothic-Book> <EH J>; JH;7JC;DJ E< I;L;H;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 79J?L; 7D: FHE=H;II?L; H>;KC7JE?: 7HJ>H?J?Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; :7J7 M7I FH;I;DJ;: 7J J>; glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>DDK7B KHEF;7D glyph<c=30,font=/PIIBEG+FranklinGothic-Book>ED=H;II E< ->;KC7JEBE=Oglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- T $D .;FJ;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> J>;  (glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 799;FJ;: <EH H;L?;M J>; (glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> <EH glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$$glyph<c=29,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- T $D glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 799;FJ;: <EH H;L?;M J>; 788H;L?7J;: glyph<c=29,font=/PIIBEG+FranklinGothic-Book>'glyph<c=28,font=/PIIBEG+FranklinGothic-Book> <EH glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$$glyph<c=29,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>7A1=<B7<C32 $@=5@/;A\n\n- T $D (7H9> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> M; 7D: $ED?I +>7HC79;KJ?97BI $D9glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book>$ED?Iglyph<c=9,font=/PIIBEG+FranklinGothic-Book> 7DDEKD9;: J>7J J>; +>7I; glyph<c=17,font=/PIIBEG+FranklinGothic-Book> IJK:O E< glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$$glyph<c=29,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book> ?D glyph<c=28,font=/PIIBEG+FranklinGothic-Book>'. :?: DEJ C;;J 7DO I;9ED:7HO ;<<?979O ;D:FE?DJI 7D: ?J :?: DEJ :;CEDIJH7J; 9B?D?97B 8;D;<?Jglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>7I;: ED J>;I; H;IKBJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; :?I9EDJ?DK;: :;L;BEFC;DJ E< glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$$glyph<c=29,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- T $D %KD; glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> M; :?I9EDJ?DK;: <KHJ>;H :;L;BEFC;DJ E< glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$$glyph<c=29,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> <EH J>; FEJ;DJ?7B JH;7JC;DJ E< 9;HJ7?D D;KHEBE=?97B 7D: D;KHE:;=;D;H7J?L; :?I;7I;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FH?C7H?BO ?D glyph<c=28,font=/PIIBEG+FranklinGothic-Book>'.glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 87I;: ED J>; :;9?I?ED 8O C7D7=;C;DJ 7I F7HJ E< ?JI IJH7J;=?9 H;L?;M FHE9;IIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- T $D %KBO glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> M; 7DDEKD9;: J>7J J>; +>7I; glyph<c=18,font=/PIIBEG+FranklinGothic-Book> /glyph<c=28,font=/PIIBEG+FranklinGothic-Book>''4 IJK:O E< glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$$glyph<c=29,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book> ?D 9E=D?J?L; ?CF7?HC;DJ 7IIE9?7J;: M?J> I9>?PEF>H;D?7 :?: DEJ C;;J ?JI FH?C7HO EH I;9ED:7HO ;<<?979O ;D:FE?DJIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> \"?L;D J>; 9EDI?IJ;DJ B79A E< ;<<?979O E8I;HL;: 79HEII J>; FH?C7HO 7D: I;9ED:7HO C;7IKH;I E< 9E=D?J?ED 7D: <KD9J?ED?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; :;9?:;: JE :?I9EDJ?DK; J>; glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$$glyph<c=29,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book> FHE=H7Cglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- M @ glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book> I7 6;E5A@F;@G76 8GDF:7D 67H7>AB?7@F A8 glyph<c=25,font=/PIIBCD+FranklinGothic-Book>  glyph<c=25,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=21,font=/PIIBCD+FranklinGothic-Book> glyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>\"glyph<c=14,font=/PIIBCD+FranklinGothic-Book> ;@:;4;FADglyph<c=7,font=/PIIBCD+FranklinGothic-Book> 8AD F:7 BAF7@F;3> FD73F?7@F A8 B3F;7@FE I;F: 47:3H;AD3> 3@6 @7GDA>A9;53> EK?BFA?E 35DAEE H3D;AGE BEK5:;3FD;5 3@6 @7GDA>A9;53> 6;E73E7Eglyph<c=9,font=/PIIBCD+FranklinGothic-Book> 43E76 A@ F:7 675;E;A@ 4K ?3@397?7@F 3E B3DF A8 ;FE EFD3F79;5 D7H;7I BDA57EEglyph<c=11,font=/PIIBCD+FranklinGothic-Book>\n- M $D glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> M; :?I9EDJ?DK;: <KHJ>;H :;L;BEFC;DJ E< L?NEJH?=?D; glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$$glyph<c=29,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book> <EH J>; FEJ;DJ?7B JH;7JC;DJ E< JH?=;C?D7B D;KH7B=?7 glyph<c=8,font=/PIIBEG+FranklinGothic-Book>/\")glyph<c=9,font=/PIIBEG+FranklinGothic-Book> 7D: :?78;J?9 F7?D<KB D;KHEF7J>O glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>+)glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 87I;: ED H;=KB7JEHOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> :;L;BEFC;DJ 7D: 9ECC;H9?7B?P7J?ED 9>7BB;D=;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- < $D !;8HK7HO glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book> M; J;HC?D7J;: EKH B?9;DI; 7D: 9EBB78EH7J?ED 7=H;;C;DJ M?J> $DDEglyph<c=30,font=/PIIBEG+FranklinGothic-Book>7H; +>7HC7 '?C?J;: glyph<c=8,font=/PIIBEG+FranklinGothic-Book>$DDEglyph<c=30,font=/PIIBEG+FranklinGothic-Book>7H;glyph<c=9,font=/PIIBEG+FranklinGothic-Book> <EH EH;B78HKJ?D?8glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D EH7B IC7BB CEB;9KB; glyph<c=29,font=/PIIBEG+FranklinGothic-Book>HKJEDglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I JOHEI?D; A?D7I; ?D>?8?JEH <EH J>; FEJ;DJ?7B JH;7JC;DJ E< (.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>",
        "metadata": {
            "page": 14
        },
        "id": "92d794a0-c627-407c-b01a-019901a5f9c6"
    },
    {
        "page_content": "## $3D=7F76 'DA6G5FE\n\n/>; <EBBEM?D= =H7F> I>EMI EKH H;L;DK; 8O FHE:K9J 7D: H;L;DK; <HEC 7DJ?glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> J>;H7F;KJ?9 FHE=H7CI <EH J>; O;7HI ;D:;: glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book> 7D: glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n!;8->,= *7- glyph<c=21,font=/PIIBFI+Quivira>7=2glyph<c=9,font=/PIIBFI+Quivira>glyph<c=23,font=/PIIBFI+Quivira>glyph<c=24,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira> $1.;*9.>=2, !;80;*6 \".?.7>.\n\n<!-- image -->\n\n+HE:K9J I7B;I <EH / glyph<c=30,font=/PIIBEG+FranklinGothic-Book>!$glyph<c=31,font=/PIIBEG+FranklinGothic-Book> -glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> /4.glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=29,font=/PIIBEG+FranklinGothic-Book>-$ 7D: .+$)-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>5glyph<c=28,font=/PIIBEG+FranklinGothic-Book> ;79> 799EKDJ;: <EH CEH; J>7D glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=5,font=/PIIBEG+FranklinGothic-Book> E< EKH JEJ7B H;L;DK; <EH J>; O;7HI ;D:;: glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book> 7D: glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> !EH 7::?J?ED7B <?D7D9?7B ?D<EHC7J?ED 78EKJ EKH FHE:K9J 7D: EJ>;H H;L;DK; 7D: =;E=H7F>?9 7H;7I M>;H; M; EF;H7J;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> FB;7I; H;7: \"=B3 glyph<c=15,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> &3D3<C3 7D: \"=B3 glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=15,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> '35;3<B glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><4=@;/B7=<glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> JE EKH 9EDIEB?:7J;: <?D7D9?7B IJ7J;C;DJI ?D9BK:;: ?D J>?I H;FEHJ 7D: glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>B3; glyph<c=17,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal> !/</53;3<Bglyph<c=4,font=/PIIBDE+FranklinGothic-BookItal>A glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>7A1CAA7=< /<2 glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal></:GA7A =4 glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>7</<17/: glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=<27B7=< /<2 &3AC:BA =4 #>3@/B7=<A ?D9BK:;: ?D J>?I H;FEHJglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book> :?I9KII?ED E< J>; H?IAI 7JJ;D:7DJ JE EKH EF;H7J?EDI ?I I;J <EHJ> ?D glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>B3; glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal> &7A9 glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>/1B=@A ?D9BK:;: ?D J>?I H;FEHJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>",
        "metadata": {
            "page": 15
        },
        "id": "39187a96-aa97-48d7-82e0-635c582ee2de"
    },
    {
        "page_content": "## !C:B7>:3 '1:3@=A7A\n\n2; :;L;BEFglyph<c=12,font=/PIIBEG+FranklinGothic-Book> C7DK<79JKH; 7D: C7HA;J 7 DKC8;H E< FHE:K9JI :;I?=D;: JE JH;7J F7J?;DJI M?J> (.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> (. ?I 7 FHE=H;II?L; :?I;7I; ?D M>?9> J>; 8E:O BEI;I J>; 78?B?JO JE JH7DIC?J C;II7=;I 7BED= D;HL; 9;BBIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> B;7:?D= JE 7 BEII E< CKI9B; 9EDJHEBglyph<c=12,font=/PIIBEG+FranklinGothic-Book> F7H7BOI?I 7D:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D IEC; 97I;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> :;7J>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> +7J?;DJI M?J> 79J?L; -(. ;NF;H?;D9; 7D KD;L;D F7JJ;HD E< :?I;7I; FHE=H;II?ED 9>7H79J;H?P;: 8O F;H?E:I E< IJ78?B?JO J>7J 7H; ?DJ;HHKFJ;: 8O <B7H;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>KFI E< J>; :?I;7I; 7<J;H M>?9> J>; F7J?;DJ C7O H;JKHD JE 7 BEM;H 87I;B?D; E< <KD9J?ED?D=glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n/>; (. FHE:K9JI M; C7HA;J 7D: EKH C7@EH C7HA;JI 7H; 7I <EBBEMIglyph<c=26,font=/PIIBEG+FranklinGothic-Book>\n\n<!-- image -->\n\n<!-- image -->\n\n| 'DA6G5F                                                                                                                                                                                                                                                                                                                                                              | @6;53F;A@                                                                                                                                                                                                                                                                                                                                | glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A>>34AD3FAD $3<AD $3D=7FE                                                                                                                                                  |\n|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| -(. ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> -;B7FI?D=glyph<c=13,font=/PIIBEG+FranklinGothic-Book>H;C?JJ?D= (. glyph<c=8,font=/PIIBEG+FranklinGothic-Book>--(.glyph<c=9,font=/PIIBEG+FranklinGothic-Book> ?D J>;  glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book> | )ED;                                                                                                                                                                                                                                                                                                                                     | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> !H7D9; \";HC7DO $J7BO %7F7D .F7?D 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>&glyph<c=14,font=/PIIBEG+FranklinGothic-Book> |\n| -(. ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> --(. ?D J>;  glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                         | glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BA;HC;I +>7HC7 $H;B7D: '?C?J;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 IK8I?:?7HO E< glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BA;HC;I FB9 glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BA;HC;Iglyph<c=9,font=/PIIBEG+FranklinGothic-Book> | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> \";HC7DO $IH7;B .M?JP;HB7D: 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>&glyph<c=14,font=/PIIBEG+FranklinGothic-Book>       |\n| -(.                                                                                                                                                                                                                                                                                                                                                                  | )ED;                                                                                                                                                                                                                                                                                                                                     | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> !H7D9; \";HC7DO $J7BO %7F7D .F7?D                                                                                            |\n| -(. ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> --(. ?D J>;  glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                         | )ED;                                                                                                                                                                                                                                                                                                                                     | !H7D9; \";HC7DO $J7BO .F7?D 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>&glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                                                                                  |\n| -(. --(. ?D J>;  glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>HE>Dglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I :?I;7I; ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                                    | )ED;                                                                                                                                                                                                                                                                                                                                     | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> !H7D9; \";HC7DO $J7BO .F7?D 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>&glyph<c=14,font=/PIIBEG+FranklinGothic-Book>       |\n| 27BA?D= 78?B?JO <EH F7J?;DJI M?J> (.                                                                                                                                                                                                                                                                                                                                 | glyph<c=28,font=/PIIBEG+FranklinGothic-Book>9EH:7 />;H7F;KJ?9Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> $D9glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>9EH:7glyph<c=9,font=/PIIBEG+FranklinGothic-Book>                                       | !H7D9; \";HC7DO                                                                                                                                                                                                         |\n\n!EH 7::?J?ED7B ?D<EHC7J?ED ED EKH 9EBB78EH7J?ED 7HH7D=;C;DJI M?J> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BA;HC;I 7D: glyph<c=28,font=/PIIBEG+FranklinGothic-Book>9EH:7glyph<c=12,font=/PIIBEG+FranklinGothic-Book> FB;7I; H;7: \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>Aglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> JE EKH 9EDIEB?:7J;: <?D7D9?7B IJ7J;C;DJI ?D9BK:;: ?D J>?I H;FEHJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## \"3C@=;CA1C:/@ glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>7A=@23@A\n\n.(glyph<c=28,font=/PIIBEG+FranklinGothic-Book> ?I 9>7H79J;H?P;: 8O BEII E< CEJEH D;KHEDI ?D J>; IF?D7B 9EH: 7D: BEM;H 8H7?D IJ;Cglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;IKBJ?D= ?D I;L;H; 7D: FHE=H;II?L; CKI9KB7H 7JHEF>O 7D: M;7AD;IIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 0BJ?C7J;BOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D:?L?:K7BI M?J> J>; CEIJ I;L;H; JOF; E< .(glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 97D 8;9EC; F7H7BOP;: 7D: >7L; :?<<?9KBJO F;H<EHC?D= J>; 87I?9 <KD9J?EDI E< B?<;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> B?A; 8H;7J>?D= 7D: IM7BBEM?D=glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=31,font=/PIIBEG+FranklinGothic-Book>K; JE 7 :;B;J?ED EH CKJ7J?EDI ?D J>; .()glyph<c=17,font=/PIIBEG+FranklinGothic-Book> =;D;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> F;EFB; M?J> .(glyph<c=28,font=/PIIBEG+FranklinGothic-Book> :E DEJ FHE:K9; ;DEK=> IKHL?L7B CEJEH D;KHED glyph<c=8,font=/PIIBEG+FranklinGothic-Book>.()glyph<c=9,font=/PIIBEG+FranklinGothic-Book> FHEJ;?Dglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> ?I 9H?J?97B JE J>; IKHL?L7B E< J>; D;KHEDI J>7J 9EDJHEB CKI9B;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; I;L;H?JO E< .(glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 9EHH;B7J;I M?J> J>; 7CEKDJ E< .() FHEJ;?Dglyph<c=14,font=/PIIBEG+FranklinGothic-Book> +;EFB; M?J> /OF; glyph<c=17,font=/PIIBEG+FranklinGothic-Book> .(glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; CEIJ I;L;H; B?<;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>J>H;7J;D?D= <EHCglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FHE:K9; L;HO B?JJB; .() FHEJ;?D 7D: :E DEJ",
        "metadata": {
            "page": 16
        },
        "id": "eddfe86b-bff1-42aa-9254-dcffde180324"
    },
    {
        "page_content": "79>?;L; J>; 78?B?JO JE I?J M?J>EKJ IKFFEHJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: JOF?97BBO :E DEJ B?L; 8;OED: JME O;7HI E< 7=; M?J>EKJ H;IF?H7JEHO IKFFEHJ 7D: DKJH?J?ED7B ?DJ;HL;DJ?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> +;EFB; M?J> /OF; glyph<c=18,font=/PIIBEG+FranklinGothic-Book> 7D: /OF; glyph<c=19,font=/PIIBEG+FranklinGothic-Book> .(glyph<c=28,font=/PIIBEG+FranklinGothic-Book> FHE:K9; =H;7J;H 7CEKDJI E< .() FHEJ;?D 7D: >7L; B;II I;L;H;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 8KJ IJ?BB B?<;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>7BJ;H?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> <EHCI E< .(glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n*KH .(glyph<c=28,font=/PIIBEG+FranklinGothic-Book> FHE:K9J 7D: C7@EH C7HA;JI 7H; 7I <EBBEMIglyph<c=26,font=/PIIBEG+FranklinGothic-Book>\n\n<!-- image -->\n\n| 'DA6G5F   | @6;53F;A@                                      | glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A>>34AD3FAD   | $3<AD $3D=7FE                                                                                                                                                                                                                                                                    |\n|-----------|------------------------------------------------|-----------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n|           | .(glyph<c=28,font=/PIIBEG+FranklinGothic-Book> | $ED?I                                                     | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>H7P?B glyph<c=30,font=/PIIBEG+FranklinGothic-Book>7D7:7 glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>?D7 !H7D9; \";HC7DO $J7BO %7F7D .F7?D |\n\n!EH 7::?J?ED7B ?D<EHC7J?ED ED EKH 9EBB78EH7J?ED 7HH7D=;C;DJI M?J> $ED?Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FB;7I; H;7: \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>Aglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> JE EKH 9EDIEB?:7J;: <?D7D9?7B IJ7J;C;DJI ?D9BK:;: ?D J>?I H;FEHJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>:H637;3@glyph<c=4,font=/PIIBDE+FranklinGothic-BookItal>A glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>7A3/A3\n\nglyph<c=28,font=/PIIBEG+FranklinGothic-Book>BP>;?C;Hglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I :?I;7I; ?I 9>7H79J;H?P;: 8O JME 78DEHC7B?J?;I ?D J>; 8H7?Dglyph<c=26,font=/PIIBEG+FranklinGothic-Book> 7COBE?: FB7GK;I 7D: D;KHE<?8H?BB7HO J7D=B;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>COBE?: FB7GK;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> 7H; <EKD: ?D J>; J?IIK; 8;JM;;D J>; D;HL; 9;BBIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7H; KDKIK7B 9BKCFI E< 7 FHEJ;?D 97BB;: 8;J7 7COBE?: 7BED= M?J> :;=;D;H7J?D= 8?JI E< D;KHEDI 7D: EJ>;H 9;BBIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n*KH glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BP>;?C;Hglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I :?I;7I; FHE:K9JI 7D: C7@EH C7HA;JI 7H; 7I <EBBEMIglyph<c=26,font=/PIIBEG+FranklinGothic-Book>\n\n<!-- image -->\n\n<!-- image -->\n\n| 'DA6G5F   | @6;53F;A@                                                                                                | $3<AD $3D=7F                                                                               |\n|-----------|----------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|\n|           | glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BP>;?C;Hglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I :?I;7I; | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> |\n|           | glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BP>;?C;Hglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I :?I;7I; | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> |\n\n!EH 7::?J?ED7B ?D<EHC7J?ED ED EKH 9EBB78EH7J?ED 7HH7D=;C;DJI M?J>  ?I7?glyph<c=12,font=/PIIBEG+FranklinGothic-Book> FB;7I; H;7: \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>Aglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> JE EKH 9EDIEB?:7J;: <?D7D9?7B IJ7J;C;DJI ?D9BK:;: ?D J>?I H;FEHJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>7=A7;7:/@A\n\nglyph<c=29,font=/PIIBEG+FranklinGothic-Book>?EI?C?B7HI 7H; 7 =HEKF E< 8?EBE=?9 C;:?9?D;I J>7J 7H; >?=>BO I?C?B7H JE 9KHH;DJBO 7L7?B78B; 8?EBE=?9 J>;H7F?;I :;L;BEF;: 8O 9ECF7D?;I ADEMD 7I glyph<c=2,font=/PIIBEG+FranklinGothic-Book>EH?=?D7JEHIglyph<c=2,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 0D:;H EKH 7=H;;C;DJI M?J> .7CIKD= glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E;F?Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 9ECC;H9?7B?P; J>H;; 7DJ?glyph<c=13,font=/PIIBEG+FranklinGothic-Book>JKCEH D;9HEI?I <79JEH glyph<c=8,font=/PIIBEG+FranklinGothic-Book>/)!glyph<c=9,font=/PIIBEG+FranklinGothic-Book> 8?EI?C?B7HI ?D 9;HJ7?D 9EKDJH?;I ?D  KHEF;glyph<c=26,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book> ) +glyph<c=28,font=/PIIBEG+FranklinGothic-Book>'$glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D ;J7D;H9;FJ 8?EI?C?B7H H;<;H;D9?D=  )glyph<c=29,font=/PIIBEG+FranklinGothic-Book>- 'glyph<c=12,font=/PIIBEG+FranklinGothic-Book> $(-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>'glyph<c=31,font=/PIIBEG+FranklinGothic-Book>$glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D 7:7B?CKC78 8?EI?C?B7H H;<;H;D9?D= #0($-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: !'$3glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D ?D<B?N?C78 8?EI?C?B7H H;<;H;D9?D= - ($glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book> glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; >7L; 7BIE I;9KH;: J>; ;N9BKI?L; H?=>JI JE 9ECC;H9?7B?P; glyph<c=29,font=/PIIBEG+FranklinGothic-Book>4**1$5glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 H7D?8?PKC78 8?EI?C?B7H H;<;H;D9?D= '0glyph<c=30,font=/PIIBEG+FranklinGothic-Book> )/$.glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> M7I 7FFHEL;: ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>;  glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 7D: J>; 0D?J;: &?D=:EC glyph<c=8,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>&glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book> :KH?D= J>; J>?H: GK7HJ;H E< glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>4**1$5 B7KD9>;: ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> ?D %KD; glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> 7D: 8;97C; 9ECC;H9?7BBO 7L7?B78B; :KH?D= J>; J>?H: GK7HJ;H E< glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>",
        "metadata": {
            "page": 17
        },
        "id": "0db7c061-061c-4e2d-ac4d-2313e3c3835b"
    },
    {
        "page_content": "<!-- image -->\n\n<!-- image -->\n\n<!-- image -->\n\n<!-- image -->\n\n| 'DA6G5F   | @6;53F;A@                                                                                                                                                                                                                                                            | $3<AD $3D=7FE                                                                                                                                               |\n|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|\n|           | ->;KC7JE?: 7HJ>H?J?I %KL;D?B; ?:?EF7J>?9 7HJ>H?J?I +IEH?7J?9 7HJ>H?J?I glyph<c=28,font=/PIIBEG+FranklinGothic-Book>N?7B IFED:OBE7HJ>H?J?I +B7GK; FIEH?7I?I +7;:?7JH?9 FB7GK; FIEH?7I?I                                                                               | !H7D9; \";HC7DO $J7BO .F7?D 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>&glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                       |\n|           | ->;KC7JE?: 7HJ>H?J?I glyph<c=30,font=/PIIBEG+FranklinGothic-Book>HE>D^I :?I;7I; :?I;7I; +7;:?7JH?9 KB9;H7J?L; 9EB?J?I IFED:OB?J?I                                                                                                                                    | +7;:?7JH?9 glyph<c=30,font=/PIIBEG+FranklinGothic-Book>HE>D^I 0B9;H7J?L; 9EB?J?I glyph<c=28,font=/PIIBEG+FranklinGothic-Book>DAOBEI?D= !H7D9; \";HC7DO $J7BO |\n|           | );EL7I9KB7H glyph<c=8,font=/PIIBEG+FranklinGothic-Book>M;Jglyph<c=9,font=/PIIBEG+FranklinGothic-Book> 7=;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>H;B7J;: C79KB7H :;=;D;H7J?ED (79KB7H ;:;C7 <EBBEM?D= H;J?D7B L;?D E99BKI?ED (OEF?9 9>EHE?:7B D;EL7I9KB7H?P7J?ED | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                                                  |\n\n!EH 7::?J?ED7B ?D<EHC7J?ED ED EKH 9EBB78EH7J?ED 7HH7D=;C;DJI M?J> .7CIKD= glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E;F?Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FB;7I; H;7: \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>Aglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> JE EKH 9EDIEB?:7J;: <?D7D9?7B IJ7J;C;DJI ?D9BK:;: ?D J>?I H;FEHJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>",
        "metadata": {
            "page": 18
        },
        "id": "8c43a5df-843c-4f8e-a943-f6c972c11212"
    },
    {
        "page_content": "## glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>3<3<B316 &3:/B7=<A67>A\n\n2; >7L; 7=H;;C;DJI M?J> \";D;DJ;9> J>7J ;DJ?JB; KI JE 9;HJ7?D 8KI?D;II 7D: <?D7D9?7B H?=>JI M?J> H;IF;9J JE -$/03glyph<c=28,font=/PIIBEG+FranklinGothic-Book>)glyph<c=12,font=/PIIBEG+FranklinGothic-Book> -$/03glyph<c=28,font=/PIIBEG+FranklinGothic-Book>) #4glyph<c=30,font=/PIIBEG+FranklinGothic-Book> 'glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> \"glyph<c=28,font=/PIIBEG+FranklinGothic-Book>541glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> *glyph<c=30,font=/PIIBEG+FranklinGothic-Book>- 10.glyph<c=12,font=/PIIBEG+FranklinGothic-Book> '0).0($*glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> M7I =H7DJ;: 799;B;H7J;: 7FFHEL7B ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> :KH?D= J>; <EKHJ> GK7HJ;H E< glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> =BE<?J7C78 7D: EFJ?EDI JE 7:: EJ>;H FEJ;DJ?7B 7DJ?glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> J>;H7F?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n*KH 9KHH;DJ 7DJ?glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> J>;H7F;KJ?9 FHE=H7CI 7D: C7@EH C7HA;JI 7H; 7I <EBBEMIglyph<c=26,font=/PIIBEG+FranklinGothic-Book>\n\n<!-- image -->\n\n<!-- image -->\n\n| 'DA6G5F   | @6;53F;A@                                                                                                                                                                                                                                                                                                                                                                                                                            | $3<AD $3D=7FE                                                                              |\n|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|\n|           | glyph<c=30,font=/PIIBEG+FranklinGothic-Book>'' ->;KC7JE?: 7HJ>H?J?I /ME <EHCI E< glyph<c=28,font=/PIIBEG+FranklinGothic-Book>)glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=13,font=/PIIBEG+FranklinGothic-Book>7IIE9?7J;: L7I9KB?J?I 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>7D7:7 |                                                                                            |\n|           | )EDglyph<c=13,font=/PIIBEG+FranklinGothic-Book>#E:=A?Dglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I BOCF>EC7 glyph<c=30,font=/PIIBEG+FranklinGothic-Book>''                                                                                                                                                                                                                                                                           | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> |\n|           | $D 9EC8?D7J?ED M?J> 9>BEH7C8K9?B <EH FH;L?EKIBO KDJH;7J;: glyph<c=30,font=/PIIBEG+FranklinGothic-Book>'' !EBB?9KB7H BOCF>EC7 $D 9EC8?D7J?ED M?J> 9>;CEJ>;H7FO <EBBEM;: 8O \"glyph<c=28,font=/PIIBEG+FranklinGothic-Book>541glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 7BED; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                                              |                                                                                            |\n|           | -(. ++(. 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                  |                                                                                            |\n|           | -;B7FI;: EH H;<H79JEHO <EBB?9KB7H BOCF>EC7                                                                                                                                                                                                                                                                                                                                                                                           | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> |\n\n!EH 7::?J?ED7B ?D<EHC7J?ED ED EKH 9EBB78EH7J?ED 7HH7D=;C;DJI M?J> \";D;DJ;9>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> FB;7I; H;7: \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>Aglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> JE EKH 9EDIEB?:7J;: <?D7D9?7B IJ7J;C;DJI ?D9BK:;: ?D J>?I H;FEHJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n#B63@\n\n<!-- image -->\n\n| 'DA6G5F   | @6;53F;A@                           | glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A>>34AD3FAD   | $3<AD $3D=7FE   |\n|-----------|-------------------------------------|-----------------------------------------------------------|-----------------|\n|           | (E:;H7J; JE I;L;H; FB7GK; FIEH?7I?I | )ED;                                                      | \";HC7DO         |\n\n## '3F;7@F *GBBADF 3@6 glyph<c=24,font=/PIIBCD+FranklinGothic-Book>557EE\n\n2; ?DJ;H79J M?J> F7J?;DJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7:LE979O EH=7D?P7J?EDI 7D: >;7BJ>97H; IE9?;J?;I ?D EH:;H JE =7?D ?DI?=>JI ?DJE KDC;J D;;:Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; ?DI?=>JI =7?D;: <HEC J>;I; ;D=7=;C;DJI >;BF KI IKFFEHJ F7J?;DJI M?J> I;HL?9;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FHE=H7CI 7D: 7FFB?97J?EDI J>7J 7H; :;I?=D;: JE >;BF F7J?;DJI B;7: 8;JJ;H B?L;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>CED= EJ>;H J>?D=Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; FHEL?:; 9KIJEC;H I;HL?9; 7D: EJ>;H H;B7J;: FHE=H7CI <EH EKH FHE:K9JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> IK9> 7I :?I;7I; 7D: FHE:K9J IF;9?<?9 M;8I?J;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?DIKH7D9; H;I;7H9> I;HL?9;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> <?D7D9?7B 7II?IJ7D9; FHE=H7CI 7D: J>;\n\n<79?B?J7J?ED E< J>; FHE9KH;C;DJ E< EKH C7HA;J;: FHE:K9JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n2; 7H; :;:?97J;: JE >;BF?D= F7J?;DJI E8J7?D 799;II JE EKH J>;H7F?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> *KH F7J?;DJ H;FH;I;DJ7J?L;I >7L; 799;II JE 7 IK?J; E< <?D7D9?7B 7II?IJ7D9; JEEBIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2?J> J>EI; JEEBIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; >;BF F7J?;DJI KD:;HIJ7D: J>;?H ?DIKH7D9; 9EL;H7=; 7D:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?< D;;:;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> >;BF F7J?;DJI 9ECF7H; ?DIKH7D9; EFJ?EDI 7D: FHE=H7CIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; >7L; ;IJ78B?I>;: FHE=H7CI J>7J FHEL?:; 9Eglyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7O 7II?IJ7D9; EH <H;; FHE:K9J <EH GK7B?<?;: KD?DIKH;: EH KD:;H?DIKH;: F7J?;DJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 87I;: ED IF;9?<?9 ;B?=?8?B?JO 9H?J;H?7glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; 7BIE FHEL?:; 9>7H?J78B; 9EDJH?8KJ?EDI JE",
        "metadata": {
            "page": 19
        },
        "id": "92b45e98-359f-4276-9c1f-8544caf6525e"
    },
    {
        "page_content": "?D:;F;D:;DJ 9>7H?J78B; EH=7D?P7J?EDI J>7J 7II?IJ F7J?;DJI M?J> EKJglyph<c=13,font=/PIIBEG+FranklinGothic-Book>E<glyph<c=13,font=/PIIBEG+FranklinGothic-Book>FE9A;J ;NF;DI;I 7IIE9?7J;: M?J> J>;?H J>;H7FOglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n2; 8;B?;L; 7BB >;7BJ>97H; IJ7A;>EB:;HI >7L; 7 I>7H;: H;IFEDI?8?B?JO JE ;DIKH; F7J?;DJI >7L; ;GK?J78B; 799;II JE D;Mglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?DDEL7J?L; C;:?9?D;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; H;=KB7HBO H;L?;M EKH FH?9?D= IJH7J;=O 7D: FH?EH?J?P; F7J?;DJ 799;II JE EKH J>;H7F?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; >7L; 7 L7BK;glyph<c=13,font=/PIIBEG+FranklinGothic-Book> 87I;: 9EDJH79J?D= FHE=H7C :;I?=D;: JE 7B?=D J>; FH?9; E< EKH J>;H7F?;I JE J>; L7BK; EKH J>;H7F?;I :;B?L;H JE F7J?;DJIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; 7BIE MEHA M?J> H;=KB7JEHIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9B?D?97B H;I;7H9>;HIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ;J>?9?IJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> F>OI?9?7DI 7D: F7J?;DJ 7:LE979O EH=7D?P7J?EDI 7D: 9ECCKD?J?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7CED= EJ>;HIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> JE :;J;HC?D; >EM 8;IJ JE 7::H;II H;GK;IJI <EH 799;II JE EKH ?DL;IJ?=7J?ED7B J>;H7F?;I ?D 7 C7DD;H J>7J ?I 9EDI?IJ;DJ M?J> EKH F7J?;DJglyph<c=13,font=/PIIBEG+FranklinGothic-Book><E9KI;: L7BK;I 7D: 9ECFB?7DJ M?J> H;=KB7JEHO IJ7D:7H:I 7D: FHEJE9EBIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D 7FFHEFH?7J; I?JK7J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> F7J?;DJI C7O >7L; 799;II JE ?DL;IJ?=7J?ED7B J>;H7F?;I J>HEK=>  7HBO glyph<c=28,font=/PIIBEG+FranklinGothic-Book>99;II +HE=H7CIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> I?D=B; F7J?;DJ 799;II EH ;C;H=;D9O KI; 87I;: ED >KC7D?J7H?7D EH 9ECF7II?ED7J; =HEKD:Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## $3D=7F;@9 3@6 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>;EFD;4GF;A@\n\n## '/:3A glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>=@13 /<2 !/@93B7<5\n\n2; FHECEJ; EKH C7HA;J;: FHE:K9JI MEHB:M?:;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> KHEF; 7D: %7F7Dglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FH?C7H?BO J>HEK=> EKH EMD I7B;I <EH9;I 7D: C7HA;J?D= =HEKFIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D IEC; 9EKDJH?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> F7HJ?9KB7HBO ?D 7H;7I M>;H; M; 9EDJ?DK; JE ;NF7D: ?DJE D;M =;E=H7F>?9 7H;7Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; F7HJD;H M?J> J>?H: F7HJ?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n-$/03glyph<c=28,font=/PIIBEG+FranklinGothic-Book>)glyph<c=12,font=/PIIBEG+FranklinGothic-Book> -$/03glyph<c=28,font=/PIIBEG+FranklinGothic-Book>) #4glyph<c=30,font=/PIIBEG+FranklinGothic-Book> 'glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> \"glyph<c=28,font=/PIIBEG+FranklinGothic-Book>541glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> *glyph<c=30,font=/PIIBEG+FranklinGothic-Book>- 10. 7D: '0).0($* 7H; C7HA;J;: 8O J>; -E9>; \"HEKF 7D: ?JI IK8B?9;DI;;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n2; 9ECC;H9?7B?P; glyph<c=29,font=/PIIBEG+FranklinGothic-Book> ) +glyph<c=28,font=/PIIBEG+FranklinGothic-Book>'$glyph<c=12,font=/PIIBEG+FranklinGothic-Book> $(-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>'glyph<c=31,font=/PIIBEG+FranklinGothic-Book>$ 7D: !'$3glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$ FKHIK7DJ JE EKH 7=H;;C;DJ M?J> .7CIKD= glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E;F?I ?D 9;HJ7?D 9EKDJH?;I ?D  KHEF;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7I M;BB 7I glyph<c=29,font=/PIIBEG+FranklinGothic-Book>4**1$5 ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n2; <E9KI EKH I7B;I 7D: C7HA;J?D= ;<<EHJI ED IF;9?7B?IJ F>OI?9?7DI ?D FH?L7J; FH79J?9; EH 7J C7@EH C;:?97B 9;DJ;HIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; KI; 9KIJEC7HO ?D:KIJHO FH79J?9;I JE C7HA;J EKH FHE:K9JI 7D: JE ;:K97J; F>OI?9?7DIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />?I ?D9BK:;I EKH I7B;I H;FH;I;DJ7J?L;I 97BB?D= ED ?D:?L?:K7B >;7BJ> 97H; FHEL?:;HI glyph<c=8,font=/PIIBEG+FranklinGothic-Book>?Dglyph<c=13,font=/PIIBEG+FranklinGothic-Book>F;HIED 7D: L?HJK7BBOglyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7:L;HJ?I;C;DJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FHE<;II?ED7B IOCFEI?7glyph<c=12,font=/PIIBEG+FranklinGothic-Book> :?H;9J C7?Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> :?=?J7B C7HA;J?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> FE?DJ E< 97H; C7HA;J?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> FK8B?9 H;B7J?EDI 7D: EJ>;H C;J>E:Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; <E9KI ED >;7BJ> 97H; FHEL?:;H I7B;I 7D: C7HA;J?D= ;<<EHJI ED IF;9?7BJO FHEL?:;HI ?D 8EJ> FH?L7J; FH79J?9; 7D: 7J C7@EH C;:?97B 9;DJ;HIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>7AB@70CB7=< glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>@@/<53;3<BA\n\n2; :?IJH?8KJ; EKH FHE:K9JI ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> FH?D9?F7BBO J>HEK=> M>EB;I7B; 7D: IF;9?7BJO :?IJH?8KJEHI E< F>7HC79;KJ?97B FHE:K9JI 7D: IF;9?7BJO F>7HC79?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> C7?B EH:;H IF;9?7BJO :?IJH?8KJEHI EH I>?FF?D= I;HL?9; FHEL?:;HIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D EJ>;H 9EKDJH?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; :?IJH?8KJ?ED E< EKH\n\nFHE:K9JI L7H?;I <HEC 9EKDJHO JE 9EKDJHOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= J>HEK=> M>EB;I7B; :?IJH?8KJEHI E< F>7HC79;KJ?97B FHE:K9JI 7D: J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJO :?IJH?8KJ?ED F7HJD;HI M>E 7H; H;IFEDI?8B; <EH CEIJ C7HA;J?D= 7D: :?IJH?8KJ?ED 79J?L?J?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n?I7? :?IJH?8KJ;I glyph<c=28,font=/PIIBEG+FranklinGothic-Book>1*) 3glyph<c=12,font=/PIIBEG+FranklinGothic-Book> /4.glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=29,font=/PIIBEG+FranklinGothic-Book>-$glyph<c=12,font=/PIIBEG+FranklinGothic-Book> / glyph<c=30,font=/PIIBEG+FranklinGothic-Book>!$glyph<c=31,font=/PIIBEG+FranklinGothic-Book> -glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 7D: +' \"-$glyph<c=31,font=/PIIBEG+FranklinGothic-Book>4 ?D $D:?7 7D: EJ>;H glyph<c=28,font=/PIIBEG+FranklinGothic-Book>I?7glyph<c=13,font=/PIIBEG+FranklinGothic-Book>+79?<?9 C7HA;JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ;N9BK:?D= glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>?D7glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n-$/03glyph<c=28,font=/PIIBEG+FranklinGothic-Book>)glyph<c=12,font=/PIIBEG+FranklinGothic-Book> -$/03glyph<c=28,font=/PIIBEG+FranklinGothic-Book>) #4glyph<c=30,font=/PIIBEG+FranklinGothic-Book> 'glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> \"glyph<c=28,font=/PIIBEG+FranklinGothic-Book>541glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> *glyph<c=30,font=/PIIBEG+FranklinGothic-Book>- 10. 7D: '0).0($* 7H; :?IJH?8KJ;: 8O J>; -E9>; \"HEKF 7D: ?JI IK8B?9;DI;;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n2; :?IJH?8KJ; glyph<c=29,font=/PIIBEG+FranklinGothic-Book> ) +glyph<c=28,font=/PIIBEG+FranklinGothic-Book>'$glyph<c=12,font=/PIIBEG+FranklinGothic-Book> $(-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>'glyph<c=31,font=/PIIBEG+FranklinGothic-Book>$ 7D: !'$3glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$ ?D 9;HJ7?D 9EKDJH?;I ?D  KHEF; 7D: >7L; 7D EFJ?ED JE 79GK?H; ;N9BKI?L; H?=>JI JE :?IJH?8KJ; J>;I; FHE:K9JI ?D glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>?D7glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7I M;BB 7I glyph<c=29,font=/PIIBEG+FranklinGothic-Book>4**1$5 ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n*KH FHE:K9J I7B;I JE JME M>EB;I7B; :?IJH?8KJEHI ;79> 799EKDJ;: <EH CEH; J>7D glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=5,font=/PIIBEG+FranklinGothic-Book> E< EKH JEJ7B H;L;DK; <EH J>; O;7HI ;D:;: glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book> 7D: glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: ED 7 9EC8?D;: 87I?Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 799EKDJ;: <EH 7FFHEN?C7J;BO glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=5,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=5,font=/PIIBEG+FranklinGothic-Book> 7D: glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=5,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;IF;9J?L;BOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> E< EKH =HEII FHE:K9J H;L;DK;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> !EH 7::?J?ED7B ?D<EHC7J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FB;7I; H;7: \"=B3 glyph<c=15,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> &3D3<C3 glyph<c=12,font=/PIIBEG+FranklinGothic-Book> JE EKH 9EDIEB?:7J;: <?D7D9?7B IJ7J;C;DJI ?D9BK:;: ?D J>?I H;FEHJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## '3F7@FE 3@6 &F:7D 'DABD;7F3DK );9:FE\n\n+7J;DJI 7H; ?CFEHJ7DJ <EH E8J7?D?D= 7D: FHEJ;9J?D= ;N9BKI?L; H?=>JI ?D EKH FHE:K9JI 7D: FHE:K9J 97D:?:7J;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; H;=KB7HBO I;;A F7J;DJ FHEJ;9J?ED ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 7D: ?D I;B;9J;: 9EKDJH?;I EKJI?:; J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> <EH ?DL;DJ?EDI EH?=?D7J?D= <HEC EKH H;I;7H9> 7D: :;L;BEFC;DJ ;<<EHJI 7D: J>EI; M; B?9;DI; EH 79GK?H;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D 7::?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; B?9;DI; H?=>JI JE L7H?EKI F7J;DJI 7D: F7J;DJ 7FFB?97J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> F7J;DJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7I M;BB 7I CEIJ <EH;?=D F7J;DJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7H; =;D;H7BBO ;<<;9J?L; <EH glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> O;7HI <HEC J>; :7J; J>; ;7HB?;IJ 7FFB?97J?ED M7I <?B;:glyph<c=27,font=/PIIBEG+FranklinGothic-Book> >EM;L;Hglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> F7J;DJI ED 7FFB?97J?EDI <?B;: 8;<EH; %KD; glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> C7O 8; ;<<;9J?L; KDJ?B glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book> O;7HI <HEC J>; ?IIK; :7J;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?< J>7J ?I B7J;H J>7D J>; glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=13,font=/PIIBEG+FranklinGothic-Book>O;7H :7J;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D IEC; 97I;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; F7J;DJ J;HC C7O 8; ;NJ;D:;: JE H;97FJKH; 7 FEHJ?ED E< J>; J;HC BEIJ :KH?D= H;=KB7JEHO H;L?;M E< J>; 9B7?C;: J>;H7F;KJ?9 EHglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D J>; 97I; E< J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 8;97KI; E< 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> +7J;DJ 7D: /H7:;C7HA *<<?9; glyph<c=8,font=/PIIBEG+FranklinGothic-Book>0.+/*glyph<c=9,font=/PIIBEG+FranklinGothic-Book> :;B7OI ?D FHEI;9KJ?D= J>; 7FFB?97J?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book> .F;9?<?97BBOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> KD:;H J>; glyph<c=31,font=/PIIBEG+FranklinGothic-Book>HK= +H?9; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>ECF;J?J?ED 7D: +7J;DJ /;HC -;IJEH7J?ED glyph<c=28,font=/PIIBEG+FranklinGothic-Book>9J E< glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9ECCEDBO ADEMD 7I J>; #7J9>glyph<c=13,font=/PIIBEG+FranklinGothic-Book>27NC7D glyph<c=28,font=/PIIBEG+FranklinGothic-Book>9Jglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 F7J;DJ J>7J 9EL;HI 7 :HK= 7FFHEL;: 8O J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> C7O 8; ;B?=?8B; <EH F7J;DJ J;HC ;NJ;DI?ED glyph<c=8,font=/PIIBEG+FranklinGothic-Book><EH KF JE glyph<c=21,font=/PIIBEG+FranklinGothic-Book> O;7HIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 8KJ DEJ 8;OED: 7 JEJ7B E< glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book> O;7HI <HEC J>; :7J; E< FHE:K9J 7FFHEL7Bglyph<c=9,font=/PIIBEG+FranklinGothic-Book> 7I 9ECF;DI7J?ED <EH F7J;DJ J;HC BEIJ :KH?D= J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> H;=KB7JEHO H;L?;M FHE9;IIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; :KH7J?ED 7D: ;NJ;DI?ED E< J>; J;HC E< <EH;?=D F7J;DJI L7H?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D 799EH:7D9; M?J> BE97B B7Mglyph<c=14,font=/PIIBEG+FranklinGothic-Book> !EH ;N7CFB;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> IKFFB;C;DJ7HO FHEJ;9J?ED 9;HJ?<?97J;I glyph<c=8,font=/PIIBEG+FranklinGothic-Book>.+glyph<c=30,font=/PIIBEG+FranklinGothic-Book>Iglyph<c=9,font=/PIIBEG+FranklinGothic-Book> ED IEC; E< EKH FHE:K9JI >7L;",
        "metadata": {
            "page": 20
        },
        "id": "a3b26bd7-6fdc-4cf8-b17a-7d6dc6d21b98"
    },
    {
        "page_content": "8;;D =H7DJ;: ?D 7 DKC8;H E<  KHEF;7D 9EKDJH?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9ECF;DI7J?D= ?D F7HJ <EH :;B7OI ?D E8J7?D?D= C7HA;J?D= 7FFHEL7Bglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n-;=KB7JEHO ;N9BKI?L?JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> C7O 9EDI?IJ E< H;=KB7JEHO :7J7 FHEJ;9J?ED 7D: C7HA;J FHEJ;9J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7BIE 97D FHEL?:; C;7D?D=<KB FHEJ;9J?ED <EH EKH FHE:K9JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> -;=KB7JEHO :7J7 FHEJ;9J?ED FHEL?:;I JE J>; >EB:;H E< 7 :HK= EH 8?EBE=?9 C7HA;J?D= 7KJ>EH?P7J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> <EH 7 I;J F;H?E: E< J?C;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; ;N9BKI?L; KI; E< J>; FHEFH?;J7HO FH;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>9B?D?97B 7D: 9B?D?97B :7J7 J>7J ?J 9H;7J;: 7J I?=D?<?97DJ 9EIJ 7D: IK8C?JJ;: JE J>; 7FFB?978B; H;=KB7JEHO 7KJ>EH?JO JE E8J7?D 7FFHEL7B E< ?JI FHE:K9Jglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book><J;H J>; F;H?E: E< ;N9BKI?L; KI;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>?H: F7HJ?;I 7H; F;HC?JJ;: JE H;<;H;D9; IK9> :7J7 ?D 788H;L?7J;: 7FFB?97J?EDI <EH 7FFHEL7B 7D: JE C7HA;J glyph<c=8,font=/PIIBEG+FranklinGothic-Book>IK8@;9J JE 7DO 7FFB?978B; C7HA;J FHEJ;9J?EDglyph<c=9,font=/PIIBEG+FranklinGothic-Book> J>;?H =;D;H?9 :HK=I 7D: 8?EI?C?B7HIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> (7HA;J FHEJ;9J?ED FHEL?:;I J>; >EB:;H E< 7 :HK= EH 8?EBE=?9 C7HA;J?D= 7KJ>EH?P7J?ED J>; ;N9BKI?L; H?=>J JE 9ECC;H9?7B?P; ?JI FHE:K9J <EH 7 F;H?E: E< J?C;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>;H;8O FH;L;DJ?D= J>; 9ECC;H9?7B?P7J?ED E< 7DEJ>;H FHE:K9J 9EDJ7?D?D= J>; I7C; 79J?L; ?D=H;:?;DJglyph<c=8,font=/PIIBEG+FranklinGothic-Book>Iglyph<c=9,font=/PIIBEG+FranklinGothic-Book> :KH?D= J>7J F;H?E:glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BJ>EK=> J>; 2EHB: /H7:; *H=7D?P7J?EDglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I 7=H;;C;DJ ED JH7:;glyph<c=13,font=/PIIBEG+FranklinGothic-Book> H;B7J;: 7IF;9JI E< ?DJ;BB;9JK7B FHEF;HJO H?=>JI glyph<c=8,font=/PIIBEG+FranklinGothic-Book>/-$+.glyph<c=9,font=/PIIBEG+FranklinGothic-Book> H;GK?H;I I?=D7JEHO 9EKDJH?;I JE FHEL?:; H;=KB7JEHO ;N9BKI?L?JO JE ?DDEL7J?L; F>7HC79;KJ?97B FHE:K9JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?CFB;C;DJ7J?ED 7D: ;D<EH9;C;DJ L7H?;I M?:;BO <HEC 9EKDJHO JE 9EKDJHOglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n2; 7BIE H;BO KFED EJ>;H <EHCI E< KDF7J;DJ;: 9ED<?:;DJ?7B ?D<EHC7J?ED JE H;C7?D 9ECF;J?J?L;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; FHEJ;9J IK9> ?D<EHC7J?ED FH?D9?F7BBO J>HEK=> H;<H7?D?D= <HEC FK8B?9 :?I9BEIKH; 7D: 9ED<?:;DJ?7B?JO 7=H;;C;DJI M?J> EKH ;CFBEO;;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9EDIKBJ7DJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> EKJI?:; I9?;DJ?<?9 9EBB78EH7JEHIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> I9?;DJ?IJI M>EI; H;I;7H9> M; IFEDIEH 7D: EJ>;H 7:L?I;HIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D J>; 97I; E< EKH ;CFBEO;;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>;I; 7=H;;C;DJI 7BIE FHEL?:;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D 9ECFB?7D9; M?J> H;B;L7DJ B7Mglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>7J ?DL;DJ?EDI 7D: EJ>;H ?DJ;BB;9JK7B FHEF;HJO 9ED9;?L;: 8O IK9> ;CFBEO;;I :KH?D= J>;?H ;CFBEOC;DJ 7H; EKH ;N9BKI?L; FHEF;HJOglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n*KH JH7:;C7HAI 7H; ?CFEHJ7DJ JE KI 7D: 7H; =;D;H7BBO 9EL;H;: 8O JH7:;C7HA 7FFB?97J?EDI EH H;=?IJH7J?EDI ?D J>; 0.+/* 7D: J>; F7J;DJ EH JH7:;C7HA E<<?9;I E< EJ>;H 9EKDJH?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; 7BIE KI; JH7:;C7HAI B?9;DI;: <HEC J>?H: F7HJ?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> IK9> 7I J>; JH7:;C7HA !glyph<c=28,font=/PIIBEG+FranklinGothic-Book>(+4-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> M; B?9;DI; <HEC glyph<c=28,font=/PIIBEG+FranklinGothic-Book>9EH:7glyph<c=14,font=/PIIBEG+FranklinGothic-Book> /H7:;C7HA FHEJ;9J?ED L7H?;I ?D 799EH:7D9; M?J> BE97B B7Mglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: 9EDJ?DK;I ?D IEC; 9EKDJH?;I 7I BED= 7I J>; JH7:;C7HA ?I KI;: 7D: ?D EJ>;H 9EKDJH?;I 7I BED= 7I J>; JH7:;C7HA ?I H;=?IJ;H;:glyph<c=14,font=/PIIBEG+FranklinGothic-Book> /H7:;C7HA H;=?IJH7J?EDI =;D;H7BBO 7H; <EH <?N;: 8KJ H;D;M78B; J;HCIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## #C@ $/B3<B $=@B4=:7=\n\n/>; <EBBEM?D= J78B; :;I9H?8;I 9;HJ7?D F7J;DJI ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 7D:  KHEF; J>7J M; 9KHH;DJBO 9EDI?:;H E< FH?C7HO ?CFEHJ7D9; JE EKH C7HA;J;: FHE:K9JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= J>; J;HH?JEHOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> F7J;DJ DKC8;Hglyph<c=12,font=/PIIBEG+FranklinGothic-Book> =;D;H7B IK8@;9J C7JJ;H 7D: ;NF;9J;: ;NF?H7J?ED :7J;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>  N9;FJ 7I EJ>;HM?I; DEJ;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; ;NF;9J;: ;NF?H7J?ED :7J;I\n\n?D9BK:; 7DO =H7DJ;: F7J;DJ J;HC ;NJ;DI?EDI 7D: ?IIK;: .+glyph<c=30,font=/PIIBEG+FranklinGothic-Book>Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D IEC; ?DIJ7D9;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>;H; 7H; 7::?J?ED7B B7J;Hglyph<c=13,font=/PIIBEG+FranklinGothic-Book>;NF?H?D= F7J;DJI H;B7J?D= JE EKH FHE:K9JI :?H;9J;: JEglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7CED= EJ>;H J>?D=Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> F7HJ?9KB7H <EHCI EH 9ECFEI?J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> C;J>E:I E< C7DK<79JKH?D= EH KI; E< J>; :HK= ?D J>; JH;7JC;DJ E< F7HJ?9KB7H :?I;7I;I EH 9ED:?J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; 7BIE 9EDJ?DK; JE FKHIK; 7::?J?ED7B F7J;DJI 7D: F7J;DJ J;HC ;NJ;DI?EDI ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 7D: EJ>;H J;HH?JEH?;I 9EL;H?D= L7H?EKI 7IF;9JI E< EKH FHE:K9JI J>7J C7Oglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?< ?IIK;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ;NJ;D: ;N9BKI?L?JO 8;OED: J>; ;NF?H7J?ED E< J>; F7J;DJI B?IJ;: ?D J>; J78B;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>",
        "metadata": {
            "page": 21
        },
        "id": "3976a6c5-dfcd-452b-8a37-a29612f0bb5b"
    },
    {
        "page_content": "IFB?9?D=\n\n| 'DA6G5F                                                                                                                                    | +7DD;FADK                                                                                                                                                                             | '3F7@F %Aglyph<c=11,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | glyph<c=30,font=/PIIBCD+FranklinGothic-Book>7@7D3> *G4<75F $3FF7D                                                                                                                                                                                                                                      | glyph<c=28,font=/PIIBCD+FranklinGothic-Book>JB;D3F;A@ glyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=7,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                          |\n|--------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| / glyph<c=30,font=/PIIBEG+FranklinGothic-Book>!$glyph<c=31,font=/PIIBEG+FranklinGothic-Book> -glyph<c=28,font=/PIIBEG+FranklinGothic-Book> | KHEF;                                                                                                                                                                                 | glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | !EHCKB7J?EDI E< :?7BAOB <KC7H7J;I 7D: J>;?H KI; <EH JH;7J?D= 7KJE?CCKD; :?I;7I;I                                                                                                                                                                                                                       | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book>                                               |\n|                                                                                                                                            | KHEF;                                                                                                                                                                                 | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | (;J>E:I E< KI;                                                                                                                                                                                                                                                                                         | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                  |\n| +' \"-$glyph<c=31,font=/PIIBEG+FranklinGothic-Book>4                                                                                        | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                                                                            | glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | (;J>E:I E< JH;7JC;DJ                                                                                                                                                                                                                                                                                   | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                  |\n|                                                                                                                                            | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                                                                            | glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | +EBOC;H 9ED@K=7J;I E< ?DJ;H<;HED 8;J7glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>7                                                                                                                                                                         | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                  |\n|                                                                                                                                            | KHEF;                                                                                                                                                                                 | glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | +EBOC;H 9ED@K=7J;I E< ?DJ;H<;HEDglyph<c=13,font=/PIIBEG+FranklinGothic-Book>8;J7glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>7 7D: KI;I J>;H;E<                                                                                                             | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book>                                               |\n|                                                                                                                                            | KHEF;                                                                                                                                                                                 | glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | +EBOC;H 9ED@K=7J;I E< ?DJ;H<;HEDglyph<c=13,font=/PIIBEG+FranklinGothic-Book>8;J7glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>7 7D: KI;I J>;H;E<                                                                                                             | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book>                                               |\n| /4.glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=29,font=/PIIBEG+FranklinGothic-Book>-$                                              | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                                                                            | glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | (;J>E:I E< JH;7JC;DJ                                                                                                                                                                                                                                                                                   | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                  |\n|                                                                                                                                            | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                                                                            | glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | !EHCKB7J?ED                                                                                                                                                                                                                                                                                            | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                  |\n|                                                                                                                                            | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                                                                            | glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | !EHCKB7J?ED                                                                                                                                                                                                                                                                                            | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                  |\n|                                                                                                                                            | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                                                                            | glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | (;J>E:I E< JH;7JC;DJ                                                                                                                                                                                                                                                                                   | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                  |\n|                                                                                                                                            | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                                                                            | glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | !EHCKB7J?ED                                                                                                                                                                                                                                                                                            | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                  |\n|                                                                                                                                            | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                                                                            | glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | .7<;JOglyph<c=13,font=/PIIBEG+FranklinGothic-Book>H;B7J;: 7II7O                                                                                                                                                                                                                                        | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                  |\n|                                                                                                                                            | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                                                                            | glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | (;J>E:I E< JH;7JC;DJ                                                                                                                                                                                                                                                                                   | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                  |\n|                                                                                                                                            | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                                                                            | glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | (;J>E:I E< JH;7JC;DJ                                                                                                                                                                                                                                                                                   | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                  |\n|                                                                                                                                            | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                                                                            | glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                          | (;J>E:I E< ;L7BK7J?D= F7J?;DJ H?IA                                                                                                                                                                                                                                                                     | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                  |\n|                                                                                                                                            | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                                                                            | glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                          | (;J>E:I E< JH;7JC;DJ                                                                                                                                                                                                                                                                                   | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                  |\n|                                                                                                                                            | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                                                                            | glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                          | .7<;JOglyph<c=13,font=/PIIBEG+FranklinGothic-Book>H;B7J;: 7II7O                                                                                                                                                                                                                                        | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                  |\n|                                                                                                                                            | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                                                                            | glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                          | (;J>E:I E< JH;7JC;DJ                                                                                                                                                                                                                                                                                   | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                  |\n|                                                                                                                                            | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                                                                            | glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                          | (;J>E:I E< JH;7JC;DJ                                                                                                                                                                                                                                                                                   | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                  |\n|                                                                                                                                            | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> | glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book> glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book> | (;J>E:I E< JH;7JC;DJ .7<;JOglyph<c=13,font=/PIIBEG+FranklinGothic-Book>H;B7J;: 7II7O                                                                                                                                                                                                                   | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book> |\n|                                                                                                                                            | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                                                                            | glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                          | (;J>E:I E< JH;7JC;DJ                                                                                                                                                                                                                                                                                   | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                  |\n|                                                                                                                                            | KHEF;                                                                                                                                                                                 | glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | (;J>E:I E< KI;                                                                                                                                                                                                                                                                                         | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book>                                               |\n|                                                                                                                                            | KHEF;                                                                                                                                                                                 | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | !EHCKB7J?ED                                                                                                                                                                                                                                                                                            | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                  |\n|                                                                                                                                            | KHEF;                                                                                                                                                                                 | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | !EHCKB7J?ED                                                                                                                                                                                                                                                                                            | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                  |\n|                                                                                                                                            | KHEF;                                                                                                                                                                                 | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | (;J>E:I E< KI;                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                   |\n|                                                                                                                                            | KHEF;                                                                                                                                                                                 | glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | .7<;JOglyph<c=13,font=/PIIBEG+FranklinGothic-Book>H;B7J;: 7II7O                                                                                                                                                                                                                                        | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book> |\n|                                                                                                                                            | KHEF;                                                                                                                                                                                 | glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | !EHCKB7J?ED                                                                                                                                                                                                                                                                                            | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                  |\n|                                                                                                                                            | KHEF;                                                                                                                                                                                 | glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>                                                                                         | .7<;JOglyph<c=13,font=/PIIBEG+FranklinGothic-Book>H;B7J;: 7II7O .KIJ7?D;:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>H;B;7I; 7C?DEFOH?:?D; 9ECFEI?J?EDI<EH                                                                                                                                             | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                  |\n| !glyph<c=28,font=/PIIBEG+FranklinGothic-Book>(+4-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>                                              | KHEF;                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | ?D9H;7I?D= M7BA?D= IF;;: ?D F7J?;DJI M?J> (.                                                                                                                                                                                                                                                           | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book>                                               |\n|                                                                                                                                            | KHEF; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                                                                      | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | .KIJ7?D;:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>H;B;7I; 7C?DEFOH?:?D; 9ECFEI?J?EDI <EH JH;7J?D= (.                                                                                                                                                                                                | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book>                                               |\n| 10( -$/4                                                                                                                                   |                                                                                                                                                                                       | glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | glyph<c=30,font=/PIIBEG+FranklinGothic-Book>ECFEKD:I 7D: F>7HC79;KJ?97B 9ECFEI?J?EDI                                                                                                                                                                                                                   | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                  |\n|                                                                                                                                            | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                                                                            | glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | (;J>E:I E< JH;7JC;DJ                                                                                                                                                                                                                                                                                   | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                  |\n|                                                                                                                                            | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>  KHEF;                                                                                     | glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>                                             | glyph<c=30,font=/PIIBEG+FranklinGothic-Book>HOIJ7BB?D; <EHCIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> F>7HC79;KJ?97B 9ECFEI?J?EDI 7D: C;J>E:I E< JH;7JC;DJ glyph<c=30,font=/PIIBEG+FranklinGothic-Book>HOIJ7BB?D; <EHCIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> F>7HC79;KJ?97B 9ECFEI?J?EDI 7D: | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book> |\n| .+$)-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>5glyph<c=28,font=/PIIBEG+FranklinGothic-Book>                                             | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                                                                            | glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | *B?=EDK9B;EJ?:;I 9EDJ7?D?D= glyph<c=18,font=/PIIBEG+FranklinGothic-Book>^glyph<c=13,font=/PIIBEG+FranklinGothic-Book>*glyph<c=13,font=/PIIBEG+FranklinGothic-Book>CE:?<?;: FKH?D;I                                                                                                                     | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                  |\n|                                                                                                                                            | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                                                                            | glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | .(glyph<c=28,font=/PIIBEG+FranklinGothic-Book> JH;7JC;DJ L?7 J7H=;J?D= E< .()glyph<c=18,font=/PIIBEG+FranklinGothic-Book> IFB?9; I?J; ?D>?8?JEHO I;GK;D9;I                                                                                                                                             | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                  |\n|                                                                                                                                            | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                                                                            | glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | .(glyph<c=28,font=/PIIBEG+FranklinGothic-Book> JH;7JC;DJ L?7 J7H=;J?D= E< .()glyph<c=18,font=/PIIBEG+FranklinGothic-Book> IFB?9; I?J; ?D>?8?JEHO I;GK;D9;I                                                                                                                                             | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                  |\n|                                                                                                                                            | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                                                                            | glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | glyph<c=30,font=/PIIBEG+FranklinGothic-Book>ECFEI?J?EDI 7D: C;J>E:I <EH CE:KB7J?ED E< .()glyph<c=18,font=/PIIBEG+FranklinGothic-Book> IFB?9?D=                                                                                                                                                         | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                  |\n|                                                                                                                                            | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                                                                            | glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | glyph<c=30,font=/PIIBEG+FranklinGothic-Book>ECFEI?J?EDI 7D: C;J>E:I <EH CE:KB7J?ED E< .()glyph<c=18,font=/PIIBEG+FranklinGothic-Book> IFB?9?D=                                                                                                                                                         | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                  |\n|                                                                                                                                            | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                                                                            | glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | glyph<c=30,font=/PIIBEG+FranklinGothic-Book>ECFEI?J?EDI 7D: C;J>E:I <EH CE:KB7J?ED E< .()glyph<c=18,font=/PIIBEG+FranklinGothic-Book> IFB?9?D=                                                                                                                                                         | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                  |\n|                                                                                                                                            | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                                                                            | glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | glyph<c=30,font=/PIIBEG+FranklinGothic-Book>ECFEI?J?EDI 7D: C;J>E:I <EH CE:KB7J?ED E< .()glyph<c=18,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                  | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                  |\n\n'3F7@F",
        "metadata": {
            "page": 22
        },
        "id": "d91075ab-23d9-49c7-8774-0fe15e77626d"
    },
    {
        "page_content": "|                                                                                               | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>   | glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>   | .(glyph<c=28,font=/PIIBEG+FranklinGothic-Book> JH;7JC;DJ L?7 J7H=;J?D= E< .()glyph<c=18,font=/PIIBEG+FranklinGothic-Book> IFB?9; I?J; ?D>?8?JEHO I;GK;D9;I   | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                  |\n|-----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n|                                                                                               | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>   | glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>   | (;J>E:I <EH /H;7J?D= .F?D7B (KI9KB7H glyph<c=28,font=/PIIBEG+FranklinGothic-Book>JHEF>O                                                                      | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                  |\n|                                                                                               | KHEF;                                                                                        | glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>                                               | glyph<c=30,font=/PIIBEG+FranklinGothic-Book>ECFEI?J?EDI 7D: C;J>E:I <EH CE:KB7J?ED E< .()glyph<c=18,font=/PIIBEG+FranklinGothic-Book> IFB?9?D=               | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                               |\n|                                                                                               | KHEF;                                                                                        | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>                                               | glyph<c=30,font=/PIIBEG+FranklinGothic-Book>ECFEI?J?EDI 7D: C;J>E:I <EH CE:KB7J?ED E< .()glyph<c=18,font=/PIIBEG+FranklinGothic-Book> IFB?9?D=               | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                               |\n|                                                                                               | KHEF;                                                                                        | glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>                                               | glyph<c=30,font=/PIIBEG+FranklinGothic-Book>ECFEI?J?EDI 7D: C;J>E:I <EH CE:KB7J?ED E< .()glyph<c=18,font=/PIIBEG+FranklinGothic-Book> IFB?9?D=               | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                  |\n|                                                                                               | KHEF;                                                                                        | glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>                                               | glyph<c=30,font=/PIIBEG+FranklinGothic-Book>ECFEI?J?EDI 7D: C;J>E:I <EH CE:KB7J?ED E< .()glyph<c=18,font=/PIIBEG+FranklinGothic-Book> IFB?9?D=               | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                  |\n|                                                                                               | KHEF;                                                                                        | glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>                                               | glyph<c=30,font=/PIIBEG+FranklinGothic-Book>ECFEI?J?EDI 7D: C;J>E:I <EH CE:KB7J?ED E< .()glyph<c=18,font=/PIIBEG+FranklinGothic-Book> IFB?9?D=               | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                  |\n| glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>0# '( | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>   | glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>                                               | (;J>E: E< FHEL?:?D= :?I;7I;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>IF;9?<?9 8?D:?D= CEB;9KB;I 7D: J7H=;JI                                                | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                   |\n|                                                                                               | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>   | glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>   | (;J>E:I E< JH;7J?D= glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BP>;?C;Hglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I :?I;7I;                                 | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                  |\n| ' , (glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$                                            | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>   | glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>                                               | +HEJE<?8H?B I;B;9J?L; 7DJ?8E:?;I 7D: J>; KI; J>;H;E<                                                                                                         | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book> |\n\n!EEJDEJ;I <EBBEM ED D;NJ F7=;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>",
        "metadata": {
            "page": 23
        },
        "id": "1655cff6-32f2-4320-b5a3-fb4eb39a9d94"
    },
    {
        "page_content": "| 'DA6G5F                                                                                                                                    | +7DD;FADK                                                                                  | glyph<c=28,font=/PIIBCD+FranklinGothic-Book>JB75F76 glyph<c=28,font=/PIIBCD+FranklinGothic-Book>JB;D3F;A@                                                                        |\n|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| / glyph<c=30,font=/PIIBEG+FranklinGothic-Book>!$glyph<c=31,font=/PIIBEG+FranklinGothic-Book> -glyph<c=28,font=/PIIBEG+FranklinGothic-Book> | glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>  | .K8@;9J JE 7FF;7B                                                                                                                                                                |\n| +' \"-$glyph<c=31,font=/PIIBEG+FranklinGothic-Book>4                                                                                        | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book> |\n|                                                                                                                                            | glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>  | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book> |\n| .+$)-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>5glyph<c=28,font=/PIIBEG+FranklinGothic-Book>                                             | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book> |\n|                                                                                                                                            | glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>  | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book> |\n| glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>0# '(                                              | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book> |\n| ' , (glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$                                                                                         | 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book> |\n\n/>; ;N?IJ;D9; E< F7J;DJI :E;I DEJ =K7H7DJ;; EKH H?=>J JE FH79J?9; J>; F7J;DJ;: J;9>DEBE=O EH 9ECC;H9?7B?P; J>; F7J;DJ;: FHE:K9Jglyph<c=14,font=/PIIBEG+FranklinGothic-Book> +7J;DJI H;B7J?D= JE F>7HC79;KJ?97Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 8?EF>7HC79;KJ?97B 7D: 8?EJ;9>DEBE=O FHE:K9JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9ECFEKD:I 7D: FHE9;II;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> IK9> 7I J>EI; J>7J 9EL;H EKH ;N?IJ?D= FHE:K9JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9ECFEKD:I 7D: FHE9;II;I 7D: J>EI; J>7J M; M?BB B?A;BO <?B; ?D J>; <KJKH;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> :E DEJ 7BM7OI FHEL?:; 9ECFB;J; EH 7:;GK7J; FHEJ;9J?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book> '?J?=7J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?DJ;H<;H;D9;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> EFFEI?J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7<B3@ >/@B3A H;L?;MIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7:C?D?IJH7J?L; 9>7BB;D=;I EH EJ>;H I?C?B7H JOF;I E< FHE9;;:?D=I 7H;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> >7L; 8;;D 7D: C7O ?D J>; <KJKH; 8; D;9;II7HO ?D IEC; ?DIJ7D9;I JE :;J;HC?D; J>; L7B?:?JO 7D: I9EF; E< 9;HJ7?D E< EKH F7J;DJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;=KB7JEHO ;N9BKI?L?J?;I EH EJ>;H FHEFH?;J7HO H?=>JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: ?D EJ>;H ?DIJ7D9;I JE :;J;HC?D; J>; L7B?:?JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> I9EF; EH DEDglyph<c=13,font=/PIIBEG+FranklinGothic-Book>?D<H?D=;C;DJ E< 9;HJ7?D F7J;DJ H?=>JI 9B7?C;: 8O J>?H: F7HJ?;I JE 8; F;HJ?D;DJ JE J>; C7DK<79JKH;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> KI; EH I7B; E< EKH FHE:K9JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; 7BIE <79; 9>7BB;D=;I JE EKH F7J;DJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;=KB7JEHO ;N9BKI?L?J?;I EH EJ>;H FHEFH?;J7HO H?=>JI 9EL;H?D= EKH FHE:K9JI 8O J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book> F7HJ?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> IK9> 7I C7DK<79JKH;HI E< =;D;H?9Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 8?EI?C?B7HIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FHE:HK=I 7D: FHE:K9JI 7FFHEL;: KD:;H 788H;L?7J;: H;=KB7JEHO F7J>M7OIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book> :?I9KII?ED E< 9;HJ7?D H?IAI 7D: KD9;HJ7?DJ?;I J>7J C7O 7<<;9J EKH F7J;DJ FEI?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;=KB7JEHO ;N9BKI?L?J?;I EH EJ>;H FHEFH?;J7HO H?=>JI ?I I;J <EHJ> ?D glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>B3; glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal> &7A9 glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>/1B=@A ?D9BK:;: ?D J>?I H;FEHJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: J>; :?I9KII?ED E< B;=7B FHE9;;:?D=I H;B7J;: JE 9;HJ7?D F7J;DJI :;I9H?8;: 78EL; ?I I;J <EHJ> ?D \"=B3 glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> 7B75/B7=<glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> JE EKH 9EDIEB?:7J;: <?D7D9?7B IJ7J;C;DJI ?D9BK:;: ?D J>?I H;FEHJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>",
        "metadata": {
            "page": 24
        },
        "id": "824c967f-1ae7-43d6-960b-8dbab6b570ee"
    },
    {
        "page_content": "## glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A?B7F;F;A@\n\nglyph<c=30,font=/PIIBEG+FranklinGothic-Book>ECF;J?J?ED ?D J>; 8?EF>7HC79;KJ?97B ?D:KIJHO 7D: J>; C7HA;JI ?D M>?9> M; EF;H7J; ?I ?DJ;DI;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />;H; 7H; C7DO 9ECF7D?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= 8?EJ;9>DEBE=O 7D: F>7HC79;KJ?97B 9ECF7D?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ;D=7=;: ?D :;L;BEF?D= FHE:K9JI <EH J>; ?D:?97J?EDI EKH 7FFHEL;: FHE:K9JI 7H; 7FFHEL;: JE JH;7J 7D: J>; J>;H7F;KJ?9 7H;7I M; 7H; J7H=;J?D= M?J> EKH H;I;7H9> 7D: :;L;BEFC;DJ 79J?L?J?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> .EC; E< EKH 9ECF;J?JEHI C7O >7L; IK8IJ7DJ?7BBO =H;7J;H <?D7D9?7Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> C7HA;J?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;I;7H9> 7D: :;L;BEFC;DJ 7D: EJ>;H H;IEKH9;I J>7D M; :Eglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n2; 8;B?;L; J>7J 9ECF;J?J?ED 7D: B;7:;HI>?F ?D J>; ?D:KIJHO ?I 87I;: ED C7D7=;H?7B 7D: J;9>DEBE=?97B ;N9;BB;D9; 7D: ?DDEL7J?ED 7I M;BB 7I ;IJ78B?I>?D= F7J;DJ 7D: EJ>;H FHEFH?;J7HO FEI?J?EDI J>HEK=> H;I;7H9> 7D: :;L;BEFC;DJglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; 79>?;L;C;DJ E< 7 B;7:;HI>?F FEI?J?ED 7BIE :;F;D:I B7H=;BO KFED EKH 78?B?JO JE C7N?C?P; J>; 7FFHEL7Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 799;FJ7D9; 7D: KI; E< EKH FHE:K9J 97D:?:7J;I 7D: J>; 7L7?B78?B?JO E< 7:;GK7J; <?D7D9?7B H;IEKH9;I JE <KD: <79?B?J?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ;GK?FC;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> F;HIEDD;Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9B?D?97B J;IJ?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> C7DK<79JKH?D= 7D: C7HA;J?D=glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>DEJ>;H A;O 7IF;9J E< H;C7?D?D= 9ECF;J?J?L; ?D J>; ?D:KIJHO ?I H;9HK?J?D= 7D: H;J7?D?D= B;7:?D= I9?;DJ?IJI 7D: J;9>D?9?7DI JE 9ED:K9J EKH H;I;7H9> 79J?L?J?;I 7D: 7:L7D9; EKH :;L;BEFC;DJ FHE=H7CIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= M?J> J>; 9ECC;H9?7B ;NF;HJ?I; JE ;<<;9J?L;BO C7HA;J EKH FHE:K9JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=30,font=/PIIBEG+FranklinGothic-Book>ECF;J?J?ED 7CED= FHE:K9JI 7FFHEL;: <EH I7B; C7O 8; 87I;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7CED= EJ>;H J>?D=Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ED F7J;DJ FEI?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FHE:K9J ;<<?979Oglyph<c=12,font=/PIIBEG+FranklinGothic-Book> I7<;JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> F7J?;DJ 9EDL;D?;D9;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> :;B?L;HO :;L?9;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;B?78?B?JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7L7?B78?B?JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;?C8KHI;C;DJ 7D: FH?9;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D 7::?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ;7HBO ;DJHO E< 7 D;M F>7HC79;KJ?97B FHE:K9J ?DJE J>; C7HA;J C7O >7L; ?CFEHJ7DJ 7:L7DJ7=;I ?D =7?D?D= FHE:K9J 799;FJ7D9; 7D: C7HA;J I>7H;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>99EH:?D=BOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; H;B7J?L; IF;;: M?J> M>?9> M; 97D :;L;BEF FHE:K9JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9ECFB;J; J>; J;IJ?D= 7D: 7FFHEL7B FHE9;II 7D: IKFFBO 9ECC;H9?7B GK7DJ?J?;I E< FHE:K9JI M?BB >7L; 7 I?=D?<?97DJ ?CF79J ED EKH 9ECF;J?J?L; FEI?J?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n/>; ?DJHE:K9J?ED E< D;M FHE:K9JI EH J;9>DEBE=?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= J>; :;L;BEFC;DJ E< D;M FHE9;II;I EH J;9>DEBE=?;I 8O 9ECF;J?JEHI EH D;M ?D<EHC7J?ED 78EKJ ;N?IJ?D= FHE:K9JI EH J;9>DEBE=?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;IKBJI ?D ?D9H;7I;: 9ECF;J?J?ED <EH EKH C7HA;J;: FHE:K9JI 7D: FH?9?D= FH;IIKH; ED EKH C7HA;J;: FHE:K9JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; :;L;BEFC;DJ E< D;M EH ?CFHEL;: JH;7JC;DJ EFJ?EDI EH IJ7D:7H:I E< 97H; EH 9KH;I <EH J>; :?I;7I;I EKH FHE:K9JI JH;7J H;:K9;I 7D: 9EKB: ;B?C?D7J; J>; KI; E< EKH FHE:K9JI EH C7O B?C?J J>; KJ?B?JO 7D: 7FFB?97J?ED E< ED=E?D= 9B?D?97B JH?7BI <EH EKH FHE:K9J 97D:?:7J;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n$D 7::?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; 9ECC;H9?7B?P7J?ED E< 9;HJ7?D E< EKH EMD 7FFHEL;: FHE:K9JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FHE:K9JI E< EKH 9EBB78EH7JEHI 7D: F?F;B?D; FHE:K9J 97D:?:7J;I C7O D;=7J?L;BO ?CF79J <KJKH; I7B;I E< EKH ;N?IJ?D= FHE:K9JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n*KH FHE:K9JI 7D: H;L;DK; IJH;7CI 9EDJ?DK; JE <79; ?D9H;7I?D= 9ECF;J?J?ED ?D C7DO C7HA;JI <HEC J>; ?DJHE:K9J?ED E< =;D;H?9 L;HI?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FHE:HK=I 7D: 8?EI?C?B7HI E< ;N?IJ?D= FHE:K9JI 7D: FHE:K9JI 7FFHEL;: KD:;H 788H;L?7J;: H;=KB7JEHO F7J>M7OIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> .K9> FHE:K9JI 7H; B?A;BO JE 8; IEB: 7J IK8IJ7DJ?7BBO BEM;H FH?9;I J>7D 8H7D:;: FHE:K9JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>99EH:?D=BOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; ?DJHE:K9J?ED E< IK9> FHE:K9JI 7I M;BB 7I EJ>;H BEM;Hglyph<c=13,font=/PIIBEG+FranklinGothic-Book> FH?9;: 9ECF;J?D= FHE:K9JI C7O I?=D?<?97DJBO H;:K9; 8EJ> J>; FH?9; J>7J M; 7H; 78B; JE 9>7H=; <EH EKH FHE:K9JI 7D: J>; LEBKC; E< FHE:K9JI M; I;BBglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> M?BB D;=7J?L;BO ?CF79J EKH H;L;DK;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D 7::?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D IEC; C7HA;JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>;D 7 =;D;H?9 EH 8?EI?C?B7H L;HI?ED E< ED; E< EKH FHE:K9JI ?I 9ECC;H9?7B?P;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?J C7O 8; 7KJEC7J?97BBO IK8IJ?JKJ;: <EH EKH FHE:K9J 7D: I?=D?<?97DJBO H;:K9; EKH H;L;DK; ?D 7 I>EHJ F;H?E: E< J?C;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n2; 8;B?;L; EKH BED=glyph<c=13,font=/PIIBEG+FranklinGothic-Book>J;HC 9ECF;J?J?L; FEI?J?ED :;F;D:I KFED EKH IK99;II ?D :?I9EL;H?D= 7D: :;L;BEF?D= ?DDEL7J?L;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9EIJglyph<c=13,font=/PIIBEG+FranklinGothic-Book>;<<;9J?L; FHE:K9JI J>7J I;HL; KDC;J C;:?97B D;;:Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7BED= M?J> EKH 78?B?JO JE C7DK<79JKH; FHE:K9JI ;<<?9?;DJBO 7D: JE B7KD9> 7D: C7HA;J J>;C ;<<;9J?L;BO ?D 7 >?=>BO 9ECF;J?J?L; ;DL?HEDC;DJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=28,font=/PIIBEG+FranklinGothic-Book>::?J?ED7B ?D<EHC7J?ED 78EKJ J>; 9ECF;J?J?ED J>7J EKH C7HA;J;: FHE:K9JI <79; ?I I;J <EHJ> 8;BEM 7D: ?D glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>B3; glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal> &7A9 glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>/1B=@A ?D9BK:;: ?D J>?I H;FEHJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## !C:B7>:3 '1:3@=A7A\n\n/ glyph<c=30,font=/PIIBEG+FranklinGothic-Book>!$glyph<c=31,font=/PIIBEG+FranklinGothic-Book> -glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>1*) 3glyph<c=12,font=/PIIBEG+FranklinGothic-Book> +' \"-$glyph<c=31,font=/PIIBEG+FranklinGothic-Book>4glyph<c=12,font=/PIIBEG+FranklinGothic-Book> /4.glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=29,font=/PIIBEG+FranklinGothic-Book>-$ 7D: 10( -$/4 ;79> 9ECF;J; M?J> ED; EH CEH; E< J>; <EBBEM?D= 8H7D:;: FHE:K9JI 7I M;BB 7I =;D;H?9 7D: 8?EI?C?B7H L;HI?EDI E< J>;I; FHE:K9JIglyph<c=26,font=/PIIBEG+FranklinGothic-Book>\n\n| glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A?B7F;@9 'DA6G5F                                                                                                                                                                                                                                                                                                                                                                                                                         | glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A?B7F;FAD                                                                                      |\n|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=28,font=/PIIBEG+FranklinGothic-Book>0glyph<c=29,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>\"$* glyph<c=8,font=/PIIBEG+FranklinGothic-Book>J;H?<BKDEC?:;glyph<c=9,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                         | .7DE<? \";DPOC;                                                                                                                             |\n| glyph<c=29,font=/PIIBEG+FranklinGothic-Book> /glyph<c=28,font=/PIIBEG+FranklinGothic-Book>. -*)glyph<c=15,font=/PIIBEG+FranklinGothic-Book>glyph<c=29,font=/PIIBEG+FranklinGothic-Book> /glyph<c=28,font=/PIIBEG+FranklinGothic-Book>! -*) glyph<c=8,font=/PIIBEG+FranklinGothic-Book>?DJ;H<;HEDglyph<c=13,font=/PIIBEG+FranklinGothic-Book>8;J7glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>8glyph<c=9,font=/PIIBEG+FranklinGothic-Book> | glyph<c=29,font=/PIIBEG+FranklinGothic-Book>7O;H \"HEKF                                                                                     |\n| glyph<c=29,font=/PIIBEG+FranklinGothic-Book>-$0(1$ glyph<c=8,font=/PIIBEG+FranklinGothic-Book>K8B?JKN?C78glyph<c=13,font=/PIIBEG+FranklinGothic-Book>N??Oglyph<c=9,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                 | /\" />;H7F;KJ?9Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> $D9glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                |\n| glyph<c=30,font=/PIIBEG+FranklinGothic-Book>*+glyph<c=28,font=/PIIBEG+FranklinGothic-Book>3*)  glyph<c=8,font=/PIIBEG+FranklinGothic-Book>=B7J?H7C;H 79;J7J;glyph<c=9,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                              | /;L7 +>7HC79;KJ?97BI $D:KIJH?;I 'J:glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                                            |\n| 3/glyph<c=28,font=/PIIBEG+FranklinGothic-Book>1$glyph<c=28,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book>?DJ;H<;HEDglyph<c=13,font=/PIIBEG+FranklinGothic-Book>8;J7glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>8glyph<c=9,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                               | )EL7HJ?I glyph<c=28,font=/PIIBEG+FranklinGothic-Book>\"                                                                                     |\n| \"$' )4glyph<c=28,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book><?D=EB?CE:glyph<c=9,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                  | )EL7HJ?I glyph<c=28,font=/PIIBEG+FranklinGothic-Book>\"                                                                                     |\n| \"'glyph<c=28,font=/PIIBEG+FranklinGothic-Book>/*+glyph<c=28,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book>=B7J?H7C;H 79;J7J;glyph<c=9,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                               | .7D:EPglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 :?L?I?ED E< )EL7HJ?I glyph<c=28,font=/PIIBEG+FranklinGothic-Book>\"                    |\n| ' (/-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book>7B;CJKPKC78glyph<c=9,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                          | .7DE<? \";DPOC;                                                                                                                             |\n| (glyph<c=28,font=/PIIBEG+FranklinGothic-Book>1 )glyph<c=30,font=/PIIBEG+FranklinGothic-Book>'glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book>9B7:H?8?D;glyph<c=9,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                               | (glyph<c=31,font=/PIIBEG+FranklinGothic-Book> .;HEDE                                                                                       |\n| (glyph<c=28,font=/PIIBEG+FranklinGothic-Book>45 )/ glyph<c=8,font=/PIIBEG+FranklinGothic-Book>I?FED?CE:glyph<c=9,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                   | )EL7HJ?I glyph<c=28,font=/PIIBEG+FranklinGothic-Book>\"                                                                                     |\n| *glyph<c=30,font=/PIIBEG+FranklinGothic-Book>- 10. glyph<c=8,font=/PIIBEG+FranklinGothic-Book>E9H;B?PKC78glyph<c=9,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                 | \";D;DJ;9>                                                                                                                                  |\n| +*)1*-4 glyph<c=8,font=/PIIBEG+FranklinGothic-Book>FED;I?CE:glyph<c=9,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                              | %7DII;D +>7HC79;KJ?97B glyph<c=30,font=/PIIBEG+FranklinGothic-Book>ECF7D?;I E< %E>DIED glyph<c=6,font=/PIIBEG+FranklinGothic-Book> %E>DIED |\n| - glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$! glyph<c=8,font=/PIIBEG+FranklinGothic-Book>?DJ;H<;HEDglyph<c=13,font=/PIIBEG+FranklinGothic-Book>8;J7glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                            | (glyph<c=31,font=/PIIBEG+FranklinGothic-Book> .;HEDE                                                                                       |\n| 5 +*.$glyph<c=28,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book>EP7D?CE:glyph<c=9,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                    | glyph<c=29,font=/PIIBEG+FranklinGothic-Book>(.                                                                                             |\n| glyph<c=29,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>!$ -/glyph<c=28,font=/PIIBEG+FranklinGothic-Book>( glyph<c=8,font=/PIIBEG+FranklinGothic-Book>CEDEC;J>OB <KC7H7J;glyph<c=9,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                 | glyph<c=29,font=/PIIBEG+FranklinGothic-Book>7DD;H '?<; .9?;D9;I                                                                            |\n| & .$(+/glyph<c=28,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book>E<7JKCKC78glyph<c=9,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                 | )EL7HJ?I glyph<c=28,font=/PIIBEG+FranklinGothic-Book>\"                                                                                     |\n\n(KBJ?FB; / glyph<c=30,font=/PIIBEG+FranklinGothic-Book>!$glyph<c=31,font=/PIIBEG+FranklinGothic-Book> -glyph<c=28,font=/PIIBEG+FranklinGothic-Book> =;D;H?9 ;DJH7DJI 7H; DEM ?D )EHJ> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>C;H?97glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>H7P?B 7D: 9;HJ7?D  glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 9EKDJH?;I 7D: >7L; :;;FBO :?I9EKDJ;: FH?9;I 9ECF7H;: JE",
        "metadata": {
            "page": 25
        },
        "id": "94ec0d1d-a1b0-48c8-bfab-e67633b30bfa"
    },
    {
        "page_content": "/ glyph<c=30,font=/PIIBEG+FranklinGothic-Book>!$glyph<c=31,font=/PIIBEG+FranklinGothic-Book> -glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; =;D;H?9 9ECF;J?J?ED <EH / glyph<c=30,font=/PIIBEG+FranklinGothic-Book>!$glyph<c=31,font=/PIIBEG+FranklinGothic-Book> -glyph<c=28,font=/PIIBEG+FranklinGothic-Book> >7I I?=D?<?97DJBO H;:K9;: EKH / glyph<c=30,font=/PIIBEG+FranklinGothic-Book>!$glyph<c=31,font=/PIIBEG+FranklinGothic-Book> -glyph<c=28,font=/PIIBEG+FranklinGothic-Book> H;L;DK; 7D: M; ;NF;9J J>7J / glyph<c=30,font=/PIIBEG+FranklinGothic-Book>!$glyph<c=31,font=/PIIBEG+FranklinGothic-Book> -glyph<c=28,font=/PIIBEG+FranklinGothic-Book> H;L;DK; M?BB 9EDJ?DK; JE :;9B?D; ?D J>; <KJKH;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n$D J>;  glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 7H; I;;A?D= JE ;D<EH9; 7 F7J;DJ =H7DJ;: ?D %KD; glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> J>7J H;B7J;I JE / glyph<c=30,font=/PIIBEG+FranklinGothic-Book>!$glyph<c=31,font=/PIIBEG+FranklinGothic-Book> -glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 7D: ;NF?H;I ?D glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D 7::?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 7H; B?J?=7J?D= JE 7<<?HC J>7J / glyph<c=30,font=/PIIBEG+FranklinGothic-Book>!$glyph<c=31,font=/PIIBEG+FranklinGothic-Book> -glyph<c=28,font=/PIIBEG+FranklinGothic-Book> ?I ;DJ?JB;: JE H;=KB7JEHO :7J7 7D: C7HA;J FHEJ;9J?ED KDJ?B 7J B;7IJ !;8HK7HO glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> *KH glyph<c=30,font=/PIIBEG+FranklinGothic-Book>ECF7DOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>;  (glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 7D: J>;  glyph<c=30,font=/PIIBEG+FranklinGothic-Book> >7L; ;79> 7FF;7B;: J>; (7O glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book> :;9?I?ED E< J>;  KHEF;7D \";D;H7B glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EKHJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> 7DDKBB;: J>;  (glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=7,font=/PIIBEG+FranklinGothic-Book>I :;9?I?ED DEJ JE L7B?:7J; 7D 7FFB?97J?ED <EH 7FFHEL7B E< 7 / glyph<c=30,font=/PIIBEG+FranklinGothic-Book>!$glyph<c=31,font=/PIIBEG+FranklinGothic-Book> -glyph<c=28,font=/PIIBEG+FranklinGothic-Book> =;D;H?9 ED J>; 87I?I J>7J J>;  (glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 7D:  glyph<c=30,font=/PIIBEG+FranklinGothic-Book> 9ED:K9J;: J>; MHED= 7II;IIC;DJ M>;D :;J;HC?D?D= / glyph<c=30,font=/PIIBEG+FranklinGothic-Book>!$glyph<c=31,font=/PIIBEG+FranklinGothic-Book> -glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=7,font=/PIIBEG+FranklinGothic-Book>I ;DJ?JB;C;DJ JE H;=KB7JEHO :7J7 7D: C7HA;J?D= FHEJ;9J?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book> *KH glyph<c=30,font=/PIIBEG+FranklinGothic-Book>ECF7DOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>;  (glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 7D: J>; glyph<c=30,font=/PIIBEG+FranklinGothic-Book> >7L; ;79> 7FF;7B;: J>; \";D;H7B glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EKHJ^I :;9?I?ED 7I MHED=BO :;9?:;: 7D: J>; 7FF;7B ?I F;D:?D=glyph<c=14,font=/PIIBEG+FranklinGothic-Book> *D *9JE8;H glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; glyph<c=28,font=/PIIBEG+FranklinGothic-Book>:LE97J; \";D;H7B E< J>; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>% 0 ?IIK;: 7 DED8?D:?D= 7:L?IEHO EF?D?ED ?D glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E=;Dglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I <7LEHglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />?I EF?D?ED H;9ECC;D:I J>7J J>; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>% 0 I;J 7I?:; J>; @K:=C;DJ E< J>;  KHEF;7D \";D;H7B glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EKHJglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; 7H; 7M7?J?D= J>; :;9?I?ED E< J>; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>% 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n!glyph<c=28,font=/PIIBEG+FranklinGothic-Book>(+4-glyph<c=28,font=/PIIBEG+FranklinGothic-Book> ?I ?D:?97J;: 7I 7 JH;7JC;DJ JE ?CFHEL; M7BA?D= ?D 7:KBJ F7J?;DJI M?J> (. M>E >7L; 7 M7BA?D= :?I78?B?JO 7D: ?I J>; <?HIJ JH;7JC;DJ J>7J 7::H;II;I J>?I KDC;J C;:?97B D;;: M?J> :;CEDIJH7J;: ;<<?979O ?D F;EFB; M?J> 7BB JOF;I E< (.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> !glyph<c=28,font=/PIIBEG+FranklinGothic-Book>(+4-glyph<c=28,font=/PIIBEG+FranklinGothic-Book> ?I 9KHH;DJBO J>; EDBO J>;H7FO 7FFHEL;: JE ?CFHEL; M7BA?D= ?D F7J?;DJI M?J> (.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=30,font=/PIIBEG+FranklinGothic-Book>ECF;J?J?ED ?D J>; (. C7HA;J ?I ?DJ;DI;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BED= M?J> KIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 DKC8;H E< 9ECF7D?;I 7H; MEHA?D= JE :;L;BEF 7::?J?ED7B JH;7JC;DJI <EH (. J>7J C7O ?D J>; <KJKH; 9ECF;J; M?J> EKH (. FHE:K9JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> *D; IK9> FHE:K9J J>7J M7I 7FFHEL;: ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> ?D glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book> 7D: ?D J>;  glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book> ?D glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book> ?I *glyph<c=30,font=/PIIBEG+FranklinGothic-Book>- 10.glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 JH;7JC;DJ <EH -(. 7D: ++(. J>7J M7I :;L;BEF;: 8O \";D;DJ;9>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2>?B; M; >7L; 7 <?D7D9?7B ?DJ;H;IJ ?D *glyph<c=30,font=/PIIBEG+FranklinGothic-Book>- 10.glyph<c=12,font=/PIIBEG+FranklinGothic-Book> <KJKH; I7B;I E< EKH (. FHE:K9JI C7O 8; 7:L;HI;BO 7<<;9J;: ?< *glyph<c=30,font=/PIIBEG+FranklinGothic-Book>- 10. 9EDJ?DK;I JE =7?D C7HA;J I>7H;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> EH ?< EJ>;H (. FHE:K9JI J>7J M; EH EKH 9ECF;J?JEHI 7H; :;L;BEF?D= 7H; 9ECC;H9?7B?P;:glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## '>7</: !CA1C:/@ glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>B@=>6G\n\n2; <79; 9ECF;J?J?ED <HEC 7 =;D; J>;H7FO FHE:K9J 7D: 7D EH7B FHE:K9Jglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; ;NF;9J J>7J M; M?BB ;NF;H?;D9; 9ECF;J?J?ED <HEC 8EJ> FHE:K9JI ?D 7::?J?ED7B @KH?I:?9J?EDI ?D J>; <KJKH;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> C7O 7:L;HI;BO 7<<;9J EKH I7B;I E< .+$)-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>5glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=28,font=/PIIBEG+FranklinGothic-Book>::?J?ED7BBOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 7H; 7M7H; E< EJ>;H FHE:K9JI DEM ?D :;L;BEFC;DJ J>7Jglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?< B7KD9>;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> C7O 7BIE 9ECF;J; M?J> .+$)-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>5glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> !KJKH; I7B;I E< .+$)-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>5glyph<c=28,font=/PIIBEG+FranklinGothic-Book> C7O 8; 7:L;HI;BO 7<<;9J;: 8O J>; 9ECC;H9?7B?P7J?ED E< 9ECF;J?D= FHE:K9JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## $A=@7/A7A\n\n!0(glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book> -( 9ECF;J;I M?J> I;L;H7B :?<<;H;DJ JOF;I E< J>;H7F?;I ?D J>; FIEH?7I?I C7HA;J M?J>?D \";HC7DOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= EH7B IOIJ;C?9I IK9> 7I C;J>EJH;N7J; 7D: 9O9BEIFEH?D;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>7=A7;7:/@A\n\nglyph<c=29,font=/PIIBEG+FranklinGothic-Book> ) +glyph<c=28,font=/PIIBEG+FranklinGothic-Book>'$glyph<c=12,font=/PIIBEG+FranklinGothic-Book> $(-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>'glyph<c=31,font=/PIIBEG+FranklinGothic-Book>$ 7D: !'$3glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; J>H;; 8?EI?C?B7H FHE:K9JI M; 9KHH;DJBO 9ECC;H9?7B?P; ?D 9;HJ7?D 9EKDJH?;I ?D  KHEF; FKHIK7DJ JE 7D 7=H;;C;DJ M?J> .7CIKD= glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E;F?Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9ECF;J; M?J> J>;?H H;<;H;D9; FHE:K9JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> )glyph<c=29,font=/PIIBEG+FranklinGothic-Book>- 'glyph<c=12,font=/PIIBEG+FranklinGothic-Book> #0($-glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 7D: - ($glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book> glyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;IF;9J?L;BOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7I M;BB 7I EJ>;H 8?EI?C?B7HI E< J>EI; H;<;H;D9; FHE:K9JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n$D 7::?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>4**1$5glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 8?EI?C?B7H FHE:K9J M; 9KHH;DJBO 9ECC;H9?7B?P; ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> FKHIK7DJ JE 7D 7=H;;C;DJ M?J> .7CIKD= glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E;F?Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9ECF;J;I M?J> ?JI H;<;H;D9; FHE:K9J '0glyph<c=30,font=/PIIBEG+FranklinGothic-Book> )/$.glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7I M;BB 7I EJ>;H 8?EI?C?B7HI E< J>?I H;<;H;D9; FHE:K9Jglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>3<3<B316 &3:/B7=<A67>A 7< #B63@ glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><271/B7=<A\n\n&glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>(),glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>\"glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> &glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>(),glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>\" glyph<c=28,font=/PIIBDE+FranklinGothic-BookItal>-glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal> /<2 glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>.-*glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal> 7< #<1=:=5G\n\n-$/03glyph<c=28,font=/PIIBEG+FranklinGothic-Book>)glyph<c=12,font=/PIIBEG+FranklinGothic-Book> -$/03glyph<c=28,font=/PIIBEG+FranklinGothic-Book>) #4glyph<c=30,font=/PIIBEG+FranklinGothic-Book> 'glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 7D: \"glyph<c=28,font=/PIIBEG+FranklinGothic-Book>541glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 9ECF;J; M?J> 7 DKC8;H E< J>;H7F?;I ?D J>; ED9EBE=O C7HA;Jglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= /- glyph<c=28,font=/PIIBEG+FranklinGothic-Book>)glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book>8;D:7CKIJ?D; #glyph<c=30,font=/PIIBEG+FranklinGothic-Book>'glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>-5 --glyph<c=28,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book>E<7JKCKC78glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> $(glyph<c=29,font=/PIIBEG+FranklinGothic-Book>-01$glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book>?8HKJ?D?8glyph<c=9,font=/PIIBEG+FranklinGothic-Book> 7D: 54glyph<c=31,font=/PIIBEG+FranklinGothic-Book> '$\" glyph<c=8,font=/PIIBEG+FranklinGothic-Book>?:;B7B?I?8glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n2; 7BIE ;NF;9J J>7J EL;H J?C; -$/03glyph<c=28,font=/PIIBEG+FranklinGothic-Book>) #4glyph<c=30,font=/PIIBEG+FranklinGothic-Book> 'glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 7D: \"glyph<c=28,font=/PIIBEG+FranklinGothic-Book>541glyph<c=28,font=/PIIBEG+FranklinGothic-Book> M?BB ?D9H;7I?D=BO 9ECF;J; M?J> -$/03glyph<c=28,font=/PIIBEG+FranklinGothic-Book>) ?D J>; ED9EBE=O C7HA;Jglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D 7::?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 7H; 7M7H; E< I;L;H7B EJ>;H 7DJ?glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> CEB;9KB;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= 8?EI?C?B7H FHE:K9JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>7J >7L; 8;;D 7FFHEL;: 7D: 7H; 9ECF;J?D= M?J> -$/03glyph<c=28,font=/PIIBEG+FranklinGothic-Book>)glyph<c=12,font=/PIIBEG+FranklinGothic-Book> -$/03glyph<c=28,font=/PIIBEG+FranklinGothic-Book>) #4glyph<c=30,font=/PIIBEG+FranklinGothic-Book> 'glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 7D: \"glyph<c=28,font=/PIIBEG+FranklinGothic-Book>541glyph<c=28,font=/PIIBEG+FranklinGothic-Book> ?D J>; ED9EBE=O 7D: EJ>;H C7HA;JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?EI?C?B7H FHE:K9JI H;<;H;D9?D= -$/03glyph<c=28,font=/PIIBEG+FranklinGothic-Book>) >7L; B7KD9>;: ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>. 7D: 7H; 8;?D= E<<;H;: 7J BEM;H FH?9;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />?I 9ECF;J?J?ED >7I >7: 7 I?=D?<?97DJ 7:L;HI; ?CF79J ED J>; FH;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>J7N FHE<?JI E< EKH 9EBB78EH7J?ED 7HH7D=;C;DJI M?J> \";D;DJ;9>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7I J>; I7B;I E< -$/03glyph<c=28,font=/PIIBEG+FranklinGothic-Book>) >7L; :;9H;7I;: IK8IJ7DJ?7BBO 9ECF7H;: JE FH?EH F;H?E:Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; ;NF;9J J>7J 8?EI?C?B7H 9ECF;J?J?ED M?BB 9EDJ?DK; JE ?D9H;7I; 7I J>;I; FHE:K9JI 97FJKH; 7::?J?ED7B C7HA;J I>7H; 7D: J>7J J>?I M?BB >7L; 7 I?=D?<?97DJ 7:L;HI; ?CF79J ED EKH 9Eglyph<c=13,font=/PIIBEG+FranklinGothic-Book>FHECEJ?ED FHE<?JI ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> ?D <KJKH; O;7HIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## &glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>(),glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>\" 7< &63C;/B=72 glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>@B6@7B7A\n\n-$/03glyph<c=28,font=/PIIBEG+FranklinGothic-Book>) 9ECF;J;I M?J> I;L;H7B :?<<;H;DJ JOF;I E< J>;H7F?;I ?D J>; H>;KC7JE?: 7HJ>H?J?I C7HA;Jglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7CED= EJ>;HIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> JH7:?J?ED7B :?I;7I;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>CE:?<O?D= 7DJ?glyph<c=13,font=/PIIBEG+FranklinGothic-Book>H>;KC7J?9 :HK=I IK9> 7I IJ;HE?:Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> C;J>EJH;N7J; 7D: 9O9BEIFEH?D;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> /)! ?D>?8?JEHIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> *- )glyph<c=30,font=/PIIBEG+FranklinGothic-Book>$glyph<c=28,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book>787J79;FJglyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=30,font=/PIIBEG+FranklinGothic-Book>/ (-glyph<c=28,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book>JE9?B?PKC78glyph<c=9,font=/PIIBEG+FranklinGothic-Book> 7D: 3 '%glyph<c=28,font=/PIIBEG+FranklinGothic-Book>)5 glyph<c=8,font=/PIIBEG+FranklinGothic-Book>JE<79?J?D?8glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n2; 7H; 7BIE 7M7H; E< EJ>;H FHE:K9JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= 8?EI?C?B7HIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D :;L;BEFC;DJ J>7Jglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?< 7FFHEL;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> C7O",
        "metadata": {
            "page": 26
        },
        "id": "8860905e-008a-46af-88ae-ef6f4319805f"
    },
    {
        "page_content": "## 9ECF;J; M?J> -$/03glyph<c=28,font=/PIIBEG+FranklinGothic-Book>) ?D J>; H>;KC7JE?: 7HJ>H?J?I C7HA;Jglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## )7E73D5: 3@6 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>7H7>AB?7@F 'DA9D3?E\n\nglyph<c=28,font=/PIIBEG+FranklinGothic-Book> 9ECC?JC;DJ JE H;I;7H9> ?I <KD:7C;DJ7B JE EKH C?II?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book> *KH H;I;7H9> ;<<EHJI 7H; <E9KI;: ED 8;JJ;H KD:;HIJ7D:?D= J>; KD:;HBO?D= 8?EBE=O E< :?I;7I;I IE M; 97D :?I9EL;H 7D: :;B?L;H JH;7JC;DJI J>7J >7L; J>; FEJ;DJ?7B JE C7A; 7 H;7B :?<<;H;D9; ?D J>; B?L;I E< F7J?;DJI M?J> >?=> KDC;J C;:?97B D;;:Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>O 7FFBO?D= EKH ;NF;HJ?I; ?D 8?EBE=?9I 7D: EKH =HEM?D= 97F78?B?J?;I ?D IC7BB CEB;9KB;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7DJ?I;DI;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> =;D; J>;H7FOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> =;D; ;:?J?D= 7D: EJ>;H J;9>DEBE=?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; J7H=;J IF;9?<?9 C;:?97B D;;:I M>;H; M; 8;B?;L; D;M EH 8;JJ;H JH;7JC;DJI 7H; D;;:;:glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n2; ?DJ;D: JE 9EDJ?DK; 9ECC?JJ?D= I?=D?<?97DJ H;IEKH9;I JE J7H=;J;: H;I;7H9> 7D: :;L;BEFC;DJ\n\nEFFEHJKD?J?;I M>;H; J>;H; ?I 7 I?=D?<?97DJ KDC;J D;;: 7D: M>;H; 7 :HK= 97D:?:7J; >7I J>; FEJ;DJ?7B JE 8; >?=>BO :?<<;H;DJ?7J;:glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>I F7HJ E< EKH ED=E?D= H;I;7H9> 7D: :;L;BEFC;DJ ;<<EHJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; >7L; :;LEJ;: I?=D?<?97DJ H;IEKH9;I JE 9ED:K9J?D= 9B?D?97B IJK:?;I JE 7:L7D9; J>; :;L;BEFC;DJ E< D;M F>7HC79;KJ?97B FHE:K9JI 7D: J;9>DEBE=?;I 7D: JE ;NFBEH; J>; KJ?B?JO E< EKH ;N?IJ?D= FHE:K9JI ?D JH;7J?D= :?IEH:;HI 8;OED: J>EI; 9KHH;DJBO 7FFHEL;: ?D J>;?H B78;BIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n!EH 7::?J?ED7B ?D<EHC7J?ED ED EKH H;I;7H9> 7D: :;L;BEFC;DJ ;NF;DI; ?D9BK:;: ?D EKH 9EDIEB?:7J;: IJ7J;C;DJI E< ?D9EC;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> FB;7I; H;7: glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>B3; glyph<c=17,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal> !/</53;3<Bglyph<c=4,font=/PIIBDE+FranklinGothic-BookItal>A glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>7A1CAA7=< /<2 glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal></:GA7A =4 glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>7</<17/: glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=<27B7=< /<2 &3AC:BA =4 #>3@/B7=<A ?D9BK:;: ?D J>?I H;FEHJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>",
        "metadata": {
            "page": 27
        },
        "id": "f57edd7f-977c-48a9-9f97-9f4fff34184a"
    },
    {
        "page_content": "/>; J78B; 8;BEM >?=>B?=>JI EKH 9KHH;DJ H;I;7H9> 7D: :;L;BEFC;DJ FHE=H7CI J>7J 7H; ?D 9B?D?97B JH?7BI 7D: J>; 9KHH;DJ F>7I; E< IK9> FHE=H7CIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=31,font=/PIIBEG+FranklinGothic-Book>HK= :;L;BEFC;DJ ?DLEBL;I 7 >?=> :;=H;; E< H?IA 7D: ?DL;IJC;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: J>; IJ7JKIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J?C?D= 7D: I9EF; E< EKH :;L;BEFC;DJ FHE=H7CI 7H; IK8@;9J JE 9>7D=;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $CFEHJ7DJ <79JEHI J>7J 9EKB: 7:L;HI;BO 7<<;9J EKH :HK= :;L;BEFC;DJ ;<<EHJI 7H; :?I9KII;: ?D glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>B3; glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal> &7A9 glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>/1B=@A ?D9BK:;: ?D J>?I H;FEHJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n<!-- image -->\n\n| glyph<c=24,font=/PIIBCD+FranklinGothic-Book>>L:7;?7Dglyph<c=5,font=/PIIBCD+FranklinGothic-Book>E glyph<c=27,font=/PIIBCD+FranklinGothic-Book>7?7@F;3   | #753@7?34 glyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book> G ?glyph<c=24,font=/PIIBCD+FranklinGothic-Book>4glyph<c=7,font=/PIIBCD+FranklinGothic-Book>glyph<c=8,font=/PIIBCD+FranklinGothic-Book>glyph<c=8,font=/PIIBCD+FranklinGothic-Book>glyph<c=8,font=/PIIBCD+FranklinGothic-Book> glyph<c=10,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>>L:7;?7Dglyph<c=5,font=/PIIBCD+FranklinGothic-Book>E                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | !?B;: ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>  glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 7D: %7F7D   |\n|--------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=24,font=/PIIBCD+FranklinGothic-Book>>L:7;?7Dglyph<c=5,font=/PIIBCD+FranklinGothic-Book>E glyph<c=27,font=/PIIBCD+FranklinGothic-Book>7?7@F;3   | #753@7?34 glyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book> G ?glyph<c=24,font=/PIIBCD+FranklinGothic-Book>4glyph<c=7,font=/PIIBCD+FranklinGothic-Book>glyph<c=8,font=/PIIBCD+FranklinGothic-Book> glyph<c=10,font=/PIIBCD+FranklinGothic-Book> 'D75>;@;53> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>>L:7;?7Dglyph<c=5,font=/PIIBCD+FranklinGothic-Book>E glyph<c=24,font=/PIIBCD+FranklinGothic-Book>6G53@G?34 glyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book> G ?glyph<c=24,font=/PIIBCD+FranklinGothic-Book>4glyph<c=7,font=/PIIBCD+FranklinGothic-Book>glyph<c=8,font=/PIIBCD+FranklinGothic-Book>glyph<c=8,font=/PIIBCD+FranklinGothic-Book> glyph<c=10,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>>L:7;?7Dglyph<c=5,font=/PIIBCD+FranklinGothic-Book>E glyph<c=25,font=/PIIBCD+FranklinGothic-Book>  glyph<c=25,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=21,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book> glyph<c=6,font=/PIIBCD+FranklinGothic-Book>F3G glyph<c=24,font=/PIIBCD+FranklinGothic-Book>*&glyph<c=7,font=/PIIBCD+FranklinGothic-Book>glyph<c=8,font=/PIIBCD+FranklinGothic-Book> glyph<c=10,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>>L:7;?7Dglyph<c=5,font=/PIIBCD+FranklinGothic-Book>E | +>7I; glyph<c=19,font=/PIIBEG+FranklinGothic-Book> !?B;: ?D %7F7D 7D: *J>;H (7HA;JI +>7I; glyph<c=18,font=/PIIBEG+FranklinGothic-Book>                                                                                                                     |\n|                                                                                                                                                        | glyph<c=25,font=/PIIBCD+FranklinGothic-Book>  glyph<c=25,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=16,font=/PIIBCD+FranklinGothic-Book> glyph<c=6,font=/PIIBCD+FranklinGothic-Book>&glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book> ;@:;4;FADglyph<c=7,font=/PIIBCD+FranklinGothic-Book> glyph<c=10,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>>L:7;?7Dglyph<c=5,font=/PIIBCD+FranklinGothic-Book>E                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | +>7I; glyph<c=17,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                         |\n|                                                                                                                                                        | 1GD3@A>A@7 glyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>glyph<c=25,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book> 'glyph<c=24,font=/PIIBCD+FranklinGothic-Book>$glyph<c=7,font=/PIIBCD+FranklinGothic-Book>glyph<c=8,font=/PIIBCD+FranklinGothic-Book> glyph<c=10,font=/PIIBCD+FranklinGothic-Book> $glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | !?B;:?DJ>;0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                       |\n|                                                                                                                                                        | 1GD3@A>A@7 glyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>glyph<c=25,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book> 'glyph<c=24,font=/PIIBCD+FranklinGothic-Book>$glyph<c=7,font=/PIIBCD+FranklinGothic-Book>glyph<c=8,font=/PIIBCD+FranklinGothic-Book> glyph<c=10,font=/PIIBCD+FranklinGothic-Book> ''glyph<c=27,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | !?B;:?DJ>;0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                       |\n| *B75;3>;L76  ??G@A>A9K                                                                                                                                 | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>3B;DA>;LG?34 B79A> glyph<c=6,font=/PIIBCD+FranklinGothic-Book>3@F;glyph<c=10,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=17,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>#glyph<c=7,font=/PIIBCD+FranklinGothic-Book>glyph<c=8,font=/PIIBCD+FranklinGothic-Book> glyph<c=10,font=/PIIBCD+FranklinGothic-Book> *#glyph<c=28,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | +>7I; glyph<c=19,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                         |\n| *B75;3>;L76  ??G@A>A9K                                                                                                                                 | #;F;8;>;?34 glyph<c=6,font=/PIIBCD+FranklinGothic-Book>3@F;glyph<c=10,font=/PIIBCD+FranklinGothic-Book>glyph<c=25,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=7,font=/PIIBCD+FranklinGothic-Book> glyph<c=10,font=/PIIBCD+FranklinGothic-Book> *#glyph<c=28,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | +>7I; glyph<c=19,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                         |\n|                                                                                                                                                        | #;F;8;>;?34 glyph<c=6,font=/PIIBCD+FranklinGothic-Book>3@F;glyph<c=10,font=/PIIBCD+FranklinGothic-Book>glyph<c=25,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=7,font=/PIIBCD+FranklinGothic-Book> glyph<c=10,font=/PIIBCD+FranklinGothic-Book> glyph<c=26,font=/PIIBCD+FranklinGothic-Book>#glyph<c=28,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | +>7I; glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=15,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>                                                                                                                 |\n| %7GDA?GE5G>3D glyph<c=27,font=/PIIBCD+FranklinGothic-Book>;EAD67DE                                                                                     | +A87DE7@ glyph<c=6,font=/PIIBCD+FranklinGothic-Book>*&glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>*&glyph<c=7,font=/PIIBCD+FranklinGothic-Book>glyph<c=8,font=/PIIBCD+FranklinGothic-Book> glyph<c=10,font=/PIIBCD+FranklinGothic-Book> *&glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>#*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | !?B;: ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 7D:  glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                                     |\n| %7GDA?GE5G>3D glyph<c=27,font=/PIIBCD+FranklinGothic-Book>;EAD67DE                                                                                     | glyph<c=25,font=/PIIBCD+FranklinGothic-Book>  glyph<c=25,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=18,font=/PIIBCD+FranklinGothic-Book> glyph<c=6,font=/PIIBCD+FranklinGothic-Book>3F3J;@glyph<c=10,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>*&glyph<c=7,font=/PIIBCD+FranklinGothic-Book> glyph<c=2,font=/PIIBCD+FranklinGothic-Book> glyph<c=10,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>#*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | +>7I; glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=15,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>                                                                                                                 |\n| %7GDA?GE5G>3D glyph<c=27,font=/PIIBCD+FranklinGothic-Book>;EAD67DE                                                                                     | glyph<c=25,font=/PIIBCD+FranklinGothic-Book>  glyph<c=25,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=18,font=/PIIBCD+FranklinGothic-Book> glyph<c=6,font=/PIIBCD+FranklinGothic-Book>*$% glyph<c=24,font=/PIIBCD+FranklinGothic-Book>*&glyph<c=7,font=/PIIBCD+FranklinGothic-Book>glyph<c=8,font=/PIIBCD+FranklinGothic-Book> glyph<c=10,font=/PIIBCD+FranklinGothic-Book> *$glyph<c=24,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | +>7I; glyph<c=17,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                         |\n| '3D=;@EA@glyph<c=5,font=/PIIBCD+FranklinGothic-Book>E $AH7?7@F glyph<c=27,font=/PIIBCD+FranklinGothic-Book>;EAD67DE                                    | glyph<c=8,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                            |\n|                                                                                                                                                        | glyph<c=25,font=/PIIBCD+FranklinGothic-Book>  glyph<c=25,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book> glyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book>%#glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=18,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=7,font=/PIIBCD+FranklinGothic-Book> glyph<c=10,font=/PIIBCD+FranklinGothic-Book> #))\"glyph<c=15,font=/PIIBCD+FranklinGothic-Book> '3D=;@EA@glyph<c=5,font=/PIIBCD+FranklinGothic-Book>E                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | +>7I; glyph<c=19,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                         |\n|                                                                                                                                                        | glyph<c=25,font=/PIIBCD+FranklinGothic-Book>  glyph<c=25,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=17,font=/PIIBCD+FranklinGothic-Book> glyph<c=6,font=/PIIBCD+FranklinGothic-Book>*glyph<c=24,font=/PIIBCD+FranklinGothic-Book>glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=10,font=/PIIBCD+FranklinGothic-Book>glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=17,font=/PIIBCD+FranklinGothic-Book>glyph<c=7,font=/PIIBCD+FranklinGothic-Book>glyph<c=8,font=/PIIBCD+FranklinGothic-Book> glyph<c=10,font=/PIIBCD+FranklinGothic-Book> glyph<c=28,font=/PIIBCD+FranklinGothic-Book>EE7@F;3> +D7?AD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | +>7I; glyph<c=18,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                         |\n|                                                                                                                                                        | glyph<c=2,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                            |\n|                                                                                                                                                        | glyph<c=25,font=/PIIBCD+FranklinGothic-Book>  glyph<c=25,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=22,font=/PIIBCD+FranklinGothic-Book>glyph<c=17,font=/PIIBCD+FranklinGothic-Book> glyph<c=6,font=/PIIBCD+FranklinGothic-Book> &%glyph<c=21,font=/PIIBCD+FranklinGothic-Book>glyph<c=18,font=/PIIBCD+FranklinGothic-Book>glyph<c=22,font=/PIIBCD+FranklinGothic-Book>glyph<c=7,font=/PIIBCD+FranklinGothic-Book> glyph<c=10,font=/PIIBCD+FranklinGothic-Book> '3D=;@EA@glyph<c=5,font=/PIIBCD+FranklinGothic-Book>E                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | +>7I; glyph<c=17,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                         |\n|                                                                                                                                                        | glyph<c=25,font=/PIIBCD+FranklinGothic-Book>  glyph<c=25,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book> glyph<c=6,font=/PIIBCD+FranklinGothic-Book> &%glyph<c=17,font=/PIIBCD+FranklinGothic-Book>glyph<c=19,font=/PIIBCD+FranklinGothic-Book>glyph<c=17,font=/PIIBCD+FranklinGothic-Book>glyph<c=7,font=/PIIBCD+FranklinGothic-Book> glyph<c=2,font=/PIIBCD+FranklinGothic-Book> glyph<c=10,font=/PIIBCD+FranklinGothic-Book> $G>F;B>7 *KEF7? glyph<c=24,font=/PIIBCD+FranklinGothic-Book>FDAB:K                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | +>7I; glyph<c=17,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                         |\n|                                                                                                                                                        | glyph<c=25,font=/PIIBCD+FranklinGothic-Book>  glyph<c=25,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=22,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book> glyph<c=6,font=/PIIBCD+FranklinGothic-Book>B7D;B:7D3> glyph<c=25,font=/PIIBCD+FranklinGothic-Book>+\" ;@:;4;FADglyph<c=7,font=/PIIBCD+FranklinGothic-Book> glyph<c=10,font=/PIIBCD+FranklinGothic-Book> $*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | +>7I; glyph<c=17,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                         |\n| %7GDAH3E5G>3D                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                            |\n| %7GDAH3E5G>3D                                                                                                                                          | glyph<c=30,font=/PIIBCD+FranklinGothic-Book>>;47@5>3?;67  - glyph<c=6,font=/PIIBCD+FranklinGothic-Book>*,)glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=10,font=/PIIBCD+FranklinGothic-Book>+)'$glyph<c=17,font=/PIIBCD+FranklinGothic-Book>  @:;4;FADglyph<c=7,font=/PIIBCD+FranklinGothic-Book> glyph<c=10,font=/PIIBCD+FranklinGothic-Book> #glyph<c=31,font=/PIIBCD+FranklinGothic-Book> 2 *FDA=7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | +>7I; glyph<c=19,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                         |\n\n- glyph<c=10,font=/PIIBEG+FranklinGothic-Book>glyph<c=10,font=/PIIBEG+FranklinGothic-Book> \"H7DJ;: 799;B;H7J;: 7FFHEL7B ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> ?D %KD; glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book> KD:;H J>; 8H7D: D7C; glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>0# '(glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- glyph<c=10,font=/PIIBEG+FranklinGothic-Book>glyph<c=10,font=/PIIBEG+FranklinGothic-Book>glyph<c=10,font=/PIIBEG+FranklinGothic-Book> \"H7DJ;: 799;B;H7J;: 7FFHEL7B ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> ?D %7DK7HO glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book> KD:;H J>; 8H7D: D7C; ' , (glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$ 7D: <?B;: <EH JH7:?J?ED7B 7FFHEL7B ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 7D: %7F7Dglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n!EH ?D<EHC7J?ED 78EKJ 9;HJ7?D E< EKH 7=H;;C;DJI M?J> 9EBB78EH7JEHI 7D: EJ>;H J>?H: F7HJ?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FB;7I; H;7: J>; IK8I;9J?ED ;DJ?JB;: glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>CA7<3AA &3:/B7=<A67>A 8;BEM 7D: \"=B3 glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>1?C7A7B7=<A glyph<c=12,font=/PIIBEG+FranklinGothic-Book> \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>Aglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> 7D: \"=B3 glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=10,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><D3AB;3<BA 7< */@7/0:3 glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><B3@3AB glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal><B7B73Aglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> JE EKH 9EDIEB?:7J;: <?D7D9?7B IJ7J;C;DJI ?D9BK:;: ?D J>?I H;FEHJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>",
        "metadata": {
            "page": 28
        },
        "id": "770a8d54-cde8-4628-8b95-d2a0f7722606"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book>GE;@7EE )7>3F;A@E:;BE\n\nglyph<c=28,font=/PIIBEG+FranklinGothic-Book>I F7HJ E< EKH 8KI?D;II IJH7J;=Oglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; ;IJ78B?I> 8KI?D;II H;B7J?EDI>?FIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= ;DJ;H?D= ?DJE B?9;DI;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> @E?DJ L;DJKH;I 7D: 9EBB78EH7J?L; 7HH7D=;C;DJI M?J> EJ>;H 9ECF7D?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> KD?L;HI?J?;I 7D: C;:?97B H;I;7H9> ?DIJ?JKJ?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> JE 7II?IJ ?D J>; 9B?D?97B :;L;BEFC;DJ 7D:glyph<c=15,font=/PIIBEG+FranklinGothic-Book>EH 9ECC;H9?7B?P7J?ED E< 9;HJ7?D E< EKH FHE:K9JI 7D: FHE:K9J 97D:?:7J;I 7D: JE FHEL?:; IKFFEHJ <EH EKH H;I;7H9> FHE=H7CIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; 7BIE ;L7BK7J; EFFEHJKD?J?;I <EH 79GK?H?D= FHE:K9JI EH H?=>JI JE FHE:K9JI 7D: J;9>DEBE=?;I J>7J 7H; 9ECFB;C;DJ7HO JE EKH 8KI?D;II <HEC EJ>;H 9ECF7D?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> KD?L;HI?J?;I 7D: C;:?97B H;I;7H9> ?DIJ?JKJ?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=29,font=/PIIBEG+FranklinGothic-Book>;BEM ?I 7 8H?;< :;I9H?FJ?ED E< 9;HJ7?D 8KI?D;II H;B7J?EDI>?FI 7D: 9EBB78EH7J?EDI J>7J ;NF7D: EKH F?F;B?D; 7D: FHEL?:; KI M?J> 9;HJ7?D H?=>JI JE ;N?IJ?D= 7D: FEJ;DJ?7B D;M FHE:K9JI 7D: J;9>DEBE=?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> !EH 7::?J?ED7B ?D<EHC7J?ED ED 9;HJ7?D E< J>;I; H;B7J?EDI>?FIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= J>;?H ED=E?D= <?D7D9?7B 7D: 799EKDJ?D= ?CF79J ED EKH 8KI?D;IIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FB;7I; H;7: \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>A glyph<c=12,font=/PIIBEG+FranklinGothic-Book> JE EKH 9EDIEB?:7J;: <?D7D9?7B IJ7J;C;DJI ?D9BK:;: ?D J>?I H;FEHJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>7A/7 glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> B2glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal>\n\n2; >7L; 7 9EBB78EH7J?ED 7=H;;C;DJ M?J>  ?I7? JE @E?DJBO :;L;BEF 7D: 9ECC;H9?7B?P; ' , (glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$ glyph<c=8,font=/PIIBEG+FranklinGothic-Book>B;97D;C78glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D 7DJ?glyph<c=13,font=/PIIBEG+FranklinGothic-Book>7COBE?: 7DJ?8E:O <EH J>; JH;7JC;DJ E< glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BP>;?C;Hglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I :?I;7I;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> ?I7? I;HL;I 7I J>; B;7: E< ' , (glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$ :;L;BEFC;DJ 7D: H;=KB7JEHO IK8C?II?EDI =BE87BBO M?J> 8EJ> 9ECF7D?;I 9Eglyph<c=13,font=/PIIBEG+FranklinGothic-Book> 9ECC;H9?7B?P?D= 7D: 9Eglyph<c=13,font=/PIIBEG+FranklinGothic-Book>FHECEJ?D= J>; FHE:K9Jglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: ?I7? >7L?D= <?D7B :;9?I?EDglyph<c=13,font=/PIIBEG+FranklinGothic-Book>C7A?D= 7KJ>EH?JOglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BB 9EIJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= H;I;7H9>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> :;L;BEFC;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> I7B;I 7D: C7HA;J?D= ;NF;DI;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7H; I>7H;: ;GK7BBO 8;JM;;D KI 7D:  ?I7?glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 0FED ' , (glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$ C7HA;J?D= 7FFHEL7Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 7D:  ?I7? M?BB 9Eglyph<c=13,font=/PIIBEG+FranklinGothic-Book>FHECEJ; ' , (glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$ 7D: I>7H; FHE<?JI 7D: BEII;I ;GK7BBOglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; 9KHH;DJBO C7DK<79JKH; ' , (glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$ :HK= IK8IJ7D9; 7D: :HK= FHE:K9J 7D: ?D (7H9> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> M; ;NJ;D:;: EKH IKFFBO 7=H;;C;DJ M?J>  ?I7? H;B7J;: JE ' , (glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$ <HEC <?L; O;7HI JE J;D O;7HI <EH J>; C7DK<79JKH; E< ' , (glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$ :HK= IK8IJ7D9;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n2; 7BIE >7L; 7 9EBB78EH7J?ED 7=H;;C;DJ M?J> ?I7? <EH glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>0# '(glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 0D:;H EKH ?D?J?7B glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>0# '( glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EBB78EH7J?ED glyph<c=28,font=/PIIBEG+FranklinGothic-Book>=H;;C;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; MEKB: B;7: J>; ED=E?D= :;L;BEFC;DJ E< glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>0# '(glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: M; 7D:  ?I7? MEKB: 9Eglyph<c=13,font=/PIIBEG+FranklinGothic-Book> FHECEJ; glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>0# '( M?J> 7 H;=?EDglyph<c=13,font=/PIIBEG+FranklinGothic-Book>87I;: FHE<?J IFB?Jglyph<c=14,font=/PIIBEG+FranklinGothic-Book> *D (7H9> glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 7C;D:;: EKH glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>0# '( glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EBB78EH7J?ED glyph<c=28,font=/PIIBEG+FranklinGothic-Book>=H;;C;DJ M?J>  ?I7?glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>I E< J>; 7C;D:C;DJ :7J;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; >7L; IEB; :;9?I?ED C7A?D= 7D: 9ECC;H9?7B?P7J?ED H?=>JI MEHB:M?:; ED glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>0# '(glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: 8;=?DD?D= %7DK7HO glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?I7? H;9;?L;I EDBO 7 J?;H;: HEO7BJO 87I;: ED D;J I7B;I E< glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>0# '(glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: DE BED=;H F7HJ?9?F7J;I ?D I>7H?D= glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>0# '(glyph<c=7,font=/PIIBEG+FranklinGothic-Book>I =BE87B FHE<?JI 7D: BEII;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> ?I7?glyph<c=7,font=/PIIBEG+FranklinGothic-Book>I I>7H; E< :;L;BEFC;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9ECC;H9?7B?P7J?ED 7D: C7DK<79JKH?D= ;NF;DI; M7I B?C?J;: JE glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> C?BB?ED <EH J>; F;H?E: <HEC %7DK7HO\n\nglyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> JE glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> M7I 79>?;L;: 7I E< glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> *D9; J>?I B?C?J M7I 79>?;L;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 8;97C; H;IFEDI?8B; <EH 7BB glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>0# '( H;B7J;: 9EIJIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n$D 7::?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 7D:  ?I7? 9Eglyph<c=13,font=/PIIBEG+FranklinGothic-Book>FHECEJ; glyph<c=28,font=/PIIBEG+FranklinGothic-Book>1*) 3glyph<c=12,font=/PIIBEG+FranklinGothic-Book> /4.glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=29,font=/PIIBEG+FranklinGothic-Book>-$ 7D: / glyph<c=30,font=/PIIBEG+FranklinGothic-Book>!$glyph<c=31,font=/PIIBEG+FranklinGothic-Book> -glyph<c=28,font=/PIIBEG+FranklinGothic-Book> ?D %7F7D ?D 9;HJ7?D I;JJ?D=I 7D:  ?I7? :?IJH?8KJ;I glyph<c=28,font=/PIIBEG+FranklinGothic-Book>1*) 3glyph<c=12,font=/PIIBEG+FranklinGothic-Book> /4.glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=29,font=/PIIBEG+FranklinGothic-Book>-$glyph<c=12,font=/PIIBEG+FranklinGothic-Book> / glyph<c=30,font=/PIIBEG+FranklinGothic-Book>!$glyph<c=31,font=/PIIBEG+FranklinGothic-Book> -glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 7D: +' \"-$glyph<c=31,font=/PIIBEG+FranklinGothic-Book>4 ?D $D:?7 7D: EJ>;H glyph<c=28,font=/PIIBEG+FranklinGothic-Book>I?7glyph<c=13,font=/PIIBEG+FranklinGothic-Book>+79?<?9 C7HA;JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ;N9BK:?D= glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>?D7glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## '/53 (63@/>3CB71Aglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><1glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal>\n\n2; >7L; 7 =BE87B 9EBB78EH7J?ED 7D: B?9;DI; 7=H;;C;DJ M?J> .7=; JE @E?DJBO :;L;BEF 7D: 9ECC;H9?7B?P; PKH7DEBED; <EH J>; FEJ;DJ?7B JH;7JC;DJ E< (glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book> 7D: ++glyph<c=31,font=/PIIBEG+FranklinGothic-Book> 7D: glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$$glyph<c=29,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book>.glyph<c=28,font=/PIIBEG+FranklinGothic-Book>\" glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book> <EH J>; FEJ;DJ?7B JH;7JC;DJ E< ;II;DJ?7B JH;CEH M?J> FEJ;DJ?7B ?D EJ>;H D;KHEBE=?97B 9ED:?J?EDI IK9> 7I ;F?B;FIOglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 0D:;H J>?I 9EBB78EH7J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 8EJ> 9ECF7D?;I M?BB I>7H; ;GK7B H;IFEDI?8?B?JO 7D: 9EIJI <EH :;L;BEFC;DJ 7I M;BB 7I FHE<?JI 7D: BEII;I <EH 9ECC;H9?7B?P7J?ED ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> *KJI?:; J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 7H; H;IFEDI?8B; <EH :;L;BEFC;DJ 7D: 9ECC;H9?7B?P7J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ;N9BK:?D= %7F7Dglyph<c=12,font=/PIIBEG+FranklinGothic-Book> /7?M7D 7D: .EKJ> &EH;7glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M?J> H;IF;9J JE PKH7DEBED; 7D: C7O F7O .7=; FEJ;DJ?7B J?;H;: HEO7BJ?;I ?D J>; >?=> J;;DI JE BEM JM;DJ?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>=<7A $6/@;/13CB71/:Aglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><1glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal>\n\n2; >7L; 7D ;N9BKI?L;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> MEHB:M?:; EFJ?ED 7D: 9EBB78EH7J?ED 7=H;;C;DJ M?J> $ED?I H;B7J?D= JE J>; :;L;BEFC;DJ 7D: 9ECC;H9?7B?P7J?ED E< 7DJ?I;DI; J>;H7F;KJ?9I <EH KF JE J>H;; =;D; J7H=;JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 0D:;H 7 I;F7H7J; 9EBB78EH7J?ED 7D: B?9;DI; 7=H;;C;DJ M?J> $ED?Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; >7L; 7D ;N9BKI?L;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> MEHB:M?:; B?9;DI; JE :;L;BEF 7D: 9ECC;H9?7B?P; .+$)-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>5glyph<c=28,font=/PIIBEG+FranklinGothic-Book> <EH J>; JH;7JC;DJ E< .(glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; 7BIE >7L; 7 glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=13,font=/PIIBEG+FranklinGothic-Book>O;7H ;N9BKI?L; 9EBB78EH7J?ED 7=H;;C;DJ M?J> $ED?I JE :;L;BEF DEL;B glyph<c=28,font=/PIIBEG+FranklinGothic-Book>.* :HK= 97D:?:7J;I <EH 7 8HE7: H7D=; E< D;KHEBE=?97B :?I;7I;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n$D 7::?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; >7L; H;I;7H9> 9EBB78EH7J?ED 7=H;;C;DJI M?J> $ED?I KD:;H M>?9> 8EJ> 9ECF7D?;I F;H<EHC :?I9EL;HO B;L;B H;I;7H9> 7D: M?BB :;L;BEF 7D: 9ECC;H9?7B?P; D;M glyph<c=28,font=/PIIBEG+FranklinGothic-Book>.* :HK= 97D:?:7J;I <EH J>; FEJ;DJ?7B JH;7JC;DJ E< .(glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 7D: 7::?J?ED7B 7DJ?I;DI; EH EJ>;H J>;H7F;KJ?9I <EH J>; FEJ;DJ?7B JH;7JC;DJ E< D;KHEBE=?97B :?I;7I;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>3<3<B316glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><1glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=5,font=/PIIBDE+FranklinGothic-BookItal>&=163 glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>@=C>glyph<c=6,font=/PIIBDE+FranklinGothic-BookItal>\n\n2; >7L; 7=H;;C;DJI M?J> \";D;DJ;9> J>7J ;DJ?JB; KI JE 9;HJ7?D 8KI?D;II 7D: <?D7D9?7B H?=>JI M?J> H;IF;9J JE -$/03glyph<c=28,font=/PIIBEG+FranklinGothic-Book>)glyph<c=12,font=/PIIBEG+FranklinGothic-Book> -$/03glyph<c=28,font=/PIIBEG+FranklinGothic-Book>) #4glyph<c=30,font=/PIIBEG+FranklinGothic-Book> 'glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> \"glyph<c=28,font=/PIIBEG+FranklinGothic-Book>541glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> *glyph<c=30,font=/PIIBEG+FranklinGothic-Book>- 10.glyph<c=12,font=/PIIBEG+FranklinGothic-Book> '0).0($*glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> M7I =H7DJ;: 799;B;H7J;: 7FFHEL7B ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> :KH?D= J>; <EKHJ> GK7HJ;H E< glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> =BE<?J7C78 7D: EFJ?EDI JE 7:: EJ>;H FEJ;DJ?7B 7DJ?glyph<c=13,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> J>;H7F?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>",
        "metadata": {
            "page": 29
        },
        "id": "22e485bd-838e-4359-babb-4708cf687e2d"
    },
    {
        "page_content": "## glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>3</:7 (63@/>3CB71A glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><1glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal>\n\n2; >7L; 7 9EBB78EH7J?ED 7D: B?9;DI; 7=H;;C;DJ M?J> glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;D7B? JE 9Eglyph<c=13,font=/PIIBEG+FranklinGothic-Book>:;L;BEF 7D: 9Eglyph<c=13,font=/PIIBEG+FranklinGothic-Book>9ECC;H9?7B?P; glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;D7B?^I IC7BB CEB;9KB; ?D>?8?JEHI E< '--&glyph<c=18,font=/PIIBEG+FranklinGothic-Book> <EH +7HA?DIED^I :?I;7I;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 0D:;H J>?I 9EBB78EH7J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 8EJ> 9ECF7D?;I I>7H; H;IFEDI?8?B?JO 7D: 9EIJI <EH =BE87B :;L;BEFC;DJ 87I;: ED IF;9?<?;: F;H9;DJ7=;I 7I M;BB 7I FHE<?JI 7D: BEII;I <EH 9ECC;H9?7B?P7J?ED ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 7D: glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>?D7glyph<c=14,font=/PIIBEG+FranklinGothic-Book> *KJI?:; J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 7D: glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>?D7glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 7H; H;IFEDI?8B; <EH 9ECC;H9?7B?P7J?ED 7D: C7O F7O glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;D7B? FEJ;DJ?7B J?;H;: HEO7BJ?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n$D 7::?J?ED JE J>; '--&glyph<c=18,font=/PIIBEG+FranklinGothic-Book> FHE=H7Cglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 7BIE >7L; 7D ;N9BKI?L; EFJ?ED JE B?9;DI; JME FH;9B?D?97B FHE=H7CI <HEC glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;D7B?^I /H7DIFEHJ 1;>?9B; FB7J<EHCglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= ?JI glyph<c=28,font=/PIIBEG+FranklinGothic-Book>DJ?8E:O /H7DIFEHJ 1;>?9B; glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>/1glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=26,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>/1 ;D78B;: 7DJ?glyph<c=13,font=/PIIBEG+FranklinGothic-Book> 7COBE?: 8;J7 FHE=H7C 7D: 7 I;9ED: FHE=H7C KJ?B?P?D= ?JI /H7DIFEHJ 1;>?9B; J;9>DEBE=Oglyph<c=14,font=/PIIBEG+FranklinGothic-Book> !KHJ>;Hglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; >7L; J>; H?=>J E< <?HIJ D;=EJ?7J?ED ED JME 7::?J?ED7B glyph<c=28,font=/PIIBEG+FranklinGothic-Book>/1glyph<c=13,font=/PIIBEG+FranklinGothic-Book>;D78B;: J>;H7F;KJ?9I <EH ?D:?97J?EDI M?J>?D IF;9?<?9 D;KHE:;=;D;H7J?L; :?I;7I;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> I>EKB: glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;D7B? :;9?:; JE I;;A 7 9EBB78EH7J?ED <EH IK9> FHE=H7CIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## '/;AC<5 glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>7=3>7A glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> B2glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal>\n\n$D !;8HK7HO glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> M; ;DJ;H;: ?DJE 7 @E?DJ L;DJKH; 7=H;;C;DJ M?J> .7CIKD= glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E'E=?9I ;IJ78B?I>?D= 7D ;DJ?JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> .7CIKD= glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E;F?Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> JE :;L;BEFglyph<c=12,font=/PIIBEG+FranklinGothic-Book> C7DK<79JKH; 7D: C7HA;J 8?EI?C?B7H FHE:K9JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; 7BIE >7L; 7D 7=H;;C;DJ M?J> .7CIKD= glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E;F?I JE 9ECC;H9?7B?P;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> EL;H 7 glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=13,font=/PIIBEG+FranklinGothic-Book>O;7H J;HCglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>H;; 7DJ?glyph<c=13,font=/PIIBEG+FranklinGothic-Book>/)! 8?EI?C?B7H FHE:K9J 97D:?:7J;I ?D 9;HJ7?D 9EKDJH?;I ?D  KHEF; 7D:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D J>; 97I; E< glyph<c=29,font=/PIIBEG+FranklinGothic-Book> ) +glyph<c=28,font=/PIIBEG+FranklinGothic-Book>'$glyph<c=12,font=/PIIBEG+FranklinGothic-Book> %7F7Dglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 0D:;H J>?I 7=H;;C;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 7H; 9ECC;H9?7B?P?D= glyph<c=29,font=/PIIBEG+FranklinGothic-Book> ) +glyph<c=28,font=/PIIBEG+FranklinGothic-Book>'$glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D ;J7D;H9;FJ 8?EI?C?B7H H;<;H;D9?D=  )glyph<c=29,font=/PIIBEG+FranklinGothic-Book>- 'glyph<c=12,font=/PIIBEG+FranklinGothic-Book> $(-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>'glyph<c=31,font=/PIIBEG+FranklinGothic-Book>$glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D 7:7B?CKC78 8?EI?C?B7H H;<;H;D9?D= #0($-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: !'$3glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D ?D<B?N?C78 8?EI?C?B7H H;<;H;D9?D= - ($glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book> glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D 9;HJ7?D 9EKDJH?;I ?D  KHEF;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n$D glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book> M; 9ECFB;J;: 7 JH7DI79J?ED M?J> .7CIKD= glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E;F?I 7D: 79GK?H;: 7D EFJ?ED JE ;NJ;D: EKH ;N?IJ?D= 9ECC;H9?7B 7=H;;C;DJ M?J> .7CIKD= glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E;F?I <EH glyph<c=29,font=/PIIBEG+FranklinGothic-Book> ) +glyph<c=28,font=/PIIBEG+FranklinGothic-Book>'$glyph<c=12,font=/PIIBEG+FranklinGothic-Book> $(-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>'glyph<c=31,font=/PIIBEG+FranklinGothic-Book>$ 7D: !'$3glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$ ?D 9;HJ7?D 9EKDJH?;I ?D  KHEF;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; >7L; 7BIE I;9KH;: J>; ;N9BKI?L; H?=>JI JE 9ECC;H9?7B?P; glyph<c=29,font=/PIIBEG+FranklinGothic-Book>4**1$5glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 H7D?8?PKC78 8?EI?C?B7H H;<;H;D9?D= '0glyph<c=30,font=/PIIBEG+FranklinGothic-Book> )/$.glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> M7I 7FFHEL;: ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>;  glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 7D: J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>&glyph<c=14,font=/PIIBEG+FranklinGothic-Book> :KH?D= J>; J>?H: GK7HJ;H E< glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>4**1$5 B7KD9>;: ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> ?D %KD; glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> 7D: 8;97C; 9ECC;H9?7BBO 7L7?B78B; :KH?D= J>; J>?H: GK7HJ;H E< glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D 7::?J?ED JE EKH 9ECC;H9?7B?P7J?ED 7=H;;C;DJI M?J> .7CIKD= glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E;F?Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; B?9;DI; 9;HJ7?D E< EKH FHEFH?;J7HO J;9>DEBE=O JE .7CIKD= glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E;F?I ?D 9EDD;9J?ED M?J> .7CIKD= glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E;F?Iglyph<c=7,font=/PIIBEG+FranklinGothic-Book> :;L;BEFC;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> C7DK<79JKH; 7D: 9ECC;H9?7B?P7J?ED E< ?JI 8?EI?C?B7H FHE:K9JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n$D glyph<c=28,font=/PIIBEG+FranklinGothic-Book>FH?B glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> M; 9ECFB;J;: J>; I7B; E< EKH glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=5,font=/PIIBEG+FranklinGothic-Book> ;GK?JO ?DJ;H;IJ ?D .7CIKD= glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E;F?I JE .7CIKD= glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E'E=?9Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 0D:;H J>; J;HCI E< J>?I JH7DI79J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; H;9;?L;: 7FFHEN?C7J;BO glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> 8?BB?ED ?D 97I> 7J 9BEI?D= 7D: ;NF;9J JE H;9;?L; 7FFHEN?C7J;BO\n\nglyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book> 8?BB?ED ?D 97I> JE 8; :;<;HH;: EL;H JME F7OC;DJI E< 7FFHEN?C7J;BO glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book> C?BB?ED :K; 7J J>; <?HIJ 7DD?L;HI7HO 7D: 7FFHEN?C7J;BO glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book> C?BB?ED :K; 7J J>; I;9ED: 7DD?L;HI7HO E< J>; 9BEI?D= E< J>?I JH7DI79J?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=28,font=/PIIBEG+FranklinGothic-Book>I F7HJ E< J>?I JH7DI79J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 7H; 7BIE ;B?=?8B; JE H;9;?L; KF JE 7D 7::?J?ED7B glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> C?BB?ED KFED J>; 79>?;L;C;DJ E< 9;HJ7?D 9ECC;H9?7B C?B;IJED;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> *KH FEB?9O <EH 9EDJ?D=;DJ F7OC;DJI E< J>?I D7JKH; ?I JE H;9E=D?P; J>; F7OC;DJI ?D J>; F;H?E: J>7J J>;O 8;9EC; H;7B?P78B;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> ?I =;D;H7BBO J>; I7C; F;H?E: ?D M>?9> J>; F7OC;DJI 7H; ;7HD;:glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n!EH 7::?J?ED7B ?D<EHC7J?ED ED J>; I7B; E< EKH ;GK?JO ?DJ;H;IJ ?D .7CIKD= glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E;F?Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FB;7I; H;7: \"=B3 glyph<c=13,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>7A>=A7B7=<Aglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> JE EKH 9EDIEB?:7J;: <?D7D9?7B IJ7J;C;DJI ?D9BK:;: ?D J>?I H;FEHJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n)glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>\n\n2; >7L; 7 9EBB78EH7J?ED 7=H;;C;DJ M?J> 0glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=29,font=/PIIBEG+FranklinGothic-Book> JE @E?DJBO :;L;BEF 7D: 9ECC;H9?7B?P; :7F?HEB?PKC78 F;=EBglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D 7DJ?glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>' F;=OB7J;: !78glyph<c=12,font=/PIIBEG+FranklinGothic-Book> <EH J>; FEJ;DJ?7B JH;7JC;DJ E< .'  7D: EJ>;H <KJKH; 7=H;;: ?D:?97J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>EJ> 9ECF7D?;I M?BB I>7H; ;GK7BBO 9EIJI ?D9KHH;: <EH 7=H;;: ?D:?97J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= H;I;7H9>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> :;L;BEFC;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> I7B;I 7D: C7HA;J?D= ;NF;DI;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $< C7HA;J?D= 7FFHEL7B ?I E8J7?D;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 8EJ> 9ECF7D?;I M?BB 9Eglyph<c=13,font=/PIIBEG+FranklinGothic-Book>FHECEJ; :7F?HEB?PKC78 F;=EB 7D: I>7H; FHE<?JI 7D: BEII;I ;GK7BBOglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## '/<5/;= (63@/>3CB71Aglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><1glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal>\n\n2; >7L; 7 9EBB78EH7J?ED 7D: B?9;DI; 7=H;;C;DJ M?J> .7D=7CE />;H7F;KJ?9Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> $D9glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book>.7D=7CEglyph<c=9,font=/PIIBEG+FranklinGothic-Book> JE :;L;BEF 7D: 9ECC;H9?7B?P; ./glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book> <EH J7KEF7J>?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BP>;?C;H^I :?I;7I;glyph<c=27,font=/PIIBEG+FranklinGothic-Book> ./glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> <EH IODK9B;?DEF7J>?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= +7HA?DIED^I :?I;7I;glyph<c=27,font=/PIIBEG+FranklinGothic-Book> 7 J>?H: D;KHECKI9KB7H :?I;7I; J7H=;Jglyph<c=27,font=/PIIBEG+FranklinGothic-Book> 7D: KF JE D?D; 7::?J?ED7B D;KHEBE=?97B :?I;7I; J7H=;JI JE 8; ?:;DJ?<?;: 7D: I;B;9J;: M?J>?D 7 <?L;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>O;7H F;H?E:glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; 9ECF7D?;I 7H; B;L;H7=?D= .7D=7CEglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I FHEFH?;J7HO P?D9 <?D=;H FHEJ;?D J;9>DEBE=O :;B?L;H;: L?7 7:;DEglyph<c=13,font=/PIIBEG+FranklinGothic-Book>7IIE9?7J;: L?HKI JE CE:KB7J; J>; ;NFH;II?ED E< A;O =;D;I ?DLEBL;: ?D D;KHEBE=?97B :?I;7I;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 0D:;H J>?I 9EBB78EH7J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; C7O F7O .7D=7CE J?;H;: HEO7BJ?;I ED FEJ;DJ?7B D;J I7B;I E< 7DO FHE:K9JI :;L;BEF;: KD:;H J>?I 9EBB78EH7J?ED ?D J>; >?=> I?D=B; :?=?J JE IK8glyph<c=13,font=/PIIBEG+FranklinGothic-Book>J;;D F;H9;DJ7=;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>",
        "metadata": {
            "page": 30
        },
        "id": "1e446178-6627-40da-9db6-fd477b3065f6"
    },
    {
        "page_content": "## )79G>3FADK\n\n*KH 9KHH;DJ 7D: 9EDJ;CFB7J;: 79J?L?J?;I 7D: J>; FHE:K9JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J;9>DEBE=?;I 7D: FHE9;II;I J>7J H;IKBJ <HEC IK9> 79J?L?J?;I 7H; IK8@;9J JE IK8IJ7DJ?7B =EL;HDC;DJ H;=KB7J?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n&35C:/B7=< =4 $6/@;/13CB71/:A\n\n$@=2C1B glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>>>@=D/: /<2 $=ABglyph<c=8,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>>>@=D/: &35C:/B7=< 7< B63 )glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal>'glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal>\n\n## glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>$$&#*glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal> $&#glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>''\n\nglyph<c=29,font=/PIIBEG+FranklinGothic-Book>;<EH; D;M F>7HC79;KJ?97B FHE:K9JI C7O 8; IEB: ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> FH;9B?D?97B IJK:?;I 7D: 9B?D?97B JH?7BI E< J>; FHE:K9JI CKIJ 8; 9ED:K9J;: 7D: J>; H;IKBJI IK8C?JJ;: JE J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> <EH 7FFHEL7Bglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2?J> B?C?J;: ;N9;FJ?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> H;GK?H;I 9ECF7D?;I JE H;=?IJ;H 8EJ> FH;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>7FFHEL7B 7D: FEIJglyph<c=13,font=/PIIBEG+FranklinGothic-Book>7FFHEL7B 9B?D?97B JH?7BI 7D: :?I9BEI; 9B?D?97B JH?7B H;IKBJI ?D FK8B?9 :7J787I;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> !7?BKH; JE H;=?IJ;H 7 JH?7B EH :?I9BEI; IJK:O H;IKBJI M?J>?D J>; H;GK?H;: J?C; F;H?E:I 9EKB: H;IKBJ ?D F;D7BJ?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= 9?L?B CED;J7HO F;D7BJ?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>B?D?97B JH?7B FHE=H7CI CKIJ ;IJ78B?I> ;<<?979Oglyph<c=12,font=/PIIBEG+FranklinGothic-Book> :;J;HC?D; 7D 7FFHEFH?7J; :EI; 7D: :EI?D= H;=?C;D 7D: :;<?D; J>; 9ED:?J?EDI <EH I7<; KI;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />?I ?I 7 >?=>glyph<c=13,font=/PIIBEG+FranklinGothic-Book>H?IA FHE9;II J>7J H;GK?H;I IJ;FM?I; 9B?D?97B IJK:?;I ?D M>?9> J>; 97D:?:7J; FHE:K9J CKIJ IK99;II<KBBO C;;J FH;:;J;HC?D;: ;D:FE?DJIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; H;IKBJI E< J>; FH;9B?D?97B 7D: 9B?D?97B J;IJ?D= E< 7 FHE:K9J 7H; J>;D IK8C?JJ;: JE J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> ?D J>; <EHC E< 7 glyph<c=29,font=/PIIBEG+FranklinGothic-Book>'glyph<c=28,font=/PIIBEG+FranklinGothic-Book> EH 7 )glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D H;IFEDI; JE 7 glyph<c=29,font=/PIIBEG+FranklinGothic-Book>'glyph<c=28,font=/PIIBEG+FranklinGothic-Book> EH )glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> C7O =H7DJ C7HA;J?D= 7FFHEL7Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;GK;IJ 7::?J?ED7B ?D<EHC7J?ED EH :;DO J>; 7FFB?97J?ED ?< ?J :;J;HC?D;I J>; 7FFB?97J?ED :E;I DEJ FHEL?:; 7D 7:;GK7J; 87I?I <EH 7FFHEL7Bglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n+HE:K9J :;L;BEFC;DJ 7D: H;9;?FJ E< H;=KB7JEHO 7FFHEL7B J7A;I 7 DKC8;H E< O;7HIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?DLEBL;I J>; ;NF;D:?JKH; E< IK8IJ7DJ?7B H;IEKH9;I 7D: :;F;D:I ED 7 DKC8;H E< <79JEHIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= J>; I;L;H?JO E< J>; :?I;7I; ?D GK;IJ?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; 7L7?B78?B?JO E< IK?J78B; 7BJ;HD7J?L; JH;7JC;DJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FEJ;DJ?7B I7<;JO I?=D7BI E8I;HL;: ?D FH;9B?D?97B EH 9B?D?97B J;IJI 7D: J>; H?IAI 7D: 8;D;<?JI E< J>; FHE:K9J 7I :;CEDIJH7J;: ?D 9B?D?97B JH?7BIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> >7I IK8IJ7DJ?7B :?I9H;J?ED ?D J>; FHE:K9J 7FFHEL7B FHE9;IIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: ?J ?I ?CFEII?8B; JE FH;:?9J M?J> 7DO 9;HJ7?DJO M>;J>;H 7D: M>;D J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> M?BB =H7DJ C7HA;J?D= 7FFHEL7Bglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; 7=;D9O C7O H;GK?H; J>; IFEDIEH E< 7 glyph<c=29,font=/PIIBEG+FranklinGothic-Book>'glyph<c=28,font=/PIIBEG+FranklinGothic-Book> EH )glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> JE 9ED:K9J 7::?J?ED7B 9B?D?97B IJK:?;I EH JE FHEL?:; EJ>;H I9?;DJ?<?9 EH J;9>D?97B ?D<EHC7J?ED 78EKJ J>; FHE:K9Jglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: J>;I; 7::?J?ED7B H;GK?H;C;DJI C7O B;7: JE KD7DJ?9?F7J;: :;B7OI EH ;NF;DI;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> !KHJ>;HCEH;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ;L;D ?< 7 FHE:K9J ?I 7FFHEL;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; 7FFHEL7B C7O 8; IK8@;9J JE B?C?J7J?EDI 87I;: ED J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=7,font=/PIIBEG+FranklinGothic-Book>I ?DJ;HFH;J7J?ED E< J>; ;N?IJ?D= FH;glyph<c=13,font=/PIIBEG+FranklinGothic-Book> 9B?D?97B 7D:glyph<c=15,font=/PIIBEG+FranklinGothic-Book>EH 9B?D?97B :7J7glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n/>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> >7I :;L;BEF;: <EKH :?IJ?D9J 7FFHE79>;I ?DJ;D:;: JE <79?B?J7J; J>; :;L;BEFC;DJ 7D: ;NF;:?J; J>; H;=KB7JEHO H;L?;M E< J>;H7F;KJ?97BBO ?CFEHJ7DJ :HK=Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ;IF;9?7BBO M>;D J>; :HK=I 7H; J>; <?HIJ\n\n7L7?B78B; JH;7JC;DJ EH >7L; 7:L7DJ7=;I EL;H ;N?IJ?D= JH;7JC;DJIglyph<c=26,font=/PIIBEG+FranklinGothic-Book> 799;B;H7J;: 7FFHEL7Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> <7IJ JH79Aglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 8H;7AJ>HEK=> J>;H7FO 7D: FH?EH?JO H;L?;Mglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n- I glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>113:3@/B32 glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>>>@=D/: glyph<c=26,font=/PIIBEG+FranklinGothic-Book> />; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> C7O =H7DJ [799;B;H7J;: 7FFHEL7B\\ JE FHE:K9JI J>7J JH;7J I;H?EKI EH B?<;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>J>H;7J;D?D= ?BBD;II;I 7D: J>7J FHEL?:; C;7D?D=<KB J>;H7F;KJ?9 8;D;<?JI JE F7J?;DJI EL;H ;N?IJ?D= JH;7JC;DJIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 0D:;H J>?I F7J>M7Oglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> C7O 7FFHEL; 7 FHE:K9J 87I;: ED IKHHE=7J; ;D:FE?DJI EH 9B?D?97B ;D:FE?DJI EJ>;H J>7D IKHL?L7B EH ?HH;L;HI?8B; CEH8?:?JOglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2>;D 7FFHEL7B ?I 87I;: ED IKHHE=7J; ;D:FE?DJI EH 9B?D?97B ;D:FE?DJI EJ>;H J>7D IKHL?L7B EH CEH8?:?JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; IFEDIEH M?BB 8; H;GK?H;: JE FHEL?:; J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> M?J> 9ED<?HC7JEHO :7J7 FEIJglyph<c=13,font=/PIIBEG+FranklinGothic-Book>7FFHEL7B JE L;H?<O 7D: :;I9H?8; 9B?D?97B 8;D;<?Jglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 0D:;H J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=7,font=/PIIBEG+FranklinGothic-Book>I 799;B;H7J;: 7FFHEL7B H;=KB7J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?< J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 9ED9BK:;I J>7J 7 :HK= J>7J >7I 8;;D I>EMD JE 8; ;<<;9J?L; 97D 8; I7<;BO KI;: EDBO ?< :?IJH?8KJ?ED EH KI; ?I H;IJH?9J;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?J C7O H;GK?H; 9;HJ7?D FEIJglyph<c=13,font=/PIIBEG+FranklinGothic-Book>C7HA;J?D= H;IJH?9J?EDI JE 7IIKH; I7<; KI;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D 7::?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> <EH FHE:K9JI 7FFHEL;: KD:;H 799;B;H7J;: 7FFHEL7Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> IFEDIEHI C7O 8; H;GK?H;: JE IK8C?J 7BB 9EF?;I E< J>;?H FHECEJ?ED7B C7J;H?7BIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= 7:L;HJ?I;C;DJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> JE J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 7J B;7IJ glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> :7OI FH?EH JE ?D?J?7B :?II;C?D7J?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> C7O M?J>:H7M 7FFHEL7B ?<glyph<c=12,font=/PIIBEG+FranklinGothic-Book> <EH ?DIJ7D9;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> FEIJglyph<c=13,font=/PIIBEG+FranklinGothic-Book>C7HA;J?D= IJK:?;I <7?B JE L;H?<O 9B?D?97B 8;D;<?Jglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?J 8;9EC;I 9B;7H J>7J H;IJH?9J?EDI ED J>; :?IJH?8KJ?ED E< J>; FHE:K9J 7H; ?D7:;GK7J; JE ;DIKH; ?JI I7<; KI; EH ?< 7 IFEDIEH <7?BI JE 9ECFBO M?J> J>; 9ED:?J?EDI E< J>; 799;B;H7J;: 7FFHEL7Bglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- T glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>/AB (@/19 glyph<c=26,font=/PIIBEG+FranklinGothic-Book> />; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> C7O =H7DJ glyph<c=2,font=/PIIBEG+FranklinGothic-Book><7IJ JH79Aglyph<c=2,font=/PIIBEG+FranklinGothic-Book> IJ7JKI JE FHE:K9JI J>7J JH;7J 7 I;H?EKI 9ED:?J?ED 7D: >7L; :7J7 :;CEDIJH7J?D= J>; FEJ;DJ?7B JE 7::H;II 7D KDC;J C;:?97B D;;: EH 7 :HK= J>7J >7I 8;;D :;I?=D7J;: 7I 7 GK7B?<?;: ?D<;9J?EKI :?I;7I; FHE:K9Jglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- I glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>@3/9B6@=C56 (63@/>G glyph<c=26,font=/PIIBEG+FranklinGothic-Book> />; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> C7O =H7DJ [8H;7AJ>HEK=> J>;H7FO\\ IJ7JKI JE :HK=I :;I?=D;: JE JH;7Jglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7BED; EH ?D 9EC8?D7J?ED M?J> 7DEJ>;H :HK= EH :HK=Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 I;H?EKI EH B?<;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>J>H;7J;D?D= :?I;7I; EH 9ED:?J?ED 7D: <EH M>?9> FH;B?C?D7HO 9B?D?97B ;L?:;D9; IK==;IJI 7 IK8IJ7DJ?7B ?CFHEL;C;DJ EL;H ;N?IJ?D= J>;H7F?;I 87I;: ED 7 9B?D?97BBO I?=D?<?97DJ ;D:FE?DJglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>H;7AJ>HEK=> J>;H7FO IJ7JKI ;DJ?JB;I J>; IFEDIEH JE ;7HB?;H 7D: CEH; <H;GK;DJ C;;J?D=I M?J> J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> H;=7H:?D= J>; :;L;BEFC;DJ E< DED9B?D?97B 7D: 9B?D?97B :7J7 7D: F;HC?JI J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> JE E<<;H FHE:K9J :;L;BEFC;DJ EH H;=KB7JEHO 7:L?9; <EH J>; FKHFEI; E< I>EHJ;D?D= J>; J?C; JE FHE:K9J 7FFHEL7Bglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>H;7AJ>HEK=> J>;H7FO IJ7JKI :E;I DEJ =K7H7DJ;; J>7J 7 FHE:K9J M?BB 8; ;B?=?8B; <EH FH?EH?JO H;L?;M 7D: :E;I DEJ ;DIKH; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 7FFHEL7Bglyph<c=14,font=/PIIBEG+FranklinGothic-Book>",
        "metadata": {
            "page": 31
        },
        "id": "36d0dccf-4a63-44e3-8467-1d84097d48fb"
    },
    {
        "page_content": "- I $@7=@7BG &3D73E glyph<c=26,font=/PIIBEG+FranklinGothic-Book> [+H?EH?JO H;L?;M\\ EDBO 7FFB?;I JE 7FFB?97J?EDI glyph<c=8,font=/PIIBEG+FranklinGothic-Book>EH?=?D7B EH ;<<?979O IKFFB;C;DJglyph<c=9,font=/PIIBEG+FranklinGothic-Book> <EH 7 :HK= J>7J JH;7JI 7 I;H?EKI 9ED:?J?ED 7D:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?< 7FFHEL;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> MEKB: FHEL?:; 7 I?=D?<?97DJ ?CFHEL;C;DJ ?D I7<;JO EH ;<<;9J?L;D;II E< J>; JH;7JC;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> :?7=DEI?I EH FH;L;DJ?ED E< 7 I;H?EKI 9ED:?J?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book> +H?EH?JO H;L?;M C7O 7BIE 8; =H7DJ;: <EH 7DO IKFFB;C;DJ J>7J FHEFEI;I 7 B78;B?D= 9>7D=; :K; JE IJK:?;I 9ECFB;J;: ?D H;IFEDI; JE 7 MH?JJ;D H;GK;IJ <HEC J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> <EH F;:?7JH?9 IJK:?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> <EH 7D 7FFB?97J?ED <EH 7 :HK= J>7J >7I 8;;D :;I?=D7J;: 7I 7 GK7B?<?;: ?D<;9J?EKI :?I;7I; FHE:K9J EH <EH 7DO 7FFB?97J?ED EH IKFFB;C;DJ <EH 7 :HK= IK8C?JJ;: M?J> 7 FH?EH?JO H;L?;M LEK9>;Hglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n$D glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book> J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> ?IIK;: 7 H7H; F;:?7JH?9 :?I;7I; FH?EH?JO H;L?;M LEK9>;H JE KI ?D 9EDD;9J?ED M?J> J>; 7FFHEL7B E< .+$)-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>5glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## $#'(glyph<c=8,font=/PIIBDE+FranklinGothic-BookItal>!glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>&glyph<c=31,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>(glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>\"glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal> '()glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>'\n\n-;=7H:B;II E< J>; 7FFHEL7B F7J>M7O ;CFBEO;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> C7O H;GK?H; 7 IFEDIEH JE 9ED:K9J 7::?J?ED7B FEIJglyph<c=13,font=/PIIBEG+FranklinGothic-Book>C7HA;J?D= IJK:?;I 7I 7 9ED:?J?ED E< 7FFHEL7B JE FHEL?:; :7J7 ED I7<;JO 7D: ;<<;9J?L;D;IIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $< 7 IFEDIEH <7?BI JE 9ED:K9J J>; H;GK?H;: IJK:?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> C7O M?J>:H7M ?JI 7FFHEL7Bglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D 7::?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?< J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 9ED9BK:;I J>7J 7 :HK= J>7J >7I 8;;D I>EMD JE 8; ;<<;9J?L; 97D 8; I7<;BO KI;: EDBO ?< :?IJH?8KJ?ED EH KI; ?I H;IJH?9J;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?J 97D C7D:7J; FEIJglyph<c=13,font=/PIIBEG+FranklinGothic-Book>C7HA;J?D= H;IJH?9J?EDI JE 7IIKH; I7<; KI;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D IK9> 7 97I;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; IFEDIEH C7O 8; H;GK?H;: JE ;IJ78B?I> H?=EHEKI IOIJ;CI JE 7IIKH; KI; E< J>; FHE:K9J KD:;H I7<; 9ED:?J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />;I; IOIJ;CI 7H; KIK7BBO H;<;HH;: JE 7I -?IA  L7BK7J?ED 7D: (?J?=7J?ED .JH7J;=?;I glyph<c=8,font=/PIIBEG+FranklinGothic-Book>- (.glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 97D ?CFEI; <?D7D9?7B F;D7BJ?;I <EH <7?B?D= JE 9ECFBO M?J> 9;HJ7?D FEIJglyph<c=13,font=/PIIBEG+FranklinGothic-Book>C7HA;J?D= 9ECC?JC;DJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= - (.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D 7::?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7DO 9>7D=;I JE 7D 7FFHEL;: - (. CKIJ 8; H;L?;M;: 7D: 7FFHEL;: 8O J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> FH?EH JE ?CFB;C;DJ7J?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>*glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>&'glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>*glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>\"( &glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>$#&(glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>\"glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>\n\n2; CED?JEH ?D<EHC7J?ED ED I?:; ;<<;9JI 7D: 7:L;HI; ;L;DJI H;FEHJ;: :KH?D= 9B?D?97B IJK:?;I 7D: 7<J;H C7HA;J?D= 7FFHEL7B 7D: H;FEHJ IK9> ?D<EHC7J?ED 7D: ;L;DJI JE H;=KB7JEHO 7=;D9?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> )EDglyph<c=13,font=/PIIBEG+FranklinGothic-Book>9ECFB?7D9; M?J> J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=7,font=/PIIBEG+FranklinGothic-Book>I I7<;JO H;FEHJ?D= H;GK?H;C;DJI C7O H;IKBJ ?D 9?L?B EH 9H?C?D7B F;D7BJ?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> .?:; ;<<;9JI EH 7:L;HI; ;L;DJI J>7J 7H; H;FEHJ;: :KH?D= 9B?D?97B JH?7BI 97D :;B7Oglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?CF;:; EH FH;L;DJ C7HA;J?D= 7FFHEL7Bglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>7I;: ED D;M I7<;JO ?D<EHC7J?ED J>7J ;C;H=;I 7<J;H 7FFHEL7Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 97D C7D:7J; FHE:K9J B78;B?D= 9>7D=;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?CFEI; 7 D;M - (. EH J>; 7::?J?ED E< ;B;C;DJI JE 7D ;N?IJ?D= - (.glyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;GK?H; D;M FEIJglyph<c=13,font=/PIIBEG+FranklinGothic-Book> C7HA;J?D= IJK:?;I glyph<c=8,font=/PIIBEG+FranklinGothic-Book>?D9BK:?D= 7::?J?ED7B 9B?D?97B JH?7BIglyph<c=9,font=/PIIBEG+FranklinGothic-Book> EH IKIF;D: EH M?J>:H7M 7FFHEL7B E< J>; FHE:K9Jglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />;I; H;GK?H;C;DJI C7O 7<<;9J EKH 78?B?JO JE C7?DJ7?D C7HA;J?D= 7FFHEL7B E< EKH FHE:K9JI EH H;GK?H; KI JE\n\nC7A; I?=D?<?97DJ ;NF;D:?JKH;I JE E8J7?D EH C7?DJ7?D IK9> 7FFHEL7BIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>$$&#*glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal> #glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=28,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>\"glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>' (# glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>\" glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>$$&#*glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal> $&#glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>)glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>(\n\n$< M; I;;A JE C7A; 9;HJ7?D JOF;I E< 9>7D=;I JE 7D 7FFHEL;: FHE:K9Jglyph<c=12,font=/PIIBEG+FranklinGothic-Book> IK9> 7I 7::?D= 7 D;M ?D:?97J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> C7A?D= 9;HJ7?D C7DK<79JKH?D= 9>7D=;I EH 9>7D=?D= C7DK<79JKH;HI EH IKFFB?;HI E< 9;HJ7?D ?D=H;:?;DJI EH 9ECFED;DJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> M?BB D;;: JE H;L?;M 7D: 7FFHEL; IK9> 9>7D=;I ?D 7:L7D9;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D J>; 97I; E< 7 D;M ?D:?97J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 7H; H;GK?H;: JE :;CEDIJH7J; M?J> 7::?J?ED7B 9B?D?97B :7J7 J>7J J>; FHE:K9J ?I I7<; 7D: ;<<;9J?L; <EH 7 KI; EJ>;H J>7D M>7J M7I ?D?J?7BBO 7FFHEL;:glyph<c=14,font=/PIIBEG+FranklinGothic-Book> !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> H;=KB7JEHO H;L?;M C7O H;IKBJ ?D :;D?7B EH CE:?<?97J?ED E< J>; FB7DD;: 9>7D=;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> EH H;GK?H;C;DJI JE 9ED:K9J 7::?J?ED7B J;IJI EH ;L7BK7J?EDI J>7J 97D IK8IJ7DJ?7BBO :;B7O EH ?D9H;7I; J>; 9EIJ E< J>; FB7DD;: 9>7D=;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## &glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>) glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>(glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>#\" #glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal> $&#glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>)glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>( glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>*glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>&(glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>'glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>\"glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>\"glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal> $&#!#(glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>#\"\n\n/>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> H;=KB7J;I 7BB 7:L;HJ?I?D= 7D: FHECEJ?ED 79J?L?J?;I 7D: 9ECCKD?97J?EDI <EH FHE:K9JI KD:;H ?JI @KH?I:?9J?ED 8EJ> 8;<EH; 7D: 7<J;H 7FFHEL7Bglyph<c=14,font=/PIIBEG+FranklinGothic-Book> +KHIK7DJ JE !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> =K?:7D9;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 9ECF7DO 97D C7A; I7<;JO 7D: ;<<?979O 9B7?CI ;?J>;H ?D EH 9EDI?IJ;DJ M?J> J>; FHE:K9J B78;Bglyph<c=14,font=/PIIBEG+FranklinGothic-Book> #EM;L;Hglyph<c=12,font=/PIIBEG+FranklinGothic-Book> F>OI?9?7DI C7O FH;I9H?8; B;=7BBO 7L7?B78B; :HK=I <EH KI;I J>7J 7H; DEJ :;I9H?8;: ?D J>; :HK=glyph<c=7,font=/PIIBEG+FranklinGothic-Book>I B78;B?D=glyph<c=14,font=/PIIBEG+FranklinGothic-Book> .K9> E<<glyph<c=13,font=/PIIBEG+FranklinGothic-Book>B78;B FH;I9H?8?D= ?I 9ECCED 79HEII C;:?97B IF;9?7BJ?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: E<J;D H;<B;9JI 7 F>OI?9?7Dglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I 8;B?;< J>7J J>; E<<glyph<c=13,font=/PIIBEG+FranklinGothic-Book>B78;B KI; ?I J>; 8;IJ JH;7JC;DJ <EH F7J?;DJIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> :E;I DEJ H;=KB7J; J>; 8;>7L?EH E< F>OI?9?7DI ?D J>;?H 9>E?9; E< JH;7JC;DJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 8KJ !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> H;=KB7J?EDI :E ?CFEI; IJH?D=;DJ H;IJH?9J?EDI ED C7DK<79JKH;HIglyph<c=7,font=/PIIBEG+FranklinGothic-Book> 9ECCKD?97J?EDI H;=7H:?D= E<<glyph<c=13,font=/PIIBEG+FranklinGothic-Book>B78;B KI;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> !7?BKH; JE 9ECFBO M?J> 7FFB?978B; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> H;GK?H;C;DJI C7O IK8@;9J 7 9ECF7DO JE 7:L;HI; FK8B?9?JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ;D<EH9;C;DJ 79J?ED 8O J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9EHH;9J?L; 7:L;HJ?I?D= 7D: J>; <KBB H7D=; E< 9?L?B 7D: 9H?C?D7B F;D7BJ?;I 7L7?B78B; JE J>; =EL;HDC;DJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## &35C:/B7=< =4 glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=;07</B7=< $@=2C1BA\n\nglyph<c=30,font=/PIIBEG+FranklinGothic-Book>EC8?D7J?ED FHE:K9JI 7H; :;<?D;: 8O J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> JE ?D9BK:; FHE:K9JI 9ECFH?I?D= JME EH CEH; H;=KB7J;: 9ECFED;DJI glyph<c=8,font=/PIIBEG+FranklinGothic-Book>;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>=glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 8?EBE=?9 7D: 7 :;L?9;glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?EBE=?9I 7D: :;L?9;I ;79> >7L; J>;?H EMD H;=KB7JEHO H;GK?H;C;DJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: 9EC8?D7J?ED FHE:K9JI C7O >7L; 7::?J?ED7B H;GK?H;C;DJIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> .EC; E< EKH C7HA;J;: FHE:K9JI C;;J J>?I :;<?D?J?ED 7D: 7H; H;=KB7J;: KD:;H J>?I <H7C;MEHA 7D: I?C?B7H H;=KB7J?EDI EKJI?:; J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: M; ;NF;9J J>7J IEC; E< EKH F?F;B?D; FHE:K9J 97D:?:7J;I C7O 8; ;L7BK7J;: <EH H;=KB7JEHO 7FFHEL7B KD:;H J>?I <H7C;MEHA 7I M;BBglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n$D (7O glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book> D;M H;=KB7J?EDI =EL;HD?D= C;:?97B :;L?9;I glyph<c=8,font=/PIIBEG+FranklinGothic-Book>(glyph<c=31,font=/PIIBEG+FranklinGothic-Book>-glyph<c=9,font=/PIIBEG+FranklinGothic-Book> 7D: ?Dglyph<c=13,font=/PIIBEG+FranklinGothic-Book>L?JHE :?7=DEIJ?9 C;:?97B :;L?9;I glyph<c=8,font=/PIIBEG+FranklinGothic-Book>$1glyph<c=31,font=/PIIBEG+FranklinGothic-Book>-glyph<c=9,font=/PIIBEG+FranklinGothic-Book> ;DJ;H;: ?DJE <EH9; ?D J>;  glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; (glyph<c=31,font=/PIIBEG+FranklinGothic-Book>H;=KB7J?EDI 8;97C; 7FFB?978B; ?D (7O glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book> 7D: J>;",
        "metadata": {
            "page": 32
        },
        "id": "5b4cec7a-beef-49fb-a062-90512750e8d4"
    },
    {
        "page_content": "$1glyph<c=31,font=/PIIBEG+FranklinGothic-Book>H;=KB7J?EDI 8;97C; 7FFB?978B; ?D (7O glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BB FHE:K9JI 9EL;H;: 8O J>;I; H;=KB7J?EDI M?BB 8; H;GK?H;: JE 9ECFBO M?J> J>;C 7J J>; ;D: E< J>; JH7DI?J?ED7B F;H?E:Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />;I; H;=KB7J?EDI ?DJHE:K9; D;M H;GK?H;C;DJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= <EH 9B?D?97B ?DL;IJ?=7J?ED E< 9;HJ7?D 9B7II?<?97J?EDI E< C;:?97B :;L?9;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;GK?H; ?D9H;7I;: H;=KB7JEHO I9HKJ?DOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ;D>7D9; J>; H;GK?H;C;DJI <EH FEIJ C7HA;J IKHL;?BB7D9; 7D: L?=?B7D9; 7D: FHEL?:; <EH =H;7J;H JH7DIF7H;D9Oglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />;I; H;=KB7J?EDI 7BIE 9>7D=; J>; H;GK?H;C;DJI <EH 7II;IIC;DJ E< J>; C;:?97B :;L?9; 9ECFED;DJI E< ?DJ;=H7B :HK=glyph<c=13,font=/PIIBEG+FranklinGothic-Book>:;L?9; 9EC8?D7J?ED FHE:K9JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> D;9;II?J7J?D= 7II;IIC;DJ E< J>; :;L?9; 9ECFED;DJI KD:;H 8EJ> J>; C;:?97B :;L?9; 7D: C;:?9?D7B FHE:K9J H;=KB7JEHO H;=?C;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n$@=2C1B glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>>>@=D/: /<2 $=ABglyph<c=8,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>>>@=D/: &35C:/B7=< #CBA723 B63 )glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal>'glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal>\n\n2; C7HA;J EKH FHE:K9JI ?D DKC;HEKI @KH?I:?9J?EDI EKJI?:; J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> (EIJ E< J>;I; @KH?I:?9J?EDI >7L; FHE:K9J 7FFHEL7B 7D: FEIJglyph<c=13,font=/PIIBEG+FranklinGothic-Book>7FFHEL7B H;=KB7JEHO FHE9;II;I J>7J 7H; I?C?B7H ?D FH?D9?FB; JE J>EI; ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D  KHEF;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> <EH ;N7CFB;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>;H; 7 IK8IJ7DJ?7B F7HJ E< EKH ;Nglyph<c=13,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> ;<<EHJI 7H; <E9KI;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>;H; 7H; I;L;H7B HEKJ;I <EH C7HA;J?D= 7FFHEL7Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> :;F;D:?D= ED J>; JOF; E< FHE:K9J <EH M>?9> 7FFHEL7B ?I IEK=>Jglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 0D:;H J>; 9;DJH7B?P;: FHE9;:KH;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 9ECF7DO IK8C?JI 7 I?D=B; 7FFB?97J?ED JE J>;  (glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; C7HA;J?D= 7KJ>EH?P7J?ED 7FFB?97J?ED ?I I?C?B7H JE J>; )glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> EH glyph<c=29,font=/PIIBEG+FranklinGothic-Book>'glyph<c=28,font=/PIIBEG+FranklinGothic-Book> ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 7D: ?I ;L7BK7J;: 8O J>; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>#(+glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; ;NF;HJ I9?;DJ?<?9 9ECC?JJ;; E< J>;  (glyph<c=28,font=/PIIBEG+FranklinGothic-Book> H;IFEDI?8B; <EH >KC7D C;:?9?D;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $< J>; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>#(+ :;J;HC?D;I J>7J J>; (glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> <KB<?BBI J>; H;GK?H;C;DJI <EH GK7B?JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> I7<;JO 7D: ;<<?979O 7D: J>7J J>; C;:?9?D; >7I 7 FEI?J?L; 8;D;<?J H?IA 87B7D9;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?J M?BB 7:EFJ 7 FEI?J?L; EF?D?ED H;9ECC;D:?D= J>; =H7DJ?D= E< J>; C7HA;J?D= 7KJ>EH?P7J?ED 8O J>;  glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>#(+ EF?D?ED ?I DEJ 8?D:?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 8KJ ?I JOF?97BBO 7:EFJ;: 8O J>;  glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book> (glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 7FFHEL;: 8O J>;  glyph<c=30,font=/PIIBEG+FranklinGothic-Book> ?I L7B?: ?D 7BB C;C8;H IJ7J;I E< J>;  glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; 9;DJH7B?P;: FHE9;:KH; ?I H;GK?H;: <EH 7BB 8?EBE=?97B FHE:K9JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> EHF>7D C;:?9?D7B FHE:K9JI 7D: D;M JH;7JC;DJI <EH D;KHE:;=;D;H7J?L; :?IEH:;HIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: ?J ?I 7L7?B78B; <EH 9;HJ7?D EJ>;H FHE:K9JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= J>EI; M>?9> 9EDIJ?JKJ; 7 I?=D?<?97DJ J>;H7F;KJ?9glyph<c=12,font=/PIIBEG+FranklinGothic-Book> I9?;DJ?<?9 EH J;9>D?97B ?DDEL7J?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n$D 7::?J?ED JE J>; 9;DJH7B?P;: FHE9;:KH;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; KHEF;7D H;=KB7JEHO <H7C;MEHA ?D9BK:;I J>; <EBBEM?D= EFJ?EDI <EH H;=KB7JEHO H;L?;M 7D: 7FFHEL7B ?D J>;  glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book> C;C8;H IJ7J;Iglyph<c=26,font=/PIIBEG+FranklinGothic-Book>\n\n- T 7 D7J?ED7B FHE9;:KH;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>;H; J>; <?HIJ 7FFB?97J?ED ?I C7:; JE J>; 9ECF;J;DJ 7KJ>EH?JO ?D ED;  glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book> C;C8;H IJ7J; EDBOglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T 7 :;9;DJH7B?P;: FHE9;:KH;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>;H; 7FFB?97DJI IK8C?J ?:;DJ?97B 7FFB?97J?EDI JE I;L;H7B  glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book> C;C8;H IJ7J;I 7D: H;9;?L; I?CKBJ7D;EKI 7FFHEL7Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?< J>; C;:?9?D; >7I DEJ O;J 8;;D 7KJ>EH?P;: ?D 7DO  glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book> C;C8;H IJ7J;glyph<c=27,font=/PIIBEG+FranklinGothic-Book> 7D:\n\n- T 7 CKJK7B H;9E=D?J?ED FHE9;:KH;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>;H; 7FFB?97DJI J>7J >7L; 7 C;:?9?D; 7KJ>EH?P;: ?D ED;  glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book> C;C8;H IJ7J; 97D 7FFBO <EH CKJK7B H;9E=D?J?ED E< J>?I 7KJ>EH?P7J?ED ?D EJ>;H  glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book> C;C8;H IJ7J;I\n\nglyph<c=28,font=/PIIBEG+FranklinGothic-Book>I ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>;  glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 7BIE >7I :?IJ?D9J 7FFHE79>;I ?DJ;D:;: JE EFJ?C?P; J>; H;=KB7JEHO F7J>M7OI <EH J>;H7F;KJ?97BBO ?CFEHJ7DJ :HK=Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= J>; +H?EH?JO (;:?9?D;I  L7BK7J?ED .9>;C; glyph<c=8,font=/PIIBEG+FranklinGothic-Book>+-$( glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 799;B;H7J;: 7II;IIC;DJ 7D: 9ED:?J?ED7B C7HA;J?D= 7KJ>EH?P7J?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book> +-$(  ?I ?DJ;D:;: JE FHEL?:; 7::?J?ED7B IKFFEHJ JE C;:?9?D; :;L;BEF;HI J>HEK=>EKJ J>; :;L;BEFC;DJ FHE9;IIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> -;=KB7JEHO H;L?;M J?C;B?D;I ?D J>;  glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book> C7O 8; JHKD97J;: KD:;H 799;B;H7J;: 7II;IIC;DJ <EH FHE:K9JI J>7J 7::H;II 7D KDC;J C;:?97B D;;:glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D 7::?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9ED:?J?ED7B C7HA;J?D= 7KJ>EH?P7J?EDI C7O 8; =H7DJ;: <EH FHE:K9JI ?D J>; ?DJ;H;IJ E< FK8B?9 >;7BJ>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>;H; J>; 8;D;<?J E< ?CC;:?7J; 7L7?B78?B?JO EKJM;?=>I J>; H?IA E< >7L?D= B;II 9ECFH;>;DI?L; :7J7 J>7D DEHC7BBO H;GK?H;:glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>ED:?J?ED7B C7HA;J?D= 7KJ>EH?P7J?EDI 7H; L7B?: <EH ED; O;7H 7D: 97D 8; H;D;M;: 7DDK7BBOglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; C7HA;J?D= 7KJ>EH?P7J?ED >EB:;H ?I H;GK?H;: JE 9ECFB;J; IF;9?<?9 E8B?=7J?EDI glyph<c=8,font=/PIIBEG+FranklinGothic-Book>ED=E?D= EH D;M IJK:?;I 7D:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D IEC; 97I;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7::?J?ED7B 79J?L?J?;Iglyph<c=9,font=/PIIBEG+FranklinGothic-Book> M?J> 7 L?;M JE FHEL?:?D= 9ECFH;>;DI?L; :7J7 9ED<?HC?D= J>7J J>; 8;D;<?J H?IA 87B7D9; ?I FEI?J?L;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> *D9; 9ECFH;>;DI?L; :7J7 ED J>; FHE:K9J >7L; 8;;D E8J7?D;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; C7HA;J?D= 7KJ>EH?P7J?ED C7O 8; 9EDL;HJ;: ?DJE 7 IJ7D:7H: C7HA;J?D= 7KJ>EH?P7J?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=28,font=/PIIBEG+FranklinGothic-Book>I?:; <HEC J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 7D: J>;  glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>;H; 7H; 9EKDJH?;I ?D EJ>;H H;=?EDI M>;H; ?J ?I FEII?8B; JE H;9;?L; 7D glyph<c=2,font=/PIIBEG+FranklinGothic-Book>799;B;H7J;:glyph<c=2,font=/PIIBEG+FranklinGothic-Book> H;L?;M M>;H;8O J>; D7J?ED7B H;=KB7JEHO 7KJ>EH?JO M?BB 9ECC?J JE JHKD97J;: H;L?;M J?C;B?D;I <EH FHE:K9JI J>7J C;;J IF;9?<?9 C;:?97B D;;:Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n$D J>;  glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book> J>;H; ?I :;J7?B;: B;=?IB7J?ED ED F>7HC79EL?=?B7D9; 7D: ;NJ;DI?L; =K?:7D9; ED =EE: F>7HC79EL?=?B7D9; FH79J?9;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book> <7?BKH; JE 9ECFBO M?J> J>;  glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book> F>7HC79EL?=?B7D9; E8B?=7J?EDI C7O H;IKBJ ?D I?=D?<?97DJ <?D7D9?7B F;D7BJ?;I <EH J>; C7HA;J?D= 7KJ>EH?P7J?ED >EB:;Hglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n-;=7H:B;II E< J>; 7FFHEL7B FHE9;II ;CFBEO;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> L7H?EKI F7HJ?;I I>7H; H;IFEDI?8?B?J?;I <EH J>; CED?JEH?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> :;J;9J?ED 7D: ;L7BK7J?ED E< 7:L;HI; ;L;DJI FEIJglyph<c=13,font=/PIIBEG+FranklinGothic-Book>7FFHEL7Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= D7J?ED7B 9ECF;J;DJ 7KJ>EH?J?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>;  (glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>;  glyph<c=30,font=/PIIBEG+FranklinGothic-Book> 7D: J>; C7HA;J?D= 7KJ>EH?P7J?ED >EB:;Hglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />;  (glyph<c=28,font=/PIIBEG+FranklinGothic-Book>^I +>7HC79EL?=?B7D9; -?IA glyph<c=28,font=/PIIBEG+FranklinGothic-Book>II;IIC;DJ glyph<c=30,font=/PIIBEG+FranklinGothic-Book>ECC?JJ;; ?I H;IFEDI?8B; <EH 7II;II?D= 7D: CED?JEH?D= J>; I7<;JO E< >KC7D C;:?9?D;I 7D: C7A;I H;9ECC;D:7J?EDI ED FHE:K9J I7<;JO ?IIK;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> (7HA;J?D= 7KJ>EH?P7J?ED >EB:;HI >7L; 7D E8B?=7J?ED JE ?D<EHC H;=KB7JEHO 7=;D9?;I E< 7DO D;M ?D<EHC7J?ED M>?9> C7O ?D<BK;D9; J>; ;L7BK7J?ED E< 8;D;<?JI 7D: H?IAI E< J>; C;:?9?D7B FHE:K9J 9ED9;HD;:glyph<c=14,font=/PIIBEG+FranklinGothic-Book>",
        "metadata": {
            "page": 33
        },
        "id": "b0d8dba6-a5e3-47ba-b56a-e39e2c28c19f"
    },
    {
        "page_content": "$D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>;  glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 7D: EJ>;H @KH?I:?9J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;=KB7JEHO 7=;D9?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9ED:K9J F;H?E:?9 ?DIF;9J?EDI E< )glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>'glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 7D: C7HA;J?D= 7KJ>EH?P7J?ED >EB:;HI JE 7II;II J>;?H 9ECFB?7D9; M?J> F>7HC79EL?=?B7D9; E8B?=7J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>==2 !/<C4/1BC@7<5 $@/1B713A\n\n-;=KB7JEHO 7=;D9?;I H;=KB7J; 7D: ?DIF;9J ;GK?FC;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> <79?B?J?;I 7D: FHE9;II;I KI;: ?D J>; C7DK<79JKH?D= 7D: J;IJ?D= E< F>7HC79;KJ?97B 7D: 8?EBE=?9 FHE:K9JI FH?EH JE 7FFHEL?D= 7 FHE:K9Jglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $<glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7<J;H H;9;?L?D= 7FFHEL7B <HEC H;=KB7JEHO 7=;D9?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 9ECF7DO C7A;I 7 C7J;H?7B 9>7D=; ?D C7DK<79JKH?D= ;GK?FC;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> BE97J?ED EH FHE9;IIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7::?J?ED7B H;=KB7JEHO H;L?;M 7D: 7FFHEL7B C7O 8; H;GK?H;:glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; 7BIE CKIJ 7:>;H; JE 9KHH;DJ \"EE: (7DK<79JKH?D= +H79J?9;I glyph<c=8,font=/PIIBEG+FranklinGothic-Book>9\"(+glyph<c=9,font=/PIIBEG+FranklinGothic-Book> 7D: FHE:K9Jglyph<c=13,font=/PIIBEG+FranklinGothic-Book>IF;9?<?9 H;=KB7J?EDI ;D<EH9;: 8O H;=KB7JEHO 7=;D9?;I <EBBEM?D= FHE:K9J 7FFHEL7Bglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>;  (glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 7D: EJ>;H H;=KB7JEHO 7=;D9?;I 7BIE 9ED:K9J F;H?E:?9 L?I?JI JE H;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>?DIF;9J ;GK?FC;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> <79?B?J?;I 7D: FHE9;II;I <EBBEM?D= J>; ?D?J?7B 7FFHEL7B E< 7 FHE:K9Jglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $<glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7I 7 H;IKBJ E< J>;I; ?DIF;9J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?J ?I :;J;HC?D;: J>7J EKH ;GK?FC;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> <79?B?J?;I EH FHE9;II;I :E DEJ 9ECFBO M?J> 7FFB?978B; H;=KB7J?EDI 7D: 9ED:?J?EDI E< FHE:K9J 7FFHEL7Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;=KB7JEHO 7=;D9?;I C7O I;;A 9?L?Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9H?C?D7B EH 7:C?D?IJH7J?L; I7D9J?EDI EH H;C;:?;I 7=7?DIJ KIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= I?=D?<?97DJ <?D7D9?7B F;D7BJ?;I 7D: J>; IKIF;DI?ED E< EKH C7DK<79JKH?D= EF;H7J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>==2 glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>:7<71/: $@/1B713A\n\n/>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>;  (glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 7D: EJ>;H H;=KB7JEHO 7=;D9?;I FHECKB=7J; H;=KB7J?EDI 7D: IJ7D:7H:I <EH :;I?=D?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9ED:K9J?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> CED?JEH?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7K:?J?D= 7D: H;FEHJ?D= J>; H;IKBJI E< 9B?D?97B JH?7BI JE ;DIKH; J>7J J>; :7J7 7D: H;IKBJI 7H; 799KH7J; 7D: J>7J J>; H?=>JI 7D: M;B<7H; E< JH?7B F7HJ?9?F7DJI 7H; 7:;GK7J;BO FHEJ;9J;: glyph<c=8,font=/PIIBEG+FranklinGothic-Book>9ECCEDBO H;<;HH;: JE 7I 9KHH;DJ \"EE: glyph<c=30,font=/PIIBEG+FranklinGothic-Book>B?D?97B +H79J?9;I glyph<c=8,font=/PIIBEG+FranklinGothic-Book>9\"glyph<c=30,font=/PIIBEG+FranklinGothic-Book>+glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> -;=KB7JEHO 7=;D9?;I ;D<EH9; 9\"glyph<c=30,font=/PIIBEG+FranklinGothic-Book>+ J>HEK=> F;H?E:?9 ?DIF;9J?EDI E< JH?7B IFEDIEHIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FH?D9?F7B ?DL;IJ?=7JEHI 7D: JH?7B I?J;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9EDJH79J H;I;7H9> EH=7D?P7J?EDI glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=30,font=/PIIBEG+FranklinGothic-Book>-*Iglyph<c=9,font=/PIIBEG+FranklinGothic-Book> 7D: ?DIJ?JKJ?ED7B H;L?;M 8E7H:Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $< EKH IJK:?;I <7?B JE 9ECFBO M?J> 7FFB?978B; 9\"glyph<c=30,font=/PIIBEG+FranklinGothic-Book>+ =K?:;B?D;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; 9B?D?97B :7J7 =;D;H7J;: ?D EKH 9B?D?97B JH?7BI C7O 8; :;;C;: KDH;B?78B; 7D: H;B;L7DJ H;=KB7JEHO 7=;D9?;I C7O H;GK?H; KI JE F;H<EHC 7::?J?ED7B 9B?D?97B JH?7BI 8;<EH; 7FFHEL?D= EKH C7HA;J?D= 7FFB?97J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> )ED9ECFB?7D9; 97D 7BIE H;IKBJ ?D 9?L?B EH 9H?C?D7B I7D9J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; H;BO ED J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJ?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= glyph<c=30,font=/PIIBEG+FranklinGothic-Book>-*Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> JE 97HHO EKJ C7DO E< EKH 9B?D?97B JH?7Bglyph<c=13,font=/PIIBEG+FranklinGothic-Book>H;B7J;: 79J?L?J?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> !7?BKH; E< IK9> J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book> F7HJ?;I JE 9ECFBO M?J> 9\"glyph<c=30,font=/PIIBEG+FranklinGothic-Book>+ 97D B?A;M?I; H;IKBJ ?D H;@;9J?ED E< EKH 9B?D?97B JH?7B :7J7 EH EJ>;H I7D9J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n$D glyph<c=28,font=/PIIBEG+FranklinGothic-Book>FH?B glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book> J>;  glyph<c=30,font=/PIIBEG+FranklinGothic-Book> 7:EFJ;: 7 D;M glyph<c=30,font=/PIIBEG+FranklinGothic-Book>B?D?97B /H?7B -;=KB7J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> M7I ;DJ;H;: ?DJE <EH9; ?D %KD; glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book> 8KJ :?: DEJ 7FFBO KDJ?B %7DK7HO glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />;H; 7H; JH7DI?J?ED7B FHEL?I?EDI <EH 9B?D?97B JH?7BI M>?9> 7H; ED=E?D= 7J J>; :7J; E< 7FFB?97J?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>B?D?97B JH?7B 7FFB?97J?EDI C7O 7BIE 9EDJ?DK; JE 8; C7:; KD:;H J>;\n\nglyph<c=30,font=/PIIBEG+FranklinGothic-Book>B?D?97B /H?7B glyph<c=31,font=/PIIBEG+FranklinGothic-Book>?H;9J?L; glyph<c=8,font=/PIIBEG+FranklinGothic-Book>J>; ;N?IJ?D= H;=KB7JEHO <H7C;MEHAglyph<c=9,font=/PIIBEG+FranklinGothic-Book> KDJ?B %7DK7HO glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BB 9B?D?97B JH?7BI CKIJ <KBBO 9ECFBO M?J> J>; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>B?D?97B /H?7B -;=KB7J?ED 8O %7DK7HO glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; H;=KB7J?ED >7HCED?P;I J>; FHE9;:KH;I <EH 7II;IIC;DJ 7D: =EL;HD7D9; E< 9B?D?97B JH?7BI J>HEK=>EKJ J>;  glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 7D: M?BB H;GK?H; J>7J ?D<EHC7J?ED ED J>; 7KJ>EH?P7J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9ED:K9J 7D: H;IKBJI E< ;79> 9B?D?97B JH?7B 9ED:K9J;: ?D J>;  glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 8; FK8B?9BO 7L7?B78B;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>>>@=D/: =4 glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>7=A7;7:/@A\n\n$D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> J>; +7J?;DJ +HEJ;9J?ED 7D: glyph<c=28,font=/PIIBEG+FranklinGothic-Book><<EH:78B; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>7H; glyph<c=28,font=/PIIBEG+FranklinGothic-Book>9J glyph<c=8,font=/PIIBEG+FranklinGothic-Book>++glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book> 7C;D:;: J>; +K8B?9 #;7BJ> .;HL?9; glyph<c=28,font=/PIIBEG+FranklinGothic-Book>9J glyph<c=8,font=/PIIBEG+FranklinGothic-Book>+#.glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book> JE 7KJ>EH?P; J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> JE 7FFHEL; 8?EBE=?97B FHE:K9JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;<;HH;: JE 7I 8?EI?C?B7HI EH <EBBEMglyph<c=13,font=/PIIBEG+FranklinGothic-Book>ED 8?EBE=?9Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>7J 7H; I>EMD JE 8; glyph<c=2,font=/PIIBEG+FranklinGothic-Book>>?=>BO I?C?B7Hglyph<c=2,font=/PIIBEG+FranklinGothic-Book> JE FH;L?EKIBO 7FFHEL;: 8?EBE=?97B FHE:K9JI 87I;: KFED FEJ;DJ?7BBO 788H;L?7J;: :7J7 F79A7=;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; 8?EI?C?B7H CKIJ I>EM ?J >7I DE 9B?D?97BBO C;7D?D=<KB :?<<;H;D9;I ?D J;HCI E< I7<;JO 7D: ;<<;9J?L;D;II <HEC J>; H;<;H;D9; FHE:K9Jglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: EDBO C?DEH :?<<;H;D9;I ?D 9B?D?97BBO ?D79J?L; 9ECFED;DJI 7H; 7BBEM78B; ?D 8?EI?C?B7H FHE:K9JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; 7FFHEL7B F7J>M7O <EH 8?EI?C?B7HI :E;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> >EM;L;Hglyph<c=12,font=/PIIBEG+FranklinGothic-Book> =H7DJ 7 8?EBE=?9I C7DK<79JKH;H 7 glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=13,font=/PIIBEG+FranklinGothic-Book>O;7H F;H?E: E< ;N9BKI?L?JO <HEC J>; :7J; E< 7FFHEL7B E< ?JI 8?EBE=?97B FHE:K9J 8;<EH; 8?EI?C?B7H 9ECF;J?J?ED 97D 8; ?DJHE:K9;:glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />;H; ?I KD9;HJ7?DJOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> >EM;L;Hglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7I J>; 7FFHEL7B <H7C;MEHA <EH 8?EI?C?B7HI EH?=?D7BBO M7I ;D79J;: 7I F7HJ E< J>; ++glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />;H; >7L; 8;;Dglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: J>;H; 7H; B?A;BO JE 9EDJ?DK; JE 8;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> <;:;H7B B;=?IB7J?L; 7D: 7:C?D?IJH7J?L; ;<<EHJI JE H;F;7Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> IK8IJ7DJ?7BBO CE:?<O EH ?DL7B?:7J; IEC; EH 7BB E< J>; FHEL?I?EDI E< J>; ++glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $< J>; ++glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> ?I H;F;7B;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> IK8IJ7DJ?7BBO CE:?<?;: EH ?DL7B?:7J;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?J ?I KD9B;7H M>7Jglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?< 7DOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?CF79J IK9> 79J?ED MEKB: >7L; ED 8?EI?C?B7H H;=KB7J?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=28,font=/PIIBEG+FranklinGothic-Book> 8?EI?C?B7HI 7FFHEL7B F7J>M7O >7I 8;;D ?D FB79; ?D J>;  glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book> I?D9; glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />;  (glyph<c=28,font=/PIIBEG+FranklinGothic-Book> >7I ?IIK;: 7 DKC8;H E< I9?;DJ?<?9 7D: FHE:K9J IF;9?<?9 8?EI?C?B7H =K?:;B?D;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= H;GK?H;C;DJI <EH 7FFHEL?D= 8?EI?C?B7HI 9EDJ7?D?D= CEDE9BED7B 7DJ?8E:?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D J>;  glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 8?EI?C?B7HI 7H; =;D;H7BBO 7FFHEL;: KD:;H J>; 9;DJH7B?P;: FHE9;:KH;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; 7FFHEL7B F7J>M7O 7BBEMI IFEDIEHI E< 7 8?EI?C?B7H JE I;;A 7D: E8J7?D H;=KB7JEHO 7FFHEL7B 87I;: ?D F7HJ ED H;B?7D9; ED J>; 9B?D?97B JH?7B :7J7 E< 7D ?DDEL7JEH FHE:K9J JE M>?9> J>; 8?EI?C?B7H >7I 8;;D :;CEDIJH7J;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>HEK=> 9ECFH;>;DI?L; 9ECF7H78?B?JO IJK:?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> JE 8; [I?C?B7Hglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\\ $D C7DO 97I;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>?I 7BBEMI 8?EI?C?B7HI JE 8; 8HEK=>J JE C7HA;J M?J>EKJ 9ED:K9J?D= J>; <KBB 9ECFB;C;DJ E< 9B?D?97B JH?7BI JOF?97BBO H;GK?H;: <EH DEL;B 8?EBE=?9 :HK=Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## #@>6/< glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>@C5 glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>1B\n\n0D:;H J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> *HF>7D glyph<c=31,font=/PIIBEG+FranklinGothic-Book>HK= glyph<c=28,font=/PIIBEG+FranklinGothic-Book>9Jglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> C7O =H7DJ EHF>7D :HK= :;I?=D7J?ED JE :HK=I EH 8?EBE=?9I ?DJ;D:;: JE JH;7J 7 [H7H; :?I;7I; EH 9ED:?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book>\\ M>?9> =;D;H7BBO ?I 7 :?I;7I; EH 9ED:?J?ED J>7J 7<<;9JI <;M;H J>7D glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> ?D:?L?:K7BI ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $< 7 FHE:K9J",
        "metadata": {
            "page": 34
        },
        "id": "0e577375-5b22-43a4-9aba-d9588b005e73"
    },
    {
        "page_content": "M>?9> >7I 7D EHF>7D :HK= :;I?=D7J?ED IK8I;GK;DJBO H;9;?L;I 7D ?D?J?7B !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 7FFHEL7B <EH J>; ?D:?97J?ED <EH M>?9> ?J >7I IK9> :;I?=D7J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; FHE:K9J ?I ;DJ?JB;: JE EHF>7D ;N9BKI?L?JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?glyph<c=14,font=/PIIBEG+FranklinGothic-Book>;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> C7O DEJ 7FFHEL; 7DO EJ>;H 7FFB?97J?EDI JE C7HA;J J>; I7C; :HK= <EH J>; I7C; ?D:?97J?ED <EH 7 F;H?E: E< I;L;D O;7HI <EBBEM?D= C7HA;J?D= 7FFHEL7Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ;N9;FJ ?D 9;HJ7?D L;HO B?C?J;: 9?H9KCIJ7D9;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> IK9> 7I ?< J>; B7J;H FHE:K9J ?I I>EMD JE 8; 9B?D?97BBO IKF;H?EH JE J>; EHF>7D FHE:K9Jglyph<c=14,font=/PIIBEG+FranklinGothic-Book> ';=?IB7J?ED I?C?B7H JE J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> *HF>7D glyph<c=31,font=/PIIBEG+FranklinGothic-Book>HK= glyph<c=28,font=/PIIBEG+FranklinGothic-Book>9J >7I 8;;D ;D79J;: ?D EJ>;H 9EKDJH?;I JE ;D9EKH7=; J>; H;I;7H9>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> :;L;BEFC;DJ 7D: C7HA;J?D= E< C;:?9?D;I JE JH;7Jglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FH;L;DJ EH :?7=DEI; H7H; :?I;7I;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D J>;  glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> C;:?9?D7B FHE:K9JI J>7J H;9;?L; 7D: C7?DJ7?D 7D EHF>7D :;I?=D7J?ED 7H; ;DJ?JB;: JE glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> O;7HI E< C7HA;J ;N9BKI?L?JO <EBBEM?D= 7FFHEL7Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FHEJE9EB 7II?IJ7D9; 7D: 799;II JE J>; 9;DJH7B?P;: FHE9;:KH; <EH C7HA;J?D= 7KJ>EH?P7J?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book> .+$)-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>5glyph<c=28,font=/PIIBEG+FranklinGothic-Book> >7I 8;;D =H7DJ;: EHF>7D :HK= :;I?=D7J?ED ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>;  glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 7D: %7F7Dglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## &35C:/B7=< $3@B/7<7<5 B= $@717<5 /<2 &37;0C@A3;3<B\n\n$D 8EJ> :EC;IJ?9 7D: <EH;?=D C7HA;JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> I7B;I E< EKH FHE:K9JI :;F;D:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> JE 7 I?=D?<?97DJ ;NJ;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ED J>; 7L7?B78?B?JO 7D: 7CEKDJ E< H;?C8KHI;C;DJ 8O J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book> F7HJO F7OEHIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= =EL;HDC;DJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FH?L7J; >;7BJ> FB7DI 7D: EJ>;H EH=7D?P7J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> .K8IJ7DJ?7B KD9;HJ7?DJO ;N?IJI H;=7H:?D= J>; FH?9?D= 7D: H;?C8KHI;C;DJ E< EKH FHE:K9JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: :HK= FH?9;I 9EDJ?DK; JE H;9;?L; I?=D?<?97DJ I9HKJ?DOglyph<c=14,font=/PIIBEG+FranklinGothic-Book> \"EL;HDC;DJI C7O H;=KB7J; 9EL;H7=;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;?C8KHI;C;DJ 7D: FH?9?D= E< EKH FHE:K9JI JE 9EDJHEB 9EIJ EH 7<<;9J KJ?B?P7J?ED E< EKH FHE:K9JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>7BB;D=;I JE EKH FH?9?D= IJH7J;=?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 8O ;?J>;H =EL;HDC;DJ EH FH?L7J; IJ7A;>EB:;HIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9EKB: >7HC EKH 8KI?D;IIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 7D: <EH;?=D =EL;HDC;DJI >7L; ;D79J;: 7D: H;=KB7HBO 9EDI?:;H 7::?J?ED7B H;<EHC C;7IKH;I J>7J 7<<;9J >;7BJ> 97H; 9EL;H7=; 7D: 9EIJIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> +H?L7J; >;7BJ> FB7DI C7O 7BIE I;;A JE C7D7=; 9EIJ 7D: KJ?B?P7J?ED 8O ?CFB;C;DJ?D= 9EL;H7=; 7D: H;?C8KHI;C;DJ B?C?J7J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> *J>;H F7OEHIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= C7D7=;: 97H; EH=7D?P7J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> >;7BJ> ?DIKH;HIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> F>7HC79O 8;D;<?J C7D7=;HIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> =EL;HDC;DJ >;7BJ> 7:C?D?IJH7J?ED 7KJ>EH?J?;I 7D: FH?L7J; >;7BJ> ?DIKH;HIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> I;;A FH?9; :?I9EKDJI EH H;87J;I ?D 9EDD;9J?ED M?J> J>; FB79;C;DJ E< EKH FHE:K9JI ED J>;?H <EHCKB7H?;I 7D:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D IEC; 97I;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> C7O ?CFEI; H;IJH?9J?EDI ED 799;IIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9EL;H7=; EH FH?9?D= E< F7HJ?9KB7H :HK=I 87I;: ED F;H9;?L;: L7BK;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## +7B67< B63 )glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal>'glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal>\n\n- T !3271/72 glyph<c=26,font=/PIIBEG+FranklinGothic-Book> (;:?97?: ?I 7 @E?DJ <;:;H7B 7D: IJ7J; FHE=H7C J>7J ?I 7:C?D?IJ;H;: 8O J>; IJ7J;I <EH BEM ?D9EC; 7D: :?I78B;: 8;D;<?9?7H?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 0D:;H J>; (;:?97?: glyph<c=31,font=/PIIBEG+FranklinGothic-Book>HK= -;87J; +HE=H7Cglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 7H; H;GK?H;: JE F7O 7 H;87J; <EH ;79> KD?J E< FHE:K9J H;?C8KHI;: 8O J>; IJ7J; (;:?97?: FHE=H7CIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; 7CEKDJ E< J>; H;87J; ?I ;IJ78B?I>;: 8O B7M 7D: ?I 7:@KIJ;: KFM7H: ?< J>; 7L;H7=; C7DK<79JKH;H FH?9; glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>(+glyph<c=9,font=/PIIBEG+FranklinGothic-Book> ?D9H;7I;I CEH; J>7D ?D<B7J?ED glyph<c=8,font=/PIIBEG+FranklinGothic-Book>C;7IKH;: 8O J>; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EDIKC;H +H?9; $D:;N glyph<c=13,font=/PIIBEG+FranklinGothic-Book> 0H87Dglyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n/>; H;87J; 7CEKDJ ?I 97B9KB7J;: ;79> GK7HJ;H 87I;: ED EKH H;FEHJ E< 9KHH;DJ glyph<c=28,font=/PIIBEG+FranklinGothic-Book>(+ 7D: 8;IJ FH?9; <EH ;79> E< EKH FHE:K9JI JE J>; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>(.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; H;GK?H;C;DJI <EH 97B9KB7J?D= glyph<c=28,font=/PIIBEG+FranklinGothic-Book>(+ 7D: 8;IJ FH?9; 7H; 9ECFB;Nglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; 7H; H;GK?H;: JE H;FEHJ 7DO H;L?I?EDI JE glyph<c=28,font=/PIIBEG+FranklinGothic-Book>(+ EH 8;IJ FH?9; FH;L?EKIBO H;FEHJ;: M?J>?D 7 9;HJ7?D F;H?E:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> H;L?I?EDI 9EKB: 7<<;9J EKH H;87J; B?78?B?JO <EH FH?EH GK7HJ;HIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D 7::?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?< M; <7?B JE FHEL?:; ?D<EHC7J?ED J?C;BO EH M; 7H; <EKD: JE >7L; ADEM?D=BO IK8C?JJ;: <7BI; ?D<EHC7J?ED JE J>; =EL;HDC;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; IJ7JKJ; =EL;HD?D= J>; (;:?97?: glyph<c=31,font=/PIIBEG+FranklinGothic-Book>HK= -;87J; +HE=H7C FHEL?:;I <EH 9?L?B CED;J7HO F;D7BJ?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n- I !3271/@3 glyph<c=26,font=/PIIBEG+FranklinGothic-Book> (;:?97H; ?I 7 <;:;H7B FHE=H7C J>7J ?I 7:C?D?IJ;H;: 8O J>; <;:;H7B =EL;HDC;DJglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; FHE=H7C 9EL;HI ?D:?L?:K7BI 7=; glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book> 7D: EL;H 7I M;BB 7I J>EI; M?J> 9;HJ7?D :?I78?B?J?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> (;:?97H; +7HJ glyph<c=29,font=/PIIBEG+FranklinGothic-Book> =;D;H7BBO 9EL;HI :HK=I J>7J CKIJ 8; 7:C?D?IJ;H;: 8O F>OI?9?7DI EH EJ>;H >;7BJ> 97H; FH79J?J?ED;HIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7H; FHEL?:;: ?D 9EDD;9J?ED M?J> 9;HJ7?D :KH78B; C;:?97B ;GK?FC;DJ EH 7H; 9;HJ7?D EH7B 7DJ?glyph<c=13,font=/PIIBEG+FranklinGothic-Book>97D9;H :HK=I 7D: 9;HJ7?D EH7B ?CCKDEIKFFH;II?L; :HK=Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> (;:?97H; +7HJ glyph<c=29,font=/PIIBEG+FranklinGothic-Book> F7OI <EH IK9> :HK=I KD:;H 7 F7OC;DJ C;J>E:EBE=O 87I;: ED J>; 7L;H7=; I7B;I FH?9; glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>.+glyph<c=9,font=/PIIBEG+FranklinGothic-Book> E< J>; :HK=Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> (7DK<79JKH;HIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= KIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7H; H;GK?H;: JE FHEL?:; glyph<c=28,font=/PIIBEG+FranklinGothic-Book>.+ ?D<EHC7J?ED JE J>; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>(. ED 7 GK7HJ;HBO 87I?Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; C7DK<79JKH;Hglyph<c=13,font=/PIIBEG+FranklinGothic-Book>IK8C?JJ;: ?D<EHC7J?ED ?I KI;: JE 97B9KB7J; (;:?97H; F7OC;DJ H7J;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $< 7 C7DK<79JKH;H ?I <EKD: JE >7L; C7:; 7 C?IH;FH;I;DJ7J?ED ?D J>; H;FEHJ?D= E< glyph<c=28,font=/PIIBEG+FranklinGothic-Book>.+glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; =EL;HD?D= IJ7JKJ; FHEL?:;I <EH 9?L?B CED;J7HO F;D7BJ?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n(;:?97H; +7HJ glyph<c=31,font=/PIIBEG+FranklinGothic-Book> FHEL?:;I 9EL;H7=; JE ;DHEBB;: (;:?97H; F7J?;DJI <EH I;B<glyph<c=13,font=/PIIBEG+FranklinGothic-Book>7:C?D?IJ;H;: :HK=I glyph<c=8,font=/PIIBEG+FranklinGothic-Book>?glyph<c=14,font=/PIIBEG+FranklinGothic-Book>;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> :HK=I J>7J 7H; DEJ 7:C?D?IJ;H;: 8O 7 F>OI?9?7Dglyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> (;:?97H; +7HJ glyph<c=31,font=/PIIBEG+FranklinGothic-Book> ?I 7:C?D?IJ;H;: 8O FH?L7J; FH;I9H?FJ?ED :HK= FB7DI 7FFHEL;: 8O J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> =EL;HDC;DJglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 79> :HK= FB7D ;IJ78B?I>;I ?JI EMD (;:?97H; +7HJ glyph<c=31,font=/PIIBEG+FranklinGothic-Book> <EHCKB7HO <EH FH;I9H?FJ?ED :HK= 9EL;H7=; 7D: FH?9?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> J>; :HK= FB7D C7O CE:?<O <HEC J?C;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>JEglyph<c=13,font=/PIIBEG+FranklinGothic-Book>J?C;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; FH;I9H?FJ?ED :HK= FB7DI D;=EJ?7J; FH?9?D= M?J> C7DK<79JKH;HI 7D: F>7HC79?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: C7O 9ED:?J?ED <EHCKB7HO FB79;C;DJ ED J>; 7L7?B78?B?JO E< C7DK<79JKH;H :?I9EKDJIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D 7::?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> C7DK<79JKH;HIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= KIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7H; H;GK?H;: JE FHEL?:; JE J>; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>(. 7 :?I9EKDJ E< KF JE glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=5,font=/PIIBEG+FranklinGothic-Book> ED 8H7D: D7C; FH;I9H?FJ?ED :HK=I KJ?B?P;: 8O (;:?97H; +7HJ glyph<c=31,font=/PIIBEG+FranklinGothic-Book> 8;D;<?9?7H?;I M>;D J>EI; 8;D;<?9?7H?;I H;79> J>; 9EL;H7=; =7F ?D J>;?H :HK= 8;D;<?JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n*D glyph<c=28,font=/PIIBEG+FranklinGothic-Book>K=KIJ glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> +H;I?:;DJ glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?:;D I?=D;: ?DJE B7M J>; $-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> FHEL?:;I <EH glyph<c=8,font=/PIIBEG+FranklinGothic-Book>?glyph<c=9,font=/PIIBEG+FranklinGothic-Book> J>; =EL;HDC;DJ JE D;=EJ?7J; FH?9;I <EH I;B;9J >?=>glyph<c=13,font=/PIIBEG+FranklinGothic-Book>9EIJ (;:?97H; +7HJ glyph<c=31,font=/PIIBEG+FranklinGothic-Book> :HK=I glyph<c=8,font=/PIIBEG+FranklinGothic-Book>8;=?DD?D= ?D glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book> 7D: +7HJ glyph<c=29,font=/PIIBEG+FranklinGothic-Book> :HK=I glyph<c=8,font=/PIIBEG+FranklinGothic-Book>8;=?DD?D= ?D glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book>??glyph<c=9,font=/PIIBEG+FranklinGothic-Book> C7DK<79JKH;HI JE F7O 7 H;87J; <EH (;:?97H; +7HJ glyph<c=29,font=/PIIBEG+FranklinGothic-Book> 7D: +7HJ glyph<c=31,font=/PIIBEG+FranklinGothic-Book> :HK=I M>;D FH?9;I ?D9H;7I; <7IJ;H J>7D ?D<B7J?ED",
        "metadata": {
            "page": 35
        },
        "id": "2c4562be-1bfe-4742-a88d-ef1dc8623b9b"
    },
    {
        "page_content": "8;=?DD?D= ?D glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> <EH +7HJ glyph<c=31,font=/PIIBEG+FranklinGothic-Book> 7D: glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book> <EH +7HJ glyph<c=29,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: glyph<c=8,font=/PIIBEG+FranklinGothic-Book>???glyph<c=9,font=/PIIBEG+FranklinGothic-Book> (;:?97H; +7HJ glyph<c=31,font=/PIIBEG+FranklinGothic-Book> H;:;I?=D M>?9> H;FB79;I J>; 9KHH;DJ 9EL;H7=; =7F FHEL?I?EDI 7D: ;IJ78B?I>;I 7 glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> 97F <EH EKJglyph<c=13,font=/PIIBEG+FranklinGothic-Book>E<glyph<c=13,font=/PIIBEG+FranklinGothic-Book>FE9A;J 9EIJI <EH (;:?97H; 8;D;<?9?7H?;I 8;=?DD?D= ?D glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M?J> C7DK<79JKH;HI 8;?D= H;IFEDI?8B; <EH glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=5,font=/PIIBEG+FranklinGothic-Book> E< 9EIJI KF JE J>; glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> 97F 7D: glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=5,font=/PIIBEG+FranklinGothic-Book> 7<J;H J>7J 97F ?I H;79>;:glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n/>; H;IKBJ E< J>;I; <EHJ>9EC?D= 9>7D=;I <EH C7DK<79JKH;HIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= KIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> C7O ?D9BK:;glyph<c=26,font=/PIIBEG+FranklinGothic-Book> ?glyph<c=9,font=/PIIBEG+FranklinGothic-Book> 7 C7J;H?7B 7:L;HI; ;<<;9J ED EKH H;L;DK; ED :HK=I IK8@;9J JE [D;=EJ?7J?ED\\glyph<c=27,font=/PIIBEG+FranklinGothic-Book> ??glyph<c=9,font=/PIIBEG+FranklinGothic-Book> D;M H;87J; B?78?B?JO <EH :HK=I IK8@;9J JE J>; ?D<B7J?ED FHEL?I?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: ???glyph<c=9,font=/PIIBEG+FranklinGothic-Book> FEJ;DJ?7B I?=D?<?97DJ 7::?J?ED7B 9EIJI H;B7J;: JE J>; +7HJ glyph<c=31,font=/PIIBEG+FranklinGothic-Book> H;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>:;I?=Dglyph<c=14,font=/PIIBEG+FranklinGothic-Book> #EM;L;Hglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7I J>; :;=H;; E< ?CF79J <HEC J>?I B;=?IB7J?ED ED EKH 8KI?D;II :;F;D:I ED 7 DKC8;H E< <EHJ>9EC?D= ?CFB;C;DJ7J?ED 79J?EDI 8O H;=KB7JEHO 7KJ>EH?J?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; <KBB ;NJ;DJ E< J>; $-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>^I ?CF79J ED EKH I7B;I 7D:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D JKHDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> EKH 8KI?D;IIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;C7?DI KD9B;7Hglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n- I glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>323@/: glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>53<1G glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>7A1=C<B32 $@717<5 glyph<c=26,font=/PIIBEG+FranklinGothic-Book> *KH FHE:K9JI 7H; IK8@;9J JE :?I9EKDJ;: FH?9?D= M>;D FKH9>7I;: 8O <;:;H7B 7=;D9?;I L?7 J>; !;:;H7B .KFFBO .9>;:KB; glyph<c=8,font=/PIIBEG+FranklinGothic-Book>!..glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> !.. F7HJ?9?F7J?ED ?I H;GK?H;: <EH EKH FHE:K9JI JE 8; 9EL;H;: 7D: H;?C8KHI;: 8O J>; 1;J;H7DI glyph<c=28,font=/PIIBEG+FranklinGothic-Book>:C?D?IJH7J?ED glyph<c=8,font=/PIIBEG+FranklinGothic-Book>1glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;F7HJC;DJ E< glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;<;DI;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>E7IJ \"K7H: 7D: +K8B?9 #;7BJ> .;HL?9; glyph<c=8,font=/PIIBEG+FranklinGothic-Book>+#.glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EL;H7=; KD:;H (;:?97?:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> (;:?97H; 7D: J>; +#. F>7HC79;KJ?97B FH?9?D= FHE=H7C ?I 7BIE 9ED:?J?ED;: KFED !.. F7HJ?9?F7J?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book> !.. FH?9?D= ?I ?DJ;D:;: DEJ JE ;N9;;: J>; FH?9; J>7J M; 9>7H=; EKH CEIJglyph<c=13,font=/PIIBEG+FranklinGothic-Book><7LEH;: DEDglyph<c=13,font=/PIIBEG+FranklinGothic-Book><;:;H7B 9KIJEC;H <EH 7 FHE:K9Jglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D 7::?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FH?9;I <EH :HK=I FKH9>7I;: 8O J>; 1glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;F7HJC;DJ E< glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;<;DI; glyph<c=8,font=/PIIBEG+FranklinGothic-Book>?D9BK:?D= :HK=I FKH9>7I;: 8O C?B?J7HO F;HIEDD;B 7D: :;F;D:;DJI J>HEK=> J>; /H?glyph<c=30,font=/PIIBEG+FranklinGothic-Book>7H; H;J7?B F>7HC79O FHE=H7Cglyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>E7IJ \"K7H: 7D: +#. 7H; IK8@;9J JE 7 97F ED FH?9?D= ;GK7B JE glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=5,font=/PIIBEG+FranklinGothic-Book> E< J>; DEDglyph<c=13,font=/PIIBEG+FranklinGothic-Book><;:;H7B 7L;H7=; C7DK<79JKH;H FH?9; glyph<c=8,font=/PIIBEG+FranklinGothic-Book>DEDglyph<c=13,font=/PIIBEG+FranklinGothic-Book>!glyph<c=28,font=/PIIBEG+FranklinGothic-Book>(+glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>D 7::?J?ED7B :?I9EKDJ 7FFB?;I ?< DEDglyph<c=13,font=/PIIBEG+FranklinGothic-Book>!glyph<c=28,font=/PIIBEG+FranklinGothic-Book>(+ ?D9H;7I;I CEH; J>7D ?D<B7J?ED glyph<c=8,font=/PIIBEG+FranklinGothic-Book>C;7IKH;: 8O J>; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EDIKC;H +H?9; $D:;N glyph<c=13,font=/PIIBEG+FranklinGothic-Book> 0H87Dglyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D 7::?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?< M; <7?B JE FHEL?:; ?D<EHC7J?ED J?C;BO EH M; 7H; <EKD: JE >7L; ADEM?D=BO IK8C?JJ;: <7BI; ?D<EHC7J?ED JE J>; =EL;HDC;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; =EL;HD?D= IJ7JKJ; FHEL?:;I <EH 9?L?B CED;J7HO F;D7BJ?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- I glyph<c=13,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=14,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=10,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>7A1=C<B32 $@717<5 glyph<c=26,font=/PIIBEG+FranklinGothic-Book> /E C7?DJ7?D 9EL;H7=; E< EKH FHE:K9JI KD:;H J>; (;:?97?: glyph<c=31,font=/PIIBEG+FranklinGothic-Book>HK= -;87J; +HE=H7C 7D: (;:?97H; +7HJ glyph<c=29,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 7H; H;GK?H;: JE ;NJ;D: I?=D?<?97DJ :?I9EKDJI JE 9;HJ7?D 9EL;H;: ;DJ?J?;I J>7J FKH9>7I; FHE:K9JI KD:;H .;9J?ED glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=29,font=/PIIBEG+FranklinGothic-Book> E< J>; +#. F>7HC79;KJ?97B FH?9?D= FHE=H7Cglyph<c=14,font=/PIIBEG+FranklinGothic-Book> +KH9>7I;HI ;B?=?8B; <EH :?I9EKDJI ?D9BK:; >EIF?J7BI J>7J I;HL; 7 :?IFHEFEHJ?ED7J; I>7H; E< <?D7D9?7BBO D;;:O F7J?;DJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9ECCKD?JO >;7BJ> 9B?D?9I 7D: EJ>;H ;DJ?J?;I J>7J H;9;?L; 9;HJ7?D JOF;I E< =H7DJI KD:;H J>; +#.glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> !EH 7BB E<\n\nEKH FHE:K9JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; CKIJ 7=H;; JE 9>7H=; 7 FH?9; J>7J M?BB DEJ ;N9;;: J>; 7CEKDJ :;J;HC?D;: KD:;H IJ7JKJ; glyph<c=8,font=/PIIBEG+FranklinGothic-Book>J>; [9;?B?D= FH?9;\\glyph<c=9,font=/PIIBEG+FranklinGothic-Book> M>;D M; I;BB EKJF7J?;DJ :HK=I JE J>;I; 9EL;H;: ;DJ?J?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D 7::?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; C7Oglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 8KJ 7H; DEJ H;GK?H;: JEglyph<c=12,font=/PIIBEG+FranklinGothic-Book> E<<;H J>;I; 9EL;H;: ;DJ?J?;I 7 FH?9; BEM;H J>7D J>; glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=29,font=/PIIBEG+FranklinGothic-Book> 9;?B?D= FH?9;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=29,font=/PIIBEG+FranklinGothic-Book> :?I9EKDJ <EHCKB7 ?I 87I;: ED glyph<c=28,font=/PIIBEG+FranklinGothic-Book>(+ 7D: ?I =;D;H7BBO I?C?B7H JE J>; B;L;B E< H;87J;I 97B9KB7J;: KD:;H J>; (;:?97?: glyph<c=31,font=/PIIBEG+FranklinGothic-Book>HK= -;87J; +HE=H7Cglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## #CBA723 B63 )glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal>'glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal>\n\n*KJI?:; J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> EKH FHE:K9JI 7H; F7?: <EH 8O 7 L7H?;JO E< F7OEHIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M?J> =EL;HDC;DJI 8;?D= J>; FH?C7HO IEKH9; E< F7OC;DJglyph<c=14,font=/PIIBEG+FranklinGothic-Book> \"EL;HDC;DJI C7O :;J;HC?D; EH ?D<BK;D9; H;?C8KHI;C;DJ E< FHE:K9JI 7D: C7O 7BIE I;J FH?9;I EH EJ>;HM?I; H;=KB7J; FH?9?D=glyph<c=14,font=/PIIBEG+FranklinGothic-Book> );=EJ?7J?D= FH?9;I M?J> =EL;HDC;DJ7B 7KJ>EH?J?;I 97D :;B7O 9ECC;H9?7B?P7J?ED E< EKH FHE:K9JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> \"EL;HDC;DJI C7O KI; 7 L7H?;JO E< 9EIJglyph<c=13,font=/PIIBEG+FranklinGothic-Book>9EDJ7?DC;DJ C;7IKH;I JE 9EDJHEB J>; 9EIJ E< FHE:K9JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= FH?9; 9KJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> C7D:7JEHO H;87J;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> L7BK;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>87I;: FH?9?D= 7D: H;<;H;D9; FH?9?D= glyph<c=8,font=/PIIBEG+FranklinGothic-Book>?glyph<c=14,font=/PIIBEG+FranklinGothic-Book>;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;<;H;D9?D= FH?9;I ?D EJ>;H 9EKDJH?;I 7D: KI?D= J>EI; H;<;H;D9; FH?9;I JE I;J 7 FH?9;glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>K:=;J7HO FH;IIKH;I ?D C7DO 9EKDJH?;I 7H; 9EDJ?DK?D= JE 97KI; =EL;HDC;DJI JE 9EDI?:;H EH ?CFB;C;DJ L7H?EKI 9EIJglyph<c=13,font=/PIIBEG+FranklinGothic-Book> 9EDJ7?DC;DJ C;7IKH;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> IK9> 7I FH?9; <H;;P;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9H;7I;: FH?9; 9KJI 7D: H;87J;I 7D: ;NF7D:;: =;D;H?9 IK8IJ?JKJ?ED 7D: F7J?;DJ 9EIJglyph<c=13,font=/PIIBEG+FranklinGothic-Book>I>7H?D=glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n&35C:/B7=< $3@B/7<7<5 B= '/:3A /<2 !/@93B7<5\n\n2; 7H; IK8@;9J JE L7H?EKI <;:;H7B 7D: IJ7J; B7MI F;HJ7?D?D= JE >;7BJ> 97H; [<H7K: 7D: 78KI;glyph<c=12,font=/PIIBEG+FranklinGothic-Book>\\ ?D9BK:?D= 7DJ?glyph<c=13,font=/PIIBEG+FranklinGothic-Book>A?9A879A B7MI 7D: <7BI; 9B7?CI B7MIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>DJ?glyph<c=13,font=/PIIBEG+FranklinGothic-Book> A?9A879A B7MI =;D;H7BBO FHE>?8?J 7 FH;I9H?FJ?ED :HK= C7DK<79JKH;H <HEC IEB?9?J?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> E<<;H?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;9;?L?D= EH F7O?D= 7DO H;CKD;H7J?ED JE =;D;H7J; 8KI?D;IIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= J>; FKH9>7I; EH FH;I9H?FJ?ED E< 7 F7HJ?9KB7H :HK=glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BJ>EK=> J>; IF;9?<?9 FHEL?I?EDI E< J>;I; B7MI L7HOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>;?H I9EF; ?I =;D;H7BBO 8HE7: 7D: J>;H; C7O 8; DE H;=KB7J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> =K?:7D9; EH 9EKHJ :;9?I?EDI J>7J 9B7H?<O >EM J>; B7MI 7FFBO JE F7HJ?9KB7H ?D:KIJHO FH79J?9;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />;H; ?I J>;H;<EH; 7 FEII?8?B?JO J>7J EKH FH79J?9;I C?=>J 8; 9>7BB;D=;: KD:;H 7DJ?glyph<c=13,font=/PIIBEG+FranklinGothic-Book>A?9A879A EH I?C?B7H B7MIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> !7BI; 9B7?CI B7MI FHE>?8?J 7DOED; <HEC ADEM?D=BO 7D: M?BB?D=BO FH;I;DJ?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> EH 97KI?D= JE 8; FH;I;DJ;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> <EH F7OC;DJ JE J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJO F7OEHI glyph<c=8,font=/PIIBEG+FranklinGothic-Book>?D9BK:?D= (;:?97H; 7D: (;:?97?:glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9B7?CI <EH H;?C8KHI;: :HK=I EH I;HL?9;I J>7J 7H; <7BI; EH <H7K:KB;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9B7?CI <EH ?J;CI EH I;HL?9;I DEJ FHEL?:;: 7I 9B7?C;: EH 9B7?CI <EH C;:?97BBO KDD;9;II7HO ?J;CI EH I;HL?9;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> *KH 79J?L?J?;I H;B7J?D= JE J>; I7B; 7D: C7HA;J?D= E< EKH FHE:K9JI C7O 8; IK8@;9J JE I9HKJ?DO KD:;H J>;I; B7MIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 1?EB7J?EDI E< <H7K: 7D: 78KI; B7MI C7O 8; FKD?I>78B; 8O 9H?C?D7B EH 9?L?B I7D9J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= <?D;I 7D: 9?L?B CED;J7HO F;D7BJ?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: ;N9BKI?ED <HEC <;:;H7B >;7BJ> 97H; FHE=H7CI glyph<c=8,font=/PIIBEG+FranklinGothic-Book>?D9BK:?D= (;:?97H; 7D: (;:?97?:glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> <;:;H7B 7D: IJ7J; 7KJ>EH?J?;I 7H; F7O?D= ?D9H;7I;: 7JJ;DJ?ED JE ;D<EH9;C;DJ E< J>;I; B7MI",
        "metadata": {
            "page": 36
        },
        "id": "33ca86ad-9013-4c17-bcf4-74fe2a4c0012"
    },
    {
        "page_content": "M?J>?D J>; F>7HC79;KJ?97B ?D:KIJHO 7D: FH?L7J; ?D:?L?:K7BI >7L; 8;;D 79J?L; ?D 7BB;=?D= L?EB7J?EDI E< J>; B7MI 7D: 8H?D=?D= IK?JI ED 8;>7B< E< J>; =EL;HDC;DJ KD:;H J>; <;:;H7B 9?L?B !7BI; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>B7?CI glyph<c=28,font=/PIIBEG+FranklinGothic-Book>9Jglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $< M; M;H; IK8@;9J JE 7BB;=7J?EDI 9ED9;HD?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> EH M;H; 9EDL?9J;: E< L?EB7J?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>;I; B7MIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> EKH 8KI?D;II 9EKB: 8; >7HC;:glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n'7MI 7D: H;=KB7J?EDI >7L; 8;;D ;D79J;: 8O J>; <;:;H7B =EL;HDC;DJ 7D: L7H?EKI IJ7J;I JE H;=KB7J; J>; I7B;I 7D: C7HA;J?D= FH79J?9;I E< F>7HC79;KJ?97B C7DK<79JKH;HIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; B7MI 7D: H;=KB7J?EDI =;D;H7BBO B?C?J <?D7D9?7B ?DJ;H79J?EDI 8;JM;;D C7DK<79JKH;HI 7D: >;7BJ> 97H; FHEL?:;HI EH H;GK?H; :?I9BEIKH; JE J>; =EL;HDC;DJ 7D: FK8B?9 E< IK9> ?DJ;H79J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; B7MI ?D9BK:; <;:;H7B [IKDI>?D;\\ FHEL?I?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; IKDI>?D; FHEL?I?EDI 7FFBO JE F>7HC79;KJ?97B C7DK<79JKH;HI M?J> FHE:K9JI H;?C8KHI;: KD:;H 9;HJ7?D =EL;HDC;DJ FHE=H7CI 7D: H;GK?H; J>EI; C7DK<79JKH;HI JE :?I9BEI; 7DDK7BBO JE J>; <;:;H7B =EL;HDC;DJ glyph<c=8,font=/PIIBEG+FranklinGothic-Book><EH H;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>:?I9BEIKH; JE J>; FK8B?9glyph<c=9,font=/PIIBEG+FranklinGothic-Book> 9;HJ7?D F7OC;DJI C7:; JE F>OI?9?7DI 7D: 9;HJ7?D EJ>;H >;7BJ>97H; FH79J?J?ED;HI EH JE J;79>?D= >EIF?J7BIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> .J7J; B7MI C7O 7BIE H;GK?H; :?I9BEIKH; E< F>7HC79;KJ?97B FH?9?D= ?D<EHC7J?ED 7D: C7HA;J?D= ;NF;D:?JKH;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> (7DO E< J>;I; B7MI 7D: H;=KB7J?EDI 9EDJ7?D 7C8?=KEKI H;GK?H;C;DJIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> \"?L;D J>; B79A E< 9B7H?JO ?D B7MI 7D: J>;?H ?CFB;C;DJ7J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> EKH H;FEHJ?D= 79J?EDI 9EKB: 8; IK8@;9J JE J>; F;D7BJO FHEL?I?EDI E< J>; F;HJ?D;DJ <;:;H7B 7D: IJ7J; B7MI 7D: H;=KB7J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> *KJI?:; J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> EJ>;H 9EKDJH?;I >7L; ?CFB;C;DJ;: H;GK?H;C;DJI <EH :?I9BEIKH; E< <?D7D9?7B ?DJ;H79J?EDI M?J> >;7BJ>97H; FHEL?:;HI 7D: 7::?J?ED7B 9EKDJH?;I C7O 9EDI?:;H EH ?CFB;C;DJ IK9> B7MIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## #B63@ &35C:/B7=<A\n\n## glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>=@375< glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal><B7glyph<c=8,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=@@C>B7=<\n\n2; 7H; IK8@;9J JE L7H?EKI <;:;H7B 7D: <EH;?=D B7MI J>7J =EL;HD EKH ?DJ;HD7J?ED7B 8KI?D;II FH79J?9;I M?J> H;IF;9J JE F7OC;DJI JE =EL;HDC;DJ E<<?9?7BIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />EI; B7MI ?D9BK:; J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> !EH;?=D glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EHHKFJ +H79J?9;I glyph<c=28,font=/PIIBEG+FranklinGothic-Book>9J glyph<c=8,font=/PIIBEG+FranklinGothic-Book>!glyph<c=30,font=/PIIBEG+FranklinGothic-Book>+glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> FHE>?8?JI 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 9ECF7D?;I 7D: J>;?H H;FH;I;DJ7J?L;I <HEC F7O?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> E<<;H?D= JE F7Oglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FHEC?I?D= JE F7O EH 7KJ>EH?P?D= J>; F7OC;DJ E< 7DOJ>?D= E< L7BK; JE 7DO <EH;?=D =EL;HDC;DJ E<<?9?7Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> =EL;HDC;DJ IJ7<< C;C8;Hglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FEB?J?97B F7HJO EH FEB?J?97B 97D:?:7J; <EH J>; FKHFEI; E< E8J7?D?D= EH H;J7?D?D= 8KI?D;II EH JE EJ>;HM?I; E8J7?D <7LEH78B; JH;7JC;DJ EH ?D<BK;D9; 7 F;HIED MEHA?D= ?D 7D E<<?9?7B 97F79?JOglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D C7DO 9EKDJH?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; >;7BJ> 97H; FHE<;II?ED7BI M; H;=KB7HBO ?DJ;H79J M?J> C7O C;;J J>; !glyph<c=30,font=/PIIBEG+FranklinGothic-Book>+glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=7,font=/PIIBEG+FranklinGothic-Book>I :;<?D?J?ED E< 7 <EH;?=D =EL;HDC;DJ E<<?9?7Bglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; !glyph<c=30,font=/PIIBEG+FranklinGothic-Book>+glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 7BIE H;GK?H;I FK8B?9 9ECF7D?;I JE C7A; 7D: A;;F 8EEAI 7D: H;9EH:I J>7J 799KH7J;BO 7D: <7?HBO H;<B;9J J>;?H JH7DI79J?EDI 7D: JE :;L?I; 7D: C7?DJ7?D 7D 7:;GK7J; IOIJ;C E< ?DJ;HD7B 799EKDJ?D= 9EDJHEBIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n/>; B7MI JE M>?9> M; 7H; IK8@;9J 7BIE ?D9BK:; J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>&glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>H?8;HO glyph<c=28,font=/PIIBEG+FranklinGothic-Book>9J glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=29,font=/PIIBEG+FranklinGothic-Book>H?8;HO glyph<c=28,font=/PIIBEG+FranklinGothic-Book>9Jglyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> FHEI9H?8;I =?L?D= 7D: H;9;?L?D= 8H?8;I ?D J>; FK8B?9\n\n7D: FH?L7J; I;9JEHIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 8H?8?D= 7 <EH;?=D FK8B?9 E<<?9?7B 7D: <7?B?D= JE >7L; 7:;GK7J; FHE9;:KH;I JE FH;L;DJ ;CFBEO;;I 7D: EJ>;H 7=;DJI <HEC =?L?D= 8H?8;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 9ECF7D?;I J>7J 9ED:K9J 8KI?D;II ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>&glyph<c=14,font=/PIIBEG+FranklinGothic-Book> =;D;H7BBO M?BB 8; IK8@;9J JE J>; glyph<c=29,font=/PIIBEG+FranklinGothic-Book>H?8;HO glyph<c=28,font=/PIIBEG+FranklinGothic-Book>9Jglyph<c=14,font=/PIIBEG+FranklinGothic-Book> +;D7BJ?;I KD:;H J>; glyph<c=29,font=/PIIBEG+FranklinGothic-Book>H?8;HO glyph<c=28,font=/PIIBEG+FranklinGothic-Book>9J ?D9BK:; I?=D?<?97DJ <?D;I <EH 9ECF7D?;I 7D: 9H?C?D7B I7D9J?EDI <EH 9EHFEH7J; E<<?9;HI KD:;H 9;HJ7?D 9?H9KCIJ7D9;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## \"glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=28,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>C723:7<3A\n\n2; I;;A JE 9ED:K9J H;I;7H9> 7J EKH 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> <79?B?J?;I ?D 9ECFB?7D9; M?J> J>; 9KHH;DJ 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> )7J?ED7B $DIJ?JKJ;I E< #;7BJ> \"K?:;B?D;I <EH -;I;7H9> $DLEBL?D= -;9EC8?D7DJ glyph<c=31,font=/PIIBEG+FranklinGothic-Book>)glyph<c=28,font=/PIIBEG+FranklinGothic-Book> (EB;9KB;I glyph<c=8,font=/PIIBEG+FranklinGothic-Book>)$# \"K?:;B?D;Iglyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>O BE97B EH:?D7D9;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 7H; H;GK?H;: JEglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7CED= EJ>;H J>?D=Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9ECFBO M?J> J>; )$# \"K?:;B?D;I ?D H;B7J?ED JE EKH <79?B?J?;I ?D -/+glyph<c=12,font=/PIIBEG+FranklinGothic-Book> )glyph<c=30,font=/PIIBEG+FranklinGothic-Book> 7D: 7H; H;GK?H;: JE EF;H7J; FKHIK7DJ JE 9;HJ7?D F;HC?JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## #B63@  /EA\n\n*KH FH;I;DJ 7D: <KJKH; 8KI?D;II >7I 8;;D 7D: M?BB 9EDJ?DK; JE 8; IK8@;9J JE L7H?EKI EJ>;H B7MI 7D: H;=KB7J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 17H?EKI B7MIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;=KB7J?EDI 7D: H;9ECC;D:7J?EDI H;B7J?D= JE :7J7 FH?L79O 7D: FHEJ;9J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> I7<; MEHA?D= 9ED:?J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> B78EH7JEHO FH79J?9;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; ;NF;H?C;DJ7B KI; E< 7D?C7BI 7D: J>; FKH9>7I;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> IJEH7=;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> CEL;C;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?CFEHJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ;NFEHJ 7D: KI; 7D: :?IFEI7B E< >7P7H:EKI EH FEJ;DJ?7BBO >7P7H:EKI IK8IJ7D9;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= H7:?E79J?L; 9ECFEKD:I 7D: ?D<;9J?EKI :?I;7I; 7=;DJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> KI;: ?D 9EDD;9J?ED M?J> EKH H;I;7H9> MEHA 7H; EH C7O 8; 7FFB?978B; JE EKH 79J?L?J?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>;HJ7?D 7=H;;C;DJI ;DJ;H;: ?DJE 8O KI ?DLEBL?D= ;N9BKI?L; B?9;DI; H?=>JI C7O 8; IK8@;9J JE D7J?ED7B EH ?DJ;HD7J?ED7B 7DJ?JHKIJ H;=KB7JEHO 9EDJHEBglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; ;<<;9J E< M>?9> 97DDEJ 8; FH;:?9J;:glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; ;NJ;DJ E< =EL;HDC;DJ H;=KB7J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> C?=>J H;IKBJ <HEC <KJKH; B;=?IB7J?ED EH 7:C?D?IJH7J?L; 79J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 97DDEJ 799KH7J;BO 8; FH;:?9J;:glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n/>;  KHEF;7D +7HB?7C;DJ 7D: J>; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EKD9?B E< J>; glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 7:EFJ;: 7 9ECFH;>;DI?L; =;D;H7B :7J7 FH?L79O H;=KB7J?ED glyph<c=8,font=/PIIBEG+FranklinGothic-Book>\"glyph<c=31,font=/PIIBEG+FranklinGothic-Book>+-glyph<c=9,font=/PIIBEG+FranklinGothic-Book> ?D glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book> JE H;FB79; J>; 9KHH;DJ  glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=31,font=/PIIBEG+FranklinGothic-Book>7J7 +HEJ;9J?ED glyph<c=31,font=/PIIBEG+FranklinGothic-Book>?H;9J?L; 7D: H;B7J;: 9EKDJHOglyph<c=13,font=/PIIBEG+FranklinGothic-Book>IF;9?<?9 B;=?IB7J?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; \"glyph<c=31,font=/PIIBEG+FranklinGothic-Book>+JEEA ;<<;9J ?D (7O glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book> 7D: =EL;HDI J>; 9EBB;9J?ED 7D: KI; E< F;HIED7B :7J7 ?D J>; glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; \"glyph<c=31,font=/PIIBEG+FranklinGothic-Book>+-glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> ?I M?:;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>H7D=?D= ?D I9EF;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?CFEI;I I;L;H7B H;GK?H;C;DJI H;B7J?D= JE J>; 9EDI;DJ E< J>; ?D:?L?:K7BI JE M>EC J>; F;HIED7B :7J7 H;B7J;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; ?D<EHC7J?ED FHEL?:;: JE J>; ?D:?L?:K7BIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; I;9KH?JO 7D: 9ED<?:;DJ?7B?JO E< J>; F;HIED7B :7J7glyph<c=12,font=/PIIBEG+FranklinGothic-Book> :7J7 8H;79> DEJ?<?97J?ED 7D: J>; KI; E< J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJO FHE9;IIEHI ?D 9EDD;9J?ED M?J> J>; FHE9;II?D= E< J>; F;HIED7B :7J7glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; \"glyph<c=31,font=/PIIBEG+FranklinGothic-Book>+7BIE ?CFEI;I IJH?9J HKB;I ED J>; JH7DI<;H E< F;HIED7B :7J7 EKJ E< J>;  glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book> JE J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> FHEL?:;I 7D ;D<EH9;C;DJ 7KJ>EH?JO 7D: ?CFEI;I B7H=; F;D7BJ?;I <EH DED9ECFB?7D9;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= J>; FEJ;DJ?7B <EH <?D;I E< KF JE \\_glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> C?BB?ED EH glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=5,font=/PIIBEG+FranklinGothic-Book> E< J>; 7DDK7B =BE87B H;L;DK; E< J>; ?D<H?D=;Hglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9>;L;H ?I =H;7J;Hglyph<c=14,font=/PIIBEG+FranklinGothic-Book>",
        "metadata": {
            "page": 37
        },
        "id": "e59e720b-231e-4296-8a54-3a1add768650"
    },
    {
        "page_content": "## $3@G835FGD;@9\n\n2; I;;A JE ;DIKH; 7D KD?DJ;HHKFJ;: IKFFBO E< C;:?9?D;I JE F7J?;DJI 7HEKD: J>; MEHB:glyph<c=14,font=/PIIBEG+FranklinGothic-Book> /E J>7J ;D:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 9EDJ?DK7BBO H;L?;M EKH C7DK<79JKH?D= 97F79?JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 97F78?B?J?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FHE9;II;I 7D: <79?B?J?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; 8;B?;L; J>7J EKH C7DK<79JKH?D= <79?B?J?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> JE=;J>;H M?J> J>; J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book> F7HJO 9EDJH79J C7DK<79JKH?D= EH=7D?P7J?EDI M; EKJIEKH9; JEglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9KHH;DJBO FHEL?:; IK<<?9?;DJ 97F79?JO <EH EKH FHE:K9JI 7D: JE .7CIKD= glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E;F?Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> EKH 9EBB78EH7J?ED F7HJD;H J>7J :;L;BEFIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> C7DK<79JKH;I 7D: C7HA;JI 8?EI?C?B7H FHE:K9JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: EJ>;H IJH7J;=?9 9EDJH79J C7DK<79JKH?D= F7HJD;HIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n$D (7H9> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book> M; 7DDEKD9;: EKH FB7DI JE 8K?B: 7 D;M =;D; J>;H7FO C7DK<79JKH?D= <79?B?JO ?D -/+glyph<c=12,font=/PIIBEG+FranklinGothic-Book> )glyph<c=30,font=/PIIBEG+FranklinGothic-Book> JE IKFFEHJ EKH =;D; J>;H7FO F?F;B?D; 79HEII CKBJ?FB; J>;H7F;KJ?9 7H;7Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; D;M C7DK<79JKH?D= <79?B?JO M?BB 8; 7FFHEN?C7J;BO glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> IGK7H; <;;J 7D: ?I ;NF;9J;: JE 8; EF;H7J?ED7B 8O J>; ;D: E< glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M?J> 7D ;IJ?C7J;: JEJ7B ?DL;IJC;DJ E< 7FFHEN?C7J;BO glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> C?BB?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EDIJHK9J?ED <EH J>?I D;M <79?B?JO 8;=7D :KH?D= J>; <EKHJ> GK7HJ;H E< glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## !/<C4/1BC@7<5 glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>/17:7B73A\n\n*KH :HK= IK8IJ7D9; C7DK<79JKH?D= <79?B?J?;I ?D9BK:;glyph<c=26,font=/PIIBEG+FranklinGothic-Book>\n\n| glyph<c=29,font=/PIIBCD+FranklinGothic-Book>35;>;FK                                                       | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>DG9 *G4EF3@57 $3@G835FGD76                                                                                                                                                                                |\n|-----------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| -/+glyph<c=12,font=/PIIBEG+FranklinGothic-Book> )EHJ> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>7HEB?D7 | glyph<c=28,font=/PIIBEG+FranklinGothic-Book>1*) 3 +' \"-$glyph<c=31,font=/PIIBEG+FranklinGothic-Book>4 /4.glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=29,font=/PIIBEG+FranklinGothic-Book>-$ *J>;Hglyph<c=10,font=/PIIBEG+FranklinGothic-Book> |\n| .EBEJ>KHDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> .M?JP;HB7D:                                         | glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>0# '( ' , (glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$                                                                                                      |\n\n$D 7::?J?ED JE EKH :HK= IK8IJ7D9; C7DK<79JKH?D= <79?B?J?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; >7L; 7 :HK= FHE:K9J C7DK<79JKH?D= <79?B?JO 7D: IKFFEHJ?D= ?D<H7IJHK9JKH; ?D -/+glyph<c=12,font=/PIIBEG+FranklinGothic-Book> )glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= 7 F7H;DJ;H7B <79?B?JO 7D: 7D EH7B IEB?: :EI; FHE:K9JI C7DK<79JKH?D= <79?B?JOglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n/>; F7H;DJ;H7B <79?B?JO 7::I 97F78?B?J?;I 7D: 97F79?JO <EH <?BB?D= 8?EBE=?9I ?DJE L?7BI 7D: ?I KI;: <EH <?BB?D= FHE:K9J 97D:?:7J;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; EH7B IEB?: :EI; FHE:K9JI <79?B?JO 97D IKFFB;C;DJ EKH EKJIEKH9;: IC7BB CEB;9KB; C7DK<79JKH?D= 97F78?B?J?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n2; 7BIE >7L; 7D EB?=EDK9B;EJ?:; IODJ>;I?I C7DK<79JKH?D= <79?B?JO ?D -/+glyph<c=12,font=/PIIBEG+FranklinGothic-Book> )glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />?I <79?B?JO =?L;I KI J>; 97F78?B?JO JE C7DK<79JKH; glyph<c=28,font=/PIIBEG+FranklinGothic-Book>.* 97D:?:7J;I 9KHH;DJBO ?D EKH 9B?D?97B F?F;B?D;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n$D EH:;H JE IKFFEHJ EKH <KJKH; =HEMJ> 7D: :HK= :;L;BEFC;DJ F?F;B?D;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 7H; 8K?B:?D= 7 B7H=;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>I97B; 8?EBE=?9I C7DK<79JKH?D= <79?B?JO ?D .EBEJ>KHDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> .M?JP;HB7D:glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D J>; I;9ED: GK7HJ;H E< glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book> 7 FEHJ?ED E< J>; <79?B?JO H;9;?L;: 7 \"EE: (7DK<79JKH?D= +H79J?9; glyph<c=8,font=/PIIBEG+FranklinGothic-Book>\"(+glyph<c=9,font=/PIIBEG+FranklinGothic-Book> CKBJ?glyph<c=13,font=/PIIBEG+FranklinGothic-Book>FHE:K9J B?9;DI; <HEC J>; .M?II glyph<c=28,font=/PIIBEG+FranklinGothic-Book>=;D9O <EH\n\n/>;H7F;KJ?9 +HE:K9JI glyph<c=8,font=/PIIBEG+FranklinGothic-Book>.2$..( glyph<c=31,font=/PIIBEG+FranklinGothic-Book>$glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> .EBEJ>KHD >7I 8;;D 7FFHEL;: <EH J>; C7DK<79JKH; E< glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>0# '( 7D: ' , (glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$ 8O J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; ;IJ?C7J; J>; I;9ED: C7DK<79JKH?D= IK?J; 7J J>; .EBEJ>KHD <79?B?JO M?BB 8; EF;H7J?ED7B 8O J>; ;D: E< glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n\";D;DJ;9> ?I H;IFEDI?8B; <EH 7BB MEHB:M?:; C7DK<79JKH?D= 79J?L?J?;I <EH 8KBA -$/03glyph<c=28,font=/PIIBEG+FranklinGothic-Book>)glyph<c=12,font=/PIIBEG+FranklinGothic-Book> -$/03glyph<c=28,font=/PIIBEG+FranklinGothic-Book>) #4glyph<c=30,font=/PIIBEG+FranklinGothic-Book> 'glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 7D: \"glyph<c=28,font=/PIIBEG+FranklinGothic-Book>541glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 7D: >7I IEKH9;: J>; C7DK<79JKH; E< 9;HJ7?D 8KBA -$/03glyph<c=28,font=/PIIBEG+FranklinGothic-Book>)glyph<c=12,font=/PIIBEG+FranklinGothic-Book> -$/03glyph<c=28,font=/PIIBEG+FranklinGothic-Book>) #4glyph<c=30,font=/PIIBEG+FranklinGothic-Book> 'glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 7D: \"glyph<c=28,font=/PIIBEG+FranklinGothic-Book>541glyph<c=28,font=/PIIBEG+FranklinGothic-Book> H;GK?H;C;DJI JE 7 J>?H: F7HJOglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $ED?I IKFFB?;I J>; 79J?L; F>7HC79;KJ?97B ?D=H;:?;DJ glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>+$glyph<c=9,font=/PIIBEG+FranklinGothic-Book> <EH .+$)-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>5glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BA;HC;I 9KHH;DJBO IKFFB?;I 8EJ> 10( -$/4 7D: !glyph<c=28,font=/PIIBEG+FranklinGothic-Book>(+4-glyph<c=28,font=/PIIBEG+FranklinGothic-Book> JE KI FKHIK7DJ JE I;F7H7J; IKFFBO 7=H;;C;DJIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D *9JE8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book> M; ;DJ;H;: ?DJE 7 D;M IKFFBO 7=H;;C;DJ 7D: 7C;D:;: EKH B?9;DI; 7D: 9EBB78EH7J?ED 7=H;;C;DJ M?J> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BA;HC;I <EH 10( -$/4glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; >7L; ;B;9J;: JE ?D?J?7J; 7 J;9>DEBE=O JH7DI<;H 7D:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> <EBBEM?D= 7 JH7DI?J?ED F;H?E:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> JE C7DK<79JKH; 10( -$/4 EH >7L; 10( -$/4 C7DK<79JKH;: 8O 7 J>?H: F7HJO M; >7L; ;D=7=;: ?D ;N9>7D=; <EH F7O?D= 7D ?D9H;7I;: HEO7BJO H7J; JE glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BA;HC;I ED 7DO FEHJ?ED E< <KJKH; MEHB:M?:; D;J 9ECC;H9?7B I7B;I E< 10( -$/4 J>7J ?I C7DK<79JKH;: 8O KI EH EKH :;I?=D;;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D *9JE8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> M; ;DJ;H;: ?DJE 7 D;M IKFFBO 7=H;;C;DJ M?J> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BA;HC;I <EH !glyph<c=28,font=/PIIBEG+FranklinGothic-Book>(+4-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>9EH:7 FH;L?EKIBO IKFFB?;: !glyph<c=28,font=/PIIBEG+FranklinGothic-Book>(+4-glyph<c=28,font=/PIIBEG+FranklinGothic-Book> JE KI FKHIK7DJ JE 7 IK8B?9;DI?D= 7HH7D=;C;DJ M?J> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BA;HC;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> M7I J;HC?D7J;: ?D *9JE8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> 7I 7 H;IKBJ E< 7D 7H8?JH7J?ED EKJ9EC; 8;JM;;D glyph<c=28,font=/PIIBEG+FranklinGothic-Book>9EH:7 7D: glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BA;HC;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## (67@2glyph<c=8,font=/PIIBDE+FranklinGothic-BookItal>$/@BG 'C>>:73@A /<2 !/<C4/1BC@3@A\n\n2; FH?D9?F7BBO KI; J>?H: F7HJ?;I JE C7DK<79JKH; J>; glyph<c=28,font=/PIIBEG+FranklinGothic-Book>+$ 7D: J>; <?D7B FHE:K9J <EH EKH IC7BB CEB;9KB; FHE:K9JI 7D: FHE:K9J 97D:?:7J;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= / glyph<c=30,font=/PIIBEG+FranklinGothic-Book>!$glyph<c=31,font=/PIIBEG+FranklinGothic-Book> -glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 7D: !0(glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book> -(glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: J>; <?D7B :HK= FHE:K9J <EH EKH B7H=; CEB;9KB; FHE:K9JI 7D:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> JE 7 B;II;H ;NJ;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FHE:K9J 97D:?:7J;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n2; IEKH9; J>; C7@EH?JO E< EKH <?BBglyph<c=13,font=/PIIBEG+FranklinGothic-Book><?D?I> 7D: 7BB E< EKH <?D7B FHE:K9J 7II;C8BO 7D: IJEH7=; EF;H7J?EDI <EH EKH FHE:K9JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7BED= M?J> 7 IK8IJ7DJ?7B F7HJ E< EKH B78;B 7D: F79A7=?D= EF;H7J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> JE 7 9ED9;DJH7J;: =HEKF E< J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJO 9EDJH79J C7DK<79JKH?D= EH=7D?P7J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> -7M C7J;H?7BIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> :;B?L;HO :;L?9;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> IK9> 7I IOH?D=;I 7D: 7KJEglyph<c=13,font=/PIIBEG+FranklinGothic-Book>?D@;9JEHIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: EJ>;H IKFFB?;I H;GK?H;: <EH J>; FHE:K9J?ED E< EKH FHE:K9JI 7D: FHE:K9J 97D:?:7J;I 7H; FHE9KH;: <HEC L7H?EKI J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJO IKFFB?;HI 7D: C7DK<79JKH;HI ?D GK7DJ?J?;I 7:;GK7J; JE C;;J EKH D;;:Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EDJ?DK?JO E< IKFFBO E< IK9> H7M C7J;H?7BIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> :;L?9;I 7D: IKFFB?;I ?I 7IIKH;: J>HEK=> ?DL;DJEHO C7D7=;C;DJ 7D: :K7B IEKH9?D= 7I 7FFHEFH?7J;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> *KH J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJO I;HL?9; FHEL?:;HIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> IKFFB?;HI 7D: C7DK<79JKH;HI C7O 8; IK8@;9J JE HEKJ?D; 9\"(+ ?DIF;9J?EDI 8O J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> EH 9ECF7H78B; 7=;D9?;I ?D EJ>;H @KH?I:?9J?EDI 7D: KD:;H=E 7II;IIC;DJ 7D: 9;HJ?<?97J?ED 8O EKH GK7B?JO C7D7=;C;DJ =HEKFglyph<c=14,font=/PIIBEG+FranklinGothic-Book>",
        "metadata": {
            "page": 38
        },
        "id": "caba5f77-2f0f-4658-b5f3-c39ea7b22d4b"
    },
    {
        "page_content": "## glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*glyph<c=30,font=/PIIBCD+FranklinGothic-Book> 3@6 glyph<c=26,font=/PIIBCD+FranklinGothic-Book>>;?3F7glyph<c=10,font=/PIIBCD+FranklinGothic-Book>)7>3F76 $3FF7DE\n\n## glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><B@=2C1B7=<\n\n*KH ;DL?HEDC;DJ7Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> IE9?7B 7D: =EL;HD7D9; glyph<c=8,font=/PIIBEG+FranklinGothic-Book> .\"glyph<c=9,font=/PIIBEG+FranklinGothic-Book> ;<<EHJI FH?EH?J?P; 9B?C7J;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> >;7BJ> 7D: ;GK?JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M?J> 7 <E9KI ED LKBD;H78B; FEFKB7J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7I M;BB 7I ED=E?D= B;7:;HI>?F ?D IKIJ7?D78?B?JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> =EL;HD7D9;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> JH7DIF7H;D9O 7D: :?I9BEIKH;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n2; H;C7?D 9ECC?JJ;: JE H;:K9?D= EKH ;DL?HEDC;DJ7B <EEJFH?DJ 8O ;B?C?D7J?D= >7HC<KB ;C?II?EDI 7D: 8O C?D?C?P?D= H;IEKH9;I KI;: JE C7DK<79JKH; EKH FHE:K9JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> .?D9; glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book> M; >7L; J7A;D H;IFEDI?8?B?JO <EH EKH ?CF79J ED 9B?C7J; 9>7D=; 8O C7J9>?D= glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=5,font=/PIIBEG+FranklinGothic-Book> E< EKH ;B;9JH?9?JO KI7=; M?J> H;D;M78B; ;D;H=Oglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9H;:?JI 7D: E<<I;JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> :H?L?D= ;<<?9?;D9O ?D?J?7J?L;I ?DJ;HD7BBO 7D: MEHA?D= M?J> EKH IKFFB?;HIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> \"H;;D 9>;C?IJHO ?I ;C8H79;: J>HEK=>EKJ EKH 9ECF7DOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9EDJ?DK7BBO ;NFBEH?D= D;M M7OI JE C7A; EKH :HK= :;L;BEFC;DJ FHE9;II;I I7<;Hglyph<c=12,font=/PIIBEG+FranklinGothic-Book> CEH; ;<<?9?;DJ 7D: CEH; IKIJ7?D78B; M>?B; 7BIE I7L?D= H;IEKH9;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>=D3@</<13\n\n.\" EL;HI?=>J ?I <EHC7BBO ;C8;::;: ?DJE EKH glyph<c=29,font=/PIIBEG+FranklinGothic-Book>E7H: E< glyph<c=31,font=/PIIBEG+FranklinGothic-Book>?H;9JEHglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I =EL;HD7D9; FH?D9?FB;I 7D: ?D9BK:;I 7D 7DDK7B H;L?;M E< EKH  .\" IJH7J;=O 7D: I>EHJglyph<c=13,font=/PIIBEG+FranklinGothic-Book>7D: BED=glyph<c=13,font=/PIIBEG+FranklinGothic-Book>J;HC =E7BIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; H;=KB7HBO H;L?;M EKH ;DL?HEDC;DJ7B 9ECC?JC;DJI M?J>?D J>; B7D:I97F; E< EKH 8KI?D;II F;H<EHC7D9;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> H?I?D= 9EIJI 7D: IKFFBO 9>7?D 9>7BB;D=;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; H;C7?D 9ECC?JJ;: JE ;D=7=?D= ;CFBEO;;I 7D: IKFFB?;HI 7D: 9EBB78EH7J?D= M?J> H;DEMD;: ?DIJ?JKJ?EDI JE 7:L7D9; J>; I9?;D9; 7D: 79J?ED JE ?CFHEL; >;7BJ> EKJ9EC;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=28,font=/PIIBEG+FranklinGothic-Book>I F7HJ E< EKH 8HE7:;H 9ECC?JC;DJ JE J>;I; FH?EH?J?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 9EDJ?DK; JE J?; 7 FEHJ?ED E< EKH ;CFBEO;;Iglyph<c=7,font=/PIIBEG+FranklinGothic-Book> 7D: ;N;9KJ?L; E<<?9;HIglyph<c=7,font=/PIIBEG+FranklinGothic-Book> 9ECF;DI7J?ED JE 7:L7D9?D= EKH  .\" ;<<EHJIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n2; IJH?L; JE 9ECFBO ?D 7BB C7J;H?7B H;IF;9JI M?J> 7FFB?978B; B7MI 7D: H;=KB7J?EDI 9ED9;HD?D= J>; ;DL?HEDC;DJglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2>?B; ?J ?I ?CFEII?8B; JE FH;:?9J 799KH7J;BO J>; <KJKH; 9EIJI 7IIE9?7J;: M?J> ;DL?HEDC;DJ7B 9ECFB?7D9; 7D: FEJ;DJ?7B H;C;:?7J?ED 79J?L?J?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9ECFB?7D9; M?J> ;DL?HEDC;DJ7B B7MI ?I DEJ ;NF;9J;: JE H;GK?H; I?=D?<?97DJ 97F?J7B ;NF;D:?JKH;I 7D: >7I DEJ >7:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: ?I DEJ ;NF;9J;: JE >7L;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 C7J;H?7B 7:L;HI; ;<<;9J ED EKH EF;H7J?EDI EH 9ECF;J?J?L; FEI?J?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book> *KH  N;9KJ?L; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>ECC?JJ;; >7I H;IFEDI?8?B?JO <EH ;L7BK7J?D= J>; ?CF79J E< 9B?C7J; 9>7D=; ED J>; 8KI?D;II 7D: EL;HI;;?D= 79J?EDI J7A;D 8O J>; 9ECF7DO JE B?C?J ?JI 7:L;HI; ?CF79J ED J>; ;DL?HEDC;DJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n*KH  DJ;HFH?I; -?IA (7D7=;C;DJ glyph<c=8,font=/PIIBEG+FranklinGothic-Book> -(glyph<c=9,font=/PIIBEG+FranklinGothic-Book> <H7C;MEHA ?I :;I?=D;: JE ;DIKH; 9B?C7J;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>H;B7J;: H?IAI 7D: EFFEHJKD?J?;I 7H; ?DJ;=H7J;: ?DJE EKH EL;H7BB 8KI?D;II IJH7J;=Oglyph<c=14,font=/PIIBEG+FranklinGothic-Book> *KH  -( J;7C CED?JEHI IJH7J;=?9 9B?C7J;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>H;B7J;: H?IAI 79HEII 7BB 7IF;9JI E< EKH 8KI?D;II 7D: KJ?B?P;I 9B?C7J; I9;D7H?EI 7I F7HJ E< ?JI\n\n7II;IIC;DJIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> *D 7D 7DDK7B 87I?Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>;  -( J;7C ;L7BK7J;I ?:;DJ?<?;: H?IAIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= 7DO 9B?C7J;glyph<c=13,font=/PIIBEG+FranklinGothic-Book> H;B7J;: F>OI?97B 7D: JH7DI?J?ED7B H?IAIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 8O ;D=7=?D= B;7:;HI 79HEII J>; 9ECF7DOglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />;  -( J;7C FHEL?:;I 7DDK7B KF:7J;I ED J>;?H <?D:?D=I 7D: 79J?L?J?;I JE EKH N;9KJ?L; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>ECC?JJ;; 7D: glyph<c=29,font=/PIIBEG+FranklinGothic-Book>E7H: E< glyph<c=31,font=/PIIBEG+FranklinGothic-Book>?H;9JEHIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## &7A9 !/</53;3<B\n\nglyph<c=28,font=/PIIBEG+FranklinGothic-Book>::H;II?D= .\" C7JJ;HI ?I F7HJ E< EKH BED=glyph<c=13,font=/PIIBEG+FranklinGothic-Book>J;HC =BE87B IJH7J;=O 7D: ?DL;IJC;DJ ?D EKH <KJKH; 7D: M; >7L; I;;D ?D9H;7I;: ?DJ;H;IJ <HEC IJ7A;>EB:;HI 7D: ?DL;IJEHI ED EKH  .\" FH79J?9;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2>?B; M; 9EDJ?DK; JE JE 7:L7D9; EKH  .\" ;<<EHJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>;H; ?I DE 9;HJ7?DJO J>7J M; M?BB C7D7=;  .\" C7JJ;HI ?D M7OI J>7J IK99;II<KBBO C;;J H7F?:BO 9>7D=?D= ;NF;9J7J?EDI <HEC ?DL;IJEHIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;=KB7JEHIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>?H: F7HJO H7DA?D=I <?HCIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9KIJEC;HI 7D: IE9?;JO 7I 7 M>EB;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> *KH ?D78?B?JO JE C7D7=;  .\" C7JJ;HI ?D 799EH:7D9; M?J> ;NF;9J7J?EDI 97D D;=7J?L;BO ?CF79J EKH H;FKJ7J?ED 7D: 8KI?D;IIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>:7;/B3 &7A9 !/</53;3<B\n\n2; ?:;DJ?<O 9B?C7J; H?IA 7I J>; H?IA E< BEII 7H?I?D= <HEC 9B?C7J; 9>7D=; 7D: ?I 9ECFH?I;: E< 8EJ> F>OI?97B H?IA 7D: JH7DI?J?ED H?IAglyph<c=14,font=/PIIBEG+FranklinGothic-Book> +>OI?97B H?IA 9EDI?:;HI >EM J>; F>OI?97B ?CF79JI E< 9B?C7J; 9>7D=; glyph<c=8,font=/PIIBEG+FranklinGothic-Book>;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>=glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9H;7I;: IJEHCIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> :HEK=>Jglyph<c=12,font=/PIIBEG+FranklinGothic-Book> <?H;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> <BEE:Iglyph<c=9,font=/PIIBEG+FranklinGothic-Book> 97D :?H;9JBO :7C7=; F>OI?97B 7II;JI EH EJ>;HM?I; ?CF79J J>;?H L7BK; EH FHE:K9J?L?JOglyph<c=14,font=/PIIBEG+FranklinGothic-Book> /H7DI?J?ED H?IA 9EDI?:;HI >EM 9>7D=;I ?D FEB?9Oglyph<c=14,font=/PIIBEG+FranklinGothic-Book> H;=KB7J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9KBJKH;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J;9>DEBE=Oglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 8KI?D;II FH79J?9;I 7D: C7HA;J FH;<;H;D9;I JE 7::H;II 9B?C7J; 9>7D=; glyph<c=8,font=/PIIBEG+FranklinGothic-Book>;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>=glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 97H8ED FH?9?D= FEB?9?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FEM;H =;D;H7J?ED I>?<JI <HEC <EII?B <K;BI JE H;D;M78B; ;D;H=Oglyph<c=9,font=/PIIBEG+FranklinGothic-Book> 97D B;7: JE 9>7D=;I ?D J>; L7BK; E< 7II;JI 7D: 8KI?D;II;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=31,font=/PIIBEG+FranklinGothic-Book>?IHKFJ?ED ?D IKFFBO 9>7?DIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9>7D=?D= 9KIJEC;H ;NF;9J7J?EDI ?D J>; 8?EI?C?B7H C7HA;J 7D: FEJ;DJ?7B I>?<JI ?D J>; H;=KB7JEHO ;DL?HEDC;DJ J>7J :?I7:L7DJ7=; J>; KI; E< <EII?B <K;BIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> C7O C7A; ?J :?<<?9KBJ <EH KI JE <KB<?BB 8KI?D;II E8B?=7J?EDI EH 97KI; KI JE ?D9KH IK8IJ7DJ?7B ;NF;DI;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n$:;DJ?<?;: C7J;H?7B H?IAI 7D: EFFEHJKD?J?;I 7H; H;FEHJ;: JE EKH  -( J;7Cglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> H;FEHJI JE EKH N;9KJ?L; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>ECC?JJ;; 7D: glyph<c=29,font=/PIIBEG+FranklinGothic-Book>E7H: E< glyph<c=31,font=/PIIBEG+FranklinGothic-Book>?H;9JEHIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; 9EDI?:;H 7D: 7::H;II J>EI; H?IAI 7D: EFFEHJKD?J?;I J>7J 7H; <?D7D9?7BBO C7J;H?7B 7D: C7O ?CF79J EKH 8KI?D;II CE:;Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7I M;BB 7I C?J?=7J?ED C;7IKH;I J>7J 7H; ?D FB79; EH D;;: JE 8; 7:EFJ;:glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n!EH 7::?J?ED7B ?D<EHC7J?ED ED EKH ;DL?HEDC;DJglyph<c=13,font=/PIIBEG+FranklinGothic-Book> H;B7J;: H?IAIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FB;7I; H;7: glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>B3; glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal> &7A9 glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>/1B=@A ?D9BK:;: ?D J>?I H;FEHJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=31,font=/PIIBCD+FranklinGothic-Book>G?3@ glyph<c=26,font=/PIIBCD+FranklinGothic-Book>3B;F3>\n\nglyph<c=28,font=/PIIBEG+FranklinGothic-Book>I E< glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; >7: 7FFHEN?C7J;BO glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book> ;CFBEO;;I MEHB:M?:;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>FFHEN?C7J;BO glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> ;CFBEO;;I M;H; ;CFBEO;: ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 7D: 7FFHEN?C7J;BO glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book> ;CFBEO;;I M;H; ;CFBEO;: ?D <EH;?=D 9EKDJH?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>",
        "metadata": {
            "page": 39
        },
        "id": "4abfafb7-42e0-4bf8-b6d8-aaa3968e78d7"
    },
    {
        "page_content": "## glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>7D3@A7BGglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>?C7BG /<2 glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><1:CA7=<\n\nglyph<c=28,font=/PIIBEG+FranklinGothic-Book>J glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E=;Dglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FH;@K:?9;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> H79?IC 7D: ?DJEB;H7D9; 7H; KD799;FJ78B;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; 7H; 9ECC?JJ;: JE glyph<c=31,font=/PIIBEG+FranklinGothic-Book>?L;HI?JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> GK?JO 7D: $D9BKI?ED glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book> glyph<c=6,font=/PIIBEG+FranklinGothic-Book>$glyph<c=9,font=/PIIBEG+FranklinGothic-Book> 79HEII 7BB 7IF;9JI E< EKH EH=7D?P7J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= H;9HK?JC;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> >?H?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> FHECEJ?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;J;DJ?ED 7D: :;L;BEFC;DJ FH79J?9;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>I E< glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=5,font=/PIIBEG+FranklinGothic-Book> E< glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E=;D^I C7D7=;Hglyph<c=13,font=/PIIBEG+FranklinGothic-Book>B;L;B 7D: 78EL; FEI?J?EDI M;H; >;B: 8O ;J>D?9 EH H79?7B C?DEH?J?;I ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> *KH FEB?9?;I 7D: FH79J?9;I 7H; =BE87Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 8KJ J>; B7MI ?D C7DO 9EKDJH?;I EKJI?:; J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> :E DEJ F;HC?J KI JE 9EBB;9J ;J>D?9 EH H79?7B :7J7 ED EKH ;CFBEO;;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> \"BE87BBOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=5,font=/PIIBEG+FranklinGothic-Book> E< glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E=;D^I FEI?J?EDI 7J :?H;9JEHglyph<c=13,font=/PIIBEG+FranklinGothic-Book>B;L;B 7D: 78EL; M;H; >;B: 8O MEC;D 7I E< glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n*KH glyph<c=31,font=/PIIBEG+FranklinGothic-Book> glyph<c=6,font=/PIIBEG+FranklinGothic-Book>$ IJH7J;=O EKJB?D;I 79J?ED78B; IJ;FI JE :;;F;D EKH 9ECC?JC;DJ 79HEII J>; 8KI?D;IIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 8K?B:?D= KFED 7 IJHED= <EKD:7J?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />?I FB7D ?D9BK:;I J>; IJH7J;=O JE 8K?B: EKH J7B;DJ 7D: IJH;D=J>;D EKH B;7:;HI>?Fglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?CFHEL; >;7BJ> EKJ9EC;I <EH KD:;HI;HL;: 9ECCKD?J?;I ?D J>; :?I;7I; 7H;7I M; JH;7J 7D: 9EDJH?8KJ; JE J>; 9ECCKD?J?;I ?CF79J?D= EKH ;CFBEO;;I 7D: F7J?;DJIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; FB7D JE 9H;7J; =H;7J;H 7M7H;D;II 7D: 97F78?B?JO ?D EKH EH=7D?P7J?ED J>HEK=> B;7:;HI>?F 799EKDJ78?B?JO 7D: JH7DIF7H;D9Oglyph<c=14,font=/PIIBEG+FranklinGothic-Book> /E ;IJ78B?I> 7D: FHE=H;II J>?I IJH7J;=Oglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; H;BO ED 7 9HEIIglyph<c=13,font=/PIIBEG+FranklinGothic-Book>9ECF7DO =EL;HD?D= 8E:O E< ;CFBEO;;I ADEMD 7I J>; glyph<c=31,font=/PIIBEG+FranklinGothic-Book>?L;HI?JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> GK?JO glyph<c=6,font=/PIIBEG+FranklinGothic-Book> $D9BKI?ED .JH7J;=?9 glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EKD9?Bglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n2; 7H; >EDEH;: JE 8; H;9E=D?P;: 7I 7D ;CFBEO;H E< 9>E?9;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> !EH J>; <?<J> 9EDI;9KJ?L; O;7Hglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; I9EH;: glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=5,font=/PIIBEG+FranklinGothic-Book> ED J>; glyph<c=31,font=/PIIBEG+FranklinGothic-Book>?I78?B?JOglyph<c=26,font=/PIIBEG+FranklinGothic-Book>$)glyph<c=7,font=/PIIBEG+FranklinGothic-Book>I glyph<c=31,font=/PIIBEG+FranklinGothic-Book>?I78?B?JO GK7B?JO $D:;Nglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> C;7IKH;I EKH FEB?9?;I 7D: FH79J?9;I H;B7J;: JE :?I78?B?JO ?D9BKI?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>::?J?ED7BBOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> <EH J>; J>?H: 9EDI;9KJ?L; O;7Hglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; M;H; 7M7H:;: J>; glyph<c=31,font=/PIIBEG+FranklinGothic-Book>$glyph<c=13,font=/PIIBEG+FranklinGothic-Book>)glyph<c=30,font=/PIIBEG+FranklinGothic-Book> CFBEO;H glyph<c=28,font=/PIIBEG+FranklinGothic-Book>M7H: 8O glyph<c=31,font=/PIIBEG+FranklinGothic-Book>?I78?B?JOglyph<c=26,font=/PIIBEG+FranklinGothic-Book>$) )EHJ> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>7HEB?D7 <EH EKH 9ECC?JC;DJ JE 9>7CF?ED 7D: ?DL;IJ ?D :?I78?B?JO ?D9BKI?ED 7J J>; 7<<?B?7J; 7D: D7J?ED7B B;L;BIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> !EH J>; D?DJ> 9EDI;9KJ?L; O;7Hglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; M;H; H;9E=D?P;: 7I 7 glyph<c=29,font=/PIIBEG+FranklinGothic-Book>;IJ +B79; JE 2EHA <EH '\"glyph<c=29,font=/PIIBEG+FranklinGothic-Book>/,glyph<c=11,font=/PIIBEG+FranklinGothic-Book> GK7B?JO 8O J>; #KC7D -?=>JI glyph<c=30,font=/PIIBEG+FranklinGothic-Book>7CF7?=Dglyph<c=12,font=/PIIBEG+FranklinGothic-Book> I9EH?D= glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=5,font=/PIIBEG+FranklinGothic-Book> ED J>;?H glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EHFEH7J; GK7B?JO $D:;Nglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## 'B@3<5B63<7<5 =C@ glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>:=0/: glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=;>3B3<1G\n\n2; 7H; 9ECC?JJ;: JE IJH;D=J>;D?D= J>; glyph<c=31,font=/PIIBEG+FranklinGothic-Book> glyph<c=6,font=/PIIBEG+FranklinGothic-Book>$ 7M7H;D;II 7D: 97F78?B?JO E< EKH ;CFBEO;;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; >7L; <E9KI;: ED ;DIKH?D= J>7J EKH ;CFBEO;;I >7L; J>; H;IEKH9;I 7D: B;7HD?D= J>;O D;;: JE 9EDJH?8KJ; JE EKH IJH7J;=Oglyph<c=14,font=/PIIBEG+FranklinGothic-Book> *KH F;EFB; C7D7=;HI 7H; JH7?D;: ED ?D9BKI?L; H;9HK?J?D= 7D: >?H?D= 7D: EKH =BE87B ;CFBEO;;I 7H; JH7?D;: ED glyph<c=31,font=/PIIBEG+FranklinGothic-Book> glyph<c=6,font=/PIIBEG+FranklinGothic-Book>$ 9KHH?9KBKCglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n$D glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> M; ?DJHE:K9;: \"BE8;.C7HJUglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 JEEB JE ;D>7D9; 9HEIIglyph<c=13,font=/PIIBEG+FranklinGothic-Book>9KBJKH7B 9EBB78EH7J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9H;7I; 9KBJKH7B 7=?B?JO 7D: <KHJ>;H 9EDD;9J EKH =BE87B J;7CIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> *KH F;EFB; B;7:;HI >7L; KI;: \"BE8;.C7HJUglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7BBEM?D= J>;C JE ;NFBEH; :?<<;H;DJ MEHA?D= IJOB;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> F;HIF;9J?L;I 7D: 7FFHE79>;I J>7J ;N?IJ 7HEKD: J>; =BE8;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> =;JJ?D= 79J?ED78B;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> F;HIED7B?P;: 7:L?9; <EH 8;JJ;H 9EBB78EH7J?ED 7D: J;7CMEHA 79HEII 9KBJKH;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D:\n\n;NFBEH?D= D;M M7OI <EH J;7CI JE 8K?B: JHKIJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> IJH;D=J>;D 9EBB78EH7J?ED 7D: B;L;H7=; :?L;HI?JOglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## $67:=A=>6G =< $/G glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>?C7BG\n\n2; 7H; 9ECC?JJ;: JE ;DIKH?D= EKH ;CFBEO;;I H;9;?L; ;GK7B F7O <EH ;GK7B MEHAglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; ;IJ78B?I> 9ECFED;DJI 7D: H7D=;I E< 9ECF;DI7J?ED 87I;: ED C7HA;J 7D: 8;D9>C7HA :7J7glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2?J>?D J>?I 9EDJ;NJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; IJH?L; JE F7O 7BB ;CFBEO;;I ;GK?J78BO M?J>?D 7 H;7IED78B; H7D=;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J7A?D= ?DJE 9EDI?:;H7J?ED <79JEHI IK9> 7I HEB;glyph<c=27,font=/PIIBEG+FranklinGothic-Book> C7HA;J :7J7glyph<c=27,font=/PIIBEG+FranklinGothic-Book> ?DJ;HD7B ;GK?JOglyph<c=27,font=/PIIBEG+FranklinGothic-Book> @E8 BE97J?EDglyph<c=27,font=/PIIBEG+FranklinGothic-Book> H;B;L7DJ ;NF;H?;D9;glyph<c=27,font=/PIIBEG+FranklinGothic-Book> 7D: ?D:?L?:K7Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 8KI?D;II KD?J 7D: 9ECF7DO F;H<EHC7D9;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D 7::?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 7H; 9ECC?JJ;: JE FHEL?:?D= <B;N?8B; 8;D;<?JI :;I?=D;: JE 7BBEM EKH :?L;HI; =BE87B MEHA<EH9; JE >7L; H;M7H: EFFEHJKD?J?;I J>7J C;;J J>;?H L7H?;: D;;:I IE J>7J J>;O 7H; ?DIF?H;: JE F;H<EHC J>;?H 8;IJ ED 8;>7B< E< F7J?;DJI 7D: IJE9A>EB:;HI ;79> :7Oglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n2; H;=KB7HBO H;L?;M EKH 9ECF;DI7J?ED FH79J?9;I 7D: 7D7BOP; J>; ;GK?JO E< 9ECF;DI7J?ED :;9?I?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> <EH ?D:?L?:K7B ;CFBEO;;I 7D: EKH MEHA<EH9; 7I 7 M>EB;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> M; I>7H;: J>; H;IKBJI E< 7 =BE87B =;D:;H F7O 7II;IIC;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D7BOP?D= F7O 7J J>; ;N;9KJ?L;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> C7D7=;C;DJ 7D: EJ>;H FHE<;II?ED7B B;L;BIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n2; ?DIJ?JKJ; C;7IKH;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> IK9> 7I 9ECCKD?97J?EDI 7D: JH7?D?D=Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> JE H;9E=D?P;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?DJ;HHKFJ 7D: FH;L;DJ 8?7I ?D >?H?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> F;H<EHC7D9; C7D7=;C;DJ 7D: 9ECF;DI7J?ED :;9?I?EDI 7D: M; FHEL?:; H;IEKH9;I JE <KHJ>;H :;L;BEF C7D7=;HI 7D: B;7:;HI JE >;BF J>;C C7A; ;GK?J78B; :;9?I?EDI 78EKJ F7Oglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## (/:3<B /<2 glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>3D3:=>;3<B\n\n(7DO <79JEHI ?D<BK;D9; ;CFBEO;; IK99;II 7D: M;BBglyph<c=13,font=/PIIBEG+FranklinGothic-Book>8;?D=glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; <EIJ;H 7 MEHAFB79; JE 7BBEM ;CFBEO;;I JE :;B?L;H ED EKH I>7H;: C?II?ED M>?B; >;BF?D= JE C?J?=7J; J>;?H 9>7BB;D=;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> !HEC 97H;;H :;L;BEFC;DJ JE M;BBD;II JE MEHAFB79; ;DL?HEDC;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>;H; 7H; C7DO EFFEHJKD?J?;I JE C;;J ;CFBEO;; D;;:Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: JE 8K?B: 7 MEHAFB79; M>;H; F;EFB; 7H; ;CFEM;H;: JE B;7HDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> =HEM 7D: 8K?B: H;M7H:?D= 97H;;HIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> *KH ;CFBEO;;I 7H; ;D9EKH7=;: JE J7A; 7:L7DJ7=; E< 7D 7HH7O E< FHE<;II?ED7B :;L;BEFC;DJ H;IEKH9;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> (7D7=;HI 9E79> ;CFBEO;;I <EH F;H<EHC7D9;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: 7BIE ;D=7=; ?D ;CFBEO;; :;L;BEFC;DJ :?I9KII?EDI JE IKFFEHJ =HEMJ> 7D: B;7HD?D=glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n*FFEHJKD?J?;I <EH ED=E?D= B;7HD?D= 97D 9EDJH?8KJ; JE ;CFBEO;; H;B7J;: ;D=7=;C;DJ 7D: IK99;IIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>J glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E=;Dglyph<c=12,font=/PIIBEG+FranklinGothic-Book> :;L;BEFC;DJ E99KHI J>HEK=> EDglyph<c=13,font=/PIIBEG+FranklinGothic-Book>J>;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>@E8 B;7HD?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9>7BB;D=?D= D;M 7II?=DC;DJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> <EHC7B JH7?D?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> EDB?D; B;7HD?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> C;DJEH?D= 7D: CEH;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2?J> C7DO ;CFBEO;;I 9EDJ?DK?D= JE MEHA <HEC >EC;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> L?HJK7B B;7HD?D= FB7OI 7 A;O HEB;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 1?HJK7B B;7HD?D=I 7H; 7L7?B78B; J>HEK=> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E=;D 0D?L;HI?JO 7I M;BB 7I '?DA;:$D ';7HD?D=glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />HEK=> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E=;D 0D?L;HI?JO M; E<<;H CEH; J>7D glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> ?DIJHK9JEHglyph<c=13,font=/PIIBEG+FranklinGothic-Book>87I;: 9EKHI;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> E< M>?9> 7FFHEN?C7J;BO glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> 7H; 7L7?B78B; L?HJK7BBOglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />HEK=> '?DA;:$D ';7HD?D= M; FHEL?:;: ;CFBEO;;I M?J> 799;II",
        "metadata": {
            "page": 40
        },
        "id": "07921c4e-8fc8-43b2-a17f-cdf57de558e6"
    },
    {
        "page_content": "JE CEH; J>7D glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> EDglyph<c=13,font=/PIIBEG+FranklinGothic-Book>:;C7D: B;7HD?D= CE:KB;I ?D glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book> B7D=K7=;Iglyph<c=26,font=/PIIBEG+FranklinGothic-Book> D=B?I>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> \";HC7Dglyph<c=12,font=/PIIBEG+FranklinGothic-Book> !H;D9>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> .F7D?I>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> %7F7D;I;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> +EHJK=K;I;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> $J7B?7Dglyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=31,font=/PIIBEG+FranklinGothic-Book>KJ9>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> +EB?I>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> /KHA?I> 7D: (7D:7H?Dglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n/E 9H;7J; 7D: IKIJ7?D 7 MEHAFB79; 7I :?L;HI; 7D: ?D9BKI?L; 7I J>; F7J?;DJI M; I;HL;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; E<<;H FHE=H7CI J>7J ?DL;IJ ?D EKH J7B;DJ F?F;B?D; 7D: ?D EKH 9KHH;DJ B;7:;HIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D=glyph<c=26,font=/PIIBEG+FranklinGothic-Book>\n\n- T glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>1B7D/B3glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> &34:31B /<2 glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=glyph<c=8,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>@3/B3glyph<c=20,font=/PIIBDE+FranklinGothic-BookItal> +H;F7H?D= JEF J7B;DJ <EH J>; H?=EHI E< ;N;9KJ?L; HEB;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- T +=;3<MA  3/23@A67> $@=5@/;glyph<c=20,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>::H;II?D= J>; KD?GK; 9>7BB;D=;I <79;: 8O <;C7B; B;7:;HI JE ?D9H;7I; ?D<BK;D9; 7D: ?CF79Jglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- T glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>F31CB7D3 3/23@A67> &3B@3/Bglyph<c=20,font=/PIIBDE+FranklinGothic-BookItal> $CC;HI?D= B;7:;HI ?D JEF?9I :;I?=D;: JE >;BF J>;C I>7F; 9KBJKH; 7D: 8K?B: H;I?B?;D9;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- T (63 $/@B<3@A67>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><1glyph<c=4,font=/PIIBDE+FranklinGothic-BookItal>A glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>7=glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>7D3@A7BG glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>3::=EA $@=5@/;glyph<c=20,font=/PIIBDE+FranklinGothic-BookItal> /E 9EDJ?DK; JE 8EBIJ;H EKH J7B;DJ F?F;B?D; M?J> 7 :?L;HI; C?N E< B;7:;HIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> >?=> FEJ;DJ?7Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> C?:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>97H;;Hglyph<c=12,font=/PIIBEG+FranklinGothic-Book> KD:;HH;FH;I;DJ;: C?DEH?J?;I F7HJ?9?F7J; ?D J>?I FHE=H7Cglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> M; >;BF;: 9H;7J;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- T +=;3< =< B63 &7A3glyph<c=20,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>::H;II?D= J>; KD?GK; 9>7BB;D=;I <79;: 8O C?:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>B;L;B <;C7B; B;7:;HI JE ?D9H;7I; ?D<BK;D9; 7D: ?CF79Jglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- T glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>;3@57<5 3/23@Aglyph<c=20,font=/PIIBDE+FranklinGothic-BookItal> +H;F7H?D= >?=>glyph<c=13,font=/PIIBEG+FranklinGothic-Book>FEJ;DJ?7B ?D:?L?:K7B 9EDJH?8KJEHI <EH <?HIJglyph<c=13,font=/PIIBEG+FranklinGothic-Book>B;L;B B;7:;HI>?F HEB;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- T glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>3BB3@)>glyph<c=20,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>E79>?D= FHE=H7C 7L7?B78B; JE IKFFEHJ ?D:?L?:K7BI 7I J>;O MEHA JEM7H: ;D>7D9?D= J>;?H ?CF79J ?D J>; EH=7D?P7J?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n*KH  CFBEO;; -;IEKH9; );JMEHAI glyph<c=8,font=/PIIBEG+FranklinGothic-Book> -)Iglyph<c=9,font=/PIIBEG+FranklinGothic-Book> FHEL?:; ?DL7BK78B; EFFEHJKD?J?;I <EH ;CFBEO;;I JE I>7H; ADEMB;:=; 7D: 8K?B: 9EDD;9J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> *KH 9KHH;DJ  -)I ?D9BK:;glyph<c=26,font=/PIIBEG+FranklinGothic-Book>\n\n- T $/@3<B7<5 \"3BE=@9 glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>@=C>glyph<c=20,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E=;Dglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I D;M;IJ -) FHEL?:;I IKFFEHJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> D;JMEHA?D= 7D: :;L;BEFC;DJ EFFEHJKD?J?;I JE MEHA?D= F7H;DJI 7D: 97H;=?L;HIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7I M;BB 7I >;BF?D= ;CFBEO;;I D7L?=7J; J>; 9>7BB;D=;I E< MEHAglyph<c=13,font=/PIIBEG+FranklinGothic-Book>B?<; 87B7D9;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- T glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>\"glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>(glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=20,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>H?D=I JE=;J>;H ;7HBOglyph<c=13,font=/PIIBEG+FranklinGothic-Book>97H;;H FHE<;II?ED7BI 7D: J>;?H 7:LE97J;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- T glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>113AAglyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>07:7BGglyph<c=20,font=/PIIBDE+FranklinGothic-BookItal> .KFFEHJI ;CFBEO;;I M?J> :?I78?B?J?;I 7D: ;CFBEO;;I M>E 7H; 97H;J7A;HI E< ?D:?L?:K7BI M?J> :?I78?B?J?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- T glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>7=53< *3B3@/<A \"3BE=@9glyph<c=20,font=/PIIBDE+FranklinGothic-BookItal> D9EKH7=;I L;J;H7DI 7D: 7BB?;I E< L;J;H7DI JE 9EDD;9J 7D: IKFFEHJ ED; 7DEJ>;Hglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- T !=A/71glyph<c=20,font=/PIIBDE+FranklinGothic-BookItal> !EIJ;HI 7M7H;D;II 7D: 7FFH;9?7J?ED E< :?<<;H;DJ 9KBJKH7B 879A=HEKD:Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D 7::?J?ED JE FHECEJ?D= D;JMEHA?D= 7D: :;L;BEFC;DJ EFFEHJKD?J?;I <EH C;C8;HIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n- T &3/16#)(glyph<c=20,font=/PIIBDE+FranklinGothic-BookItal> .KFFEHJI 7 8;IJglyph<c=13,font=/PIIBEG+FranklinGothic-Book>?Dglyph<c=13,font=/PIIBEG+FranklinGothic-Book>9B7II MEHA?D= ;DL?HEDC;DJ <EH '\"glyph<c=29,font=/PIIBEG+FranklinGothic-Book>/,glyph<c=11,font=/PIIBEG+FranklinGothic-Book> ;CFBEO;;I 7D: ;C8H79;I 7BB '\"glyph<c=29,font=/PIIBEG+FranklinGothic-Book>/,glyph<c=11,font=/PIIBEG+FranklinGothic-Book> ;CFBEO;;I 7D: J>;?H 7BB?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- T +=;3<MA glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><<=D/B7=< \"3BE=@9glyph<c=20,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>H;7J;I D;JMEHA?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> C;DJEH?D= 7D: B;7HD?D= EFFEHJKD?J?;I <EH MEC;D 7D: 7BB?;I MEHB:M?:;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- T =C@glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>!$glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>(glyph<c=20,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>:L7D9;I 9B?C7J;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> >;7BJ> 7D: ;GK?JO 7J MEHAglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D ;CFBEO;;Iglyph<c=7,font=/PIIBEG+FranklinGothic-Book> F;HIED7B B?L;I 7D: ?D J>; 9ECCKD?J?;I M>;H; M; B?L; 7D: MEHAglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n2; 9EDJ?DK; JE ;LEBL; EKH FHE=H7CI JE C;;J EKH ;CFBEO;;I^ >;7BJ> 7D: M;BBD;II D;;:Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> M; 8;B?;L; ?I ;II;DJ?7B JE 7JJH79J 7D: H;J7?D ;CFBEO;;I E< J>; >?=>;IJ 97B?8;Hglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; >7L; H;<H;I>;: EKH <B;N?8B; MEHA?D= 7HH7D=;C;DJ FEB?9?;I JE 7BBEM <EH CEH; <B;N?8?B?JO 7HEKD: MEHA >EKHI JE >;BF ;CFBEO;;I 87B7D9; J>; :;C7D:I E< J>;?H MEHA 7D: >EC; B?L;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> I>?<J;: C7DO E< EKH EDglyph<c=13,font=/PIIBEG+FranklinGothic-Book>I?J; M;BBD;II I;HL?9;I JE L?HJK7Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= L?HJK7B 8;>7L?EH >;7BJ>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> DKJH?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> <?JD;II 7D: EL;H7BB M;BBglyph<c=13,font=/PIIBEG+FranklinGothic-Book>8;?D= 9B7II;I 7D: 9EKDI;B?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> HEBB;: EKJ J>; #;7:IF79; C;:?J7J?ED 7FF =BE87BBO 7J DE 9EIJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FHEL?:;: MEHAI>EFI 7D: FHE=H7CC?D= JE >;BF ;CFBEO;;I 9EF; M?J> IJH;IIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?IEB7J?ED 7D: 8K?B:?D= H;I?B?;D9;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7BED= M?J> <?D7D9?7B FB7DD?D= MEHAI>EFI 7D: 9EKDI;B?D= I;II?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ;NF7D:;: EKH 97H;=?L;H I;HL?9;I JE C;;J J>; =HEM?D= D;;:I E< EKH ;CFBEO;;I 7D: FHEL?:;: 7::?J?ED7B >EB?:7OI 7D: J?C; E<< <EH H;9>7H=?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> LEJ?D= 7D: LEBKDJ;;H?D=glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>;>:=G33 'C@D3GA\n\n2; KJ?B?P; 7D ;CFBEO;; IKHL;O FHE=H7C JE FKBI; ;CFBEO;;I J>HEK=> ;C7?B 7D: CE8?B; 7FFI 7I M;BB 7I FHEL?:; 7D EFFEHJKD?JO <EH 9ECC;DJ7HO 7D: <79?B?J7J; <;;:879A JE GK;IJ?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; IKHL;O ?I :;I?=D;: JE ;CFEM;H C7D7=;HI 7D: B;7:;HI M?J> 7DEDOCEKI ?D<EHC7J?ED ED J>;?H FH79J?9;I H;B7J;: JE 8K?B:?D= 9KBJKH;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> F;H<EHC7D9; 7D: 7D ;D=7=;: MEHA<EH9;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7BBEM?D= J>;C JE 9H;7J; FB7DI 7D: C;7IKH; ;<<?979O <EH 9EDJ?DKEKI ?CFHEL;C;DJglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; 97H; :;;FBO 78EKJ ;CFBEO;; <;;:879A 7D: 7H; 8K?B:?D= 7D 7D7BOJ?9I 9ECCKD?JO 79HEII #KC7D -;IEKH9;I JE 8H?D= CEH; H?=EH 7D: IEF>?IJ?97J?ED JE J>; 9EBB;9J?ED 7D: 7D7BOI?I E< ;CFBEO;; EF?D?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; KI; J>;?H F;HIF;9J?L;I JE =K?:; KI JE J7A; 79J?EDI J>7J ?CFHEL; ;D=7=;C;DJ 7D: IKFFEHJ 7D: >;BF C7?DJ7?D EKH H;FKJ7J?ED 7I 7 =H;7J FB79; JE MEHA <EH 7BB EKH ;CFBEO;;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>D ;N7CFB; E< IK9> 7D 79J?ED M7I EKH glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> 2;BBD;II 2;;Aglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 M;;ABED= C?:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>O;7H I>KJ:EMDglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## 'C113AA7=< $:/<<7<5\n\n79> O;7H M; 9ED:K9J 7 J7B;DJ H;L?;M 79HEII EKH =BE87B ;DJ;HFH?I; J>7J ?D9BK:;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7CED= EJ>;H ?CFEHJ7DJ JEF?9Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 H;L?;M E< IK99;II?ED FB7DI <EH C7DO E< EKH HEB;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> /E >;BF ;DIKH; J>; BED=glyph<c=13,font=/PIIBEG+FranklinGothic-Book>J;HC 9EDJ?DK?JO E< EKH 8KI?D;IIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 79J?L;BO C7D7=; J>; :;L;BEFC;DJ E< J7B;DJ JE <?BB J>; HEB;I J>7J 7H; CEIJ 9H?J?97B JE J>;",
        "metadata": {
            "page": 41
        },
        "id": "9cc925e2-a8a9-4c02-8597-fc6cea0195ef"
    },
    {
        "page_content": "ED=E?D= IK99;II E< EKH 9ECF7DOglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D 7::?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ;79> O;7H EKH glyph<c=29,font=/PIIBEG+FranklinGothic-Book>E7H: E< glyph<c=31,font=/PIIBEG+FranklinGothic-Book>?H;9JEHI H;L?;MI J>; IK99;II?ED FB7D <EH EKH ;N;9KJ?L;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## +=@9>:/13 glyph<c=28,font=/PIIBDE+FranklinGothic-BookItal>3/:B6 /<2 '/43BG\n\n/>; M;BBglyph<c=13,font=/PIIBEG+FranklinGothic-Book>8;?D= E< EKH ;CFBEO;;I ?I J>; FH?EH?JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: M; 8;B?;L; ;L;HO ;CFBEO;; FB7OI 7 HEB; ?D 9H;7J?D= 7 I7<; 7D: >;7BJ>O MEHAFB79;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> *KH ;CFBEO;;I >7L; L7H?;: HEB;I 7D: <KD9J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> ?I M>O M; ;CFEM;H J>;C JE FHECEJ; 7 I7<; MEHA?D= ;DL?HEDC;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;=7H:B;II E< M>;J>;H MEHA >7FF;DI ?D J>; B78glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D 7D E<<?9; EH ?D 7 C7DK<79JKH?D= FB7DJglyph<c=14,font=/PIIBEG+FranklinGothic-Book> *KH FEB?9?;I 7D: FH79J?9;I 7H; ?DJ;D:;: JE FHEJ;9J DEJ EDBO EKH ;CFBEO;;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 8KJ 7BIE J>; IKHHEKD:?D= 9ECCKD?J?;I M>;H; M; EF;H7J;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n$D glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> M; 9EDJ?DK;: JE C7A; I?=D?<?97DJ FHE=H;II ?DJ;=H7J?D= #KC7D +;H<EHC7D9; ?DJE EKH DL?HEDC;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> #;7BJ> 7D: .7<;JO FHE=H7CIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; 8;B?;L; J>7Jglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>;D ?J 9EC;I JE I7<;JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> MEHA;HI 7H; F7HJ E< J>; IEBKJ?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; ;D9EKH7=; ;CFBEO;;I JE 9EBB78EH7J?L;BO ;D=7=; ?D FHE79J?L; FHE8B;C IEBL?D= J>HEK=> FH79J?9;I IK9> 7I *F;D -;FEHJ?D= 7D: 2EHA *8I;HL7J?ED 7D: -?IA glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EDL;HI7J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>::?J?ED7BBOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> EKH F>OI?97B I7<;JO FHE=H7C <E9KI;: ED :;J7?B;: ;L7BK7J?EDI E< 9H?J?97B J7IAI J>7J 9EKB: ;NFEI; ;CFBEO;;I JE I;H?EKI ?D@KHO EH <7J7B?JO ?< 9EDJHEBI 7H; 78I;DJ EH DEJ KI;:glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; 79J?EDI M; ?CFB;C;DJ 7I 7 H;IKBJ E< J>;I; ;L7BK7J?EDI H;:K9; J>; H?IAI 7IIE9?7J;: M?J> J>;I; ;II;DJ?7B 79J?L?J?;I 7D: ;DIKH; EKH EF;H7J?ED7B IOIJ;CI 7H; I7<;H 7D: CEH; H;I?B?;DJ <EH ;CFBEO;;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; 7BIE KI; [glyph<c=28,font=/PIIBEG+FranklinGothic-Book><J;H glyph<c=28,font=/PIIBEG+FranklinGothic-Book>9J?ED -;L?;MI\\ <EBBEM?D= J>; 9ECFB;J?ED E< 7 FHE@;9Jglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />;I; H;L?;MI ;D78B; KI JE DEJ EDBO <E9KI ED 7H;7I <EH ?CFHEL;C;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 8KJ 7BIE JE B;7HD 7D: 7FFBO =EE: FH79J?9;I <HEC M>7J =E;I M;BBglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>O ;D=7=?D= 7D: ;CFEM;H?D= EKH ;CFBEO;;I J>HEK=> IK9> FHE=H7CIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 8;B?;L; J>7J M; 97D >;BF 9>7D=; >EM J>; ;DJ?H; ?D:KIJHO 7FFHE79>;I I7<;JO F;H<EHC7D9; 7D: H?IA C7D7=;C;DJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>",
        "metadata": {
            "page": 42
        },
        "id": "699b7432-a4c8-4ed6-8796-90b675e0a13c"
    },
    {
        "page_content": "@8AD?3F;A@ 34AGF AGD glyph<c=28,font=/PIIBCD+FranklinGothic-Book>J75GF;H7 &88;57DE glyph<c=6,font=/PIIBCD+FranklinGothic-Book>3E A8 glyph<c=29,font=/PIIBCD+FranklinGothic-Book>74DG3DK glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=18,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\n| &88;57D                                                                                                                                                                                                                                                                                                                                                                                                                      | glyph<c=26,font=/PIIBCD+FranklinGothic-Book>GDD7@F 'AE;F;A@                                                                                                                      | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>97                                           | 073D !A;@76 glyph<c=25,font=/PIIBCD+FranklinGothic-Book>;A97@                                                                                                                    |\n|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=26,font=/PIIBCD+FranklinGothic-Book>:D;EFAB:7D glyph<c=24,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> -;7:435:7D                                                                                                                                                                                                                                                                   | +H;I?:;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>?;<  N;9KJ?L; *<<?9;H                                                         | glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> |\n| *GE3@ glyph<c=31,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>>7J3@67D                                                                                                                                                                                                                                                                          | N;9KJ?L; 1?9; +H;I?:;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>?;< ';=7B *<<?9;H 7D: .;9H;J7HO                                 | glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book> | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book> |\n| $;5:37> )glyph<c=11,font=/PIIBCD+FranklinGothic-Book> $5glyph<c=27,font=/PIIBCD+FranklinGothic-Book>A@@7>>                                                                                                                                                                                                                                                                                                                   | N;9KJ?L; 1?9; +H;I?:;DJ 7D: glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>?;< !?D7D9?7B *<<?9;H                                                                                   | glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book> | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> |\n| %;5A>7 $GDB:K                                                                                                                                                                                                                                                                                                                                                                                                                | N;9KJ?L; 1?9; +H;I?:;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> +>7HC79;KJ?97B *F;H7J?EDI 7D: /;9>DEBE=O                                                                     | glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book> |\n| glyph<c=30,font=/PIIBCD+FranklinGothic-Book>;@97D glyph<c=30,font=/PIIBCD+FranklinGothic-Book>D79ADKglyph<c=9,font=/PIIBCD+FranklinGothic-Book> ':glyph<c=11,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                       | N;9KJ?L; 1?9; +H;I?:;DJ 7D: glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>?;< #KC7D -;IEKH9;I *<<?9;H                                                                             | glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book> | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book> |\n| )35:;6  LL3D                                                                                                                                                                                                                                                                                                                                                                                                                 | N;9KJ?L; 1?9; +H;I?:;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> \"BE87B +HE:K9J .JH7J;=O 7D: glyph<c=30,font=/PIIBEG+FranklinGothic-Book>ECC;H9?7B?P7J?ED                     | glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book> | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book> |\n| 'D;K3 *;@9:3>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> $glyph<c=11,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> $glyph<c=11,font=/PIIBCD+FranklinGothic-Book>'glyph<c=11,font=/PIIBCD+FranklinGothic-Book>glyph<c=31,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> | N;9KJ?L; 1?9; +H;I?:;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> #;7: E< glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;L;BEFC;DJ                                               | glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book> | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> |\n| )A4;@ glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> \"D3?7D                                                                                                                                                                                                                                                                                                                        | .;D?EH 1?9; +H;I?:;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>?;< glyph<c=28,font=/PIIBEG+FranklinGothic-Book>99EKDJ?D= *<<?9;H | glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book> | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book> |\n| glyph<c=26,font=/PIIBCD+FranklinGothic-Book>:D;EFAB:7D glyph<c=24,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> -;7:435:7D                                                                                                                                                                                                                                                                   | glyph<c=26,font=/PIIBCD+FranklinGothic-Book>:D;EFAB:7D glyph<c=24,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> -;7:435:7D                       |                                                                                          |                                                                                                                                                                                  |\n\nglyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>F>3@73<13\n\n(Hglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 1?;>879>;H >7I I;HL;: 7I EKH +H;I?:;DJ 7D: glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>?;<  N;9KJ?L; *<<?9;H 7D: C;C8;H E< EKH glyph<c=29,font=/PIIBEG+FranklinGothic-Book>E7H: E< glyph<c=31,font=/PIIBEG+FranklinGothic-Book>?H;9JEHI I?D9; )EL;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> +H?EH JE @E?D?D= glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E=;Dglyph<c=12,font=/PIIBEG+FranklinGothic-Book> (Hglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 1?;>879>;H I;HL;: 7I (7D7=?D= +7HJD;H E< \"KHD;J +E?DJ glyph<c=30,font=/PIIBEG+FranklinGothic-Book>7F?J7Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 glyph<c=29,font=/PIIBEG+FranklinGothic-Book>EIJED 87I;: ?DL;IJC;DJ <KD: <HEC glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book> JE glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> +H?EH JE J>7Jglyph<c=12,font=/PIIBEG+FranklinGothic-Book> (Hglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 1?;>879>;H I;HL;: 7I \"BE87B glyph<c=30,font=/PIIBEG+FranklinGothic-Book> * E< .7DE<?glyph<c=12,font=/PIIBEG+FranklinGothic-Book> <HEC glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book> JE glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> +H?EH JE @E?D?D= .7DE<?glyph<c=12,font=/PIIBEG+FranklinGothic-Book> (Hglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 1?;>879>;H IF;DJ EL;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> O;7HI M?J> \"B7NE.C?J>&B?D; ?D \";HC7DOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>7D7:7glyph<c=12,font=/PIIBEG+FranklinGothic-Book> !H7D9; 7D:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> B7JJ;HBOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 7I FH;I?:;DJ E< ?JI )EHJ> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>C;H?97D F>7HC79;KJ?97B :?L?I?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book> (Hglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 1?;>879>;H 8;=7D >?I 97H;;H M?J> +H?9;M7J;H>EKI;glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EEF;HI ''+ 7D: GK7B?<?;: 7I 7 9>7HJ;H;: 799EKDJ7DJglyph<c=14,font=/PIIBEG+FranklinGothic-Book> (Hglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 1?;>879>;H FH;L?EKIBO I;HL;: ED J>; 8E7H: E< :?H;9JEHI E< 1;:7DJ7 glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?EI9?;D9;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> $D9glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 7I 9>7?Hglyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book> !*glyph<c=29,font=/PIIBEG+FranklinGothic-Book>H7D:Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> $D9glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: glyph<c=30,font=/PIIBEG+FranklinGothic-Book>HEIIEL;H #;7BJ>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> #; ?I 7BIE 7 JHKIJ;; E< )EHJ>;7IJ;HD 0D?L;HI?JO 7D: 7 C;C8;H E< J>; 8E7H: E< <;BBEMI 7J .J7D<EH: (;:?97B .9>EEBglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## $C0:71 glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=;>/<G glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>=/@2A\n\n- glyph<c=2,font=/PIIBFH+Wingdings-Regular> +KH;/;9> #;7BJ> +B9glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>2C1/B7=<\n\n- glyph<c=2,font=/PIIBFH+Wingdings-Regular> ,K;;Dglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I 0D?L;HI?JO ?D &?D=IJEDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> *DJ7H?Eglyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>7D7:7glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## *GE3@ glyph<c=31,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>>7J3@67D\n\n## glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>F>3@73<13\n\n(Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>B;N7D:;H >7I I;HL;: 7I EKH  N;9KJ?L; 1?9; +H;I?:;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>?;< ';=7B *<<?9;H 7D: .;9H;J7HO I?D9; glyph<c=28,font=/PIIBEG+FranklinGothic-Book>FH?B glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> +H?EH JE J>7Jglyph<c=12,font=/PIIBEG+FranklinGothic-Book> (Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>B;N7D:;H I;HL;: 7I EKH  N;9KJ?L; 1?9; +H;I?:;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>?;< ';=7Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EHFEH7J; .;HL?9;I 7D: .;9H;J7HO <HEC (7H9> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book> JE (7H9> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7I EKH  N;9KJ?L; 1?9; +H;I?:;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>?;< ';=7B *<<?9;H 7D: .;9H;J7HO <HEC glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book> JE (7H9> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book> 7D: 7I EKH  N;9KJ?L; 1?9; +H;I?:;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> \";D;H7B glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EKDI;B 7D: glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EHFEH7J; .;9H;J7HO <HEC glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book> JE glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> +H?EH JE @E?D?D= glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E=;Dglyph<c=12,font=/PIIBEG+FranklinGothic-Book> (Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>B;N7D:;H I;HL;: 7I J>; .;D?EH 1?9; +H;I?:;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> \";D;H7B glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EKDI;B 7D: glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EHFEH7J; .;9H;J7HO E< +glyph<c=28,font=/PIIBEG+FranklinGothic-Book>- 3 ' $DJ;HD7J?ED7B glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EHFEH7J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 8?EF>7HC79;KJ?97B I;HL?9;I 9ECF7DOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> <HEC glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book> JE %7DK7HO glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> !HEC glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book> JE glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book> (Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>B;N7D:;H I;HL;: 7I \";D;H7B glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EKDI;B E< $*)glyph<c=28,font=/PIIBEG+FranklinGothic-Book> /;9>DEBE=?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 IE<JM7H; 9ECF7DOglyph<c=14,font=/PIIBEG+FranklinGothic-Book> !HEC glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book> JE glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book> (Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>B;N7D:;H I;HL;: 7I glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EKDI;B 7J glyph<c=30,font=/PIIBEG+FranklinGothic-Book>78EJ glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EHFEH7J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 IF;9?7BJO 9>;C?97BI 7D: F;H<EHC7D9; C7J;H?7BI 9ECF7DOglyph<c=14,font=/PIIBEG+FranklinGothic-Book> +H?EH JE J>7Jglyph<c=12,font=/PIIBEG+FranklinGothic-Book> (Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>B;N7D:;H M7I 7 F7HJD;H 7J J>; B7M <?HCI E< #?D9AB;Oglyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BB;D glyph<c=6,font=/PIIBEG+FranklinGothic-Book> .DO:;H 7D: !?D; glyph<c=6,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>C8HE=D;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>2C1/B7=<\n\n- glyph<c=2,font=/PIIBFH+Wingdings-Regular> 2;BB;IB;O glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EBB;=;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- glyph<c=2,font=/PIIBFH+Wingdings-Regular> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>EIJED 0D?L;HI?JO .9>EEB E< '7Mglyph<c=12,font=/PIIBEG+FranklinGothic-Book> %glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>",
        "metadata": {
            "page": 43
        },
        "id": "03c3350d-bad7-45be-9b79-bf278a09d0e8"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>F>3@73<13\n\n(Hglyph<c=14,font=/PIIBEG+FranklinGothic-Book> (9glyph<c=31,font=/PIIBEG+FranklinGothic-Book>EDD;BB >7I I;HL;: 7I EKH  N;9KJ?L; 1?9; +H;I?:;DJ 7D: glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>?;< !?D7D9?7B *<<?9;H I?D9; glyph<c=28,font=/PIIBEG+FranklinGothic-Book>K=KIJ glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> +H?EH JE @E?D?D= glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E=;Dglyph<c=12,font=/PIIBEG+FranklinGothic-Book> (Hglyph<c=14,font=/PIIBEG+FranklinGothic-Book> (9glyph<c=31,font=/PIIBEG+FranklinGothic-Book>EDD;BB I;HL;: 7I  N;9KJ?L; 1?9; +H;I?:;DJ 7D: glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>?;< !?D7D9?7B *<<?9;H E< $,1$glyph<c=28,font=/PIIBEG+FranklinGothic-Book> #EB:?D=I $D9glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 B;7:?D= =BE87B FHEL?:;H E< 7:L7D9;: 7D7BOJ?9Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J;9>DEBE=O IEBKJ?EDI 7D: 9EDJH79J H;I;7H9> I;HL?9;I JE J>; B?<; I9?;D9;I ?D:KIJHOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> <HEC glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book> KDJ?B %KBO glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> +H?EH JE J>7Jglyph<c=12,font=/PIIBEG+FranklinGothic-Book> (Hglyph<c=14,font=/PIIBEG+FranklinGothic-Book> (9glyph<c=31,font=/PIIBEG+FranklinGothic-Book>EDD;BB I;HL;: 7I J>;  N;9KJ?L; 1?9; +H;I?:;DJ 7D: glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>?;< !?D7D9?7B *<<?9;H E< $DJ;BI7Jglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 B;7:?D= =BE87B FHEL?:;H E< I7J;BB?J; I;HL?9;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> <HEC )EL;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book> JE glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7I  N;9KJ?L; 1?9; +H;I?:;DJ 7D: glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>?;< !?D7D9?7B *<<?9;H E< (glyph<c=30,font=/PIIBEG+FranklinGothic-Book>\" glyph<c=30,font=/PIIBEG+FranklinGothic-Book>7F?J7B glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EHFEH7J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 FK8B?9BOglyph<c=13,font=/PIIBEG+FranklinGothic-Book> >;B: 9ECC;H9?7B <?D7D9; 9ECF7DOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> <HEC .;FJ;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book> KDJ?B *9JE8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book> 7D: 7I (glyph<c=30,font=/PIIBEG+FranklinGothic-Book>\" glyph<c=30,font=/PIIBEG+FranklinGothic-Book>7F?J7B glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EHFEH7J?ED^I glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>?;< *F;H7J?D= *<<?9;H <HEC glyph<c=28,font=/PIIBEG+FranklinGothic-Book>K=KIJ glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book> KDJ?B *9JE8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>;<EH; @E?D?D= (glyph<c=30,font=/PIIBEG+FranklinGothic-Book>\" glyph<c=30,font=/PIIBEG+FranklinGothic-Book>7F?J7B glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EHFEH7J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> (Hglyph<c=14,font=/PIIBEG+FranklinGothic-Book> (9glyph<c=31,font=/PIIBEG+FranklinGothic-Book>EDD;BB I;HL;: 7I  N;9KJ?L; 1?9; +H;I?:;DJ 7D: glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>?;< !?D7D9?7B *<<?9;H <EH  9>E.J7H glyph<c=30,font=/PIIBEG+FranklinGothic-Book>ECCKD?97J?EDI glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EHFEH7J?ED glyph<c=8,font=/PIIBEG+FranklinGothic-Book><glyph<c=15,font=/PIIBEG+FranklinGothic-Book>Aglyph<c=15,font=/PIIBEG+FranklinGothic-Book>7 glyph<c=31,font=/PIIBEG+FranklinGothic-Book>$.# );JMEHA glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EHFEH7J?EDglyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 :?H;9Jglyph<c=13,font=/PIIBEG+FranklinGothic-Book>JEglyph<c=13,font=/PIIBEG+FranklinGothic-Book>>EC; I7J;BB?J; J;B;L?I?ED EF;H7JEHglyph<c=12,font=/PIIBEG+FranklinGothic-Book> <HEC %KBO glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book> KDJ?B glyph<c=28,font=/PIIBEG+FranklinGothic-Book>K=KIJ glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book> 7D: 7I ?JI .;D?EH 1?9; +H;I?:;DJ 7D: glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>?;< !?D7D9?7B *<<?9;H <HEC glyph<c=28,font=/PIIBEG+FranklinGothic-Book>K=KIJ glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> JE %KBO glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> (Hglyph<c=14,font=/PIIBEG+FranklinGothic-Book> (9glyph<c=31,font=/PIIBEG+FranklinGothic-Book>EDD;BB IF;DJ glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book> O;7HI 7J +H?9;M7J;H>EKI;glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EEF;HI ''+glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= glyph<c=20,font=/PIIBEG+FranklinGothic-Book> O;7HI 7I 7 F7HJD;Hglyph<c=14,font=/PIIBEG+FranklinGothic-Book> (Hglyph<c=14,font=/PIIBEG+FranklinGothic-Book> (9glyph<c=31,font=/PIIBEG+FranklinGothic-Book>EDD;BB ?I 7 B?9;DI;: 9;HJ?<?;: FK8B?9 799EKDJ7DJ glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=30,font=/PIIBEG+FranklinGothic-Book>+glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## $C0:71 glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=;>/<G glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>=/@2A\n\n- glyph<c=2,font=/PIIBFH+Wingdings-Regular> (;H?J (;:?97B .OIJ;CIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> $D9glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>2C1/B7=<\n\n- glyph<c=2,font=/PIIBFH+Wingdings-Regular> \";EH=;JEMD 0D?L;HI?JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>99EKDJ?D=\n\n## %;5A>7 $GDB:K\n\n## glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>F>3@73<13\n\n(Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> (KHF>O >7I I;HL;: 7I EKH  N;9KJ?L; 1?9; +H;I?:;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> +>7HC79;KJ?97B *F;H7J?EDI 7D: /;9>DEBE=O I?D9; !;8HK7HO glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> +H?EH JE J>7Jglyph<c=12,font=/PIIBEG+FranklinGothic-Book> (Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> (KHF>O >7I >;B: I;D?EH ;N;9KJ?L; FEI?J?EDI 7J glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E=;Dglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= CEIJ H;9;DJBO 7I EKH .;D?EH 1?9; +H;I?:;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> #;7: E< \"BE87B (7DK<79JKH?D= glyph<c=6,font=/PIIBEG+FranklinGothic-Book> /;9>D?97B *F;H7J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> <HEC %KD; glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book> JE %7DK7HO glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> (Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> (KHF>O FB7O;: 7 9H?J?97B HEB; :KH?D= J>; IK99;II<KB IF?Dglyph<c=13,font=/PIIBEG+FranklinGothic-Book>E<< E< glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E=;Dglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I >;CEF>?B?7 <H7D9>?I;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7I J>; 1?9; +H;I?:;DJ 7D: #;7: E< /;9>D?97B *F;H7J?EDI E< glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?EL;H7J?L H;IFEDI?8B; <EH 9B?D?97B 7D: 9ECC;H9?7B :;L;BEFC;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> GK7B?JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;=KB7JEHOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> C7DK<79JKH?D= 7D: FHE9KH;C;DJglyph<c=14,font=/PIIBEG+FranklinGothic-Book> +H?EH JE J>; IF?Dglyph<c=13,font=/PIIBEG+FranklinGothic-Book>E<< (Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> (KHF>O M7I J>; \";D;H7B (7D7=;H 7D: #;7: E< glyph<c=30,font=/PIIBEG+FranklinGothic-Book>7C8H?:=; .?J; *F;H7J?EDI 7J glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E=;D <HEC (7O glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book> JE glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> +H?EH JE @E?D?D= glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E=;Dglyph<c=12,font=/PIIBEG+FranklinGothic-Book> (Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> (KHF>O M7I  N;9KJ?L; glyph<c=31,font=/PIIBEG+FranklinGothic-Book>?H;9JEHglyph<c=12,font=/PIIBEG+FranklinGothic-Book> #;7: E< .KFFBO glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>7?D 7J glyph<c=28,font=/PIIBEG+FranklinGothic-Book>C=;Dglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 8?EF>7HC79;KJ?97B 9ECF7DOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>;H; >;H H;IFEDI?8?B?J?;I ?D9BK:;: B;7:;HI>?F E< 9ECC;H9?7B C7DK<79JKH?D= 7D: J;9>D?97B EF;H7J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> (Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> (KHF>O 7BIE >;B: DKC;HEKI J;9>D?97B 7D: EF;H7J?ED7B HEB;I :KH?D= >;H J?C; 7J glyph<c=28,font=/PIIBEG+FranklinGothic-Book>C=;D <HEC glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book> JE glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book> M>;H; I>; 9EDJH?8KJ;: I?=D?<?97DJBO JE L7H?EKI <79?B?JO IJ7HJglyph<c=13,font=/PIIBEG+FranklinGothic-Book>KFIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 8KI?D;II :;L;BEFC;DJ ?DJ;=H7J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> IJH7J;=?9 JH7DI<EHC7J?EDI 7D: D;M FHE:K9J ?DJHE:K9J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> +H?EH JE glyph<c=28,font=/PIIBEG+FranklinGothic-Book>C=;Dglyph<c=12,font=/PIIBEG+FranklinGothic-Book> (Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> (KHF>O >;B: 7 L7H?;JO E< FHE9;II :;L;BEFC;DJ 7D: ;D=?D;;H?D= FEI?J?EDI 7J $CCKD;N +>7HC79;KJ?97BI 7D: J>; (EDI7DJE glyph<c=30,font=/PIIBEG+FranklinGothic-Book>ECF7DOglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>2C1/B7=<\n\n- glyph<c=2,font=/PIIBFH+Wingdings-Regular> 0D?L;HI?JO E< (7II79>KI;JJI glyph<c=28,font=/PIIBEG+FranklinGothic-Book>C>;HIJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> D=?D;;H?D=\n- glyph<c=2,font=/PIIBFH+Wingdings-Regular> -;DII;B7;H +EBOJ;9>D?9 $DIJ?JKJ;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> (glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> D=?D;;H?D= 7D: 7 (7IJ;HI E< glyph<c=29,font=/PIIBEG+FranklinGothic-Book>KI?D;II glyph<c=28,font=/PIIBEG+FranklinGothic-Book>:C?D?IJH7J?ED\n\n## glyph<c=30,font=/PIIBCD+FranklinGothic-Book>;@97D glyph<c=30,font=/PIIBCD+FranklinGothic-Book>D79ADKglyph<c=9,font=/PIIBCD+FranklinGothic-Book> ':glyph<c=11,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book>\n\n## glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>F>3@73<13\n\nglyph<c=31,font=/PIIBEG+FranklinGothic-Book>Hglyph<c=14,font=/PIIBEG+FranklinGothic-Book> \"H;=EHO >7I I;HL;: 7I EKH  N;9KJ?L; 1?9; +H;I?:;DJ 7D: glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>?;< #KC7D -;IEKH9;I *<<?9;H I?D9; %KBO glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> +H?EH JE @E?D?D= glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E=;Dglyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=31,font=/PIIBEG+FranklinGothic-Book>Hglyph<c=14,font=/PIIBEG+FranklinGothic-Book> \"H;=EHO I;HL;: 7I  N;9KJ?L; 1?9; +H;I?:;DJ 7D: glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>?;< #KC7D -;IEKH9;I *<<?9;H 7J .>?H; +'glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 =BE87B IF;9?7BJO 8?EF>7HC79;KJ?97B 9ECF7DOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> <HEC !;8HK7HO glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book> JE glyph<c=28,font=/PIIBEG+FranklinGothic-Book>FH?B glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> +H?EH JE J>7Jglyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=31,font=/PIIBEG+FranklinGothic-Book>Hglyph<c=14,font=/PIIBEG+FranklinGothic-Book> \"H;=EHO >;B: ;N;9KJ?L;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>B;L;B >KC7D H;IEKH9;I FEI?J?EDI <EH I;L;H7B CKBJ?D7J?ED7B 9ECF7D?;I 79HEII 7 L7H?;JO E< ?D:KIJH?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= glyph<c=31,font=/PIIBEG+FranklinGothic-Book>KDA?D^ glyph<c=29,font=/PIIBEG+FranklinGothic-Book>H7D:I \"HEKF $D9glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 H;IJ7KH7DJ >EB:?D= 9ECF7DOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>;H; I>; I;HL;: 7I glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>?;< #KC7D -;IEKH9; *<<?9;Hglyph<c=12,font=/PIIBEG+FranklinGothic-Book> )EL7HJ?I glyph<c=28,font=/PIIBEG+FranklinGothic-Book>\"glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 F>7HC79;KJ?97B 9ECF7DOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>;H; I>; M7I J>; :?L?I?ED >;7: E< #KC7D -;IEKH9;I <EH )EL7HJ?I 1799?D;I 7D: glyph<c=31,font=/PIIBEG+FranklinGothic-Book>?7=DEIJ?9Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> )EL7HJ?I glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EDIKC;H #;7BJ> 7D: )EL7HJ?I $DIJ?JKJ;I E< glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E(;:?97B -;I;7H9> 7D: )ELE )EH:?IA glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=15,font=/PIIBEG+FranklinGothic-Book>.glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 F>7HC79;KJ?97B 9ECF7DOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>;H; I>; I;HL;: 7I .;D?EH 1?9; +H;I?:;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EHFEH7J; +;EFB; glyph<c=6,font=/PIIBEG+FranklinGothic-Book> *H=7D?P7J?ED 7J J>; 9ECF7DO^I >;7:GK7HJ;HI ?D glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EF;D>7=;Dglyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;DC7HAglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 7HB?;H ?D >;H 97H;;Hglyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=31,font=/PIIBEG+FranklinGothic-Book>Hglyph<c=14,font=/PIIBEG+FranklinGothic-Book> \"H;=EHO >;B: 7 L7H?;JO E< >KC7D H;IEKH9;I =;D;H7B?IJ 7D: IF;9?7B?IJ FEI?J?EDI 7J glyph<c=29,font=/PIIBEG+FranklinGothic-Book>(.glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 F>7HC79;KJ?97B 9ECF7DOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: I;HL;: 7I 7 9EDIKBJ7DJ M?J> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>EEP glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BB;D glyph<c=6,font=/PIIBEG+FranklinGothic-Book> #7C?BJEDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D ?D<EHC7J?ED J;9>DEBE=O 9EDIKBJ?D= 9ECF7DOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D J>; 7H;7 E< EH=7D?P7J?ED 9>7D=; 7D: ;<<;9J?L;D;IIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>2C1/B7=<\n\n- glyph<c=2,font=/PIIBFH+Wingdings-Regular> 0D?L;HI?JO E< (7II79>KI;JJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> +IO9>EBE=O\n- glyph<c=2,font=/PIIBFH+Wingdings-Regular> />; \";EH=; 27I>?D=JED 0D?L;HI?JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> +>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> +IO9>EBE=O",
        "metadata": {
            "page": 44
        },
        "id": "0635e796-2376-433a-805a-d8d9f000cbf8"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>F>3@73<13\n\n(Hglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $PP7H >7I I;HL;: 7I EKH  N;9KJ?L; 1?9; +H;I?:;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> #;7: E< \"BE87B +HE:K9J .JH7J;=O 7D: glyph<c=30,font=/PIIBEG+FranklinGothic-Book>ECC;H9?7B?P7J?ED I?D9; %KBO glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> +H?EH JE J>7J (Hglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $PP7H I;HL;: 7I EKH +H;I?:;DJ <EH J>; $DJ;H9EDJ?D;DJ7B -;=?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> ?D9BK:;I '7J?D glyph<c=28,font=/PIIBEG+FranklinGothic-Book>C;H?97glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>KIJH7B?7glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>I?7glyph<c=12,font=/PIIBEG+FranklinGothic-Book> %7F7Dglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; (?::B;  7IJ 7D: glyph<c=28,font=/PIIBEG+FranklinGothic-Book><H?97glyph<c=12,font=/PIIBEG+FranklinGothic-Book> /KHA;O 7D: -KII?7glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: J>; \"BE87B glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E=;D glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?EI?C?B7HI 0D?Jglyph<c=14,font=/PIIBEG+FranklinGothic-Book> +H?EH JE @E?D?D= glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E=;Dglyph<c=12,font=/PIIBEG+FranklinGothic-Book> (Hglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $PP7H M7I 7 glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EKDJHO +H;I?:;DJ <EH glyph<c=28,font=/PIIBEG+FranklinGothic-Book>IJH75;D;97 ?D !H7D9;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>;H; >?I H;IFEDI?8?B?J?;I ?D9BK:;: B;7:;HI>?F <EH 9ECC;H9?7B 7D: C7DK<79JKH?D= EF;H7J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> #; >;B: DKC;HEKI HEB;I 7J >?I J?C; M?J> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>IJH75;D;97glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= J>; FEI?J?ED E< \"BE87B 1?9; +H;I?:;DJ E< J>; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>7H:?EL7I9KB7H !H7D9>?I; M>;H; >; 9EDJH?8KJ;: I?=D?<?97DJBO JE J>; :;L;BEFC;DJ E< J>; <H7D9>?I; M?J>?D J>; )EHJ> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>C;H?97D IK8I?:?7HOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7I M;BB 7I ?D  KHEF; 7D: glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>?D7glyph<c=14,font=/PIIBEG+FranklinGothic-Book> +H?EH JE J>7Jglyph<c=12,font=/PIIBEG+FranklinGothic-Book> (Hglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $PP7H M7I 1?9; +H;I?:;DJ .JH7J;=?9 /H7DI<EHC7J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7BIEglyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>?D7 +EHJ<EB?E <EH glyph<c=30,font=/PIIBEG+FranklinGothic-Book> * 87I;: ?D .>7D=>7? 7D: 1?9; +H;I?:;DJ glyph<c=30,font=/PIIBEG+FranklinGothic-Book>ECC;H9?7B $DJ;HD7J?ED7B 9EL;H?D= glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>?D7glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>KIJH7B?7glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>H7P?Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> -KII?7glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>C;H?97 '7J?Dglyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>I?7glyph<c=12,font=/PIIBEG+FranklinGothic-Book> /KHA;Oglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; (?::B;  7IJ 7D: glyph<c=28,font=/PIIBEG+FranklinGothic-Book><H?97glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>2C1/B7=<\n\n- glyph<c=2,font=/PIIBFH+Wingdings-Regular> 0D?L;HI?JO E< .>;H8HEEA;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> (7IJ;HI E< glyph<c=29,font=/PIIBEG+FranklinGothic-Book>KI?D;II glyph<c=28,font=/PIIBEG+FranklinGothic-Book>:C?D?IJH7J?ED\n- glyph<c=2,font=/PIIBFH+Wingdings-Regular> #7HL7H: glyph<c=29,font=/PIIBEG+FranklinGothic-Book>KI?D;II .9>EEBglyph<c=12,font=/PIIBEG+FranklinGothic-Book> DJ;HFH?I;  N;9KJ?L; /H7DI<EHC7J?ED +HE=H7C\n\n## 'D;K3 *;@9:3>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> $glyph<c=11,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> $glyph<c=11,font=/PIIBCD+FranklinGothic-Book>'glyph<c=11,font=/PIIBCD+FranklinGothic-Book>glyph<c=31,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book>\n\n## glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>F>3@73<13\n\nglyph<c=31,font=/PIIBEG+FranklinGothic-Book>Hglyph<c=14,font=/PIIBEG+FranklinGothic-Book> .?D=>7B >7I I;HL;: 7I EKH  N;9KJ?L; 1?9; +H;I?:;DJ 7D: #;7: E< glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;L;BEFC;DJ I?D9; %7DK7HO glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> +H?EH JE J>7J glyph<c=31,font=/PIIBEG+FranklinGothic-Book>Hglyph<c=14,font=/PIIBEG+FranklinGothic-Book> .?D=>7B I;HL;: 7I EKH $DJ;H?C #;7: E< -;I;7H9> 7D: glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;L;BEFC;DJ I?D9; glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book> ?D 7::?J?ED JE I;HL?D= 7I #;7: E< \"BE87B .7<;JO 7D: -;=KB7JEHO .9?;D9;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>?D7 7D: %7F7D -;I;7H9> 7D: glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;L;BEFC;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> I?D9; H;@E?D?D= glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E=;D ?D glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=31,font=/PIIBEG+FranklinGothic-Book>Hglyph<c=14,font=/PIIBEG+FranklinGothic-Book> .?D=>7B M7I ?D?J?7BBO 7J glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E=;D <HEC glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> JE glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book> 7D: I;HL;: ?D FEI?J?EDI E< ?D9H;7I?D= I;D?EH?JO 7I 1?9; +H;I?:;DJ glyph<c=30,font=/PIIBEG+FranklinGothic-Book>B?D?97B /H?7BI glyph<c=29,font=/PIIBEG+FranklinGothic-Book>;D;<?Jglyph<c=13,font=/PIIBEG+FranklinGothic-Book>-?IA (7D7=;C;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> \"BE87B #;7: E< .7<;JO 7D: glyph<c=29,font=/PIIBEG+FranklinGothic-Book>;D;<?J -?IA (7D7=;C;DJ 7D: 7I J>; $DJ;H?C glyph<c=30,font=/PIIBEG+FranklinGothic-Book>Eglyph<c=13,font=/PIIBEG+FranklinGothic-Book>B;7: 7D: .;D?EH 1?9; +H;I?:;DJ E< \"BE87B glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;L;BEFC;DJglyph<c=14,font=/PIIBEG+FranklinGothic-Book> +H?EH JE >;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> H;JKHD JE glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E=;Dglyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=31,font=/PIIBEG+FranklinGothic-Book>Hglyph<c=14,font=/PIIBEG+FranklinGothic-Book> .?D=>7B I;HL;: 7I #;7: E< -;I;7H9> 7D: glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;L;BEFC;DJ 7D: (7DK<79JKH?D= 7J 57<=;D $D9glyph<c=14,font=/PIIBEG+FranklinGothic-Book> <HEC glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book> JE glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> !HEC glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book> JE glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> glyph<c=31,font=/PIIBEG+FranklinGothic-Book>Hglyph<c=14,font=/PIIBEG+FranklinGothic-Book> .?D=>7B >;B: HEB;I 7J 1;HJ;N +>7HC79;KJ?97BIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= 1?9; +H;I?:;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> (;:?97B glyph<c=28,font=/PIIBEG+FranklinGothic-Book><<7?HIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=31,font=/PIIBEG+FranklinGothic-Book>Hglyph<c=14,font=/PIIBEG+FranklinGothic-Book> .?D=>7B 8;=7D >;H :HK=glyph<c=13,font=/PIIBEG+FranklinGothic-Book>:;L;BEFC;DJ 97H;;H 7J (?BB;DD?KC +>7HC79;KJ?97BIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> $D9glyph<c=14,font=/PIIBEG+FranklinGothic-Book> ?D glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book> 7D: B;: 8;D;<?Jglyph<c=13,font=/PIIBEG+FranklinGothic-Book>H?IA C7D7=;C;DJ <EH 1;B97:; 7D: EJ>;H 9ECFEKD:Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>2C1/B7=<\n\n- glyph<c=2,font=/PIIBFH+Wingdings-Regular> #7HL7H: .9>EEB E< +K8B?9 #;7BJ>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> (glyph<c=14,font=/PIIBEG+FranklinGothic-Book>+glyph<c=14,font=/PIIBEG+FranklinGothic-Book>#glyph<c=14,font=/PIIBEG+FranklinGothic-Book> ?D $DJ;HD7J?ED7B #;7BJ>\n- glyph<c=2,font=/PIIBFH+Wingdings-Regular> 0D?L;HI?JO E< (KC87?glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=31,font=/PIIBEG+FranklinGothic-Book>E9JEH E< (;:?9?D; glyph<c=8,font=/PIIBEG+FranklinGothic-Book>(glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book>\n\n## )A4;@ glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> \"D3?7D\n\n## glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>F>3@73<13\n\n(Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> &H7C;H >7I I;HL;: 7I EKH .;D?EH 1?9; +H;I?:;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>?;< glyph<c=28,font=/PIIBEG+FranklinGothic-Book>99EKDJ?D= *<<?9;H I?D9; glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> +H?EH JE J>7Jglyph<c=12,font=/PIIBEG+FranklinGothic-Book> (Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> &H7C;H I;HL;: 7I EKH 1?9; +H;I?:;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>?;< glyph<c=28,font=/PIIBEG+FranklinGothic-Book>99EKDJ?D= *<<?9;H <HEC )EL;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book> JE glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> +H?EH JE @E?D?D= glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E=;Dglyph<c=12,font=/PIIBEG+FranklinGothic-Book> (Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> &H7C;H I;HL;: 7I J>; .;D?EH 1?9; +H;I?:;DJ 7D: glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>?;< glyph<c=28,font=/PIIBEG+FranklinGothic-Book>99EKDJ?D= *<<?9;H E< #;HJP \"BE87B #EB:?D=Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> $D9glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 97H H;DJ7B 9ECF7DOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> <HEC (7O glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book> JE )EL;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> +H?EH JE J>7Jglyph<c=12,font=/PIIBEG+FranklinGothic-Book> (Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> &H7C;H M7I 7D 7K:?J F7HJD;H 7J glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;BE?JJ; glyph<c=6,font=/PIIBEG+FranklinGothic-Book> /EK9>; ''+ glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;BE?JJ;glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 FHE<;II?ED7B I;HL?9;I <?HCglyph<c=12,font=/PIIBEG+FranklinGothic-Book> <HEC glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book> JE glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= I;HL?D= ?D glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;BE?JJ;glyph<c=7,font=/PIIBEG+FranklinGothic-Book>I )7J?ED7B *<<?9; glyph<c=28,font=/PIIBEG+FranklinGothic-Book>99EKDJ?D= .J7D:7H:I 7D: glyph<c=30,font=/PIIBEG+FranklinGothic-Book>ECCKD?97J?EDI \"HEKF <HEC glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book> JE glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> !HEC glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book> JE glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book> (Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> &H7C;H I;HL;: 7I glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>?;< glyph<c=28,font=/PIIBEG+FranklinGothic-Book>99EKDJ?D= *<<?9;H E< !?I>;H .9?;DJ?<?9 $DJ;HD7J?ED7Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> $D9glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 B78EH7JEHO IKFFBO 7D: 8?EJ;9>DEBE=O 9ECF7DOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: <HEC glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book> JE glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book> (Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> &H7C;H I;HL;: 7I glyph<c=31,font=/PIIBEG+FranklinGothic-Book>?H;9JEHglyph<c=12,font=/PIIBEG+FranklinGothic-Book> NJ;HD7B -;FEHJ?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>99EKDJ?D= 7D: glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EDJHEB <EH J>; \"?BB;JJ; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>ECF7DOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 F;HIED7B 97H; 9ECF7DOglyph<c=14,font=/PIIBEG+FranklinGothic-Book> (Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> &H7C;H 7BIE >;B: F7HJD;H FEI?J?EDI ?D J>; FK8B?9 799EKDJ?D= <?HCI E<  HDIJ glyph<c=6,font=/PIIBEG+FranklinGothic-Book> 4EKD= ''+ 7D: glyph<c=28,font=/PIIBEG+FranklinGothic-Book>HJ>KH glyph<c=28,font=/PIIBEG+FranklinGothic-Book>D:;HI;D ''+glyph<c=14,font=/PIIBEG+FranklinGothic-Book> (Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> &H7C;H ?I 7 B?9;DI;: glyph<c=30,font=/PIIBEG+FranklinGothic-Book>+glyph<c=28,font=/PIIBEG+FranklinGothic-Book> ?D (7II79>KI;JJIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> .>; ?I 7 C;C8;H E< J>; (7II79>KI;JJI .E9?;JO E< glyph<c=30,font=/PIIBEG+FranklinGothic-Book>+glyph<c=28,font=/PIIBEG+FranklinGothic-Book>I 7D: J>; glyph<c=28,font=/PIIBEG+FranklinGothic-Book>C;H?97D $DIJ?JKJ; E< glyph<c=30,font=/PIIBEG+FranklinGothic-Book>+glyph<c=28,font=/PIIBEG+FranklinGothic-Book>Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> (Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> &H7C;H 9KHH;DJBO I;HL;I ED J>; 8E7H: E< :?H;9JEHI E< J>; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>;DJ;H <EH 2EC;D 7D:  DJ;HFH?I;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> (Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> &H7C;H FH;L?EKIBO I;HL;: 7I 7 glyph<c=29,font=/PIIBEG+FranklinGothic-Book>E7H: (;C8;H <EH J>; (7II79>KI;JJI .J7J; glyph<c=29,font=/PIIBEG+FranklinGothic-Book>E7H: E< glyph<c=28,font=/PIIBEG+FranklinGothic-Book>99EKDJ7D9O <HEC .;FJ;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book> JE glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book> 7D: +HE8KI $DIKH7D9; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>ECF7DO KHEF; glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=30,font=/PIIBEG+FranklinGothic-Book> <HEC glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book> JE glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## $C0:71 glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=;>/<G glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>=/@2A\n\n- glyph<c=2,font=/PIIBFH+Wingdings-Regular> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>HC7J7 +>7HC79;KJ?97BIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> $D9glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 8?EJ;9>DEBE=O 9ECF7DO\n\n## glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>2C1/B7=<\n\n- glyph<c=2,font=/PIIBFH+Wingdings-Regular> .7B;C .J7J; 0D?L;HI?JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=29,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>99EKDJ?D=",
        "metadata": {
            "page": 45
        },
        "id": "1edbe759-06ce-4aef-8132-4bb51a4634c4"
    },
    {
        "page_content": "## glyph<c=24,font=/PIIBCD+FranklinGothic-Book>H3;>34>7 @8AD?3F;A@\n\n*KH FH?D9?F7B ;N;9KJ?L; E<<?9;I 7H; BE97J;: 7J glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?DD;O .JH;;Jglyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>7C8H?:=;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> (glyph<c=28,font=/PIIBEG+FranklinGothic-Book> glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> 7D: EKH J;B;F>ED; DKC8;H ?I glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book> glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> *KH M;8I?J; 7::H;II ?I MMMglyph<c=14,font=/PIIBEG+FranklinGothic-Book>8?E=;Dglyph<c=14,font=/PIIBEG+FranklinGothic-Book>9ECglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; C7A; 7L7?B78B; <H;; E< 9>7H=; J>HEK=> J>; glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><D3AB=@A I;9J?ED E< EKH M;8I?J; EKH glyph<c=28,font=/PIIBEG+FranklinGothic-Book>DDK7B -;FEHJI ED !EHC glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=13,font=/PIIBEG+FranklinGothic-Book>&glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ,K7HJ;HBO -;FEHJI ED !EHC glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=13,font=/PIIBEG+FranklinGothic-Book>,glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>KHH;DJ -;FEHJI ED !EHC glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=13,font=/PIIBEG+FranklinGothic-Book>& 7D: 7BB 7C;D:C;DJI JE J>EI; H;FEHJI 7I IEED 7I H;7IED78BO FH79J?978B; 7<J;H IK9> C7J;H?7B ?I ;B;9JHED?97BBO <?B;: M?J> EH <KHD?I>;: JE J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> .;9KH?J?;I 7D:  N9>7D=; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>ECC?II?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; ?D9BK:; EKH M;8I?J; 7::H;II ?D J>?I H;FEHJ EDBO 7I 7D ?D79J?L; J;NJK7B H;<;H;D9; 7D: :E DEJ ?DJ;D: ?J JE 8; 7D 79J?L; B?DA JE EKH M;8I?J;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; 9EDJ;DJI E< EKH M;8I?J; 7H; DEJ ?D9EHFEH7J;: ?DJE J>?I H;FEHJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>",
        "metadata": {
            "page": 46
        },
        "id": "b2f228e8-01d7-47c9-afbc-e659f9c1bd7e"
    },
    {
        "page_content": "## +glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$ glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> ) *\" glyph<c=29,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>+&)*\n\n## );E=E )7>3F76 FA &GD glyph<c=25,font=/PIIBCD+FranklinGothic-Book>GE;@7EE\n\n!& \"3& 46#45\"/5*\"--: %&1&/%&/5 0/ 3&7&/6& '30. 063 130%6$54glyph<c=7,font=/PIICNA+FranklinGothic-BookItal>\n\n*KH H;L;DK; :;F;D:I KFED 9EDJ?DK;: I7B;I E< EKH FHE:K9JI 7I M;BB 7I J>; <?D7D9?7B H?=>JI M; >7L; ?D EKH 7DJ?glyph<c=13,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> J>;H7F;KJ?9 FHE=H7CIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book> I?=D?<?97DJ FEHJ?ED E< EKH H;L;DK; ?I 9ED9;DJH7J;: ED I7B;I E< EKH FHE:K9JI ?D ?D9H;7I?D=BO 9ECF;J?J?L; C7HA;JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>DO E< J>; <EBBEM?D= D;=7J?L; :;L;BEFC;DJI H;B7J?D= JE 7DO E< EKH FHE:K9JI EH 7DO E< EKH 7DJ?glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> J>;H7F;KJ?9 FHE=H7CI C7O 7:L;HI;BO 7<<;9J EKH H;L;DK; 7D: H;IKBJI E< EF;H7J?EDI EH 9EKB: 97KI; 7 :;9B?D; ?D EKH IJE9A FH?9;glyph<c=26,font=/PIIBEG+FranklinGothic-Book>\n\n- T J>; ?DJHE:K9J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> =H;7J;H 799;FJ7D9; EH CEH; <7LEH78B; H;?C8KHI;C;DJ E< 9ECF;J?D= FHE:K9JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= D;M EH?=?D7JEH J>;H7F?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> =;D;H?9Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FHE:HK=I 7D: 8?EI?C?B7HI E< ;N?IJ?D= FHE:K9JI 7D: FHE:K9JI 7FFHEL;: KD:;H 788H;L?7J;: H;=KB7JEHO F7J>M7OIglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T I7<;JO EH ;<<?979O ?IIK;Iglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T B?C?J7J?EDI 7D: 7::?J?ED7B FH;IIKH;I ED FHE:K9J FH?9?D= EH FH?9; ?D9H;7I;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= J>EI; H;IKBJ?D= <HEC =EL;HDC;DJ7B EH H;=KB7JEHO H;GK?H;C;DJIglyph<c=27,font=/PIIBEG+FranklinGothic-Book> ?D9H;7I;: 9ECF;J?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= <HEC =;D;H?9 EH 8?EI?C?B7H L;HI?EDI E< EKH FHE:K9JIglyph<c=27,font=/PIIBEG+FranklinGothic-Book> EH 9>7D=;I ?Dglyph<c=12,font=/PIIBEG+FranklinGothic-Book> EH ?CFB;C;DJ7J?ED E<glyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;?C8KHI;C;DJ FEB?9?;I 7D: FH79J?9;I E< F7OEHI 7D: EJ>;H J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJ?;Iglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T 7:L;HI; B;=7Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7:C?D?IJH7J?L;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;=KB7JEHO EH B;=?IB7J?L; :;L;BEFC;DJIglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T EKH 78?B?JO JE C7?DJ7?D 7 FEI?J?L; H;FKJ7J?ED 7CED= F7J?;DJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> >;7BJ>97H; FHEL?:;HI 7D: EJ>;HIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> C7O 8; ?CF79J;: 8O EKH FH?9?D= 7D: H;?C8KHI;C;DJ :;9?I?EDIglyph<c=27,font=/PIIBEG+FranklinGothic-Book> EH\n- T J>; ?D78?B?JO EH H;BK9J7D9; E< F7J?;DJI JE H;9;?L; 7 :?7=DEI?Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FH;I9H?FJ?ED EH 7:C?D?IJH7J?ED E< EKH FHE:K9JI EH 7 :;9?I?ED JE FH;I9H?8; 7D: 7:C?D?IJ;H 9ECF;J?J?L; J>;H7F?;I 7I 7 :?H;9J EH ?D:?H;9J H;IKBJ E< J>; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>*1$glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book> F7D:;C?9glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n' , (glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$ ?I ?D J>; ;7HBO IJ7=;I E< 9ECC;H9?7B B7KD9> ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D 7::?J?ED JE H?IAI 7IIE9?7J;: M?J> D;M FHE:K9J B7KD9>;I 7D: J>; EJ>;H <79JEHI :;I9H?8;: ?D J>;I; -?IA !79JEHIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E=;D^I 7D:  ?I7?^I 78?B?JO JE IK99;II<KBBO 9ECC;H9?7B?P; ' , (glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$ C7O 8; 7:L;HI;BO 7<<;9J;: :K; JEglyph<c=26,font=/PIIBEG+FranklinGothic-Book>\n\n- T ?I7?^I 78?B?JO JE E8J7?D 7D: C7?DJ7?D 7:;GK7J; H;?C8KHI;C;DJ <EH ' , (glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$glyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T J>; ;<<;9J?L;D;II E<  ?I7?glyph<c=7,font=/PIIBEG+FranklinGothic-Book>I 7D: glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E=;D^I 9ECC;H9?7B IJH7J;=O <EH C7HA;J?D= ' , (glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$glyph<c=27,font=/PIIBEG+FranklinGothic-Book> 7D:\n- T ?I7?^I 7D: glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E=;D^I 78?B?JO JE C7?DJ7?D 7 FEI?J?L; H;FKJ7J?ED 7CED= F7J?;DJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> >;7BJ>97H; FHEL?:;HI 7D: EJ>;HI ?D J>; glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BP>;?C;H^I :?I;7I; 9ECCKD?JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> C7O 8; ?CF79J;: 8O FH?9?D= 7D: H;?C8KHI;C;DJ :;9?I?EDI H;B7J?D= JE ' , (glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> 7H; C7:; 8O  ?I7?glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n/>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> C7O M?J>:H7M 7FFHEL7B ?<  ?I7? 7D: glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E=;D <7?B JE 9ECFBO M?J> J>; 9ED:?J?EDI E< J>; 799;B;H7J;: 7FFHEL7Bglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=27,font=/PIICNA+FranklinGothic-BookItal>63 -0/(glyph<c=6,font=/PIICNA+FranklinGothic-BookItal>5&3. 46$$&44 %&1&/%4 610/ 5)& 46$$&44'6- %&7&-01.&/5 0' /&8 130%6$54 \"/% \"%%*5*0/\"- */%*$\"5*0/4 '03 063 &9*45*/( 130%6$54glyph<c=7,font=/PIICNA+FranklinGothic-BookItal>\n\n*KH BED=glyph<c=13,font=/PIIBEG+FranklinGothic-Book>J;HC IK99;II M?BB :;F;D: KFED J>; IK99;II<KB :;L;BEFC;DJ E< D;M FHE:K9JI <HEC EKH H;I;7H9> 7D: :;L;BEFC;DJ 79J?L?J?;I EH EKH B?9;DI;I EH 79GK?I?J?EDI <HEC J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJ?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7I M;BB 7I 7::?J?ED7B ?D:?97J?EDI <EH EKH ;N?IJ?D= FHE:K9JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n+HE:K9J :;L;BEFC;DJ ?I L;HO ;NF;DI?L; 7D: ?DLEBL;I 7 >?=> :;=H;; E< KD9;HJ7?DJO 7D: H?IA 7D: C7O DEJ 8; IK99;II<KBglyph<c=14,font=/PIIBEG+FranklinGothic-Book> *DBO 7 IC7BB DKC8;H E< H;I;7H9> 7D: :;L;BEFC;DJ FHE=H7CI H;IKBJ ?D J>; 9ECC;H9?7B?P7J?ED E< 7 FHE:K9Jglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $J ?I :?<<?9KBJ JE FH;:?9J J>; IK99;II 7D: J>; J?C; 7D: 9EIJ E< FHE:K9J :;L;BEFC;DJ E< DEL;B 7FFHE79>;I <EH J>; JH;7JC;DJ E< :?I;7I;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; :;L;BEFC;DJ E< DEL;B 7FFHE79>;I <EH J>; JH;7JC;DJ E< :?I;7I;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= :;L;BEFC;DJ ;<<EHJI ?D D;M CE:7B?J?;I IK9> 7I J>EI; 87I;: ED J>; 7DJ?I;DI; EB?=EDK9B;EJ?:; FB7J<EHC 7D: =;D; J>;H7FOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> C7O FH;I;DJ 7::?J?ED7B 9>7BB;D=;I 7D: H?IAIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= E8J7?D?D= 7FFHEL7B <HEC H;=KB7JEHO 7KJ>EH?J?;I J>7J >7L; B?C?J;: ;NF;H?;D9; M?J> J>; :;L;BEFC;DJ E< IK9> J>;H7F?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=30,font=/PIIBEG+FranklinGothic-Book>B?D?97B JH?7B :7J7 7H; IK8@;9J JE :?<<;H?D= ?DJ;HFH;J7J?EDI 7D: ;L;D ?< M; L?;M :7J7 7I IK<<?9?;DJ JE IKFFEHJ J>; I7<;JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ;<<;9J?L;D;II 7D:glyph<c=15,font=/PIIBEG+FranklinGothic-Book>EH 7FFHEL7B E< 7D ?DL;IJ?=7J?ED7B J>;H7FOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;=KB7JEHO 7KJ>EH?J?;I C7O :?I7=H;; 7D: C7O H;GK?H; 7::?J?ED7B :7J7glyph<c=12,font=/PIIBEG+FranklinGothic-Book> B?C?J J>; I9EF; E< J>; 7FFHEL7B EH :;DO 7FFHEL7B 7BJE=;J>;Hglyph<c=14,font=/PIIBEG+FranklinGothic-Book> !KHJ>;HCEH;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; 7FFHEL7B E< 7 FHE:K9J 97D:?:7J; 8O ED; H;=KB7JEHO 7=;D9O :E;I DEJ C;7D J>7J EJ>;H H;=KB7JEHO 7=;D9?;I M?BB 7BIE 7FFHEL; IK9> FHE:K9J 97D:?:7J;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>",
        "metadata": {
            "page": 47
        },
        "id": "66f4cf60-8b04-4f87-8fbd-4eb3cbb8419b"
    },
    {
        "page_content": ".K99;II ?D FH;9B?D?97B MEHA EH ;7HBOglyph<c=13,font=/PIIBEG+FranklinGothic-Book>IJ7=; 9B?D?97B JH?7BI :E;I DEJ ;DIKH; J>7J B7J;H IJ7=; EH B7H=;H I97B; 9B?D?97B JH?7BI M?BB 8; IK99;II<KBglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>B?D?97B JH?7BI C7O ?D:?97J; J>7J EKH FHE:K9J 97D:?:7J;I B79A ;<<?979Oglyph<c=12,font=/PIIBEG+FranklinGothic-Book> >7L; >7HC<KB I?:; ;<<;9JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;IKBJ ?D KD;NF;9J;: 7:L;HI; ;L;DJI EH H7?I; EJ>;H 9ED9;HDI J>7J C7O I?=D?<?97DJBO H;:K9; J>; B?A;B?>EE: E< H;=KB7JEHO 7FFHEL7Bglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />?I C7O H;IKBJ ?D J;HC?D7J;: FHE=H7CIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> I?=D?<?97DJ H;IJH?9J?EDI ED KI; 7D: I7<;JO M7HD?D=I ?D 7D 7FFHEL;: B78;Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7:L;HI; FB79;C;DJ M?J>?D J>; JH;7JC;DJ F7H7:?=C EH I?=D?<?97DJ H;:K9J?ED ?D J>; 9ECC;H9?7B FEJ;DJ?7B E< J>; FHE:K9J 97D:?:7J;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nL;D ?< M; 9EKB: IK99;II<KBBO :;L;BEF D;M FHE:K9JI EH ?D:?97J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; C7O C7A; 7 IJH7J;=?9 :;9?I?ED JE :?I9EDJ?DK; :;L;BEFC;DJ E< 7 FHE:K9J 97D:?:7J; EH ?D:?97J?ED ?<glyph<c=12,font=/PIIBEG+FranklinGothic-Book> <EH ;N7CFB;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 8;B?;L; 9ECC;H9?7B?P7J?ED M?BB 8; :?<<?9KBJ H;B7J?L; JE J>; IJ7D:7H: E< 97H; EH M; FH;<;H JE FKHIK; EJ>;H EFFEHJKD?J?;I ?D EKH F?F;B?D;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n.7B;I E< D;M FHE:K9JI EH FHE:K9JI M?J> 7::?J?ED7B ?D:?97J?EDI C7O DEJ C;;J ?DL;IJEH ;NF;9J7J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=22,font=/PIICNA+FranklinGothic-BookItal>' 8& '\"*- 50 $0.1&5& &''&$5*7&-:glyph<c=5,font=/PIICNA+FranklinGothic-BookItal> 063 #64*/&44 \"/% .\"3,&5 104*5*0/ 806-% 46''&3glyph<c=7,font=/PIICNA+FranklinGothic-BookItal>\n\n/>; 8?EF>7HC79;KJ?97B ?D:KIJHO 7D: J>; C7HA;JI ?D M>?9> M; EF;H7J; 7H; ?DJ;DI;BO 9ECF;J?J?L;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; 9ECF;J; ?D J>; C7HA;J?D= 7D: I7B; E< EKH FHE:K9JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; :;L;BEFC;DJ E< D;M FHE:K9JI 7D: FHE9;II;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; 79GK?I?J?ED E< H?=>JI JE D;M FHE:K9JI M?J> 9ECC;H9?7B FEJ;DJ?7B 7D: J>; >?H?D= 7D: H;J;DJ?ED E< F;HIEDD;Bglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; 9ECF;J; M?J> 8?EJ;9>DEBE=O 7D: F>7HC79;KJ?97B 9ECF7D?;I J>7J >7L; 7 =H;7J;H DKC8;H E< FHE:K9JI ED J>; C7HA;J 7D: ?D J>; FHE:K9J F?F;B?D;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> IK8IJ7DJ?7BBO =H;7J;H <?D7D9?7Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> C7HA;J?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;I;7H9> 7D: :;L;BEFC;DJ 7D: EJ>;H H;IEKH9;I 7D: EJ>;H J;9>DEBE=?97B EH 9ECF;J?J?L; 7:L7DJ7=;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n*KH FHE:K9JI 9EDJ?DK; JE <79; ?D9H;7I?D= 9ECF;J?J?ED <HEC J>; ?DJHE:K9J?ED E< D;M EH?=?D7JEH J>;H7F?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> =;D;H?9Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FHE:HK=I 7D: 8?EI?C?B7HI E< ;N?IJ?D= FHE:K9JI 7D: FHE:K9JI 7FFHEL;: KD:;H 788H;L?7J;: H;=KB7JEHO F7J>M7OIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> .EC; E< J>;I; FHE:K9JI 7H; B?A;BO JE 8; IEB: 7J IK8IJ7DJ?7BBO BEM;H FH?9;I J>7D EKH 8H7D:;: FHE:K9JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; ?DJHE:K9J?ED E< IK9> FHE:K9JI 7I M;BB 7I EJ>;H BEM;Hglyph<c=13,font=/PIIBEG+FranklinGothic-Book>FH?9;: 9ECF;J?D= FHE:K9JI >7I H;:K9;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: C7O ?D J>; <KJKH;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> I?=D?<?97DJBO H;:K9; 8EJ> J>; FH?9; J>7J M; 7H; 78B; JE 9>7H=; <EH EKH FHE:K9JI 7D: J>; LEBKC; E< FHE:K9JI M; I;BBglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> M?BB D;=7J?L;BO ?CF79J EKH H;L;DK;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> !EH ?DIJ7D9;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> :;C7D: 7D: FH?9; <EH / glyph<c=30,font=/PIIBEG+FranklinGothic-Book>!$glyph<c=31,font=/PIIBEG+FranklinGothic-Book> -glyph<c=28,font=/PIIBEG+FranklinGothic-Book> :;9B?D;: I?=D?<?97DJBO 7I 7 H;IKBJ E< CKBJ?FB; / glyph<c=30,font=/PIIBEG+FranklinGothic-Book>!$glyph<c=31,font=/PIIBEG+FranklinGothic-Book> -glyph<c=28,font=/PIIBEG+FranklinGothic-Book> =;D;H?9 ;DJH7DJI ;DJ;H?D= J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> C7HA;J ?D glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D 7::?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D IEC; C7HA;JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>;D 7 =;D;H?9 EH 8?EI?C?B7H L;HI?ED E< ED; E< EKH FHE:K9JI ?I 9ECC;H9?7B?P;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?J C7O 8; 7KJEC7J?97BBO IK8IJ?JKJ;: <EH EKH FHE:K9J 7D: I?=D?<?97DJBO H;:K9; EKH H;L;DK; ?D 7 I>EHJ F;H?E: E< J?C;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n*KH 78?B?JO JE 9ECF;J;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> C7?DJ7?D 7D: =HEM EKH 8KI?D;II C7O 7BIE 8; 7:L;HI;BO 7<<;9J;: :K; JE 7 DKC8;H E< <79JEHIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D=glyph<c=26,font=/PIIBEG+FranklinGothic-Book>\n\n- T J>; ?DJHE:K9J?ED E< EJ>;H FHE:K9JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= FHE:K9JI J>7J C7O 8; CEH; ;<<?979?EKIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> I7<;Hglyph<c=12,font=/PIIBEG+FranklinGothic-Book> B;II ;NF;DI?L; EH CEH; 9EDL;D?;DJ 7BJ;HD7J?L;I JE EKH FHE:K9JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= EKH EMD FHE:K9JI 7D: FHE:K9JI E< EKH 9EBB78EH7JEHIglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T J>; E<<glyph<c=13,font=/PIIBEG+FranklinGothic-Book>B78;B KI; 8O F>OI?9?7DI E< J>;H7F?;I ?D:?97J;: <EH EJ>;H 9ED:?J?EDI JE JH;7J F7J?;DJIglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T F7J?;DJ :OD7C?9Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= J>; I?P; E< J>; F7J?;DJ FEFKB7J?ED 7D: EKH 78?B?JO JE ?:;DJ?<Oglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7JJH79J 7D: C7?DJ7?D D;M 7D: 9KHH;DJ F7J?;DJI JE EKH J>;H7F?;Iglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T J>; H;BK9J7D9; E< F>OI?9?7DI JE FH;I9H?8;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: F7J?;DJI JE KI;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> EKH FHE:K9JI M?J>EKJ 7::?J?ED7B :7J7 ED J>; ;<<?979O 7D: I7<;JO E< IK9> FHE:K9JIglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T :7C7=; JE F>OI?9?7D 7D: F7J?;DJ 9ED<?:;D9; ?D 7DO E< EKH FHE:K9JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> =;D;H?9 EH 8?EI?C?B7HI E< EKH FHE:K9JI EH 7DO EJ>;H FHE:K9J <HEC J>; I7C; 9B7II 7I ED; E< EKH FHE:K9JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> EH JE EKH I7B;I 7D: H;FKJ7J?ED 7I 7 H;IKBJ E< B78;B 9>7D=;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FH?9?D= 7D: H;?C8KHI;C;DJ :;9?I?EDI EH 7:L;HI; ;NF;H?;D9;I EH ;L;DJI J>7J C7O E99KH M?J> F7J?;DJI JH;7J;: M?J> EKH FHE:K9JI EH =;D;H?9 EH 8?EI?C?B7HI E< EKH FHE:K9JIglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T ?D78?B?JO JE E8J7?D 7FFHEFH?7J; FH?9?D= 7D: 7:;GK7J; H;?C8KHI;C;DJ <EH EKH FHE:K9JI 9ECF7H;: JE EKH 9ECF;J?JEHI ?D A;O ?DJ;HD7J?ED7B C7HA;JIglyph<c=27,font=/PIIBEG+FranklinGothic-Book> EH\n- T EKH 78?B?JO JE E8J7?D 7D: C7?DJ7?D F7J;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> :7J7 EH C7HA;J ;N9BKI?L?JO <EH EKH FHE:K9JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=27,font=/PIICNA+FranklinGothic-BookItal>63 #64*/&44 .\": #& \"%7&34&-: \"''&$5&% *' 8& %0 /05 46$$&44'6--: &9&$65& 03 3&\"-*;& 5)& \"/5*$*1\"5&% #&/&'*54 0' 063 453\"5&(*$ \"/% (3085) */*5*\"5*7&4glyph<c=7,font=/PIICNA+FranklinGothic-BookItal>\n\n/>; IK99;II<KB ;N;9KJ?ED E< EKH IJH7J;=?9 7D: =HEMJ> ?D?J?7J?L;I C7O :;F;D: KFED ?DJ;HD7B :;L;BEFC;DJ FHE@;9JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9ECC;H9?7B ?D?J?7J?L;I 7D: ;NJ;HD7B EFFEHJKD?J?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> C7O ?D9BK:; J>; 79GK?I?J?ED 7D: ?Dglyph<c=13,font=/PIIBEG+FranklinGothic-Book>B?9;DI?D= E< FHE:K9JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J;9>DEBE=?;I 7D: 9ECF7D?;I EH J>; ;DJHO ?DJE IJH7J;=?9 7BB?7D9;I 7D: 9EBB78EH7J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n2>?B; M; 8;B?;L; M; >7L; 7 DKC8;H E< FHEC?I?D= FHE=H7CI ?D EKH F?F;B?D;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> <7?BKH; EH :;B7O E< ?DJ;HD7B :;L;BEFC;DJ FHE@;9JI JE 7:L7D9; EH :?<<?9KBJ?;I ?D ;N;9KJ?D= ED EKH 9ECC;H9?7B ?D?J?7J?L;I 9EKB: ?CF79J EKH 9KHH;DJ 7D: <KJKH; =HEMJ>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;IKBJ?D= ?D 7::?J?ED7B H;B?7D9; ED ;NJ;HD7B :;L;BEFC;DJ EFFEHJKD?J?;I <EH =HEMJ>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>",
        "metadata": {
            "page": 48
        },
        "id": "fd8ee0b8-2358-4812-bd9a-f12dc6e1c01c"
    },
    {
        "page_content": ".KFFEHJ?D= J>; <KHJ>;H :;L;BEFC;DJ E< EKH ;N?IJ?D= FHE:K9JI 7D: FEJ;DJ?7B D;M FHE:K9JI ?D EKH F?F;B?D; M?BB H;GK?H; I?=D?<?97DJ 97F?J7B ;NF;D:?JKH;I 7D: C7D7=;C;DJ H;IEKH9;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= ?DL;IJC;DJI ?D H;I;7H9> 7D: :;L;BEFC;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> I7B;I 7D: C7HA;J?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> C7DK<79JKH?D= 97F78?B?J?;I 7D: EJ>;H 7H;7I E< EKH 8KI?D;IIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; >7L; C7:;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: C7O 9EDJ?DK; JE C7A;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> I?=D?<?97DJ EF;H7J?D= 7D: 97F?J7B ;NF;D:?JKH;I <EH FEJ;DJ?7B D;M FHE:K9JI FH?EH JE H;=KB7JEHO 7FFHEL7B M?J> DE 7IIKH7D9; J>7J IK9> ?DL;IJC;DJ M?BB 8; H;9EKF;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> C7O 7:L;HI;BO 7<<;9J EKH <?D7D9?7B 9ED:?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 8KI?D;II 7D: EF;H7J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n/>; 7L7?B78?B?JO E< >?=> GK7B?JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> <7?HBO L7BK;: ;NJ;HD7B FHE:K9J :;L;BEFC;DJ ?I B?C?J;: 7D: J>; EFFEHJKD?JO <EH J>;?H 79GK?I?J?ED ?I >?=>BO 9ECF;J?J?L;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>I IK9>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 7H; DEJ 9;HJ7?D J>7J M; M?BB 8; 78B; JE ?:;DJ?<O IK?J78B; 97D:?:7J;I <EH 79GK?I?J?ED EH ?< M; M?BB 8; 78B; JE H;79> 7=H;;C;DJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n2; C7O <7?B JE ?D?J?7J; EH 9ECFB;J; JH7DI79J?EDI <EH C7DO H;7IEDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= <7?BKH; JE E8J7?D H;=KB7JEHO EH EJ>;H 7FFHEL7BI 7I M;BB 7I :?IFKJ;I EH B?J?=7J?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book> !KHJ>;HCEH;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; C7O DEJ 8; 78B; JE 79>?;L; J>; <KBB IJH7J;=?9 7D: <?D7D9?7B 8;D;<?JI ;NF;9J;: JE H;IKBJ <HEC JH7DI79J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> EH J>; 8;D;<?JI C7O 8; :;B7O;: EH DEJ E99KH 7J 7BBglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; C7O 7BIE <79; 7::?J?ED7B 9EIJI EH B?78?B?J?;I ?D 9ECFB;J;: JH7DI79J?EDI J>7J M;H; DEJ 9EDJ;CFB7J;: FH?EH JE 9ECFB;J?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=28,font=/PIIBEG+FranklinGothic-Book>DO <7?BKH; ?D J>; ;N;9KJ?ED E< 7 JH7DI79J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D J>; ?DJ;=H7J?ED E< 7D 79GK?H;: 7II;J EH 8KI?D;II EH ?D 79>?;L?D= ;NF;9J;: IOD;H=?;I 9EKB: H;IKBJ ?D IBEM;H =HEMJ>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> >?=>;H J>7D ;NF;9J;: 9EIJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; H;9EH:?D= E< 7II;J ?CF7?HC;DJ 9>7H=;I 7D: EJ>;H 79J?EDI M>?9> 9EKB: 7:L;HI;BO 7<<;9J EKH 8KI?D;IIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> <?D7D9?7B 9ED:?J?ED 7D: H;IKBJI E< EF;H7J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=30,font=/PIICNA+FranklinGothic-BookItal>\"-&4 0' 063 130%6$54 %&1&/%glyph<c=5,font=/PIICNA+FranklinGothic-BookItal> 50 \" 4*(/*'*$\"/5 &95&/5glyph<c=5,font=/PIICNA+FranklinGothic-BookItal> 0/ \"%&26\"5& $07&3\"(&glyph<c=5,font=/PIICNA+FranklinGothic-BookItal> 13*$*/( \"/% 3&*.#634&.&/5 '30. 5)*3%glyph<c=6,font=/PIICNA+FranklinGothic-BookItal> 1\"35: 1\":034glyph<c=5,font=/PIICNA+FranklinGothic-BookItal> 8)*$) \"3& 46#+&$5 50 */$3&\"4*/( \"/% */5&/4& 13&4463& '30. 10-*5*$\"-glyph<c=5,font=/PIICNA+FranklinGothic-BookItal> 40$*\"-glyph<c=5,font=/PIICNA+FranklinGothic-BookItal> $0.1&5*5*7& \"/% 05)&3 4063$&4glyph<c=7,font=/PIICNA+FranklinGothic-BookItal> glyph<c=27,font=/PIICNA+FranklinGothic-BookItal>63 */\"#*-*5: 50 0#5\"*/ \"/% .\"*/5\"*/ \"%&26\"5& $07&3\"(&glyph<c=5,font=/PIICNA+FranklinGothic-BookItal> 03 \" 3&%6$5*0/ */ 13*$*/( 03 3&*.#634&.&/5glyph<c=5,font=/PIICNA+FranklinGothic-BookItal> $06-% )\"7& \"/ \"%7&34& &''&$5 0/ 063 #64*/&44glyph<c=5,font=/PIICNA+FranklinGothic-BookItal> 3&165\"5*0/glyph<c=5,font=/PIICNA+FranklinGothic-BookItal> 3&7&/6& \"/% 3&46-54 0' 01&3\"5*0/4glyph<c=7,font=/PIICNA+FranklinGothic-BookItal>\n\n.7B;I E< EKH FHE:K9JI :;F;D:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> JE 7 I?=D?<?97DJ ;NJ;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ED 7:;GK7J; 9EL;H7=;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> FH?9?D= 7D: H;?C8KHI;C;DJ <HEC J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJO F7OEHIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2>;D 7 D;M F>7HC79;KJ?97B FHE:K9J ?I 7FFHEL;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; 7L7?B78?B?JO E< =EL;HDC;DJ 7D: FH?L7J; H;?C8KHI;C;DJ <EH J>7J FHE:K9J C7O 8; KD9;HJ7?Dglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7I ?I J>; FH?9?D= 7D: 7CEKDJ <EH M>?9> J>7J FHE:K9J M?BB 8; H;?C8KHI;:glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n+H?9?D= 7D: H;?C8KHI;C;DJ <EH EKH FHE:K9JI C7O 8; 7:L;HI;BO 7<<;9J;: 8O 7 DKC8;H E< <79JEHIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D=glyph<c=26,font=/PIIBEG+FranklinGothic-Book>\n\n- T 9>7D=;I ?Dglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: ?CFB;C;DJ7J?ED E<glyph<c=12,font=/PIIBEG+FranklinGothic-Book> <;:;H7Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> IJ7J; EH <EH;?=D =EL;HDC;DJ H;=KB7J?EDI EH FH?L7J; J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJO F7OEHI^ H;?C8KHI;C;DJ FEB?9?;Iglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T FH;IIKH; 8O ;CFBEO;HI ED FH?L7J; >;7BJ> ?DIKH7D9; FB7DI JE H;:K9; 9EIJIglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T 9EDIEB?:7J?ED 7D: ?D9H;7I?D= 7II;HJ?L;D;II E< F7OEHI I;;A?D= FH?9; :?I9EKDJI EH H;87J;I ?D 9EDD;9J?ED M?J> J>; FB79;C;DJ E< EKH FHE:K9JI ED J>;?H <EHCKB7H?;I 7D:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D IEC; 97I;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; ?CFEI?J?ED E< H;IJH?9J?EDI ED 799;II EH 9EL;H7=; E< F7HJ?9KB7H :HK=I EH FH?9?D= :;J;HC?D;: 87I;: ED F;H9;?L;: L7BK;glyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T EKH 78?B?JO JE H;9;?L; H;?C8KHI;C;DJ <EH EKH FHE:K9JI EH EKH 78?B?JO JE H;9;?L; 9ECF7H78B; H;?C8KHI;C;DJ JE J>7J E< 9ECF;J?D= FHE:K9JIglyph<c=27,font=/PIIBEG+FranklinGothic-Book> 7D:\n- T EKH L7BK;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>87I;: 9EDJH79J?D= FHE=H7C FKHIK7DJ JE M>?9> M; 7?C JE J?; J>; FH?9?D= E< EKH FHE:K9JI JE J>;?H 9B?D?97B L7BK;I 8O ;?J>;H 7B?=D?D= FH?9; JE F7J?;DJ EKJ9EC;I EH 7:@KIJ?D= FH?9; <EH F7J?;DJI M>E :?I9EDJ?DK; J>;H7FO <EH 7DO H;7IEDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= ;<<?979O EH JEB;H78?B?JO 9ED9;HDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n*KH 78?B?JO JE I;J J>; FH?9; <EH EKH FHE:K9JI L7H?;I I?=D?<?97DJBO <HEC 9EKDJHO JE 9EKDJHO 7D:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7I 7 H;IKBJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> IE 97D J>; FH?9; E< EKH FHE:K9JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> \"EL;HDC;DJI C7O KI; 7 L7H?;JO E< 9EIJglyph<c=13,font=/PIIBEG+FranklinGothic-Book>9EDJ7?DC;DJ C;7IKH;I JE 9EDJHEB J>; 9EIJ E< FHE:K9JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= FH?9; 9KJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> C7D:7JEHO H;87J;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> L7BK;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>87I;: FH?9?D= 7D: H;<;H;D9; FH?9?D= glyph<c=8,font=/PIIBEG+FranklinGothic-Book>?glyph<c=14,font=/PIIBEG+FranklinGothic-Book>;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;<;H;D9?D= FH?9;I ?D EJ>;H 9EKDJH?;I 7D: KI?D= J>EI; H;<;H;D9; FH?9;I JE I;J 7 FH?9;glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=31,font=/PIIBEG+FranklinGothic-Book>HK= FH?9;I 7H; KD:;H I?=D?<?97DJ I9HKJ?DO ?D J>; C7HA;JI ?D M>?9> EKH FHE:K9JI 7H; FH;I9H?8;:glyph<c=27,font=/PIIBEG+FranklinGothic-Book> <EH ;N7CFB; J>; $-glyph<c=28,font=/PIIBEG+FranklinGothic-Book> >7I 9;HJ7?D FHEL?I?EDI H;B7J;: JE :HK= FH?9?D=glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; ;NF;9J :HK= FH?9?D= 7D: EJ>;H >;7BJ> 97H; 9EIJI JE 9EDJ?DK; JE 8; IK8@;9J JE ?DJ;DI; FEB?J?97B 7D: IE9?;J7B FH;IIKH;I ED 7 =BE87B 87I?Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>;HJ7?D 9EKDJH?;I I;J FH?9;I 8O H;<;H;D9; JE J>; FH?9;I ?D EJ>;H 9EKDJH?;I M>;H; EKH FHE:K9JI 7H; C7HA;J;:glyph<c=14,font=/PIIBEG+FranklinGothic-Book> *KH ?D78?B?JO JE E8J7?D 7D: C7?DJ7?D 7:;GK7J; FH?9;I ?D 7 F7HJ?9KB7H 9EKDJHO C7O DEJ EDBO B?C?J J>; H;L;DK; <HEC EKH FHE:K9JI M?J>?D J>7J 9EKDJHO 8KJ C7O 7BIE 7:L;HI;BO 7<<;9J EKH 78?B?JO JE I;9KH; 799;FJ78B; FH?9;I ?D ;N?IJ?D= 7D: FEJ;DJ?7B D;M C7HA;JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> C7O B?C?J C7HA;J =HEMJ>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />?I C7O 9H;7J; J>; EFFEHJKD?JO <EH J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJO 9HEIIglyph<c=13,font=/PIIBEG+FranklinGothic-Book> 8EH:;H JH7:; EH ?D<BK;D9; EKH :;9?I?ED JE I;BB EH DEJ JE I;BB 7 FHE:K9Jglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>KI 7:L;HI;BO 7<<;9J?D= EKH =;E=H7F>?9 ;NF7DI?ED FB7DI 7D: H;L;DK;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>::?J?ED7BBO 7D: ?D F7HJ :K; JE J>; ?CF79J E< J>; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>*1$glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book> F7D:;C?9glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D 9;HJ7?D @KH?I:?9J?EDI =EL;HDC;DJ7B >;7BJ> 7=;D9?;I C7O 7:@KIJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;JHE79J?L;BO 7D:glyph<c=15,font=/PIIBEG+FranklinGothic-Book>EH FHEIF;9J?L;BOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;?C8KHI;C;DJ H7J;I <EH EKH FHE:K9JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=30,font=/PIIBEG+FranklinGothic-Book>ECF;J?J?ED <HEC 9KHH;DJ 7D: <KJKH; 9ECF;J?JEHI C7O D;=7J?L;BO ?CF79J EKH 78?B?JO JE C7?DJ7?D FH?9?D= 7D: EKH C7HA;J I>7H;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> );M FHE:K9JI C7HA;J;: 8O EKH 9ECF;J?JEHI 9EKB: 97KI; EKH H;L;DK; JE :;9H;7I; :K; JE FEJ;DJ?7B FH?9;",
        "metadata": {
            "page": 49
        },
        "id": "28a7fe16-1264-4701-8721-8a0e3296c63e"
    },
    {
        "page_content": "H;:K9J?EDI 7D: BEM;H I7B;I LEBKC;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>::?J?ED7BBOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; ?DJHE:K9J?ED E< =;D;H?9 EH 8?EI?C?B7H L;HI?EDI E< EKH FHE:K9JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> <EBBEMglyph<c=13,font=/PIIBEG+FranklinGothic-Book>ED FHE:K9JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FHE:HK=I EH FHE:K9JI 7FFHEL;: KD:;H 788H;L?7J;: H;=KB7JEHO F7J>M7OI C7O I?=D?<?97DJBO H;:K9; J>; FH?9; J>7J M; 7H; 78B; JE 9>7H=; <EH EKH FHE:K9JI 7D: J>; LEBKC; E< FHE:K9JI M; I;BBglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n(7DO F7OEHI 9EDJ?DK; JE 7:EFJ 8;D;<?J FB7D 9>7D=;I J>7J I>?<J 7 =H;7J;H FEHJ?ED E< FH;I9H?FJ?ED 9EIJI JE F7J?;DJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= CEH; B?C?J;: 8;D;<?J FB7D :;I?=DIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> >?=>;H F7J?;DJ 9Eglyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7O EH 9Eglyph<c=13,font=/PIIBEG+FranklinGothic-Book>?DIKH7D9; E8B?=7J?EDI 7D: B?C?J7J?EDI ED F7J?;DJIglyph<c=7,font=/PIIBEG+FranklinGothic-Book> KI; E< 9ECC;H9?7B C7DK<79JKH;H 9Eglyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7O F7OC;DJ 7II?IJ7D9; FHE=H7CI glyph<c=8,font=/PIIBEG+FranklinGothic-Book>?D9BK:?D= J>HEK=> 9Eglyph<c=13,font=/PIIBEG+FranklinGothic-Book> F7O 799KCKB7JEH 7:@KIJC;DJ EH C7N?C?P7J?ED FHE=H7CIglyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> .?=D?<?97DJ 9EDIEB?:7J?ED ?D J>; >;7BJ> ?DIKH7D9; ?D:KIJHO >7I H;IKBJ;: ?D 7 <;M B7H=; ?DIKH;HI 7D: F>7HC79O 8;D;<?J C7D7=;HI ;N;HJ?D= =H;7J;H FH;IIKH; ?D FH?9?D= 7D: KI7=; D;=EJ?7J?EDI M?J> :HK= C7DK<79JKH;HIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> I?=D?<?97DJBO ?D9H;7I?D= :?I9EKDJI 7D: H;87J;I H;GK?H;: E< C7DK<79JKH;HI 7D: B?C?J?D= F7J?;DJ 799;II 7D: KI7=;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> !KHJ>;H 9EDIEB?:7J?ED 7CED= ?DIKH;HIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> F>7HC79O 8;D;<?J C7D7=;HI 7D: EJ>;H F7OEHI MEKB: ?D9H;7I; J>; D;=EJ?7J?D= B;L;H7=; IK9> ;DJ?J?;I >7L; EL;H KI 7D: EJ>;H :HK= C7DK<79JKH;HIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>::?J?ED7B :?I9EKDJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;87J;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9EL;H7=; EH FB7D 9>7D=;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;IJH?9J?EDI EH ;N9BKI?EDI 7I :;I9H?8;: 78EL; 9EKB: >7L; 7 C7J;H?7B 7:L;HI; ;<<;9J ED I7B;I E< EKH 7<<;9J;: FHE:K9JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n*KH <7?BKH; JE E8J7?D EH C7?DJ7?D 7:;GK7J; 9EL;H7=;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> FH?9?D= EH H;?C8KHI;C;DJ <EH EKH FHE:K9JI 9EKB: >7L; 7D 7:L;HI; ;<<;9J ED EKH 8KI?D;IIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;FKJ7J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;L;DK; 7D: H;IKBJI E< EF;H7J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n!& %&1&/% 0/ 3&-\"5*0/4)*14 8*5) $0--\"#03\"5034 \"/% 05)&3 5)*3%glyph<c=6,font=/PIICNA+FranklinGothic-BookItal>1\"35*&4 '03 3&7&/6&glyph<c=5,font=/PIICNA+FranklinGothic-BookItal> \"/% '03 5)& %&7&-01.&/5glyph<c=5,font=/PIICNA+FranklinGothic-BookItal> 3&(6-\"503: \"11307\"-glyph<c=5,font=/PIICNA+FranklinGothic-BookItal> $0..&3$*\"-*;\"5*0/ \"/% .\"3,&5*/( 0' $&35\"*/ 0' 063 130%6$54 \"/% 130%6$5 $\"/%*%\"5&4glyph<c=5,font=/PIICNA+FranklinGothic-BookItal> 8)*$) \"3& 0654*%& 0' 063 '6-- $0/530-glyph<c=7,font=/PIICNA+FranklinGothic-BookItal>\n\n2; H;BO ED 7 DKC8;H E< 9EBB78EH7J?L; 7D: EJ>;H J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJO H;B7J?EDI>?FI <EH H;L;DK; 7D: J>; :;L;BEFC;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;=KB7JEHO 7FFHEL7Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9ECC;H9?7B?P7J?ED 7D: C7HA;J?D= E< 9;HJ7?D E< EKH FHE:K9JI 7D: FHE:K9J 97D:?:7J;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; 7BIE EKJIEKH9; 9;HJ7?D 7IF;9JI E< EKH H;=KB7JEHO 7<<7?HI 7D: 9B?D?97B :;L;BEFC;DJ H;B7J?D= JE EKH FHE:K9JI 7D: FHE:K9J 97D:?:7J;I JE J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJ?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> -;B?7D9; ED J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJ?;I IK8@;9JI KI JE 7 DKC8;H E< H?IAIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D=glyph<c=26,font=/PIIBEG+FranklinGothic-Book>\n\n- T M; C7O 8; KD78B; JE 9EDJHEB J>; H;IEKH9;I EKH 9EBB78EH7JEHI EH J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJ?;I :;LEJ; JE EKH FHE=H7CIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FHE:K9JI EH FHE:K9J 97D:?:7J;Iglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T :?IFKJ;I C7O 7H?I; KD:;H 7D 7=H;;C;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= M?J> H;IF;9J JE J>; 79>?;L;C;DJ 7D: F7OC;DJ E< C?B;IJED;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> F7OC;DJ E< :;L;BEFC;DJ EH 9ECC;H9?7B 9EIJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> EMD;HI>?F E< H?=>JI JE J;9>DEBE=O :;L;BEF;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: J>; KD:;HBO?D= 7=H;;C;DJ C7O <7?B JE FHEL?:; KI M?J> I?=D?<?97DJ FHEJ;9J?ED EH C7O <7?B JE 8; ;<<;9J?L;BO ;D<EH9;: ?< J>; 9EBB78EH7JEHI EH J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJ?;I <7?B JE F;H<EHCglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T J>; ?DJ;H;IJI E< EKH 9EBB78EH7JEHI EH J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJ?;I C7O DEJ 7BM7OI 8; 7B?=D;: M?J> EKH ?DJ;H;IJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: IK9> F7HJ?;I C7O DEJ FKHIK; H;=KB7JEHO 7FFHEL7BI EH C7HA;J 7 FHE:K9J ?D J>; I7C; C7DD;H EH JE J>; I7C; ;NJ;DJ J>7J M; MEKB:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> 9EKB: 7:L;HI;BO 7<<;9J EKH H;L;DK;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> EH C7O 7:EFJ J7N IJH7J;=?;I J>7J 9EKB: >7L; 7D 7:L;HI; ;<<;9J ED EKH 8KI?D;IIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;IKBJI E< EF;H7J?EDI EH <?D7D9?7B 9ED:?J?EDglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJO H;B7J?EDI>?FI H;GK?H; J>; F7HJ?;I JE 9EEF;H7J;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: <7?BKH; JE :E IE ;<<;9J?L;BO 9EKB: 7:L;HI;BO 7<<;9J FHE:K9J I7B;I EH J>; 9B?D?97B :;L;BEFC;DJ EH H;=KB7JEHO 7FFHEL7BI E< FHE:K9J 97D:?:7J;I KD:;H @E?DJ 9EDJHEBglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9EKB: H;IKBJ ?D J;HC?D7J?ED E< J>; H;I;7H9>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> :;L;BEFC;DJ EH 9ECC;H9?7B?P7J?ED E< FHE:K9J 97D:?:7J;I EH 9EKB: H;IKBJ ?D B?J?=7J?ED EH 7H8?JH7J?EDglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T 7DO <7?BKH; ED J>; F7HJ E< EKH 9EBB78EH7JEHI EH J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJ?;I JE 9ECFBO M?J> 7FFB?978B; B7MIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= J7N B7MIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;=KB7JEHO H;GK?H;C;DJI 7D:glyph<c=15,font=/PIIBEG+FranklinGothic-Book>EH 7FFB?978B; 9EDJH79JK7B E8B?=7J?EDI EH JE <KB<?BB 7DO H;IFEDI?8?B?J?;I J>;O C7O >7L; JE FHEJ;9J 7D: ;D<EH9; 7DO ?DJ;BB;9JK7B FHEF;HJO H?=>JI KD:;HBO?D= EKH FHE:K9JI 9EKB: >7L; 7D 7:L;HI; ;<<;9J ED EKH H;L;DK; 7I M;BB 7I ?DLEBL; KI ?D FEII?8B; B;=7B FHE9;;:?D=Iglyph<c=27,font=/PIIBEG+FranklinGothic-Book> 7D:\n- T 7DO ?CFHEF;H 9ED:K9J EH 79J?EDI ED J>; F7HJ E< EKH 9EBB78EH7JEHI EH J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJ?;I 9EKB: IK8@;9J KI JE 9?L?B EH 9H?C?D7B ?DL;IJ?=7J?EDI 7D: CED;J7HO 7D: ?D@KD9J?L; F;D7BJ?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?CF79J J>; 799KH79O 7D: J?C?D= E< EKH <?D7D9?7B H;FEHJ?D= 7D:glyph<c=15,font=/PIIBEG+FranklinGothic-Book>EH 7:L;HI;BO ?CF79J EKH 78?B?JO JE 9ED:K9J 8KI?D;IIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> EKH EF;H7J?D= H;IKBJI 7D: EKH H;FKJ7J?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n\"?L;D J>;I; H?IAIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>;H; ?I 9EDI?:;H78B; KD9;HJ7?DJO H;=7H:?D= J>; IK99;II E< EKH 9KHH;DJ 7D: <KJKH; 9EBB78EH7J?L; ;<<EHJIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $< J>;I; ;<<EHJI <7?Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> EKH FHE:K9J :;L;BEFC;DJ EH 9ECC;H9?7B?P7J?ED E< D;M FHE:K9JI 9EKB: 8; :;B7O;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;L;DK; <HEC FHE:K9JI 9EKB: :;9B?D; 7D:glyph<c=15,font=/PIIBEG+FranklinGothic-Book>EH M; C7O DEJ H;7B?P; J>; 7DJ?9?F7J;: 8;D;<?JI E< J>;I; 7HH7D=;C;DJIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=27,font=/PIICNA+FranklinGothic-BookItal>63 3&46-54 0' 01&3\"5*0/4 .\": #& \"%7&34&-: \"''&$5&% #: $633&/5 \"/% 105&/5*\"- '6563& )&\"-5)$\"3& 3&'03.4glyph<c=7,font=/PIICNA+FranklinGothic-BookItal>\n\n$D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> <;:;H7B 7D: IJ7J; B;=?IB7JKH;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> >;7BJ> 7=;D9?;I 7D: J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJO F7OEHI 9EDJ?DK; JE <E9KI ED 9EDJ7?D?D= J>; 9EIJ E< >;7BJ> 97H;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> ';=?IB7J?L; 7D: H;=KB7JEHO FHEFEI7BIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ;D79JC;DJI JE H;<EHC >;7BJ> 97H; ?DIKH7D9; FHE=H7CI glyph<c=8,font=/PIIBEG+FranklinGothic-Book>?D9BK:?D= J>EI; 9EDJ7?D;: ?D J>; $-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book> 7D: ?D9H;7I?D= FH;IIKH; <HEC IE9?7B IEKH9;I 9EKB: I?=D?<?97DJBO",
        "metadata": {
            "page": 50
        },
        "id": "90029561-b0c2-4c30-9cf6-aa00fa41ae0b"
    },
    {
        "page_content": "?D<BK;D9; J>; C7DD;H ?D M>?9> EKH FHE:K9JI 7H; FH;I9H?8;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> FKH9>7I;: 7D: H;?C8KHI;:glyph<c=14,font=/PIIBEG+FranklinGothic-Book> !EH ;N7CFB;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> FHEL?I?EDI E< J>; +7J?;DJ +HEJ;9J?ED 7D: glyph<c=28,font=/PIIBEG+FranklinGothic-Book><<EH:78B; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>7H; glyph<c=28,font=/PIIBEG+FranklinGothic-Book>9J glyph<c=8,font=/PIIBEG+FranklinGothic-Book>++glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book> >7L; H;IKBJ;: ?D 9>7D=;I ?D J>; M7O >;7BJ> 97H; ?I F7?: <EH 8O 8EJ> =EL;HDC;DJ7B 7D: FH?L7J; ?DIKH;HIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= ?D9H;7I;: H;87J;I EM;: 8O C7DK<79JKH;HI KD:;H J>; (;:?97?: glyph<c=31,font=/PIIBEG+FranklinGothic-Book>HK= -;87J; +HE=H7Cglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7DDK7B <;;I 7D: J7N;I ED C7DK<79JKH;HI E< 9;HJ7?D 8H7D:;: FH;I9H?FJ?ED :HK=Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; H;GK?H;C;DJ J>7J C7DK<79JKH;HI F7HJ?9?F7J; ?D 7 :?I9EKDJ FHE=H7C <EH 9;HJ7?D EKJF7J?;DJ :HK=I KD:;H (;:?97H; +7HJ glyph<c=31,font=/PIIBEG+FranklinGothic-Book> 7D: J>; ;NF7DI?ED E< J>; DKC8;H E< >EIF?J7BI ;B?=?8B; <EH :?I9EKDJI KD:;H .;9J?ED glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=29,font=/PIIBEG+FranklinGothic-Book> E< J>; +K8B?9 #;7BJ> .;HL?9; glyph<c=28,font=/PIIBEG+FranklinGothic-Book>9Jglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />;I; 9>7D=;I >7L; >7: 7D: 7H; ;NF;9J;: JE 9EDJ?DK; JE >7L; 7 I?=D?<?97DJ ?CF79J ED EKH 8KI?D;IIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n2; C7O <79; KD9;HJ7?DJ?;I 7I 7 H;IKBJ E< ;<<EHJI JE H;F;7Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> IK8IJ7DJ?7BBO CE:?<O EH ?DL7B?:7J; IEC; EH 7BB E< J>; FHEL?I?EDI E< J>; ++glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />;H; ?I DE 7IIKH7D9; J>7J J>; ++glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7I 9KHH;DJBO ;D79J;: EH 7I 7C;D:;: ?D J>; <KJKH;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M?BB DEJ 7:L;HI;BO 7<<;9J EKH 8KI?D;II 7D: <?D7D9?7B H;IKBJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: M; 97DDEJ FH;:?9J >EM <KJKH; <;:;H7B EH IJ7J; B;=?IB7J?L; EH 7:C?D?IJH7J?L; 9>7D=;I H;B7J?D= JE >;7BJ>97H; H;<EHC M?BB 7<<;9J EKH 8KI?D;IIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n/>;H; ?I ?D9H;7I?D= FK8B?9 7JJ;DJ?ED ED J>; 9EIJI E< FH;I9H?FJ?ED :HK=I 7D: M; ;NF;9J :HK= FH?9?D= 7D: EJ>;H >;7BJ> 97H; 9EIJI JE 9EDJ?DK; JE 8; IK8@;9J JE ?DJ;DI; FEB?J?97B 7D: IE9?;J7B FH;IIKH;I ED 7 =BE87B 87I?Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> !EH ;N7CFB;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> JME 9ECC?JJ;;I E< J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> #EKI; E< -;FH;I;DJ7J?L;I FH;L?EKIBO ?DL;IJ?=7J;: J>; 7FFHEL7B 7D: FH?9; E< glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>0# '(glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D 7::?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>;H; >7L; 8;;D glyph<c=8,font=/PIIBEG+FranklinGothic-Book>?D9BK:?D= ;B;C;DJI E< J>; $-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: 7H; ;NF;9J;: JE 9EDJ?DK; JE 8;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> B;=?IB7J?L; FHEFEI7BI JE 7::H;II FH;I9H?FJ?ED :HK= FH?9?D=glyph<c=14,font=/PIIBEG+FranklinGothic-Book> .EC; E< J>;I; FHEFEI7BI 9EKB: >7L; I?=D?<?97DJ ;<<;9JI ED EKH 8KI?D;IIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= 7D ;N;9KJ?L; EH:;H ?IIK;: ?D .;FJ;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> JE J;IJ 7 [CEIJ <7LEH;: D7J?ED\\ CE:;B <EH +7HJ glyph<c=29,font=/PIIBEG+FranklinGothic-Book> 7D: +7HJ glyph<c=31,font=/PIIBEG+FranklinGothic-Book> :HK=I J>7J J?; H;?C8KHI;C;DJ H7J;I JE ?DJ;HD7J?ED7B :HK= FH?9?D= C;JH?9Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />;I; 79J?EDI 7D: J>; KD9;HJ7?DJO 78EKJ J>; <KJKH; E< J>; ++glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 7D: >;7BJ>97H; B7MI C7O FKJ :EMDM7H: FH;IIKH; ED F>7HC79;KJ?97B FH?9?D= 7D: ?D9H;7I; EKH H;=KB7JEHO 8KH:;DI 7D: EF;H7J?D= 9EIJIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n/>;H; ?I 7BIE I?=D?<?97DJ ;9EDEC?9 FH;IIKH; ED IJ7J; 8K:=;JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= 7I 7 H;IKBJ E< J>; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>*1$glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book> F7D:;C?9glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>7J C7O H;IKBJ ?D IJ7J;I ?D9H;7I?D=BO I;;A?D= JE 79>?;L; 8K:=;J I7L?D=I J>HEK=> C;9>7D?ICI J>7J B?C?J 9EL;H7=; EH F7OC;DJ <EH EKH :HK=Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D H;9;DJ O;7HIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> IEC; IJ7J;I >7L; 9EDI?:;H;: B;=?IB7J?ED 7D: 87BBEJ ?D?J?7J?L;I J>7J MEKB: 9EDJHEB J>; FH?9;I E< :HK=Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= B7MI JE 7BBEM ?CFEHJ7J?ED E< F>7HC79;KJ?97B FHE:K9JI <HEC BEM;H 9EIJ @KH?I:?9J?EDI EKJI?:; J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 7D: B7MI ?DJ;D:;: JE ?CFEI; FH?9; 9EDJHEBI ED IJ7J; :HK= FKH9>7I;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> .J7J; (;:?97?: FHE=H7CI 7H; ?D9H;7I?D=BO H;GK;IJ?D= C7DK<79JKH;HI JE F7O IKFFB;C;DJ7B H;87J;I 7D: H;GK?H?D= FH?EH 7KJ>EH?P7J?ED 8O J>; IJ7J; FHE=H7C <EH KI; E< 7DO :HK= <EH M>?9> IKFFB;C;DJ7B H;87J;I 7H; DEJ 8;?D= F7?:glyph<c=14,font=/PIIBEG+FranklinGothic-Book> \"EL;HDC;DJ ;<<EHJI JE H;:K9; (;:?97?: ;NF;DI; C7O B;7: JE ?D9H;7I;: KI; E< C7D7=;: 97H; EH=7D?P7J?EDI 8O (;:?97?: FHE=H7CIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />?I C7O H;IKBJ ?D C7D7=;: 97H; EH=7D?P7J?EDI ?D<BK;D9?D= FH;I9H?FJ?ED :;9?I?EDI <EH 7 B7H=;H I;=C;DJ E< J>; FEFKB7J?ED 7D: 7 9EHH;IFED:?D= B?C?J7J?ED ED FH?9;I 7D: H;?C8KHI;C;DJ <EH EKH FHE:K9JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n$D J>;  glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 7D: IEC; EJ>;H ?DJ;HD7J?ED7B C7HA;JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; =EL;HDC;DJ FHEL?:;I >;7BJ> 97H; 7J BEM 9EIJ JE 9EDIKC;HI 7D: H;=KB7J;I F>7HC79;KJ?97B FH?9;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> F7J?;DJ ;B?=?8?B?JO EH H;?C8KHI;C;DJ B;L;BI JE 9EDJHEB 9EIJI <EH J>; =EL;HDC;DJglyph<c=13,font=/PIIBEG+FranklinGothic-Book>IFEDIEH;: >;7BJ> 97H; IOIJ;Cglyph<c=14,font=/PIIBEG+FranklinGothic-Book> (7DO 9EKDJH?;I >7L; 7DDEKD9;: EH ?CFB;C;DJ;: C;7IKH;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: C7O ?D J>; <KJKH; ?CFB;C;DJ D;M EH 7::?J?ED7B C;7IKH;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> JE H;:K9; >;7BJ> 97H; 9EIJI JE B?C?J J>; EL;H7BB B;L;B E< =EL;HDC;DJ ;NF;D:?JKH;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />;I; C;7IKH;I L7HO 8O 9EKDJHO 7D: C7O ?D9BK:;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7CED= EJ>;H J>?D=Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> F7J?;DJ 799;II H;IJH?9J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> IKIF;DI?EDI ED FH?9; ?D9H;7I;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FHEIF;9J?L; 7D: FEII?8B; H;JHE79J?L; FH?9; H;:K9J?EDI 7D: EJ>;H H;9EKFC;DJI 7D: ?D9H;7I;: C7D:7JEHO :?I9EKDJI EH H;87J;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;9EL;H?;I E< F7IJ FH?9; ?D9H;7I;I 7D: =H;7J;H ?CFEHJ7J?ED E< :HK=I <HEC BEM;Hglyph<c=13,font=/PIIBEG+FranklinGothic-Book>9EIJ 9EKDJH?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />;I; C;7IKH;I >7L; D;=7J?L;BO ?CF79J;: EKH H;L;DK; 7D: C7O 9EDJ?DK; JE 7:L;HI;BO 7<<;9J EKH H;L;DK; 7D: H;IKBJI E< EF;H7J?EDI ?D J>; <KJKH;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=27,font=/PIICNA+FranklinGothic-BookItal>63 46$$&44 */ $0..&3$*\"-*;*/( #*04*.*-\"34 *4 46#+&$5 50 3*4,4 \"/% 6/$&35\"*/5*&4 */)&3&/5 */ 5)& %&7&-01.&/5glyph<c=5,font=/PIICNA+FranklinGothic-BookItal> .\"/6'\"$563& \"/% $0..&3$*\"-*;\"5*0/ 0' #*04*.*-\"34glyph<c=7,font=/PIICNA+FranklinGothic-BookItal> glyph<c=22,font=/PIICNA+FranklinGothic-BookItal>' 8& \"3& 6/46$$&44'6- */ 46$) \"$5*7*5*&4glyph<c=5,font=/PIICNA+FranklinGothic-BookItal> 063 #64*/&44 .\": #& \"%7&34&-: \"''&$5&%glyph<c=7,font=/PIICNA+FranklinGothic-BookItal>\n\n/>; :;L;BEFC;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> C7DK<79JKH; 7D: 9ECC;H9?7B?P7J?ED E< 8?EI?C?B7H FHE:K9JI H;GK?H; IF;9?7B?P;: ;NF;HJ?I; 7D: 7H; L;HO 9EIJBO 7D: IK8@;9J JE 9ECFB;N H;=KB7J?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book> *KH IK99;II ?D 9ECC;H9?7B?P?D= 8?EI?C?B7HI ?I IK8@;9J JE 7 DKC8;H E< H?IAIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D=glyph<c=26,font=/PIIBEG+FranklinGothic-Book>\n\n- T &3:7/<13 =< (67@2glyph<c=8,font=/PIIBDE+FranklinGothic-BookItal>$/@B73Aglyph<c=9,font=/PIIBDE+FranklinGothic-BookItal> 2; 7H; :;F;D:;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D F7HJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ED J>; ;<<EHJI E< 9EBB78EH7J?ED F7HJD;HI 7D: EJ>;H J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book> F7HJ?;I EL;H M>EC M; >7L; B?C?J;: EH DE 9EDJHEB ?D J>; :;L;BEFC;DJ 7D: C7DK<79JKH?D= E< 8?EI?C?B7HI FHE:K9JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $< J>;I; J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJ?;I <7?B JE F;H<EHC IK99;II<KBBOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> EKH 8?EI?C?B7H FHE:K9J :;L;BEFC;DJ EH 9ECC;H9?7B?P7J?ED E< 8?EI?C?B7H FHE:K9JI 9EKB: 8; :;B7O;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;L;DK; <HEC 8?EI?C?B7H FHE:K9JI 9EKB: :;9B?D; 7D:glyph<c=15,font=/PIIBEG+FranklinGothic-Book>EH M; C7O DEJ H;7B?P; J>; 7DJ?9?F7J;: 8;D;<?JI E< J>;I; 7HH7D=;C;DJIglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T &35C:/B=@G glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=;>:7/<13glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?EI?C?B7H FHE:K9JI C7O <79; H;=KB7JEHO >KH:B;I EH :;B7OI :K; JE J>; ;LEBL?D= 7D: KD9;HJ7?D H;=KB7JEHO 7D: 9ECC;H9?7B F7J>M7O E< 8?EI?C?B7HI FHE:K9JI ?D 9;HJ7?D @KH?I:?9J?EDIglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>07:7BG B= $@=D723 glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>23?C/B3 'C>>:Gglyph<c=9,font=/PIIBDE+FranklinGothic-BookItal> (7DK<79JKH?D= 8?EI?C?B7HI ?I 9ECFB;Nglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $< M; ;D9EKDJ;H 7DO C7DK<79JKH?D= EH IKFFBO 9>7?D :?<<?9KBJ?;I M; C7O 8; KD78B; JE C;;J :;C7D:glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; 7H; :;F;D:;DJ ED 7 J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJO <EH J>; C7DK<79JKH; E< EKH 8?EI?C?B7H FHE:K9JI 7D: IK9> J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJO C7O DEJ F;H<EHC ?JI E8B?=7J?EDI ?D 7 J?C;BO 7D:",
        "metadata": {
            "page": 51
        },
        "id": "2f605576-d325-4637-88c3-19e810815276"
    },
    {
        "page_content": "9EIJglyph<c=13,font=/PIIBEG+FranklinGothic-Book>;<<;9J?L; C7DD;H EH ?D 9ECFB?7D9; M?J> 7FFB?978B; H;=KB7J?EDI 7D: C7O 8; KD78B; EH KDM?BB?D= JE ?D9H;7I; FHE:K9J?ED 97F79?JO 9ECC;DIKH7J; M?J> :;C7D: <EH EKH ;N?IJ?D= EH <KJKH; 8?EI?C?B7H FHE:K9JIglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n\n- T glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><B3::31BC/: $@=>3@BG /<2 &35C:/B=@G glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>6/::3<53Aglyph<c=9,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?EI?C?B7H FHE:K9JI C7O <79; ;NJ;DI?L; F7J;DJ 9B;7H7D9;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> F7J;DJ ?D<H?D=;C;DJ B?J?=7J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D@KD9J?EDI EH H;=KB7JEHO 9>7BB;D=;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> 9EKB: FH;L;DJ J>; 9ECC;H9?7B B7KD9> E< 7 FHE:K9J EH :;B7O ?J <EH C7DO O;7HI EH H;IKBJ ?D ?CFEI?J?ED E< CED;J7HO :7C7=;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> F;D7BJ?;I EH EJ>;H 9?L?B I7D9J?EDI 7D: :7C7=; EKH H;FKJ7J?EDglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>/7:C@3 B= glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>/7< !/@93B /<2 $/B73<B glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>113>B/<13glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal> (7HA;J IK99;II E< 8?EI?C?B7H FHE:K9JI M?BB 8; 7:L;HI;BO 7<<;9J;: ?< F7J?;DJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> F>OI?9?7DI 7D:glyph<c=15,font=/PIIBEG+FranklinGothic-Book>EH F7OEHI :E DEJ 799;FJ 8?EI?C?B7H FHE:K9JI 7I I7<; 7D: ;<<?979?EKI FHE:K9JI E<<;H?D= 7 CEH; 9ECF;J?J?L; FH?9; EH EJ>;H 8;D;<?J EL;H ;N?IJ?D= J>;H7F?;Iglyph<c=27,font=/PIIBEG+FranklinGothic-Book> 7D:\n- T glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=;>3B7B7D3 glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>6/::3<53Aglyph<c=9,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?EI?C?B7H FHE:K9JI <79; I?=D?<?97DJ 9ECF;J?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= <HEC ?DDEL7JEH FHE:K9JI 7D: 8?EI?C?B7H FHE:K9JI E<<;H;: 8O EJ>;H 9ECF7D?;I J>7J C7O H;9;?L; =H;7J;H 799;FJ7D9; EH CEH; <7LEH78B; H;?C8KHI;C;DJglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 'E97B J;D:;H?D= FHE9;II;I C7O H;IJH?9J 8?EI?C?B7H FHE:K9JI <HEC 8;?D= C7HA;J;: 7D: IEB: ?D IEC; @KH?I:?9J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; DKC8;H E< 9ECF;J?JEHI ?D 7 @KH?I:?9J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; J?C?D= E< 7FFHEL7B 7D: J>; 78?B?JO JE C7HA;J 8?EI?C?B7H FHE:K9JI IK99;II<KBBO ?D 7 J?C;BO 7D: 9EIJglyph<c=13,font=/PIIBEG+FranklinGothic-Book>;<<;9J?L; C7DD;H 7H; 7::?J?ED7B <79JEHI J>7J C7O ?CF79J EKH IK99;II ?D J>?I 8KI?D;II 7H;7glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## );E=E )7>3F76 FA  @F7>>75FG3> 'DAB7DFK\n\nglyph<c=22,font=/PIICNA+FranklinGothic-BookItal>' 8& \"3& 6/\"#-& 50 0#5\"*/ \"/% .\"*/5\"*/ \"%&26\"5& 1305&$5*0/ '03 063 %\"5\"glyph<c=5,font=/PIICNA+FranklinGothic-BookItal> */5&--&$56\"- 1301&35: \"/% 05)&3 13013*&5\"3: 3*()54glyph<c=5,font=/PIICNA+FranklinGothic-BookItal> 063 #64*/&44 .\": #& )\"3.&%glyph<c=7,font=/PIICNA+FranklinGothic-BookItal>\n\n*KH IK99;IIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= EKH BED=glyph<c=13,font=/PIIBEG+FranklinGothic-Book>J;HC L?78?B?JO 7D: =HEMJ>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> :;F;D:Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D F7HJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ED EKH 78?B?JO JE E8J7?D 7D: :;<;D: F7J;DJ 7D: EJ>;H ?DJ;BB;9JK7B FHEF;HJO H?=>JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= 9;HJ7?D H;=KB7JEHO <EHCI E< ;N9BKI?L?JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>7J 7H; ?CFEHJ7DJ JE J>; 9ECC;H9?7B?P7J?ED E< EKH FHE:K9JI 7D: FHE:K9J 97D:?:7J;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> +7J;DJ FHEJ;9J?ED 7D:glyph<c=15,font=/PIIBEG+FranklinGothic-Book>EH H;=KB7JEHO ;N9BKI?L?JO ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 7D: EJ>;H ?CFEHJ7DJ C7HA;JI H;C7?DI KD9;HJ7?D 7D: :;F;D:Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D F7HJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> KFED :;9?I?EDI E< J>; F7J;DJ E<<?9;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9EKHJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7:C?D?IJH7J?L; 8E:?;I 7D: B7MC7A;HI ?D J>;I; 9EKDJH?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; C7O <7?B JE E8J7?D EH FH;I;HL; F7J;DJ 7D: EJ>;H ?DJ;BB;9JK7B FHEF;HJO H?=>JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= 9;HJ7?D H;=KB7JEHO <EHCI E< ;N9BKI?L?JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> EH J>; FHEJ;9J?ED M; E8J7?D C7O DEJ 8; E< IK<<?9?;DJ 8H;7:J> 7D: :;=H;; JE FHEJ;9J EKH 9ECC;H9?7B ?DJ;H;IJI ?D 7BB 9EKDJH?;I M>;H; M; 9ED:K9J 8KI?D;IIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> 9EKB: H;IKBJ ?D <?D7D9?7Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 8KI?D;II EH H;FKJ7J?ED7B >7HC JE KI EH 9EKB: 97KI; 7 :;9B?D; EH LEB7J?B?JO ?D EKH IJE9A FH?9;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D 7::?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> I;JJB;C;DJI E< IK9> FHE9;;:?D=I E<J;D H;IKBJ ?D H;:K9?D= J>; F;H?E: E< ;N9BKI?L?JO 7D: EJ>;H FHEJ;9J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;IKBJ?D= ?D 7 H;:K9J?ED ?D H;L;DK; <HEC 7<<;9J;: FHE:K9JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n$D C7DO C7HA;JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> C7DK<79JKH;HI C7O 8; 7BBEM;: JE H;BO ED J>; I7<;JO 7D: ;<<?979O :7J7 E< J>; ?DDEL7JEHglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I FHE:K9J 7D: :E DEJ D;;: JE 9ED:K9J 9B?D?97B JH?7BI 8;<EH; C7HA;J?D= 7 9ECF;J?D= L;HI?ED E< 7 FHE:K9J 7<J;H J>;H; ?I DE BED=;H F7J;DJ EH H;=KB7JEHO ;N9BKI?L?JOglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D IK9> 97I;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> C7DK<79JKH;HI E<J;D 9>7H=; I?=D?<?97DJBO BEM;H FH?9;I 7D: 7 C7@EH FEHJ?ED E< J>; 9ECF7DOglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I H;L;DK; C7O 8; H;:K9;: ?D 7 I>EHJ F;H?E: E< J?C;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D 7::?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> C7DK<79JKH;HI E< =;D;H?9I 7D: 8?EI?C?B7HI C7O 9>EEI; JE B7KD9> EH 7JJ;CFJ JE B7KD9> J>;?H FHE:K9JI 8;<EH; J>; ;NF?H7J?ED E< EKH F7J;DJ EH EJ>;H ?DJ;BB;9JK7B FHEF;HJO FHEJ;9J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n!KHJ>;HCEH;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> EKH FHE:K9JI C7O 8; :;J;HC?D;: JE ?D<H?D=; F7J;DJI EH EJ>;H ?DJ;BB;9JK7B FHEF;HJO H?=>JI >;B: 8O J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJ?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> ';=7B FHE9;;:?D=Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7:C?D?IJH7J?L; 9>7BB;D=;I EH EJ>;H JOF;I E< FHE9;;:?D=I 7H; 7D: C7O ?D J>; <KJKH; 8; D;9;II7HO JE :;J;HC?D; J>; L7B?:?JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> I9EF; EH DEDglyph<c=13,font=/PIIBEG+FranklinGothic-Book>?D<H?D=;C;DJ E< 9;HJ7?D F7J;DJ H?=>JI 9B7?C;: 8O J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJ?;I JE 8; F;HJ?D;DJ JE J>; C7DK<79JKH;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> KI; EH I7B; E< EKH FHE:K9JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> ';=7B FHE9;;:?D=I C7O 7BIE 8; D;9;II7HO JE :;J;HC?D; J>; H?=>JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> E8B?=7J?EDI 7D: F7OC;DJI 9B7?C;: :KH?D= 7D: 7<J;H J>; ;NF?H7J?ED E< ?DJ;BB;9JK7B FHEF;HJO B?9;DI; 7=H;;C;DJI M; >7L; ;DJ;H;: M?J> J>?H: F7HJ?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> .K9> FHE9;;:?D=I 7H; KDFH;:?9J78B; 7D: 7H; E<J;D FHEJH79J;: 7D: ;NF;DI?L;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> );=7J?L; EKJ9EC;I E< IK9> FHE9;;:?D=I 9EKB: >?D:;H EH FH;L;DJ KI <HEC C7DK<79JKH?D= 7D: C7HA;J?D= EKH FHE:K9JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;GK?H; KI JE I;;A 7 B?9;DI; <EH J>; ?D<H?D=;: FHE:K9J EH J;9>DEBE=O EH H;IKBJ ?D J>; 7II;IIC;DJ E< I?=D?<?97DJ CED;J7HO :7C7=;I 7=7?DIJ KI J>7J C7O ;N9;;: 7CEKDJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?< 7DOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 799HK;: ?D EKH <?D7D9?7B IJ7J;C;DJIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book> <7?BKH; JE E8J7?D D;9;II7HO B?9;DI;I <EH 7D ?D<H?D=;: FHE:K9J EH J;9>DEBE=O 9EKB: FH;L;DJ KI <HEC C7DK<79JKH?D= EH I;BB?D= EKH FHE:K9JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> !KHJ>;HCEH;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> F7OC;DJI KD:;H 7DO B?9;DI;I J>7J M; 7H; 78B; JE E8J7?D 9EKB: H;:K9; EKH FHE<?JI <HEC J>; 9EL;H;: FHE:K9JI 7D: I;HL?9;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>DO E< J>;I; 9?H9KCIJ7D9;I 9EKB: H;IKBJ ?D <?D7D9?7Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 8KI?D;II EH H;FKJ7J?ED7B >7HC JE KI EH 9EKB: 97KI; 7 :;9B?D; EH LEB7J?B?JO ?D EKH IJE9A FH?9;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n);E=E )7>3F76 FA glyph<c=27,font=/PIIBCD+FranklinGothic-Book>7H7>AB?7@Fglyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=26,font=/PIIBCD+FranklinGothic-Book>>;@;53> +7EF;@9 3@6 )79G>3F;A@ A8 &GD 'DA6G5FE 3@6 'DA6G5F glyph<c=26,font=/PIIBCD+FranklinGothic-Book>3@6;63F7E\n\nglyph<c=30,font=/PIICNA+FranklinGothic-BookItal>6$$&44'613&$-*/*$\"- 803, 03 &\"3-: 45\"(& $-*/*$\"- 53*\"-4 %0&4 /05 &/463& 46$$&44 */ -\"5&3 45\"(& 53*\"-4glyph<c=5,font=/PIICNA+FranklinGothic-BookItal> 3&(6-\"503: \"11307\"03 $0..&3$*\"- 7*\"#*-*5: 0' \" 130%6$5glyph<c=7,font=/PIICNA+FranklinGothic-BookItal>\n\n+EI?J?L; H;IKBJI ?D 7 9B?D?97B JH?7B C7O DEJ 8; H;FB?97J;: ?D IK8I;GK;DJ EH 9ED<?HC7JEHO JH?7BIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>::?J?ED7BBOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> IK99;II ?D FH;9B?D?97B MEHA EH ;7HBO IJ7=; 9B?D?97B JH?7BI :E;I DEJ ;DIKH; J>7J B7J;H IJ7=; EH B7H=;H I97B; 9B?D?97B JH?7BI M?BB 8; IK99;II<KB EH J>7J H;=KB7JEHO 7FFHEL7B M?BB 8; E8J7?D;:glyph<c=14,font=/PIIBEG+FranklinGothic-Book>  L;D ?< B7J;H IJ7=; 9B?D?97B JH?7BI 7H; IK99;II<KBglyph<c=12,font=/PIIBEG+FranklinGothic-Book>",
        "metadata": {
            "page": 52
        },
        "id": "a3136f81-80b1-4f13-8853-83230a6879b8"
    },
    {
        "page_content": "H;=KB7JEHO 7KJ>EH?J?;I C7O :;B7O EH :;9B?D; 7FFHEL7B E< EKH FHE:K9J 97D:?:7J;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> -;=KB7JEHO 7KJ>EH?J?;I C7O :?I7=H;; M?J> EKH L?;M E< J>; :7J7glyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;GK?H; 7::?J?ED7B IJK:?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> :?I7=H;; M?J> EKH JH?7B :;I?=D EH ;D:FE?DJI EH DEJ 7FFHEL; 7:;GK7J; H;?C8KHI;C;DJglyph<c=14,font=/PIIBEG+FranklinGothic-Book> -;=KB7JEHO 7KJ>EH?J?;I C7O 7BIE <7?B JE 7FFHEL; J>; <79?B?J?;I EH FHE9;II;I KI;: JE C7DK<79JKH; 7 FHE:K9J 97D:?:7J;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> EKH :EI?D= EH :;B?L;HO C;J>E:I EH 9ECF7D?ED :;L?9;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> -;=KB7JEHO 7KJ>EH?J?;I C7O =H7DJ C7HA;J?D= 7FFHEL7B J>7J ?I CEH; H;IJH?9J;: J>7D 7DJ?9?F7J;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= B?C?J?D= ?D:?97J?EDI JE D7HHEM F7J?;DJ FEFKB7J?EDI 7D: J>; ?CFEI?J?ED E< I7<;JO CED?JEH?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ;:K97J?ED7B H;GK?H;C;DJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;GK?H?D= 9ED<?HC7JEHO JH?7BI 7D: H?IA ;L7BK7J?ED 7D: C?J?=7J?ED IJH7J;=?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; E99KHH;D9; E< 7DO E< J>;I; ;L;DJI 9EKB: H;IKBJ ?D I?=D?<?97DJ 9EIJI 7D: ;NF;DI;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> >7L; 7D 7:L;HI; ;<<;9J ED EKH 8KI?D;IIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> <?D7D9?7B 9ED:?J?ED 7D: H;IKBJI E< EF;H7J?EDI 7D:glyph<c=15,font=/PIIBEG+FranklinGothic-Book>EH 97KI; EKH IJE9A FH?9; JE :;9B?D; EH ;NF;H?;D9; F;H?E:I E< LEB7J?B?JOglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=16,font=/PIICNA+FranklinGothic-BookItal>-*/*$\"53*\"-4 \"/% 5)& %&7&-01.&/5 0' #*01)\"3.\"$&65*$\"- 130%6$54 *4 \" -&/(5): \"/% $0.1-&9 130$&44glyph<c=7,font=/PIICNA+FranklinGothic-BookItal> glyph<c=22,font=/PIICNA+FranklinGothic-BookItal>' 8& '\"*- 50 \"%&26\"5&-: .\"/\"(& 063 $-*/*$\"- \"$5*7*5*&4glyph<c=5,font=/PIICNA+FranklinGothic-BookItal> 063 $-*/*$\"- 53*\"-4 03 105&/5*\"- 3&(6-\"503: \"11307\"-4 .\": #& %&-\":&% 03 %&/*&%glyph<c=7,font=/PIICNA+FranklinGothic-BookItal>\n\nglyph<c=30,font=/PIIBEG+FranklinGothic-Book>ED:K9J?D= 9B?D?97B JH?7BI ?I 7 9ECFB;Nglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J?C;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>9EDIKC?D= 7D: ;NF;DI?L; FHE9;IIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> *KH 78?B?JO JE 9ECFB;J; 9B?D?97B JH?7BI ?D 7 J?C;BO <7I>?ED :;F;D:I ED 7 DKC8;H E< A;O <79JEHIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= FHEJE9EB :;I?=Dglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;=KB7JEHO 7D: ?DIJ?JKJ?ED7B H;L?;M 8E7H: 7FFHEL7Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> F7J?;DJ ;DHEBBC;DJ H7J;I 7D: 9ECFB?7D9; M?J> 9KHH;DJ \"EE: glyph<c=30,font=/PIIBEG+FranklinGothic-Book>B?D?97B +H79J?9;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $< M; EH EKH J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJO 9B?D?97B JH?7B FHEL?:;HI EH J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJO glyph<c=30,font=/PIIBEG+FranklinGothic-Book>-*I :E DEJ IK99;II<KBBO 97HHO EKJ J>;I; 9B?D?97B 79J?L?J?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> EKH 9B?D?97B JH?7BI EH J>; FEJ;DJ?7B H;=KB7JEHO 7FFHEL7B E< 7 FHE:K9J 97D:?:7J; C7O 8; :;B7O;: EH :;D?;:glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n2; >7L; EF;D;: 9B?D?97B JH?7B I?J;I 7D: 7H; ;DHEBB?D= F7J?;DJI ?D 7 DKC8;H E< 9EKDJH?;I M>;H; EKH ;NF;H?;D9; ?I B?C?J;:glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D CEIJ 97I;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; KI; J>; I;HL?9;I E< J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJ?;I JE 97HHO EKJ EKH 9B?D?97B JH?7B H;B7J;: 79J?L?J?;I 7D: H;BO ED IK9> F7HJ?;I JE 799KH7J;BO H;FEHJ J>;?H H;IKBJIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> *KH H;B?7D9; ED J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJ?;I <EH J>;I; 79J?L?J?;I C7O ?CF79J EKH 78?B?JO JE 9EDJHEB J>; J?C?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9ED:K9Jglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ;NF;DI; 7D: GK7B?JO E< EKH 9B?D?97B JH?7BIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> *D; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>-* >7I H;IFEDI?8?B?JO <EH 7 IK8IJ7DJ?7B FEHJ?ED E< EKH 79J?L?J?;I 7D: H;FEHJ?D= H;B7J;: JE EKH 9B?D?97B JH?7BIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7:L;HI;BO 7<<;9J EKH ;NF;DI; 7IIE9?7J;: M?J> IK9> JH?7BI 7D: ?< IK9> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>-* :E;I DEJ 7:;GK7J;BO F;H<EHCglyph<c=12,font=/PIIBEG+FranklinGothic-Book> C7DO E< EKH JH?7BI C7O 8; 7<<;9J;:glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; C7O D;;: JE H;FB79; EKH glyph<c=30,font=/PIIBEG+FranklinGothic-Book>-*Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> C7O H;IKBJ ?D J>; :;B7O E< J>; 7<<;9J;: JH?7BI EH EJ>;HM?I; 7:L;HI;BO 7<<;9J EKH ;<<EHJI JE E8J7?D H;=KB7JEHO 7FFHEL7BI 7D: 9ECC;H9?7B?P; EKH FHE:K9J 97D:?:7J;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=14,font=/PIICNA+FranklinGothic-BookItal>%7&34& 4\"'&5: &7&/54 03 3&453*$5*0/4 0/ 64& \"/% 4\"'&5: 8\"3/*/(4 '03 063 130%6$54 $\"/ /&(\"5*7&-: \"''&$5 063 #64*/&44glyph<c=5,font=/PIICNA+FranklinGothic-BookItal> 130%6$5 4\"-&4 \"/% 450$, 13*$&glyph<c=7,font=/PIICNA+FranklinGothic-BookItal>\n\nglyph<c=28,font=/PIIBEG+FranklinGothic-Book>:L;HI; I7<;JO ;L;DJI ?DLEBL?D= EKH C7HA;J;: FHE:K9JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> =;D;H?9 EH 8?EI?C?B7H L;HI?EDI E< EKH C7HA;J;: FHE:K9JI EH FHE:K9JI <HEC J>; I7C; 9B7II 7I ED; E< EKH FHE:K9JI C7O >7L; 7 D;=7J?L; ?CF79J ED EKH 8KI?D;IIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=31,font=/PIIBEG+FranklinGothic-Book>?I9EL;HO E< I7<;JO ?IIK;I M?J> EKH FHE:K9JI 9EKB: 9H;7J; FHE:K9J B?78?B?JO 7D: 9EKB: 97KI; 7::?J?ED7B H;=KB7JEHO I9HKJ?DO 7D: H;GK?H;C;DJI <EH 7::?J?ED7B B78;B?D= EH I7<;JO CED?JEH?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M?J>:H7M7B E< FHE:K9JI <HEC J>; C7HA;J 7D:glyph<c=15,font=/PIIBEG+FranklinGothic-Book>EH J>; ?CFEI?J?ED E< <?D;I EH 9H?C?D7B F;D7BJ?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>:L;HI; I7<;JO ;L;DJI C7O 7BIE :7C7=; F>OI?9?7Dglyph<c=12,font=/PIIBEG+FranklinGothic-Book> F7J?;DJ 7D:glyph<c=15,font=/PIIBEG+FranklinGothic-Book>EH ?DL;IJEH 9ED<?:;D9; ?D EKH FHE:K9JI 7D: EKH H;FKJ7J?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>DO E< J>;I; 9EKB: H;IKBJ ?D 7:L;HI; ?CF79JI ED EKH H;IKBJI E< EF;H7J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n-;=KB7JEHO 7KJ>EH?J?;I 7H; C7A?D= =H;7J;H 7CEKDJI E< IJ7D:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>7BED; I7<;JO ?D<EHC7J?ED :?H;9JBO 7L7?B78B; JE J>; FK8B?9 J>HEK=> F;H?E:?9 I7<;JO KF:7J; H;FEHJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> F7J?;DJ H;=?IJH?;I 7D: EJ>;H H;FEHJ?D= H;GK?H;C;DJIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; H;FEHJ?D= E< 7:L;HI; I7<;JO ;L;DJI ?DLEBL?D= EKH FHE:K9JI EH FHE:K9JI I?C?B7H JE EKHI 7D: FK8B?9 HKCEHI 78EKJ IK9> ;L;DJI C7O ?D9H;7I; 9B7?CI 7=7?DIJ KI 7D: C7O 7BIE 97KI; EKH FHE:K9J I7B;I JE :;9B?D; EH EKH IJE9A FH?9; JE ;NF;H?;D9; F;H?E:I E< LEB7J?B?JOglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n-;IJH?9J?EDI ED KI; EH I7<;JO M7HD?D=I J>7J C7O 8; H;GK?H;: JE 8; ?D9BK:;: ?D J>; B78;B E< EKH FHE:K9JI C7O I?=D?<?97DJBO H;:K9; ;NF;9J;: H;L;DK; <EH J>EI; FHE:K9JI 7D: H;GK?H; I?=D?<?97DJ ;NF;DI; 7D: C7D7=;C;DJ J?C;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## );E=E )7>3F76 FA &GD &B7D3F;A@E\n\nglyph<c=14,font=/PIICNA+FranklinGothic-BookItal> #3&\",%08/ 03 #3&\"$) 0' 063 5&$)/0-0(: 4:45&.4 $06-% 46#+&$5 64 50 -*\"#*-*5: 03 */5&33615 5)& 01&3\"5*0/ 0' 063 #64*/&44glyph<c=7,font=/PIICNA+FranklinGothic-BookItal>\n\n2; 7H; ?D9H;7I?D=BO :;F;D:;DJ KFED J;9>DEBE=O IOIJ;CI 7D: :7J7 JE EF;H7J; EKH 8KI?D;IIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>*1$glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book> F7D:;C?9 >7I 97KI;: KI JE CE:?<O EKH 8KI?D;II FH79J?9;I ?D M7OI J>7J >;?=>J;D J>?I :;F;D:;D9;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= 9>7D=?D= J>; H;GK?H;C;DJ J>7J CEIJ E< EKH E<<?9;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>87I;: ;CFBEO;;I ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 7D: EKH EJ>;H A;O C7HA;JI MEHA <HEC J>; E<<?9;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M?J> 7 DKC8;H E< EKH ;CFBEO;;I DEM MEHA?D= ?D >O8H?: EH <KBBglyph<c=13,font=/PIIBEG+FranklinGothic-Book>H;CEJ; FEI?J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>I 7 H;IKBJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 7H; ?D9H;7I?D=BO :;F;D:;DJ KFED EKH J;9>DEBE=O IOIJ;CI JE EF;H7J; EKH 8KI?D;II 7D: EKH 78?B?JO JE ;<<;9J?L;BO C7D7=; EKH 8KI?D;II :;F;D:I ED J>; I;9KH?JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;B?78?B?JO 7D: 7:;GK79O E< EKH J;9>DEBE=O IOIJ;CI 7D: :7J7glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> ?D9BK:;I KI; E< 9BEK: J;9>DEBE=?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= .E<JM7H; 7I 7 .;HL?9; glyph<c=8,font=/PIIBEG+FranklinGothic-Book>.77.glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> +B7J<EHC 7I 7 .;HL?9; glyph<c=8,font=/PIIBEG+FranklinGothic-Book>+77.glyph<c=9,font=/PIIBEG+FranklinGothic-Book> 7D: $D<H7IJHK9JKH; 7I 7 .;HL?9; glyph<c=8,font=/PIIBEG+FranklinGothic-Book>$77.glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>H;7A:EMDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?DL7I?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9EHHKFJ?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> :;IJHK9J?EDI 7D:glyph<c=15,font=/PIIBEG+FranklinGothic-Book>EH 8H;79>;I E< EKH J;9>DEBE=O IOIJ;CI EH J>EI; E< EKH 8KI?D;II F7HJD;HIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= EKH 9BEK: J;9>DEBE=?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D:glyph<c=15,font=/PIIBEG+FranklinGothic-Book>EH KD7KJ>EH?P;: 799;II JE EKH :7J7 7D: ?D<EHC7J?ED 9EKB: IK8@;9J KI JE B?78?B?JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> D;=7J?L;BO ?CF79J EKH 8KI?D;II EF;H7J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D:glyph<c=15,font=/PIIBEG+FranklinGothic-Book>EH H;GK?H; H;FB79;C;DJ E< J;9>DEBE=O 7D:glyph<c=15,font=/PIIBEG+FranklinGothic-Book>EH H7DIEC F7OC;DJIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> *KH J;9>DEBE=O IOIJ;CIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= EKH 9BEK: J;9>DEBE=?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9EDJ?DK; JE ?D9H;7I; ?D CKBJ?JK:; 7D: 9ECFB;N?JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9H;7I?D= EKH LKBD;H78?B?JO M>;D 8H;7A:EMDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> C7B?9?EKI ?DJHKI?EDI 7D: H7D:EC 7JJ79AI E99KHglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=31,font=/PIIBEG+FranklinGothic-Book>7J7",
        "metadata": {
            "page": 53
        },
        "id": "120df916-a5ac-4953-9ddf-309648cced9b"
    },
    {
        "page_content": "FH?L79O EH I;9KH?JO 8H;79>;I 7BIE FEI; 7 H?IA J>7J I;DI?J?L; :7J7glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= ?DJ;BB;9JK7B FHEF;HJOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> JH7:; I;9H;JI EH F;HIED7B ?D<EHC7J?ED 8;BED=?D= JE KIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> F7J?;DJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9KIJEC;HI EH EJ>;H 8KI?D;II F7HJD;HIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> C7O 8; ;NFEI;: JE KD7KJ>EH?P;: F;HIEDI EH JE J>; FK8B?9glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=30,font=/PIIBEG+FranklinGothic-Book>O8;Hglyph<c=13,font=/PIIBEG+FranklinGothic-Book>7JJ79AI 7H; ?D9H;7I?D= ?D J>;?H <H;GK;D9Oglyph<c=12,font=/PIIBEG+FranklinGothic-Book> IEF>?IJ?97J?ED 7D: ?DJ;DI?JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: 7H; 8;9EC?D= ?D9H;7I?D=BO :?<<?9KBJ JE :;J;9Jglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>;D J>;O ?CF79J L;D:EHIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9KIJEC;HI EH 9ECF7D?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= L;D:EHIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> IKFFB?;HI 7D: EJ>;H 9ECF7D?;I ?D EKH IKFFBO 9>7?Dglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />;O 7H; E<J;D 97HH?;: EKJ 8O CEJ?L7J;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M;BBglyph<c=13,font=/PIIBEG+FranklinGothic-Book>H;IEKH9;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> IA?BB;: 7D: F;HI?IJ;DJ 79JEHIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= D7J?ED IJ7J;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> EH=7D?P;: 9H?C; =HEKFIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> [>79AJ?L?IJI\\ 7D: ;CFBEO;;I EH 9EDJH79JEHI 79J?D= M?J> 97H;B;II EH C7B?9?EKI ?DJ;DJglyph<c=14,font=/PIIBEG+FranklinGothic-Book> \";EFEB?J?97B ?DIJ78?B?JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= J>7J H;B7J;: JE -KII?7glyph<c=7,font=/PIIBEG+FranklinGothic-Book>I ?DL7I?ED E< 0AH7?D; C7O ?D9H;7I; 9O8;Hglyph<c=13,font=/PIIBEG+FranklinGothic-Book> 7JJ79AIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>O8;Hglyph<c=13,font=/PIIBEG+FranklinGothic-Book>7JJ79AI ?D9BK:; :;FBEOC;DJ E< >7HC<KB C7BM7H; 7D: A;O BE==;HIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H7DIECM7H;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 :;D?7Bglyph<c=13,font=/PIIBEG+FranklinGothic-Book>E<glyph<c=13,font=/PIIBEG+FranklinGothic-Book>I;HL?9; 7JJ79Aglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 C7B?9?EKI M;8I?J;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; KI; E< IE9?7B ;D=?D;;H?D= 7D: EJ>;H C;7DI JE 7<<;9J J>; 9ED<?:;DJ?7B?JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?DJ;=H?JO 7D: 7L7?B78?B?JO E< EKH J;9>DEBE=O IOIJ;CI 7D: :7J7glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>O8;Hglyph<c=13,font=/PIIBEG+FranklinGothic-Book>7JJ79AI 7BIE ?D9BK:; C7DK<79JKH?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> >7H:M7H; EH IE<JM7H; IKFFBO 9>7?D 7JJ79AIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> 9EKB: 97KI; 7 :;B7O ?D J>; C7DK<79JKH?D= E< FHE:K9JI EH FHE:K9JI FHE:K9;: <EH 9EDJH79J C7DK<79JKH?D= EH B;7: JE 7 :7J7 FH?L79O EH I;9KH?JO 8H;79>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> *KH A;O 8KI?D;II F7HJD;HI <79; I?C?B7H H?IAI 7D: 7DO I;9KH?JO 8H;79> E< J>;?H IOIJ;CI 9EKB: 7:L;HI;BO 7<<;9J EKH I;9KH?JO FEIJKH;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D 7::?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> EKH ?D9H;7I;: KI; E< 9BEK: J;9>DEBE=?;I >;?=>J;DI J>;I; 7D: EJ>;H EF;H7J?ED7B H?IAIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: 7DO <7?BKH; 8O 9BEK: EH EJ>;H J;9>DEBE=O I;HL?9; FHEL?:;HI JE 7:;GK7J;BO I7<;=K7H: J>;?H IOIJ;CI 7D: FH;L;DJ 9O8;Hglyph<c=13,font=/PIIBEG+FranklinGothic-Book>7JJ79AI 9EKB: :?IHKFJ EKH EF;H7J?EDI 7D: H;IKBJ ?D C?I7FFHEFH?7J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9EHHKFJ?ED EH BEII E< 9ED<?:;DJ?7B EH FHEFH?;JO ?D<EHC7J?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n2>?B; M; 9EDJ?DK; JE 8K?B: 7D: ?CFHEL; EKH IOIJ;CI 7D: ?D<H7IJHK9JKH;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= EKH 8KI?D;II 9EDJ?DK?JO FB7DIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>;H; 97D 8; DE 7IIKH7D9; J>7J EKH ;<<EHJI M?BB FH;L;DJ 8H;7A:EMDI EH 8H;79>;I ?D EKH IOIJ;CI J>7J 9EKB: 7:L;HI;BO 7<<;9J EKH 8KI?D;II 7D: EF;H7J?EDI 7D:glyph<c=15,font=/PIIBEG+FranklinGothic-Book>EH H;IKBJ ?D J>; BEII E< 9H?J?97B EH I;DI?J?L; ?D<EHC7J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> 9EKB: H;IKBJ ?D <?D7D9?7Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> B;=7Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> EF;H7J?ED7B EH H;FKJ7J?ED7B >7HC JE KIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> BEII E< 9ECF;J?J?L; 7:L7DJ7=; EH BEII E< 9EDIKC;H 9ED<?:;D9;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> *KH B?78?B?JO ?DIKH7D9; C7O DEJ 8; IK<<?9?;DJ ?D JOF; EH 7CEKDJ JE 9EL;H KI 7=7?DIJ 9B7?CI H;B7J;: JE I;9KH?JO 8H;79>;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9O8;Hglyph<c=13,font=/PIIBEG+FranklinGothic-Book>7JJ79AI 7D: EJ>;H H;B7J;: 8H;79>;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n-;=KB7JEHI 7H; 9EDI?:;H?D= D;M 9O8;H I;9KH?JO H;=KB7J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> !EH ;N7CFB;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; . glyph<c=30,font=/PIIBEG+FranklinGothic-Book> >7I FHEFEI;: 7C;D:C;DJI JE ?JI :?I9BEIKH; HKB;I H;=7H:?D= 9O8;H I;9KH?JO H?IA C7D7=;C;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> IJH7J;=Oglyph<c=12,font=/PIIBEG+FranklinGothic-Book> =EL;HD7D9; 7D: ?D9?:;DJ H;FEHJ?D= 8O FK8B?9 9ECF7D?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />;I; FHEFEI;: H;=KB7J?EDI C7O ?CF79J J>; C7DD;H ?D M>?9> M; EF;H7J;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n-;=KB7JEHI 7H; ?CFEI?D= D;M :7J7 FH?L79O 7D: I;9KH?JO H;GK?H;C;DJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= D;M 7D: =H;7J;H CED;J7HO <?D;I <EH FH?L79O L?EB7J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> !EH ;N7CFB;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>;  glyph<c=14,font=/PIIBEG+FranklinGothic-Book>0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>^I \";D;H7B glyph<c=31,font=/PIIBEG+FranklinGothic-Book>7J7 +HEJ;9J?ED -;=KB7J?ED ;IJ78B?I>;: H;=KB7J?EDI H;=7H:?D= J>; >7D:B?D= E< F;HIED7B :7J7glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: FHEL?:;I 7D ;D<EH9;C;DJ 7KJ>EH?JO 7D: ?CFEI;I B7H=; F;D7BJ?;I <EH DED9ECFB?7D9;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> );M 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> :7J7 FH?L79O 7D: I;9KH?JO B7MIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> IK9> 7I J>; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>7B?<EHD?7 glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EDIKC;H +H?L79O glyph<c=28,font=/PIIBEG+FranklinGothic-Book>9J glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=30,font=/PIIBEG+FranklinGothic-Book>+glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: EJ>;HI J>7J C7O 8; F7II;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> I?C?B7HBO ?DJHE:K9; H;GK?H;C;DJI M?J> H;IF;9J JE F;HIED7B ?D<EHC7J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: DEDglyph<c=13,font=/PIIBEG+FranklinGothic-Book> 9ECFB?7D9; M?J> J>; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=30,font=/PIIBEG+FranklinGothic-Book>+glyph<c=28,font=/PIIBEG+FranklinGothic-Book> C7O H;IKBJ ?D B?78?B?JO J>HEK=> FH?L7J; 79J?EDI glyph<c=8,font=/PIIBEG+FranklinGothic-Book>IK8@;9J JE IJ7JKJEH?BO :;<?D;: :7C7=;I ?D J>; ;L;DJ E< 9;HJ7?D :7J7 8H;79>;Iglyph<c=9,font=/PIIBEG+FranklinGothic-Book> 7D: ;D<EH9;C;DJglyph<c=14,font=/PIIBEG+FranklinGothic-Book> !7?BKH; JE 9ECFBO M?J> J>;I; 9KHH;DJ 7D: <KJKH; B7MIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FEB?9?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D:KIJHO IJ7D:7H:I EH B;=7B E8B?=7J?EDI EH 7DO I;9KH?JO ?D9?:;DJ H;IKBJ?D= ?D J>; KD7KJ>EH?P;: 799;II JEglyph<c=12,font=/PIIBEG+FranklinGothic-Book> EH 79GK?I?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;B;7I; EH JH7DI<;H E< F;HIED7B ?D<EHC7J?ED C7O H;IKBJ ?D =EL;HDC;DJ7B ;D<EH9;C;DJ 79J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> B?J?=7J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> <?D;I 7D: F;D7BJ?;I EH 7:L;HI; FK8B?9?JO 7D: 9EKB: 97KI; EKH 9KIJEC;HI JE BEI; JHKIJ ?D KIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> 9EKB: >7L; 7 C7J;H?7B 7:L;HI; ;<<;9J ED EKH 8KI?D;II 7D: H;IKBJI E< EF;H7J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=25,font=/PIICNA+FranklinGothic-BookItal>\"/6'\"$563*/( *446&4 $06-% 46#45\"/5*\"--: */$3&\"4& 063 $0454glyph<c=5,font=/PIICNA+FranklinGothic-BookItal> -*.*5 4611-: 0' 063 130%6$54 \"/%glyph<c=8,font=/PIICNA+FranklinGothic-BookItal>03 3&%6$& 063 3&7&/6&glyph<c=7,font=/PIICNA+FranklinGothic-BookItal>\n\n/>; FHE9;II E< C7DK<79JKH?D= EKH FHE:K9JI ?I 9ECFB;Nglyph<c=12,font=/PIIBEG+FranklinGothic-Book> >?=>BO H;=KB7J;: 7D: IK8@;9J JE DKC;HEKI H?IAIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D=glyph<c=26,font=/PIIBEG+FranklinGothic-Book>\n\n- T &7A9A =4 &3:7/<13 =< (67@2glyph<c=8,font=/PIIBDE+FranklinGothic-BookItal>$/@B73A /<2 '7<5:3 '=C@13 $@=D723@Aglyph<c=9,font=/PIIBDE+FranklinGothic-BookItal> 2; H;BO ED J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJO IKFFB?;HI 7D: C7DK<79JKH;HI <EH C7DO 7IF;9JI E< EKH C7DK<79JKH?D= FHE9;II <EH EKH FHE:K9JI 7D: FHE:K9J 97D:?:7J;I ?D9BK:?D= 10( -$/4glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D IEC; 97I;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> :K; JE J>; KD?GK; C7DD;H ?D M>?9> EKH FHE:K9JI 7H; C7DK<79JKH;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; H;BO ED I?D=B; IEKH9; FHEL?:;HI E< H7M C7J;H?7BI 7D: C7DK<79JKH?D= IKFFB?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />;I; J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJ?;I 7H; ?D:;F;D:;DJ ;DJ?J?;I IK8@;9J JE J>;?H EMD KD?GK; EF;H7J?ED7B 7D: <?D7D9?7B H?IAI J>7J 7H; EKJI?:; E< EKH 9EDJHEBglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />;I; J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJ?;I C7O DEJ F;H<EHC J>;?H E8B?=7J?EDI ?D 7 J?C;BO 7D: 9EIJglyph<c=13,font=/PIIBEG+FranklinGothic-Book>;<<;9J?L; C7DD;H EH ?D 9ECFB?7D9; M?J> 7FFB?978B; H;=KB7J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: J>;O C7O 8; KD78B; EH KDM?BB?D= JE ?D9H;7I; FHE:K9J?ED 97F79?JO 9ECC;DIKH7J; M?J> :;C7D: <EH EKH ;N?IJ?D= EH <KJKH; FHE:K9JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> !?D:?D= 7BJ;HD7J?L; FHEL?:;HI 9EKB: J7A; 7 I?=D?<?97DJ 7CEKDJ E< J?C; 7D: ?DLEBL; I?=D?<?97DJ ;NF;DI; :K; JE J>; IF;9?7B?P;: D7JKH; E< J>; I;HL?9;I 7D: J>; D;;: JE E8J7?D H;=KB7JEHO 7FFHEL7B E< 7DO I?=D?<?97DJ 9>7D=;I JE EKH IKFFB?;HI EH C7DK<79JKH?D= C;J>E:Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; 97DDEJ 8; 9;HJ7?D J>7J M; 9EKB: H;79> 7=H;;C;DJ M?J> 7BJ;HD7J?L; FHEL?:;HI EH J>7J J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> EH EJ>;H H;=KB7JEHO 7KJ>EH?J?;I MEKB: 7FFHEL; EKH KI; E< IK9> 7BJ;HD7J?L;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> !KHJ>;HCEH;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> <79JEHI IK9> 7I J>; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>*1$glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book> F7D:;C?9glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M;7J>;H ;L;DJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> B78EH EH H7M C7J;H?7B I>EHJ7=;I 7D: EJ>;H IKFFBO 9>7?D :?IHKFJ?EDI 9EKB: H;IKBJ ?D :?<<?9KBJ?;I 7D: :;B7OI ?D C7DK<79JKH?D= EKH FHE:K9JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> 9EKB: >7L; 7D 7:L;HI; ?CF79J ED EKH H;IKBJI ?D EF;H7J?EDI EH H;IKBJ ?D FHE:K9J I>EHJ7=;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>",
        "metadata": {
            "page": 54
        },
        "id": "0d2443ae-3660-406b-a5b4-0b27e931b324"
    },
    {
        "page_content": "- T glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>:=0/: glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>C:9 'C>>:G &7A9Aglyph<c=9,font=/PIIBDE+FranklinGothic-BookItal> 2; H;BO ED EKH C7DK<79JKH?D= <79?B?J?;I <EH J>; FHE:K9J?ED E< :HK= IK8IJ7D9; <EH EKH B7H=; CEB;9KB; FHE:K9JI 7D: FHE:K9J 97D:?:7J;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> *KH =BE87B 8KBA IKFFBO E< J>;I; FHE:K9JI 7D: FHE:K9J 97D:?:7J;I :;F;D:I ED J>; KD?DJ;HHKFJ;: 7D: ;<<?9?;DJ EF;H7J?ED E< J>;I; <79?B?J?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> 9EKB: 8; 7:L;HI;BO 7<<;9J;: 8O ;GK?FC;DJ <7?BKH;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> B78EH EH H7M C7J;H?7B I>EHJ7=;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FK8B?9 >;7BJ> ;F?:;C?9Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> D7JKH7B :?I7IJ;HIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FEM;H <7?BKH;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9O8;Hglyph<c=13,font=/PIIBEG+FranklinGothic-Book>7JJ79AI 7D: C7DO EJ>;H <79JEHIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- T &7A9A &3:/B7<5 B= glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=;>:7/<13 E7B6 1C@@3<B glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>!$ glyph<c=5,font=/PIIBDE+FranklinGothic-BookItal>1glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>!$glyph<c=6,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal> 2; 7D: EKH J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJO FHEL?:;HI 7H; =;D;H7BBO H;GK?H;: JE C7?DJ7?D 9ECFB?7D9; M?J> 9\"(+ 7D: EJ>;H IJH?D=;DJ H;GK?H;C;DJI 7D: 7H; IK8@;9J JE ?DIF;9J?EDI 8O J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 7D: EJ>;H H;=KB7JEHO 7KJ>EH?J?;I JE 9ED<?HC 9ECFB?7D9;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>DO :;B7Oglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?DJ;HHKFJ?ED EH EJ>;H ?IIK;I J>7J 7H?I; ?D J>; C7DK<79JKH;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> <?BBglyph<c=13,font=/PIIBEG+FranklinGothic-Book><?D?I>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> F79A7=?D= EH IJEH7=; E< EKH FHE:K9JI 7I 7 H;IKBJ E< 7 <7?BKH; E< EKH <79?B?J?;I EH EF;H7J?EDI EH J>EI; E< J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJ?;I JE H;9;?L; H;=KB7JEHO 7FFHEL7B EH F7II 7DO H;=KB7JEHO 7=;D9O ?DIF;9J?ED 9EKB: I?=D?<?97DJBO ?CF7?H EKH 78?B?JO JE :;L;BEF 7D: 9ECC;H9?7B?P; EKH FHE:K9JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> .?=D?<?97DJ DED9ECFB?7D9; 9EKB: 7BIE H;IKBJ ?D J>; ?CFEI?J?ED E< CED;J7HO F;D7BJ?;I EH EJ>;H 9?L?B EH 9H?C?D7B I7D9J?EDI 7D: :7C7=; EKH H;FKJ7J?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n- T &7A9 =4 $@=2C1B  =AAglyph<c=9,font=/PIIBDE+FranklinGothic-BookItal> />; C7DK<79JKH?D= FHE9;II <EH EKH FHE:K9JI ?I ;NJH;C;BO IKI9;FJ?8B; JE FHE:K9J BEII :K; JE 9EDJ7C?D7J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> EN?:7J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ;GK?FC;DJ <7?BKH; EH ?CFHEF;H ?DIJ7BB7J?ED EH EF;H7J?ED E< ;GK?FC;DJ EH L;D:EH EH EF;H7JEH ;HHEHglyph<c=14,font=/PIIBEG+FranklinGothic-Book> L;D C?DEH :;L?7J?EDI <HEC DEHC7B C7DK<79JKH?D= FHE9;II;I 9EKB: H;IKBJ ?D H;:K9;: FHE:K9J?ED O?;B:Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FHE:K9J :;<;9JI 7D: EJ>;H IKFFBO :?IHKFJ?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $< C?9HE8?7Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> L?H7B EH EJ>;H 9EDJ7C?D7J?EDI 7H; :?I9EL;H;: ?D EKH FHE:K9JI EH C7DK<79JKH?D= <79?B?J?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; C7O D;;: JE 9BEI; EKH C7DK<79JKH?D= <79?B?J?;I <EH 7D ;NJ;D:;: F;H?E: E< J?C; JE ?DL;IJ?=7J; 7D: H;C;:?7J; J>; 9EDJ7C?D7DJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=28,font=/PIIBEG+FranklinGothic-Book>DO 7:L;HI; :;L;BEFC;DJI 7<<;9J?D= EKH C7DK<79JKH?D= EF;H7J?EDI EH J>; EF;H7J?EDI E< EKH J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJO IKFFB?;HI 7D: C7DK<79JKH;HI C7O H;IKBJ ?D I>?FC;DJ :;B7OIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?DL;DJEHO I>EHJ7=;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> BEJ <7?BKH;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FHE:K9J M?J>:H7M7BI EH H;97BBI EH EJ>;H ?DJ;HHKFJ?EDI ?D J>; 9ECC;H9?7B IKFFBO E< EKH FHE:K9JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; C7O 7BIE >7L; JE J7A; ?DL;DJEHO MH?J;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>E<<I 7D: ?D9KH EJ>;H 9>7H=;I 7D: ;NF;DI; <EH FHE:K9JI J>7J <7?B JE C;;J IF;9?<?97J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> KD:;HJ7A; 9EIJBO H;C;:?7J?ED ;<<EHJI EH I;;A CEH; 9EIJBO C7DK<79JKH?D= 7BJ;HD7J?L;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> .K9> :;L;BEFC;DJI 9EKB: ?D9H;7I; EKH C7DK<79JKH?D= 9EIJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 97KI; KI JE BEI; H;L;DK; EH C7HA;J I>7H; 7I F7J?;DJI 7D: F>OI?9?7DI JKHD JE 9ECF;J?D= J>;H7F;KJ?9Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> :?C?D?I> EKH FHE<?J78?B?JO EH :7C7=; EKH H;FKJ7J?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n$D 7::?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7BJ>EK=> M; >7L; 8KI?D;II 9EDJ?DK?JO FB7DI JE H;:K9; J>; FEJ;DJ?7B <EH C7DK<79JKH?D= :?IHKFJ?EDI EH :;B7OI 7D: H;:K9; J>; I;L;H?JO E< 7 :?IHKFJ?L; ;L;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>;H; ?I DE =K7H7DJ;; J>7J J>;I; FB7DI M?BB 8; 7:;GK7J;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> 9EKB: 7:L;HI;BO 7<<;9J EKH 8KI?D;II 7D: EF;H7J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=25,font=/PIICNA+FranklinGothic-BookItal>\"/\"(&.&/5 \"/% 05)&3 1&340//&- $)\"/(&4 .\": %*43615 063 01&3\"5*0/4glyph<c=5,font=/PIICNA+FranklinGothic-BookItal> \"/% 8& .\": )\"7& %*''*$6-5: 3&5\"*/*/( 1&340//&03 \"553\"$5*/( \"/% 3&5\"*/*/( 26\"-*'*&% 3&1-\"$&.&/54 0/ \" 5*.&-: #\"4*4 '03 5)& .\"/\"(&.&/5 \"/% 05)&3 1&340//&- 8)0 .\": -&\"7& 5)& glyph<c=16,font=/PIICNA+FranklinGothic-BookItal>0.1\"/:glyph<c=7,font=/PIICNA+FranklinGothic-BookItal>\n\nglyph<c=30,font=/PIIBEG+FranklinGothic-Book>>7D=;I ?D C7D7=;C;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> EJ>;H F;HIEDD;B 7D: EKH EL;H7BB H;J;DJ?ED H7J; C7O :?IHKFJ EKH 8KI?D;IIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: 7DO IK9> :?IHKFJ?ED 9EKB: 7:L;HI;BO 7<<;9J EKH EF;H7J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FHE=H7CIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> =HEMJ>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> <?D7D9?7B 9ED:?J?ED EH H;IKBJI E< EF;H7J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> );M C;C8;HI E< C7D7=;C;DJ C7O >7L; :?<<;H;DJ F;HIF;9J?L;I ED FHE=H7CI 7D: EFFEHJKD?J?;I <EH EKH 8KI?D;IIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> C7O 97KI; KI JE <E9KI ED D;M EFFEHJKD?J?;I EH H;:K9; EH 9>7D=; ;CF>7I?I ED EKH ;N?IJ?D= FHE=H7CIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n*KH IK99;II ?I :;F;D:;DJ KFED EKH 78?B?JO JE 7JJH79J 7D: H;J7?D GK7B?<?;: C7D7=;C;DJ 7D: EJ>;H F;HIEDD;B ?D 7 >?=>BO 9ECF;J?J?L; ;DL?HEDC;DJglyph<c=14,font=/PIIBEG+FranklinGothic-Book> ,K7B?<?;: ?D:?L?:K7BI 7H; ?D >?=> :;C7D:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: M; C7O ?D9KH I?=D?<?97DJ 9EIJI JE 7JJH79J EH H;J7?D J>;Cglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; C7O <79; :?<<?9KBJO ?D 7JJH79J?D= 7D: H;J7?D?D= J7B;DJ <EH 7 DKC8;H E< H;7IEDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= C7D7=;C;DJ 9>7D=;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; KD:;HF;H<EHC7D9; EH :?I9EDJ?DK7J?ED E< ED; EH CEH; C7HA;J;: EH B7J; IJ7=; FHE=H7CIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;9HK?JC;DJ 8O 9ECF;J?JEHI EH 9>7D=;I ?D J>; EL;H7BB B78EH C7HA;Jglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D 7::?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9>7D=;I ?D EKH EH=7D?P7J?ED7B IJHK9JKH; EH ?D EKH <B;N?8B; MEHA?D= 7HH7D=;C;DJI 9EKB: ?CF79J ;CFBEO;;Iglyph<c=7,font=/PIIBEG+FranklinGothic-Book> FHE:K9J?L?JO 7D: CEH7B; 7I M;BB 7I EKH 78?B?JO JE 7JJH79Jglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;J7?D 7D: CEJ?L7J; ;CFBEO;;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; 97DDEJ ;DIKH; J>7J M; M?BB 8; 78B; JE >?H; EH H;J7?D J>; F;HIEDD;B D;9;II7HO <EH EKH EF;H7J?EDI EH J>7J J>; BEII E< 7DO F;HIEDD;B M?BB DEJ >7L; 7 C7J;H?7B ?CF79J ED EKH <?D7D9?7B 9ED:?J?ED 7D: H;IKBJI E< EF;H7J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=22,font=/PIICNA+FranklinGothic-BookItal>' 8& '\"*- 50 $0.1-: 8*5) 5)& &95&/4*7& -&(\"- \"/% 3&(6-\"503: 3&26*3&.&/54 \"''&$5*/( 5)& )&\"-5) $\"3& */%6453:glyph<c=5,font=/PIICNA+FranklinGothic-BookItal> 8& $06-% '\"$& */$3&\"4&% $0454glyph<c=5,font=/PIICNA+FranklinGothic-BookItal> 1&/\"-5*&4 \"/% \" -044 0' #64*/&44glyph<c=7,font=/PIICNA+FranklinGothic-BookItal>\n\n*KH 79J?L?J?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: J>; 79J?L?J?;I E< EKH 9EBB78EH7JEHIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> :?IJH?8KJEHI 7D: EJ>;H J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJO FHEL?:;HIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7H; IK8@;9J JE ;NJ;DI?L; =EL;HDC;DJ H;=KB7J?ED 7D: EL;HI?=>J ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 7D: ?D <EH;?=D @KH?I:?9J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: 7H; IK8@;9J JE 9>7D=; 7D: ;LEBL?D= ?DJ;HFH;J7J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> 9EKB: H;GK?H; KI JE ?D9KH IK8IJ7DJ?7B 9EIJI 7IIE9?7J;: M?J> 9ECFB?7D9; EH JE 7BJ;H ED; EH CEH; E< EKH 8KI?D;II FH79J?9;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 7D: 9ECF7H78B; <EH;?=D 7=;D9?;I :?H;9JBO H;=KB7J; C7DO E< EKH CEIJ 9H?J?97B 8KI?D;II 79J?L?J?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= J>; 9ED:K9J E< FH;9B?D?97B 7D: 9B?D?97B IJK:?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FHE:K9J C7DK<79JKH?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7:L;HJ?I?D= 7D: FHECEJ?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FHE:K9J :?IJH?8KJ?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7:L;HI; ;L;DJ H;FEHJ?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> FHE:K9J H?IA C7D7=;C;DJ 7D: EKH 9ECFB?7D9; M?J> =EE: FH79J?9; GK7B?JO =K?:;B?D;I 7D: H;=KB7J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> *KH ?DJ;H79J?EDI M?J> F>OI?9?7DI 7D: EJ>;H >;7BJ>",
        "metadata": {
            "page": 55
        },
        "id": "21d39bf7-e047-48b1-9af4-5db9323220c7"
    },
    {
        "page_content": "97H; FHEL?:;HI J>7J FH;I9H?8; EH FKH9>7I; EKH FHE:K9JI 7H; 7BIE IK8@;9J JE =EL;HDC;DJ H;=KB7J?ED :;I?=D;: JE FH;L;DJ <H7K: 7D: 78KI; ?D J>; I7B; 7D: KI; E< FHE:K9JI 7D: FB79; I?=D?<?97DJ H;IJH?9J?EDI ED J>; C7HA;J?D= FH79J?9;I E< >;7BJ> 97H; 9ECF7D?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> #;7BJ> 97H; 9ECF7D?;I 7H; <79?D= >;?=>J;D;: I9HKJ?DO E< J>;?H H;B7J?EDI>?FI M?J> >;7BJ> 97H; FHEL?:;HI 7D: >7L; 8;;D J>; J7H=;J E< B7MIK?JI 7D: ?DL;IJ?=7J?EDI 7BB;=?D= L?EB7J?EDI E< =EL;HDC;DJ H;=KB7J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= 9B7?CI 7II;HJ?D= IK8C?II?ED E< ?D9EHH;9J FH?9?D= ?D<EHC7J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?CF;HC?II?8B; E<<glyph<c=13,font=/PIIBEG+FranklinGothic-Book>B78;B FHECEJ?ED E< F>7HC79;KJ?97B FHE:K9JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> F7OC;DJI ?DJ;D:;: JE ?D<BK;D9; J>; H;<;HH7B E< >;7BJ> 97H; 8KI?D;IIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> IK8C?II?ED E< <7BI; 9B7?CI <EH =EL;HDC;DJ H;?C8KHI;C;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7DJ?JHKIJ L?EB7J?EDI EH L?EB7J?EDI H;B7J;: JE ;DL?HEDC;DJ7B C7JJ;HIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />;H; ?I 7BIE ;D>7D9;: I9HKJ?DO E< 9ECF7DOglyph<c=13,font=/PIIBEG+FranklinGothic-Book>IFEDIEH;: F7J?;DJ 7II?IJ7D9; FHE=H7CIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= ?DIKH7D9; FH;C?KC 7D: 9Eglyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7O 7II?IJ7D9; FHE=H7CI 7D: :ED7J?EDI JE J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJO 9>7H?J?;I J>7J FHEL?:; IK9> 7II?IJ7D9;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> =EL;HDC;DJ >7I 9>7BB;D=;: IEC; E< EKH :ED7J?EDI JE J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJO 9>7H?J?;I J>7J FHEL?:; F7J?;DJ 7II?IJ7D9;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $< M;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> EH EKH L;D:EHI EH :ED7J?ED H;9?F?;DJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7H; <EKD: JE <7?B JE 9ECFBO M?J> H;B;L7DJ B7MIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;=KB7J?EDI EH =EL;HDC;DJ =K?:7D9; ?D J>; EF;H7J?ED E< J>;I; FHE=H7CIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 9EKB: 8; IK8@;9J JE I?=D?<?97DJ <?D;I EH F;D7BJ?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> -?IAI H;B7J?D= JE 9ECFB?7D9; M?J> B7MI 7D: H;=KB7J?EDI C7O 8; >;?=>J;D;: 7I M; 9EDJ?DK; JE ;NF7D: EKH =BE87B EF;H7J?EDI 7D: ;DJ;H D;M J>;H7F;KJ?9 7H;7I M?J> :?<<;H;DJ F7J?;DJ FEFKB7J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> C7O >7L; :?<<;H;DJ FHE:K9J :?IJH?8KJ?ED C;J>E:Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> C7HA;J?D= FHE=H7CI EH F7J?;DJ 7II?IJ7D9; FHE=H7CI <HEC J>EI; M; 9KHH;DJBO KJ?B?P; EH IKFFEHJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=30,font=/PIIBEG+FranklinGothic-Book>ED:?J?EDI 7D: H;=KB7J?EDI =EL;HD?D= J>; >;7BJ> 97H; ?D:KIJHO 7H; IK8@;9J JE 9>7D=;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M?J> FEII?8B; H;JHE79J?L; ;<<;9Jglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D=glyph<c=26,font=/PIIBEG+FranklinGothic-Book>\n\n- T D;M B7MIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;=KB7J?EDI EH @K:?9?7B :;9?I?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> EH D;M ?DJ;HFH;J7J?EDI E< ;N?IJ?D= B7MIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;=KB7J?EDI EH @K:?9?7B :;9?I?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;B7J;: JE >;7BJ> 97H; 7L7?B78?B?JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FH?9?D= EH C7HA;J?D= FH79J?9;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9ECFB?7D9; M?J> ;CFBEOC;DJ FH79J?9;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> C;J>E: E< :;B?L;HOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> F7OC;DJ <EH >;7BJ> 97H; FHE:K9JI 7D: I;HL?9;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9ECFB?7D9; M?J> >;7BJ> ?D<EHC7J?ED 7D: :7J7 FH?L79O 7D: I;9KH?JO B7MI 7D: H;=KB7J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> JH79A?D= 7D: H;FEHJ?D= F7OC;DJI 7D: EJ>;H JH7DI<;HI E< L7BK; C7:; JE F>OI?9?7DI 7D: J;79>?D= >EIF?J7BIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ;NJ;DI?L; 7DJ?glyph<c=13,font=/PIIBEG+FranklinGothic-Book>8H?8;HO 7D: 7DJ?glyph<c=13,font=/PIIBEG+FranklinGothic-Book>9EHHKFJ?ED FHE>?8?J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FHE:K9J I;H?7B?P7J?ED 7D: B78;B?D= H;GK?H;C;DJI 7D: KI;: FHE:K9J J7A;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>879A H;GK?H;C;DJIglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T 9>7D=;I ?D J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 7D: <EH;?=D H;=KB7JEHO 7FFHEL7B FHE9;II;I EH F;HIF;9J?L;I J>7J C7O :;B7O EH FH;L;DJ J>; 7FFHEL7B E< D;M FHE:K9JI 7D: H;IKBJ ?D BEIJ C7HA;J EFFEHJKD?JOglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T =EL;HDC;DJ I>KJ:EMDI EH H;BE97J?EDI C7O H;IKBJ ?D :;B7OI JE J>; H;L?;M 7D: 7FFHEL7B FHE9;IIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> IBEM?D= J>; J?C; D;9;II7HO <EH D;M :HK= 97D:?:7J;I JE 8; H;L?;M;: 7D:glyph<c=15,font=/PIIBEG+FranklinGothic-Book>EH 7FFHEL;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> C7O 7:L;HI;BO 7<<;9J EKH 8KI?D;IIglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T H;GK?H;C;DJI J>7J FHEL?:; <EH ?D9H;7I;: JH7DIF7H;D9O E< 9B?D?97B JH?7B H;IKBJI 7D: GK7B?JO :7J7glyph<c=12,font=/PIIBEG+FranklinGothic-Book> IK9> 7I J>; (glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=7,font=/PIIBEG+FranklinGothic-Book>I 9B?D?97B JH7DIF7H;D9O FEB?9Oglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> 9EKB: ?CF79J EKH 78?B?JO JE FHEJ;9J JH7:; I;9H;JI 7D: 9ECF;J?J?L;BOglyph<c=13,font=/PIIBEG+FranklinGothic-Book> I;DI?J?L; ?D<EHC7J?ED 9EDJ7?D;: ?D 7FFHEL7B 7FFB?97J?EDI EH 9EKB: 8; C?I?DJ;HFH;J;: B;7:?D= JE H;FKJ7J?ED7B :7C7=;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> C?IF;H9;FJ?ED EH B;=7B 79J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> 9EKB: >7HC EKH 8KI?D;IIglyph<c=27,font=/PIIBEG+FranklinGothic-Book> 7D:\n- T 9>7D=;I ?D !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 7D: <EH;?=D H;=KB7J?EDI J>7J C7O H;GK?H; 7::?J?ED7B I7<;JO CED?JEH?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> B78;B?D= 9>7D=;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;IJH?9J?EDI ED FHE:K9J :?IJH?8KJ?ED EH KI; EH EJ>;H C;7IKH;I 7<J;H J>; ?DJHE:K9J?ED E< EKH FHE:K9JI JE C7HA;Jglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> 9EKB: ?D9H;7I; EKH 9EIJI E< :E?D= 8KI?D;IIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7:L;HI;BO 7<<;9J J>; <KJKH; F;HC?JJ;: KI;I E< 7FFHEL;: FHE:K9JI EH EJ>;HM?I; 7:L;HI;BO 7<<;9J J>; C7HA;J <EH EKH FHE:K9JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n1?EB7J?EDI E< =EL;HDC;DJ7B H;=KB7J?ED C7O 8; FKD?I>78B; 8O 9H?C?D7B 7D: 9?L?B I7D9J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= <?D;I 7D: 9?L?B CED;J7HO F;D7BJ?;I 7D: ;N9BKI?ED <HEC F7HJ?9?F7J?ED ?D =EL;HDC;DJ FHE=H7CIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= (;:?97H; 7D: (;:?97?:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7I M;BB 7I 7=7?DIJ ;N;9KJ?L;I EL;HI;;?D= EKH 8KI?D;IIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; 9EKB: 7BIE 8; H;GK?H;: JE H;F7O 7CEKDJI M; H;9;?L;: <HEC =EL;HDC;DJ F7OEHI EH F7O 7::?J?ED7B H;87J;I 7D: ?DJ;H;IJ ?< M; 7H; <EKD: JE >7L; C?I97B9KB7J;: J>; FH?9?D= ?D<EHC7J?ED M; IK8C?JJ;: JE J>; =EL;HDC;DJglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D 7::?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> B;=7B FHE9;;:?D=I 7D: ?DL;IJ?=7J?EDI 7H; ?D>;H;DJBO KDFH;:?9J78B;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: B7H=; @K:=C;DJI EH I;JJB;C;DJI IEC;J?C;I E99KHglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2>?B; M; 8;B?;L; J>7J M; >7L; 7FFHEFH?7J; 9ECFB?7D9; 9EDJHEBIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FEB?9?;I 7D: FHE9;:KH;I ?D FB79; JE 9ECFBO M?J> J>; B7MI EH H;=KB7J?EDI E< J>; @KH?I:?9J?EDI ?D M>?9> M; EF;H7J;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>;H; ?I 7 H?IA J>7J 79JI 9ECC?JJ;: 8O EKH ;CFBEO;;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7=;DJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> :?IJH?8KJEHIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9EBB78EH7JEHI EH J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book> F7HJO FHEL?:;HI C?=>J L?EB7J; IK9> B7MI EH H;=KB7J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2>;J>;H EH DEJ M; >7L; 9ECFB?;: M?J> J>; B7Mglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D ?DL;IJ?=7J?ED EH B?J?=7J?ED H;B7J;: JE 7BB;=;: KDB7M<KB 9ED:K9J 9EKB: ?D9H;7I; EKH ;NF;DI;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> :7C7=; EKH H;FKJ7J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> :?L;HJ C7D7=;C;DJ J?C; 7D: 7JJ;DJ?ED 7D: 7:L;HI;BO 7<<;9J EKH 8KI?D;IIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=27,font=/PIICNA+FranklinGothic-BookItal>63 4\"-&4 \"/% 01&3\"5*0/4 \"3& 46#+&$5 50 5)& 3*4,4 0' %0*/( #64*/&44 */5&3/\"5*0/\"--:glyph<c=7,font=/PIICNA+FranklinGothic-BookItal>\n\n2; 7H; ?D9H;7I?D= EKH FH;I;D9; ?D ?DJ;HD7J?ED7B C7HA;JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> IK8@;9J?D= KI JE C7DO H?IAI J>7J 9EKB: 7:L;HI;BO 7<<;9J EKH 8KI?D;II 7D: H;L;DK;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />;H; ?I DE =K7H7DJ;; J>7J EKH ;<<EHJI 7D: IJH7J;=?;I JE ;NF7D: I7B;I ?D ?DJ;HD7J?ED7B C7HA;JI M?BB IK99;;:glyph<c=14,font=/PIIBEG+FranklinGothic-Book> C;H=?D= C7HA;J 9EKDJH?;I C7O 8; ;IF;9?7BBO LKBD;H78B; JE F;H?E:I E< =BE87B 7D: BE97B FEB?J?97Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> B;=7Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;=KB7JEHO 7D: <?D7D9?7B ?DIJ78?B?JO 7D: C7O >7L; 7 >?=>;H ?D9?:;D9; E< 9EHHKFJ?ED 7D: <H7K:KB;DJ 8KI?D;II FH79J?9;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>;HJ7?D 9EKDJH?;I C7O H;GK?H; BE97B 9B?D?97B JH?7B :7J7 7I F7HJ E< J>; :HK= H;=?IJH7J?ED FHE9;II ?D 7::?J?ED JE =BE87B 9B?D?97B JH?7BIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> 97D 7:: JE EL;H7BB :HK= :;L;BEFC;DJ 7D: H;=?IJH7J?ED J?C;B?D;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; C7O 7BIE 8; H;GK?H;:",
        "metadata": {
            "page": 56
        },
        "id": "aa3b20c3-0f8a-4292-9fff-5534ae01ca54"
    },
    {
        "page_content": "JE ?D9H;7I; EKH H;B?7D9; ED J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJO 7=;DJI EH :?IJH?8KJEHI 7D: KD<7C?B?7H EF;H7J?EDI 7D: 7HH7D=;C;DJI FH;L?EKIBO KJ?B?P;: 8O 9ECF7D?;I M; 9EBB78EH7J; M?J> EH 79GK?H; ?D ;C;H=?D= C7HA;JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n*KH I7B;I 7D: EF;H7J?EDI 7H; IK8@;9J JE J>; H?IAI E< :E?D= 8KI?D;II ?DJ;HD7J?ED7BBOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D=glyph<c=26,font=/PIIBEG+FranklinGothic-Book>\n\n- T J>; ?CF79J E< FK8B?9 >;7BJ> ;F?:;C?9Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> IK9> 7I J>; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>*1$glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book> F7D:;C?9glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ED J>; =BE87B ;9EDECO 7D: J>; :;B?L;HO E< >;7BJ>97H; JH;7JC;DJIglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T B;II <7LEH78B; ?DJ;BB;9JK7B FHEF;HJO EH EJ>;H 7FFB?978B; B7MIglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T J>; ?D78?B?JO JE E8J7?D D;9;II7HO <EH;?=D H;=KB7JEHO 7FFHEL7BI E< FHE:K9JI ?D 7 J?C;BO C7DD;Hglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T B?C?J7J?EDI 7D: 7::?J?ED7B FH;IIKH;I ED EKH 78?B?JO JE E8J7?D 7D: C7?DJ7?D FHE:K9J FH?9?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;?C8KHI;C;DJ EH H;9;?L; FH?9; ?D9H;7I;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= J>EI; H;IKBJ?D= <HEC =EL;HDC;DJ7B EH H;=KB7JEHO H;GK?H;C;DJIglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T ?D9H;7I;: 9EIJ E< =EE:I :K; JE <79JEHI IK9> 7I ?D<B7J?ED 7D: IKFFBO 9>7?D :?IHKFJ?EDIglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T 7::?J?ED7B 9ECFB;N?JO ?D C7DK<79JKH?D= ?DJ;HD7J?ED7BBOglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T :;B7OI ?D 9B?D?97B JH?7BI H;B7J?D= JE =;EFEB?J?97B ?DIJ78?B?JO H;B7J;: JE -KII?7glyph<c=7,font=/PIIBEG+FranklinGothic-Book>I ?DL7I?ED E< 0AH7?D;glyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T J>; ?D78?B?JO JE IK99;II<KBBO 9ECFB;J; IK8I;GK;DJ EH 9ED<?HC7JEHO 9B?D?97B JH?7BI ?D 9EKDJH?;I M>;H; EKH ;NF;H?;D9; ?I B?C?J;:glyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T BED=;H F7OC;DJ 7D: H;?C8KHI;C;DJ 9O9B;I 7D: KD9;HJ7?DJ?;I H;=7H:?D= J>; 9EBB;9J78?B?JO E< 799EKDJI H;9;?L78B;glyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T <BK9JK7J?EDI ?D <EH;?=D 9KHH;D9O ;N9>7D=; H7J;I J>7J C7O 7:L;HI;BO ?CF79J EKH H;L;DK;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> D;J ?D9EC; 7D: L7BK; E< 9;HJ7?D E< EKH ?DL;IJC;DJIglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T J>; ?CFEI?J?ED E< =EL;HDC;DJ7B 9EDJHEBIglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T :?L;HI; :7J7 FH?L79O 7D: FHEJ;9J?ED H;GK?H;C;DJIglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T ?D9H;7I?D=BO 9ECFB;N IJ7D:7H:I <EH 9ECFBO?D= M?J> <EH;?=D B7MI 7D: H;=KB7J?EDI J>7J C7O :?<<;H IK8IJ7DJ?7BBO <HEC 9EKDJHO JE 9EKDJHO 7D: C7O 9ED<B?9J M?J> 9EHH;IFED:?D= 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> B7MI 7D: H;=KB7J?EDIglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T J>; <7Hglyph<c=13,font=/PIIBEG+FranklinGothic-Book>H;79>?D= 7DJ?glyph<c=13,font=/PIIBEG+FranklinGothic-Book>8H?8;HO 7D: 7DJ?glyph<c=13,font=/PIIBEG+FranklinGothic-Book>9EHHKFJ?ED B;=?IB7J?ED ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>&glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>&glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>H?8;HO glyph<c=28,font=/PIIBEG+FranklinGothic-Book>9J glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: ;BI;M>;H; 7D: ;I97B7J?ED E< ?DL;IJ?=7J?EDI 7D: FHEI;9KJ?EDI FKHIK7DJ JE IK9> B7MIglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T 9ECFB?7D9; M?J> 9ECFB;N ?CFEHJ 7D: ;NFEHJ 9EDJHEB B7MIglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T 9>7D=;I ?D J7N B7MIglyph<c=27,font=/PIIBEG+FranklinGothic-Book> 7D:\n- T J>; ?CFEI?J?ED E< J7H?<<I EH ;C87H=E;I 7D: EJ>;H JH7:; H;IJH?9J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n$D 7::?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> EKH ?DJ;HD7J?ED7B EF;H7J?EDI 7H; IK8@;9J JE H;=KB7J?ED KD:;H 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> B7Mglyph<c=14,font=/PIIBEG+FranklinGothic-Book> !EH ;N7CFB;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> !EH;?=D glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EHHKFJ +H79J?9;I glyph<c=28,font=/PIIBEG+FranklinGothic-Book>9J glyph<c=8,font=/PIIBEG+FranklinGothic-Book>!glyph<c=30,font=/PIIBEG+FranklinGothic-Book>+glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book> FHE>?8?JI 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 9ECF7D?;I 7D: J>;?H H;FH;I;DJ7J?L;I <HEC F7O?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> E<<;H?D= JE F7Oglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FHEC?I?D= JE F7O EH 7KJ>EH?P?D= J>; F7OC;DJ E< 7DOJ>?D= E< L7BK; JE 7DO <EH;?=D =EL;HDC;DJ E<<?9?7Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> =EL;HDC;DJ IJ7<< C;C8;Hglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FEB?J?97B F7HJO EH FEB?J?97B 97D:?:7J; <EH J>; FKHFEI; E< E8J7?D?D= EH H;J7?D?D= 8KI?D;II EH JE EJ>;HM?I; E8J7?D <7LEH78B; JH;7JC;DJ EH ?D<BK;D9; 7 F;HIED MEHA?D= ?D 7D E<<?9?7B 97F79?JOglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D C7DO 9EKDJH?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; >;7BJ> 97H; FHE<;II?ED7BI M; H;=KB7HBO ?DJ;H79J M?J> C7O C;;J J>; !glyph<c=30,font=/PIIBEG+FranklinGothic-Book>+glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=7,font=/PIIBEG+FranklinGothic-Book>I :;<?D?J?ED E< 7 <EH;?=D =EL;HDC;DJ E<<?9?7Bglyph<c=14,font=/PIIBEG+FranklinGothic-Book> !7?BKH; JE 9ECFBO M?J> :EC;IJ?9 EH <EH;?=D B7MI 9EKB: H;IKBJ ?D L7H?EKI 7:L;HI; 9EDI;GK;D9;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= FEII?8B; :;B7O ?D 7FFHEL7B EH H;<KI7B JE 7FFHEL; 7 FHE:K9Jglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;97BBIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> I;?PKH;I EH M?J>:H7M7B E< 7D 7FFHEL;: FHE:K9J <HEC J>; C7HA;Jglyph<c=12,font=/PIIBEG+FranklinGothic-Book> :?IHKFJ?ED ?D J>; IKFFBO EH 7L7?B78?B?JO E< EKH FHE:K9JI EH IKIF;DI?ED E< ;NFEHJ EH ?CFEHJ FH?L?B;=;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; ?CFEI?J?ED E< 9?L?B EH 9H?C?D7B I7D9J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; FHEI;9KJ?ED E< ;N;9KJ?L;I EL;HI;;?D= EKH ?DJ;HD7J?ED7B EF;H7J?EDI 7D: :7C7=; JE EKH H;FKJ7J?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>DO I?=D?<?97DJ ?CF7?HC;DJ E< EKH 78?B?JO JE I;BB FHE:K9JI EKJI?:; E< J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 9EKB: 7:L;HI;BO ?CF79J EKH 8KI?D;II 7D: <?D7D9?7B H;IKBJIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D 7::?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?B; M; 8;B?;L; J>7J M; >7L; 7FFHEFH?7J; 9ECFB?7D9; 9EDJHEBIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FEB?9?;I 7D: FHE9;:KH;I ?D FB79; JE 9ECFBO M?J> J>; !glyph<c=30,font=/PIIBEG+FranklinGothic-Book>+glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>;H; ?I 7 H?IA J>7J 79JI 9ECC?JJ;: 8O EKH ;CFBEO;;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7=;DJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> :?IJH?8KJEHIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9EBB78EH7JEHI EH J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJO FHEL?:;HI C?=>J L?EB7J; J>; !glyph<c=30,font=/PIIBEG+FranklinGothic-Book>+glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 7D: M; C?=>J 8; >;B: H;IFEDI?8B;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $< EKH ;CFBEO;;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7=;DJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> :?IJH?8KJEHIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9EBB78EH7JEHI EH J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJO FHEL?:;HI 7H; <EKD: JE >7L; ;D=7=;: ?D IK9> FH79J?9;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 9EKB: IK<<;H I;L;H; F;D7BJ?;I 7D: C7O 8; IK8@;9J JE EJ>;H B?78?B?J?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> 9EKB: D;=7J?L;BO 7<<;9J EKH 8KI?D;IIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> EF;H7J?D= H;IKBJI 7D: <?D7D9?7B 9ED:?J?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n!& \"3& #6*-%*/( \" -\"3(&glyph<c=6,font=/PIICNA+FranklinGothic-BookItal>4$\"-& #*0-0(*$4 .\"/6'\"$563*/( '\"$*-*5:glyph<c=5,font=/PIICNA+FranklinGothic-BookItal> 8)*$) 8*-- 3&46-5 */ 5)& */$633&/$& 0' 4*(/*'*$\"/5 */7&45.&/5 8*5) /0 \"4463\"/$& 5)\"5 46$) */7&45.&/5 8*-- #& 3&$061&%glyph<c=7,font=/PIICNA+FranklinGothic-BookItal>\n\n$D EH:;H JE IKFFEHJ EKH <KJKH; =HEMJ> 7D: :HK= :;L;BEFC;DJ F?F;B?D;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 7H; ;NF7D:?D= EKH B7H=; CEB;9KB; FHE:K9J?ED 97F79?JO 8O 8K?B:?D= 7 B7H=;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>I97B; 8?EBE=?9I C7DK<79JKH?D= <79?B?JO ?D .EBEJ>KHDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> .M?JP;HB7D: M?J> DE 7IIKH7D9; J>7J J>; 7::?J?ED7B 97F79?JO M?BB 8; H;GK?H;: EH J>?I ?DL;IJC;DJ M?BB 8; H;9EKF;:glyph<c=14,font=/PIIBEG+FranklinGothic-Book>",
        "metadata": {
            "page": 57
        },
        "id": "4f22294c-d6a4-4b3f-9711-178266ab8cc6"
    },
    {
        "page_content": "$< M; 7H; KD78B; JE <KBBO KJ?B?P; EKH C7DK<79JKH?D= <79?B?J?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> EKH 8KI?D;II C7O 8; >7HC;:glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>7H=;I H;IKBJ?D= <HEC ;N9;II 97F79?JO C7O 9EDJ?DK; JE E99KH 7D: MEKB: >7L; 7 D;=7J?L; ;<<;9J ED EKH <?D7D9?7B 9ED:?J?ED 7D: H;IKBJI E< EF;H7J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=28,font=/PIIBEG+FranklinGothic-Book>BJ>EK=> J>; .EBEJ>KHD <79?B?JO M7I 7FFHEL;: 8O J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> <EH glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>0# '( 7D: ' , (glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>;H; 97D 8; DE 7IIKH7D9; J>7J J>; H;=KB7JEHO 7KJ>EH?J?;I M?BB 7FFHEL; J>; .EBEJ>KHD <79?B?JO <EH J>; C7DK<79JKH?D= E< EJ>;H FHE:K9JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=31,font=/PIICNA+FranklinGothic-BookItal>)& 0/(0*/( glyph<c=16,font=/PIICNA+FranklinGothic-BookItal>glyph<c=27,font=/PIICNA+FranklinGothic-BookItal> glyph<c=22,font=/PIICNA+FranklinGothic-BookItal>glyph<c=17,font=/PIICNA+FranklinGothic-BookItal>glyph<c=6,font=/PIICNA+FranklinGothic-BookItal>glyph<c=9,font=/PIICNA+FranklinGothic-BookItal>glyph<c=12,font=/PIICNA+FranklinGothic-BookItal> 1\"/%&.*$ \"/% 05)&3 (-0#\"- )&\"-5) 065#3&\",4 .\":glyph<c=5,font=/PIICNA+FranklinGothic-BookItal> %*3&$5-: 03 */%*3&$5-:glyph<c=5,font=/PIICNA+FranklinGothic-BookItal> \"%7&34&-: \"''&$5 063 #64*/&44glyph<c=5,font=/PIICNA+FranklinGothic-BookItal> 3&46-54 0' 01&3\"5*0/4 \"/% '*/\"/$*\"- $0/%*5*0/glyph<c=7,font=/PIICNA+FranklinGothic-BookItal>\n\n*KH 8KI?D;II >7I 7D: 9EKB: 9EDJ?DK; JE 8; 7:L;HI;BO 7<<;9J;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> :?H;9JBO EH ?D:?H;9JBOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 8O J>; ED=E?D= glyph<c=30,font=/PIIBEG+FranklinGothic-Book>*1$glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book> F7D:;C?9 7D: EJ>;H =BE87B >;7BJ> EKJ8H;7AIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n2; 9EDJ?DK; JE CED?JEH EKH EF;H7J?EDI 7D: 7FFB?978B; =EL;HDC;DJ H;9ECC;D:7J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: M; >7L; C7:; CE:?<?97J?EDI JE EKH DEHC7B EF;H7J?EDI 8;97KI; E< J>; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>*1$glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book> F7D:;C?9 7D: EJ>;H =BE87B >;7BJ> EKJ8H;7AIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= B?C?J?D= JH7L;B 7D: 7:EFJ?D= <B;N?8B; MEHA?D= 7HH7D=;C;DJIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>KIJEC;Hglyph<c=13,font=/PIIBEG+FranklinGothic-Book><79?D= FHE<;II?ED7BI ?DJ;H79J?EDI ?D >;7BJ>97H; I;JJ?D=I >7L; 9>7D=;: 7I 7 H;IKBJ E< J>; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>*1$glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book> F7D:;C?9 7D: EJ>;H =BE87B >;7BJ> EKJ8H;7AIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />?I B?C?JI EKH 78?B?JO JE C7HA;J EKH FHE:K9JI 7D: ;:K97J; F>OI?9?7DIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D JKHDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9EKB: >7L; 7D 7:L;HI; ;<<;9J ED EKH 78?B?JO JE 9ECF;J; ?D J>; C7HA;J?D= 7D: I7B;I E< EKH FHE:K9JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=30,font=/PIIBEG+FranklinGothic-Book>>7D=;I ?D <B;N?8B; MEHA?D= 7HH7D=;C;DJI 9EKB: ?CF79J ;CFBEO;; H;J;DJ?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ;CFBEO;;Iglyph<c=7,font=/PIIBEG+FranklinGothic-Book> FHE:K9J?L?JO 7D: CEH7B;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> IJH7?D EKH J;9>DEBE=O H;IEKH9;I 7D: ?DJHE:K9; EF;H7J?ED7B H?IAIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>::?J?ED7BBOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; H?IA E< 9O8;Hglyph<c=13,font=/PIIBEG+FranklinGothic-Book>7JJ79AI EH EJ>;H FH?L79O EH :7J7 I;9KH?JO ?D9?:;DJI C7O 8; >;?=>J;D;: 7I 7 H;IKBJ E< EKH CEL?D= ?D9H;7I?D=BO JEM7H:I 7 H;CEJ; MEHA?D= ;DL?HEDC;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> C7O 8; B;II I;9KH; 7D: CEH; IKI9;FJ?8B; JE >79A?D= 7JJ79AIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n/>; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>*1$glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book> F7D:;C?9 7D: EJ>;H =BE87B >;7BJ> EKJ8H;7AI 9EKB: 7<<;9J J>; >;7BJ> 7D: 7L7?B78?B?JO E< EKH MEHA<EH9; 7I M;BB 7I J>EI; E< J>; J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJ?;I M; H;BO EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book> !KHJ>;HCEH;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> :;B7OI 7D: :?IHKFJ?EDI ;NF;H?;D9;: 8O EKH 9EBB78EH7JEHI EH EJ>;H J>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJ?;I :K; JE J>; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>*1$glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book> F7D:;C?9 7D: EJ>;H =BE87B >;7BJ> EKJ8H;7AI 9EKB: 7:L;HI;BO ?CF79J J>; 78?B?JO E< IK9> F7HJ?;I JE <KB<?BB J>;?H E8B?=7J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> 9EKB: 7<<;9J FHE:K9J I7B;I EH J>; 9B?D?97B :;L;BEFC;DJ EH H;=KB7JEHO 7FFHEL7BI E< FHE:K9J 97D:?:7J;I KD:;H @E?DJ 9EDJHEBglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n*KH 78?B?JO JE 9EDJ?DK; EKH ;N?IJ?D= 9B?D?97B JH?7BI EH JE ?D?J?7J; D;M 9B?D?97B JH?7BI >7I 8;;D 7D: C7O 9EDJ?DK; JE 8; 7:L;HI;BO 7<<;9J;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> :?H;9JBO EH ?D:?H;9JBOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 8O J>; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>*1$glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book> F7D:;C?9 7D: EJ>;H =BE87B >;7BJ> EKJ8H;7AIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> -;IJH?9J?EDI ED JH7L;B 7D:glyph<c=15,font=/PIIBEG+FranklinGothic-Book>EH JH7DIFEHJ E< 9B?D?97B C7J;H?7BI 7I M;BB 7I :?L;HI?ED E< >EIF?J7B IJ7<< 7D: H;IEKH9;I JE glyph<c=30,font=/PIIBEG+FranklinGothic-Book>*1$glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book> ?D<;9J;: F7J?;DJI 9EKB: :?IHKFJ JH?7B EF;H7J?EDI 7D: H;9HK?JC;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FEII?8BO H;IKBJ?D= ?D 7 IBEM:EMD ?D ;DHEBBC;DJ 7D:glyph<c=15,font=/PIIBEG+FranklinGothic-Book> EH :;L?7J?EDI <HEC EH :?IHKFJ?EDI ?D A;O 9B?D?97B JH?7B 79J?L?J?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> IK9> 7I 9B?D?97B JH?7B I?J; CED?JEH?D=glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />;I; 9>7BB;D=;I C7O B;7: JE :?<<?9KBJ?;I ?D C;;J?D= FHEJE9EBglyph<c=13,font=/PIIBEG+FranklinGothic-Book>IF;9?<?;: FHE9;:KH;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; C7O D;;: JE C7A; 9;HJ7?D 7:@KIJC;DJI JE J>; EF;H7J?ED E< 9B?D?97B JH?7BI ?D 7D ;<<EHJ JE C?D?C?P; H?IAI JE JH?7B :7J7 ?DJ;=H?JO :KH?D= J>; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>*1$glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book> F7D:;C?9 7D: EJ>;H =BE87B >;7BJ> EKJ8H;7AIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D 7::?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; ?CF79J E< J>; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>*1$glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book> F7D:;C?9 7D: EJ>;H =BE87B >;7BJ> EKJ8H;7AI ED J>; EF;H7J?EDI E< J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 7D: EJ>;H >;7BJ> 7KJ>EH?J?;I C7O :;B7O FEJ;DJ?7B 7FFHEL7BI E< EKH FHE:K9J 97D:?:7J;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n.J7J; 7D: <;:;H7B >;7BJ>97H; H;<EHC C;7IKH;I >7L; 8;;D 7:EFJ;: ?D J>; F7IJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: C7O 8; 7:EFJ;: ?D J>; <KJKH;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7DO E< M>?9> 9EKB: B?C?J J>; 7CEKDJI J>7J <;:;H7B 7D: IJ7J; =EL;HDC;DJI M?BB F7O <EH >;7BJ>97H; FHE:K9JI 7D: I;HL?9;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> 9EKB: H;IKBJ ?D H;:K9;: :;C7D: <EH EKH FHE:K9JI EH 7::?J?ED7B FH?9?D= FH;IIKH;I 7D: >7L; 7 <?D7D9?7B ?CF79J ED EKH 8KI?D;II J>7J M; 97DDEJ FH;:?9Jglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n2>?B; ?J ?I DEJ FEII?8B; 7J J>?I J?C; JE ;IJ?C7J; J>; ;DJ?H;JO E< J>; ?CF79J J>7J J>; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>*1$glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book> F7D:;C?9 7D: EJ>;H =BE87B >;7BJ> EKJ8H;7AI M?BB 9EDJ?DK; JE >7L; ED EKH 8KI?D;IIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; 8HE7: ?CF79J E< J>; F7D:;C?9 ED 7BB 8KI?D;II 79J?L?J?;I C7O C7J;H?7BBO 7D: 7:L;HI;BO 7<<;9J EKH 8KI?D;IIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> IKFFBO 9>7?D 7D: :?IJH?8KJ?ED IOIJ;CIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;IKBJI E< EF;H7J?EDI 7D: <?D7D9?7B 9ED:?J?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=31,font=/PIICNA+FranklinGothic-BookItal>)& *--&(\"- %*453*#65*0/ \"/% 4\"-& #: 5)*3%glyph<c=6,font=/PIICNA+FranklinGothic-BookItal>1\"35*&4 0' $06/5&3'&*5 03 6/'*5 7&34*0/4 0' 063 130%6$54 03 450-&/ 130%6$54 $06-% )\"7& \" /&(\"5*7& *.1\"$5 0/ 063 3&165\"5*0/ \"/% #64*/&44glyph<c=7,font=/PIICNA+FranklinGothic-BookItal>\n\n/>?H:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>F7HJ?;I C?=>J ?BB;=7BBO :?IJH?8KJ; 7D: I;BB 9EKDJ;H<;?J EH KD<?J L;HI?EDI E< EKH FHE:K9JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> :E DEJ C;;J EKH H?=EHEKI C7DK<79JKH?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> :?IJH?8KJ?ED 7D: J;IJ?D= IJ7D:7H:Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book> F7J?;DJ M>E H;9;?L;I 7 9EKDJ;H<;?J EH KD<?J :HK= C7O 8; 7J H?IA <EH 7 DKC8;H E< :7D=;HEKI >;7BJ> 9EDI;GK;D9;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> *KH H;FKJ7J?ED 7D: 8KI?D;II 9EKB: IK<<;H >7HC 7I 7 H;IKBJ E< 9EKDJ;H<;?J EH KD<?J :HK=I IEB: KD:;H EKH 8H7D: D7C;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $DL;DJEHO J>7J ?I IJEB;D <HEC M7H;>EKI;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FB7DJI EH M>?B; ?Dglyph<c=13,font=/PIIBEG+FranklinGothic-Book>JH7DI?Jglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: J>7J ?I IK8I;GK;DJBO ?CFHEF;HBO IJEH;: 7D: IEB: J>HEK=> KD7KJ>EH?P;: 9>7DD;BIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9EKB: 7:L;HI;BO ?CF79J F7J?;DJ I7<;JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> EKH H;FKJ7J?ED 7D: EKH 8KI?D;IIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=31,font=/PIICNA+FranklinGothic-BookItal>)& */$3&\"4*/( 64& 0' 40$*\"- .&%*\" 1-\"5'03.4 13&4&/54 /&8 3*4,4 \"/% $)\"--&/(&4glyph<c=7,font=/PIICNA+FranklinGothic-BookItal>\n\n.E9?7B C;:?7 ?I ?D9H;7I?D=BO 8;?D= KI;: JE 9ECCKD?97J; 78EKJ EKH FHE:K9JI 7D: J>; :?I;7I;I EKH J>;H7F?;I 7H; :;I?=D;: JE JH;7Jglyph<c=14,font=/PIIBEG+FranklinGothic-Book> .E9?7B C;:?7 FH79J?9;I ?D J>; 8?EF>7HC79;KJ?97B ?D:KIJHO 9EDJ?DK; JE ;LEBL; 7D: H;=KB7J?EDI H;B7J?D= JE IK9> KI; 7H; DEJ 7BM7OI 9B;7H 7D: 9H;7J; KD9;HJ7?DJO 7D: H?IA E< DED9ECFB?7D9; M?J> H;=KB7J?EDI",
        "metadata": {
            "page": 58
        },
        "id": "2fb31736-fb1c-4e1d-9d6d-1e4841cb33f6"
    },
    {
        "page_content": "7FFB?978B; JE EKH 8KI?D;IIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> !EH ;N7CFB;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> F7J?;DJI C7O KI; IE9?7B C;:?7 9>7DD;BI JE 9ECC;DJ ED J>; ;<<;9J?L;D;II E< 7 FHE:K9J EH JE H;FEHJ 7D 7BB;=;: 7:L;HI; ;L;DJglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2>;D IK9> :?I9BEIKH;I E99KHglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>;H; ?I 7 H?IA J>7J M; <7?B JE CED?JEH 7D: 9ECFBO M?J> 7FFB?978B; 7:L;HI; ;L;DJ H;FEHJ?D= E8B?=7J?EDI EH M; C7O DEJ 8; 78B; JE :;<;D: J>; 9ECF7DO EH J>; FK8B?9glyph<c=7,font=/PIIBEG+FranklinGothic-Book>I B;=?J?C7J; ?DJ;H;IJI ?D J>; <79; E< J>; FEB?J?97B 7D: C7HA;J FH;IIKH;I =;D;H7J;: 8O IE9?7B C;:?7 :K; JE H;IJH?9J?EDI ED M>7J M; C7O I7O 78EKJ EKH FHE:K9JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />;H; ?I 7BIE 7 H?IA E< ?D7FFHEFH?7J; :?I9BEIKH; E< I;DI?J?L; ?D<EHC7J?ED EH D;=7J?L; EH ?D799KH7J; FEIJI EH 9ECC;DJI 78EKJ KI ED IE9?7B C;:?7glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; C7O 7BIE ;D9EKDJ;H 9H?J?9?IC ED IE9?7B C;:?7 H;=7H:?D= EKH 9ECF7DOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> C7D7=;C;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FHE:K9J 97D:?:7J;I EH FHE:K9JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; ?CC;:?79O E< IE9?7B C;:?7 FH;9BK:;I KI <HEC >7L?D= H;7Bglyph<c=13,font=/PIIBEG+FranklinGothic-Book>J?C; 9EDJHEB EL;H FEIJ?D=I C7:; H;=7H:?D= KI L?7 IE9?7B C;:?7glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>;J>;H C7JJ;HI E< <79J EH EF?D?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book> *KH H;FKJ7J?ED 9EKB: 8; :7C7=;: 8O D;=7J?L; FK8B?9?JO EH ?< 7:L;HI; ?D<EHC7J?ED 9ED9;HD?D= KI ?I FEIJ;: ED IE9?7B C;:?7 FB7J<EHCI EH I?C?B7H C;:?KCIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> M; C7O DEJ 8; 78B; JE H;L;HI;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $< 7DO E< J>;I; ;L;DJI M;H; JE E99KH EH M; EJ>;HM?I; <7?B JE 9ECFBO M?J> 7FFB?978B; H;=KB7J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 9EKB: ?D9KH B?78?B?JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> <79; H;IJH?9J?L; H;=KB7JEHO 79J?EDI EH ?D9KH EJ>;H >7HC JE EKH 8KI?D;IIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## );E=E )7>3F76 FA glyph<c=31,font=/PIIBCD+FranklinGothic-Book>A>6;@9 &GD glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A??A@ *FA5=\n\n## glyph<c=27,font=/PIICNA+FranklinGothic-BookItal>63 01&3\"5*/( 3&46-54 \"3& 46#+&$5 50 4*(/*'*$\"/5 '-6$56\"5*0/4glyph<c=7,font=/PIICNA+FranklinGothic-BookItal>\n\n*KH GK7HJ;HBO H;L;DK;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ;NF;DI; 7D: D;J ?D9EC; glyph<c=8,font=/PIIBEG+FranklinGothic-Book>BEIIglyph<c=9,font=/PIIBEG+FranklinGothic-Book> >7L; <BK9JK7J;: ?D J>; F7IJ 7D: 7H; B?A;BO JE <BK9JK7J; I?=D?<?97DJBO ?D J>; <KJKH; :K; JE J>; H?IAI :;I9H?8;: ?D J>;I; &7A9 glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>/1B=@A 7I M;BB 7I J>; J?C?D= E< 9>7H=;I 7D: ;NF;DI; J>7J M; C7O J7A;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; >7L; H;9EH:;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> EH C7O 8; H;GK?H;: JE H;9EH:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9>7H=;I J>7J ?D9BK:;glyph<c=26,font=/PIIBEG+FranklinGothic-Book>\n\n- T J>; 9EIJ E< H;IJHK9JKH?D=I EH EJ>;H ?D?J?7J?L;I JE IJH;7CB?D; EKH EF;H7J?EDI 7D: H;7BBE97J; H;IEKH9;Iglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T ?CF7?HC;DJI M?J> H;IF;9J JE ?DL;IJC;DJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> <?N;: 7II;JI 7D: BED=glyph<c=13,font=/PIIBEG+FranklinGothic-Book>B?L;: 7II;JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= ?Dglyph<c=13,font=/PIIBEG+FranklinGothic-Book>FHE9;II H;I;7H9> 7D: :;L;BEFC;DJ glyph<c=8,font=/PIIBEG+FranklinGothic-Book>$+-glyph<c=6,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book> 7D: EJ>;H ?DJ7D=?8B; 7II;JIglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T ?DL;DJEHO MH?J;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>:EMDI <EH <7?B;: GK7B?JO IF;9?<?97J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;9KHH?D= 9>7H=;I <EH ;N9;II EH E8IEB;J; ?DL;DJEHO 7D: 9>7H=;I <EH ?DL;DJEHO MH?J;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>:EMDI H;B7J?D= JE FHE:K9J IKIF;DI?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ;NF?H7J?EDI EH H;97BBIglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T 9>7D=;I ?D J>; <7?H L7BK; E< 9EDJ?D=;DJ 9EDI?:;H7J?ED EH EKH ;GK?JO ?DL;IJC;DJIglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T 87: :;8J ;NF;DI; 7D: ?D9H;7I;: 87: :;8J H;I;HL;Iglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T EKJ9EC;I E< B?J?=7J?ED 7D: EJ>;H B;=7B EH 7:C?D?IJH7J?L; FHE9;;:?D=Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;=KB7JEHO C7JJ;HI 7D: J7N C7JJ;HIglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T F7OC;DJI ?D 9EDD;9J?ED M?J> 79GK?I?J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> :?L;IJ?JKH;I 7D: EJ>;H 8KI?D;II :;L;BEFC;DJ 79J?L?J?;I 7D: KD:;H B?9;DI; 7D: 9EBB78EH7J?ED 7=H;;C;DJIglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T <7?BKH; JE C;;J 9;HJ7?D 9EDJH79JK7B 9ECC?JC;DJIglyph<c=27,font=/PIIBEG+FranklinGothic-Book> 7D:\n- T J>; ?CF79J E< FK8B?9 >;7BJ> ;F?:;C?9Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> IK9> 7I J>; glyph<c=30,font=/PIIBEG+FranklinGothic-Book>*1$glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book> F7D:;C?9glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ED ;CFBEO;;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; =BE87B ;9EDECO 7D: J>; :;B?L;HO E< >;7BJ>97H; JH;7JC;DJIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n*KH H;L;DK; 7D: 9;HJ7?D 7II;JI 7D: B?78?B?J?;I 7H; 7BIE IK8@;9J JE <EH;?=D 9KHH;D9O ;N9>7D=; H7J; <BK9JK7J?EDI :K; JE J>; =BE87B D7JKH; E< EKH EF;H7J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> *KH ;<<EHJI JE C?J?=7J; J>; ?CF79J E< <BK9JK7J?D= 9KHH;D9O ;N9>7D=; H7J;I C7O DEJ 8; IK99;II<KBglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>I 7 H;IKBJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9KHH;D9O <BK9JK7J?EDI 7CED= EKH H;FEHJ?D= 9KHH;D9Oglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> :EBB7Hglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: EJ>;H 9KHH;D9?;I ?D M>?9> M; :E 8KI?D;II M?BB 7<<;9J EKH EF;H7J?D= H;IKBJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> E<J;D ?D KDFH;:?9J78B; M7OIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> *KH D;J ?D9EC; C7O 7BIE <BK9JK7J; :K; JE J>; ?CF79J E< 9>7H=;I M; C7O 8; H;GK?H;: JE J7A; M?J> H;IF;9J JE <EH;?=D 9KHH;D9O >;:=; JH7DI79J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D F7HJ?9KB7Hglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; C7O ?D9KH >?=>;H J>7D ;NF;9J;: 9>7H=;I <HEC ;7HBO J;HC?D7J?ED E< 7 >;:=; H;B7J?EDI>?Fglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n*KH EF;H7J?D= H;IKBJI :KH?D= 7DO ED; F;H?E: :E DEJ D;9;II7H?BO IK==;IJ J>; 7DJ?9?F7J;: H;IKBJI E< <KJKH; F;H?E:Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=27,font=/PIICNA+FranklinGothic-BookItal>63 */7&45.&/54 */ 1301&35*&4 .\": /05 #& '6--: 3&\"-*;&%glyph<c=7,font=/PIICNA+FranklinGothic-BookItal>\n\n2; EMD EH B;7I; H;7B ;IJ7J; FH?C7H?BO 9EDI?IJ?D= E< 8K?B:?D=I J>7J 9EDJ7?D H;I;7H9> B78EH7JEH?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> E<<?9; IF79; 7D: C7DK<79JKH?D= EF;H7J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; C7O :;9?:; JE 9EDIEB?:7J; EH 9Eglyph<c=13,font=/PIIBEG+FranklinGothic-Book>BE97J; 9;HJ7?D 7IF;9JI E< EKH 8KI?D;II EF;H7J?EDI EH :?IFEI; E< ED; EH CEH; E< EKH FHEF;HJ?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> IEC; E< M>?9> C7O 8; BE97J;: ?D C7HA;JI J>7J 7H; ;NF;H?;D9?D= >?=> L797D9O H7J;I 7D: :;9H;7I?D= FHEF;HJO L7BK;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $< M; :;J;HC?D; J>7J J>; <7?H L7BK; E< 7DO E< EKH EMD;: FHEF;HJ?;I ?I BEM;H J>7D J>;?H 8EEA L7BK;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; C7O DEJ H;7B?P; J>; <KBB ?DL;IJC;DJ ?D J>;I; FHEF;HJ?;I 7D: ?D9KH I?=D?<?97DJ ?CF7?HC;DJ 9>7H=;I EH 7::?J?ED7B :;FH;9?7J?ED M>;D J>; ;NF;9J;: KI;<KB B?L;I E< 9;HJ7?D 7II;JI >7L; 8;;D I>EHJ;D;: :K; JE J>; 7DJ?9?F7J;: 9BEI?D= E< <79?B?J?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $< M; :;9?:; JE <KBBO EH F7HJ?7BBO L797J; 7 FHEF;HJOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; C7O ?D9KH I?=D?<?97DJ 9EIJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= <79?B?JO 9BEI?D= 9EIJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ;CFBEO;; I;F7H7J?ED 7D: H;J;DJ?ED ;NF;DI;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> B;7I; J;HC?D7J?ED <;;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;DJ ;NF;DI; ?D ;N9;II E< IK8B;7I; ?D9EC; 7D: ?CF7?HC;DJ E< B;7I;>EB: ?CFHEL;C;DJI 7D: 799;B;H7J;: :;FH;9?7J?ED E< 7II;JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>DO E< J>;I; ;L;DJI C7O >7L; 7D 7:L;HI; ?CF79J ED EKH H;IKBJI E< EF;H7J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=27,font=/PIICNA+FranklinGothic-BookItal>63 */7&45.&/5 1035'0-*0 *4 46#+&$5 50 .\"3,&5glyph<c=5,font=/PIICNA+FranklinGothic-BookItal> */5&3&45 \"/% $3&%*5 3*4, 5)\"5 .\": 3&%6$& *54 7\"-6&glyph<c=7,font=/PIICNA+FranklinGothic-BookItal>\n\n2; C7?DJ7?D 7 FEHJ<EB?E E< C7HA;J78B; I;9KH?J?;I <EH ?DL;IJC;DJ E< EKH 97I> 7I M;BB 7I ?DL;IJC;DJI ?D ;GK?JO I;9KH?J?;I E< 9;HJ7?D 8?EJ;9>DEBE=O 9ECF7D?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>7D=;I ?D J>; L7BK; E< EKH ?DL;IJC;DJ FEHJ<EB?E 9EKB: 7:L;HI;BO",
        "metadata": {
            "page": 59
        },
        "id": "a98a211f-6457-4942-8527-1d2624f58d02"
    },
    {
        "page_content": "7<<;9J EKH ;7HD?D=Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; L7BK; E< EKH ?DL;IJC;DJI C7O :;9B?D; :K; JEglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7CED= EJ>;H J>?D=Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9H;7I;I ?D ?DJ;H;IJ H7J;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> :EMD=H7:;I E< J>; 8ED:I 7D: EJ>;H I;9KH?J?;I ?D EKH FEHJ<EB?Eglyph<c=12,font=/PIIBEG+FranklinGothic-Book> D;=7J?L; 9ECF7DOglyph<c=13,font=/PIIBEG+FranklinGothic-Book>IF;9?<?9 D;MIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 8?EJ;9>DEBE=O C7HA;J I;DJ?C;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?DIJ78?B?JO ?D J>; =BE87B <?D7D9?7B C7HA;JI J>7J H;:K9;I J>; B?GK?:?JO E< I;9KH?J?;I ?D EKH FEHJ<EB?Eglyph<c=12,font=/PIIBEG+FranklinGothic-Book> :;9B?D;I ?D J>; L7BK; E< 9EBB7J;H7B KD:;HBO?D= J>; I;9KH?J?;I ?D EKH FEHJ<EB?E 7D: EJ>;H <79JEHIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>  79> E< J>;I; ;L;DJI C7O 97KI; KI JE H;9EH: 9>7H=;I JE H;:K9; J>; 97HHO?D= L7BK; E< EKH ?DL;IJC;DJ FEHJ<EB?E EH I;BB ?DL;IJC;DJI <EH B;II J>7D EKH 79GK?I?J?ED 9EIJglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BJ>EK=> M; 7JJ;CFJ JE C?J?=7J; J>;I; H?IAI J>HEK=> :?L;HI?<?97J?ED E< EKH ?DL;IJC;DJI 7D: 9EDJ?DKEKI CED?JEH?D= E< EKH FEHJ<EB?Eglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I EL;H7BB H?IA FHE<?B;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; L7BK; E< EKH ?DL;IJC;DJI C7O D;L;HJ>;B;II :;9B?D;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=31,font=/PIICNA+FranklinGothic-BookItal>)&3& $\"/ #& /0 \"4463\"/$& 5)\"5 8& 8*-- $0/5*/6& 50 3&163$)\"4& 4)\"3&4 03 5)\"5 8& 8*-- 3&163$)\"4& 4)\"3&4 \"5 '\"703\"#-& 13*$&4glyph<c=7,font=/PIICNA+FranklinGothic-BookItal>\n\n!HEC J?C; JE J?C; EKH glyph<c=29,font=/PIIBEG+FranklinGothic-Book>E7H: E< glyph<c=31,font=/PIIBEG+FranklinGothic-Book>?H;9JEHI 7KJ>EH?P;I I>7H; H;FKH9>7I; FHE=H7CIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; 7CEKDJ 7D: J?C?D= E< I>7H; H;FKH9>7I;I 7H; IK8@;9J JE 97F?J7B 7L7?B78?B?JO 7D: EKH :;J;HC?D7J?ED J>7J I>7H; H;FKH9>7I;I 7H; ?D J>; 8;IJ ?DJ;H;IJ E< EKH I>7H;>EB:;HI 7D: 7H; ?D 9ECFB?7D9; M?J> 7BB H;IF;9J?L; B7MI 7D: EKH 7FFB?978B; 7=H;;C;DJIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> *KH 78?B?JO JE H;FKH9>7I; I>7H;I M?BB :;F;D: KFEDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7CED= EJ>;H <79JEHIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> EKH 97I> 87B7D9;I 7D: FEJ;DJ?7B <KJKH; 97F?J7B H;GK?H;C;DJI <EH IJH7J;=?9 JH7DI79J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> EKH H;IKBJI E< EF;H7J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> EKH <?D7D9?7B 9ED:?J?ED 7D: EJ>;H <79JEHI 8;OED: EKH 9EDJHEB J>7J M; C7O :;;C H;B;L7DJglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>::?J?ED7BBOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; H;9;DJBO ;D79J;: $-glyph<c=28,font=/PIIBEG+FranklinGothic-Book> ?D9BK:;I 7D ;N9?I; J7N ED I>7H; H;FKH9>7I;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> M?BB ?D9H;7I; J>; 9EIJ E< I>7H; H;FKH9>7I;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book> H;:K9J?ED ?D H;FKH9>7I;I KD:;Hglyph<c=12,font=/PIIBEG+FranklinGothic-Book> EH J>; 9ECFB;J?ED E<glyph<c=12,font=/PIIBEG+FranklinGothic-Book> EKH I>7H; H;FKH9>7I; FHE=H7CI 9EKB: >7L; 7 D;=7J?L; ;<<;9J ED EKH IJE9A FH?9;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; 97D FHEL?:; DE 7IIKH7D9; J>7J M; M?BB H;FKH9>7I; I>7H;I 7J <7LEH78B; FH?9;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?< 7J 7BBglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n!& .\": /05 #& \"#-& 50 \"$$&44 5)& $\"1*5\"- \"/% $3&%*5 .\"3,&54 0/ 5&3.4 5)\"5 \"3& '\"703\"#-& 50 64glyph<c=7,font=/PIICNA+FranklinGothic-BookItal>\n\n2; C7O I;;A 799;II JE J>; 97F?J7B 7D: 9H;:?J C7HA;JI JE IKFFB;C;DJ EKH ;N?IJ?D= <KD:I 7D: 97I> =;D;H7J;: <HEC EF;H7J?EDI <EH MEHA?D= 97F?J7Bglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 97F?J7B ;NF;D:?JKH; 7D: :;8J I;HL?9; H;GK?H;C;DJI 7D: EJ>;H 8KI?D;II ?D?J?7J?L;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; 97F?J7B 7D: 9H;:?J C7HA;JI 7H; ;NF;H?;D9?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: >7L; ?D J>; F7IJ ;NF;H?;D9;:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ;NJH;C; LEB7J?B?JO 7D: :?IHKFJ?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> B;7:I JE KD9;HJ7?DJO 7D: B?GK?:?JO ?IIK;I <EH 8EJ> 8EHHEM;HI 7D: ?DL;IJEHIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D J>; ;L;DJ E< 7:L;HI; C7HA;J 9ED:?J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; C7O 8; KD78B; JE E8J7?D 97F?J7B EH 9H;:?J C7HA;J <?D7D9?D= ED <7LEH78B; J;HCIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>>7D=;I ?D 9H;:?J H7J?D=I ?IIK;: 8O D7J?ED7BBO H;9E=D?P;: 9H;:?J H7J?D= 7=;D9?;I 9EKB: 7BIE 7:L;HI;BO 7<<;9J EKH 9EIJ E< <?D7D9?D= 7D: J>; C7HA;J FH?9; E< EKH I;9KH?J?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=27,font=/PIICNA+FranklinGothic-BookItal>63 */%&#5&%/&44 $06-% \"%7&34&-: \"''&$5 063 #64*/&44 \"/% -*.*5 063 \"#*-*5: 50 1-\"/ '03 03 3&410/% 50 $)\"/(&4 */ 063 #64*/&44glyph<c=7,font=/PIICNA+FranklinGothic-BookItal>\n\n*KH ?D:;8J;:D;IIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> JE=;J>;H M?J> EKH I?=D?<?97DJ 9EDJ?D=;DJ B?78?B?J?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= C?B;IJED; 7D: HEO7BJO F7OC;DJ E8B?=7J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9EKB: >7L; ?CFEHJ7DJ 9EDI;GK;D9;I JE EKH 8KI?D;IIglyph<c=27,font=/PIIBEG+FranklinGothic-Book> <EH ;N7CFB;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> IK9> E8B?=7J?EDI 9EKB:glyph<c=26,font=/PIIBEG+FranklinGothic-Book>\n\n- T ?D9H;7I; EKH LKBD;H78?B?JO JE =;D;H7B 7:L;HI; ;9EDEC?9 7D: ?D:KIJHO 9ED:?J?EDIglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T B?C?J EKH 78?B?JO JE 799;II 97F?J7B C7HA;JI 7D: ?D9KH 7::?J?ED7B :;8J ?D J>; <KJKH;glyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T H;GK?H; KI JE :;:?97J; 7 IK8IJ7DJ?7B FEHJ?ED E< EKH 97I> <BEM <HEC EF;H7J?EDI JE F7OC;DJI ED EKH ?D:;8J;:D;IIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>;H;8O H;:K9?D= J>; 7L7?B78?B?JO E< EKH 97I> <BEM <EH EJ>;H FKHFEI;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= 8KI?D;II :;L;BEFC;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;I;7H9> 7D: :;L;BEFC;DJ 7D: C;H=;HI 7D: 79GK?I?J?EDIglyph<c=27,font=/PIIBEG+FranklinGothic-Book> 7D:\n- T B?C?J EKH <B;N?8?B?JO ?D FB7DD?D= <EHglyph<c=12,font=/PIIBEG+FranklinGothic-Book> EH H;79J?D= JEglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9>7D=;I ?D EKH 8KI?D;II 7D: J>; ?D:KIJHO ?D M>?9> M; EF;H7J;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>;H;8O FB79?D= KI 7J 7 :?I7:L7DJ7=; 9ECF7H;: JE EKH 9ECF;J?JEHI J>7J >7L; B;II :;8Jglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=30,font=/PIICNA+FranklinGothic-BookItal>0.& 0' 063 $0--\"#03\"5*0/ \"(3&&.&/54 $0/5\"*/ $)\"/(& */ $0/530- 1307*4*0/4 5)\"5 .\": %*4$063\"(& \" 5)*3%glyph<c=6,font=/PIICNA+FranklinGothic-BookItal>1\"35: '30. \"55&.15*/( 50 \"$26*3& 64glyph<c=7,font=/PIICNA+FranklinGothic-BookItal>\n\n.EC; E< EKH 9EBB78EH7J?ED 7=H;;C;DJI ?D9BK:; 9>7D=; ?D 9EDJHEB FHEL?I?EDI J>7J 9EKB: H;:K9; J>; FEJ;DJ?7B 79GK?I?J?ED FH?9; 7D 79GK?H;H ?I M?BB?D= JE F7O EH :?I9EKH7=; 7 J7A;EL;H 7JJ;CFJ J>7J 9EKB: 8; L?;M;: 7I 8;D;<?9?7B JE I>7H;>EB:;HIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 0FED 7 9>7D=; ?D 9EDJHEBglyph<c=12,font=/PIIBEG+FranklinGothic-Book> IEC; E< J>;I; FHEL?I?EDI 9EKB: JH?==;H H;:K9;: C?B;IJED;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> FHE<?J EH HEO7BJO F7OC;DJI JE KI EH =?L; EKH 9EBB78EH7J?ED F7HJD;H H?=>JI JE J;HC?D7J; EKH 9EBB78EH7J?ED 7=H;;C;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 79GK?H; EF;H7J?ED7B 9EDJHEB EH <EH9; J>; FKH9>7I; EH I7B; E< J>; FHE=H7CI J>7J 7H; J>; IK8@;9J E< J>; 9EBB78EH7J?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=30,font=/PIIBCD+FranklinGothic-Book>7@7D3> );E= glyph<c=29,font=/PIIBCD+FranklinGothic-Book>35FADE\n\nglyph<c=27,font=/PIICNA+FranklinGothic-BookItal>63 &''&$5*7& 5\"9 3\"5& '-6$56\"5&4glyph<c=5,font=/PIICNA+FranklinGothic-BookItal> \"/% 8& .\": */$63 0#-*(\"5*0/4 */ 5\"9 +63*4%*$5*0/4 */ &9$&44 0' \"$$36&% \".06/54glyph<c=7,font=/PIICNA+FranklinGothic-BookItal>\n\nglyph<c=28,font=/PIIBEG+FranklinGothic-Book>I 7 =BE87B 8?EF>7HC79;KJ?97B 9ECF7DOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 7H; IK8@;9J JE J7N7J?ED ?D DKC;HEKI 9EKDJH?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> IJ7J;I 7D: EJ>;H @KH?I:?9J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>I 7 H;IKBJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> EKH ;<<;9J?L; J7N H7J; ?I :;H?L;: <HEC 7 9EC8?D7J?ED E< 7FFB?978B; J7N H7J;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= M?J>>EB:?D= J7N;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D J>; L7H?EKI FB79;I J>7J M; EF;H7J;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D FH;F7H?D= EKH <?D7D9?7B IJ7J;C;DJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; ;IJ?C7J; J>; 7CEKDJ E< J7N J>7J M?BB 8;9EC; F7O78B; ?D ;79> E< IK9> FB79;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> *KH ;<<;9J?L; J7N H7J; C7O 8; :?<<;H;DJ J>7D ;NF;H?;D9;: ?D J>; F7IJ EH EKH 9KHH;DJ ;NF;9J7J?EDI :K; JE C7DO <79JEHIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= 9>7D=;I ?D J>; C?N E< EKH",
        "metadata": {
            "page": 60
        },
        "id": "ed586aa0-14d2-4da3-b428-dff6fceea669"
    },
    {
        "page_content": "FHE<?J78?B?JO <HEC 9EKDJHO JE 9EKDJHOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; H;IKBJI E< ;N7C?D7J?EDI 7D: 7K:?JI E< EKH J7N <?B?D=I glyph<c=8,font=/PIIBEG+FranklinGothic-Book>?D9BK:?D= J>EI; H;B7J;: JE J>; ?CF79J E< J>; /7N glyph<c=30,font=/PIIBEG+FranklinGothic-Book>KJI 7D: %E8I glyph<c=28,font=/PIIBEG+FranklinGothic-Book>9J E< glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7:@KIJC;DJI JE J>; L7BK; E< EKH KD9;HJ7?D J7N FEI?J?EDIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?DJ;HFH;J7J?EDI 8O J7N 7KJ>EH?J?;I EH EJ>;H 8E:?;I M?J> @KH?I:?9J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; H;IKBJ E< J7N 97I;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9>7D=;I ?D 799EKDJ?D= <EH ?D9EC; J7N;I 7D: 9>7D=;I ?D J7N B7MI 7D: H;=KB7J?EDI ;?J>;H FHEIF;9J?L;BO EH H;JHEIF;9J?L;BO glyph<c=8,font=/PIIBEG+FranklinGothic-Book>?D9BK:?D= J>EI; H;B7J;: JE J>; $-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n*KH ?D78?B?JO JE I;9KH; EH IKIJ7?D 799;FJ78B; 7HH7D=;C;DJI M?J> J7N 7KJ>EH?J?;I 7D: <KJKH; 9>7D=;I ?D J>; J7N B7MIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7CED= EJ>;H J>?D=Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> C7O H;IKBJ ?D J7N E8B?=7J?EDI ?D ;N9;II E< 7CEKDJI 799HK;: ?D EKH <?D7D9?7B IJ7J;C;DJIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n/>; ;D79JC;DJ E< IEC; EH 7BB E< J>; H;9ECC;D:7J?EDI I;J <EHJ> EH J>7J C7O 8; <EHJ>9EC?D= ?D J>; *H=7D?P7J?ED <EH  9EDEC?9 glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EEF;H7J?ED 7D: glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;L;BEFC;DJ^I FHE@;9J ED [glyph<c=29,font=/PIIBEG+FranklinGothic-Book>7I; HEI?ED 7D: +HE<?J .>?<J?D=\\ glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=29,font=/PIIBEG+FranklinGothic-Book> +.glyph<c=9,font=/PIIBEG+FranklinGothic-Book> 8O J7N 7KJ>EH?J?;I 7D: ;9EDEC?9 8BE9I ?D J>; 9EKDJH?;I ?D M>?9> M; EF;H7J;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9EKB: KD<7LEH78BO ?CF79J EKH ;<<;9J?L; J7N H7J;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />;I; ?D?J?7J?L;I <E9KI ED 9ECCED ?DJ;HD7J?ED7B FH?D9?FB;I <EH J>; ;DJ?JB;C;DJ JE J7N7J?ED E< =BE87B 9EHFEH7J; FHE<?JI 7D: C?D?CKC =BE87B J7N H7J;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=27,font=/PIICNA+FranklinGothic-BookItal>63 #64*/&44 */70-7&4 &/7*30/.&/5\"- 3*4,4glyph<c=5,font=/PIICNA+FranklinGothic-BookItal> 8)*$) */$-6%& 5)& $045 0' $0.1-*\"/$& \"/% 5)& 3*4, 0' $0/5\".*/\"5*0/ 03 */+63:glyph<c=7,font=/PIICNA+FranklinGothic-BookItal>\n\n*KH 8KI?D;II 7D: J>; 8KI?D;II E< I;L;H7B E< EKH IJH7J;=?9 F7HJD;HI ?DLEBL; J>; 9EDJHEBB;: KI; E< >7P7H:EKI C7J;H?7BIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9>;C?97BIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 8?EBE=?9I 7D: H7:?E79J?L; 9ECFEKD:Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BJ>EK=> M; 8;B?;L; J>7J EKH I7<;JO FHE9;:KH;I <EH >7D:B?D= 7D: :?IFEI?D= E< IK9> C7J;H?7BI 9ECFBO M?J> IJ7J;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> <;:;H7B 7D: <EH;?=D IJ7D:7H:Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>;H; M?BB 7BM7OI 8; J>; H?IA E< 799?:;DJ7B 9EDJ7C?D7J?ED EH ?D@KHOglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $< M; M;H; JE 8;9EC; B?78B; <EH 7D 799?:;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> EH ?< M; M;H; JE IK<<;H 7D ;NJ;D:;: <79?B?JO I>KJ:EMDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 9EKB: ?D9KH I?=D?<?97DJ 9EIJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> :7C7=;I 7D: F;D7BJ?;I J>7J 9EKB: >7HC EKH 8KI?D;IIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> (7DK<79JKH?D= E< EKH FHE:K9JI 7D: FHE:K9J 97D:?:7J;I 7BIE H;GK?H;I F;HC?JI <HEC =EL;HDC;DJ 7=;D9?;I <EH M7J;H IKFFBO 7D: M7IJ;M7J;H :?I9>7H=;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $< M; :E DEJ E8J7?D 7FFHEFH?7J; F;HC?JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= F;HC?JI <EH IK<<?9?;DJ GK7DJ?J?;I E< M7J;H 7D: M7IJ;M7J;Hglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 9EKB: ?D9KH I?=D?<?97DJ 9EIJI 7D: B?C?JI ED EKH C7DK<79JKH?D= LEBKC;I J>7J 9EKB: >7HC EKH 8KI?D;IIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>::?J?ED7BBOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;=KB7JEHI 7H; 9EDI?:;H?D= D;M ;DL?HEDC;DJ7B :?I9BEIKH; HKB;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> !EH ;N7CFB;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; . glyph<c=30,font=/PIIBEG+FranklinGothic-Book> >7I FHEFEI;: 7C;D:C;DJI JE ?JI :?I9BEIKH; HKB;I H;=7H:?D= 9B?C7J;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>H;B7J;: :?I9BEIKH; H;GK?H;C;DJIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />;I; FHEFEI;: H;=KB7J?EDI C7O ?CF79J J>; C7DD;H ?D M>?9> M; EF;H7J;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## +glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$ glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=25,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> ,%)glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*&#-glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>glyph<c=29,font=/PIIBCD+FranklinGothic-Book>glyph<c=29,font=/PIIBCD+FranklinGothic-Book> glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&$$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+*\n\n)ED;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## +glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$ glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> ')&'glyph<c=28,font=/PIIBCD+FranklinGothic-Book>)+ glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\nglyph<c=29,font=/PIIBEG+FranklinGothic-Book>;BEM ?I 7 IKCC7HO E< EKH EMD;: 7D: B;7I;: FHEF;HJ?;I 7I E< glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n,glyph<c=11,font=/PIIBCD+FranklinGothic-Book>*glyph<c=11,font=/PIIBCD+FranklinGothic-Book>\n\n## !/AA/16CA3BBA\n\n$D glyph<c=30,font=/PIIBEG+FranklinGothic-Book>7C8H?:=;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> (glyph<c=28,font=/PIIBEG+FranklinGothic-Book> M; EMD 7FFHEN?C7J;BO glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> IGK7H; <;;J E< H;7B ;IJ7J; IF79;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9EDI?IJ?D= E< 7 8K?B:?D= J>7J >EKI;I 7 H;I;7H9> B78EH7JEHO 7D: 7 9E=;D;H7J?ED FB7DJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n$D 7::?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; B;7I; 7 JEJ7B E< 7FFHEN?C7J;BO glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> IGK7H; <;;J ?D (7II79>KI;JJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> ?I IKCC7H?P;: 7I <EBBEMIglyph<c=26,font=/PIIBEG+FranklinGothic-Book>\n\n- T glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> IGK7H; <;;J ?D glyph<c=30,font=/PIIBEG+FranklinGothic-Book>7C8H?:=;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> (glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> ?I 9ECFH?I;: E< E<<?9;I <EH EKH 9EHFEH7J; >;7:GK7HJ;HI 7D: EJ>;H 7:C?D?IJH7J?L; 7D: :;L;BEFC;DJ <KD9J?EDI 7D: B78EH7JEH?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> E< M>?9> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> IGK7H; <;;J ?I IK8B;7I;: 8O CKBJ?FB; 9ECF7D?;I <EH =;D;H7B E<<?9; IF79;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> B78EH7JEH?;I 7D: C7DK<79JKH?D= <79?B?J?;Iglyph<c=27,font=/PIIBEG+FranklinGothic-Book> 7D:\n- T glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> IGK7H; <;;J E< E<<?9; IF79; ?D 2;IJEDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> (glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> E< M>?9> glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> IGK7H; <;;J ?I IK8B;7I;: J>HEK=> J>; H;C7?D?D= J;HC E< EKH B;7I; 7=H;;C;DJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n*KH (7II79>KI;JJI B;7I; 7=H;;C;DJI ;NF?H; 7J L7H?EKI :7J;I J>HEK=> J>; O;7H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=15,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>@=/2E/G glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>C7:27<5 '/:3 /<2  3/A30/19\n\n$D .;FJ;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> M; 9ECFB;J;: J>; I7B; E< EKH 8K?B:?D= 7D: B7D: F7H9;B BE97J;: 7J glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>HE7:M7Oglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D 9EDD;9J?ED M?J> J>?I I7B;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; I?CKBJ7D;EKIBO B;7I;: 879A J>; 8K?B:?D= <EH 7 J;HC E< 7FFHEN?C7J;BO glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book> O;7HIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> H;IKBJ;: ?D J>; H;9E=D?J?ED E< 7FFHEN?C7J;BO glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> C?BB?ED ?D D;M B;7I; B?78?B?J?;I 7D: H?=>Jglyph<c=13,font=/PIIBEG+FranklinGothic-Book>E<glyph<c=13,font=/PIIBEG+FranklinGothic-Book>KI; 7II;JI H;9EH:;: M?J>?D EKH 9EDIEB?:7J;: 87B7D9; I>;;JI 7I E< glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; I7B; 7D: ?CC;:?7J; B;7I;879A E< J>?I 8K?B:?D= GK7B?<?;: <EH I7B; 7D: B;7I;879A JH;7JC;DJ 7D: ?I 9B7II?<?;: 7I 7D EF;H7J?D= B;7I;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> !EH 7::?J?ED7B ?D<EHC7J?ED",
        "metadata": {
            "page": 61
        },
        "id": "fa1e8389-363e-49e0-924d-0d37f54f4e57"
    },
    {
        "page_content": "ED EKH glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>HE7:M7O I7B; 7D: B;7I;879A JH7DI79J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FB;7I; H;7: \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> $@=>3@BGglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> $:/<B /<2 glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>?C7>;3<B /<2 \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> 3/A3A glyph<c=12,font=/PIIBEG+FranklinGothic-Book> JE EKH 9EDIEB?:7J;: <?D7D9?7B IJ7J;C;DJI ?D9BK:;: ?D J>?I H;FEHJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=13,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=10,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=10,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>7<<3G 'B@33B  3/A3 !=27471/B7=<\n\n$D .;FJ;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> M; ;DJ;H;: ?DJE 7D 7=H;;C;DJ JE F7HJ?7BBO J;HC?D7J; 7 FEHJ?ED E< EKH B;7I; BE97J;: 7J glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?DD;O .JH;;Jglyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>7C8H?:=;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> (glyph<c=28,font=/PIIBEG+FranklinGothic-Book> glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?DD;O .JH;;Jglyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7I M;BB 7I JE H;:K9; J>; B;7I; J;HC <EH J>; C7@EH?JO E< J>; H;C7?D?D= IF79;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; 7=H;;C;DJ M7I :H?L;D 8O EKH glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> ;<<EHJI JE H;:K9; 9EIJI 8O 9EDIEB?:7J?D= H;7B ;IJ7J; BE97J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> !EH 7::?J?ED7B ?D<EHC7J?ED ED EKH glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?DD;O .JH;;J B;7I; CE:?<?97J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FB;7I; H;7: \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> 3/A3A glyph<c=12,font=/PIIBEG+FranklinGothic-Book>JE EKH 9EDIEB?:7J;: <?D7D9?7B IJ7J;C;DJI ?D9BK:;: ?D J>?I H;FEHJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## \"=@B6 glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>/@=:7</\n\n$D -/+glyph<c=12,font=/PIIBEG+FranklinGothic-Book> )glyph<c=30,font=/PIIBEG+FranklinGothic-Book> M; EMD 7FFHEN?C7J;BO glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> IGK7H; <;;J E< H;7B ;IJ7J; IF79;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> ?I IKCC7H?P;: 7I <EBBEMIglyph<c=26,font=/PIIBEG+FranklinGothic-Book>\n\n- T glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> IGK7H; <;;J E< B78EH7JEHO 7D: E<<?9; IF79;glyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> IGK7H; <EEJ CKBJ?glyph<c=13,font=/PIIBEG+FranklinGothic-Book>FKHFEI; <79?B?JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D= 7D glyph<c=28,font=/PIIBEG+FranklinGothic-Book>.* C7DK<79JKH?D= IK?J; 7D: 7:C?D?IJH7J?L; IF79;glyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> IGK7H; <;;J H;B7J;: JE 7 B7H=;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>I97B; 8?EBE=?9I C7DK<79JKH?D= <79?B?JOglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> IGK7H; <;;J H;B7J;: JE 7 IC7BBglyph<c=13,font=/PIIBEG+FranklinGothic-Book>I97B; 8?EBE=?9I C7DK<79JKH?D= <79?B?JOglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> IGK7H; <;;J E< M7H;>EKI; IF79; 7D: KJ?B?J?;Iglyph<c=27,font=/PIIBEG+FranklinGothic-Book>\n- T glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> IGK7H; <;;J H;B7J;: JE 7 F7H;DJ;H7B <?BBglyph<c=13,font=/PIIBEG+FranklinGothic-Book><?D?I> <79?B?JOglyph<c=27,font=/PIIBEG+FranklinGothic-Book> 7D:\n- T glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> IGK7H; <;;J H;B7J;: JE 7 B7H=;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>I97B; FKH?<?97J?ED <79?B?JOglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n$D 7::?J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; B;7I; 7FFHEN?C7J;BO glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> IGK7H; <;;J E< M7H;>EKI; IF79; ?D glyph<c=31,font=/PIIBEG+FranklinGothic-Book>KH>7Cglyph<c=12,font=/PIIBEG+FranklinGothic-Book> )glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> *KH )EHJ> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>7HEB?D7 B;7I; 7=H;;C;DJI ;NF?H; 7J L7H?EKI :7J;I J>HEK=> J>; O;7H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n$D (7H9> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book> M; 7DDEKD9;: EKH FB7DI JE 8K?B: 7 D;M =;D; J>;H7FO C7DK<79JKH?D= <79?B?JO ?D -/+glyph<c=12,font=/PIIBEG+FranklinGothic-Book> )glyph<c=30,font=/PIIBEG+FranklinGothic-Book> JE IKFFEHJ EKH =;D; J>;H7FO F?F;B?D; 79HEII CKBJ?FB; J>;H7F;KJ?9 7H;7Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; D;M C7DK<79JKH?D= <79?B?JO M?BB 8; 7FFHEN?C7J;BO glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> IGK7H; <;;J 7D: ?I ;NF;9J;: JE 8; EF;H7J?ED7B 8O J>; ;D: E< glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M?J> 7D ;IJ?C7J;: JEJ7B ?DL;IJC;DJ E< 7FFHEN?C7J;BO glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> C?BB?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>EDIJHK9J?ED <EH J>?I D;M <79?B?JO 8;=7D :KH?D= J>; <EKHJ> GK7HJ;H E< glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## @F7D@3F;A@3>\n\n## 'E7BH3@:/<2\n\n$D EH:;H JE IKFFEHJ EKH <KJKH; =HEMJ> 7D: :HK= :;L;BEFC;DJ F?F;B?D;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 7H; 8K?B:?D= 7 B7H=;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>I97B; 8?EBE=?9I C7DK<79JKH?D= <79?B?JO ?D .EBEJ>KHDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> .M?JP;HB7D:glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 0FED 9ECFB;J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>?I <79?B?JO M?BB ?D9BK:; glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> IGK7H; <;;J H;B7J;: JE 7 B7H=;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>I97B; 8?EBE=?9I C7DK<79JKH?D= <79?B?JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> IGK7H; <;;J E< M7H;>EKI;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> KJ?B?J?;I 7D: IKFFEHJ IF79; 7D: glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> IGK7H; <;;J E< 7:C?D?IJH7J?L; IF79;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D J>; I;9ED: GK7HJ;H E< glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book> 7 FEHJ?ED E< J>; <79?B?JO H;9;?L;: 7 \"(+ CKBJ?glyph<c=13,font=/PIIBEG+FranklinGothic-Book>FHE:K9J B?9;DI; <HEC .2$..( glyph<c=31,font=/PIIBEG+FranklinGothic-Book>$glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> .EBEJ>KHD >7I 8;;D 7FFHEL;: <EH J>; C7DK<79JKH; E< glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>0# '( 7D: ' , (glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$ 8O J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; ;IJ?C7J; J>; I;9ED: C7DK<79JKH?D= IK?J; 7J J>; .EBEJ>KHD <79?B?JO M?BB 8; EF;H7J?ED7B 8O J>; ;D: E< glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=27,font=/PIICNA+FranklinGothic-BookItal>5)&3 glyph<c=22,font=/PIICNA+FranklinGothic-BookItal>/5&3/\"5*0/\"-\n\n2; B;7I; E<<?9; IF79; ?D glyph<c=29,font=/PIIBEG+FranklinGothic-Book>77Hglyph<c=12,font=/PIIBEG+FranklinGothic-Book> .M?JP;HB7D:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> EKH ?DJ;HD7J?ED7B >;7:GK7HJ;HIglyph<c=27,font=/PIIBEG+FranklinGothic-Book> J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>&glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=27,font=/PIIBEG+FranklinGothic-Book> \";HC7DOglyph<c=27,font=/PIIBEG+FranklinGothic-Book> !H7D9;glyph<c=27,font=/PIIBEG+FranklinGothic-Book> %7F7Dglyph<c=27,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>7D7:7 7D: DKC;HEKI EJ>;H 9EKDJH?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> *KH ?DJ;HD7J?ED7B B;7I; 7=H;;C;DJI ;NF?H; 7J L7H?EKI :7J;I J>HEK=> J>; O;7H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## +glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$ glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> #glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book># ')&glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> %glyph<c=30,font=/PIIBCD+FranklinGothic-Book>*\n\n!EH 7 :?I9KII?ED E< B;=7B C7JJ;HI 7I E< glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> FB;7I; H;7: \"=B3 glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> 7B75/B7=<glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> JE EKH 9EDIEB?:7J;: <?D7D9?7B IJ7J;C;DJI ?D9BK:;: ?D J>?I H;FEHJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> ?I ?D9EHFEH7J;: ?DJE J>?I ?J;C 8O H;<;H;D9;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## +glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$ glyph<c=17,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> $ %glyph<c=28,font=/PIIBCD+FranklinGothic-Book> *glyph<c=24,font=/PIIBCD+FranklinGothic-Book>glyph<c=29,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>+0 glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *glyph<c=26,font=/PIIBCD+FranklinGothic-Book>#&*,)glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n)EJ 7FFB?978B;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>",
        "metadata": {
            "page": 62
        },
        "id": "88630083-b670-438b-bb70-541ddb1943c7"
    },
    {
        "page_content": "## 'glyph<c=24,font=/PIIBCD+FranklinGothic-Book>)+\n\n## +glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$ glyph<c=18,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> $glyph<c=24,font=/PIIBCD+FranklinGothic-Book>)\"glyph<c=28,font=/PIIBCD+FranklinGothic-Book>+ glyph<c=29,font=/PIIBCD+FranklinGothic-Book>&) )glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=30,font=/PIIBCD+FranklinGothic-Book> *+)glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%+glyph<c=5,font=/PIIBCD+FranklinGothic-Book>* glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&$$&% glyph<c=28,font=/PIIBCD+FranklinGothic-Book>(, +0glyph<c=9,font=/PIIBCD+FranklinGothic-Book> )glyph<c=28,font=/PIIBCD+FranklinGothic-Book>#glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *+&glyph<c=26,font=/PIIBCD+FranklinGothic-Book>\"glyph<c=31,font=/PIIBCD+FranklinGothic-Book>&#glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>) $glyph<c=24,font=/PIIBCD+FranklinGothic-Book>++glyph<c=28,font=/PIIBCD+FranklinGothic-Book>)* glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> **,glyph<c=28,font=/PIIBCD+FranklinGothic-Book>) ',)glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=31,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>*glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* &glyph<c=29,font=/PIIBCD+FranklinGothic-Book> glyph<c=28,font=/PIIBCD+FranklinGothic-Book>(, +0 *glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>,) + glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## $3D=7F 3@6 *FA5=:A>67D  @8AD?3F;A@\n\n*KH 9ECCED IJE9A JH7:;I ED />; )7I:7G \"BE87B .;B;9J (7HA;J KD:;H J>; IOC8EB [glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$$glyph<c=29,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\\ glyph<c=28,font=/PIIBEG+FranklinGothic-Book>I E< !;8HK7HO glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>;H; M;H; 7FFHEN?C7J;BO glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book> I>7H;>EB:;HI E< H;9EH: E< EKH 9ECCED IJE9Aglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=27,font=/PIIBCD+FranklinGothic-Book>;H;67@6E\n\n2; >7L; DEJ F7?: 97I> :?L?:;D:I I?D9; EKH ?D9;FJ?EDglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2>?B; M; >?IJEH?97BBO >7L; DEJ F7?: 97I> :?L?:;D:I 7D: :E DEJ >7L; 7 9KHH;DJ ?DJ;DJ?ED JE F7O 97I> :?L?:;D:Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 9EDJ?DK7BBO H;L?;M EKH 97F?J7B 7BBE97J?ED IJH7J;=?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D9BK:?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7CED= EJ>;H J>?D=Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> F7OC;DJ E< 97I> :?L?:;D:Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> I>7H; H;FKH9>7I;I 7D: 79GK?I?J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## EEG7D 'GD5:3E7E A8 glyph<c=28,font=/PIIBCD+FranklinGothic-Book>CG;FK *75GD;F;7E\n\n/>; <EBBEM?D= J78B; IKCC7H?P;I EKH 9ECCED IJE9A H;FKH9>7I; 79J?L?JO :KH?D= J>; <EKHJ> GK7HJ;H E< glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=26,font=/PIIBEG+FranklinGothic-Book>\n\n| '7D;A6                                                                                                                                                                                                                               | +AF3> %G?47D A8 *:3D7E 'GD5:3E76 glyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=2,font=/PIIBCD+FranklinGothic-Book>glyph<c=7,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>H7D397 'D;57 '3;6 B7D *:3D7 glyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=3,font=/PIIBCD+FranklinGothic-Book>glyph<c=7,font=/PIIBCD+FranklinGothic-Book>   | +AF3> %G?47D A8 *:3D7E 'GD5:3E76 3E '3DF A8 'G4>;5>K glyph<c=24,font=/PIIBCD+FranklinGothic-Book>@@AG@576 'DA9D3?E glyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=2,font=/PIIBCD+FranklinGothic-Book>glyph<c=7,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>BBDAJ;?3F7 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>A>>3D -3>G7 A8 *:3D7E +:3F $3K 07F glyph<c=25,font=/PIIBCD+FranklinGothic-Book>7 'GD5:3E76 ,@67D &GD 'DA9D3?E glyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=3,font=/PIIBCD+FranklinGothic-Book> ;@ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book>     |\n|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| *9JE8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>                                             | Z glyph<c=4,font=/PIIBEG+FranklinGothic-Book>                                                                                                                        | Z                                                                                                                                                                                                           |                                                                                                                                                                                                                                                        | Z glyph<c=4,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> |\n| )EL;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>                                            | Z glyph<c=4,font=/PIIBEG+FranklinGothic-Book>                                                                                                                        | Z                                                                                                                                                                                                           | Z glyph<c=4,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                          | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>                                               |\n| glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> | Z glyph<c=4,font=/PIIBEG+FranklinGothic-Book>                                                                                                                        | Z                                                                                                                                                                                                           | Z glyph<c=4,font=/PIIBEG+FranklinGothic-Book>                                                                                                                                                                                                          | glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>                                               |\n| /EJ7B glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=9,font=/PIIBEG+FranklinGothic-Book>                                                                                             | Z glyph<c=4,font=/PIIBEG+FranklinGothic-Book>                                                                                                                        | Z                                                                                                                                                                                                           |                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                    |\n\n$D *9JE8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> EKH glyph<c=29,font=/PIIBEG+FranklinGothic-Book>E7H: E< glyph<c=31,font=/PIIBEG+FranklinGothic-Book>?H;9JEHI 7KJ>EH?P;: 7 FHE=H7C JE H;FKH9>7I; KF JE glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> 8?BB?ED E< EKH 9ECCED IJE9A glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> .>7H; -;FKH9>7I; +HE=H7Cglyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> *KH glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> .>7H; -;FKH9>7I; +HE=H7C :E;I DEJ >7L; 7D ;NF?H7J?ED :7J;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BB I>7H; H;FKH9>7I;I KD:;H EKH glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> .>7H; -;FKH9>7I; +HE=H7C M?BB 8; H;J?H;:glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 0D:;H EKH glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> .>7H; -;FKH9>7I; +HE=H7Cglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; H;FKH9>7I;: 7D: H;J?H;: 7FFHEN?C7J;BO glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book> C?BB?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> C?BB?ED 7D: glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book> C?BB?ED I>7H;I E< EKH 9ECCED IJE9A 7J 7 9EIJ E< 7FFHEN?C7J;BO glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> C?BB?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book> 8?BB?ED 7D: glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> C?BB?ED :KH?D= J>; O;7HI ;D:;: glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book> 7D: glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;IF;9J?L;BOglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>FFHEN?C7J;BO glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book> 8?BB?ED H;C7?D;: 7L7?B78B; KD:;H EKH glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> .>7H; -;FKH9>7I; +HE=H7C 7I E< glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n$D glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book> EKH glyph<c=29,font=/PIIBEG+FranklinGothic-Book>E7H: E< glyph<c=31,font=/PIIBEG+FranklinGothic-Book>?H;9JEHI 7KJ>EH?P;: 7 FHE=H7C JE H;FKH9>7I; KF JE glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> 8?BB?ED E< EKH 9ECCED IJE9A glyph<c=8,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book> .>7H; -;FKH9>7I; +HE=H7Cglyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> M7I 9ECFB;J;: 7I E< .;FJ;C8;H glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BB I>7H;I H;FKH9>7I;: KD:;H EKH glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book> .>7H; -;FKH9>7I; +HE=H7C M;H; H;J?H;:glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 0D:;H EKH glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book> .>7H; -;FKH9>7I; +HE=H7Cglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; H;FKH9>7I;: 7D: H;J?H;: 7FFHEN?C7J;BO glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book> C?BB?ED I>7H;I E< EKH 9ECCED IJE9A 7J 7 9EIJ E< 7FFHEN?C7J;BO glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> 8?BB?ED :KH?D= J>; O;7H ;D:;: glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n$D (7H9> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book> EKH glyph<c=29,font=/PIIBEG+FranklinGothic-Book>E7H: E< glyph<c=31,font=/PIIBEG+FranklinGothic-Book>?H;9JEHI 7KJ>EH?P;: 7 FHE=H7C JE H;FKH9>7I; KF JE glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> 8?BB?ED E< EKH 9ECCED IJE9A glyph<c=8,font=/PIIBEG+FranklinGothic-Book>(7H9> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book> .>7H; -;FKH9>7I; +HE=H7Cglyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> M7I 9ECFB;J;: 7I E< (7H9> glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BB I>7H;I H;FKH9>7I;: KD:;H EKH (7H9> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book> .>7H; -;FKH9>7I; +HE=H7C M;H; H;J?H;:glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 0D:;H EKH (7H9> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book> .>7H; -;FKH9>7I; +HE=H7Cglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; H;FKH9>7I;: 7D: H;J?H;: 7FFHEN?C7J;BO glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book> C?BB?ED I>7H;I E< EKH 9ECCED IJE9A 7J 7 9EIJ E< 7FFHEN?C7J;BO glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book> 8?BB?ED :KH?D= J>; O;7H ;D:;: glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n$D glyph<c=28,font=/PIIBEG+FranklinGothic-Book>K=KIJ glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> J>; $-glyph<c=28,font=/PIIBEG+FranklinGothic-Book> M7I I?=D;: ?DJE B7Mglyph<c=14,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>CED= EJ>;H J>?D=Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; $-glyph<c=28,font=/PIIBEG+FranklinGothic-Book> B;L?;I 7 glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=5,font=/PIIBEG+FranklinGothic-Book> ;N9?I; J7N ED D;J IJE9A H;FKH9>7I;I 7<J;H glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> #?IJEH?97BBOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; >7L; C7:; :?I9H;J?ED7HO I>7H; H;FKH9>7I;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book>",
        "metadata": {
            "page": 63
        },
        "id": "03046895-28eb-4c3f-9c81-043a20ceeb55"
    },
    {
        "page_content": "## '7D8AD?3@57 glyph<c=30,font=/PIIBCD+FranklinGothic-Book>D3B:\n\n/>; F;H<EHC7D9; =H7F> 8;BEM 9ECF7H;I J>; <?L;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>O;7H 9KCKB7J?L; JEJ7B IJE9A>EB:;H H;JKHD ED EKH 9ECCED IJE9Aglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; )7I:7G +>7HC79;KJ?97B $D:;Nglyph<c=12,font=/PIIBEG+FranklinGothic-Book> J>; .glyph<c=6,font=/PIIBEG+FranklinGothic-Book>+ glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> $D:;N 7D: J>; )7I:7G glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?EJ;9>DEBE=O $D:;Nglyph<c=14,font=/PIIBEG+FranklinGothic-Book> />; F;H<EHC7D9; =H7F> 8;BEM 7IIKC;I J>; ?DL;IJC;DJ E< glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> ED glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D EKH 9ECCED IJE9A 7D: ;79> E< J>; J>H;; ?D:;N;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M?J> :?L?:;D:I 8;?D= H;?DL;IJ;:glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n/>; IJE9A FH?9; F;H<EHC7D9; ?D J>; =H7F> 8;BEM ?I DEJ D;9;II7H?BO ?D:?97J?L; E< <KJKH; FH?9; F;H<EHC7D9;glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n<!-- image -->\n\n|                                                                                                                                                                                          | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=20,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=21,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=22,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                    |\n|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E=;D $D9glyph<c=14,font=/PIIBEG+FranklinGothic-Book>                                                                                        | glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> | glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>                                             | glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>                                             | glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>                                             | glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>                                             | glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>                                             |\n| )7I:7G +>7HC79;KJ?97B $D:;N                                                                                                                                                              | glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> | glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book> | glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> | glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> | glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book> | glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book> |\n| .glyph<c=6,font=/PIIBEG+FranklinGothic-Book>+ glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> $D:;N | glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> | glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>                                             | glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=23,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> | glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book> | glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book> | glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=22,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book> |\n| )7I:7G glyph<c=29,font=/PIIBEG+FranklinGothic-Book>?EJ;9>DEBE=O $D:;N                                                                                                                    | glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> | glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>                                             | glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> | glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book> | glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book> | glyph<c=4,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book> |\n\n/>; ?D<EHC7J?ED ?D9BK:;: KD:;H J>; >;7:?D= $3@4=@;/<13 glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>@/>6 ?I [<KHD?I>;:\\ 7D: DEJ [<?B;:\\ <EH FKHFEI;I E< .;9J?ED glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book> E< J>; .;9KH?J?;I  N9>7D=; glyph<c=28,font=/PIIBEG+FranklinGothic-Book>9Jglyph<c=12,font=/PIIBEG+FranklinGothic-Book> EH EJ>;HM?I; IK8@;9J JE J>; B?78?B?J?;I E< J>7J I;9J?EDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> DEH I>7BB ?J 8; :;;C;: JE 8; [IEB?9?J?D= C7J;H?7B\\ IK8@;9J JE -;=KB7J?ED glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> EH ?D9EHFEH7J;: 8O H;<;H;D9; ?D 7DO <?B?D= KD:;H J>; .;9KH?J?;I glyph<c=28,font=/PIIBEG+FranklinGothic-Book>9J E< glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book> EH J>; .;9KH?J?;I  N9>7D=; glyph<c=28,font=/PIIBEG+FranklinGothic-Book>9J E< glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=25,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=20,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$ glyph<c=19,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> )glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*glyph<c=28,font=/PIIBCD+FranklinGothic-Book>)-glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book>",
        "metadata": {
            "page": 64
        },
        "id": "1ae7f4da-0dc5-4a05-9b30-4000c5efaae1"
    },
    {
        "page_content": "## +glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$ glyph<c=20,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> $glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=24,font=/PIIBCD+FranklinGothic-Book>glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+glyph<c=5,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *glyph<c=26,font=/PIIBCD+FranklinGothic-Book>,** &% glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=24,font=/PIIBCD+FranklinGothic-Book>#0* * &glyph<c=29,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> + &% glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> )glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*,#+* &glyph<c=29,font=/PIIBCD+FranklinGothic-Book> &'glyph<c=28,font=/PIIBCD+FranklinGothic-Book>)glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+ &%*\n\n/>; <EBBEM?D= :?I9KII?ED I>EKB: 8; H;7: ?D 9ED@KD9J?ED M?J> EKH 9EDIEB?:7J;: <?D7D9?7B IJ7J;C;DJI 7D: J>; 799ECF7DO?D= DEJ;I 8;=?DD?D= ED F7=; !glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book> E< J>?I H;FEHJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n!EH EKH :?I9KII?ED E< J>; O;7H ;D:;: glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 9ECF7H;: JE J>; O;7H ;D:;: glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> FB;7I; H;7: glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>B3; glyph<c=17,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal> !/</53;3<Bglyph<c=4,font=/PIIBDE+FranklinGothic-BookItal>A glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>7A1CAA7=< /<2 glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal></:GA7A =4 glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>7</<17/: glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=<27B7=< /<2 &3AC:BA =4 #>3@/B7=<A BE97J;: ?D EKH glyph<c=28,font=/PIIBEG+FranklinGothic-Book>DDK7B -;FEHJ ED !EHC glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=13,font=/PIIBEG+FranklinGothic-Book>& <EH J>; O;7H ;D:;: glyph<c=31,font=/PIIBEG+FranklinGothic-Book>;9;C8;H glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n## glyph<c=28,font=/PIIBCD+FranklinGothic-Book>J75GF;H7 *G??3DK\n\n## glyph<c=22,font=/PIICNA+FranklinGothic-BookItal>/530%6$5*0/\n\nglyph<c=29,font=/PIIBEG+FranklinGothic-Book>?E=;D ?I 7 =BE87B 8?EF>7HC79;KJ?97B 9ECF7DO <E9KI;: ED :?I9EL;H?D=glyph<c=12,font=/PIIBEG+FranklinGothic-Book> :;L;BEF?D= 7D: :;B?L;H?D= ?DDEL7J?L; J>;H7F?;I <EH F;EFB; B?L?D= M?J> I;H?EKI 7D: 9ECFB;N :?I;7I;I MEHB:M?:;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; >7L; 7 8HE7: FEHJ<EB?E E< C;:?9?D;I JE JH;7J (.glyph<c=12,font=/PIIBEG+FranklinGothic-Book> >7L; ?DJHE:K9;: J>; <?HIJ 7FFHEL;: JH;7JC;DJ <EH .(glyph<c=28,font=/PIIBEG+FranklinGothic-Book> 7D: 9Eglyph<c=13,font=/PIIBEG+FranklinGothic-Book> :;L;BEF;: JME JH;7JC;DJI JE 7::H;II 7 :;<?D?D= F7J>EBE=O E< glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BP>;?C;H^I :?I;7I;glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; 7H; <E9KI;: ED 7:L7D9?D= EKH F?F;B?D; ?D D;KHEBE=Oglyph<c=12,font=/PIIBEG+FranklinGothic-Book> D;KHEFIO9>?7JHOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> IF;9?7B?P;: ?CCKDEBE=O 7D: H7H; :?I;7I;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; IKFFEHJ EKH :HK= :?I9EL;HO 7D: :;L;BEFC;DJ ;<<EHJI J>HEK=> ?DJ;HD7B H;I;7H9> 7D: :;L;BEFC;DJ FHE=H7CI 7D: ;NJ;HD7B 9EBB78EH7J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n*KH C7HA;J;: FHE:K9JI ?D9BK:; / glyph<c=30,font=/PIIBEG+FranklinGothic-Book>!$glyph<c=31,font=/PIIBEG+FranklinGothic-Book> -glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 10( -$/4glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>1*) 3glyph<c=12,font=/PIIBEG+FranklinGothic-Book> +' \"-$glyph<c=31,font=/PIIBEG+FranklinGothic-Book>4glyph<c=12,font=/PIIBEG+FranklinGothic-Book> /4.glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=29,font=/PIIBEG+FranklinGothic-Book>-$ 7D: !glyph<c=28,font=/PIIBEG+FranklinGothic-Book>(+4-glyph<c=28,font=/PIIBEG+FranklinGothic-Book> <EH J>; JH;7JC;DJ E< (.glyph<c=27,font=/PIIBEG+FranklinGothic-Book> .+$)-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>5glyph<c=28,font=/PIIBEG+FranklinGothic-Book> <EH J>; JH;7JC;DJ E< .(glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=27,font=/PIIBEG+FranklinGothic-Book> glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>0# '( <EH J>; JH;7JC;DJ E< glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BP>;?C;Hglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I :?I;7I;glyph<c=27,font=/PIIBEG+FranklinGothic-Book> 7D: !0(glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book> -( <EH J>; JH;7JC;DJ E< I;L;H; FB7GK; FIEH?7I?Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; 7BIE 9EBB78EH7J; M?J>  ?I7? ED J>; 9ECC;H9?7B?P7J?ED E< ' , (glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$ <EH J>; JH;7JC;DJ E< glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BP>;?C;Hglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I :?I;7I;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> M7I =H7DJ;: 799;B;H7J;: 7FFHEL7B 8O J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book> ?D %7DK7HO glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; >7L; 9;HJ7?D 8KI?D;II 7D: <?D7D9?7B H?=>JI M?J> H;IF;9J JE -$/03glyph<c=28,font=/PIIBEG+FranklinGothic-Book>) <EH J>; JH;7JC;DJ E< DEDglyph<c=13,font=/PIIBEG+FranklinGothic-Book>#E:=A?Dglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I BOCF>EC7glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=30,font=/PIIBEG+FranklinGothic-Book>'' 7D: EJ>;H 9ED:?J?EDIglyph<c=27,font=/PIIBEG+FranklinGothic-Book> -$/03glyph<c=28,font=/PIIBEG+FranklinGothic-Book>) #4glyph<c=30,font=/PIIBEG+FranklinGothic-Book> 'glyph<c=28,font=/PIIBEG+FranklinGothic-Book> <EH J>; JH;7JC;DJ E< DEDglyph<c=13,font=/PIIBEG+FranklinGothic-Book>#E:=A?Dglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I BOCF>EC7 7D: glyph<c=30,font=/PIIBEG+FranklinGothic-Book>''glyph<c=27,font=/PIIBEG+FranklinGothic-Book> \"glyph<c=28,font=/PIIBEG+FranklinGothic-Book>541glyph<c=28,font=/PIIBEG+FranklinGothic-Book> <EH J>; JH;7JC;DJ E< glyph<c=30,font=/PIIBEG+FranklinGothic-Book>'' 7D: <EBB?9KB7H BOCF>EC7glyph<c=27,font=/PIIBEG+FranklinGothic-Book> *glyph<c=30,font=/PIIBEG+FranklinGothic-Book>- 10. <EH J>; JH;7JC;DJ E< ++(. 7D: -(.glyph<c=27,font=/PIIBEG+FranklinGothic-Book> '0).0($* glyph<c=8,font=/PIIBEG+FranklinGothic-Book>CEIKD;JKPKC78glyph<c=9,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M>?9> M7I =H7DJ;: 799;B;H7J;: 7FFHEL7B ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> :KH?D= J>; <EKHJ> GK7HJ;H E< glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book> <EH J>; JH;7JC;DJ E< H;B7FI;: EH H;<H79JEHO <EBB?9KB7H BOCF>EC7glyph<c=27,font=/PIIBEG+FranklinGothic-Book> =BE<?J7C78glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D ?DL;IJ?=7J?ED7B 8?IF;9?<?9 7DJ?8E:O <EH J>; FEJ;DJ?7B JH;7JC;DJ E< DEDglyph<c=13,font=/PIIBEG+FranklinGothic-Book>#E:=A?Dglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I BOCF>EC7glyph<c=27,font=/PIIBEG+FranklinGothic-Book> 7D: >7L; J>; EFJ?ED JE 7:: EJ>;H FEJ;DJ?7B 7DJ?glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> J>;H7F?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FKHIK7DJ JE EKH 9EBB78EH7J?ED 7HH7D=;C;DJI M?J> \";D;DJ;9>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 M>EBBOglyph<c=13,font=/PIIBEG+FranklinGothic-Book>EMD;: C;C8;H E< J>; -E9>; \"HEKFglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n$D 7::?J?ED JE 9EDJ?DK?D= JE ?DL;IJ ?D D;M FEJ;DJ?7B ?DDEL7J?ED ?D (. 7D: .(glyph<c=28,font=/PIIBEG+FranklinGothic-Book> M; 7H; 7:L7D9?D= EKH C?:glyph<c=13,font=/PIIBEG+FranklinGothic-Book>JEglyph<c=13,font=/PIIBEG+FranklinGothic-Book>B7J; IJ7=; FHE=H7CI ?D9BK:?D= PKH7DEBED; <EH (glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book> 7D: ++glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$$glyph<c=29,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> <EH glyph<c=28,font=/PIIBEG+FranklinGothic-Book>BP>;?C;Hglyph<c=7,font=/PIIBEG+FranklinGothic-Book>I :?I;7I;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> JE<;HI;D <EH glyph<c=28,font=/PIIBEG+FranklinGothic-Book>'. 7D: 8EJ> B?J?<?B?C78 7D: :7F?HEB?PKC78 F;=EB <EH 9;HJ7?D <EHCI E< BKFKIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n2; 7BIE 9ECC;H9?7B?P; 8?EI?C?B7HI E< 7:L7D9;: 8?EBE=?9I ?D9BK:?D= glyph<c=29,font=/PIIBEG+FranklinGothic-Book> ) +glyph<c=28,font=/PIIBEG+FranklinGothic-Book>'$glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D ;J7D;H9;FJ 8?EI?C?B7H H;<;H;D9?D=  )glyph<c=29,font=/PIIBEG+FranklinGothic-Book>- 'glyph<c=12,font=/PIIBEG+FranklinGothic-Book> $(-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>'glyph<c=31,font=/PIIBEG+FranklinGothic-Book>$glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D 7:7B?CKC78 8?EI?C?B7H H;<;H;D9?D= #0($-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: !'$3glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D ?D<B?N?C78 8?EI?C?B7H H;<;H;D9?D= - ($glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book> glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D 9;HJ7?D 9EKDJH?;I ?D  KHEF;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7I M;BB 7I glyph<c=29,font=/PIIBEG+FranklinGothic-Book>4**1$5glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 H7D?8?PKC78 8?EI?C?B7H H;<;H;D9?D= '0glyph<c=30,font=/PIIBEG+FranklinGothic-Book> )/$.glyph<c=12,font=/PIIBEG+FranklinGothic-Book> ?D J>; 0glyph<c=14,font=/PIIBEG+FranklinGothic-Book>.glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; 9EDJ?DK; JE :;L;BEF FEJ;DJ?7B 8?EI?C?B7H FHE:K9JI ?D9BK:?D= glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$$glyph<c=29,font=/PIIBEG+FranklinGothic-Book>glyph<c=24,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 FHEFEI;: JE9?B?PKC78 8?EI?C?B7H H;<;H;D9?D= glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=30,font=/PIIBEG+FranklinGothic-Book>/ (-glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D: .glyph<c=29,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book>glyph<c=21,font=/PIIBEG+FranklinGothic-Book>glyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7 FHEFEI;: 7<B?8;H9;FJ 8?EI?C?B7H H;<;H;D9?D=  4' glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D !;8HK7HO glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book> M; 7DDEKD9;: J>7J M; 7H; ;NFBEH?D= IJH7J;=?9 EFJ?EDI <EH EKH 8?EI?C?B7HI 8KI?D;IIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n!EH 7::?J?ED7B ?D<EHC7J?ED ED EKH 9EBB78EH7J?ED 7HH7D=;C;DJIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FB;7I; H;7: \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>A glyph<c=12,font=/PIIBEG+FranklinGothic-Book> JE EKH 9EDIEB?:7J;: <?D7D9?7B IJ7J;C;DJI ?D9BK:;: ?D J>?I H;FEHJglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n2; I;;A JE ;DIKH; 7D KD?DJ;HHKFJ;: IKFFBO E< C;:?9?D;I JE F7J?;DJI 7HEKD: J>; MEHB:glyph<c=14,font=/PIIBEG+FranklinGothic-Book> /E J>7J ;D:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 9EDJ?DK7BBO H;L?;M EKH C7DK<79JKH?D= 97F79?JOglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 97F78?B?J?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> FHE9;II;I 7D: <79?B?J?;Iglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D EH:;H JE IKFFEHJ EKH <KJKH; =HEMJ> 7D: :HK= :;L;BEFC;DJ F?F;B?D;glyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; 7H; ;NF7D:?D= EKH B7H=; CEB;9KB; FHE:K9J?ED 97F79?JO 8O 8K?B:?D= 7 B7H=;glyph<c=13,font=/PIIBEG+FranklinGothic-Book>I97B; 8?EBE=?9I C7DK<79JKH?D= <79?B?JO ?D .EBEJ>KHDglyph<c=12,font=/PIIBEG+FranklinGothic-Book> .M?JP;HB7D:glyph<c=14,font=/PIIBEG+FranklinGothic-Book> $D J>; I;9ED: GK7HJ;H E< glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=17,font=/PIIBEG+FranklinGothic-Book> 7 FEHJ?ED E< J>; <79?B?JO H;9;?L;: 7 \"(+ CKBJ?glyph<c=13,font=/PIIBEG+FranklinGothic-Book>FHE:K9J B?9;DI; <HEC .2$..( glyph<c=31,font=/PIIBEG+FranklinGothic-Book>$glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> .EBEJ>KHD >7I 8;;D 7FFHEL;: <EH J>; C7DK<79JKH; E< glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>0# '( 7D: ' , (glyph<c=29,font=/PIIBEG+FranklinGothic-Book>$ 8O J>; !glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=28,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; ;IJ?C7J; J>; I;9ED: C7DK<79JKH?D= IK?J; 7J J>; .EBEJ>KHD <79?B?JO M?BB 8; EF;H7J?ED7B 8O J>; ;D: E< glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=19,font=/PIIBEG+FranklinGothic-Book>glyph<c=14,font=/PIIBEG+FranklinGothic-Book> 2; 8;B?;L; J>7J J>; .EBEJ>KHD <79?B?JO M?BB IKFFEHJ EKH 7DJ?9?F7J;: D;7Hglyph<c=13,font=/PIIBEG+FranklinGothic-Book>J;HC D;;:I <EH J>; C7DK<79JKH?D= E< 8?EBE=?9 7II;JIglyph<c=14,font=/PIIBEG+FranklinGothic-Book> $< M; 7H; KD78B; JE <KBBO KJ?B?P; EKH C7DK<79JKH?D= <79?B?J?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> :K; JE BEM;H J>7D <EH;97IJ;: :;C7D: <EH EKH FHE:K9JIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; M?BB ?D9KH ;N9;II 97F79?JO 9>7H=;I M>?9> M?BB >7L; 7 D;=7J?L; ;<<;9J ED EKH <?D7D9?7B 9ED:?J?ED 7D: H;IKBJI E< EF;H7J?EDIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n*KH H;L;DK; :;F;D:I KFED 9EDJ?DK;: I7B;I E< EKH FHE:K9JI 7I M;BB 7I J>; <?D7D9?7B H?=>JI M; >7L; ?D EKH 7DJ?glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> J>;H7F;KJ?9 FHE=H7CIglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 7D:glyph<c=12,font=/PIIBEG+FranklinGothic-Book> KDB;II M; :;L;BEFglyph<c=12,font=/PIIBEG+FranklinGothic-Book> 79GK?H; H?=>JI JE 7D:glyph<c=15,font=/PIIBEG+FranklinGothic-Book>EH 9ECC;H9?7B?P; D;M FHE:K9JI 7D: J;9>DEBE=?;Iglyph<c=12,font=/PIIBEG+FranklinGothic-Book> M; M?BB 8; IK8IJ7DJ?7BBO :;F;D:;DJ ED I7B;I <HEC EKH FHE:K9JI 7D: EKH <?D7D9?7B H?=>JI ?D EKH 7DJ?glyph<c=13,font=/PIIBEG+FranklinGothic-Book>glyph<c=30,font=/PIIBEG+FranklinGothic-Book>glyph<c=31,font=/PIIBEG+FranklinGothic-Book>glyph<c=18,font=/PIIBEG+FranklinGothic-Book>glyph<c=16,font=/PIIBEG+FranklinGothic-Book> J>;H7F;KJ?9 FHE=H7CI <EH C7DO O;7HIglyph<c=14,font=/PIIBEG+FranklinGothic-Book>\n\n$D J>; BED=;H J;HCglyph<c=12,font=/PIIBEG+FranklinGothic-Book> EKH H;L;DK; =HEMJ> M?BB :;F;D: KFED J>; IK99;II<KB 9B?D?97B :;L;BEFC;DJglyph<c=12,font=/PIIBEG+FranklinGothic-Book> H;=KB7JEHO 7FFHEL7B 7D: B7KD9> E< D;M 9ECC;H9?7B",
        "metadata": {
            "page": 65
        },
        "id": "5a1af525-400c-429d-a336-b93fc48d6753"
    },
    {
        "page_content": "products as well as additional indications for our existing products, our ability to obtain and maintain patents and other rights related to our marketed products, assets originating from our research and development efforts and/or successful execution of external business development opportunities.\n\n## Business Environment\n\nFor a detailed discussion on our business environment, please read Item 1. Business, included in this report. For additional information on our competition and pricing risks that could negatively impact our product sales, please read Item 1A. Risk Factors, included in this report.\n\n## ADUHELM (aducanumab)\n\n## U.S.\n\nIn June 2021 the FDA granted accelerated approval of ADUHELM, which, until March of 2022, we had been collaborating on with Eisai, based on reduction in amyloid beta plaques observed in patients treated with ADUHELM. As part of the accelerated approval, we are required to conduct a confirmatory trial to verify the clinical benefit of ADUHELM in patients with Alzheimer's disease. The FDA may withdraw approval if, among other things, the confirmatory trial fails to verify clinical benefit of ADUHELM, ADUHELM's benefit-risk is no longer positive or we fail to comply with the conditions of the accelerated approval.\n\nIn April 2022 the CMS released a final NCD for the class of anti-amyloid treatments in Alzheimer's disease, including ADUHELM. The final NCD confirmed coverage with evidence development, in which patients with Medicare can only access treatment if they are part of an approved clinical trial. This decision effectively resulted in denying all Medicare beneficiaries access to ADUHELM. We expect that this decision will reduce future demand for ADUHELM to a minimal level.\n\nDuring the first quarter of 2022, as a result of the final NCD, we recorded approximately $275.0 million of charges associated with the writeoff of inventory and purchase commitments in excess of forecasted demand related to ADUHELM. Additionally, for the year ended December 31, 2022, we recorded approximately $111.0 million of aggregate gross idle capacity charges related to ADUHELM. These charges were recorded in cost of sales within our consolidated statements of income for the year ended December 31, 2022.\n\nWe have recognized approximately $197.0 million related to Eisai's 45.0% share of inventory, idle capacity charges and contractual commitments in collaboration profit (loss) sharing\n\nwithin our consolidated statements of income for the year ended December 31, 2022.\n\nAdditionally, as a result of the final NCD we have substantially eliminated our commercial infrastructure supporting ADUHELM, retaining minimal resources to manage patient access programs, including a continued free drug program for patients currently on treatment in the U.S.\n\nWe expect to continue funding certain regulatory and research and development activities for ADUHELM, including the continuation of the EMBARK re-dosing study and the Phase 4 post-marketing requirement study, ENVISION. Additional actions regarding ADUHELM may be informed by upcoming data readouts expected for this class of antibodies, as well as further engagement with the FDA and CMS.\n\nOn March 14, 2022, we amended our ADUHELM Collaboration Agreement with Eisai. As of the amendment date, we have sole decision making and commercialization rights worldwide on ADUHELM, and beginning January 1, 2023, Eisai receives only a tiered royalty based on net sales of ADUHELM, and no longer participates in sharing ADUHELM's global profits and losses. Eisai's share of development, commercialization and manufacturing expense was limited to $335.0 million for the period from January 1, 2022 to December 31, 2022, which was achieved as of December 31, 2022. Once this limit was achieved, we became responsible for all ADUHELM related costs.\n\n## Rest of World\n\nIn October 2020 the EMA accepted for review the MAA for aducanumab and in December 2020 the Ministry of Health, Labor and Welfare (MHLW) accepted for review the Japanese NDA for aducanumab.\n\nIn December 2021 the CHMP of the EMA adopted a negative opinion on the MAA for aducanumab in Europe. We sought re-examination of the opinion by the CHMP. In April 2022 we announced our decision to withdraw our MAA for aducanumab in Europe.\n\n## TECFIDERA\n\nMultiple TECFIDERA generic entrants are now in North America, Brazil and certain E.U. countries and have deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA has significantly reduced our TECFIDERA revenue and we expect that TECFIDERA revenue will continue to decline in the future.\n\nIn the E.U., we are seeking to enforce a patent granted in June 2022 that relates to TECFIDERA and expires in 2028. In addition, we are litigating to affirm that TECFIDERA is entitled to regulatory data and",
        "metadata": {
            "page": 66
        },
        "id": "c7d42987-e3fb-455e-86c8-8c81ec97b22f"
    },
    {
        "page_content": "market protection until at least February 2024. Our Company, the EMA and the EC have each appealed the May 2021 decision of the European General Court, which annulled the EMA's decision not to validate an application for approval of a TECFIDERA generic on the basis that the EMA and EC conducted the wrong assessment when determining TECFIDERA's entitlement to regulatory data and marketing protection. Our Company, the EMA and the EC have each appealed the General Court's decision as wrongly decided and the appeal is pending. On October 6, 2022, the Advocate General of the CJEU issued a nonbinding advisory opinion in Biogen's favor. This opinion recommends that the CJEU set aside the judgment of the European General Court. We are awaiting the decision of the CJEU.\n\nFor additional information, please read Note 21, Litigation , to our consolidated financial statements included in this report and the discussion under Results of Operations - Product Revenue - Multiple Sclerosis (MS) - Fumarate below.\n\nBusiness Update Regarding COVID-19 and Other Disruptions\n\n## COVID-19\n\nThe COVID-19 pandemic continues to present a substantial public health and economic challenge around the world. The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expense, reserves and allowances, the supply chain, manufacturing, clinical trials, research and development costs and employee-related costs, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets.\n\nWe are monitoring the demand for our products, including the duration and degree to which we may see delays in starting new patients on a product due to hospitals diverting the resources that are necessary to administer certain of our products to care for COVID-19 patients, including products, such as TYSABRI and SPINRAZA, that are administered in a physician's office or hospital setting. We may also see reduced demand for immunosuppressant therapies during the COVID-19 pandemic.\n\nWhile we are currently continuing the clinical trials we have underway in sites across the globe, COVID-19 precautions have impacted the timeline for some of our clinical trials and these precautions may,\n\ndirectly or indirectly, have a further impact on timing in the future.\n\n## Geopolitical Tensions\n\nThe ongoing geopolitical tensions related to Russia's invasion of Ukraine have resulted in global business disruptions and economic volatility, including sanctions and other restrictions levied on the government and businesses in Russia. Although we do not have affiliates or employees, in either Russia or Ukraine, we do provide various therapies to patients in Russia through a distributor and are currently involved in clinical trials with sites in Ukraine and Russia. The timing and costs of these trials may be impacted as a result of the conflict. In addition, new government sanctions on the export of certain manufacturing materials to Russia may delay or limit our ability to get new products approved.\n\nThe impact of the conflict on our operations and financial performance remains uncertain and will depend on future developments, including the severity and duration of the conflict, its impact on regional and global economic conditions and whether the conflict spreads or has effects on countries outside Ukraine and Russia. Revenue generated from sales in these regions represented less than 2.0% of total product revenue for the years ended December 31, 2022 and 2021.\n\nWe will continue to monitor the ongoing conflict between Russia and Ukraine and assess any potential impacts on our business, supply chain, partners or customers, as well as any factors that could have an adverse effect on our results of operations.\n\nFactors such as the COVID-19 pandemic and other global health outbreaks, adverse weather events, geopolitical events, labor or raw material shortages and other supply chain disruptions could result in product shortages or other difficulties and delays or increased costs in manufacturing our products.\n\nFor additional information on the various risks posed by the COVID-19 pandemic and the conflict in Ukraine, please read Item 1A. Risk Factors, included in this report.",
        "metadata": {
            "page": 67
        },
        "id": "9054a5f2-3e52-43a4-8e1a-adcdec6e5133"
    },
    {
        "page_content": "In August 2022 the IRA was signed into law in the U.S. The IRA introduced new tax provisions, including a 15.0% corporate alternative minimum tax and a 1.0% excise tax on stock repurchases. The provisions of the IRA will be effective for periods after December 31, 2022. The enactment of the IRA did not result in any material adjustments to our income tax provision or net deferred tax assets as of December 31, 2022. We expect additional guidance and regulations to be issued in future periods and will continue to assess its potential impact on our business and results of operations as further information becomes available.\n\nThe IRA also contains substantial drug pricing reforms that may have a significant impact on the pharmaceutical industry in the U.S. This includes allowing CMS to negotiate a maximum fair price for certain high-priced single source Medicare drugs, as well as redesigning Medicare Part D to reduce out-ofpocket prescription drug costs for beneficiaries, potentially resulting in higher contributions from plans and manufacturers. The IRA also establishes drug inflationary rebate requirements to penalize manufacturers from raising the prices of Medicare covered single-source drugs and biologics beyond the inflation-adjusted rate. Further, to incentivize biosimilar development, the IRA provides an 8.0% Medicare Part B add-on payment for qualifying biosimilar products for a five-year period.\n\nThe overall impact that the IRA will have on our business, results of operations and financial condition, and the impact on the pharmaceutical industry as a whole is not yet known. We will continue to assess as further information becomes available.\n\n## glyph<c=19,font=/PIICNA+FranklinGothic-BookItal>*/\"/$*\"glyph<c=21,font=/PIICNA+FranklinGothic-BookItal>*()-*()54\n\nDiluted earnings per share attributable to Biogen Inc. were $20.87 for 2022, representing an increase of 100.7% as compared to $10.40 in the same period in 2021.\n\nAs described below under &3AC:BA =4 #>3@/B7=<A , our net income and diluted earnings per share attributable to Biogen Inc. for the year ended December 31, 2022, compared to the year ended December 31, 2021, reflects the following glyph<c=26,font=/PIIBEG+FranklinGothic-Book>\n\n## &3D3<C3\n\n- < Total revenue was $10,173.4 million for 2022, representing an $808.3 million, or 7.4%, decrease compared to $10,981.7 million in 2021.\n- < Product revenue, net totaled $7,987.8 million for 2022, representing an $859.1 million, or 9.7%, decrease compared to $8,846.9 million in 2021. This decrease was primarily due to a $666.5 million, or 10.9%, decrease in MS product\n\nrevenue, a $111.6 million, or 5.9%, decrease in SPINRAZA product revenue and an $80.0 million, or 9.6%, decrease in revenue from our biosimilar business.\n\n- I The decrease in MS product revenue of $666.5 million, or 10.9%, from $6,096.7 million in 2021 to $5,430.2 million in 2022, was primarily due to a decrease in TECFIDERA demand as a result of multiple TECFIDERA generic entrants in North America, Brazil and certain E.U. countries, and a decrease in Interferon demand due to competition as patients transition to higher efficacy and oral MS therapies.\n- I The decrease in SPINRAZA revenue of $111.6 million, or 5.9%, from $1,905.1 million in 2021 to $1,793.5 million in 2022, was primarily due to country mix, the unfavorable impact of foreign currency exchange and the timing of shipments, partially offset by an increase in sales volumes. The increase in sales volumes reflects growth in certain Asian markets, partially offset by a decrease in sales volumes from increased competition in certain established markets, particularly Germany and Japan.\n- I The decrease in revenue from our biosimilar business of $80.0 million, or 9.6%, from $831.1 million in 2021 to $751.1 million in 2022, was primarily due to unfavorable pricing and the unfavorable impact of foreign currency exchange, partially offset by an increase in sales volumes.\n- < Revenue from anti-CD20 therapeutic programs totaled $1,700.5 million for 2022, representing a $42.0 million, or 2.5%, increase compared to $1,658.5 million in 2021. This increase was primarily due to a $144.6 million, or 14.6%, increase in royalty revenue on sales of OCREVUS, partially offset by a $103.4 million, or 18.0%, decrease in RITU 3 AN revenue. Sales of RITU 3 AN have been adversely affected by biosimilar competition.\n- < Other revenue totaled $485.1 million for 2022, representing a $8.8 million, or 1.8%, increase from $476.3 million in 2021.\n\n## glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>F>3<A3\n\n- < Total cost and expense was $6,581.6 million for 2022, representing a $2,654.9 million, or 28.7%, decrease compared to $9,236.5 million in 2021.",
        "metadata": {
            "page": 68
        },
        "id": "329c02c8-a4a8-4fc6-bccb-693b9eac4f1a"
    },
    {
        "page_content": "- I Research and development expense decreased $270.1 million, or 10.8%, from $2,501.2 million in 2021 to $2,231.1 million in 2022, primarily due to higher upfront payments in 2021. In 2021 we recorded approximately $285.0 million of upfront payments related to our collaborations with InnoCare, Ionis, Bio-Thera, Genentech, Capsigen Inc., and Ginkgo Bioworks, as compared to $28.5 million in 2022. In addition, $39.1 million of estimated clinical trial closeout costs and manufacturing commitments associated with BIIB111 (timrepigene emparvovec) and BIIB112 (cotoretigene toliparvovec) were recorded in 2021.\n- I Amortization and impairment of acquired intangible assets decreased $515.4 million, or 58.5%, from $881.3 million in 2021 to $365.9 million in 2022, primarily due to higher impairment charges recorded in 2021. In 2021 we recorded $629.3 million of impairment charges, as compared to $119.6 million in 2022.\n- I The decrease in cost and expense was also due to a pre-tax gain of $503.7 million recognized in 2022 related to the sale of one of our buildings.\n- I Other (income) expense, net for 2022 reflected a pre-tax gain of $1.5 billion related to the sale of our 49.9% equity interest in Samsung Bioepis, partially offset by a pre-tax charge of $900.0 million, plus settlement fees and expenses, related to a litigation settlement agreement to resolve a qui tam litigation relating to conduct prior to 2015.\n\nAs described below under glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>7</<17/: glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=<27B7=<glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> 7?C727BG /<2 glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>/>7B/: &3A=C@13A glyph<c=26,font=/PIIBEG+FranklinGothic-Book>\n\n- < We generated $1,384.3 million of net cash flow from operations for 2022.\n- < Cash, cash equivalents and marketable securities totaled approximately $5,598.5 million as of December 31, 2022.\n- < We repurchased and retired approximately 3.6 million shares of our common stock at a cost of approximately $750.0 million during 2022 under our 2020 Share Repurchase Program. Approximately $2.1 billion remained available under our 2020 Share Repurchase Program as of December 31, 2022.\n\n## glyph<c=17,font=/PIICNA+FranklinGothic-BookItal>&7&-01.&/54 */ glyph<c=23,font=/PIICNA+FranklinGothic-BookItal>&: glyph<c=16,font=/PIICNA+FranklinGothic-BookItal>0--\"#03\"5*7& glyph<c=29,font=/PIICNA+FranklinGothic-BookItal>&-\"5*0/4)*14\n\nFor additional information on our collaborative and other relationships discussed below, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>A , to our consolidated financial statements included in this report.\n\n## glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>7A/7 glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7=< glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>5@33;3<BA\n\n## glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>%glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>!glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=5,font=/PIIBDE+FranklinGothic-BookItal>:31/<3;/0glyph<c=6,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7=< glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>5@33;3<B\n\nIn January 2023 we and Eisai announced that the FDA granted accelerated approval of LE , EMBI, an anti-amyloid antibody for the treatment of Alzheimer's disease. Additionally, in January 2023 we and Eisai announced the completed submission of a supplemental BLA to the FDA for traditional approval of LE , EMBI.\n\nIn January 2023 the EMA accepted for review the MAA for lecanemab.\n\nIn January 2023 Eisai completed the submission of a MAA to the PMDA in Japan for lecanemab, and was granted Priority Review by the Japanese Ministry of Health, Labor and Welfare.\n\nIn December 2022 Eisai initiated a rolling submission of a BLA to the NMPA of China for the approval of lecanemab.\n\nIn March 2022 we extended our supply agreement with Eisai related to LE , EMBI from five years to ten years for the manufacture of LE , EMBI drug substance.\n\n## glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>)glyph<c=28,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal> ! glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7=< glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>5@33;3<B\n\nOn March 14, 2022, we amended our ADUHELM Collaboration Agreement with Eisai. As of the amendment date, we have sole decision making and commercialization rights worldwide on ADUHELM, and beginning January 1, 2023, Eisai receives only a tiered royalty based on net sales of ADUHELM, and no longer participates in sharing ADUHELM's global profits and losses. Eisai's share of development, commercialization and manufacturing expense was limited to $335.0 million for the period from January 1, 2022 to December 31, 2022, which was achieved as of December 31, 2022. Once this limit was achieved, we became responsible for all ADUHELM related costs.\n\nFor additional information on our collaboration arrangements with Eisai, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>Aglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> to our consolidated financial statements included in this report.",
        "metadata": {
            "page": 69
        },
        "id": "391bd597-e2e9-4460-98b8-ffc9cc69319c"
    },
    {
        "page_content": "## .C@/<=:=<3 glyph<c=5,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=15,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=6,font=/PIIBDE+FranklinGothic-BookItal>\n\nIn June 2022 we and our collaboration partner Sage announced that the Phase 3 SKYLARK study of zuranolone, for the potential treatment of MDD and PPD, met its primary and all key secondary endpoints.\n\nIn December 2022 we and Sage completed the rolling submission of a NDA to the FDA for the approval of zuranolone for the potential treatment of MDD and PPD. This submission completes the NDA filing initiated earlier in 2022.\n\nIn February 2023 the FDA accepted the NDA and granted Priority Review for zuranolone, with a PDUFA action date of August 5, 2023.\n\nFor additional information on our collaboration arrangement with Sage, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>A , to our consolidated financial statements included in this report.\n\nglyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>3<3<B316\n\n## )\"')!glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal># glyph<c=5,font=/PIIBDE+FranklinGothic-BookItal>;=AC<3BCHC;/0glyph<c=6,font=/PIIBDE+FranklinGothic-BookItal>\n\nIn January 2022 we exercised our option with Genentech to participate in the joint development and commercialization of LUNSUMIO (mosunetuzumab), a bispecific antibody for the treatment of relapsed or refractory follicular lymphoma. In connection with this exercise, we recorded a $30.0 million option exercise fee payable to Genentech in December 2021.\n\nIn December 2022 Genentech announced that the FDA granted accelerated approval of LUNSUMIO, which was also approved by the EC in June 2022.\n\n## glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>:=47B/;/0\n\nIn December 2022 we reached an agreement with Genentech related to the commercialization and sharing of economics for glofitamab, an investigational T-cell engaging bispecific antibody targeting CD20 and CD3 for the potential treatment of B-cell non-Hodgkin's lymphoma.\n\nFor additional information on our collaboration arrangements with Genentech, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>A , to our consolidated financial statements included in this report.\n\n## #B63@ glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 &3:/B7=<A67>A\n\n## glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>:1G=<3 (63@/>3CB71A\n\nIn December 2022 we entered into a license and collaboration agreement with Alcyone to jointly develop the ThecaFlex DRx V System, an implantable medical device intended for subcutaneous delivery of ASO therapies with a goal of improving the patient treatment experience and accessibility for people suffering from neurological disorders, such as SMA and ALS. Under the terms of this collaboration, we\n\nand Alcyone will jointly develop the ThecaFlex DRx V System and Alcyone will be solely responsible for its manufacture and commercialization. In connection with this transaction, we made an upfront payment of $10.0 million to Alcyone.\n\n## glyph<c=27,font=/PIICNA+FranklinGothic-BookItal>5)&3 glyph<c=23,font=/PIICNA+FranklinGothic-BookItal>&: glyph<c=17,font=/PIICNA+FranklinGothic-BookItal>&7&-01.&/54\n\n## (=43@A3< glyph<c=5,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=10,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=16,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=17,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=6,font=/PIIBDE+FranklinGothic-BookItal>\n\nIn July 2022 we announced that the FDA accepted the NDA and granted Priority Review for tofersen, an investigational antisense drug being evaluated for people with SOD1 ALS, which currently has a PDUFA action date of April 25, 2023. In December 2022 the EMA accepted for review the MAA for tofersen.\n\n## glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=18,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=10,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=10,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=5,font=/PIIBDE+FranklinGothic-BookItal>@343@3<17<5 glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>(glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>!&glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=6,font=/PIIBDE+FranklinGothic-BookItal>\n\nIn September 2022 we and our collaboration partner Bio-Thera announced that the EMA accepted for review the MAA for BIIB800, a proposed tocilizumab biosimilar referencing ACTEMRA, an antiinterleukin-6 receptor monoclonal antibody, for the treatment of severe, active and progressive rheumatoid arthritis. In December 2022 the FDA accepted for review the abbreviated BLA for BIIB800.\n\n## glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=5,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>\" glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=15,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=6,font=/PIIBDE+FranklinGothic-BookItal>\n\nIn October 2022 we and our collaboration partner Denali announced the initiation of the Phase 3 LIGHTHOUSE study of BIIB122 for the potential treatment of Parkinson's disease.\n\nFor additional information on our collaboration arrangement with Denali, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>Aglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> to our consolidated financial statements included in this report glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal>\n\n## glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=@>=@/B3 !/BB3@A\n\n'/;AC<5 glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>7=3>7A glyph<c=8,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>7=53<glyph<c=4,font=/PIIBDE+FranklinGothic-BookItal>A glyph<c=30,font=/PIIBDE+FranklinGothic-BookItal>=7<B *3<BC@3 E7B6 '/;AC<5 glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>7= =571A\n\nIn April 2022 we completed the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics. Under the terms of this transaction, we received approximately $1.0 billion in cash at closing and expect to receive approximately $1.3 billion in cash to be deferred over two payments of approximately $812.5 million due at the first anniversary and approximately $437.5 million due at the second anniversary of the closing of this transaction.\n\nAs part of this transaction, we are also eligible to receive up to an additional $50.0 million upon the achievement of certain commercial milestones. Our policy for contingent payments of this nature is to recognize the payments in the period that they become realizable, which is generally the same period in which the payments are earned.",
        "metadata": {
            "page": 70
        },
        "id": "a28ab8f9-881d-4708-8be6-bf58a4e5af0b"
    },
    {
        "page_content": "For additional information on the sale of our equity interest in Samsung Bioepis, please read \"=B3 glyph<c=13,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>7A>=A7B7=<Aglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> to our consolidated financial statements included in this report.\n\n## glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=10,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=AB '/D7<5 glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><7B7/B7D3A\n\nIn December 2021 and May 2022 we announced our plans to implement a series of costreduction measures that when completed we expect may yield approximately $1.0 billion in expense savings. These savings are being achieved through a number of initiatives, including reductions to our workforce, the substantial elimination of our commercial ADUHELM infrastructure, the consolidation of certain real estate locations and operating efficiency gains across our selling, general and administrative and research and development functions.\n\nUnder these initiatives, we estimate we will incur total restructuring charges of approximately $131.0 million, primarily related to severance. These amounts were substantially incurred during 2022. As of December 31, 2022, approximately $35.9 million remained in our restructuring reserve and payments are expected to be made through 2026.\n\nFor additional information on our 2022 cost saving initiatives, please read \"=B3 glyph<c=14,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> &3AB@C1BC@7<5 , to our consolidated financial statements included in this report.\n\n## )glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*,#+* &glyph<c=29,font=/PIIBCD+FranklinGothic-Book> &'glyph<c=28,font=/PIIBCD+FranklinGothic-Book>)glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+ &%*\n\n## )7H7@G7\n\nRevenueissummarizedasfollows glyph<c=26,font=/PIIBEG+FranklinGothic-Book>\n\n|                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                   | glyph<c=4,font=/PIIBCD+FranklinGothic-Book> glyph<c=26,font=/PIIBCD+FranklinGothic-Book>:3@97                                                                                                                                   | glyph<c=4,font=/PIIBCD+FranklinGothic-Book> glyph<c=26,font=/PIIBCD+FranklinGothic-Book>:3@97                                                                                                                                   | glyph<c=3,font=/PIIBCD+FranklinGothic-Book> glyph<c=26,font=/PIIBCD+FranklinGothic-Book>:3@97                                                                                                                                   | glyph<c=3,font=/PIIBCD+FranklinGothic-Book> glyph<c=26,font=/PIIBCD+FranklinGothic-Book>:3@97                                                                                                                                   |\n|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n|                                                                                                                                                                 | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book> HEglyph<c=11,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book> HEglyph<c=11,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book> HEglyph<c=11,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book> HEglyph<c=11,font=/PIIBCD+FranklinGothic-Book> |\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=9,font=/PIIBCD+FranklinGothic-Book> 7J57BF B7D57@F397Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                                                                                  | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                                                                                  | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                                                                                  | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                |\n| Product revenue, net glyph<c=26,font=/PIIBEG+FranklinGothic-Book>                                                                                               |                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                 |\n| United States                                                                                                                                                   | $ 3,469.3                                                                                                                                                                                                                                                                                         | $ 3,805.7                                                                                                                                                                                                                                                                                         | $ 5,900.1                                                                                                                                                                                                                                                                                         | (8.8)%                                                                                                                                                                                                                          | (35.5)%                                                                                                                                                                                                                         | $ (336.4)                                                                                                                                                                                                                       | $ (2,094.4)                                                                                                                                                                                                                     |\n| Rest of world                                                                                                                                                   | 4,518.5                                                                                                                                                                                                                                                                                           | 5,041.2                                                                                                                                                                                                                                                                                           | 4,792.1                                                                                                                                                                                                                                                                                           | (10.4)                                                                                                                                                                                                                          | 5.2                                                                                                                                                                                                                             | (522.7)                                                                                                                                                                                                                         | 249.1                                                                                                                                                                                                                           |\n| Total product revenue, net                                                                                                                                      | 7,987.8                                                                                                                                                                                                                                                                                           | 8,846.9                                                                                                                                                                                                                                                                                           | 10,692.2                                                                                                                                                                                                                                                                                          | (9.7)                                                                                                                                                                                                                           | (17.3)                                                                                                                                                                                                                          | (859.1)                                                                                                                                                                                                                         | (1,845.3)                                                                                                                                                                                                                       |\n| Revenue from anti-CD20 therapeutic programs                                                                                                                     | 1,700.5                                                                                                                                                                                                                                                                                           | 1,658.5                                                                                                                                                                                                                                                                                           | 1,977.8                                                                                                                                                                                                                                                                                           | 2.5                                                                                                                                                                                                                             | (16.1)                                                                                                                                                                                                                          | 42.0                                                                                                                                                                                                                            | (319.3)                                                                                                                                                                                                                         |\n| Other revenue                                                                                                                                                   | 485.1                                                                                                                                                                                                                                                                                             | 476.3                                                                                                                                                                                                                                                                                             | 774.6                                                                                                                                                                                                                                                                                             | 1.8                                                                                                                                                                                                                             | (38.5)                                                                                                                                                                                                                          | 8.8                                                                                                                                                                                                                             | (298.3)                                                                                                                                                                                                                         |\n| Total revenue                                                                                                                                                   | $ 10,173.4                                                                                                                                                                                                                                                                                        | $ 10,981.7                                                                                                                                                                                                                                                                                        | $ 13,444.6                                                                                                                                                                                                                                                                                        | (7.4)%                                                                                                                                                                                                                          | (18.3)%                                                                                                                                                                                                                         | $ (808.3)                                                                                                                                                                                                                       | $ (2,462.9)                                                                                                                                                                                                                     |\n\n## '3<7=@ \"=B3 &323;>B7=<\n\nIn July 2022 we redeemed our 3.625% Senior Notes totaling $1.0 billion in aggregate principal amount prior to their maturity on September 15, 2022.\n\nFor additional information on the redemption of our Senior Notes, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=13,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><230B32<3AA , to our consolidated financial statements included in this report.\n\nglyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=15,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>@=/2E/G '/:3 /<2  3/A30/19 (@/<A/1B7=<\n\nIn September 2022 we completed the sale of our building and land parcel located at 125 Broadway for an aggregate sales price of approximately $603.0 million, which is inclusive of a $10.8 million tenant allowance. Simultaneously, with the close of this transaction we leased back the building for a term of approximately 5.5 years.\n\nFor additional information on our 125 Broadway sale and leaseback transaction, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> $@=>3@BGglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> $:/<B /<2 glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>?C7>;3<B and \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> 3/A3A ,to our consolidated financial statements included in this report.",
        "metadata": {
            "page": 71
        },
        "id": "7925d943-db35-4d7c-bdf7-59ac3e5416ca"
    },
    {
        "page_content": "## 'DA6G5F )7H7@G7\n\n## Product revenue is summarized as follows glyph<c=26,font=/PIIBEG+FranklinGothic-Book>\n\n|                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                   | glyph<c=4,font=/PIIBCD+FranklinGothic-Book> glyph<c=26,font=/PIIBCD+FranklinGothic-Book>:3@97                                                                                                                                   | glyph<c=4,font=/PIIBCD+FranklinGothic-Book> glyph<c=26,font=/PIIBCD+FranklinGothic-Book>:3@97                                                                                                                                   | glyph<c=3,font=/PIIBCD+FranklinGothic-Book> glyph<c=26,font=/PIIBCD+FranklinGothic-Book>:3@97                                                                                                                                   | glyph<c=3,font=/PIIBCD+FranklinGothic-Book> glyph<c=26,font=/PIIBCD+FranklinGothic-Book>:3@97                                                                                                                                   |\n|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n|                                                                                                                                                                 | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book> HEglyph<c=11,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book> HEglyph<c=11,font=/PIIBCD+FranklinGothic-Book> |\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=9,font=/PIIBCD+FranklinGothic-Book> 7J57BF B7D57@F397Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                                                                                  | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                                                                                  | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                                                                                  | HEglyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                | HEglyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                |\n| Multiple Sclerosis (MS) glyph<c=26,font=/PIIBEG+FranklinGothic-Book>                                                                                            |                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                 |\n| TECFIDERA                                                                                                                                                       | $ 1,443.9                                                                                                                                                                                                                                                                                         | $ 1,951.9                                                                                                                                                                                                                                                                                         | $ 3,841.1                                                                                                                                                                                                                                                                                         | (26.0)%                                                                                                                                                                                                                         | (49.2)%                                                                                                                                                                                                                         | $ (508.0)                                                                                                                                                                                                                       | $ (1,889.2)                                                                                                                                                                                                                     |\n| VUMERITY (1)                                                                                                                                                    | 553.4                                                                                                                                                                                                                                                                                             | 410.4                                                                                                                                                                                                                                                                                             | 64.3                                                                                                                                                                                                                                                                                              | 34.8                                                                                                                                                                                                                            | 538.3                                                                                                                                                                                                                           | 143.0                                                                                                                                                                                                                           | 346.1                                                                                                                                                                                                                           |\n| Total Fumarate                                                                                                                                                  | 1,997.3                                                                                                                                                                                                                                                                                           | 2,362.3                                                                                                                                                                                                                                                                                           | 3,905.4                                                                                                                                                                                                                                                                                           | (15.5)                                                                                                                                                                                                                          | (39.5)                                                                                                                                                                                                                          | (365.0)                                                                                                                                                                                                                         | (1,543.1)                                                                                                                                                                                                                       |\n| AVONE 3                                                                                                                                                         | 973.5                                                                                                                                                                                                                                                                                             | 1,208.7                                                                                                                                                                                                                                                                                           | 1,491.9                                                                                                                                                                                                                                                                                           | (19.5)                                                                                                                                                                                                                          | (19.0)                                                                                                                                                                                                                          | (235.2)                                                                                                                                                                                                                         | (283.2)                                                                                                                                                                                                                         |\n| PLEGRIDY                                                                                                                                                        | 331.9                                                                                                                                                                                                                                                                                             | 357.4                                                                                                                                                                                                                                                                                             | 385.6                                                                                                                                                                                                                                                                                             | (7.1)                                                                                                                                                                                                                           | (7.3)                                                                                                                                                                                                                           | (25.5)                                                                                                                                                                                                                          | (28.2)                                                                                                                                                                                                                          |\n| Total Interferon                                                                                                                                                | 1,305.4                                                                                                                                                                                                                                                                                           | 1,566.1                                                                                                                                                                                                                                                                                           | 1,877.5                                                                                                                                                                                                                                                                                           | (16.6)                                                                                                                                                                                                                          | (16.6)                                                                                                                                                                                                                          | (260.7)                                                                                                                                                                                                                         | (311.4)                                                                                                                                                                                                                         |\n| TYSABRI                                                                                                                                                         | 2,030.9                                                                                                                                                                                                                                                                                           | 2,063.1                                                                                                                                                                                                                                                                                           | 1,946.1                                                                                                                                                                                                                                                                                           | (1.6)                                                                                                                                                                                                                           | 6.0                                                                                                                                                                                                                             | (32.2)                                                                                                                                                                                                                          | 117.0                                                                                                                                                                                                                           |\n| FAMPYRA                                                                                                                                                         | 96.6                                                                                                                                                                                                                                                                                              | 105.2                                                                                                                                                                                                                                                                                             | 103.1                                                                                                                                                                                                                                                                                             | (8.2)                                                                                                                                                                                                                           | 2.0                                                                                                                                                                                                                             | (8.6)                                                                                                                                                                                                                           | 2.1                                                                                                                                                                                                                             |\n| Subtotal glyph<c=26,font=/PIIBEG+FranklinGothic-Book> MS                                                                                                        | 5,430.2                                                                                                                                                                                                                                                                                           | 6,096.7                                                                                                                                                                                                                                                                                           | 7,832.1                                                                                                                                                                                                                                                                                           | (10.9)                                                                                                                                                                                                                          | (22.2)                                                                                                                                                                                                                          | (666.5)                                                                                                                                                                                                                         | (1,735.4)                                                                                                                                                                                                                       |\n| Spinal Muscular Atrophy glyph<c=26,font=/PIIBEG+FranklinGothic-Book>                                                                                            |                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                 |\n| SPINRAZA                                                                                                                                                        | 1,793.5                                                                                                                                                                                                                                                                                           | 1,905.1                                                                                                                                                                                                                                                                                           | 2,052.1                                                                                                                                                                                                                                                                                           | (5.9)                                                                                                                                                                                                                           | (7.2)                                                                                                                                                                                                                           | (111.6)                                                                                                                                                                                                                         | (147.0)                                                                                                                                                                                                                         |\n| Biosimilars glyph<c=26,font=/PIIBEG+FranklinGothic-Book>                                                                                                        |                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                 |\n| BENEPALI                                                                                                                                                        | 441.0                                                                                                                                                                                                                                                                                             | 498.3                                                                                                                                                                                                                                                                                             | 481.6                                                                                                                                                                                                                                                                                             | (11.5)                                                                                                                                                                                                                          | 3.5                                                                                                                                                                                                                             | (57.3)                                                                                                                                                                                                                          | 16.7                                                                                                                                                                                                                            |\n| IMRALDI                                                                                                                                                         | 224.5                                                                                                                                                                                                                                                                                             | 233.4                                                                                                                                                                                                                                                                                             | 216.3                                                                                                                                                                                                                                                                                             | (3.8)                                                                                                                                                                                                                           | 7.9                                                                                                                                                                                                                             | (8.9)                                                                                                                                                                                                                           | 17.1                                                                                                                                                                                                                            |\n| FLI 3 ABI                                                                                                                                                       | 81.3                                                                                                                                                                                                                                                                                              | 99.4                                                                                                                                                                                                                                                                                              | 97.9                                                                                                                                                                                                                                                                                              | (18.2)                                                                                                                                                                                                                          | 1.5                                                                                                                                                                                                                             | (18.1)                                                                                                                                                                                                                          | 1.5                                                                                                                                                                                                                             |\n| BYOOVIZ (2)                                                                                                                                                     | 4.3                                                                                                                                                                                                                                                                                               | Z                                                                                                                                                                                                                                                                                                 | Z                                                                                                                                                                                                                                                                                                 | nm                                                                                                                                                                                                                              | Z                                                                                                                                                                                                                               | 4.3                                                                                                                                                                                                                             | Z                                                                                                                                                                                                                               |\n| Subtotal glyph<c=26,font=/PIIBEG+FranklinGothic-Book> Biosimilars                                                                                               | 751.1                                                                                                                                                                                                                                                                                             | 831.1                                                                                                                                                                                                                                                                                             | 795.8                                                                                                                                                                                                                                                                                             | (9.6)                                                                                                                                                                                                                           | 4.4                                                                                                                                                                                                                             | (80.0)                                                                                                                                                                                                                          | 35.3                                                                                                                                                                                                                            |\n| Other glyph<c=26,font=/PIIBEG+FranklinGothic-Book>                                                                                                              |                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                 |\n| FUMADERM                                                                                                                                                        | 8.2                                                                                                                                                                                                                                                                                               | 11.0                                                                                                                                                                                                                                                                                              | 12.2                                                                                                                                                                                                                                                                                              | (25.5)                                                                                                                                                                                                                          | (9.8)                                                                                                                                                                                                                           | (2.8)                                                                                                                                                                                                                           | (1.2)                                                                                                                                                                                                                           |\n| ADUHELM                                                                                                                                                         | 4.8                                                                                                                                                                                                                                                                                               | 3.0                                                                                                                                                                                                                                                                                               | Z                                                                                                                                                                                                                                                                                                 | 60.0                                                                                                                                                                                                                            | nm                                                                                                                                                                                                                              | 1.8                                                                                                                                                                                                                             | 3.0                                                                                                                                                                                                                             |\n| Total product revenue, net                                                                                                                                      | $ 7,987.8                                                                                                                                                                                                                                                                                         | $ 8,846.9                                                                                                                                                                                                                                                                                         | $ 10,692.2                                                                                                                                                                                                                                                                                        | (9.7)%                                                                                                                                                                                                                          | (17.3)%                                                                                                                                                                                                                         | $ (859.1)                                                                                                                                                                                                                       | $ (1,845.3)                                                                                                                                                                                                                     |",
        "metadata": {
            "page": 72
        },
        "id": "49f7d4bf-6dfe-4d9d-b860-c56f1163a540"
    },
    {
        "page_content": "## glyph<c=25,font=/PIICNA+FranklinGothic-BookItal>6-5*1-& glyph<c=30,font=/PIICNA+FranklinGothic-BookItal>$-&304*4 glyph<c=3,font=/PIICNA+FranklinGothic-BookItal>glyph<c=25,font=/PIICNA+FranklinGothic-BookItal>glyph<c=30,font=/PIICNA+FranklinGothic-BookItal>glyph<c=4,font=/PIICNA+FranklinGothic-BookItal>\n\n## glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>C;/@/B3\n\nglyph<c=26,font=/PIIBFI+Quivira>8; =1. (.*;< glyph<c=25,font=/PIIBFI+Quivira>7-.glyph<c=24,font=/PIIBFI+Quivira>.,.6+.; glyph<c=14,font=/PIIBFI+Quivira>glyph<c=12,font=/PIIBFI+Quivira>glyph<c=8,font=/PIIBFI+Quivira> glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=8,font=/PIIBFI+Quivira> glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=12,font=/PIIBFI+Quivira> *7- glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>\n\n<!-- image -->\n\n<!-- image -->\n\n| $glyph<c=25,font=/PIIBFI+Quivira>glyph<c=23,font=/PIIBFI+Quivira>glyph<c=26,font=/PIIBFI+Quivira>glyph<c=28,font=/PIIBFI+Quivira>glyph<c=24,font=/PIIBFI+Quivira>glyph<c=25,font=/PIIBFI+Quivira>\"glyph<c=21,font=/PIIBFI+Quivira> glyph<c=9,font=/PIIBFI+Quivira> %72=.- #=*=.<   |\n|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| &%glyph<c=30,font=/PIIBFI+Quivira>glyph<c=25,font=/PIIBFI+Quivira>\"glyph<c=28,font=/PIIBFI+Quivira>$( glyph<c=9,font=/PIIBFI+Quivira> %72=.- #=*=.<                                                                                                                                |\n| $glyph<c=25,font=/PIIBFI+Quivira>glyph<c=23,font=/PIIBFI+Quivira>glyph<c=26,font=/PIIBFI+Quivira>glyph<c=28,font=/PIIBFI+Quivira>glyph<c=24,font=/PIIBFI+Quivira>glyph<c=25,font=/PIIBFI+Quivira>\"glyph<c=21,font=/PIIBFI+Quivira> glyph<c=9,font=/PIIBFI+Quivira> \".<= 8/ @8;5-   |\n| &%glyph<c=30,font=/PIIBFI+Quivira>glyph<c=25,font=/PIIBFI+Quivira>\"glyph<c=28,font=/PIIBFI+Quivira>$( glyph<c=9,font=/PIIBFI+Quivira> \".<= 8/ @8;5-                                                                                                                                |\n\nFumarate revenue includes sales from TECFIDERA and VUMERITY. During the fourth quarter of 2021 VUMERITY was approved for the treatment of RRMS in the E.U., Switzerland and the U.K.\n\nFor 2022 compared to 2021, the 13.8% decrease in U.S. Fumarate revenue was primarily due to a decrease in TECFIDERA demand as a result of multiple TECFIDERA generic entrants in the U.S. market, partially offset by net price increases in TECFIDERA driven by lower pharmacy rebates, managed care rebates and co-pay assistance as well as an increase in VUMERITY sales volumes.\n\nFor 2022 compared to 2021, the 16.9% decrease in rest of world Fumarate revenue was primarily due to TECFIDERA pricing reductions and a decrease in TECFIDERA demand as multiple TECFIDERA generic entrants entered into markets such as Germany and Canada. The decrease was also driven by the unfavorable impact of foreign currency exchange, partially offset by an increase in VUMERITY sales volumes.\n\nIn the E.U., we are seeking to enforce a patent granted in June 2022 that relates to TECFIDERA and expires in 2028. In addition, we are litigating to affirm that TECFIDERA is entitled to regulatory data and market protection until at least February 2024. Our Company, the EMA and the EC have each appealed the May 2021 decision of the European General Court, which annulled the EMA's decision not to\n\nvalidate an application for approval of a TECFIDERA generic on the basis that the EMA and EC conducted the wrong assessment when determining TECFIDERA's entitlement to regulatory data and marketing protection. Our Company, the EMA and the EC have each appealed the General Court's decision as wrongly decided and the appeal is pending. On October 6, 2022, the Advocate General of the CJEU issued a nonbinding advisory opinion in Biogen's favor. This opinion recommends that the CJEU set aside the judgment of the European General Court. We are awaiting the decision of the CJEU.\n\nFor additional information, please read \"=B3 glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> 7B75/B7=<glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> to our consolidated financial statements included in this report.\n\nWe expect that TECFIDERA revenue will continue to decline in 2023, compared to 2022, as a result of generic competition in the North America, Latin America and certain E.U. countries.\n\nWe expect an increase in VUMERITY sales volumes in 2023, compared to 2022, mostly due to demand growth in the U.S. and select European markets. We believe that we have resolved previously reported manufacturing issues at our contract manufacturer. In addition, we are in the process of securing regulatory approval for a secondary source of supply. We do not anticipate a supply shortage in 2023 and are currently focused on rebuilding adequate inventory.",
        "metadata": {
            "page": 73
        },
        "id": "a1e8bab1-0d09-4562-b2d0-26b01283335d"
    },
    {
        "page_content": "glyph<c=26,font=/PIIBFI+Quivira>8; =1. (.*;< glyph<c=25,font=/PIIBFI+Quivira>7-.glyph<c=24,font=/PIIBFI+Quivira>.,.6+.; glyph<c=14,font=/PIIBFI+Quivira>glyph<c=12,font=/PIIBFI+Quivira>glyph<c=8,font=/PIIBFI+Quivira> glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=8,font=/PIIBFI+Quivira> glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=12,font=/PIIBFI+Quivira> *7- glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>\n\n<!-- image -->\n\nglyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>\n\nglyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=12,font=/PIIBFI+Quivira>\n\nglyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>\n\nglyph<c=21,font=/PIIBFI+Quivira>& glyph<c=31,font=/PIIBFI+Quivira>glyph<c=25,font=/PIIBFI+Quivira>'\n\nglyph<c=9,font=/PIIBFI+Quivira>\n\n%72=.- #=*=.<\n\nglyph<c=21,font=/PIIBFI+Quivira>& glyph<c=31,font=/PIIBFI+Quivira>glyph<c=25,font=/PIIBFI+Quivira>'\n\nglyph<c=9,font=/PIIBFI+Quivira>\n\n\".<= 8/ @8;5-\n\n!glyph<c=29,font=/PIIBFI+Quivira>glyph<c=25,font=/PIIBFI+Quivira>glyph<c=27,font=/PIIBFI+Quivira>\"glyph<c=28,font=/PIIBFI+Quivira>glyph<c=24,font=/PIIBFI+Quivira>(\n\nglyph<c=9,font=/PIIBFI+Quivira>\n\n%72=.- #=*=.<\n\n!glyph<c=29,font=/PIIBFI+Quivira>glyph<c=25,font=/PIIBFI+Quivira>glyph<c=27,font=/PIIBFI+Quivira>\"glyph<c=28,font=/PIIBFI+Quivira>glyph<c=24,font=/PIIBFI+Quivira>(\n\nglyph<c=9,font=/PIIBFI+Quivira>\n\n\".<= 8/ @8;5-\n\nFor 2022 compared to 2021, the 18.9% decrease in U.S. Interferon revenue was primarily due to a decrease in Interferon sales volumes of 15.5%. The net decline in sales volumes reflects the continued decline of the Interferon market as patients transition to higher efficacy and oral MS therapies.\n\nFor 2022 compared to 2021, the 12.9% decrease in rest of world Interferon revenue was primarily due to a decrease in Interferon sales volumes of 6.0% resulting from the continued decline of the Interferon market as patients transition to higher efficacy and oral MS therapies, as well as the unfavorable impact of foreign currency exchange.\n\nWe expect that Interferon revenue will continue to decline in both the U.S. and rest of world markets in 2023, compared to 2022, as a result of increasing competition from other MS products.\n\nglyph<c=26,font=/PIIBFI+Quivira>8; =1. (.*;< glyph<c=25,font=/PIIBFI+Quivira>7-.glyph<c=24,font=/PIIBFI+Quivira>.,.6+.; glyph<c=14,font=/PIIBFI+Quivira>glyph<c=12,font=/PIIBFI+Quivira>glyph<c=8,font=/PIIBFI+Quivira> glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=8,font=/PIIBFI+Quivira> glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=12,font=/PIIBFI+Quivira> *7- glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>\n\n<!-- image -->\n\nFor 2022 compared to 2021, U.S. TYSABRI revenue was relatively flat, with a modest decrease in sales volumes, partially offset by an increase in pricing, net of higher discounts and allowances.\n\nFor 2022 compared to 2021, rest of world TYSABRI revenue was relatively flat, with a modest decrease in pricing and the unfavorable impact of foreign currency exchange, partially offset by an increase in sales volumes.\n\nWe anticipate TYSABRI revenue to be relatively flat on a global basis in 2023, compared to 2022, despite increasing competition from additional treatments for MS. We expect to continue to face price reductions in certain European markets. We are also aware of a potential biosimilar entrant of TYSABRI that may enter the U.S. and European markets as early as 2023.",
        "metadata": {
            "page": 74
        },
        "id": "860adcbe-43d4-4c83-8f5c-b676498e777c"
    },
    {
        "page_content": "## '$glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>\"&glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>.glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>\n\nglyph<c=26,font=/PIIBFI+Quivira>8; =1. (.*;< glyph<c=25,font=/PIIBFI+Quivira>7-.glyph<c=24,font=/PIIBFI+Quivira>.,.6+.; glyph<c=14,font=/PIIBFI+Quivira>glyph<c=12,font=/PIIBFI+Quivira>glyph<c=8,font=/PIIBFI+Quivira> glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=8,font=/PIIBFI+Quivira> glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=12,font=/PIIBFI+Quivira> *7- glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>\n\n<!-- image -->\n\nFor 2022 compared to 2021, U.S. SPINRAZA revenue was relatively flat, with a modest increase in sales volumes of 3.7%, resulting from the timing of shipments, partially offset by higher discounts and allowances.\n\nFor 2022 compared to 2021, the 9.4% decrease in rest of world SPINRAZA revenue was primarily due to country mix, the unfavorable impact of foreign currency exchange and the timing of shipments, partially offset by an increase in sales volumes. The increase in sales volumes reflects growth in certain Asian markets, partially offset by a decrease in sales volumes from increased competition in certain established markets, particularly Germany and Japan.\n\nDespite competition from a gene therapy product and an oral product, we anticipate SPINRAZA revenue to be relatively flat in 2023, compared to 2022. Moderate growth in the U.S. as well as continued access expansion in emerging markets is expected to offset increased competition and the impact of loading dose dynamics.\n\nFor additional information on our collaboration arrangements with Ionis, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>Aglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> to our consolidated financial statements included in this report.\n\n## glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>\"glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>$glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>!&glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>,glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal> /<2 glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>-##*glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>.\n\nglyph<c=26,font=/PIIBFI+Quivira>8; =1. (.*;< glyph<c=25,font=/PIIBFI+Quivira>7-.glyph<c=24,font=/PIIBFI+Quivira>.,.6+.; glyph<c=14,font=/PIIBFI+Quivira>glyph<c=12,font=/PIIBFI+Quivira>glyph<c=8,font=/PIIBFI+Quivira> glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=8,font=/PIIBFI+Quivira> glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=12,font=/PIIBFI+Quivira> *7- glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>\n\n255287<glyph<c=7,font=/PIIBFI+Quivira>\n\n6\n\nglyph<c=6,font=/PIIBFI+Quivira>glyph<c=28,font=/PIIBFI+Quivira>7\n\n<!-- image -->\n\nDuring the third quarter of 2021 BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS, was approved in the U.S., the E.U and the U.K. BYOOVIZ launched in the U.S. in June 2022 and became commercially available in July 2022 through major distributors in the U.S.\n\nFor 2022 compared to 2021, the 9.6% decrease in biosimilar revenue was primarily due to unfavorable pricing and the unfavorable impact of foreign currency exchange, partially offset by an increase in sales volumes.\n\nWe anticipate modest growth in revenue from our biosimilars business in 2023, compared to 2022, driven by the continued launch of BYOOVIZ in the U.S. and rest of world, offset in part by continued price reductions in certain markets.\n\nWe are currently working with our contract manufacturer for IMRALDI to address facility regulatory inspection deficiencies at two filling locations, which could impact supply and have an adverse impact on 2023 IMRALDI sales, if not resolved. Manufacturing of BENEPALI also utilizes one of these facilities and therefore could have an adverse impact on 2023 BENEPALI sales. We are working with our existing secondary supplier for BENEPALI with the aim to secure additional capacity.",
        "metadata": {
            "page": 75
        },
        "id": "312ca362-7b0b-4c37-8d1d-e8f47228c173"
    },
    {
        "page_content": "For additional information on our collaboration arrangements with Samsung Bioepis, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>Aglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> to our consolidated financial statements included in this report.\n\n)7H7@G7 8DA? glyph<c=24,font=/PIIBCD+FranklinGothic-Book>@F;glyph<c=10,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book> +:7D3B7GF;5 'DA9D3?E\n\nglyph<c=20,font=/PIICNA+FranklinGothic-BookItal>&/&/5&$) glyph<c=3,font=/PIICNA+FranklinGothic-BookItal>glyph<c=29,font=/PIICNA+FranklinGothic-BookItal>0$)& glyph<c=20,font=/PIICNA+FranklinGothic-BookItal>3061glyph<c=4,font=/PIICNA+FranklinGothic-BookItal>\n\nOur share of RITU 3 AN, including RITU 3 AN HYCELA, and GAZYVA collaboration operating profits in the U.S., royalty revenue on sales of OCREVUS and other revenue from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this discussion, we refer to RITU 3 AN and RITU 3 AN HYCELA collectively as RITU 3 AN.\n\nglyph<c=26,font=/PIIBFI+Quivira>8; =1. (.*;< glyph<c=25,font=/PIIBFI+Quivira>7-.glyph<c=24,font=/PIIBFI+Quivira>.,.6+.; glyph<c=14,font=/PIIBFI+Quivira>glyph<c=12,font=/PIIBFI+Quivira>glyph<c=8,font=/PIIBFI+Quivira> glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=8,font=/PIIBFI+Quivira> glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=12,font=/PIIBFI+Quivira> *7- glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>\n\n<!-- image -->\n\n- glyph<c=22,font=/PIIBFI+Quivira>280.7glyph<c=5,font=/PIIBFI+Quivira>< <1*;. 8/ 9;.glyph<c=9,font=/PIIBFI+Quivira>=*A 9;8/2=< 27 =1. %glyph<c=10,font=/PIIBFI+Quivira>#glyph<c=10,font=/PIIBFI+Quivira> /8; \"glyph<c=28,font=/PIIBFI+Quivira>$%'glyph<c=21,font=/PIIBFI+Quivira>glyph<c=31,font=/PIIBFI+Quivira> *7- glyph<c=27,font=/PIIBFI+Quivira>glyph<c=21,font=/PIIBFI+Quivira>)(&glyph<c=21,font=/PIIBFI+Quivira>\n- \"8B*5=B ;.?.7>. 87 <*5.< 8/  glyph<c=23,font=/PIIBFI+Quivira>\"glyph<c=25,font=/PIIBFI+Quivira>&%#\n- =1.; ;.?.7>. /;86 *7=2glyph<c=9,font=/PIIBFI+Quivira>glyph<c=23,font=/PIIBFI+Quivira>glyph<c=24,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira> =1.;*9.>=2, 9;80;*6<\n\nglyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>7=53<MA '6/@3 =4 $@3glyph<c=8,font=/PIIBDE+FranklinGothic-BookItal>B/F $@=47BA 7< B63 )glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal>'glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal> 4=@ &glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>(),glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>\" /<2 glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>.-*glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>\n\nThe following table provides a summary of amounts comprising our share of pre-tax profits in the U.S. for RITU 3 AN and GAZYVA glyph<c=26,font=/PIIBEG+FranklinGothic-Book>\n\n|                                                                                                   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    |\n| Product revenue, net                                                                              | $ 1,729.2                                                                                                                                                                                                                                                                                           | $ 2,032.0                                                                                                                                                                                                                                                                                           | $ 3,334.1                                                                                                                                                                                                                                                                                           |\n| Cost and expense                                                                                  | 253.6                                                                                                                                                                                                                                                                                               | 291.8                                                                                                                                                                                                                                                                                               | 433.0                                                                                                                                                                                                                                                                                               |\n| Pre-tax profits in the U.S.                                                                       | $ 1,475.6                                                                                                                                                                                                                                                                                           | $ 1,740.2                                                                                                                                                                                                                                                                                           | $ 2,901.1                                                                                                                                                                                                                                                                                           |\n| Biogen's share of pre- tax profits                                                                | $ 547.0                                                                                                                                                                                                                                                                                             | $ 647.7                                                                                                                                                                                                                                                                                             | $ 1,080.2                                                                                                                                                                                                                                                                                           |\n\nFor 2022 compared to 2021, the decrease in U.S. product revenue, net was primarily due to a decrease in sales volumes of RITU 3 AN in the U.S. of\n\n28.4%, primarily due to the onset of competition from multiple biosimilar products.\n\nFor 2022 compared to 2021, the decrease in collaboration costs and expense was primarily due to lower cost of sales, selling and marketing expense, distribution costs and other costs and expense related to RITU 3 AN.\n\nWe are aware of several other anti-CD20 molecules, including biosimilar products, that have been approved and are competing with RITU 3 AN and GAZYVA in the oncology and other markets. Biosimilar products referencing RITU 3 AN have launched in the U.S and are being offered at lower prices. This competition has had a significant adverse impact on the pre-tax profits of our collaboration arrangements with Genentech, as the sales of RITU 3 AN have decreased substantially compared to prior periods. We expect that biosimilar competition will continue to increase as these products capture additional market share and that this will have a significant adverse impact on our co-promotion profits in the U.S. in future years.\n\n&=G/:BG &3D3<C3 =< '/:3A =4 #glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>&glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>*)'\n\nFor 2022 compared to 2021, the increase in royalty revenue on sales of OCREVUS was primarily due to sales growth of OCREVUS in the U.S.\n\nOCREVUS royalty revenue is based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenue will be adjusted for in the period in which they become known, which is generally expected to be the following quarter.\n\n#B63@ &3D3<C3 4@=; glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal><B7glyph<c=8,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=10,font=/PIIBDE+FranklinGothic-BookItal> (63@/>3CB71 $@=5@/;A\n\nOther revenue from anti-CD20 therapeutic programs consists of our share of pre-tax copromotion profits from RITU 3 AN in Canada.\n\nIn December 2022 the FDA approved LUNSUMIO, a bispecific antibody for the treatment of relapsed or refractory follicular lymphoma. Our share of pre-tax profits and losses on LUNSUMIO will be included as a component of revenue from anti-CD20 therapeutic programs in our consolidated statements of income. For the year ended December 31, 2022, LUNSUMIO revenue was immaterial.\n\nFor additional information on our collaboration arrangements with Genentech, including information regarding the pre-tax profit-sharing formula and its impact on future revenue from anti-CD20 therapeutic programs, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>Aglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> to our consolidated financial statements included in this report.",
        "metadata": {
            "page": 76
        },
        "id": "b60ea493-0511-4644-adad-faac5951d841"
    },
    {
        "page_content": "## &F:7D )7H7@G7\n\nOther revenue consists of royalty revenue and contract manufacturing and other revenue and is summarized as follows glyph<c=26,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=29,font=/PIICNA+FranklinGothic-BookItal>0:\"-5: glyph<c=29,font=/PIICNA+FranklinGothic-BookItal>&7&/6& \"/% glyph<c=16,font=/PIICNA+FranklinGothic-BookItal>0/53\"$5 glyph<c=25,font=/PIICNA+FranklinGothic-BookItal>\"/6'\"$563*/( \"/% glyph<c=27,font=/PIICNA+FranklinGothic-BookItal>5)&3 glyph<c=29,font=/PIICNA+FranklinGothic-BookItal>&7&/6&\n\nglyph<c=26,font=/PIIBFI+Quivira>8; =1. (.*;< glyph<c=25,font=/PIIBFI+Quivira>7-.glyph<c=24,font=/PIIBFI+Quivira>.,.6+.; glyph<c=14,font=/PIIBFI+Quivira>glyph<c=12,font=/PIIBFI+Quivira>glyph<c=8,font=/PIIBFI+Quivira> glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=8,font=/PIIBFI+Quivira> glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=12,font=/PIIBFI+Quivira> *7- glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>\n\nglyph<c=2,font=/PIIBFI+Quivira>glyph<c=18,font=/PIIBFI+Quivira>glyph<c=18,font=/PIIBFI+Quivira>glyph<c=15,font=/PIIBFI+Quivira>glyph<c=10,font=/PIIBFI+Quivira>glyph<c=17,font=/PIIBFI+Quivira>\n\n<!-- image -->\n\n\"8B*5=B\n\nglyph<c=23,font=/PIIBFI+Quivira>87=;*,=\n\n6*7>/*,=>;270 *7- 8=1.;\n\nglyph<c=16,font=/PIICNA+FranklinGothic-BookItal>0/53\"$5 glyph<c=25,font=/PIICNA+FranklinGothic-BookItal>\"/6'\"$563*/( \"/% glyph<c=27,font=/PIICNA+FranklinGothic-BookItal>5)&3 glyph<c=29,font=/PIICNA+FranklinGothic-BookItal>&7&/6&\n\nWe record contract manufacturing and other revenue primarily from amounts earned under contract manufacturing agreements.\n\nFor 2022 compared to 2021, the decrease in contract manufacturing and other revenue was primarily due to lower contract manufacturing revenue related to the timing of batch releases.\n\n## glyph<c=29,font=/PIICNA+FranklinGothic-BookItal>0:\"-5: glyph<c=29,font=/PIICNA+FranklinGothic-BookItal>&7&/6&\n\nWe receive royalties from net sales on products related to patents that we have out-licensed, as well as royalty revenue on biosimilar products from our collaboration arrangements with Samsung Bioepis.\n\nFor additional information on our collaborative arrangements with Samsung Bioepis, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>A , to our consolidated financial statements included in this report.\n\n## )7E7DH7E 8AD glyph<c=27,font=/PIIBCD+FranklinGothic-Book>;E5AG@FE 3@6 glyph<c=24,font=/PIIBCD+FranklinGothic-Book>>>AI3@57E\n\nRevenue from product sales is recorded net of reserves established for applicable discounts and\n\nallowances, including those associated with the implementation of pricing actions in certain international markets where we operate.\n\nThese reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). These estimates reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.\n\nReserves for discounts, contractual adjustments and returns that reduced gross product revenue are summarized as follows glyph<c=26,font=/PIIBEG+FranklinGothic-Book>\n\nglyph<c=26,font=/PIIBFI+Quivira>8; =1. (.*;< glyph<c=25,font=/PIIBFI+Quivira>7-.glyph<c=24,font=/PIIBFI+Quivira>.,.6+.; glyph<c=14,font=/PIIBFI+Quivira>glyph<c=12,font=/PIIBFI+Quivira>glyph<c=8,font=/PIIBFI+Quivira> glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=8,font=/PIIBFI+Quivira> glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=12,font=/PIIBFI+Quivira> *7- glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>\n\n255287<glyph<c=7,font=/PIIBFI+Quivira>\n\n6\n\nglyph<c=6,font=/PIIBFI+Quivira>glyph<c=28,font=/PIIBFI+Quivira>7\n\n<!-- image -->\n\n<!-- image -->\n\n<!-- image -->\n\nglyph<c=24,font=/PIIBFI+Quivira>2<,8>7=<\n\nglyph<c=23,font=/PIIBFI+Quivira>87=;*,=>*5\n\n*-3><=6.7=<\n\n\".=>;7<",
        "metadata": {
            "page": 77
        },
        "id": "cf86caf4-7ac5-4747-8a85-47e928cf973a"
    },
    {
        "page_content": "For the years ended December 31, 2022, 2021 and 2020, reserves for discounts and allowances as a percentage of gross product revenue were 30.1%, 28.6% and 27.1%, respectively.\n\n## glyph<c=17,font=/PIICNA+FranklinGothic-BookItal>*4$06/54\n\nDiscounts include trade term discounts and wholesaler incentives.\n\nFor 2022 compared to 2021, the decrease in discounts was primarily due to a decrease in gross sales, driven by lower TECFIDERA sales, offset by higher purchase discounts for TYSABRI.\n\n## glyph<c=16,font=/PIICNA+FranklinGothic-BookItal>0/53\"$56\"glyph<c=14,font=/PIICNA+FranklinGothic-BookItal>%+645.&/54\n\nContractual adjustments primarily relate to Medicaid and managed care rebates in the U.S., pharmacy rebates, co-payment (copay) assistance, Veterans Administration, 340B discounts, specialty pharmacy program fees and other government rebates or applicable allowances.\n\nFor 2022 compared to 2021, the decrease in contractual adjustments was primarily driven by lower\n\n## glyph<c=26,font=/PIIBCD+FranklinGothic-Book>AEF 3@6 glyph<c=28,font=/PIIBCD+FranklinGothic-Book>JB7@E7\n\nA summary of total cost and expense is as follows glyph<c=26,font=/PIIBEG+FranklinGothic-Book>\n\n|                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                   | glyph<c=4,font=/PIIBCD+FranklinGothic-Book> glyph<c=26,font=/PIIBCD+FranklinGothic-Book>:3@97                                                                                                                                   | glyph<c=4,font=/PIIBCD+FranklinGothic-Book> glyph<c=26,font=/PIIBCD+FranklinGothic-Book>:3@97                                                                                                                                   | glyph<c=3,font=/PIIBCD+FranklinGothic-Book> glyph<c=26,font=/PIIBCD+FranklinGothic-Book>:3@97                                                                                                                                   | glyph<c=3,font=/PIIBCD+FranklinGothic-Book> glyph<c=26,font=/PIIBCD+FranklinGothic-Book>:3@97                                                                                                                                   |\n|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n|                                                                                                                                                                 | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book> HEglyph<c=11,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                |\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=9,font=/PIIBCD+FranklinGothic-Book> 7J57BF B7D57@F397Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                                                                                  | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                                                                                  | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                                                                                  | HEglyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book> | HEglyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                | HEglyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book> |\n| Cost of sales, excluding amortization and impairment of acquired intangible assets                                                                              | $ 2,278.3                                                                                                                                                                                                                                                                                         | $ 2,109.7                                                                                                                                                                                                                                                                                         | $ 1,805.2                                                                                                                                                                                                                                                                                         | 8.0 %                                                                                                                                                                                                                           | 16.9 %                                                                                                                                                                                                                          | $ 168.6                                                                                                                                                                                                                         | $ 304.5                                                                                                                                                                                                                         |\n| Research and development                                                                                                                                        | 2,231.1                                                                                                                                                                                                                                                                                           | 2,501.2                                                                                                                                                                                                                                                                                           | 3,990.9                                                                                                                                                                                                                                                                                           | (10.8)                                                                                                                                                                                                                          | (37.3)                                                                                                                                                                                                                          | (270.1)                                                                                                                                                                                                                         | (1,489.7)                                                                                                                                                                                                                       |\n| Selling, general and administrative                                                                                                                             | 2,403.6                                                                                                                                                                                                                                                                                           | 2,674.3                                                                                                                                                                                                                                                                                           | 2,504.5                                                                                                                                                                                                                                                                                           | (10.1)                                                                                                                                                                                                                          | 6.8                                                                                                                                                                                                                             | (270.7)                                                                                                                                                                                                                         | 169.8                                                                                                                                                                                                                           |\n| Amortization and impairment of acquired intangible assets                                                                                                       | 365.9                                                                                                                                                                                                                                                                                             | 881.3                                                                                                                                                                                                                                                                                             | 464.8                                                                                                                                                                                                                                                                                             | (58.5)                                                                                                                                                                                                                          | 89.6                                                                                                                                                                                                                            | (515.4)                                                                                                                                                                                                                         | 416.5                                                                                                                                                                                                                           |\n| Collaboration profit (loss) sharing                                                                                                                             | (7.4)                                                                                                                                                                                                                                                                                             | 7.2                                                                                                                                                                                                                                                                                               | 232.9                                                                                                                                                                                                                                                                                             | (202.8)                                                                                                                                                                                                                         | (96.9)                                                                                                                                                                                                                          | (14.6)                                                                                                                                                                                                                          | (225.7)                                                                                                                                                                                                                         |\n| (Gain) loss on divestiture of Hiller X d, Denmark manufacturing operations                                                                                      | Z                                                                                                                                                                                                                                                                                                 | Z                                                                                                                                                                                                                                                                                                 | (92.5)                                                                                                                                                                                                                                                                                            | Z                                                                                                                                                                                                                               | nm                                                                                                                                                                                                                              | Z                                                                                                                                                                                                                               | 92.5                                                                                                                                                                                                                            |\n| (Gain) loss on fair value remeasurement of contingent consideration                                                                                             | (209.1)                                                                                                                                                                                                                                                                                           | (50.7)                                                                                                                                                                                                                                                                                            | (86.3)                                                                                                                                                                                                                                                                                            | 312.4                                                                                                                                                                                                                           | (41.3)                                                                                                                                                                                                                          | (158.4)                                                                                                                                                                                                                         | 35.6                                                                                                                                                                                                                            |\n| Acquired in-process research and development                                                                                                                    | Z                                                                                                                                                                                                                                                                                                 | 18.0                                                                                                                                                                                                                                                                                              | 75.0                                                                                                                                                                                                                                                                                              | (100.0)                                                                                                                                                                                                                         | (76.0)                                                                                                                                                                                                                          | (18.0)                                                                                                                                                                                                                          | (57.0)                                                                                                                                                                                                                          |\n| Restructuring charges                                                                                                                                           | 131.1                                                                                                                                                                                                                                                                                             | Z                                                                                                                                                                                                                                                                                                 | Z                                                                                                                                                                                                                                                                                                 | nm                                                                                                                                                                                                                              | Z                                                                                                                                                                                                                               | 131.1                                                                                                                                                                                                                           | Z                                                                                                                                                                                                                               |\n| Gain on sale of building                                                                                                                                        | (503.7)                                                                                                                                                                                                                                                                                           | Z                                                                                                                                                                                                                                                                                                 | Z                                                                                                                                                                                                                                                                                                 | nm                                                                                                                                                                                                                              | Z                                                                                                                                                                                                                               | (503.7)                                                                                                                                                                                                                         | Z                                                                                                                                                                                                                               |\n| Other (income) expense, net                                                                                                                                     | (108.2)                                                                                                                                                                                                                                                                                           | 1,095.5                                                                                                                                                                                                                                                                                           | (497.4)                                                                                                                                                                                                                                                                                           | (109.9)                                                                                                                                                                                                                         | (320.2)                                                                                                                                                                                                                         | (1,203.7)                                                                                                                                                                                                                       | 1,592.9                                                                                                                                                                                                                         |\n| Total cost and expense                                                                                                                                          | $ 6,581.6                                                                                                                                                                                                                                                                                         | $ 9,236.5                                                                                                                                                                                                                                                                                         | $ 8,397.1                                                                                                                                                                                                                                                                                         | (28.7)%                                                                                                                                                                                                                         | 10.0 %                                                                                                                                                                                                                          | $(2,654.9)                                                                                                                                                                                                                      | $ 839.4                                                                                                                                                                                                                         |\n\nTECFIDERA sales in the U.S., resulting in lower pharmacy rebates, Medicaid rebates and managed care rebates, as well as lower Medicaid rebates in the U.S. driven by a favorable change in estimates for VUMERITY.\n\n## glyph<c=29,font=/PIICNA+FranklinGothic-BookItal>&563/4\n\nProduct return reserves are established for returns made by wholesalers. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Provisions for product returns are recognized in the period the related revenue is recognized, resulting in a reduction to product sales.\n\nFor 2022 compared to 2021, return reserves were relatively consistent.\n\nFor additional information on our revenue reserves, please read \"=B3 glyph<c=15,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> &3D3<C3glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> to our consolidated financial statements included in this report.",
        "metadata": {
            "page": 78
        },
        "id": "c512fdae-688d-41ca-b974-93bf331cf5b9"
    },
    {
        "page_content": "glyph<c=16,font=/PIICNA+FranklinGothic-BookItal>045 0' glyph<c=30,font=/PIICNA+FranklinGothic-BookItal>\"-&4glyph<c=5,font=/PIICNA+FranklinGothic-BookItal> glyph<c=18,font=/PIICNA+FranklinGothic-BookItal>9$-6%*/( glyph<c=14,font=/PIICNA+FranklinGothic-BookItal>.035*;\"5*0/ \"/% glyph<c=22,font=/PIICNA+FranklinGothic-BookItal>.1\"*3.&/5 0' glyph<c=14,font=/PIICNA+FranklinGothic-BookItal>$26*3&% glyph<c=22,font=/PIICNA+FranklinGothic-BookItal>/5\"/(*#-& glyph<c=14,font=/PIICNA+FranklinGothic-BookItal>44&54\n\nglyph<c=26,font=/PIIBFI+Quivira>8; =1. (.*;< glyph<c=25,font=/PIIBFI+Quivira>7-.glyph<c=24,font=/PIIBFI+Quivira>.,.6+.; glyph<c=14,font=/PIIBFI+Quivira>glyph<c=12,font=/PIIBFI+Quivira>glyph<c=8,font=/PIIBFI+Quivira> glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=8,font=/PIIBFI+Quivira> glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=12,font=/PIIBFI+Quivira> *7- glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>\n\n<!-- image -->\n\nCost of sales, as a percentage of total revenue, were 22.4%, 19.2% and 13.4% for the years ended December 31, 2022, 2021 and 2020, respectively.\n\n## $@=2C1B glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=AB =4 '/:3A\n\nFor 2022 compared to 2021, the increase in product cost of sales was primarily due to higher charges in 2022 associated with the write-off of excess ADUHELM inventory and purchase commitments, higher gross idle capacity charges associated with our manufacturing facilities and increased product cost of sales driven by product mix.\n\nInventory amounts written down as a result of excess, obsolescence or unmarketability totaled $336.2 million, $167.6 million and $26.6 million for the years ended December 31, 2022, 2021 and 2020, respectively.\n\nFor the years ended December 31, 2022 and 2021, we recorded approximately $286.0 million and $170.0 million, respectively, of charges associated with the write-off of ADUHELM inventory and purchase commitments in excess of forecasted demand.\n\nFor the years ended December 31, 2022 and 2021, we recorded approximately $119.0 million and $48.0 million, respectively, of aggregate gross idle capacity charges.\n\nWe have also recognized approximately $197.0 million and $99.0 million related to Eisai's 45.0% share of inventory, idle capacity charges and contractual commitments, which was recorded in collaboration profit (loss) sharing within our consolidated statements of income for the years ended December 31, 2022 and 2021, respectively.\n\nFor additional information on our collaboration arrangements with Eisai, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>A , to our consolidated financial statements included in this report.\n\n## &=G/:BG glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=AB =4 '/:3A\n\nFor 2022 compared to 2021, the decrease in royalty cost of sales was primarily due to lower royalties payable on lower sales of SPINRAZA, TYSABRI and AVONE 3 , partially offset by higher royalties payable on higher sales of VUMERITY.\n\nglyph<c=29,font=/PIICNA+FranklinGothic-BookItal>&4&\"3$) \"/% glyph<c=17,font=/PIICNA+FranklinGothic-BookItal>&7&-01.&/5\n\nglyph<c=26,font=/PIIBFI+Quivira>8; =1. (.*;< glyph<c=25,font=/PIIBFI+Quivira>7-.glyph<c=24,font=/PIIBFI+Quivira>.,.6+.; glyph<c=14,font=/PIIBFI+Quivira>glyph<c=12,font=/PIIBFI+Quivira>glyph<c=8,font=/PIIBFI+Quivira> glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=8,font=/PIIBFI+Quivira> glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=12,font=/PIIBFI+Quivira> *7- glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>glyph<c=13,font=/PIIBFI+Quivira>glyph<c=11,font=/PIIBFI+Quivira>\n\n<!-- image -->\n\n\".<.*;,1 *7- -.?.5896.7= .A9.7<.\n\n\".<.*;,1 *7- -.?.5896.7= .A9.7<. *< * 9.;,.7=*0. 8/ =8=*5 ;.?.7>.",
        "metadata": {
            "page": 79
        },
        "id": "18cf0788-0edb-4b85-a5c1-ea10539ee03e"
    },
    {
        "page_content": "illions)\n\nm\n\n(In\n\nFor the Years Ended December 31, 2022, 2021 and 2020\n\n<!-- image -->\n\n2022\n\n2021\n\n2020\n\nMarketed products\n\n- Late stage programs\n- Early stage programs\n- Research and discovery\n- Other research and development costs\n- Milestone and upfront expense\n\nWe support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.\n\nA significant amount of our research and development costs consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as management costs, as well as depreciation, information technology and facility-based expenses. These costs are considered other research and development costs in the table above and are not allocated to a specific program or stage.\n\nResearch and development expense incurred in support of our marketed products includes costs associated with product lifecycle management activities including, if applicable, costs associated with the development of new indications for existing products. Late stage programs are programs in Phase 3 development or in registration stage. Early stage programs are programs in Phase 1 or Phase 2 development. Research and discovery represents costs incurred to support our discovery research and translational science efforts. Costs are reflected in the development stage based upon the program status when incurred. Therefore, the same program could be reflected in different development stages in the same year. For several of our programs, the research and development activities are part of our collaborative and other relationships. Our costs reflect our share of the total costs incurred.\n\nFor 2022 compared to 2021, the decrease in research and development expense was primarily due to higher milestone payments in 2021, partially offset by the advancement of BIIB059 (anti-BDCA2) for the potential treatment of SLE and CLE, the development of LUNSUMIO, a bispecific antibody for the treatment of relapsed or refractory follicular lymphoma, the development of BIIB124 (SAGE-324) for the potential treatment of essential tremor, which we are developing in collaboration with Sage, the development of BIIB122 (DNL151) for the potential treatment of Parkinson's disease, which we are developing in collaboration with Denali, and the development of BIIB800, a proposed tocilizumab biosimilar referencing ACTEMRA.\n\nExcluding upfront payments, we expect our core research and development expense to modestly increase in 2023, as we continue to invest in our pipeline. We intend to continue committing significant resources to targeted research and development opportunities where there is a significant unmet need and where a drug candidate has the potential to be highly differentiated.\n\n## Milestone and Upfront Expense\n\nResearch and development expense for 2022 includes:\n\n- \u00b7 $37.0 million in charges to research and development expense in connection with milestone payments to Ionis;\n- \u00b7 $15.0 million charge to research and development expense in connection with the upfront payment associated with entering into our collaboration with Alectos in the second quarter of 2022; and\n- \u00b7 $10.0 million charge to research and development expense in connection with the upfront payment associated with entering into",
        "metadata": {
            "page": 80
        },
        "id": "dcd28409-4de2-418c-ab35-f2df728f4c8f"
    },
    {
        "page_content": "our collaboration with Alcyone in the fourth quarter of 2022.\n\nResearch and development expense for 2021 includes:\n\n- \u00b7 $125.0 million charge to research and development expense in connection with the upfront payment associated with entering into our collaboration with InnoCare in the third quarter of 2021;\n- \u00b7 $60.0 million charge to research and development expense upon the exercise of our option under our collaboration agreement with Ionis to develop and commercialize BIIB115, an investigational ASO in development for SMA;\n- I $30.0 million charge to research and development expense related to the option exercise fee payable to Genentech to jointly develop and commercialize LUNSUMIO; and\n- I $30.0 million charge to research and development expense in connection with the upfront payment associated with entering into a commercialization and license agreement with Bio-Thera to develop, manufacture and commercialize BIIB800.\n\nThe upfront payments associated with these collaborations are classified as research and development expense as the programs they relate to had not achieved regulatory approval as of the payment date.\n\nFor additional information about these collaboration arrangements, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>Aglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> to our consolidated financial statements included in this report.\n\n## glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>/@:G 'B/53 $@=5@/;A\n\nFor 2022 compared to 2021, the decrease in spending related to our early stage programs was primarily due to a decrease in costs associated with:\n\n- \u00b7 the discontinuation of cinpanemab (BIIB054) in Parkinson's disease;\n- \u00b7 the discontinuation of gosuranemab (BIIB092) in Alzheimer's disease;\n- \u00b7 the discontinuation of cotoretigene toliparvovec (BIIB112) in 3 -linked retinitis pigmentosa;\n- \u00b7 the advancement of litifilimab (BIIB059) for the potential treatment of SLE into late stage;\n- \u00b7 the advancement of BIIB122 for the potential treatment of Parkinson's disease into late stage;\n- \u00b7 the discontinuation of vixotrigine (BIIB074) in TGN and DPN; and\n\n- \u00b7 the discontinuation of BIIB078 for the potential treatment of Alzheimer's disease.\n\nThe decrease was partially offset by an increase in costs associated with:\n\n- \u00b7 an increase in spending in the development of BIIB124 for the potential treatment of essential tremor;\n- \u00b7 an increase in spending in the development of litifilimab (BIIB059) for the potential treatment of CLE;\n- \u00b7 an increase in spending in the development of BIIB113 for the potential treatment of Alzheimer's disease;\n- \u00b7 an increase in spending in the development of BIIB131 for the potential treatment of acute ischemic stroke; and\n- \u00b7 an increase in spending in the development of BIIB121 for the potential treatment of Angelman syndrome.\n\n## /B3 'B/53 $@=5@/;A\n\nFor 2022 compared to 2021, the decrease in spending associated with our late stage programs was primarily due to a decrease in costs associated with:\n\n- \u00b7 the advancement of ADUHELM from late stage to marketed upon the accelerated approval of ADUHELM in the U.S.; and\n- \u00b7 the discontinuation of BIIB111 in choroideremia.\n\nThe decrease was partially offset by an increase in costs associated with:\n\n- \u00b7 the advancement of litifilimab (BIIB059) for the potential treatment of SLE into late stage;\n- \u00b7 the advancement of BIIB122 for the potential treatment of Parkinson's disease into late stage; and\n- I the advancement of BIIB800, a proposed tocilizumab biosimilar referencing ACTEMRA, into late stage.\n\n## !/@93B32 $@=5@/;A\n\nFor 2022 compared to 2021, the increase in spending associated with our marketed programs was primarily due to an increase in costs associated with:\n\n- \u00b7 the advancement of ADUHELM from late stage to marketed upon the accelerated approval of ADUHELM in the U.S.; and\n- \u00b7 the advancement of LUNSUMIO from late stage to marketed upon the accelerated approval of LUNSUMIO in the U.S.",
        "metadata": {
            "page": 81
        },
        "id": "8f5e0d3c-ae50-4997-b9ef-e3f57b3bdb8b"
    },
    {
        "page_content": "In March 2019 Eisai initiated a global Phase 3 trial for the development of LE , EMBI in early Alzheimer's disease. Under our collaboration arrangement, Eisai serves as the lead of LE , EMBI development and regulatory submissions globally with both companies co-commercializing and co-promoting the product, and Eisai having final decision-making authority. All costs, including research, development, sales and marketing expense, are shared equally between us and Eisai. In January 2023 the FDA granted accelerated approval of LE , EMBI. Additionally, in January 2023 Eisai completed the submission of a supplemental BLA to the FDA for approval under the traditional pathway for LE , EMBI.\n\nAs of December 31, 2022, we had approximately $89.8 million of work-in-process inventory related to LE , EMBI.\n\nFor additional information on our collaboration arrangements with Eisai, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>Aglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> to our consolidated financial statements included in this report.\n\nglyph<c=30,font=/PIICNA+FranklinGothic-BookItal>&--*/(glyph<c=5,font=/PIICNA+FranklinGothic-BookItal> glyph<c=20,font=/PIICNA+FranklinGothic-BookItal>&/&3\"\"/% glyph<c=14,font=/PIICNA+FranklinGothic-BookItal>%.*/*453\"5*7&\n\nFor the Years Ended December 31, 2022, 2021 and 2020\n\n<!-- image -->\n\nFor 2022 compared to 2021, the decrease in selling, general and administrative expense was primarily due to cost-reduction measures realized during 2022.\n\nAs a result of the final NCD we have substantially eliminated our commercial infrastructure supporting ADUHELM, retaining minimal resources to manage patient access programs, including a continued free drug program for patients currently on treatment in the U.S.\n\nBeginning in the second quarter of 2021 reimbursement from Eisai for its share of U.S.\n\nADUHELM selling, general and administrative expense is recognized in collaboration profit (loss) sharing in our consolidated statements of income.\n\nWe expect selling, general and administrative costs to continue to decline in 2023 due to the implementation of our cost saving initiatives during 2022, which include the substantial elimination of our commercial infrastructure supporting ADUHELM as well as other cost-reduction measures.\n\nglyph<c=14,font=/PIICNA+FranklinGothic-BookItal>.035*;\"5*0/ \"/% glyph<c=22,font=/PIICNA+FranklinGothic-BookItal>.1\"*3.&/5 0' glyph<c=14,font=/PIICNA+FranklinGothic-BookItal>$26*3&% glyph<c=22,font=/PIICNA+FranklinGothic-BookItal>/5\"/(*#-& glyph<c=14,font=/PIICNA+FranklinGothic-BookItal>44&54\n\nFor the Years Ended December 31, 2022, 2021 and 2020\n\n<!-- image -->\n\nOur amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant amortizable intangible assets are related to our TYSABRI, AVONE 3 , SPINRAZA, VUMERITY and TECFIDERA (rest of world) products and other programs acquired through business combinations.\n\nFor 2022 compared to 2021, the decrease in amortization and impairment of acquired intangible assets was primarily due to higher impairment charges in 2021 of approximately $629.3 million, compared to impairment charges of approximately $119.6 million in 2022.\n\nFor the year ended December 31, 2022, amortization and impairment of acquired intangible assets reflects the impact of a $119.6 million impairment charge related to vixotrigine for the potential treatment of DPN.\n\nFor the year ended December 31, 2021, amortization and impairment of acquired intangible assets reflects the impact of a $365.0 million impairment charge related to BIIB111, a $220.0 million impairment charge related to BIIB112 and a $44.3 million impairment charge related to vixotrigine for the potential treatment of TGN.",
        "metadata": {
            "page": 82
        },
        "id": "e66d0f29-1a82-4a6a-a2e2-6a9c7c1f6c04"
    },
    {
        "page_content": "Amortization of acquired intangible assets, excluding impairment charges, totaled $246.3 million, $252.0 million and $255.1 million for the years ended December 31, 2022, 2021 and 2020, respectively.\n\nWe monitor events and expectations regarding product performance. If new information indicates that the assumptions underlying our most recent analysis are substantially different than those utilized in our current estimates, our analysis would be updated and may result in a significant change in the anticipated lifetime revenue of the relevant products. The occurrence of an adverse event could substantially increase the amount of amortization expense related to our acquired intangible assets as compared to previous periods or our current expectations, which may result in a significant negative impact on our future results of operations.\n\nIPR&D Related to Business Combinations\n\nIPR&D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. We review amounts capitalized as acquired IPR&D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable.\n\nOverall, the value of our acquired IPR&D assets is dependent upon several variables, including estimates of future revenue and the effects of competition, our ability to secure sufficient pricing in a competitive market, our ability to confirm safety and efficacy based on data from clinical trials and regulatory feedback, the level of anticipated development costs and the probability and timing of successfully advancing a particular research program from one clinical trial phase to the next. We are continually reevaluating our estimates concerning these and other variables, including our life cycle management strategies, research and development priorities and development risk, changes in program and portfolio economics and related impact of foreign currency exchange rates and economic trends and evaluating industry and company data regarding the productivity of clinical research and the development process. Changes in our estimates may result in a significant change to our valuation of our IPR&D assets.\n\n## Vixotrigine\n\nIn the periods following our acquisition of vixotrigine, there were numerous delays in the initiation of Phase 3 studies for the potential treatment of TGN and for the potential treatment of DPN, another form of neuropathic pain. We engaged with the FDA regarding the design of the potential Phase 3 studies of vixotrigine for the potential treatment of TGN and DPN and performed an additional clinical trial of vixotrigine, which was completed during 2022.\n\nThe performance of this additional clinical trial delayed the initiation of the Phase 3 studies of vixotrigine for the potential treatment of TGN, and, as a result, we recognized an impairment charge of $44.3 million related to vixotrigine for the potential treatment of TGN during the first quarter of 2021.\n\nDuring the fourth quarter of 2022 we discontinued further development of vixotrigine based on regulatory, development and commercialization challenges. For the year ended December 31, 2022, we recognized an impairment charge of approximately $119.6 million related to vixotrigine for the potential treatment of DPN, reducing the remaining book value of this IPR&D intangible asset to zero.Wealso adjusted the value of our contingent consideration obligations related to this asset resulting in a pre-tax gain of approximately $209.1 million, which was recognized in (gain) loss on fair value remeasurement of contingent consideration within our consolidated statements of income.\n\n## BIIB111 and BIIB112\n\nDuring the second quarter of 2021 we announced that our Phase 3 STAR study of BIIB111 and our Phase 2/3 XIRIUS study of BIIB112 did not meet their primary endpoints. In the third quarter of 2021 we suspended further development on these programs based on the decision by management as part of its strategic review process. For the year ended December 31, 2021, we recognized an impairment charge of $365.0 million related to BIIB111 and an impairment charge of $220.0 million related to BIIB112, reducing the remaining book values of these IPR&D intangible assets to zero.\n\nIn addition, as a result of our decision to suspend further development of BIIB111 and BIIB112, we recorded charges of approximately $39.1 million during the third quarter of 2021 related to our manufacturing arrangements and other costs that we expect to incur as a result of suspending these programs. These charges were recognized in research and development expense in our consolidated statements of income for the year ended December 31, 2021.",
        "metadata": {
            "page": 83
        },
        "id": "2a3a34bc-1051-4a86-99f0-d43e44a038b0"
    },
    {
        "page_content": "For additional information on the amortization and impairment of our acquired intangible assets, please read \"=B3 glyph<c=17,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><B/<570:3 glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>AA3BA /<2 glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>==2E7:: ,to our consolidated financial statements included in this report.\n\nglyph<c=16,font=/PIICNA+FranklinGothic-BookItal>0--\"#03\"5*0/ glyph<c=28,font=/PIICNA+FranklinGothic-BookItal>30'*5 glyph<c=3,font=/PIICNA+FranklinGothic-BookItal>glyph<c=24,font=/PIICNA+FranklinGothic-BookItal>044glyph<c=4,font=/PIICNA+FranklinGothic-BookItal> glyph<c=30,font=/PIICNA+FranklinGothic-BookItal>)\"3*/(\n\nFor the Years Ended December 31, 2022, 2021 and 2020\n\n<!-- image -->\n\nCollaboration profit (loss) sharing primarily includes Samsung Bioepis' 50.0% share of the profit or loss related to our biosimilars 2013 commercial agreement with Samsung Bioepis and, beginning in the second quarter of 2021, Eisai's 45.0% share of income and expense in the U.S. related to the ADUHELM Collaboration Agreement. Beginning January 1, 2023, Eisai receives only a tiered royalty based on net sales of ADUHELM, and will no longer share global profits and losses.\n\nFor the years ended December 31, 2022 and 2021, we recognized net profit-sharing expense of $217.4 million and $285.4 million, respectively, to reflect Samsung Bioepis' 50.0% sharing of the net collaboration profits.\n\nFor the years ended December 31, 2022 and 2021 we recognized net reductions to our operating expense of approximately $224.7 million and $233.2 million, respectively, to reflect Eisai's 45.0% share of net collaboration losses in the U.S.\n\nFor the year ended December 31, 2021, we also recognized net reductions to our operating expense of $45.0 million to reflect Eisai's 45.0% share of the $100.0 million milestone payment made to Neurimmune related to the launch of ADUHELM in the U.S. during the second quarter of 2021.\n\nFor additional information on our collaboration arrangements with Samsung Bioepis and Eisai, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>A ,to our consolidated financial statements included in this report.\n\nglyph<c=3,font=/PIICNA+FranklinGothic-BookItal>glyph<c=20,font=/PIICNA+FranklinGothic-BookItal>\"*/glyph<c=4,font=/PIICNA+FranklinGothic-BookItal> glyph<c=24,font=/PIICNA+FranklinGothic-BookItal>044 0/ glyph<c=19,font=/PIICNA+FranklinGothic-BookItal>\"*3 \"-6& glyph<c=29,font=/PIICNA+FranklinGothic-BookItal>&.&\"463&.&/5 0' glyph<c=16,font=/PIICNA+FranklinGothic-BookItal>0/5*/(&/5 glyph<c=16,font=/PIICNA+FranklinGothic-BookItal>0/4*%&3\"5*0/\n\nFor the Years Ended December 31, 2022, 2021 and 2020\n\n<!-- image -->\n\nFor the year ended December 31, 2022, the changes in fair value of our contingent consideration obligations were primarily due to the discontinuation of further development efforts related to vixotrigine for the potential treatment of TGN and DPN, resulting in a reduction of our contingent consideration obligations of approximately $195.4 million, and changes in the interest rates used to revalue our contingent consideration liabilities.\n\nFor the year ended December 31, 2021, the changes in fair value of our contingent consideration obligations were primarily due to reductions in the probability of technical and regulatory success and delays in the expected timing of the achievement of certain remaining developmental milestones related to our vixotrigine programs.\n\nFor additional information on our IPR&D intangible assets, please read \"=B3 glyph<c=17,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><B/<570:3 glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>AA3BA /<2 glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>==2E7:: , to our consolidated financial statements included in this report.",
        "metadata": {
            "page": 84
        },
        "id": "33377024-579f-4816-abb7-2e2581fd3f74"
    },
    {
        "page_content": "## Restructuring Charges\n\nFor the Years Ended December 31, 2022, 2021 and 2020\n\n<!-- image -->\n\n## 2022 Cost Saving Initiatives\n\nIn December 2021 and May 2022 we announced our plans to implement a series of costreduction measures that when completed we expect may yield approximately $1.0 billion in expense savings. These savings are being achieved through a number of initiatives, including reductions to our workforce, the substantial elimination of our commercial ADUHELM infrastructure, the consolidation of certain real estate locations and operating efficiency gains across our selling, general and administrative and research and development functions.\n\nUnder these initiatives, we estimate we will incur total restructuring charges of approximately $131.0 million, primarily related to severance. These amounts were substantially incurred during 2022. As of December 31, 2022, approximately $35.9 million remained in our restructuring reserve and payments are expected to be made through 2026.\n\nFor the year ended December 31, 2022, we recognized approximately $131.1 million of net pre-tax restructuring charges related to our 2022 cost saving initiatives, of which approximately $112.6 million consisted of employee severance costs. Our restructuring reserve is included in accrued expense and other in our consolidated balance sheets.\n\nIn September 2022 we entered into an agreement to partially terminate a portion of our lease located at 300 Binney Street, as well as to reduce the lease term for the majority of the remaining space. This resulted in a gain of approximately $5.3 million, which was recorded within restructuring charges in our consolidated statements of income for the year ended December 31, 2022. For additional information on our 300 Binney Street lease modification, please read\n\nNote 12, Leases , to these consolidated financial statements included in this report.\n\nFollowing an evaluation of our current capacity needs, in March 2022 we ceased using a patient services office space in Durham, NC. Our decision to cease use of the facility resulted in the immediate expense of certain leasehold improvements and other assets at this facility. As a result, we recognized approximately $10.4 million of accelerated depreciation expense, which was recorded in restructuring charges in our consolidated statements of income for the year ended December 31, 2022. In May 2022 we entered into a lease assignment agreement whereby we assigned our remaining lease obligations to an external third party. As a result of the lease assignment, we derecognized the related operating lease obligation and right-of-use asset during the second quarter of 2022.\n\nFor the year ended December 31, 2022, we recognized other restructuring costs of approximately $13.2 million, which were recorded in restructuring charges in our consolidated statements of income. Other restructuring costs include items such as facility closure costs, employee non-severance expense, asset write-offs and other costs.\n\nThe following table summarizes the charges and spending related to our 2022 workforce reductions for the year ended December 31, 2022:\n\n| (In millions)                            | Total   |\n|------------------------------------------|---------|\n| Restructuring reserve, December 31, 2021 | $ -     |\n| Expense                                  | 112.6   |\n| Payment                                  | (78.0)  |\n| Foreign currency and other adjustments   | 1.3     |\n| Restructuring reserve, December 31, 2022 | $ 35.9  |",
        "metadata": {
            "page": 85
        },
        "id": "83dd4bae-ec10-4b3d-bfb3-abbf896de00e"
    },
    {
        "page_content": "For the Years Ended December 31, 2022, 2021 and 2020\n\n<!-- image -->\n\nIn September 2022 we completed the sale of our building and land parcel located at 125 Broadway for an aggregate sales price of approximately $603.0 million, which is inclusive of a $10.8 million tenant allowance. This sale resulted in a pre-tax gain on sale of approximately $503.7 million, net of transaction costs, for the year ended December 31, 2022.\n\nSimultaneously, with the close of this transaction we leased back the building for a term of approximately 5.5 years, which resulted in the recognition of approximately $168.2 million in new lease liabilities and right-of-use assets recorded within our consolidated balance sheets as of December 31, 2022. The sale and immediate leaseback of this building qualified for sale and leaseback treatment and is classified as an operating lease.\n\nFor additional information on our 125 Broadway sale and leaseback transaction, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> $@=>3@BGglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> $:/<B /<2 glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>?C7>;3<B and \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> 3/A3A ,to our consolidated financial statements included in this report.\n\nFor the Years Ended December 31, 2022, 2021 and 2020\n\n$1,095.5\n\n<!-- image -->\n\nFor 2022 compared to 2021, the change in other (income) expense, net primarily reflects a pre-tax gain during 2022 of approximately $1.5 billion related to the sale of our 49.9% equity interest in Samsung Bioepis, partially offset by a pre-tax charge of $900.0 million, plus settlement fees and expenses, related to a litigation settlement agreement to resolve a qui tam litigation relating to conduct prior to 2015.\n\nFor the year ended December 31, 2022, net unrealized losses and realized (gains) losses on our holdings in equity securities were approximately $264.7 million and zero, respectively, compared to net unrealized losses and realized gains of $831.4 million and $10.3 million, respectively, in 2021.\n\nThe net unrealized losses recognized during the year ended December 31, 2022, primarily reflect a decrease in the aggregate fair value of our investments in Denali and Sangamo common stock of approximately $278.0 million.\n\nThe net unrealized losses recognized during the year ended December 31, 2021, primarily reflect decreases in the aggregate fair value of our investments in Denali, Sage, Sangamo and Ionis common stock of approximately $819.6 million.\n\nFor the year ended December 31, 2022, net interest expense was $157.3 million, compared to $242.6 million in 2021. This decrease was primarily due to higher interest income earned on our investments in 2022, compared to 2021, and lower interest expense in 2022 due to the redemption of our 3.625% Senior Notes due September 15, 2022, with an aggregate principal amount of $1.0 billion.\n\nFor 2023 compared to 2022, we anticipate a decrease in net interest expense as a result of lower average debt balances in 2023 and an increase in",
        "metadata": {
            "page": 86
        },
        "id": "85fd1169-471b-41de-a33a-238cada4c204"
    },
    {
        "page_content": "interest income driven by higher interest rates on our cash and marketable securities.\n\nFor additional information on the sale of our equity interest in Samsung Bioepis, please read \"=B3 glyph<c=13,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>7A>=A7B7=<A , to our consolidated financial statements included in this report.\n\nFor additional information on the redemption of our Senior Notes, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=13,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><230B32<3AA , to our consolidated financial statements included in this report.\n\nFor additional information on the litigation settlement agreement, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=18,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> #B63@ glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=<A=:72/B32 glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>7</<17/: 'B/B3;3<B glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>3B/7: , to our consolidated financial statements included in this report.\n\n## @5A?7 +3J 'DAH;E;A@\n\nFor the Years Ended December 31, 2022, 2021 and 2020\n\n<!-- image -->\n\nIncome tax expense\n\nEffective tax rate on pre\n\nglyph<c=9,font=/PIIBFI+Quivira>\n\ntax income\n\nOur effective tax rate fluctuates from year to year due to the global nature of our operations. The factors that most significantly impact our effective tax rate include changes in tax laws, variability in the allocation of our taxable earnings among multiple jurisdictions, the amount and characterization of our research and development expense, the levels of\n\ncertain deductions and credits, acquisitions and licensing transactions.\n\nFor the year ended December 31, 2022, compared to 2021, the increase in our effective tax rate, excluding the impact of the net Neurimmune deferred tax asset, as discussed below, includes the tax impacts of the litigation settlement agreement and the sale of our building at 125 Broadway. These increases were partially offset by the impact of the current year tax benefits related to an international reorganization to align with global tax developments, the impacts of the sale of our equity interest in Samsung Bioepis and the tax impacts of the decision to discontinue development of vixotrigine. Further in 2021, our effective tax rate benefited from the tax effects of the BIIB111 and BIIB112 impairment charges and the non-cash tax effects of changes in the value of our equity instruments.\n\nFor additional information on the litigation settlement agreement, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=18,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> #B63@ glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=<A=:72/B32 glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>7</<17/: 'B/B3;3<B glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>3B/7: , to our consolidated financial statements included in this report.\n\n## glyph<c=26,font=/PIICNA+FranklinGothic-BookItal>&63*..6/& glyph<c=17,font=/PIICNA+FranklinGothic-BookItal>&'&33&% glyph<c=31,font=/PIICNA+FranklinGothic-BookItal>\"9 glyph<c=14,font=/PIICNA+FranklinGothic-BookItal>44&5\n\nDuring 2021 we recorded a net deferred tax asset in Switzerland of approximately $100.0 million on Neurimmune's tax basis in ADUHELM, the realization of which was dependent on future sales of ADUHELM.\n\nDuring the first quarter of 2022, upon issuance of the final NCD related to ADUHELM, we recorded an increase in a valuation allowance of approximately $85.0 million to reduce the net value of this deferred tax asset to zero.\n\nThese adjustments to our net deferred tax asset are each recorded with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.\n\nFor additional information on our collaboration arrangement with Neurimmune, please read \"=B3 glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=10,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><D3AB;3<BA 7< */@7/0:3 glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><B3@3AB glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal><B7B73A , to our consolidated financial statements included in this report.\n\n## glyph<c=22,font=/PIICNA+FranklinGothic-BookItal>/'-\"5*0/ glyph<c=29,font=/PIICNA+FranklinGothic-BookItal>&%6$5*0/ glyph<c=14,font=/PIICNA+FranklinGothic-BookItal>$5\n\nIn August 2022 the IRA was signed into law in the U.S. The IRA introduced new tax provisions, including a 15.0% corporate alternative minimum tax and a 1.0% excise tax on stock repurchases. The provisions of the IRA will be effective for periods after December 31, 2022. The enactment of the IRA did not result in any material adjustments to our income",
        "metadata": {
            "page": 87
        },
        "id": "1b1694c2-1fc6-4a79-955d-63913aabcbbf"
    },
    {
        "page_content": "tax provision or net deferred tax assets as of December 31, 2022.\n\nFor additional information on our income taxes, uncertain tax positions and income tax rate reconciliation, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=17,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><1=;3 (/F3A ,to our consolidated financial statements included in this report.\n\nglyph<c=28,font=/PIIBCD+FranklinGothic-Book>CG;FK ;@ glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @5A?7glyph<c=7,font=/PIIBCD+FranklinGothic-Book> #AEE A8  @H7EF77glyph<c=9,font=/PIIBCD+FranklinGothic-Book> %7F A8 +3J\n\nFor the Years Ended December 31, 2022, 2021 and 2020\n\n<!-- image -->\n\nIn February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.\n\nIn April 2022 we completed the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics. Following the sale of Samsung Bioepis we no longer recognize gains or losses associated with Samsung Bioepis' results of operations and amortization related to basis differences.\n\nPrior to this sale, we recognized our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity became available, which was reflected as equity in (income) loss of investee, net of tax in our consolidated statements of income. We also recognized amortization on certain basis differences resulting from our November 2018 investment.\n\nFor the year ended December 31, 2022,we recognized net income on our investment of $2.6 million, reflecting our share of Samsung Bioepis' operating profits, net of tax, totaling $17.0 million offset by amortization of basis differences totaling $14.4 million. This amount reflects our share of\n\nresults prior to the sale of Samsung Bioepis as the results are recognized one quarter in arrears.\n\nFor the year ended December 31, 2021, we recognized net income on our investment of $34.9 million, reflecting our share of Samsung Bioepis' operating profits, net of tax, totaling $64.6 million offset by amortization of basis differences totaling $29.7 million.\n\nNet income on our investment for the year ended December 31, 2021, reflects a $31.2 million benefit related to the release of a valuation allowance on deferred tax assets associated with Samsung Bioepis. The valuation allowance was released in the second quarter of 2021 based on a consideration of the positive and negative evidence, including the historic earnings of Samsung Bioepis.\n\nFor additional information on the sale of our equity interest in Samsung Bioepis, please read \"=B3 glyph<c=13,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>7A>=A7B7=<A , to our consolidated financial statements included in this report.\n\nFor additional information on our collaboration arrangements with Samsung Bioepis, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>Aglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> to our consolidated financial statements included in this report.\n\n%A@5A@FDA>>;@9  @F7D7EFEglyph<c=9,font=/PIIBCD+FranklinGothic-Book> %7F A8 +3J\n\nFor the Years Ended December 31, 2022, 2021 and 2020\n\n<!-- image -->\n\nOur consolidated financial statements include the financial results of our variable interest entity, Neurimmune, as we determined that we are the primary beneficiary.\n\nFor 2022 compared to 2021, the change in net income (loss) attributable to noncontrolling interests, net of tax, was primarily due to a deferred tax benefit and milestone payment recorded in 2021, as discussed below.",
        "metadata": {
            "page": 88
        },
        "id": "7693c751-e1c8-4410-9a54-35344b784dd2"
    },
    {
        "page_content": "During 2021 we recorded a net deferred tax asset in Switzerland of approximately $100.0 million on Neurimmune's tax basis in ADUHELM, the realization of which was dependent on future sales of ADUHELM.\n\nDuring the first quarter of 2022, upon issuance of the final NCD related to ADUHELM, we recorded an increase in a valuation allowance of approximately $85.0 million to reduce the net value of this deferred tax asset to zero.\n\nThese adjustments to our net deferred tax asset are each recorded with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.\n\nFor 2021 the change in net income (loss) attributable to noncontrolling interests, net of tax, was also due to the $100.0 million milestone payment to Neurimmune related to the launch of ADUHELM in the U.S. during 2021.\n\nFor additional information on our collaboration agreement with Neurimmune, please read \"=B3 glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=10,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><D3AB;3<BA 7< */@7/0:3 glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><B3@3AB glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal><B7B73Aglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> to our consolidated financial statements included in this report.\n\nFor additional information on our income taxes please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=17,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><1=;3 (/F3A , to our consolidated financial statements included in this report.",
        "metadata": {
            "page": 89
        },
        "id": "19bd9718-e862-4e23-a9df-b340b58c7658"
    },
    {
        "page_content": "## glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> + &%glyph<c=9,font=/PIIBCD+FranklinGothic-Book> # (, glyph<c=27,font=/PIIBCD+FranklinGothic-Book> +0 glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>' +glyph<c=24,font=/PIIBCD+FranklinGothic-Book># )glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*&,)glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\nOur financial condition is summarized as follows:\n\n|                                                                                                                                                                 | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |                                                                                               |                                                                                               |\n|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=9,font=/PIIBCD+FranklinGothic-Book> 7J57BF B7D57@F397Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                           | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                           | glyph<c=4,font=/PIIBCD+FranklinGothic-Book> glyph<c=26,font=/PIIBCD+FranklinGothic-Book>:3@97 | glyph<c=3,font=/PIIBCD+FranklinGothic-Book> glyph<c=26,font=/PIIBCD+FranklinGothic-Book>:3@97 |\n| Financial assets:                                                                                                                                               |                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                            |                                                                                               |                                                                                               |\n| Cash and cash equivalents                                                                                                                                       | $ 3,419.3                                                                                                                                                                                                                                  | $ 2,261.4                                                                                                                                                                                                                                  | 51.2 %                                                                                        | $ 1,157.9                                                                                     |\n| Marketable securities - current                                                                                                                                 | 1,473.5                                                                                                                                                                                                                                    | 1,541.1                                                                                                                                                                                                                                    | (4.4)                                                                                         | (67.6)                                                                                        |\n| Marketable securities - non-current                                                                                                                             | 705.7                                                                                                                                                                                                                                      | 892.0                                                                                                                                                                                                                                      | (20.9)                                                                                        | (186.3)                                                                                       |\n| Total cash, cash equivalents and marketable securities                                                                                                          | $ 5,598.5                                                                                                                                                                                                                                  | $ 4,694.5                                                                                                                                                                                                                                  | 19.3 %                                                                                        | $ 904.0                                                                                       |\n| Borrowings:                                                                                                                                                     |                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                            |                                                                                               |                                                                                               |\n| Current portion of notes payable                                                                                                                                | $ - $                                                                                                                                                                                                                                      | 999.1                                                                                                                                                                                                                                      | nm                                                                                            | $ (999.1)                                                                                     |\n| Notes payable                                                                                                                                                   | 6,281.0                                                                                                                                                                                                                                    | 6,274.0                                                                                                                                                                                                                                    | 0.1                                                                                           | 7.0                                                                                           |\n| Total borrowings                                                                                                                                                | $ 6,281.0                                                                                                                                                                                                                                  | $ 7,273.1                                                                                                                                                                                                                                  | (13.6)%                                                                                       | $ (992.1)                                                                                     |\n| Working Capital:                                                                                                                                                |                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                            |                                                                                               |                                                                                               |\n| Current assets                                                                                                                                                  | $ 9,791.2                                                                                                                                                                                                                                  | $ 7,856.5                                                                                                                                                                                                                                  | 24.6 %                                                                                        | $ 1,934.7                                                                                     |\n| Current liabilities                                                                                                                                             | (3,272.8)                                                                                                                                                                                                                                  | (4,298.2)                                                                                                                                                                                                                                  | (23.9)                                                                                        | 1,025.4                                                                                       |\n| Total working capital                                                                                                                                           | $ 6,518.4                                                                                                                                                                                                                                  | $ 3,558.3                                                                                                                                                                                                                                  | 83.2 %                                                                                        | $ 2,960.1                                                                                     |\n\nglyph<c=27,font=/PIICNA+FranklinGothic-BookItal>7&37*&8\n\nWe have historically financed and expect to continue to fund our operating and capital expenditures primarily through cash flow earned through our operations as well as our existing cash resources. We believe generic competition for TECFIDERA in the U.S. and other key markets and the impact of biosimilar competition on RITUXAN sales volumes will continue to reduce our cash flow from operations in 2023 and will have a significant adverse impact on our future cash flow from operations.\n\nFor the year ended December 31, 2022, certain significant cash flows were as follows:\n\n- \u00b7 $1,384.3 million in net cash flow provided by operating activities;\n- \u00b7 $990.3 million in net proceeds received from the sale of our equity interest in Samsung Bioepis;\n- \u00b7 $582.6 million in net proceeds received from the sale of one of our buildings;\n- \u00b7 $1.0 billion payment made for the redemption of our 3.625% Senior Notes due September 15, 2022;\n- < $917.0 million in total net payments for a litigation settlement agreement and settlement fees and expenses;\n- \u00b7 $932.9 million in total net payments for income taxes;\n- \u00b7 $750.0 million used for share repurchases; and\n- \u00b7 $240.3 million used for purchases of property, plant and equipment.\n\nFor the year ended December 31, 2021, certain significant cash flows were as follows:\n\n- \u00b7 $3,639.9 million in net cash flow provided by operating activities;\n- \u00b7 $1.8 billion used for share repurchases;\n- \u00b7 $170.0 million used in connection with our private offer to exchange (Exchange Offer) our tendered 5.200% Senior Notes due September 15, 2045 (2045 Senior Notes) for a new series of 3.250% Senior Notes due February 15, 2051 (2051 Senior Notes) and cash, and an offer to purchase our tendered 2045 Senior Notes for cash;\n- \u00b7 $258.1 million used for purchases of property, plant and equipment;\n- \u00b7 $247.9 million in total net payments for income taxes; and\n- < $100.0 million milestone payment to Neurimmune.\n\nWe believe that our existing funds, when combined with cash generated from operations and our access to additional financing resources, if needed, are sufficient to satisfy our operating, working capital, strategic alliance, milestone payment, capital expenditure and debt service requirements for the foreseeable future. In addition, we may choose to opportunistically return cash to shareholders and pursue other business initiatives, including acquisition and licensing activities. We may, from time to time, also seek additional funding through a combination of new collaborative agreements, strategic alliances and additional equity and debt financings or from other",
        "metadata": {
            "page": 90
        },
        "id": "87d28c48-a312-4bea-beef-a8aa72dfa4fd"
    },
    {
        "page_content": "sources should we identify a significant new opportunity glyph<c=7,font=/PIICNA+FranklinGothic-BookItal>\n\nFor additional information on the litigation settlement agreement, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=18,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> #B63@ glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=<A=:72/B32 glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>7</<17/: 'B/B3;3<B glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>3B/7: , to our consolidated financial statements included in this report.\n\nFor additional information on certain risks that could negatively impact our financial position or future results of operations, please read glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>B3; glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal> R 7A9 glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>/1B=@A and glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>B3; glyph<c=17,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal> %C/<B7B/B7D3 /<2 %C/:7B/B7D3 glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>7A1:=AC@3A glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>0=CB !/@93B &7A9 included in this report.\n\n## glyph<c=16,font=/PIICNA+FranklinGothic-BookItal>\"4)glyph<c=5,font=/PIICNA+FranklinGothic-BookItal> glyph<c=16,font=/PIICNA+FranklinGothic-BookItal>\"4) glyph<c=18,font=/PIICNA+FranklinGothic-BookItal>26*7\"-&/54 \"/% glyph<c=25,font=/PIICNA+FranklinGothic-BookItal>\"3,&5\"#-& glyph<c=30,font=/PIICNA+FranklinGothic-BookItal>&$63*5*&4\n\nUntil required for another use in our business, we typically invest our cash reserves in bank deposits, certificates of deposit, commercial paper, corporate notes, U.S. and foreign government instruments, overnight reverse repurchase agreements and other interest-bearing marketable debt instruments in accordance with our investment policy. It is our policy to mitigate credit risk in our cash reserves and marketable securities by maintaining a well-diversified portfolio that limits the amount of exposure as to institution, maturity and investment type.\n\nAs of December 31, 2022, we had cash, cash equivalents and marketable securities totaling approximately $5.6 billion compared to approximately $4.7 billion as of December 31, 2021. The change in cash, cash equivalents and marketable securities at December 31, 2022, from December 31, 2021, was primarily due to net cash flow provided by operating activities, which includes $917.0 million in total net payments for a litigation settlement agreement and settlement fees and expenses, and $990.3 million in net proceeds received from the sale of our equity interest in Samsung Bioepis and $582.6 million in net proceeds received from the sale of one of our buildings, partially offset by $1.0 billion of cash used for the redemption of our 3.625% Senior Notes due September 15, 2022 and $750.0 million used for share repurchases.\n\nThe following table summarizes the fair value of our significant common stock investments:\n\n|               | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| (In millions) | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                           | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                           |\n| Denali        | $ 370.2                                                                                                                                                                                                                                    | $ 550.7                                                                                                                                                                                                                                    |\n| Sage          | 238.0                                                                                                                                                                                                                                      | 231.9                                                                                                                                                                                                                                      |\n| Sangamo       | 74.3                                                                                                                                                                                                                                       | 173.7                                                                                                                                                                                                                                      |\n| Ionis         | 108.6                                                                                                                                                                                                                                      | 87.5                                                                                                                                                                                                                                       |\n|               | $ 791.1                                                                                                                                                                                                                                    | $ 1,043.8                                                                                                                                                                                                                                  |\n\nAlthough the contractual holding period restrictions on our investments in Denali, Sage,\n\nSangamo and Ionis have expired, our ability to liquidate these investments may be limited by the size of our interest, the volume of market related activity, our concentrated level of ownership and potential restrictions resulting from our status as a collaborator. Therefore, we may realize significantly less than the current value of such investments.\n\nFor additional information on our collaboration arrangements, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>A , to our consolidated financial statements included in this report.\n\n## glyph<c=22,font=/PIICNA+FranklinGothic-BookItal>/7&45.&/54 \"/% glyph<c=27,font=/PIICNA+FranklinGothic-BookItal>5)&3 glyph<c=14,font=/PIICNA+FranklinGothic-BookItal>44&54\n\nInvestments and other assets in our consolidated balance sheet as of December 31, 2021, includes the carrying value of our investment in Samsung Bioepis of $599.9 million. In April 2022 we completed the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics. Under the terms of this transaction, we received approximately $1.0 billion in cash at closing and expect to receive approximately $1.3 billion in cash to be deferred over two payments of approximately $812.5 million due at the first anniversary and approximately $437.5 million due at the second anniversary of the closing of this transaction.\n\nAs part of this transaction, we are also eligible to receive up to an additional $50.0 million upon the achievement of certain commercial milestones. If any payments due to us remain outstanding after the second anniversary of the closing of this transaction, we may elect to receive shares of Samsung BioLogics common stock at a 5.0% discount in lieu of a cash payment for the remaining amount due. Currently, we believe that the likelihood of Samsung BioLogics failing to make timely payments to us for the amounts due is remote.\n\nFor additional information on the sale of our equity interest in Samsung Bioepis, please read \"=B3 glyph<c=13,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>7A>=A7B7=<A , to our consolidated financial statements included in this report.\n\n## glyph<c=16,font=/PIICNA+FranklinGothic-BookItal>\"1*5\"glyph<c=18,font=/PIICNA+FranklinGothic-BookItal>91&/%*563&4\n\nIn March 2021 we announced our plans to build a new gene therapy manufacturing facility in RTP, NC to support our gene therapy pipeline across multiple therapeutic areas. The new manufacturing facility will be approximately 197,000 square feet and is expected to be operational by the end of 2023, with an estimated total investment of approximately $195.0 million. Construction for this new facility began during the fourth quarter of 2021.",
        "metadata": {
            "page": 91
        },
        "id": "fda2e5b4-e86c-4ba2-9e97-1c172a121667"
    },
    {
        "page_content": "## glyph<c=15,font=/PIICNA+FranklinGothic-BookItal>03308*/(4\n\nIn February 2021 we completed our Exchange Offer, consisting of the following:\n\n- \u00b7 $624.6 million aggregate principal amount of our 2045 Senior Notes was exchanged for $700.7 million aggregate principal amount of our 2051 Senior Notes and approximately $151.8 million of aggregate cash payments; and\n- \u00b7 $8.9 million aggregate principal amount of our 2045 Senior Notes was redeemed for approximately $12.1 million of aggregate cash payments, excluding accrued and unpaid interest.\n\nThe following is a summary of our currently outstanding senior unsecured notes issued in 2020 (2020 Senior Notes):\n\n- \u00b7 $1.5 billion aggregate principal amount of 2.25% Senior Notes due May 1, 2030; and\n- \u00b7 $1.5 billion aggregate principal amount of 3.15% Senior Notes due May 1, 2050.\n\nThe following is a summary of our currently outstanding senior unsecured notes issued in 2015 (2015 Senior Notes):\n\n- \u00b7 $1.75 billion aggregate principal amount of 4.05% Senior Notes due September 15, 2025; and\n- \u00b7 $1.12 billion aggregate principal amount of 5.20% Senior Notes due September 15, 2045.\n\nOur 2020 Senior Notes and our 2015 Senior Notes were issued at a discount, which are amortized as additional interest expense over the period from issuance through maturity.\n\nIn July 2022 we redeemed our 3.625% Senior Notes due September 15, 2022, with an aggregate principal amount of $1.0 billion.\n\nFor additional information on our Senior Notes, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=13,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><230B32<3AA , to our consolidated financial statements included in this report.\n\nFor a summary of the fair values of our outstanding borrowings as of December 31, 2022 and 2021, please read \"=B3 glyph<c=18,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>/7@ */:C3 !3/AC@3;3<BAglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> to our consolidated financial statements included in this report.\n\n## glyph<c=16,font=/PIICNA+FranklinGothic-BookItal>3&%*5 glyph<c=19,font=/PIICNA+FranklinGothic-BookItal>\"$*-*5:\n\nIn January 2020 we entered into a $1.0 billion, five-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial\n\ncovenant that requires us not to exceed a maximum consolidated leverage ratio.\n\nAs of December 31, 2022 and 2021, we had no outstanding borrowings and were in compliance with all covenants under this facility.\n\n## !03,*/( glyph<c=16,font=/PIICNA+FranklinGothic-BookItal>\"1*5\"-\n\nWorking capital is defined as current assets less current liabilities. Working capital was $6.5 billion and $3.6 billion as of December 31, 2022 and 2021, respectively. The change in working capital reflects an increase in total current assets of approximately $1.9 billion and a decrease in total current liabilities of approximately $1.0 billion.\n\n## glyph<c=16,font=/PIICNA+FranklinGothic-BookItal>633&/5 glyph<c=14,font=/PIICNA+FranklinGothic-BookItal>44&54\n\nThe increase in total current assets was primarily driven by the following:\n\n- \u00b7 net increase in cash, cash equivalents and marketable securities due to net cash flow provided by operating activities of approximately $1,384.3 million;\n- \u00b7 receipt of approximately $990.3 million in cash, net of expenses, from the sale of our equity interest in Samsung Bioepis;\n- \u00b7 recording of a receivable from Samsung BioLogics for approximately $798.8 million as part of the sale of our equity interest in Samsung Bioepis; and\n- \u00b7 cash receipt of approximately $582.6 million related to the sale of one of our buildings.\n\nThe increase was partially offset by cash used for the redemption of our 3.625% Senior Notes due September 15, 2022, of approximately $1.0 billion and share repurchases of $750.0 million and $917.0 million in total net payments for a litigation settlement agreement and settlement fees and expenses.\n\n## glyph<c=16,font=/PIICNA+FranklinGothic-BookItal>633&/5 glyph<c=24,font=/PIICNA+FranklinGothic-BookItal>*\"#*-*5*&4\n\nThe decrease in total current liabilities was primarily due to the following:\n\n- \u00b7 redemption of our 3.625% Senior Notes due September 15, 2022, of approximately $1.0 billion, which were classified within current liabilities in 2021; and\n- \u00b7 a reduction in our accounts payable.\n\n## glyph<c=30,font=/PIICNA+FranklinGothic-BookItal>)\"3& glyph<c=29,font=/PIICNA+FranklinGothic-BookItal>&163$)\"4& glyph<c=28,font=/PIICNA+FranklinGothic-BookItal>30(3\".4\n\nIn October 2020 our Board of Directors authorized our 2020 Share Repurchase Program, which is a program to repurchase up to $5.0 billion of our common stock. Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase",
        "metadata": {
            "page": 92
        },
        "id": "7f6acbd6-8456-4666-8c91-35058ed381fa"
    },
    {
        "page_content": "Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately 3.6 million, 6.0 million and 1.6 million shares of our common stock at a cost of approximately $750.0 million, $1.8 billion and $400.0 million during the years ended December 31, 2022, 2021 and 2020, respectively. Approximately $2.1 billion remained available under our 2020 Share Repurchase Program as of December 31, 2022.\n\nIn December 2019 our Board of Directors authorized our December 2019 Share Repurchase Program, which was a program to repurchase up to $5.0 billion of our common stock, which was completed as of September 30, 2020. All shares repurchased under our December 2019 Share Repurchase Program were retired. Under our December 2019 Share Repurchase Program, we repurchased and retired approximately 16.7 million shares of our common stock at a cost of\n\n## glyph<c=16,font=/PIICNA+FranklinGothic-BookItal>\"4) glyph<c=19,font=/PIICNA+FranklinGothic-BookItal>-08\n\nThe following table summarizes our cash flow activity:\n\n|                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                   | glyph<c=4,font=/PIIBCD+FranklinGothic-Book> glyph<c=26,font=/PIIBCD+FranklinGothic-Book>:3@97                                                                                                                                   | glyph<c=4,font=/PIIBCD+FranklinGothic-Book> glyph<c=26,font=/PIIBCD+FranklinGothic-Book>:3@97                                                                                                                                   |\n|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n|                                                                                                                                                                 | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                |\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=9,font=/PIIBCD+FranklinGothic-Book> 7J57BF B7D57@F397Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                                                                                  | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                                                                                  | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                                                                                  | HEglyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book> | HEglyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book> |\n| Net cash flow provided by (used in) operating activities                                                                                                        | $ 1,384.3                                                                                                                                                                                                                                                                                         | $ 3,639.9                                                                                                                                                                                                                                                                                         | $ 4,229.8                                                                                                                                                                                                                                                                                         | (62.0)%                                                                                                                                                                                                                         | (13.9)%                                                                                                                                                                                                                         |\n| Net cash flow provided by (used in) investing activities                                                                                                        | 1,576.6                                                                                                                                                                                                                                                                                           | (563.7)                                                                                                                                                                                                                                                                                           | (608.6)                                                                                                                                                                                                                                                                                           | 379.7                                                                                                                                                                                                                           | (7.4)                                                                                                                                                                                                                           |\n| Net cash flow provided by (used in) financing activities                                                                                                        | (1,747.3)                                                                                                                                                                                                                                                                                         | (2,086.2)                                                                                                                                                                                                                                                                                         | (5,272.7)                                                                                                                                                                                                                                                                                         | (16.2)                                                                                                                                                                                                                          | (60.4)                                                                                                                                                                                                                          |\n\n## #>3@/B7<5 glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>1B7D7B73A\n\nCash flow from operating activities represents the cash receipts and disbursements related to all of our activities other than investing and financing activities. We expect cash provided from operating activities will continue to be our primary source of funds to finance operating needs and capital expenditures for the foreseeable future.\n\nOperating cash flow is derived by adjusting our net income for:\n\n- \u00b7 non-cash operating items such as depreciation and amortization, impairment charges, unrealized gain (loss) on strategic investments, acquired IPR&D and share-based compensation;\n- \u00b7 changes in operating assets and liabilities, which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in results of operations; and\n- \u00b7 changes in the fair value of contingent payments associated with our acquisitions of businesses and payments related to collaborations.\n\nFor 2022 compared to 2021, the decrease in net cash flow provided by operating activities was\n\nprimarily due to lower revenue in 2022, net payments of $917.0 million for a litigation settlement agreement and settlement fees and expenses, timing of payments and higher net income tax payments in 2022. The higher tax payments are, in part, due to a change in the tax deductibility of payments made for research and development.\n\n## glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><D3AB7<5 glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>1B7D7B73A\n\nFor 2022 compared to 2021, the increase in net cash flow provided by investing activities was primarily due to proceeds received from the sale of our 49.9% equity interest in Samsung Bioepis of $990.3 million, net of expenses, during the second quarter of 2022 as well as $582.6 million in net proceeds received from the sale of one of our buildings during the third quarter of 2022.\n\n## glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>7</<17<5 glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>1B7D7B73A\n\nFor 2022 compared to 2021, the decrease in net cash flow used in financing activities was primarily due to $1.1 billion in lower share repurchases in 2022, partially offset by $832.2 million in higher debt repayments in 2022.\n\napproximately $5.0 billion during the year ended December 31, 2020.\n\nIn March 2019 our Board of Directors authorized our March 2019 Share Repurchase Program, which was a program to repurchase up to $5.0 billion of our common stock, which was completed as of March 31, 2020. All shares repurchased under our March 2019 Share Repurchase Program were retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately 4.1 million shares of our common stock at a cost of approximately $1.3 billion during the year ended December 31, 2020.\n\nIn August 2022 the IRA was signed into law. Among other things, the IRA levies a 1.0% excise tax on net stock repurchases after December 31, 2022. Historically, we have made discretionary share repurchases.",
        "metadata": {
            "page": 93
        },
        "id": "6109782c-f0ae-4c28-a7bb-8267dcdbef72"
    },
    {
        "page_content": "## glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@FD35FG3> &4>;93F;A@E 3@6 &88glyph<c=10,font=/PIIBCD+FranklinGothic-Book>glyph<c=25,font=/PIIBCD+FranklinGothic-Book>3>3@57 *:77F glyph<c=24,font=/PIIBCD+FranklinGothic-Book>DD3@97?7@FE\n\n## glyph<c=16,font=/PIICNA+FranklinGothic-BookItal>0/53\"$56\"glyph<c=27,font=/PIICNA+FranklinGothic-BookItal>#-*(\"5*0/4\n\nThe following table summarizes our contractual obligations as of December 31, 2022, excluding amounts related to uncertain tax positions, funding commitments, contingent development, regulatory and commercial milestone payments, contingent payments and contingent consideration related to our business combinations, as described below.\n\n|                                                                                                   | '3K?7@FE glyph<c=27,font=/PIIBCD+FranklinGothic-Book>G7 4K '7D;A6   | '3K?7@FE glyph<c=27,font=/PIIBCD+FranklinGothic-Book>G7 4K '7D;A6   | '3K?7@FE glyph<c=27,font=/PIIBCD+FranklinGothic-Book>G7 4K '7D;A6                                  | '3K?7@FE glyph<c=27,font=/PIIBCD+FranklinGothic-Book>G7 4K '7D;A6                                  | '3K?7@FE glyph<c=27,font=/PIIBCD+FranklinGothic-Book>G7 4K '7D;A6                                   |\n|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | +AF3>                                                               | #7EE F:3@ glyph<c=14,font=/PIIBCD+FranklinGothic-Book> 073D         | glyph<c=14,font=/PIIBCD+FranklinGothic-Book> FA glyph<c=16,font=/PIIBCD+FranklinGothic-Book> 073DE | glyph<c=16,font=/PIIBCD+FranklinGothic-Book> FA glyph<c=18,font=/PIIBCD+FranklinGothic-Book> 073DE | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>8F7D glyph<c=18,font=/PIIBCD+FranklinGothic-Book> 073DE |\n| Non-cancellable operating leases (1)(2)(3)                                                        | $ 364.2                                                             | $ 82.7                                                              | $ 140.8                                                                                            | $ 110.3                                                                                            | $ 30.4                                                                                              |\n| Long-term debt obligations (4)                                                                    | 10,262.4                                                            | 232.7                                                               | 2,197.7                                                                                            | 323.7                                                                                              | 7,508.3                                                                                             |\n| Purchase and other obligations (5)                                                                | 917.2                                                               | 306.7                                                               | 600.6                                                                                              | 1.7                                                                                                | 8.2                                                                                                 |\n| Defined benefit obligation                                                                        | 90.8                                                                | -                                                                   | -                                                                                                  | -                                                                                                  | 90.8                                                                                                |\n| Total contractual obligations                                                                     | $ 11,634.6                                                          | $ 622.1                                                             | $ 2,939.1                                                                                          | $ 435.7                                                                                            | $ 7,637.7                                                                                           |\n\n## glyph<c=29,font=/PIICNA+FranklinGothic-BookItal>0:\"-5: glyph<c=28,font=/PIICNA+FranklinGothic-BookItal>\":.&/54\n\n## (-'glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>&glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>\n\nWe are obligated to make contingent payments of 18.0% on annual worldwide net sales of TYSABRI up to $2.0 billion and 25.0% on annual worldwide net sales of TYSABRI that exceed $2.0 billion. Royalty payments are recognized as cost of sales in our consolidated statements of income.\n\n## '$glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>\"&glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>.glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>\n\nWe make royalty payments on annual worldwide net sales of SPINRAZA using a tiered royalty rate between 11.0% and 15.0%, which are recognized as cost of sales in our consolidated statements of income.\n\n## *)!glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>&glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>(-\n\nWe make royalty payments to Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc (Alkermes) on worldwide net sales of VUMERITY using a royalty rate of 15.0%, which are recognized as cost of sales in our consolidated statements of income.\n\nIn October 2019 we entered into a new supply agreement and amended our license and collaboration agreement with Alkermes for VUMERITY. We have elected to initiate a technology transfer and,\n\nfollowing a transition period, to manufacture VUMERITY or have VUMERITY manufactured by a third party we have engaged in exchange for paying an increased royalty rate to Alkermes on any portion of future worldwide net commercial sales of VUMERITY that is manufactured by us or our designee.\n\nFor additional information on our collaboration arrangement with Alkermes, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>A , to our consolidated financial statements included in this report.\n\nglyph<c=16,font=/PIICNA+FranklinGothic-BookItal>0/5*/(&/5 glyph<c=17,font=/PIICNA+FranklinGothic-BookItal>&7&-01.&/5glyph<c=5,font=/PIICNA+FranklinGothic-BookItal> glyph<c=29,font=/PIICNA+FranklinGothic-BookItal>&(6-\"503: \"/% glyph<c=16,font=/PIICNA+FranklinGothic-BookItal>0..&3$*\"glyph<c=25,font=/PIICNA+FranklinGothic-BookItal>*-&450/& glyph<c=28,font=/PIICNA+FranklinGothic-BookItal>\":.&/54\n\nBased on our development plans as of December 31, 2022, we could trigger potential future milestone payments to third parties of up to approximately $9.3 billion, including approximately $2.0 billion in development milestones, approximately $0.5 billion in regulatory milestones and approximately $6.8 billion in commercial milestones, as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones was not considered probable as",
        "metadata": {
            "page": 94
        },
        "id": "3d077ac7-e6e1-44d7-9a4e-62eb9cc63063"
    },
    {
        "page_content": "of December 31, 2022, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory or commercial milestones.\n\nIf certain clinical and commercial milestones are met, we may pay up to $356.2 million in milestones in 2023 under our current agreements. This includes milestones totaling $225.0 million due to Sage upon the first commercial sale of zuranolone, for the potential treatment of MDD and PPD, in the U.S.\n\n## glyph<c=27,font=/PIICNA+FranklinGothic-BookItal>5)&3 glyph<c=19,font=/PIICNA+FranklinGothic-BookItal>6/%*/( glyph<c=16,font=/PIICNA+FranklinGothic-BookItal>0..*5.&/54\n\nAs of December 31, 2022, we have several ongoing clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to CROs. The contracts with CROs are generally cancellable, with notice, at our option. We recorded accrued expense of approximately $20.4 million in our consolidated balance sheets for expenditures incurred by CROs as of December 31, 2022. We have approximately $929.0 million in cancellable future commitments based on existing CRO contracts as of December 31, 2022.\n\n## glyph<c=31,font=/PIICNA+FranklinGothic-BookItal>\"9 glyph<c=29,font=/PIICNA+FranklinGothic-BookItal>&-\"5&% glyph<c=27,font=/PIICNA+FranklinGothic-BookItal>#-*(\"5*0/4\n\nWe exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of December 31, 2022, we have approximately $154.6 million of liabilities associated with uncertain tax positions.\n\nAs of December 31, 2022 and 2021, we have accrued income tax liabilities of approximately $558.0 million and $633.0 million, respectively, under the Transition Toll Tax. Of the amounts accrued as of December 31, 2022, approximately $137.8 million is expected to be paid within one year. The Transition Toll Tax will be paid in installments over an eight--year period, which started in 2018, and will not accrue interest.\n\n## glyph<c=27,font=/PIICNA+FranklinGothic-BookItal>5)&3 glyph<c=27,font=/PIICNA+FranklinGothic-BookItal>''glyph<c=6,font=/PIICNA+FranklinGothic-BookItal>glyph<c=15,font=/PIICNA+FranklinGothic-BookItal>\"-\"/$& glyph<c=30,font=/PIICNA+FranklinGothic-BookItal>)&&5 glyph<c=14,font=/PIICNA+FranklinGothic-BookItal>33\"/(&.&/54\n\nWe do not have any relationships with entities often referred to as structured finance or special purpose entities that were established for the purpose of facilitating off-balance sheet arrangements. As such, we are not exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships. We consolidate variable interest entities if we are the primary beneficiary.\n\n## %7I glyph<c=24,font=/PIIBCD+FranklinGothic-Book>55AG@F;@9 *F3@63D6E\n\nFor a discussion of new accounting standards please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> 'C;;/@G =4 '75<7471/<B glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>11=C<B7<5 $=:7173Aglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> to our consolidated financial statements included in this report.\n\n## #793> $3FF7DE\n\nFor a discussion of legal matters as of December 31, 2022, please read \"=B3 glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> 7B75/B7=<glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> to our consolidated financial statements included in this report.\n\n## glyph<c=26,font=/PIIBCD+FranklinGothic-Book>D;F;53> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>55AG@F;@9 'A>;5;7E 3@6 glyph<c=28,font=/PIIBCD+FranklinGothic-Book>EF;?3F7E\n\nThe preparation of our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S. (U.S. GAAP), requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates. Other significant accounting policies are outlined in \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> 'C;;/@G =4 '75<7471/<B glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>11=C<B7<5 $=:7173A , to our consolidated financial statements included in this report.\n\n## glyph<c=29,font=/PIICNA+FranklinGothic-BookItal>&7&/6& glyph<c=29,font=/PIICNA+FranklinGothic-BookItal>&$0(/*5*0/\n\nWe recognize revenue when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenue following the five-step model prescribed under Financial Accounting Standards Board (FASB) Accounting Standards Codification 606, &3D3<C3 4@=; glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=<B@/1BA E7B6 glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>CAB=;3@A : (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations.\n\n## $@=2C1B &3D3<C3\n\nIn the U.S., we sell our products primarily to wholesale and specialty distributors and specialty pharmacies. In other countries, we sell our products primarily to wholesale distributors, hospitals, pharmacies and other third-party distribution partners. These customers subsequently resell our products to",
        "metadata": {
            "page": 95
        },
        "id": "2da80fb3-0f7c-42b0-aaf8-1efe6e9d83e0"
    },
    {
        "page_content": "health care providers and patients. In addition, we enter into arrangements with health care providers and payors that provide for government-mandated or privately-negotiated discounts and allowances related to our products.\n\nProduct revenue is recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial.\n\n## &3A3@D3A 4=@ glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>7A1=C<BA /<2 glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>::=E/<13A\n\nProduct revenue is recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, health care providers or payors, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. Our process for estimating reserves established for these variable consideration components do not differ materially from our historical practices.\n\nProduct revenue reserves, which are classified as a reduction in product revenue, are generally characterized in the following categories: discounts, contractual adjustments and returns.\n\nThese reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates of reserves established for variable consideration are calculated based upon a consistent application of our methodology utilizing the expected value method. These estimates reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.\n\nAs of December 31, 2022, a 10.0% change in our discounts, contractual adjustments and reserves\n\nwould have resulted in a decrease of our pre-tax earnings by approximately $338.6 million.\n\nIn addition to discounts, rebates and product returns, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenue. To the extent we can demonstrate a separable benefit and fair value for these services we classify these payments in selling, general and administrative expense in our consolidated statements of income.\n\nFor additional information on our revenue, please read \"=B3 glyph<c=15,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> &3D3<C3 , to our consolidated financial statements included in this report.\n\n## glyph<c=22,font=/PIICNA+FranklinGothic-BookItal>/7&/503:\n\nAt each reporting period we review our inventories for excess or obsolescence and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. The determination of obsolete or excess inventory requires management to make estimates based on assumptions about the future demand of our products, product expiration dates, estimated future sales and our general future plans. If customer demand subsequently differs from our forecasts, we may be required to record additional charges for excess inventory.\n\nAlthough we believe that the assumptions we use in estimating inventory write-downs are reasonable, no assurance can be given that significant future changes in these assumptions or changes in future events and market conditions could result in different estimates.\n\nDuring 2021 we wrote-off approximately $120.0 million of inventory in excess of forecasted demand related to ADUHELM. During the first quarter of 2022 we wrote-off approximately $275.0 million, as a result of the final CMS decision.\n\nAs of December 31, 2022, the carrying value of our ADUHELM inventory was immaterial. As of December 31, 2021, we had approximately $223.0 million of ADUHELM inventory.\n\n## glyph<c=14,font=/PIICNA+FranklinGothic-BookItal>$26*3&% glyph<c=22,font=/PIICNA+FranklinGothic-BookItal>/5\"/(*#-& glyph<c=14,font=/PIICNA+FranklinGothic-BookItal>44&54glyph<c=5,font=/PIICNA+FranklinGothic-BookItal> */$-6%*/( glyph<c=22,font=/PIICNA+FranklinGothic-BookItal>glyph<c=28,font=/PIICNA+FranklinGothic-BookItal>glyph<c=29,font=/PIICNA+FranklinGothic-BookItal>glyph<c=2,font=/PIICNA+FranklinGothic-BookItal>glyph<c=17,font=/PIICNA+FranklinGothic-BookItal>\n\nWhen we purchase a business, the acquired IPR&D is measured at fair value, capitalized as an intangible asset and tested for impairment at least annually, as of October 31, until commercialization, after which time the IPR&D is amortized over its estimated useful life. If we acquire an asset or group of assets that do not meet the definition of a business under applicable accounting standards, the acquired IPR&D is expensed on its acquisition date. Future costs to develop these assets are recorded to",
        "metadata": {
            "page": 96
        },
        "id": "6b85e519-938f-4f20-a81a-6ac581997ef0"
    },
    {
        "page_content": "research and development expense as they are incurred.\n\nWe have acquired, and expect to continue to acquire, intangible assets through the acquisition of biotechnology companies or through the consolidation of variable interest entities. These intangible assets primarily consist of technology associated with human therapeutic products and IPR&D product candidates. When significant identifiable intangible assets are acquired, we generally engage an independent thirdparty valuation firm to assist in determining the fair values of these assets as of the acquisition date. Management will determine the fair value of less significant identifiable intangible assets acquired. Discounted cash flow models are typically used in these valuations, and these models require the use of significant estimates and assumptions including but not limited to:\n\n- \u00b7 estimating the timing of and expected costs to complete the in-process projects;\n- \u00b7 projecting regulatory approvals;\n- \u00b7 estimating future cash flow from product sales resulting from completed products and in process projects; and\n- \u00b7 developing appropriate discount rates and probability rates by project.\n\nWe believe the fair values assigned to the intangible assets acquired are based upon reasonable estimates and assumptions given available facts and circumstances as of the acquisition dates.\n\nIf these projects are not successfully developed, the sales and profitability of the company may be adversely affected in future periods. Additionally, the value of the acquired intangible assets may become impaired. No assurance can be given that the underlying assumptions used to estimate expected project sales, development costs or profitability, or the events associated with such projects, will transpire as estimated.\n\n## glyph<c=22,font=/PIICNA+FranklinGothic-BookItal>.1\"*3.&/5 \"/% glyph<c=14,font=/PIICNA+FranklinGothic-BookItal>.035*;\"5*0/ 0' glyph<c=24,font=/PIICNA+FranklinGothic-BookItal>0/(glyph<c=6,font=/PIICNA+FranklinGothic-BookItal>-*7&% glyph<c=14,font=/PIICNA+FranklinGothic-BookItal>44&54\n\nLong-lived assets to be held and used include property, plant and equipment as well as intangible assets, including IPR&D and trademarks. Property, plant and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. We review our intangible assets with indefinite lives for impairment annually, as of October 31, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.\n\nWhen performing our impairment assessment, we calculate the fair value using the same methodology as described above under glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>1?C7@32\n\nglyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><B/<570:3 glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>AA3BAglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> 7<1:C27<5 glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>$&glyph<c=3,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal> . If the carrying value of our acquired IPR&D exceeds its fair value, then the intangible asset is written down to its fair value. Changes in estimates and assumptions used in determining the fair value of our acquired IPR&D could result in an impairment. Impairments are recorded within amortization and impairment of acquired intangible assets in our consolidated statements of income.\n\nBased on our most recent impairment assessment we incurred impairment charges of approximately $119.6 million and $629.3 million for the years ended December 31, 2022 and 2021, respectively, mainly related to the discontinuation of IPR&D programs. For additional information on our impairments, \"=B3 glyph<c=17,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><B/<570:3 glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>AA3BA /<2 glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>==2E7:: , to our consolidated financial statements included in this report.\n\nOur most significant intangible assets are our acquired and in-licensed rights and patents. Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI. We amortize the intangible assets related to our marketed products using the economic consumption method based on revenue generated from the products underlying the related intangible assets. An analysis of the anticipated lifetime revenue of our marketed products is performed annually during our long-range planning cycle and whenever events or changes in circumstances would significantly affect anticipated lifetime revenue of the relevant products.\n\nFor additional information on the impairment charges related to our long-lived assets during 2022, 2021 and 2020, please read \"=B3 glyph<c=17,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><B/<570:3 glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>AA3BA /<2 glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>==2E7::glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> to our consolidated financial statements included in this report.\n\n## glyph<c=16,font=/PIICNA+FranklinGothic-BookItal>0/5*/(&/5 glyph<c=16,font=/PIICNA+FranklinGothic-BookItal>0/4*%&3\"5*0/\n\nWe record contingent consideration resulting from a business combination at its fair value on the acquisition date. Each reporting period thereafter, we revalue the remaining obligations and record increases or decreases in their fair value as an adjustment to contingent consideration expense in our consolidated statements of income. Changes in the fair value of our contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates and achievement and timing of any cumulative salesbased and development milestones or changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market.",
        "metadata": {
            "page": 97
        },
        "id": "e154d316-31da-4233-abbb-c46838bca0bd"
    },
    {
        "page_content": "Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions described above, could have a material impact on the amount of contingent consideration expense we record in any given period.\n\n## glyph<c=22,font=/PIICNA+FranklinGothic-BookItal>/$0.& glyph<c=31,font=/PIICNA+FranklinGothic-BookItal>\"9&4\n\nWe prepare and file income tax returns based on our interpretation of each jurisdiction's tax laws and regulations. In preparing our consolidated financial statements, we estimate our income tax liability in each of the jurisdictions in which we operate by estimating our actual current tax expense together with assessing temporary differences resulting from differing treatment of items for tax and financial reporting purposes. These differences result in deferred tax assets and liabilities, which are included in our consolidated balance sheets. Upon our election in the fourth quarter of 2018 to record deferred taxes for global intangible low-taxed income (GILTI), we have included amounts related to GILTI taxes within temporary difference.\n\nSignificant management judgment is required in assessing the realizability of our deferred tax assets. In performing this assessment, we consider whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. In making this determination, under the applicable financial accounting standards, we are allowed to consider the scheduled reversal of deferred tax liabilities, projected future taxable income and the effects of tax planning strategies. In the event that actual results differ from our estimates, we adjust our estimates in future periods and we may need to establish a valuation allowance, which could materially impact our consolidated financial position and results of operations.\n\nWe account for uncertain tax positions using a [ more likely than not \\ threshold for recognizing and resolving uncertain tax positions. We evaluate uncertain tax positions on a quarterly basis and consider various factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. We adjust the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Our liabilities for uncertain tax positions can be relieved only if the contingency becomes legally extinguished, through\n\neither payment to the taxing authority or the expiration of the statute of limitations, the recognition of the benefits associated with the position meet the [ more likely than not \\ threshold or the liability becomes effectively settled through the examination process. We consider matters to be effectively settled once the taxing authority has completed all of its required or expected examination procedures, including all appeals and administrative reviews, we have no plans to appeal or litigate any aspect of the tax position and we believe that it is highly unlikely that the taxing authority would examine or re-examine the related tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.\n\n## +glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$ glyph<c=20,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> (,glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%+ +glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+ -glyph<c=28,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> (,glyph<c=24,font=/PIIBCD+FranklinGothic-Book># +glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+ -glyph<c=28,font=/PIIBCD+FranklinGothic-Book> glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *glyph<c=26,font=/PIIBCD+FranklinGothic-Book>#&*,)glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* glyph<c=24,font=/PIIBCD+FranklinGothic-Book>glyph<c=25,font=/PIIBCD+FranklinGothic-Book>&,+ $glyph<c=24,font=/PIIBCD+FranklinGothic-Book>)\"glyph<c=28,font=/PIIBCD+FranklinGothic-Book>+ ) *\"\n\nWe are subject to certain risks that may affect our results of operations, cash flow and fair values of assets and liabilities, including volatility in foreign currency exchange rates, interest rate movements and equity price exposure as well as changes in economic conditions in the markets in which we operate as a result of the COVID-19 pandemic and the conflict in Ukraine. We manage the impact of foreign currency exchange rates and interest rates through various financial instruments, including derivative instruments such as foreign currency forward contracts, interest rate lock contracts and interest rate swap contracts. We do not enter into financial instruments for trading or speculative purposes. The counterparties to these contracts are major financial institutions, and there is no significant concentration of exposure with any one counterparty.\n\n## glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD7;9@ glyph<c=26,font=/PIIBCD+FranklinGothic-Book>GDD7@5K glyph<c=28,font=/PIIBCD+FranklinGothic-Book>J5:3@97 );E=\n\nOur results of operations are subject to foreign currency exchange rate fluctuations due to the global nature of our operations. As a result, our consolidated financial position, results of operations and cash flow can be affected by market fluctuations in foreign currency exchange rates, primarily with respect to the Euro, British pound sterling, Canadian dollar, Swiss franc and Japanese yen.\n\nWhile the financial results of our global activities are reported in U.S. dollars, the functional currency for most of our foreign subsidiaries is their respective local currency. Fluctuations in the foreign currency exchange rates of the countries in which we do business will affect our operating results, often in ways that are difficult to predict. In particular, as the U.S. dollar strengthens versus other currencies, the value of the non-U.S. revenue will decline when reported in U.S. dollars. The impact to net income as a result of a strengthening U.S. dollar will be partially",
        "metadata": {
            "page": 98
        },
        "id": "955e6dd6-084e-4eb4-851b-d16049800c9f"
    },
    {
        "page_content": "mitigated by the value of non-U.S. expense, which will also decline when reported in U.S. dollars. As the U.S. dollar weakens versus other currencies, the value of the non-U.S. revenue and expense will increase when reported in U.S. dollars.\n\nWe have established revenue and operating expense hedging and balance sheet risk management programs to protect against volatility of future foreign currency cash flow and changes in fair value caused by volatility in foreign currency exchange rates.\n\nDuring the second quarter of 2018 the International Practices Task Force of the Center for Audit , uality categorized Argentina as a country with a projected three-year cumulative inflation rate greater than 100.0%, which indicated that Argentina's economy is highly inflationary. This categorization did not have a material impact on our results of operations or financial position as of December 31, 2022, and is not expected to have a material impact on our results of operations or financial position in the future.\n\n## &3D3<C3 /<2 #>3@/B7<5 glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>F>3<A3 glyph<c=28,font=/PIIBDE+FranklinGothic-BookItal>3257<5 $@=5@/;\n\nOur foreign currency hedging program is designed to mitigate, over time, a portion of the impact resulting from volatility in exchange rate changes on revenue and operating expense. We use foreign currency forward contracts and foreign currency options to manage foreign currency risk, with the majority of our forward contracts used to hedge certain forecasted revenue and operating expense transactions denominated in foreign currencies in the next 12 months. We do not engage in currency speculation. For a more detailed disclosure of our revenue and operating expense hedging program, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=10,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>3@7D/B7D3 glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><AB@C;3<BAglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> to our consolidated financial statements included in this report.\n\nOur ability to mitigate the impact of foreign currency exchange rate changes on revenue and net income diminishes as significant foreign currency exchange rate fluctuations are sustained over extended periods of time. In particular, devaluation or significant deterioration of foreign currency exchange rates are difficult to mitigate and likely to negatively impact earnings. The cash flow from these contracts are reported as operating activities in our consolidated statements of cash flow.\n\n## glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>/:/<13 '633B &7A9 !/</53;3<B glyph<c=28,font=/PIIBDE+FranklinGothic-BookItal>3257<5 $@=5@/;\n\nWe also use forward contracts to mitigate the foreign currency exposure related to certain balance sheet items. The primary objective of our balance sheet risk management program is to mitigate the exposure of foreign currency denominated net monetary assets and liabilities of foreign affiliates. In these instances, we principally utilize currency forward\n\ncontracts. We have not elected hedge accounting for the balance sheet related items. The cash flow from these contracts are reported as operating activities in our consolidated statements of cash flow.\n\nThe following quantitative information includes the impact of currency movements on forward contracts used in our revenue, operating expense and balance sheet hedging programs. As of December 31, 2022 and 2021, a hypothetical adverse 10.0% movement in foreign currency exchange rates compared to the U.S. dollar across all maturities would result in a hypothetical decrease in the fair value of forward contracts of approximately $293.7 million and $333.1 million, respectively. The estimated fair value change was determined by measuring the impact of the hypothetical exchange rate movement on outstanding forward contracts. Our use of this methodology to quantify the market risk of such instruments is subject to assumptions and actual impact could be significantly different. The quantitative information about market risk is limited because it does not take into account all foreign currency operating transactions.\n\n## @F7D7EF )3F7 );E=\n\nOur investment portfolio includes cash equivalents and short-term investments. The fair value of our marketable securities is subject to change as a result of potential changes in market interest rates. The potential change in fair value for interest rate sensitive instruments has been assessed on a hypothetical 100 basis point adverse movement across all maturities. As of December 31, 2022 and 2021, we estimate that such hypothetical 100 basis point adverse movement would result in a hypothetical loss in fair value of approximately $11.7 million and $14.3 million, respectively, to our interest rate sensitive instruments. The fair values of our investments were determined using third-party pricing services or other market observable data.\n\n## glyph<c=26,font=/PIIBCD+FranklinGothic-Book>D76;F );E=\n\nFinancial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties.",
        "metadata": {
            "page": 99
        },
        "id": "5684f9b0-2775-4a6e-8421-8054a944a0e5"
    },
    {
        "page_content": "We operate in certain countries where weakness in economic conditions, including the effects of the COVID-19 pandemic and the conflict in Ukraine, can result in extended collection periods. We continue to monitor these conditions, including the volatility associated with international economies and the relevant financial markets, and assess their possible impact on our business. To date, we have not experienced any significant losses with respect to the collection of our accounts receivable.\n\nWe believe that our allowance for doubtful accounts was adequate as of December 31, 2022 and 2021.\n\n## glyph<c=28,font=/PIIBCD+FranklinGothic-Book>CG;FK 'D;57 );E=\n\nOur strategic investment portfolio includes investments in equity securities of certain biotechnology companies. While we are holding such securities, we are subject to equity price risk, and this may increase the volatility of our income in future periods due to changes in the fair value of equity investments. We may sell such equity securities based on our business considerations, which may include limiting our price risk.\n\nChanges in the fair value of these equity securities are impacted by the volatility of the stock market and changes in general economic conditions, among other factors. The potential change in fair value for equity price sensitive instruments has been assessed on a hypothetical 10.0% adverse movement. As of December 31, 2022 and 2021, a hypothetical adverse 10.0% movement would result in a hypothetical decrease in fair value of approximately $79.1 million and $104.8 million, respectively.\n\n## +glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$ glyph<c=21,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,''#glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>)0 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>\n\nThe information required by this Item 8 is contained on pages F-1 through F-79 of this report and is incorporated herein by reference.\n\n## +glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$ glyph<c=22,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=31,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* % glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *glyph<c=24,font=/PIIBCD+FranklinGothic-Book>glyph<c=30,font=/PIIBCD+FranklinGothic-Book>)glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* . +glyph<c=31,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&,%+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%+* &% glyph<c=24,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&,%+ %glyph<c=30,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *glyph<c=26,font=/PIIBCD+FranklinGothic-Book>#&*,)glyph<c=28,font=/PIIBCD+FranklinGothic-Book>\n\nNone.\n\n## +glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$ glyph<c=22,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%+)&#* glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> ')&glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book>,)glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\nglyph<c=27,font=/PIIBCD+FranklinGothic-Book>;E5>AEGD7 glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@FDA>E 3@6 'DA576GD7E 3@6 @F7D@3> glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@FDA> AH7D glyph<c=29,font=/PIIBCD+FranklinGothic-Book>;@3@5;3> )7BADF;@9\n\n## glyph<c=16,font=/PIICNA+FranklinGothic-BookItal>0/530-4 \"/% glyph<c=28,font=/PIICNA+FranklinGothic-BookItal>30$&%63&4\n\nWe have carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of\n\nthe design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934, as amended), as of December 31, 2022. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in ensuring that:\n\n- (a) the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission's rules and forms; and\n- (b) such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.\n\nIn designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.\n\n## glyph<c=16,font=/PIICNA+FranklinGothic-BookItal>)\"/(&4 */ glyph<c=22,font=/PIICNA+FranklinGothic-BookItal>/5&3/\"glyph<c=16,font=/PIICNA+FranklinGothic-BookItal>0/53007&3 glyph<c=19,font=/PIICNA+FranklinGothic-BookItal>*/\"/$*\"glyph<c=29,font=/PIICNA+FranklinGothic-BookItal>&1035*/(\n\nThere were no changes in our internal control over financial reporting during the quarter ended December 31, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.\n\nglyph<c=25,font=/PIICNA+FranklinGothic-BookItal>\"/\"(&.&/5>4 glyph<c=14,font=/PIICNA+FranklinGothic-BookItal>//6\"glyph<c=29,font=/PIICNA+FranklinGothic-BookItal>&1035 0/ glyph<c=22,font=/PIICNA+FranklinGothic-BookItal>/5&3/\"glyph<c=16,font=/PIICNA+FranklinGothic-BookItal>0/53007&3 glyph<c=19,font=/PIICNA+FranklinGothic-BookItal>*/\"/$*\"glyph<c=29,font=/PIICNA+FranklinGothic-BookItal>&1035*/(\n\nOur management is responsible for establishing and maintaining adequate internal control over our financial reporting. Internal control over financial reporting is defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act as a process designed by, or under the supervision of, a company's principal executive and principal financial officers and effected by a company's board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP. Our internal control over financial reporting includes those policies and procedures that:\n\n- \u00b7 pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect our transactions and dispositions of our assets;",
        "metadata": {
            "page": 100
        },
        "id": "117a5e04-a252-40ff-ba59-c0b1eb6aac38"
    },
    {
        "page_content": "- \u00b7 provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and\n- \u00b7 provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.\n\nBecause of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.\n\nOur management assessed the effectiveness of our internal control over financial reporting as of December 31, 2022. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in its 2013 Internal Control - Integrated Framework.\n\nBased on our assessment, our management has concluded that, as of December 31, 2022, our internal control over financial reporting is effective based on those criteria.\n\nThe effectiveness of our internal control over financial reporting as of December 31, 2022, has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their attestation report, which is included herein.\n\n+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$ glyph<c=22,font=/PIIBCD+FranklinGothic-Book>glyph<c=25,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> &+glyph<c=31,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>) %glyph<c=29,font=/PIIBCD+FranklinGothic-Book>&)$glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+ &%\n\nNone.\n\n+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$ glyph<c=22,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *glyph<c=26,font=/PIIBCD+FranklinGothic-Book>#&*,)glyph<c=28,font=/PIIBCD+FranklinGothic-Book> )glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>)glyph<c=27,font=/PIIBCD+FranklinGothic-Book> %glyph<c=30,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book>&)glyph<c=28,font=/PIIBCD+FranklinGothic-Book> glyph<c=30,font=/PIIBCD+FranklinGothic-Book>% !,) *glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=26,font=/PIIBCD+FranklinGothic-Book>+ &%* +glyph<c=31,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+ ')glyph<c=28,font=/PIIBCD+FranklinGothic-Book>-glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+ %*'glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>+ &%*\n\nNot Applicable.",
        "metadata": {
            "page": 101
        },
        "id": "a1cacede-dcc4-459d-859e-96d664871969"
    },
    {
        "page_content": "## +glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$ glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=27,font=/PIIBCD+FranklinGothic-Book> )glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>+&)*glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=28,font=/PIIBCD+FranklinGothic-Book>/glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>,+ -glyph<c=28,font=/PIIBCD+FranklinGothic-Book> &glyph<c=29,font=/PIIBCD+FranklinGothic-Book>glyph<c=29,font=/PIIBCD+FranklinGothic-Book> glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>)* glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&)'&)glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book> glyph<c=30,font=/PIIBCD+FranklinGothic-Book>&-glyph<c=28,font=/PIIBCD+FranklinGothic-Book>)%glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>\n\nThe information concerning our executive officers is set forth under the heading glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><4=@;/B7=< /0=CB =C@ glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>F31CB7D3 #44713@A in Item 1 of this report. The text of our code of business conduct, which includes the code of ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, and persons performing similar functions, is posted on our website, www.biogen.com, under the [ glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=@>=@/B3 glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>=D3@</<13 \\ subsection of the [ glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><D3AB=@A \\ section of the site. We intend to make all required disclosures regarding any amendments to, or waivers from, provisions of our code of business conduct at the same location of our website.\n\nThe response to the remainder of this item is incorporated by reference from the discussion responsive thereto in the sections entitled [ $@=>=A/: glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=8,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>:31B7=< =4 glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>7@31B=@Aglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal>L Kglyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=@>=@/B3 glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>=D3@</<13 /B glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>7=53<L and [ !7A13::/<3=CA glyph<c=8,font=/PIIBDE+FranklinGothic-BookItal> 'B=196=:23@ $@=>=A/:A \\ contained in the proxy statement for our 2023 annual meeting of stockholders.\n\n## +glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$ glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=28,font=/PIIBCD+FranklinGothic-Book>/glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>,+ -glyph<c=28,font=/PIIBCD+FranklinGothic-Book> glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&$'glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%*glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+ &%\n\nThe response to this item is incorporated by reference from the discussion responsive thereto in the sections entitled [ glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>F31CB7D3 glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=;>3<A/B7=< !/BB3@A \\ and Kglyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=@>=@/B3 glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>=D3@</<13 /B glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>7=53<L contained in the proxy statement for our 2023 annual meeting of stockholders.\n\n## +glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$ glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> *glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>,) +0 &.%glyph<c=28,font=/PIIBCD+FranklinGothic-Book>)*glyph<c=31,font=/PIIBCD+FranklinGothic-Book> ' &glyph<c=29,font=/PIIBCD+FranklinGothic-Book> glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>)+glyph<c=24,font=/PIIBCD+FranklinGothic-Book> % glyph<c=25,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=29,font=/PIIBCD+FranklinGothic-Book> glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># &.%glyph<c=28,font=/PIIBCD+FranklinGothic-Book>)* glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> $glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=24,font=/PIIBCD+FranklinGothic-Book>glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+ glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> )glyph<c=28,font=/PIIBCD+FranklinGothic-Book>#glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *+&glyph<c=26,font=/PIIBCD+FranklinGothic-Book>\"glyph<c=31,font=/PIIBCD+FranklinGothic-Book>&#glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>) $glyph<c=24,font=/PIIBCD+FranklinGothic-Book>++glyph<c=28,font=/PIIBCD+FranklinGothic-Book>)*\n\nThe response to this item is incorporated by reference from the discussion responsive thereto in the sections entitled K'B=19 #E<3@A67>L and Kglyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>?C7BG glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=;>3<A/B7=< $:/< glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><4=@;/B7=<L contained in the proxy statement for our 2023 annual meeting of stockholders.\n\n## +glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$ glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>)+glyph<c=24,font=/PIIBCD+FranklinGothic-Book> % )glyph<c=28,font=/PIIBCD+FranklinGothic-Book>#glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+ &%*glyph<c=31,font=/PIIBCD+FranklinGothic-Book> '* glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> )glyph<c=28,font=/PIIBCD+FranklinGothic-Book>#glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> +)glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%*glyph<c=24,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>+ &%*glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=27,font=/PIIBCD+FranklinGothic-Book> )glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>+&) %glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>'glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>\n\nThe response to this item is incorporated by reference from the discussion responsive thereto in the sections entitled [ glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>3@B/7< &3:/B7=<A67>A /<2 &3:/B32 $3@A=< (@/<A/1B7=<A \\ and Kglyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=@>=@/B3 glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>=D3@</<13 /B glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>7=53< \\ contained in the proxy statement for our 2023 annual meeting of stockholders.\n\n## +glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$ glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=17,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> ') %glyph<c=26,font=/PIIBCD+FranklinGothic-Book> 'glyph<c=24,font=/PIIBCD+FranklinGothic-Book># glyph<c=24,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&,%+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%+ glyph<c=29,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *glyph<c=28,font=/PIIBCD+FranklinGothic-Book>)- glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\nThe response to this item is incorporated by reference from the discussion responsive thereto in the section entitled [ $@=>=A/: glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=8,font=/PIIBDE+FranklinGothic-BookItal> &/B7471/B7=< =4 B63 '3:31B7=< =4 =C@ glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><23>3<23<B &357AB3@32 $C0:71 glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>11=C<B7<5 glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>7@; \\ contained in the proxy statement for our 2023 annual meeting of stockholders.",
        "metadata": {
            "page": 102
        },
        "id": "d4ed33d8-57a1-450c-8491-1e971745d276"
    },
    {
        "page_content": "## 'glyph<c=24,font=/PIIBCD+FranklinGothic-Book>)+ -\n\n## +glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$ glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=18,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=28,font=/PIIBCD+FranklinGothic-Book>/glyph<c=31,font=/PIIBCD+FranklinGothic-Book> glyph<c=25,font=/PIIBCD+FranklinGothic-Book> +* glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+ *glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=31,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book>,#glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## \"glyph<c=7,font=/PIICNA+FranklinGothic-BookItal> glyph<c=3,font=/PIICNA+FranklinGothic-BookItal>glyph<c=9,font=/PIICNA+FranklinGothic-BookItal>glyph<c=4,font=/PIICNA+FranklinGothic-BookItal> glyph<c=16,font=/PIICNA+FranklinGothic-BookItal>0/40-*%\"5&% glyph<c=19,font=/PIICNA+FranklinGothic-BookItal>*/\"/$*\"glyph<c=30,font=/PIICNA+FranklinGothic-BookItal>5\"5&.&/54glyph<c=13,font=/PIICNA+FranklinGothic-BookItal>\n\nThe following financial statements are filed as part of this report:\n\n| glyph<c=29,font=/PIIBCD+FranklinGothic-Book>;@3@5;3> *F3F7?7@FE        | '397 %G?47D   |\n|------------------------------------------------------------------------|---------------|\n| Consolidated Statements of Income                                      | F-2           |\n| Consolidated Statements of Comprehensive Income                        | F-3           |\n| Consolidated Balance Sheets                                            | F-4           |\n| Consolidated Statements of Cash Flow                                   | F-5           |\n| Consolidated Statements of Equity                                      | F-6           |\n| Notes to Consolidated Financial Statements                             | F-9           |\n| Report of Independent Registered Public Accounting Firm (PCAOB ID 238) | F-78          |\n\nCertain totals may not sum due to rounding.\n\nThe exhibits listed on the Exhibit Index beginning on page 85, which is incorporated herein by reference, are filed or furnished as part of this report or are incorporated into this report by reference.\n\n## glyph<c=3,font=/PIICNA+FranklinGothic-BookItal>glyph<c=11,font=/PIICNA+FranklinGothic-BookItal>glyph<c=4,font=/PIICNA+FranklinGothic-BookItal> glyph<c=19,font=/PIICNA+FranklinGothic-BookItal>*/\"/$*\"glyph<c=30,font=/PIICNA+FranklinGothic-BookItal>5\"5&.&/5 glyph<c=30,font=/PIICNA+FranklinGothic-BookItal>$)&%6-&4\n\nSchedules are omitted because they are not applicable, or are not required, or because the information is included in the consolidated financial statements and notes thereto.\n\n## +glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$ glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=19,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book>&)$ glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=10,font=/PIIBCD+FranklinGothic-Book>\" *,$$glyph<c=24,font=/PIIBCD+FranklinGothic-Book>)0\n\nNot applicable.",
        "metadata": {
            "page": 103
        },
        "id": "440ca595-d1be-445a-8416-6afb9ed3d757"
    },
    {
        "page_content": "## glyph<c=28,font=/PIIBCD+FranklinGothic-Book>/glyph<c=31,font=/PIIBCD+FranklinGothic-Book> glyph<c=25,font=/PIIBCD+FranklinGothic-Book> + %glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>/\n\n| %Aglyph<c=11,font=/PIIBCD+FranklinGothic-Book>                                                 | glyph<c=28,font=/PIIBCD+FranklinGothic-Book>J:;4;F   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>7E5D;BF;A@                                                                                                                                                                                                                                                                                                                                                                                                                                                                |\n|------------------------------------------------------------------------------------------------|------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book>                                                   | 2.1 R                                                | Asset Purchase Agreement among Biogen Idec International Holding Ltd., Elan Pharma International Limited and Elan Pharmaceuticals, Inc., dated as of February 5, 2013. Filed as Exhibit 2.1 to our Current Report on Form 8-K/A filed on February 12, 2013.                                                                                                                                                                                                                                                           |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book>                                                   | 2.2                                                  | Separation Agreement between Biogen Inc. and Bioverativ Inc. dated as of January 31, 2017. Filed as Exhibit 2.1 to our Current Report on Form 8-K filed on February 2, 2017.                                                                                                                                                                                                                                                                                                                                          |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book>                                                   | 3.1                                                  | Amended and Restated Certificate of Incorporation, as amended. Filed as Exhibit 3.1 to our , uarterly Report on Form 10- , for the quarter ended June 30, 2012.                                                                                                                                                                                                                                                                                                                                                       |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book>                                                   | 3.2                                                  | Certificate of Amendment to the Certificate of Incorporation. Filed as Exhibit 3.1 to our Current Report on Form 8-K filed on March 27, 2015.                                                                                                                                                                                                                                                                                                                                                                         |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book>                                                   | 3.3                                                  | Certificate of Amendment of Biogen Inc.'s Amended and Restated Certificate of Incorporation, as amended. Filed as Exhibit 3.1 to our Current Report on Form 8-K filed on June 8, 2021.                                                                                                                                                                                                                                                                                                                                |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book>                                                   | 3.4                                                  | Fourth Amended and Restated Bylaws. Filed as Exhibit 3.1 to our Current Report on Form 8-K filed on June 9, 2017.                                                                                                                                                                                                                                                                                                                                                                                                     |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book>                                                   | 4.1                                                  | Second Supplemental Indenture, dated April 30, 2020, between Biogen Inc. and U.S. Bank National Association, including the forms of Global Notes attached as Exhibit A and Exhibit B, respectively, thereto. Filed as Exhibit 4.2 to our Current Report on Form 8-K filed on April 30, 2020.                                                                                                                                                                                                                          |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book>                                                   | 4.2                                                  | Reference is made to Exhibit 3.1 for a description of the rights, preferences and privileges of our Series A Preferred Stock and Series X Junior Participating Preferred Stock.                                                                                                                                                                                                                                                                                                                                       |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book>                                                   | 4.3                                                  | Indenture between Biogen Inc. and U.S. Bank National Association, dated as of September 15, 2015. Filed as Exhibit 4.1 to our Current Report on Form 8-K filed on September 16, 2015.                                                                                                                                                                                                                                                                                                                                 |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book>                                                   | 4.4                                                  | First Supplemental Indenture between Biogen Inc. and U.S. Bank National Association, dated September 15, 2015. Filed as Exhibit 4.2 to our Current Report on Form 8-K filed on September 16, 2015.                                                                                                                                                                                                                                                                                                                    |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book>                                                   | 4.5                                                  | Third Supplemental Indenture, dated February 16, 2021, between Biogen Inc. and U.S. Bank National Association. Filed as Exhibit 4.2 to our Current Report on Form 8-K filed on February 16, 2021.                                                                                                                                                                                                                                                                                                                     |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book>                                                   | 4.6                                                  | Form of 3.250% Senior Notes due 2051, in the form of a Global Note bearing a private placement legend. Filed as Exhibit 4.3 to our Current Report on Form 8-K filed on February 16, 2021.                                                                                                                                                                                                                                                                                                                             |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book>                                                   | 4.7                                                  | Form of 3.250% Senior Notes due 2051, in the form of a Global Note bearing a Regulation S legend. Filed as Exhibit 4.4 to our Current Report on Form 8-K filed on February 16, 2021.                                                                                                                                                                                                                                                                                                                                  |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book>                                                   | 4.8                                                  | Description of Securities.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book> glyph<c=11,font=/PIIBEG+FranklinGothic-Book> 10.1 | 4.9                                                  | Registration Rights Agreement, dated February 16, 2021, between Biogen Inc. and Deutsche Bank Securities Inc. and Citigroup Global Markets, Inc. with respect to the 3.250% Senior Notes due 2051. Filed as Exhibit 4.5 to our Current Report on Form 8-K filed on February 16, 2021. Credit Agreement between Biogen Inc., Bank of America, N.A., Goldman Sachs Bank USA and other lenders party thereto, dated August 28, 2015. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on September 1, 2015. |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book>                                                   | 10.2                                                 | Credit Agreement, dated as of January 28, 2020, among Biogen Inc., Bank of America, N.A., as administrative agent, swing line lender and the L/C issuer, and the other lenders party thereto. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on February 3, 2020.                                                                                                                                                                                                                                      |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book>                                                   | 10.3 glyph<c=11,font=/PIIBEG+FranklinGothic-Book>    | Amendment to Credit Agreement, dated as of February 7, 2023, by and among Biogen Inc., Bank of America, N.A., as administrative agent, swing line lender and the L&C issuer, and the other lenders party thereto.                                                                                                                                                                                                                                                                                                     |\n|                                                                                                |                                                      | Second Amended and Restated Collaboration Agreement between Biogen Idec Inc. and                                                                                                                                                                                                                                                                                                                                                                                                                                      |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book>                                                   | 10.4 R                                               | Genentech, Inc., dated as of October 18, 2010. Filed as Exhibit 10.5 to our Annual Report on Form 10-K for the year ended December 31, 2010.                                                                                                                                                                                                                                                                                                                                                                          |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book>                                                   | 10.5 R                                               | Letter Agreement regarding GA101 financial terms between Biogen Idec Inc. and Genentech, Inc., dated October 18, 2010. Filed as Exhibit 10.6 to our Annual Report on Form 10-K for the year ended December 31, 2010.                                                                                                                                                                                                                                                                                                  |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book>                                                   | 10.6                                                 | Settlement and License Agreement, dated January 17, 2017, between Biogen Swiss Manufacturing GmbH, Biogen International Holdings ltd., Forward Pharma A/S and other parties thereto. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on February 1, 2017.                                                                                                                                                                                                                                               |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book>                                                   | 10.7 glyph<c=10,font=/PIIBEG+FranklinGothic-Book>    | Biogen Inc. 2017 Omnibus Equity Plan. Filed as Appendix B to our Definitive Proxy Statement on Schedule 14A filed on April 26, 2017.                                                                                                                                                                                                                                                                                                                                                                                  |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book>                                                   | 10.8 glyph<c=10,font=/PIIBEG+FranklinGothic-Book>    | Form of restricted stock unit award agreement under the Biogen Inc. 2017 Omnibus Equity Plan. FiledasExhibit10.2toour , uarterly Report on Form 10- , for the quarter ended June 30, 2017.                                                                                                                                                                                                                                                                                                                            |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book>                                                   | 10.9 glyph<c=10,font=/PIIBEG+FranklinGothic-Book>    | Form of market stock unit award agreement under the Biogen Inc. 2017 Omnibus Equity Plan. FiledasExhibit10.3toour , uarterly Report on Form 10- , for the quarter ended June 30, 2017.                                                                                                                                                                                                                                                                                                                                |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book>                                                   | 10.10 glyph<c=10,font=/PIIBEG+FranklinGothic-Book>   | Form of performance unit award agreement under the Biogen Inc. 2017 Omnibus Equity Plan. Filed as Exhibit 10.4 to our , uarterly Report on Form 10- , for the quarter ended June 30, 2017.                                                                                                                                                                                                                                                                                                                            |",
        "metadata": {
            "page": 104
        },
        "id": "d7245ff8-dfb8-47f6-b817-65b7b164322a"
    },
    {
        "page_content": "|                                              | glyph<c=28,font=/PIIBCD+FranklinGothic-Book>J:;4;F %Aglyph<c=11,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>7E5D;BF;A@                                                                                                                                                                                                                                                          |\n|----------------------------------------------|-----------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book> | 10.11 glyph<c=10,font=/PIIBEG+FranklinGothic-Book>                                                  | Form of cash-settled performance unit award agreement under the Biogen Inc. 2017 Omnibus Equity Plan. Filed as Exhibit 10.5 to our , uarterly Report on Form 10- , for the quarter ended June 30, 2017.                                                                                                         |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book> | 10.12 glyph<c=10,font=/PIIBEG+FranklinGothic-Book>                                                  | Form of performance stock units award agreement (cash-settled) under the Biogen Inc. 2017 Omnibus Equity Plan. Filed as Exhibit 10.10 to our Annual Report on Form 10-K for the year ended December 31, 2017.                                                                                                   |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book> | 10.13 glyph<c=10,font=/PIIBEG+FranklinGothic-Book>                                                  | Form of performance stock units award agreement under the Biogen Inc. 2017 Omnibus Equity Plan. Filed as Exhibit 10.11 to our Annual Report on Form 10-K for the year ended December 31, 2017.                                                                                                                  |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book> | 10.14 glyph<c=10,font=/PIIBEG+FranklinGothic-Book>                                                  | Form of performance stock units award agreement under the Biogen Inc. 2017 Omnibus Equity Plan. Filed as Exhibit 10.1 to our , uarterly Report on Form 10- , for the quarter ended March 31, 2018.                                                                                                              |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book> | 10.15 glyph<c=10,font=/PIIBEG+FranklinGothic-Book>                                                  | Form of performance stock units award agreement (cash settled) under the Biogen Inc. 2017 Omnibus Equity Plan. Filed as Exhibit 10.2 to our , uarterly Report on Form 10- , for the quarter ended March 31, 2018.                                                                                               |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book> | 10.16 glyph<c=10,font=/PIIBEG+FranklinGothic-Book>                                                  | Form of restricted stock unit award agreement (2018 one-time transition grant) under the Biogen Inc. 2017 Omnibus Equity Plan. Filed as Exhibit 10.3 to our , uarterly Report on Form 10- , for the quarter ended March 31, 2018.                                                                               |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book> | 10.17 glyph<c=10,font=/PIIBEG+FranklinGothic-Book>                                                  | Form of market stock unit award agreement under the Biogen Inc. 2017 Omnibus Equity Plan (for grants commencing in July 2019). Filed as Exhibit 10.1 to our , uarterly Report on Form 10- , for the quarter ended June 30, 2019.                                                                                |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book> | 10.18 glyph<c=10,font=/PIIBEG+FranklinGothic-Book>                                                  | Form of performance stock units award agreement under the Biogen Inc. 2017 Omnibus Equity Plan (for grants commencing in July 2019). Filed as Exhibit 10.2 to our , uarterly Report on Form 10- , for the quarter ended June 30, 2019.                                                                          |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book> | 10.19 glyph<c=10,font=/PIIBEG+FranklinGothic-Book>                                                  | Form of performance stock units award agreement (cash settled) under the Biogen Inc. 2017 Omnibus Equity Plan (for grants commencing in July 2019). Filed as Exhibit 10.3 to our , uarterly Report on Form 10- , for the quarter ended June 30, 2019.                                                           |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book> | 10.20                                                                                               | Form of nonqualified stock option award agreement under Biogen Inc. 2017 Omnibus Equity Plan.                                                                                                                                                                                                                   |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book> | 10.21 glyph<c=10,font=/PIIBEG+FranklinGothic-Book>                                                  | Biogen Idec Inc. 2008 Amended and Restated Omnibus Equity Plan. Filed as Exhibit 10.1 to our , uarterly Report on Form 10- , for the quarter ended March 31, 2014.                                                                                                                                              |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book> | 10.22 glyph<c=10,font=/PIIBEG+FranklinGothic-Book>                                                  | Form of performance unit award agreement under the Biogen Idec Inc. 2008 Omnibus Equity Plan. FiledasExhibit10.2toour , uarterly Report on Form 10- , for the quarter ended March 31, 2014.                                                                                                                     |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book> | 10.23 glyph<c=10,font=/PIIBEG+FranklinGothic-Book>                                                  | Form of market stock unit award agreement under the Biogen Idec Inc. 2008 Omnibus Equity Plan. Filed as Exhibit 10.3 to our , uarterly Report on Form 10- , for the quarter ended March 31, 2014.                                                                                                               |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book> | 10.24 glyph<c=10,font=/PIIBEG+FranklinGothic-Book>                                                  | Form of restricted stock unit award agreement under the Biogen Idec Inc. 2008 Omnibus Equity Plan. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on August 1, 2008.                                                                                                                             |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book> | 10.25 glyph<c=10,font=/PIIBEG+FranklinGothic-Book>                                                  | Form of nonqualified stock option award agreement under the Biogen Idec Inc. 2008 Omnibus Equity Plan. Filed as Exhibit 10.2 to our Current Report on Form 8-K filed on August 1, 2008.                                                                                                                         |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book> | 10.26 glyph<c=10,font=/PIIBEG+FranklinGothic-Book>                                                  | Form of cash-settled performance shares award agreement under the Biogen Idec Inc. 2008 Omnibus Equity Plan. Filed as Exhibit 10.1 to our , uarterly Report on Form 10- , for the quarter ended March 31, 2010.                                                                                                 |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book> | 10.27 glyph<c=10,font=/PIIBEG+FranklinGothic-Book>                                                  | Biogen Inc. 2006 Non-Employee Directors Equity Plan, as amended. Filed as Exhibit 10.2 to our , uarterly Report on Form 10- , for the quarter ended March 31, 2022.                                                                                                                                             |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book> | 10.28 glyph<c=10,font=/PIIBEG+FranklinGothic-Book>                                                  | Biogen Inc. 2015 Employee Stock Purchase Plan. Filed as Appendix A to our Definitive Proxy Statement on Schedule 14A filed on April 30, 2015.                                                                                                                                                                   |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book> | 10.29 glyph<c=10,font=/PIIBEG+FranklinGothic-Book>                                                  | Biogen Idec Inc. 2008 Performance-Based Management Incentive Plan. Filed as Appendix B to our Definitive Proxy Statement on Schedule 14A filed on May 8, 2008.                                                                                                                                                  |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book> | 10.30 glyph<c=10,font=/PIIBEG+FranklinGothic-Book>                                                  | Biogen Inc. 2019 Form of Performance-Based Management Incentive Plan, as amended. Filed as Exhibit 10.1 to our , uarterly Report on Form 10- , for the quarter ended June 30, 2021.                                                                                                                             |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book> | 10.31 glyph<c=10,font=/PIIBEG+FranklinGothic-Book>                                                  | Biogen Idec Inc. Voluntary Executive Supplemental Savings Plan, as amended and restated effective January 1, 2004. Filed as Exhibit 10.13 to our Annual Report on Form 10-K for the year ended December 31, 2003.                                                                                               |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book> | 10.32 glyph<c=10,font=/PIIBEG+FranklinGothic-Book>                                                  | Biogen Idec Inc. Supplemental Savings Plan, as amended. Filed as Exhibit 10.23 to our Annual Report on Form 10-K for the year ended December 31, 2015.                                                                                                                                                          |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book> | 10.33 glyph<c=10,font=/PIIBEG+FranklinGothic-Book>                                                  | Biogen Idec Inc. Voluntary Board of Directors Savings Plan, as amended. Filed as Exhibit 10.24 to our Annual Report on Form 10-K for the year ended December 31, 2015.                                                                                                                                          |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book> | 10.34 glyph<c=10,font=/PIIBEG+FranklinGothic-Book>                                                  | Biogen Inc. Executive Severance Policy - U.S. Executive Vice President, as amended effective June 19, 2019. Filed as Exhibit 10.4 to our , uarterly Report on Form 10- , for the quarter ended June 30, 2019. Biogen Inc. Executive Severance Policy - U.S. Executive Vice President, as amended effective July |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book> | 10.35 glyph<c=10,font=/PIIBEG+FranklinGothic-Book>                                                  | 13, 2020. Filed as Exhibit 10.1 to our , uarterly Report on Form 10- , for the quarter ended September 30, 2020. Annual Retainer Summary for Board of Directors (effective January 1, 2020). Filed as Exhibit 10.1                                                                                              |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book> | 10.36 glyph<c=10,font=/PIIBEG+FranklinGothic-Book>                                                  | to our , uarterly Report on Form 10- , for the quarter ended September 30, 2019.                                                                                                                                                                                                                                |",
        "metadata": {
            "page": 105
        },
        "id": "4158041d-d6e4-4ac6-a319-a48f09b8002b"
    },
    {
        "page_content": "|                                              | glyph<c=28,font=/PIIBCD+FranklinGothic-Book>J:;4;F %Aglyph<c=11,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>7E5D;BF;A@                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|----------------------------------------------|-----------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book> | 10.37 glyph<c=10,font=/PIIBEG+FranklinGothic-Book>                                                  | Form of indemnification agreement for directors and executive officers. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on June 7, 2011.                                                                                                                                                                                                                                                                                                                    |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book> | 10.38 glyph<c=10,font=/PIIBEG+FranklinGothic-Book>                                                  | Employment Agreement between Biogen Inc. and Michel Vounatsos dated December 18, 2016 and effective as of January 6, 2017. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on December 19, 2016.                                                                                                                                                                                                                                                            |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book> | 10.39 glyph<c=10,font=/PIIBEG+FranklinGothic-Book>                                                  | Letter regarding employment arrangement of Michel Vounatsos dated May 2, 2022. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on May 3, 2022.                                                                                                                                                                                                                                                                                                              |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book> | 10.40 glyph<c=10,font=/PIIBEG+FranklinGothic-Book>                                                  | Employment Agreement, dated November 10, 2022, by and between Biogen Inc. and Christopher A. Viehbacher. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on November 10, 2022.                                                                                                                                                                                                                                                                              |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book> | 10.41 glyph<c=10,font=/PIIBEG+FranklinGothic-Book>                                                  | Letter regarding employment arrangement of Michael McDonnell dated July 16, 2020. Filed as Exhibit 10.2 to our , uarterly Report on Form 10- , for the quarter ended September 30, 2020.                                                                                                                                                                                                                                                                                  |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book> | 10.42 glyph<c=10,font=/PIIBEG+FranklinGothic-Book>                                                  | Letter regarding employment arrangement of Susan Alexander dated December 13, 2005. Filed as Exhibit 10.58 to our Annual Report on Form 10-K for the year ended December 31, 2009.                                                                                                                                                                                                                                                                                        |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book> | 10.43 glyph<c=10,font=/PIIBEG+FranklinGothic-Book>                                                  | Letter regarding employment arrangement of Chirfi Guindo dated October 12, 2017. Filed as Exhibit 10.41 to our Annual Report on Form 10-K for the year ended December 31, 2020.                                                                                                                                                                                                                                                                                           |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book> | 10.44                                                                                               | Joint Venture Agreement, dated December 6, 2011, by and between Samsung BioLogics Co., Ltd. and Biogen Therapeutics Inc. (f/k/a Biogen Idec Therapeutics Inc.), as amended February 28, 2012, September 29, 2014, and February 20, 2019. Filed as Exhibit 10.1 to our , uarterly Report on Form 10- , for the quarter ended March 31, 2021.                                                                                                                               |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book> | 10.45                                                                                               | Amended and Restated Collaboration Agreement, dated October 22, 2017, between Biogen MA Inc. and Eisai Co., LTD.                                                                                                                                                                                                                                                                                                                                                          |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book> | 10.46                                                                                               | First Amendment to Amended and Restated Collaboration Agreement, dated March 13, 2022, between Biogen MA Inc. and Eisai Co., LTD.                                                                                                                                                                                                                                                                                                                                         |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book> | 21                                                                                                  | Subsidiaries.                                                                                                                                                                                                                                                                                                                                                                                                                                                             |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book> | 23                                                                                                  | Consent of PricewaterhouseCoopers LLP, an Independent Registered Public Accounting Firm.                                                                                                                                                                                                                                                                                                                                                                                  |\n|                                              | 31.1                                                                                                | Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.                                                                                                                                                                                                                                                                                                                                                                   |\n| 31.2                                         |                                                                                                     | Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.                                                                                                                                                                                                                                                                                                                                                                   |\n|                                              | 32.1                                                                                                | Certification of the Chief Executive Officer and the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.                                                                                                                                                                                                                                                                                                                                   |\n| glyph<c=11,font=/PIIBEG+FranklinGothic-Book> | 101                                                                                                 | The following materials from Biogen Inc.'s Annual Report on Form 10-K for the year ended December 31, 2022, formatted in iXBRL (Inline Extensible Business Reporting Language): (i) the Consolidated Statements of Income, (ii) the Consolidated Statements of Comprehensive Income, (iii) the Consolidated Balance Sheets, (iv) the Consolidated Statements of Cash Flow, (v) the Consolidated Statements of Equity and (vi) Notes to Consolidated Financial Statements. |\n\n- glyph<c=11,font=/PIIBEG+FranklinGothic-Book> Exhibit filed with the SEC, but not printed herein.",
        "metadata": {
            "page": 106
        },
        "id": "31e98b8f-11da-4433-9e78-6bf1d377c834"
    },
    {
        "page_content": "## * glyph<c=30,font=/PIIBCD+FranklinGothic-Book>%glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+,)glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n<!-- image -->\n\nPursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.\n\nglyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book>\n\nBy:\n\n/S/\n\nCHRISTOPHER A. VIEHBACHER\n\nChristopher A. Viehbacher\n\nChief Executive Officer\n\nDate: February 15, 2023",
        "metadata": {
            "page": 107
        },
        "id": "145be621-22f6-4d22-85a8-49961c25a4f1"
    },
    {
        "page_content": "Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.\n\n|                           | %3?7                      | glyph<c=26,font=/PIIBCD+FranklinGothic-Book>3B35;FK                                | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>3F7   |\n|---------------------------|---------------------------|------------------------------------------------------------------------------------|---------------------------------------------------|\n| /S/                       | CHRISTOPHER A. VIEHBACHER | Director and Chief Executive Officer                                               | February 15, 2023                                 |\n| Christopher A. Viehbacher | Christopher A. Viehbacher | (principal executive officer)                                                      |                                                   |\n| /S/                       | MICHAEL R. MCDONNELL      | Executive Vice President and Chief Financial Officer (principal financial officer) | February 15, 2023                                 |\n| Michael R. McDonnell      | Michael R. McDonnell      |                                                                                    |                                                   |\n| /S/                       | ROBIN C. KRAMER           | Senior Vice President, Chief Accounting Officer (principal accounting officer)     | February 15, 2023                                 |\n| Robin C. Kramer           |                           |                                                                                    |                                                   |\n| /S/                       | STELIOS PAPADOPOULOS      | Director and Chairman of the Board of Directors                                    | February 15, 2023                                 |\n| Stelios Papadopoulos      | Stelios Papadopoulos      |                                                                                    |                                                   |\n| /S/                       | ALEXANDER J. DENNER       | Director                                                                           | February 15, 2023                                 |\n| Alexander J. Denner       | Alexander J. Denner       |                                                                                    |                                                   |\n| /S/                       | CAROLINE D. DORSA         | Director                                                                           | February 15, 2023                                 |\n| Caroline D. Dorsa         | Caroline D. Dorsa         |                                                                                    |                                                   |\n| /S/                       | MARIA C. FREIRE           | Director                                                                           | February 15, 2023                                 |\n| Maria C. Freire           | Maria C. Freire           |                                                                                    |                                                   |\n| /S/                       | WILLIAM A. HAWKINS        | Director                                                                           |                                                   |\n| William A. Hawkins        | William A. Hawkins        |                                                                                    | February 15, 2023                                 |\n| /S/                       | WILLIAM D. JONES          | Director                                                                           | February 15, 2023                                 |\n| William D. Jones          | William D. Jones          |                                                                                    |                                                   |\n| /S/                       | JESUS B. MANTAS           | Director                                                                           | February 15, 2023                                 |\n| Jesus B. Mantas           | Jesus B. Mantas           |                                                                                    |                                                   |\n| /S/                       | RICHARD C. MULLIGAN       | Director                                                                           | February 15, 2023                                 |\n| Richard C. Mulligan       | Richard C. Mulligan       |                                                                                    |                                                   |\n| /S/                       | ERIC K. ROWINSKY          | Director                                                                           | February 15, 2023                                 |\n| Eric K. Rowinsky          | Eric K. Rowinsky          |                                                                                    |                                                   |\n|                           | STEPHEN A. SHERWIN        | Director                                                                           |                                                   |\n| /S/                       |                           |                                                                                    | February 15, 2023                                 |\n\nStephen A. Sherwin",
        "metadata": {
            "page": 108
        },
        "id": "e704cd68-74e8-44a6-9f39-a8c114219563"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+*\n\n|                                                                        | '397 %G?47D   |\n|------------------------------------------------------------------------|---------------|\n| Consolidated Statements of Income                                      | F-2           |\n| Consolidated Statements of Comprehensive Income                        | F-3           |\n| Consolidated Balance Sheets                                            | F-4           |\n| Consolidated Statements of Cash Flow                                   | F-5           |\n| Consolidated Statements of Equity                                      | F-6           |\n| Notes to Consolidated Financial Statements                             | F-9           |\n| Report of Independent Registered Public Accounting Firm (PCAOB ID 238) | F-78          |",
        "metadata": {
            "page": 109
        },
        "id": "c52cbcec-88d0-46a1-9552-27d6b467d651"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* &glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>\n\nglyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=9,font=/PIIBCD+FranklinGothic-Book> 7J57BF B7D E:3D7 3?AG@FEglyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\n|                                                                                    | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n|                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    |\n| Revenue:                                                                           |                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                     |\n| Product, net                                                                       | $ 7,987.8                                                                                                                                                                                                                                                                                           | $ 8,846.9                                                                                                                                                                                                                                                                                           | $ 10,692.2                                                                                                                                                                                                                                                                                          |\n| Revenue from anti-CD20 therapeutic programs                                        | 1,700.5                                                                                                                                                                                                                                                                                             | 1,658.5                                                                                                                                                                                                                                                                                             | 1,977.8                                                                                                                                                                                                                                                                                             |\n| Other                                                                              | 485.1                                                                                                                                                                                                                                                                                               | 476.3                                                                                                                                                                                                                                                                                               | 774.6                                                                                                                                                                                                                                                                                               |\n| Total revenue                                                                      | 10,173.4                                                                                                                                                                                                                                                                                            | 10,981.7                                                                                                                                                                                                                                                                                            | 13,444.6                                                                                                                                                                                                                                                                                            |\n| Cost and expense:                                                                  |                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                     |\n| Cost of sales, excluding amortization and impairment of acquired intangible assets | 2,278.3                                                                                                                                                                                                                                                                                             | 2,109.7                                                                                                                                                                                                                                                                                             | 1,805.2                                                                                                                                                                                                                                                                                             |\n| Research and development                                                           | 2,231.1                                                                                                                                                                                                                                                                                             | 2,501.2                                                                                                                                                                                                                                                                                             | 3,990.9                                                                                                                                                                                                                                                                                             |\n| Selling, general and administrative                                                | 2,403.6                                                                                                                                                                                                                                                                                             | 2,674.3                                                                                                                                                                                                                                                                                             | 2,504.5                                                                                                                                                                                                                                                                                             |\n| Amortization and impairment of acquired intangible assets                          | 365.9                                                                                                                                                                                                                                                                                               | 881.3                                                                                                                                                                                                                                                                                               | 464.8                                                                                                                                                                                                                                                                                               |\n| Collaboration profit (loss) sharing                                                | (7.4)                                                                                                                                                                                                                                                                                               | 7.2                                                                                                                                                                                                                                                                                                 | 232.9                                                                                                                                                                                                                                                                                               |\n| (Gain) loss on divestiture of Hiller X d, Denmark manufacturing operations         | -                                                                                                                                                                                                                                                                                                   | -                                                                                                                                                                                                                                                                                                   | (92.5)                                                                                                                                                                                                                                                                                              |\n| (Gain) loss on fair value remeasurement of contingent consideration                | (209.1)                                                                                                                                                                                                                                                                                             | (50.7)                                                                                                                                                                                                                                                                                              | (86.3)                                                                                                                                                                                                                                                                                              |\n| Acquired in-process research and development                                       | -                                                                                                                                                                                                                                                                                                   | 18.0                                                                                                                                                                                                                                                                                                | 75.0                                                                                                                                                                                                                                                                                                |\n| Restructuring charges                                                              | 131.1                                                                                                                                                                                                                                                                                               | -                                                                                                                                                                                                                                                                                                   | -                                                                                                                                                                                                                                                                                                   |\n| Gain on sale of building                                                           | (503.7)                                                                                                                                                                                                                                                                                             | -                                                                                                                                                                                                                                                                                                   | -                                                                                                                                                                                                                                                                                                   |\n| Other (income) expense, net                                                        | (108.2)                                                                                                                                                                                                                                                                                             | 1,095.5                                                                                                                                                                                                                                                                                             | (497.4)                                                                                                                                                                                                                                                                                             |\n| Total cost and expense                                                             | 6,581.6                                                                                                                                                                                                                                                                                             | 9,236.5                                                                                                                                                                                                                                                                                             | 8,397.1                                                                                                                                                                                                                                                                                             |\n| Income before income tax expense and equity in loss of investee, net of tax        | 3,591.8                                                                                                                                                                                                                                                                                             | 1,745.2                                                                                                                                                                                                                                                                                             | 5,047.5                                                                                                                                                                                                                                                                                             |\n| Income tax (benefit) expense                                                       | 632.8                                                                                                                                                                                                                                                                                               | 52.5                                                                                                                                                                                                                                                                                                | 992.3                                                                                                                                                                                                                                                                                               |\n| Equity in (income) loss of investee, net of tax                                    | (2.6)                                                                                                                                                                                                                                                                                               | (34.9)                                                                                                                                                                                                                                                                                              | (5.3)                                                                                                                                                                                                                                                                                               |\n| Net income                                                                         | 2,961.6                                                                                                                                                                                                                                                                                             | 1,727.6                                                                                                                                                                                                                                                                                             | 4,060.5                                                                                                                                                                                                                                                                                             |\n| Net income (loss) attributable to noncontrolling interests, net of tax             | (85.3)                                                                                                                                                                                                                                                                                              | 171.5                                                                                                                                                                                                                                                                                               | 59.9                                                                                                                                                                                                                                                                                                |\n| Net income attributable to Biogen Inc.                                             | $ 3,046.9                                                                                                                                                                                                                                                                                           | $ 1,556.1                                                                                                                                                                                                                                                                                           | $ 4,000.6                                                                                                                                                                                                                                                                                           |\n| Net income per share:                                                              |                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                     |\n| Basic earnings per share attributable to Biogen Inc.                               | $ 20.96                                                                                                                                                                                                                                                                                             | $ 10.44                                                                                                                                                                                                                                                                                             | $ 24.86                                                                                                                                                                                                                                                                                             |\n| Diluted earnings per share attributable to Biogen Inc.                             | $ 20.87                                                                                                                                                                                                                                                                                             | $ 10.40                                                                                                                                                                                                                                                                                             | $ 24.80                                                                                                                                                                                                                                                                                             |\n| Weighted-average shares used in calculating:                                       |                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                     |\n| Basic earnings per share attributable to Biogen Inc.                               | 145.3                                                                                                                                                                                                                                                                                               | 149.1                                                                                                                                                                                                                                                                                               | 160.9                                                                                                                                                                                                                                                                                               |\n| Diluted earnings per share attributable to Biogen Inc.                             | 146.0                                                                                                                                                                                                                                                                                               | 149.6                                                                                                                                                                                                                                                                                               | 161.3                                                                                                                                                                                                                                                                                               |",
        "metadata": {
            "page": 110
        },
        "id": "bb426149-16c1-47fd-ada8-916046957367"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* &glyph<c=29,font=/PIIBCD+FranklinGothic-Book> glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&$')glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=31,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%* -glyph<c=28,font=/PIIBCD+FranklinGothic-Book> %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>\n\nglyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\n|                                                                                  | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n|                                                                                  | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    |\n| Net income attributable to Biogen Inc.                                           | $ 3,046.9                                                                                                                                                                                                                                                                                           | $ 1,556.1                                                                                                                                                                                                                                                                                           | $ 4,000.6                                                                                                                                                                                                                                                                                           |\n| Other comprehensive income:                                                      |                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                     |\n| Unrealized gains (losses) on securities available for sale, net of tax           | (13.5)                                                                                                                                                                                                                                                                                              | (3.6)                                                                                                                                                                                                                                                                                               | (2.8)                                                                                                                                                                                                                                                                                               |\n| Unrealized gains (losses) on cash flow hedges, net of tax                        | (38.7)                                                                                                                                                                                                                                                                                              | 232.8                                                                                                                                                                                                                                                                                               | (186.8)                                                                                                                                                                                                                                                                                             |\n| Gains (losses) on net investment hedges, net of tax                              | (25.5)                                                                                                                                                                                                                                                                                              | 34.0                                                                                                                                                                                                                                                                                                | (33.6)                                                                                                                                                                                                                                                                                              |\n| Unrealized gains (losses) on pension benefit obligation, net of tax              | 43.7                                                                                                                                                                                                                                                                                                | 21.5                                                                                                                                                                                                                                                                                                | (33.5)                                                                                                                                                                                                                                                                                              |\n| Currency translation adjustment                                                  | (24.2)                                                                                                                                                                                                                                                                                              | (92.4)                                                                                                                                                                                                                                                                                              | 92.9                                                                                                                                                                                                                                                                                                |\n| Total other comprehensive income (loss), net of tax                              | (58.2)                                                                                                                                                                                                                                                                                              | 192.3                                                                                                                                                                                                                                                                                               | (163.8)                                                                                                                                                                                                                                                                                             |\n| Comprehensive income (loss) attributable to Biogen Inc.                          | 2,988.7                                                                                                                                                                                                                                                                                             | 1,748.4                                                                                                                                                                                                                                                                                             | 3,836.8                                                                                                                                                                                                                                                                                             |\n| Comprehensive income (loss) attributable to noncontrolling interests, net of tax | (85.3)                                                                                                                                                                                                                                                                                              | 172.1                                                                                                                                                                                                                                                                                               | 60.9                                                                                                                                                                                                                                                                                                |\n| Comprehensive income (loss)                                                      | $ 2,903.4                                                                                                                                                                                                                                                                                           | $ 1,920.5                                                                                                                                                                                                                                                                                           | $ 3,897.7                                                                                                                                                                                                                                                                                           |\n\nSee accompanying notes to these consolidated financial statements.",
        "metadata": {
            "page": 111
        },
        "id": "91d7aa84-7c22-426c-b4db-508c72aaec47"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=25,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>#glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book> *glyph<c=31,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>+*\n\nglyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=9,font=/PIIBCD+FranklinGothic-Book> 7J57BF B7D E:3D7 3?AG@FEglyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\n|                                                                                                                                                                                                                                                                                          | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>                                                 | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>                                                 |\n|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n|                                                                                                                                                                                                                                                                                          | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                                                                         | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                                                                         |\n| glyph<c=24,font=/PIIBCD+FranklinGothic-Book>**glyph<c=28,font=/PIIBCD+FranklinGothic-Book>+*                                                                                                                                                                                             | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>**glyph<c=28,font=/PIIBCD+FranklinGothic-Book>+*                                                                                                                                                                                             | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>**glyph<c=28,font=/PIIBCD+FranklinGothic-Book>+*                                                                                                                                                                                             |\n| Current assets:                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                          |\n| Cash and cash equivalents                                                                                                                                                                                                                                                                | $ 3,419.3                                                                                                                                                                                                                                                                                | $ 2,261.4                                                                                                                                                                                                                                                                                |\n| $3D=7F34>7 E75GD;F;7E                                                                                                                                                                                                                                                                    | 1,473.5                                                                                                                                                                                                                                                                                  | 1,541.1                                                                                                                                                                                                                                                                                  |\n| Accounts receivable, net                                                                                                                                                                                                                                                                 | 1,705.0                                                                                                                                                                                                                                                                                  | 1,549.4                                                                                                                                                                                                                                                                                  |\n| Due from anti-CD20 therapeutic programs                                                                                                                                                                                                                                                  | 431.4                                                                                                                                                                                                                                                                                    | 412.3                                                                                                                                                                                                                                                                                    |\n| Inventory                                                                                                                                                                                                                                                                                | 1,344.4                                                                                                                                                                                                                                                                                  | 1,351.5                                                                                                                                                                                                                                                                                  |\n| Other current assets                                                                                                                                                                                                                                                                     | 1,417.6                                                                                                                                                                                                                                                                                  | 740.8                                                                                                                                                                                                                                                                                    |\n| Total current assets                                                                                                                                                                                                                                                                     | 9,791.2                                                                                                                                                                                                                                                                                  | 7,856.5                                                                                                                                                                                                                                                                                  |\n| Marketable securities                                                                                                                                                                                                                                                                    | 705.7                                                                                                                                                                                                                                                                                    | 892.0                                                                                                                                                                                                                                                                                    |\n| Property, plant and equipment, net                                                                                                                                                                                                                                                       | 3,298.6                                                                                                                                                                                                                                                                                  | 3,416.4                                                                                                                                                                                                                                                                                  |\n| Operating lease assets                                                                                                                                                                                                                                                                   | 403.9                                                                                                                                                                                                                                                                                    | 375.4                                                                                                                                                                                                                                                                                    |\n| Intangible assets, net                                                                                                                                                                                                                                                                   | 1,850.1                                                                                                                                                                                                                                                                                  | 2,221.3                                                                                                                                                                                                                                                                                  |\n| Goodwill                                                                                                                                                                                                                                                                                 | 5,749.0                                                                                                                                                                                                                                                                                  | 5,761.1                                                                                                                                                                                                                                                                                  |\n| Deferred tax asset                                                                                                                                                                                                                                                                       | 1,226.4                                                                                                                                                                                                                                                                                  | 1,415.1                                                                                                                                                                                                                                                                                  |\n| Investments and other assets                                                                                                                                                                                                                                                             | 1,529.2                                                                                                                                                                                                                                                                                  | 1,939.5                                                                                                                                                                                                                                                                                  |\n| Total assets                                                                                                                                                                                                                                                                             | $ 24,554.1                                                                                                                                                                                                                                                                               | $ 23,877.3                                                                                                                                                                                                                                                                               |\n| # glyph<c=24,font=/PIIBCD+FranklinGothic-Book>glyph<c=25,font=/PIIBCD+FranklinGothic-Book> # + glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=28,font=/PIIBCD+FranklinGothic-Book>(, +0 | # glyph<c=24,font=/PIIBCD+FranklinGothic-Book>glyph<c=25,font=/PIIBCD+FranklinGothic-Book> # + glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=28,font=/PIIBCD+FranklinGothic-Book>(, +0 | # glyph<c=24,font=/PIIBCD+FranklinGothic-Book>glyph<c=25,font=/PIIBCD+FranklinGothic-Book> # + glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=28,font=/PIIBCD+FranklinGothic-Book>(, +0 |\n| Current liabilities:                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                          |\n| Current portion of notes payable                                                                                                                                                                                                                                                         | $ - $                                                                                                                                                                                                                                                                                    | 999.1                                                                                                                                                                                                                                                                                    |\n| Taxes payable                                                                                                                                                                                                                                                                            | 259.9                                                                                                                                                                                                                                                                                    | 174.7                                                                                                                                                                                                                                                                                    |\n| Accounts payable                                                                                                                                                                                                                                                                         | 491.5                                                                                                                                                                                                                                                                                    | 589.2                                                                                                                                                                                                                                                                                    |\n| Accrued expense and other                                                                                                                                                                                                                                                                | 2,521.4                                                                                                                                                                                                                                                                                  | 2,535.2                                                                                                                                                                                                                                                                                  |\n| Total current liabilities                                                                                                                                                                                                                                                                | 3,272.8                                                                                                                                                                                                                                                                                  | 4,298.2                                                                                                                                                                                                                                                                                  |\n| Notes payable                                                                                                                                                                                                                                                                            | 6,281.0                                                                                                                                                                                                                                                                                  | 6,274.0                                                                                                                                                                                                                                                                                  |\n| Deferred tax liability                                                                                                                                                                                                                                                                   | 334.7                                                                                                                                                                                                                                                                                    | 694.5                                                                                                                                                                                                                                                                                    |\n| Long-term operating lease liabilities                                                                                                                                                                                                                                                    | 333.0                                                                                                                                                                                                                                                                                    | 330.4                                                                                                                                                                                                                                                                                    |\n| Other long-term liabilities                                                                                                                                                                                                                                                              | 944.2                                                                                                                                                                                                                                                                                    | 1,320.5                                                                                                                                                                                                                                                                                  |\n| Total liabilities                                                                                                                                                                                                                                                                        | 11,165.7                                                                                                                                                                                                                                                                                 | 12,917.6                                                                                                                                                                                                                                                                                 |\n| Commitments, contingencies and guarantees (Notes 22 and 23)                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                          |\n| Equity:                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                          |\n| Biogen Inc. shareholders' equity                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                          |\n| Preferred stock, par value $0.001 per share                                                                                                                                                                                                                                              | -                                                                                                                                                                                                                                                                                        | -                                                                                                                                                                                                                                                                                        |\n| Common stock, par value $0.0005 per share                                                                                                                                                                                                                                                | 0.1                                                                                                                                                                                                                                                                                      | 0.1                                                                                                                                                                                                                                                                                      |\n| Additional paid-in capital                                                                                                                                                                                                                                                               | 73.3                                                                                                                                                                                                                                                                                     | 68.2                                                                                                                                                                                                                                                                                     |\n| Accumulated other comprehensive loss                                                                                                                                                                                                                                                     | (164.9)                                                                                                                                                                                                                                                                                  | (106.7)                                                                                                                                                                                                                                                                                  |\n| Retained earnings                                                                                                                                                                                                                                                                        | 16,466.5                                                                                                                                                                                                                                                                                 | 13,911.7                                                                                                                                                                                                                                                                                 |\n| Treasury stock, at cost; 23.8 million and 23.8 million shares, respectively                                                                                                                                                                                                              | (2,977.1)                                                                                                                                                                                                                                                                                | (2,977.1)                                                                                                                                                                                                                                                                                |\n| Total Biogen Inc. shareholders' equity                                                                                                                                                                                                                                                   | 13,397.9                                                                                                                                                                                                                                                                                 | 10,896.2                                                                                                                                                                                                                                                                                 |\n| Noncontrolling interests                                                                                                                                                                                                                                                                 | (9.5)                                                                                                                                                                                                                                                                                    | 63.5                                                                                                                                                                                                                                                                                     |\n| Total equity                                                                                                                                                                                                                                                                             | 13,388.4                                                                                                                                                                                                                                                                                 | 10,959.7                                                                                                                                                                                                                                                                                 |\n| Total liabilities and equity                                                                                                                                                                                                                                                             | $ 24,554.1                                                                                                                                                                                                                                                                               | $ 23,877.3                                                                                                                                                                                                                                                                               |\n\nSee accompanying notes to these consolidated financial statements.",
        "metadata": {
            "page": 112
        },
        "id": "4f940a32-6008-4402-9712-2c5741efc67a"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* &glyph<c=29,font=/PIIBCD+FranklinGothic-Book> glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>*glyph<c=31,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book>#&.\n\nglyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\n|                                                                                                                            | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>   |\n|----------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n|                                                                                                                            | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                     |\n| glyph<c=26,font=/PIIBCD+FranklinGothic-Book>3E: 8>AI 8DA? AB7D3F;@9 35F;H;F;7Eglyph<c=23,font=/PIIBCD+FranklinGothic-Book> |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |\n| Net income                                                                                                                 | $ 2,961.6                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | $ 1,727.6                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | $ 4,060.5                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |\n| Adjustments to reconcile net income to net cash flow from operating activities:                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |\n| Depreciation and amortization                                                                                              | 518.4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 487.7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 457.2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |\n| Impairment of intangible assets                                                                                            | 119.6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 629.3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 209.7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |\n| Excess and obsolescence charges related to inventory                                                                       | 336.2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 167.6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 26.6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |\n| Acquired in-process research and development                                                                               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 18.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 75.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |\n| Share-based compensation                                                                                                   | 254.1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 238.6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 198.3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |\n| Contingent consideration                                                                                                   | (209.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | (50.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (86.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |\n| (Gain)/loss on divestiture of Hiller X d, Denmark manufacturing operations                                                 | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (92.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |\n| Deferred income taxes                                                                                                      | (168.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | (426.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 149.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |\n| (Gain) loss on strategic investments                                                                                       | 265.9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 826.8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (681.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |\n| (Gain) loss on equity method investment                                                                                    | (2.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (34.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (3.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |\n| Gain on sale of equity interest in Samsung Bioepis                                                                         | (1,505.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n| Gain on sale of building                                                                                                   | (503.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n| Other                                                                                                                      | 208.2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 202.2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 104.6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |\n| Changes in operating assets and liabilities, net:                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |\n| Accounts receivable                                                                                                        | (203.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 324.8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 2.8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |\n| Due from anti-CD20 therapeutic programs                                                                                    | (19.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 1.2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 176.7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |\n| Inventory                                                                                                                  | (320.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | (462.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | (316.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |\n| Accrued expense and other current liabilities                                                                              | (113.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | (95.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 154.2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |\n| Income tax assets and liabilities                                                                                          | (142.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 230.8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (67.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |\n| Other changes in operating assets and liabilities, net                                                                     | (92.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (144.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | (137.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |\n| Net cash flow provided by (used in) operating activities                                                                   | 1,384.3                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 3,639.9                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 4,229.8                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |\n| glyph<c=26,font=/PIIBCD+FranklinGothic-Book>3E: 8>AI 8DA? ;@H7EF;@9 35F;H;F;7Eglyph<c=23,font=/PIIBCD+FranklinGothic-Book> |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |\n| Purchases of property, plant and equipment                                                                                 | (240.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | (258.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | (424.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |\n| Proceeds from sales and maturities of marketable securities                                                                | 3,671.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 3,405.4                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 7,299.4                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |\n| Purchases of marketable securities                                                                                         | (3,448.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | (3,808.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | (6,397.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |\n| Proceeds from sale of equity interest in Samsung Bioepis                                                                   | 990.3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n| Proceeds from sale of building                                                                                             | 582.6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n| Purchase of Sangamo Therapeutics, Inc. stock                                                                               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (141.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |\n| Purchase of Denali Therapeutics Inc. stock                                                                                 | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (423.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |\n| Purchase of Sage Therapeutics, Inc. stock                                                                                  | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (441.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |\n| Proceeds from divestiture of Hiller X d, Denmark manufacturing operations                                                  | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 28.1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n| Acquired in-process research and development                                                                               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (18.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (75.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |\n| Acquisitions of intangible assets                                                                                          | (2.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (18.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (52.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |\n| Proceeds from sales of strategic investments                                                                               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 93.5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 74.9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |\n| Other                                                                                                                      | 24.4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 12.9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (26.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |\n| Net cash flow provided by (used in) investing activities                                                                   | 1,576.6                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | (563.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | (608.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |\n| glyph<c=26,font=/PIIBCD+FranklinGothic-Book>3E: 8>AI 8DA? 8;@3@5;@9 35F;H;F;7Eglyph<c=23,font=/PIIBCD+FranklinGothic-Book> |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |\n| Purchase of treasury stock                                                                                                 | (750.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | (1,800.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | (6,679.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |\n| Payments related to issuance of stock for share-based compensation arrangements, net                                       | (1.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (0.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (4.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |\n| Repayments of borrowings and premiums paid on debt exchange                                                                | (1,002.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | (170.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n| Proceeds from borrowings                                                                                                   | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 2,967.4                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |\n| Repayments of borrowings                                                                                                   | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (1,500.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |\n| Net (distribution) contribution to noncontrolling interest                                                                 | 12.4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (94.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (71.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |\n| Other                                                                                                                      | (5.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (21.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 14.6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |\n| Net cash flow provided by (used in) financing activities                                                                   | (1,747.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | (2,086.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | (5,272.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |\n| Net increase (decrease) in cash and cash equivalents                                                                       | 1,213.6                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 990.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (1,651.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |\n| Effect of exchange rate changes on cash and cash equivalents                                                               | (55.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (59.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 69.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |\n| Cash and cash equivalents, beginning of the year                                                                           | 2,261.4                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 1,331.2                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 2,913.7                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |\n\nSee accompanying notes to these consolidated financial statements.",
        "metadata": {
            "page": 113
        },
        "id": "ab975a97-c138-4ab8-8788-94919c05e95f"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book> %glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> * +glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* & glyph<c=29,font=/PIIBCD+FranklinGothic-Book> glyph<c=28,font=/PIIBCD+FranklinGothic-Book> (, +0\n\n?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nglyph<c=6,font=/PIIBCD+FranklinGothic-Book> @\n\n+AF3>\n\nglyph<c=24,font=/PIIBCD+FranklinGothic-Book>55G?G>3F76\n\n<!-- image -->\n\n| %A@5A@FDA>>;@9 ;@F7D7EFE $ 63.5 $ 10,959.7                                                                                                                                                                                                                                                                            | (85.3)       | (58.2) - - - 750.0)         | - -                      | 12.3            | -                              | -                                 |                        | 44.2 -            | (46.0) - 63.5 -   | 1 . 3 - 3,397.9 $ (9.5) $ 13,388.4                                                                                                                                                                                                                                                                                    |\n|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-----------------------------|--------------------------|-----------------|--------------------------------|-----------------------------------|------------------------|-------------------|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| E:3D7:A>67DEP 7CG;FK *:3D7E glyph<c=24,font=/PIIBCD+FranklinGothic-Book>?AG@F (23.8) $ ( 2,977.1) $ 10,896.2                                                                                                                                                                                                          | - - 3 ,046.9 | - - (                       | -                        | - -             | ( 3.6) (750.0)                 | 3 .6 750.0                        | - -                    | -                 | - - 2             | - - $ ( 2,977.1) $ 1                                                                                                                                                                                                                                                                                                  |\n| 5A?BD7:7@E;H7 >AEE )7F3;@7673D@;@9E (106.7) $ 13,911.7                                                                                                                                                                                                                                                                | - 3,046.9    | ( 58.2) - - - - - -         | (492.1)                  |                 |                                | - (257.9)                         |                        | - -               | - - - - -         | - 1 - $ 0 .1 $ 7 3.3 $                                                                                                                                                                                                                                                                                                |\n| B3;6glyph<c=10,font=/PIIBCD+FranklinGothic-Book>;@ 53B;F3> $                                                                                                                                                                                                                                                          | -            | - -                         | -                        | -               | -                              |                                   | - 44.2                 |                   |                   | - - $ -                                                                                                                                                                                                                                                                                                               |\n| *:3D7E 1 70.8                                                                                                                                                                                                                                                                                                         | - -          | - -                         | -                        |                 | -                              | (3.6)                             |                        | 0.2               | -                 | 1                                                                                                                                                                                                                                                                                                                     |\n| glyph<c=24,font=/PIIBCD+FranklinGothic-Book> ?AG@F -                                                                                                                                                                                                                                                                  |              |                             | -                        | -               | -                              | -                                 |                        | -                 |                   |                                                                                                                                                                                                                                                                                                                       |\n| *:3D7E glyph<c=24,font=/PIIBCD+FranklinGothic-Book> $                                                                                                                                                                                                                                                                 | -            |                             |                          | -               | -                              | -                                 |                        |                   | 0.5               | . 3 - (164.9) $                                                                                                                                                                                                                                                                                                       |\n| ?AG@F 0 .1                                                                                                                                                                                                                                                                                                            | -            |                             | -                        |                 |                                |                                   |                        |                   | 263.5             |                                                                                                                                                                                                                                                                                                                       |\n| $ 6 8.2                                                                                                                                                                                                                                                                                                               |              |                             |                          | -               | -                              |                                   |                        | - (46.0)          | -                 |                                                                                                                                                                                                                                                                                                                       |\n| glyph<c=25,font=/PIIBCD+FranklinGothic-Book>3>3@57glyph<c=9,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                                                                         |              |                             |                          | -               |                                |                                   |                        |                   | - -               | - 67.9                                                                                                                                                                                                                                                                                                                |\n|                                                                                                                                                                                                                                                                                                                       |              | -                           |                          |                 |                                |                                   |                        | - stock           |                   |                                                                                                                                                                                                                                                                                                                       |\n| - $                                                                                                                                                                                                                                                                                                                   |              |                             |                          |                 |                                |                                   |                        |                   |                   |                                                                                                                                                                                                                                                                                                                       |\n|                                                                                                                                                                                                                                                                                                                       |              |                             |                          |                 |                                |                                   |                        | tock under ward - | -                 |                                                                                                                                                                                                                                                                                                                       |\n|                                                                                                                                                                                                                                                                                                                       |              |                             | -                        | interest -      | the ost -                      | -                                 | stock option           | a                 | share-based       | -                                                                                                                                                                                                                                                                                                                     |\n| glyph<c=16,font=/PIIBCD+FranklinGothic-Book> glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book> |              | i ncome ( loss), net of tax | noncontrolling i nterest | n oncontrolling | tock pursuant to rogram, a t c | pursuant to the rogram, a t c ost | under                  |                   | to                | glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book> glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book> |\n| glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D                                                                                                                                                                                                                                                                   | ncome        | comprehensive               | t o                      | f rom           | s P                            | s tock epurchase P                | common s tock purchase | plans s           | expense r elated  | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D                                                                                                                                                                                                                                                                   |\n|                                                                                                                                                                                                                                                                                                                       | i            | Other                       |                          | Capital c       | R                              | of R                              | of                     |                   | plan              |                                                                                                                                                                                                                                                                                                                       |\n|                                                                                                                                                                                                                                                                                                                       |              |                             |                          |                 |                                | Share                             |                        |                   |                   | glyph<c=25,font=/PIIBCD+FranklinGothic-Book>3>3@57glyph<c=9,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                                                                         |\n|                                                                                                                                                                                                                                                                                                                       |              |                             |                          |                 |                                |                                   |                        | and stock         |                   |                                                                                                                                                                                                                                                                                                                       |\n|                                                                                                                                                                                                                                                                                                                       | Net          |                             |                          |                 |                                |                                   |                        |                   |                   |                                                                                                                                                                                                                                                                                                                       |\n|                                                                                                                                                                                                                                                                                                                       |              |                             |                          |                 |                                |                                   |                        |                   |                   | Other                                                                                                                                                                                                                                                                                                                 |\n|                                                                                                                                                                                                                                                                                                                       |              |                             |                          |                 | Repurchase                     | Retirement                        |                        |                   |                   |                                                                                                                                                                                                                                                                                                                       |\n|                                                                                                                                                                                                                                                                                                                       |              |                             |                          |                 |                                |                                   | Issuance               |                   | Compensation      |                                                                                                                                                                                                                                                                                                                       |\n|                                                                                                                                                                                                                                                                                                                       |              |                             |                          |                 | of Share                       |                                   |                        | Issuance          |                   |                                                                                                                                                                                                                                                                                                                       |\n|                                                                                                                                                                                                                                                                                                                       |              |                             |                          | ontribution     | common epurchase               | common                            |                        | of common         |                   |                                                                                                                                                                                                                                                                                                                       |\n|                                                                                                                                                                                                                                                                                                                       |              | Distribution                |                          | payments        |                                |                                   |                        |                   |                   |                                                                                                                                                                                                                                                                                                                       |\n|                                                                                                                                                                                                                                                                                                                       |              |                             |                          |                 | 2020                           |                                   |                        |                   |                   |                                                                                                                                                                                                                                                                                                                       |\n|                                                                                                                                                                                                                                                                                                                       |              |                             |                          |                 |                                | 2020                              |                        |                   |                   |                                                                                                                                                                                                                                                                                                                       |",
        "metadata": {
            "page": 114
        },
        "id": "506f99f8-855b-483b-9c00-9da49e51e699"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book> %glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> * +glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* & glyph<c=29,font=/PIIBCD+FranklinGothic-Book> glyph<c=28,font=/PIIBCD+FranklinGothic-Book> (, +0 glyph<c=10,font=/PIIBCD+FranklinGothic-Book> glyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\n?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nglyph<c=6,font=/PIIBCD+FranklinGothic-Book> @\n\n+AF3>\n\nglyph<c=24,font=/PIIBCD+FranklinGothic-Book>55G?G>3F76\n\n| %A@5A@FDA>>;@9 +AF3> 7CG;FK $ 10,686.1                                                                                                                                           | 1 ,727.6                                                                                                                                         | 0 .6 192.9                               | (100.0) ( 100.0)                          | 5.6                                                   | - ( 1,800.0)                                                                | - -                                                                              | - 54.4                                                         | - ( 55.0)                                  | - 246.6                                     | 1.5                                                                         | 63.5 $ 10,959.7                                                                                                                                                                                                                                                                                                                                                                                                                                                         |\n|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------|-------------------------------------------|-------------------------------------------------------|-----------------------------------------------------------------------------|----------------------------------------------------------------------------------|----------------------------------------------------------------|--------------------------------------------|---------------------------------------------|-----------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| E:3D7:A>67DEP 7CG;FK ;@F7D7EFE glyph<c=24,font=/PIIBCD+FranklinGothic-Book>?AG@F (14.2)                                                                                          | 2,977.1) $ 10,700.3 $ - 1,556.1 171.5                                                                                                            | - - 192.3                                | - -                                       | - - 5 .6                                              | (1,800.0) (1,800.0)                                                         | (1,568.1) 6.0 ,800.0 -                                                           | - - 5 4.4                                                      | - (55.0)                                   | 246.6                                       | 1.5 -                                                                       | $                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |\n| )7F3;@7673D@;@9E *:3D7E 299.0) $ 13,976.3                                                                                                                                        | (23.8) $ ( - 1 ,556.1 -                                                                                                                          | -                                        | - - -                                     | - -                                                   | - ( 6.0)                                                                    | 1                                                                                | -                                                              | - ( 52.6) -                                | - - -                                       | - - -                                                                       | 13,911.7 (23.8) $ ( 1 0,896.2                                                                                                                                                                                                                                                                                                                                                                                                                                           |\n| *:3D7E glyph<c=24,font=/PIIBCD+FranklinGothic-Book>?AG@F                                                                                                                         | -                                                                                                                                                | -                                        |                                           |                                                       | -                                                                           | (6.0)                                                                            |                                                                |                                            |                                             | -                                                                           | $ 0 .1                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |\n|                                                                                                                                                                                  |                                                                                                                                                  |                                          |                                           | -                                                     | -                                                                           |                                                                                  |                                                                |                                            |                                             |                                                                             | - 1 70.8                                                                                                                                                                                                                                                                                                                                                                                                                                                                |\n| >AEE                                                                                                                                                                             | (                                                                                                                                                | - 19 2.3                                 | -                                         | - -                                                   | -                                                                           | -                                                                                | -                                                              |                                            | 2 46.6 -                                    | -                                                                           | (106.7) $ 2,977.1) $                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n|                                                                                                                                                                                  |                                                                                                                                                  |                                          |                                           |                                                       |                                                                             |                                                                                  |                                                                |                                            |                                             |                                                                             | - $                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |\n| *:3D7E glyph<c=24,font=/PIIBCD+FranklinGothic-Book>?AG@F 76.2 $ 0 .1 $                                                                                                           |                                                                                                                                                  | -                                        |                                           |                                                       |                                                                             | -                                                                                |                                                                | ( 2.4)                                     |                                             |                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |\n| B3;6glyph<c=10,font=/PIIBCD+FranklinGothic-Book>;@ 53B;F3> 5A?BD7:7@E;H7 - $                                                                                                     | - -                                                                                                                                              | -                                        | -                                         | -                                                     | -                                                                           | (231.9)                                                                          | - 5 4.4                                                        |                                            | -                                           | glyph<c=3,font=/PIJFCI+TimesNewRoman> glyph<c=3,font=/PIJFCI+TimesNewRoman> |                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |\n|                                                                                                                                                                                  | -                                                                                                                                                |                                          |                                           |                                                       |                                                                             |                                                                                  |                                                                |                                            |                                             | glyph<c=3,font=/PIJFCI+TimesNewRoman>                                       | $ 6 8.2 $                                                                                                                                                                                                                                                                                                                                                                                                                                                               |\n|                                                                                                                                                                                  |                                                                                                                                                  |                                          |                                           |                                                       |                                                                             |                                                                                  | .2                                                             | -                                          | -                                           | 1 .5                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |\n|                                                                                                                                                                                  | - $ - 1                                                                                                                                          |                                          |                                           | -                                                     | -                                                                           |                                                                                  | 0                                                              | - 0.4                                      | -                                           |                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |\n|                                                                                                                                                                                  |                                                                                                                                                  |                                          | - -                                       |                                                       |                                                                             | -                                                                                | -                                                              | -                                          |                                             |                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |\n|                                                                                                                                                                                  |                                                                                                                                                  |                                          |                                           |                                                       |                                                                             |                                                                                  | -                                                              |                                            |                                             |                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |\n|                                                                                                                                                                                  |                                                                                                                                                  |                                          | -                                         |                                                       | -                                                                           | -                                                                                |                                                                | award                                      | hare-based -                                |                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |\n|                                                                                                                                                                                  | glyph<c=16,font=/PIIBCD+FranklinGothic-Book> glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> Net i ncome | Other c omprehensive income ( loss), net | Distribution t o n oncontrolling interest | Capital c ontribution f rom n oncontrolling nterest - | Repurchase of common s tock pursuant the 2020 Share R epurchase Program, at | Retirement of common s tock pursuant the 2020 Share R epurchase Program, at cost | Issuance of common s tock under stock and stock purchase plans | Issuance of common s tock under stock plan | Compensation expense related t o s payments | Other                                                                       | glyph<c=25,font=/PIIBCD+FranklinGothic-Book>3>3@57glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book> glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book> |\n|                                                                                                                                                                                  | -                                                                                                                                                | of tax -                                 |                                           | i                                                     | to cost                                                                     | to                                                                               |                                                                |                                            |                                             |                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |\n| glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book> |                                                                                                                                                  |                                          |                                           |                                                       |                                                                             |                                                                                  |                                                                |                                            |                                             |                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |\n| glyph<c=25,font=/PIIBCD+FranklinGothic-Book>3>3@57glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D                                |                                                                                                                                                  |                                          |                                           |                                                       |                                                                             |                                                                                  |                                                                |                                            |                                             |                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |\n|                                                                                                                                                                                  |                                                                                                                                                  |                                          |                                           |                                                       |                                                                             | option                                                                           |                                                                |                                            |                                             |                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |",
        "metadata": {
            "page": 115
        },
        "id": "abf88aef-abd1-4739-adba-96e1264c88b1"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book> %glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> * +glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* & glyph<c=29,font=/PIIBCD+FranklinGothic-Book> glyph<c=28,font=/PIIBCD+FranklinGothic-Book> (, +0 glyph<c=10,font=/PIIBCD+FranklinGothic-Book> glyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\n?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nglyph<c=6,font=/PIIBCD+FranklinGothic-Book> @\n\n| %A@5A@FDA>>;@9 +AF3> 7CG;FK (4.1) $ 13,339.1                                                                                                                                                                                                                                                                                                                                                                                    | 59.9 4,060.5   | 1 .0 (162.8)                                      |                                           |                                                      | - ( 400.0)                                                                            | -                                                                                     | - (5,000.0)                                                                              | -                                                                                                                             | - (1,279.1) -                                                                              |                                      | -                            | -                         | - 204.5                                            | - ( 14.2) $ 10,686.1                                                                                                                                                                                                                                                                                                                                                                                                                                                          |\n|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|---------------------------------------------------|-------------------------------------------|------------------------------------------------------|---------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|--------------------------------------|------------------------------|---------------------------|----------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| E:3D7:A>67DEP $                                                                                                                                                                                                                                                                                                                                                                                                                 |                |                                                   | (75.0)                                    | 4.0                                                  |                                                                                       | -                                                                                     |                                                                                          | (1,279.1)                                                                                                                     |                                                                                            |                                      |                              |                           |                                                    | $                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |\n| ;@F7D7EFE * :3D7E ( 23.8) 13,343.2                                                                                                                                                                                                                                                                                                                                                                                              | - 4,000.6      | - (163.8)                                         | - -                                       | - -                                                  | ( 1.6) ( 400.0)                                                                       | - 1.6                                                                                 | ( 16.7) 5,000.0) (5,000.0)                                                               | 16.7 -                                                                                                                        | ( 4.1) -                                                                                   |                                      | - 4 9.3                      | - (53.7)                  | (0.7)                                              | ( 10,700.3                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n| B3;6glyph<c=10,font=/PIIBCD+FranklinGothic-Book>;@ 53B;F3> 5A?BD7:7@E;H7 )7F3;@7673D@;@9E *:3D7E glyph<c=24,font=/PIIBCD+FranklinGothic-Book> ?AG@F 98.0 $ 0 .1 $                                                                                                                                                                                                                                                               | 4              |                                                   | -                                         | -                                                    |                                                                                       | ( 00.0                                                                                | -                                                                                        | ( 121.3)                                                                                                                      |                                                                                            |                                      |                              |                           |                                                    | $                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |\n| 7CG;FK glyph<c=24,font=/PIIBCD+FranklinGothic-Book>?AG@F $ (2,977.1) $                                                                                                                                                                                                                                                                                                                                                          | -              | -                                                 |                                           |                                                      | (400.0)                                                                               | 4                                                                                     | (                                                                                        | 5,000.0 (1,279.1)                                                                                                             | 1,208.1) 4.1 1 ,279.1                                                                      |                                      | -                            | -                         | - -                                                | 23.8) $ (2,977.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                             |\n| >AEE 16,455.4                                                                                                                                                                                                                                                                                                                                                                                                                   | ,000.6         | - -                                               | - -                                       | -                                                    | - -                                                                                   | - 339.2)                                                                              | - -                                                                                      | -                                                                                                                             | - (71.0)                                                                                   |                                      | 9.3 -                        | (53.7)                    | - - - 2 04.5                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |\n| $ ( 135.2) $                                                                                                                                                                                                                                                                                                                                                                                                                    |                | 63.8)                                             |                                           |                                                      |                                                                                       |                                                                                       |                                                                                          | ( 4,878.7)                                                                                                                    | - (                                                                                        |                                      |                              |                           | -                                                  | 0.7) - - $ ( 299.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                           |\n|                                                                                                                                                                                                                                                                                                                                                                                                                                 | -              |                                                   |                                           |                                                      |                                                                                       |                                                                                       |                                                                                          |                                                                                                                               | -                                                                                          |                                      | -                            |                           |                                                    | - $ 13,976.3                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |\n| -                                                                                                                                                                                                                                                                                                                                                                                                                               | -              | (1                                                | -                                         | - -                                                  | -                                                                                     |                                                                                       |                                                                                          | -                                                                                                                             | - -                                                                                        | - (4.1) -                            | - 4                          | - -                       | - 204.5                                            | - ( $ 0 .1 $                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |\n| glyph<c=24,font=/PIIBCD+FranklinGothic-Book>?AG@F glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book> glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=22,font=/PIIBCD+FranklinGothic-Book> - 1 | - - -          | - - -                                             | - - -                                     | - -                                                  | -                                                                                     | (60.8)                                                                                | - -                                                                                      | - (16.7)                                                                                                                      | - -                                                                                        | stock option                         | 0 .2 tock under stock a ward | 0.4 -                     | to - -                                             | - - - - 1 76.2                                                                                                                                                                                                                                                                                                                                                                                                                                                                |\n| $                                                                                                                                                                                                                                                                                                                                                                                                                               | -              |                                                   |                                           | -                                                    | - -                                                                                   | - (1.6)                                                                               | -                                                                                        |                                                                                                                               |                                                                                            |                                      | -                            | -                         | -                                                  | $                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |\n| *:3D7E -                                                                                                                                                                                                                                                                                                                                                                                                                        |                |                                                   | -                                         |                                                      |                                                                                       |                                                                                       | to the                                                                                   | to the a t                                                                                                                    | -                                                                                          | -                                    |                              | -                         |                                                    | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |\n| glyph<c=25,font=/PIIBCD+FranklinGothic-Book>3>3@57glyph<c=9,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                   | Net i ncome    | Other c omprehensive income ( loss), net of tax - | Distribution t o n oncontrolling interest | Capital contribution from noncontrolling i nterest - | Repurchase of common s tock pursuant to the 2020 Share R epurchase Program, at cost - | Retirement of common s tock pursuant to the 2020 Share R epurchase Program, at cost - | Repurchase of common s tock pursuant December 2 019 Share Repurchase Program, a t cost - | December 2019 Share Repurchase Program, a t cost - Repurchase of common s tock pursuant March 2019 Share R epurchase Program, | cost Retirement of common s tock pursuant to the March 2019 Share R epurchase Program, a t | cost Issuance of common s tock under | and s tock purchase plans -  | Issuance of common s plan | Compensation expense r elated share-based payments | Other glyph<c=25,font=/PIIBCD+FranklinGothic-Book>3>3@57glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book> glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book> |",
        "metadata": {
            "page": 116
        },
        "id": "ba583520-1e13-42f4-9fcf-6d0c95d93aa4"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+*\n\n## %AF7 glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=23,font=/PIIBCD+FranklinGothic-Book> *G??3DK A8 *;9@;8;53@F glyph<c=24,font=/PIIBCD+FranklinGothic-Book>55AG@F;@9 'A>;5;7E\n\nReferences in these notes to glyph<c=2,font=/PIIBEG+FranklinGothic-Book> Biogen, glyph<c=2,font=/PIIBEG+FranklinGothic-Book> the glyph<c=2,font=/PIIBEG+FranklinGothic-Book> company, glyph<c=2,font=/PIIBEG+FranklinGothic-Book>glyph<c=2,font=/PIIBEG+FranklinGothic-Book> we, glyph<c=2,font=/PIIBEG+FranklinGothic-Book>glyph<c=2,font=/PIIBEG+FranklinGothic-Book> us glyph<c=2,font=/PIIBEG+FranklinGothic-Book> and glyph<c=2,font=/PIIBEG+FranklinGothic-Book> our glyph<c=2,font=/PIIBEG+FranklinGothic-Book> refer to Biogen Inc. and its consolidated subsidiaries.\n\n## glyph<c=25,font=/PIIBCD+FranklinGothic-Book>GE;@7EE &H7DH;7I\n\nBiogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases worldwide. We have a broad portfolio of medicines to treat multiple sclerosis (MS), have introduced the first approved treatment for spinal muscular atrophy (SMA) and codeveloped two treatments to address a defining pathology of Alzheimer's disease.We are focused on advancing our pipeline in neurology, neuropsychiatry, specialized immunology and rare diseases. We support our drug discovery and development efforts through internal research and development programs and external collaborations.\n\nOur marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We also collaborate with Eisai Co., Ltd. (Eisai) on the commercialization of LE , EMBI for the treatment of Alzheimer's disease, which was granted accelerated approval by the U.S. Food and Drug Administration (FDA) in January 2023. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS); LUNSUMIO (mosunetuzumab), which was granted accelerated approval in the U.S. during the fourth quarter of 2022 for the treatment of relapsed or refractory follicular lymphoma; glofitamab, an investigational bispecific antibody for the potential treatment of non-Hodgkin's lymphoma; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group.\n\nIn addition to continuing to invest in new potential innovation in MS and SMA we are advancing our mid-to-late stage programs including zuranolone for major depressive disorder (MDD) and postpartum depression (PPD), BIIB080 for Alzheimer's disease, tofersen for amyotrophic lateral sclerosis (ALS) and both litifilimab and dapirolizumab pegol for certain forms of lupus.\n\nWe also commercialize biosimilars of advanced biologics including BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe, as well as BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS, in the U.S. We continue to develop potential biosimilar products including BIIB800, a proposed tocilizumab biosimilar referencing ACTEMRA, and SB15, a proposed aflibercept biosimilar referencing EYLEA.\n\nFor additional information on our collaboration arrangements, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>A , to our consolidated financial statements included in this report.\n\n## glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@EA>;63F;A@\n\nOur consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests, net of tax in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation.\n\nIn determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.",
        "metadata": {
            "page": 117
        },
        "id": "c337565d-f15d-4dd2-a70a-22cb4f441013"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\n## ,E7 A8 glyph<c=28,font=/PIIBCD+FranklinGothic-Book>EF;?3F7E\n\nThe preparation of our consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.\n\nThe length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expense, reserves and allowances, the supply chain, manufacturing, clinical trials, research and development costs and employee-related costs, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. Additionally, the ongoing geopolitical tensions related to the conflict in Ukraine, and the related sanctions and other penalties imposed, are creating substantial uncertainty in the global economy. The extent and duration of the conflict, sanctions and resulting market disruptions are highly unpredictable. We have made estimates of the impact of the COVID-19 pandemic and the ongoing geopolitical conflict in Ukraine within our consolidated financial statements and there may be changes to those estimates in future periods.\n\n## )7H7@G7 )75A9@;F;A@\n\nWe recognize revenue when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenue following the five-step model prescribed under Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 606, &3D3<C3 4@=; glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=<B@/1BA E7B6 glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>CAB=;3@A : (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations.\n\n## $@=2C1B &3D3<C3\n\nIn the U.S., we sell our products primarily to wholesale and specialty distributors and specialty pharmacies. In other countries, we sell our products primarily to wholesale distributors, hospitals, pharmacies and other third-party distribution partners. These customers subsequently resell our products to health care providers and patients. In addition, we enter into arrangements with health care providers and payors that provide for government-mandated or privately-negotiated discounts and allowances related to our products.\n\nProduct revenue is recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial.\n\n## &3A3@D3A 4=@ glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>7A1=C<BA /<2 glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>::=E/<13A\n\nProduct revenue is recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, health care providers or payors, including those associated with the implementation of pricing actions in certain of the international markets in which we operate.\n\nProduct revenue reserves, which are classified as a reduction in product revenue, are generally characterized in the following categories: discounts, contractual adjustments and returns.\n\nThese reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates of reserves established for variable consideration are calculated based upon a consistent application of our methodology utilizing the expected value method. These estimates reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts may ultimately differ from our",
        "metadata": {
            "page": 118
        },
        "id": "192e370b-33ab-4bab-a5cb-80f9dc1346ac"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nestimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.\n\nDiscounts include trade term discounts and wholesaler incentives. Trade term discounts and wholesaler incentives primarily relate to estimated obligations for credits to be granted to wholesalers for remitting payment on their purchases within established incentive periods and credits to be granted to wholesalers for compliance with various contractually-defined inventory management practices, respectively. We determine these reserves based on our historical experience, including the timing of customer payments.\n\nContractual adjustments primarily relate to Medicaid and managed care rebates in the U.S., pharmacy rebates, co-payment (copay) assistance, Veterans Administration (VA) and Public Health Service (PHS) discounts, specialty pharmacy program fees and other governmental rebates or applicable allowances.\n\n- \u00b7 !3271/72 @30/B3Aglyph<c=20,font=/PIIBDE+FranklinGothic-BookItal> relate to our estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expense and other current liabilities in our consolidated balance sheets. Our liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid and an estimate of potential claims that will be made for inventory that exists in the distribution channel at period end.\n- \u00b7 glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>=D3@<;3<B/: @30/B3Aglyph<c=20,font=/PIIBDE+FranklinGothic-BookItal> or chargebacks, including VA and PHS discounts, represent our estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices we charge to wholesalers which provide those products. The wholesaler charges us for the difference between what the wholesaler pays for the products and the ultimate selling price to the qualified healthcare providers. Rebate and chargeback reserves are established in the same period as the related revenue is recognized, resulting in a reduction of product revenue and a reduction in the net accounts receivable. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider from the wholesaler, and we generally issue credits for such amounts within a few weeks of the wholesaler notifying us about the resale. Our reserves for VA, PHS and other chargebacks consist of amounts for inventory that exists at the wholesalers that we expect will be sold to qualified healthcare providers and chargebacks that wholesalers have claimed for which we have not issued a credit.\n- \u00b7 !/</532 1/@3 @30/B3Aglyph<c=20,font=/PIIBDE+FranklinGothic-BookItal> represent our estimated obligations to third-parties, primarily pharmacy benefit managers. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expense and other current liabilities in our consolidated balance sheets. These rebates result from performancebased goals, formulary position and price increase limit allowances (price protection). The calculation of the accrual for these rebates is based on an estimate of the coverage patterns and the resulting applicable contractual rebate rate(s) to be earned over a contractual period.\n- \u00b7 glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=>/G /AA7AB/<13glyph<c=20,font=/PIIBDE+FranklinGothic-BookItal> represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The calculation of the accrual for copay is based on an estimate of claims and the cost per claim that we expect to receive associated with inventory that exists in the distribution channel at period end.\n- \u00b7 $6/@;/1G @30/B3Aglyph<c=20,font=/PIIBDE+FranklinGothic-BookItal> represent our estimated obligations resulting from contractual commitments to sell products to specific pharmacies. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expense and other current liabilities in our consolidated balance sheets. These rebates result from contracted discounts on product purchased or product dispensed. The calculation of the accrual for these rebates is based on an estimate of the pharmacy's buying or dispensing patterns and the resulting applicable contractual rebate rate(s) to be earned over the contractual period.\n- \u00b7 #B63@ 5=D3@<;3<B/: @30/B3Aglyph<c=20,font=/PIIBDE+FranklinGothic-BookItal> non-U.S. pharmaceutical taxes or applicable allowances primarily relate to mandatory rebates and discounts in international markets where government-sponsored healthcare systems are the primary payors for healthcare.\n\nProduct return reserves are established for returns made by wholesalers and are recorded in the period the related revenue is recognized, resulting in a reduction to product revenue. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of",
        "metadata": {
            "page": 119
        },
        "id": "05b358c0-c3b1-4546-97d3-704df512d65c"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nwholesaler returns are due to product expiration. Expired product return reserves are estimated through a comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product.\n\nIn addition to discounts, rebates and product returns, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenue. To the extent we can demonstrate a separable benefit and fair value for these services we classify these payments in selling, general and administrative expense in our consolidated statements of income.\n\n## &3D3<C3 4@=; glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal><B7glyph<c=8,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=10,font=/PIIBDE+FranklinGothic-BookItal> (63@/>3CB71 $@=5@/;A\n\nOur collaboration with Genentech is within the scope of ASC 808, glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>5@33;3<BA , which provides guidance on the presentation and disclosure of collaborative arrangements. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.\n\nOur share of the pre-tax co-promotion profits on RITUXAN and GAZYVA and royalty revenue on the sale of OCREVUS resulted from an exchange of a license. As we do not have future performance obligations under the license or collaboration agreement, revenue is recognized as the underlying sales occur.\n\nRevenue from anti-CD20 therapeutic programs consist of:\n\n- (i) our share of pre-tax profits and losses in the U.S. for RITUXAN and GAZYVA;\n- (ii) royalty revenue on sales of OCREVUS; and\n- (ii) other revenue from anti-CD20 therapeutic programs, which consists of our share of pre-tax co-promotion profits on RITUXAN in Canada.\n\nPre-tax co-promotion profits on RITUXAN and GAZYVA are calculated and paid to us by Genentech and the Roche Group. Pre-tax co-promotion profits consist of net sales to third-party customers less applicable costs to manufacture, third-party royalty expense, distribution, selling and marketing expense and joint development expense incurred by Genentech and the Roche Group. Our share of the pre-tax profits on RITUXAN and GAZYVA include estimates that are based on information received from Genentech and the Roche Group. These estimates are subject to change and actual results may differ.\n\nWe recognize royalty revenue on sales of OCREVUS based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenue will be adjusted for in the period in which they become known, which is generally expected to be the following quarter.\n\nIn January 2022 we exercised our option with Genentech to participate in the joint development and commercialization of LUNSUMIO, which was later approved by the FDA in December 2022. Under our collaboration with Genentech, we will be entitled to co-promotion operating profits and losses in the U.S. for LUNSUMIO.\n\nPrior to regulatory approval, we record our share of the expense incurred by the collaboration for the development of anti-CD20 products within research and development expense and pre-commercialization costs within selling, general and administrative expense in our consolidated statements of income. After an anti-CD20 product is approved, we record our share of the development and sales and marketing expense related to that product as a reduction of our share of pre-tax profits in revenue from anti-CD20 therapeutic programs.\n\nAccordingly, Biogen recorded its share of the expense incurred in connection with the development of LUNSUMIO within research and development expense and its share of pre-commercialization costs within selling, general and administrative expense through December 2022, when regulatory approval was granted by the FDA. Beginning in January 2023, our share of any pre-tax profits and losses in the U.S. for LUNSUMIO will be reflected as a component of revenue from anti-CD20 therapeutic programs within our consolidated statements of income.\n\nFor additional information on our relationship with Genentech, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>Aglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> to these consolidated financial statements.",
        "metadata": {
            "page": 120
        },
        "id": "7aa5c895-a1b6-413d-a83a-620a349f7782"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+*\n\n## #B63@ &3D3<C3\n\n## glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=<B@/1B !/<C4/1BC@7<5 /<2 #B63@ &3D3<C3\n\nWe record contract manufacturing and other revenue primarily from amounts earned under contract manufacturing agreements. Revenue under contract manufacturing agreements is recognized when the customer obtains control of the product, which may occur at a point in time or over time depending on the terms and conditions of the agreement.\n\n## &=G/:BG &3D3<C3\n\nRoyalty revenue reflects the royalties we receive from net sales on products related to patents that we have out-licensed, as well as royalty revenue on biosimilar products from our collaboration arrangements with Samsung Bioepis Co., Ltd. (Samsung Bioepis). These arrangements resulted from an exchange of a license and utilize the sales and usage based royalty exception. Therefore, royalties received are recognized as the underlying sales occur.\n\n## glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>A\n\nWe also have a number of significant collaborative and other third-party relationships for revenue and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates. Where we are the principal on sales transactions with third parties, we recognize revenue, cost of sales and operating expense on a gross basis in their respective lines in our consolidated statements of income. Where we are not the principal on sales transactions with third parties, our share of the revenue, cost of sales and operating expense is recorded as a component of other revenue in our consolidated statements of income.\n\nOur development and commercialization arrangements with Genentech, Eisai and Samsung Bioepis represent collaborative arrangements as each party is an active participant in one or more joint operating activities and is exposed to significant risks and rewards of these arrangements. These arrangements resulted from an exchange of a license and utilize the sales and usage based royalty exception, as applicable. Therefore, revenue relating to royalties or profit-sharing amounts received is recognized as the underlying sales occur.\n\nFor additional information on our collaboration arrangements with Genentech, Eisai and Samsung Bioepis, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>A , to these consolidated financial statements.\n\n## glyph<c=29,font=/PIIBCD+FranklinGothic-Book>3;D -3>G7 $73EGD7?7@FE\n\nWe have certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.\n\n- \u00b7 3D3: glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal> -Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access;\n- \u00b7 3D3: glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal> -Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves, foreign currency spot rates and option pricing valuation models; and\n- \u00b7 3D3: glyph<c=13,font=/PIIBDE+FranklinGothic-BookItal> -Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.\n\nThe majority of our financial assets have been classified as Level 2. Our financial assets (which typically include our cash equivalents, marketable debt securities and certain of our marketable equity securities, derivative contracts and plan assets for deferred compensation) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or option pricing valuation models. The pricing services utilize industry standard valuation models, including both income and marketbased approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events.\n\nWe validate the prices provided by our third-party pricing services by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances. The option pricing valuation models use assumptions within the model, including the term, stock price volatility, constant maturity risk-free interest rate and dividend yield. After completing our validation procedures, we did not adjust or override any fair value measurements provided by our pricing services as of December 31, 2022 and 2021.",
        "metadata": {
            "page": 121
        },
        "id": "3d25daa5-2420-4465-bd46-f62f6994fa40"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\n## #B63@ glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>AA3BA /<2  7/07:7B73A\n\nThe carrying amounts reflected in our consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expense and other, approximate fair value due to their short-term maturities.\n\n## glyph<c=26,font=/PIIBCD+FranklinGothic-Book>3E: 3@6 glyph<c=26,font=/PIIBCD+FranklinGothic-Book>3E: glyph<c=28,font=/PIIBCD+FranklinGothic-Book>CG;H3>7@FE\n\nWe consider only those investments that are highly liquid, readily convertible to cash and that mature within three months from date of purchase to be cash equivalents. As of December 31, 2022 and 2021, cash equivalents were comprised of money market funds, commercial paper, overnight reverse repurchase agreements and other debt securities with maturities less than three months from the date of purchase.\n\n## glyph<c=24,font=/PIIBCD+FranklinGothic-Book>55AG@FE )757;H34>7\n\nThe majority of our accounts receivable arise from product sales and primarily represent amounts due from our wholesale and other third-party distributors, public hospitals, pharmacies and other government entities and have standard payment terms that generally require payment within 30 to 90 days.\n\nWe do not adjust our receivables for the effects of a significant financing component at contract inception if we expect to collect the receivables in one year or less from the time of sale.\n\nWe provide reserves against accounts receivable for estimated losses that may result from a customer's inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve.\n\n## &3137D/0:3A 4@=; '/;AC<5 glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>7= =571A\n\nIn April 2022 we completed the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics Co., Ltd (Samsung BioLogics), which resulted in a receivable of approximately $1.3 billion in cash to be deferred over two payments of approximately $812.5 million due at the first anniversary and approximately $437.5 million due at the second anniversary of the closing of this transaction. The payments due to us from Samsung BioLogics have been recorded at their estimated fair values through the use of risk-adjusted discount rates. For additional information on the accounting for the sale of our equity interest in Samsung Bioepis and these receivables, please read \"=B3 glyph<c=13,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>7A>=A7B7=<A , to these consolidated financial statements.\n\n## glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@57@FD3F;A@ A8 glyph<c=26,font=/PIIBCD+FranklinGothic-Book>D76;F );E=\n\nFinancial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments as previously defined by us. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties.\n\nConcentrations of credit risk with respect to receivables, which are typically unsecured, are somewhat mitigated due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions and assess their possible impact on our business.\n\n## $3D=7F34>7 *75GD;F;7E 3@6 &F:7D  @H7EF?7@FE\n\n## !/@93B/0:3 glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>30B '31C@7B73A\n\nAvailable-for-sale marketable debt securities are recorded at fair market value and unrealized gains and losses are included in accumulated other comprehensive income (loss) in equity, net of related tax effects, unless the security has experienced a credit loss, we have determined that we have the intent to sell the security or we have determined that it is more likely than not that we will have to sell the security before its expected recovery. Realized gains and losses are reported in other (income) expense, net on a specific identification basis.",
        "metadata": {
            "page": 122
        },
        "id": "e89ddf96-fc24-484f-b54e-00033d09b1b2"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\n## !/@93B/0:3 glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>?C7BG '31C@7B73A /<2 *3<BC@3 glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>/>7B/: glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>C<2A\n\nOur marketable equity securities are recorded at fair market value and unrealized gains and losses are included in other (income) expense, net in our consolidated statements of income. Our marketable equity securities represent investments in publicly traded equity securities and are included in investments and other assets in our consolidated balance sheets.\n\nOur investments in venture capital funds are recorded at net asset value, which approximates fair value, and unrealized gains and losses are included in other (income) expense, net in our consolidated statements of income. The underlying investments of the venture capital funds in which we invest are in equity securities of certain biotechnology companies and are included in investments and other assets in our consolidated balance sheets.\n\n## \"=<glyph<c=8,font=/PIIBDE+FranklinGothic-BookItal>!/@93B/0:3 glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>?C7BG '31C@7B73A\n\nWe also invest in equity securities of companies whose securities are not publicly traded and where fair value is not readily available. These investments are recorded using either the equity method of accounting or the cost minus impairment adjusted for observable price changes, depending on our ownership percentage and other factors that suggest we have significant influence. We monitor these investments to evaluate whether any increase or decline in their value has occurred, based on the implied value of recent company financings, public market prices of comparable companies and general market conditions. These investments are included in investments and other assets in our consolidated balance sheets.\n\n## glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>D/:C/B7<5 !/@93B/0:3 glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>30B '31C@7B73A 4=@ #B63@glyph<c=8,font=/PIIBDE+FranklinGothic-BookItal>B6/<glyph<c=8,font=/PIIBDE+FranklinGothic-BookItal>(3;>=@/@G glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>;>/7@;3<BA\n\nWe conduct periodic reviews to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Unrealized losses on available-for-sale debt securities that are determined to be temporary, and not related to credit loss, are recorded, net of tax, in accumulated other comprehensive income (loss).\n\nFor available-for-sale debt securities with unrealized losses, management performs an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security's decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in earnings as an impairment loss.\n\nRegardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security.\n\n## glyph<c=28,font=/PIIBCD+FranklinGothic-Book>CG;FK $7F:A6 A8 glyph<c=24,font=/PIIBCD+FranklinGothic-Book>55AG@F;@9\n\nIn circumstances where we have the ability to exercise significant influence over the operating and financial policies of a company in which we have an investment, we utilize the equity method of accounting for recording investment activity. In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, the voting and protective rights we hold, any participation in the governance of the other company and other relevant factors such as the presence of a collaborative or other business relationship. Under the equity method of accounting, we record in our consolidated statements of income our share of income or loss of the other company. If our share of losses exceeds the carrying value of our investment, we will suspend recognizing additional losses and will continue to do so unless we commit to providing additional funding.\n\n## @H7@FADK\n\nInventories are stated at the lower of cost or net realizable value with cost based on the first-in, first-out method. We classify our inventory costs as long-term when we expect to utilize the inventory beyond our normal operating cycle and include these costs in investments and other assets in our consolidated balance sheets. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical manufacturing campaign.\n\n## glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>/>7B/:7H/B7=< =4 glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><D3<B=@G glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=ABA\n\nWe capitalize inventory costs associated with our products prior to regulatory approval, when, based on management's judgment, future commercialization is considered probable and the future economic benefit is",
        "metadata": {
            "page": 123
        },
        "id": "29c61927-ea48-4934-9e42-f583f1d32f5f"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nexpected to be realized. We consider numerous attributes in evaluating whether the costs to manufacture a particular product should be capitalized as an asset. We assess the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety or efficacy concerns, potential labeling restrictions and other impediments to approval. We evaluate our anticipated research and development initiatives and constraints relating to the product and the indication in which it will be used. We consider our manufacturing environment including our supply chain in determining logistical constraints that could hamper approval or commercialization. We consider the shelf life of the product in relation to the expected timeline for approval and we consider patent related or contract issues that may prevent or delay commercialization. We also base our judgment on the viability of commercialization, trends in the marketplace and market acceptance criteria. Finally, we consider the reimbursement strategies that may prevail with respect to the product and assess the economic benefit that we are likely to realize. We expense previously capitalized costs related to pre-approval inventory upon changes in such judgments, due to, among other potential factors, a denial or significant delay of approval by necessary regulatory bodies.\n\n## #0A=:3A13<13 /<2 )<;/@93B/0:3 glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><D3<B=@G\n\nAt each reporting period we review our inventories for excess or obsolescence and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated by us, or if it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory write-downs may be required. Additionally, our products are subject to strict quality control and monitoring that we perform throughout the manufacturing process. In the event that certain batches or units of product no longer meet quality specifications, we will record a charge to cost of sales to write-down any unmarketable inventory to its estimated net realizable value. In all cases, product inventory is carried at the lower of cost or its estimated net realizable value. Amounts written-down due to unmarketable inventory are charged to cost of sales in our consolidated statements of income.\n\n## 'DAB7DFKglyph<c=9,font=/PIIBCD+FranklinGothic-Book> '>3@F 3@6 glyph<c=28,font=/PIIBCD+FranklinGothic-Book>CG;B?7@F\n\nProperty, plant and equipment are carried at cost, subject to reviews for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring or periodic repairs and maintenance activities related to property, plant and equipment are expensed as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if the repair will result in future economic benefits.\n\nInterest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. We also capitalize certain direct and incremental costs associated with the validation effort required for licensing by regulatory agencies of new manufacturing equipment for the production of a commercially approved drug. These costs primarily include direct labor and material and are incurred in preparing the equipment for its intended use. The validation costs are either amortized over the life of the related equipment or expensed as cost of sales when the product produced in the validation process is sold.\n\nIn addition, we capitalize certain internal use computer software development costs. If the software is an integral part of production assets, these costs are included in machinery and equipment and are amortized on a straight-line basis over the estimated useful lives of the related software, which generally range from three to five years.\n\nWe generally depreciate or amortize the cost of our property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:\n\n| glyph<c=24,font=/PIIBCD+FranklinGothic-Book>EE7F glyph<c=26,font=/PIIBCD+FranklinGothic-Book>3F79ADK   | ,E78G> #;H7E Not depreciated                                  |\n|--------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|\n| Land                                                                                                   |                                                               |\n| Buildings                                                                                              | 15 to 40 years                                                |\n| Leasehold Improvements                                                                                 | Lesser of the useful life or the term of the respective lease |\n| Furniture and Fixtures                                                                                 | 5 to 7 years                                                  |\n| Machinery and Equipment                                                                                | 5 to 20 years                                                 |\n| Computer Software and Hardware                                                                         | 3 to 5 years                                                  |",
        "metadata": {
            "page": 124
        },
        "id": "5970e024-47e4-42f5-8363-2daf480c513d"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nWhen we dispose of property, plant and equipment, we remove the associated cost and accumulated depreciation from the related accounts in our consolidated balance sheets and include any resulting gain or loss in our consolidated statements of income.\n\n## #73E7E\n\nWe determine if an arrangement is a lease at contract inception. Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, we include options to extend or terminate the lease when it is reasonably certain that they will be exercised.\n\nWe use the implicit rate when readily determinable and use our incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. Our incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease.\n\nThe lease payments used to determine our operating lease assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized in our operating lease assets in our consolidated balance sheets. Our lease agreements may include both lease and non-lease components, which we account for as a single lease component when the payments are fixed. Variable payments included in the lease agreement are expensed as incurred. For certain equipment leases, such as vehicles, we apply a portfolio approach to effectively account for the operating lease assets and liabilities.\n\nOur operating leases are reflected in operating lease assets, accrued expense and other and in long-term operating lease liabilities in our consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.\n\nWe also have real estate lease agreements which are subleased to third-parties. Operating leases for which we are the sublessor are included in accrued expense and other and other long-term liabilities in our consolidated balance sheets. We recognize sublease income on a straight-line basis over the lease term in our consolidated statements of income.\n\nFor additional information on our leases, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> 3/A3A , to these consolidated financial statements.\n\n## @F3@9;4>7 glyph<c=24,font=/PIIBCD+FranklinGothic-Book>EE7FE\n\nOur intangible assets consist of completed technology (comprised of acquired and in-licensed rights and patents, developed technology, out-licensed patents), in-process research and development (IPR&D) acquired after January 1, 2009, trademarks and trade names. Our intangible assets are recorded at fair value at the time of their acquisition and are stated in our consolidated balance sheets net of accumulated amortization and impairments, if applicable.\n\nIntangible assets related to acquired and in-licensed rights and patents, developed technology and out-licensed patents are amortized over their estimated useful lives using the economic consumption method if anticipated future revenue can be reasonably estimated. The straight-line method is used when revenue cannot be reasonably estimated. Amortization is recorded within amortization and impairment of acquired intangible assets in our consolidated statements of income.\n\nWe amortize the intangible assets related to our marketed products using the economic consumption method based on revenue generated from the products underlying the related intangible assets. An analysis of the anticipated lifetime revenue of our marketed products is performed annually during our long-range planning cycle and whenever events or changes in circumstances would significantly affect anticipated lifetime revenue of the relevant products.\n\nIntangible assets related to trademarks, trade names and IPR&D prior to commercialization are not amortized because they have indefinite lives; however, they are subject to review for impairment. We review our intangible assets with indefinite lives for impairment annually, as of October 31, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.",
        "metadata": {
            "page": 125
        },
        "id": "6d3ac57d-7c17-45a7-876a-72c1a766babb"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nglyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>1?C7@32 glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><glyph<c=8,font=/PIIBDE+FranklinGothic-BookItal>>@=13AA &3A3/@16 /<2 glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>3D3:=>;3<B glyph<c=5,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>$&glyph<c=3,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=6,font=/PIIBDE+FranklinGothic-BookItal>\n\nAcquired IPR&D represents the fair value assigned to research and development assets that have not reached technological feasibility. The value assigned to acquired IPR&D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenue from the projects and discounting the net cash flow to present value. The revenue and cost projections used to value acquired IPR&D are, as applicable, reduced based on the probability of success of developing a new drug. Additionally, the projections consider the relevant market sizes and growth factors, expected trends in technology and the nature and expected timing of new product introductions by us and our competitors. The rates utilized to discount the net cash flow to present value are commensurate with the stage of development of the projects and uncertainties in the economic estimates used in the projections. Upon the acquisition of IPR&D, we complete an assessment of whether our acquisition constitutes the purchase of a single asset or a group of assets. We consider multiple factors in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flow, the development process and stage of completion, quantitative significance and our rationale for entering into the transaction.\n\nIf we acquire a business as defined under applicable accounting standards, then the acquired IPR&D is capitalized as an intangible asset. If we acquire an asset or group of assets that do not meet the definition of a business under applicable accounting standards, then the acquired IPR&D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense in our consolidated statements of income as they are incurred.\n\nWhen performing our impairment assessment, we calculate the fair value using the same methodology as described above. If the carrying value of our acquired IPR&D exceeds its fair value, then the intangible asset is written down to its fair value. Changes in estimates and assumptions used in determining the fair value of our acquired IPR&D could result in an impairment. Impairments are recorded within amortization and impairment of acquired intangible assets in our consolidated statements of income.\n\n## glyph<c=30,font=/PIIBCD+FranklinGothic-Book>AA6I;>>\n\nGoodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting. Goodwill is not amortized, but is reviewed for impairment annually, as of October 31, and whenever events or changes in circumstances indicate that the carrying value of the goodwill may not be recoverable.\n\nWe compare the fair value of our reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, we would record an impairment loss equal to the difference. As described in \"=B3 glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=15,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> '35;3<B glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><4=@;/B7=<glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> to these consolidated financial statements, we operate as one operating segment, which is our only reporting unit.\n\n## ?B3;D?7@F A8 #A@9glyph<c=10,font=/PIIBCD+FranklinGothic-Book>#;H76 glyph<c=24,font=/PIIBCD+FranklinGothic-Book>EE7FE\n\nLong-lived assets to be held and used, including property, plant and equipment, and definite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable.\n\nDetermination of recoverability is based on an estimate of undiscounted future cash flow resulting from the use of the asset and its eventual disposition. In the event that such cash flow is not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell.\n\n## glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@97@F glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@E;67D3F;A@\n\nThe consideration for our acquisitions often includes future payments that are contingent upon the occurrence of a particular event or events. We record an obligation for such contingent payments at fair value on the acquisition date. We estimate the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. We revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations are recognized in our consolidated statements of income. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flow and reserves associated with products upon",
        "metadata": {
            "page": 126
        },
        "id": "ab27fae6-0d33-498a-95ee-6192302c3920"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\ncommercialization, changes in the assumed achievement or timing of any cumulative sales-based and development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval.\n\nDiscount rates in our valuation models represent a measure of the credit risk associated with settling the liability. The period over which we discount our contingent obligations is based on the current development stage of the product candidates, our specific development plan for that product candidate adjusted for the probability of completing the development step and when the contingent payments would be triggered. In estimating the probability of success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period.\n\n## glyph<c=27,font=/PIIBCD+FranklinGothic-Book>7D;H3F;H7 @EFDG?7@FE 3@6 glyph<c=31,font=/PIIBCD+FranklinGothic-Book>769;@9 glyph<c=24,font=/PIIBCD+FranklinGothic-Book>5F;H;F;7E\n\n## glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>/A6 glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>:=E /<2 glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>/7@ */:C3 glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>3@7D/B7D3 glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><AB@C;3<BA\n\nWe recognize all derivative instruments as either assets or liabilities at fair value in our consolidated balance sheets. Changes in the fair value of our derivative instruments are recognized each period in current earnings or accumulated other comprehensive income (loss), depending on whether the derivative instrument is designated as part of a hedge transaction and, if so, the type of hedge transaction. We classify the cash flow from these instruments in the same category as the cash flow from the hedged items. We do not hold or issue derivative instruments for trading or speculative purposes.\n\nWe assess at inception and on an ongoing basis, whether the derivative instruments that are used in hedging transactions are highly effective in offsetting the changes in cash flow or fair values of the hedged items. We exclude the forward points portion of the derivative instruments used in a hedging transaction from the effectiveness test and record the fair value gain or loss related to this portion each period in our consolidated statements of income in the same line as the underlying hedged item. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in current earnings.\n\n## \"3B glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><D3AB;3<B glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>3@7D/B7D3 glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><AB@C;3<BA\n\nDesignated net investment hedges are recognized as either assets or liabilities, at fair value, in our consolidated balance sheets. We hedge the changes in the spot exchange rate in accumulated other comprehensive income (loss) and exclude changes to the forward rate and amortize the forward points in other (income) expense, net in our consolidated statements of income over the term of the contract. We classify the cash flow from these instruments in the same category as the cash flow from the hedged items.\n\nBeginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read \"=B3 glyph<c=13,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>7A>=A7B7=<A , to these consolidated financial statements.\n\nFor additional information on our derivative instruments and hedging activities, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=10,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>3@7D/B7D3 glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><AB@C;3<BA , to these consolidated financial statements.\n\n## +D3@E>3F;A@ A8 glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD7;9@ glyph<c=26,font=/PIIBCD+FranklinGothic-Book>GDD7@5;7E\n\nThe functional currency for most of our foreign subsidiaries is their local currency. For our non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign currency exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income (loss), as a separate component of equity. For subsidiaries where the functional currency of the assets and liabilities differ from the local currency, non-monetary assets and liabilities are translated at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in other (income) expense, net in our consolidated statements of income.",
        "metadata": {
            "page": 127
        },
        "id": "767ceb1b-667e-42c2-a3c8-995450246136"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\n## )AK3>FK glyph<c=26,font=/PIIBCD+FranklinGothic-Book>AEF A8 *3>7E\n\nWe make royalty payments to a number of third-parties under license or purchase agreements associated with our acquisition of intellectual property. These royalty payments are typically calculated as a percentage (royalty rate) of the sales of our products in a particular year. That royalty rate may remain constant, increase or decrease within each year based on the total amount of sales during the annual period. Each quarterly period, we estimate our total royalty obligation for the full year and recognize the proportional amount as cost of sales based on actual quarterly sales as a percentage of full year estimated sales. For example, if the level of net sales in any calendar year increases the royalty rate within the year, we will record our cost of sales at an even rate over the year, based on the estimated blended royalty rate.\n\n## glyph<c=24,font=/PIIBCD+FranklinGothic-Book>55AG@F;@9 8AD *:3D7glyph<c=10,font=/PIIBCD+FranklinGothic-Book>glyph<c=25,font=/PIIBCD+FranklinGothic-Book>3E76 glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A?B7@E3F;A@\n\nOur share-based compensation programs grant awards that have included stock options, restricted stock units that vest based on stock performance known as market stock units (MSUs), performance-vested restricted stock units that settle in cash (CSPUs), time-vested restricted stock units (RSUs), performance-vested restricted stock units that can be settled in cash or shares of our common stock (PUs) at the sole discretion of the Compensation and Management Development Committee of our Board of Directors, performance-vested stock units that settle in stock or cash (PSUs) and shares issued under our employee stock purchase plan (ESPP). Compensation expense is recognized based on the estimated fair value of the awards at grant date. We recognize compensation expense for the number of awards expected to vest after taking into consideration an estimate of award forfeitures over the requisite service period, which is generally the vesting period. Where awards are made with non-substantive vesting periods (for instance, where a portion of the award vests upon retirement eligibility), we estimate and recognize expense based on the period from the grant date to the date the employee becomes retirement eligible.\n\nThe fair values of our stock option grants are estimated as of the date of grant using a Black-Scholes option valuation model. The estimated fair values of the stock options are then expensed over the options' vesting periods.\n\nThe fair values of our MSUs are estimated using a lattice model with a Monte Carlo simulation. We apply an accelerated attribution method to recognize share-based compensation expense over the applicable service period for our MSUs. The probability of actual shares expected to be earned is considered in the grant date valuation, therefore the expense is not adjusted to reflect the actual units earned.\n\nThe fair values of our RSUs are based on the market value of our stock on the date of grant. Compensation expense for RSUs is recognized straight-line over the applicable service period.\n\nWe apply an accelerated attribution method to recognize share-based compensation expense when accounting for our CSPUs, PUs and PSUs that settle in cash, and the fair value of the liability is remeasured at the end of each reporting period through expected settlement. Compensation expense associated with CSPUs, PUs and PSUs that settle in cash are based upon the stock price and the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the targeted payout level associated with the performance criteria expected to be achieved. Cumulative adjustments are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions until the date results are determined and settled. If performance criteria are not met or not expected to be met, any compensation expense previously recognized to date associated with the awards will be reversed.\n\nThe fair values of PSUs that settle in stock are based upon the stock price on the date of grant. Compensation expense is recognized for the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the targeted payout level associated with the performance criteria expected to be achieved. Cumulative adjustments are recorded each quarter to reflect the estimated outcome of the performance-related conditions until the date results are determined and settled. If performance criteria are not met or not expected to be met, any compensation expense previously recognized to date associated with the awards will be reversed.\n\n## )7E73D5: 3@6 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>7H7>AB?7@F glyph<c=28,font=/PIIBCD+FranklinGothic-Book>JB7@E7\n\nResearch and development expense consists of expenses incurred in performing research and development activities, which include compensation and benefits, facilities and overhead expense, clinical trial expense and fees paid to contract research organizations (CROs), clinical supply and manufacturing expense, write-offs of inventory that was previously capitalized in anticipation of product launch and determined to no longer be realizable and other outside expense and upfront fees and milestones paid to third-party collaborators. Research and development",
        "metadata": {
            "page": 128
        },
        "id": "8fba49dd-ea4a-4d7f-947a-4086a716ba2a"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nexpense is expensed as incurred. Upfront and milestone payments made to third-party collaborators are expensed as incurred up to the point of regulatory approval. Milestone payments made upon regulatory approval are capitalized and amortized over the remaining useful life of the related product. Payments we make for research and development services prior to the services being rendered are recorded as prepaid assets in our consolidated balance sheets and are expensed as the services are provided. We also accrue the costs of ongoing clinical trials associated with programs that have been terminated or discontinued for which there is no future economic benefit at the time the decision is made to terminate or discontinue the program.\n\nFrom time to time, we enter into development agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of research and development expense, except as discussed in \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>Aglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> to these consolidated financial statements. Expenses incurred by Genentech in the ongoing development of RITUXAN, GAZYVA and other products for which an initial indication has been approved are not recorded as research and development expense, but rather reduce our share of profits recorded as a component of revenue from anti-CD20 therapeutic programs.\n\nFor collaborations with commercialized products, if we are the principal, we record revenue and the corresponding operating costs in their respective line items in our consolidated statements of income. If we are not the principal, we record operating costs as a reduction of revenue.\n\n## *7>>;@9glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=30,font=/PIIBCD+FranklinGothic-Book>7@7D3> 3@6 glyph<c=24,font=/PIIBCD+FranklinGothic-Book>6?;@;EFD3F;H7 glyph<c=28,font=/PIIBCD+FranklinGothic-Book>JB7@E7\n\nSelling, general and administrative expense is primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expense and other general and administrative costs.\n\nAdvertising costs are expensed as incurred. For the years ended December 31, 2022, 2021 and 2020, advertising costs totaled $54.1 million, $98.7 million and $111.8 million, respectively.\n\n## @5A?7 +3J7E\n\nThe provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. We recognize deferred taxes associated with our global intangible low-taxed income (GILTI) tax calculations.\n\nThe income tax consequences from the intra-entity transfers of inventory within our consolidated group, both current and deferred, are recorded as a prepaid tax or deferred charge and recognized through our consolidated statements of income when the inventory is sold to a third-party. The income tax consequences from the intra-entity transfer of assets other than inventory and associated changes to deferred taxes are recognized when the transfer occurs.\n\nWe account for uncertain tax positions using a [ more likely than not \\ threshold for recognizing and resolving uncertain tax positions. We evaluate uncertain tax positions on a quarterly basis and consider various factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax (benefit) expense in our consolidated statements of income.\n\n## glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@97@5;7E\n\nWe are currently involved in various claims and legal proceedings. Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management's best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure. Significant judgment is",
        "metadata": {
            "page": 129
        },
        "id": "2a04aeba-7793-4410-80c5-96e8ae6d8992"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nrequired in both the determination of probability and as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, we reassess the potential liability related to pending claims and litigation and may change our estimates. Legal costs associated with legal proceedings are expensed when incurred.\n\n## glyph<c=28,font=/PIIBCD+FranklinGothic-Book>3D@;@9E B7D *:3D7\n\nBasic earnings per share is computed by dividing undistributed net income attributable to Biogen Inc. by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed based on the treasury method by dividing net income by the weighted-average number of common shares outstanding during the period plus potentially dilutive common equivalent shares outstanding.\n\n## %7I glyph<c=24,font=/PIIBCD+FranklinGothic-Book>55AG@F;@9 'DA@AG@57?7@FE\n\nFrom time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our consolidated financial statements or disclosures.\n\n## glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>/7@ */:C3 !3/AC@3;3<BA\n\nIn June 2022 the FASB issued Accounting Standards Update (ASU) No. 2022-03, glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>/7@ */:C3 !3/AC@3;3<B (Topic 820): glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>/7@ */:C3 !3/AC@3;3<B =4 glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>?C7BG '31C@7B73A 'C0831B B= glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=<B@/1BC/: '/:3 &3AB@71B7=<A . This standard clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This standard becomes effective for us on January 1, 2024. We elected to early adopt this standard on a prospective basis during the third quarter of 2022. Upon adoption, we recorded an immaterial amount in other (income) expense, net in our consolidated statements of income, as a result of removing the impact of the remaining contractual sale restrictions from the fair value measurement of certain shares in Sage Therapeutics, Inc. (Sage).\n\n## glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><1=;3 (/F3A\n\nIn December 2019 the FASB issued ASU No. 2019-12, glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><1=;3 (/F3A (Topic 740): '7;>:74G7<5 B63 glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>11=C<B7<5 4=@ glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><1=;3 (/F3A . This standard removes certain exceptions to the general principles in Topic 740 and simplifies certain other aspects of the accounting for income taxes. This standard became effective for us on January 1, 2021, and did not have a material impact on our consolidated financial statements and related disclosures.\n\n## %AF7 glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=23,font=/PIIBCD+FranklinGothic-Book>\n\nglyph<c=24,font=/PIIBCD+FranklinGothic-Book>5CG;E;F;A@E\n\n## glyph<c=25,font=/PIIBCD+FranklinGothic-Book>  glyph<c=25,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=21,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>5CG;E;F;A@\n\nIn March 2020 we acquired BIIB118 (CK1 inhibitor) for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases from Pfizer Inc. (Pfizer). In connection with this acquisition, we made an upfront payment of $75.0 million to Pfizer, which was accounted for as an asset acquisition and recorded as acquired IPR&D in our consolidated statements of income for the year ended December 31, 2020. @ glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book> I7 6;E5A@F;@G76 8GDF:7D 67H7>AB?7@F A8 glyph<c=25,font=/PIIBCD+FranklinGothic-Book>  glyph<c=25,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=21,font=/PIIBCD+FranklinGothic-Book> 43E76 A@ F:7 675;E;A@ 4K ?3@397?7@F 3E B3DF A8 ;FE EFD3F79;5 D7H;7I BDA57EEglyph<c=11,font=/PIIBCD+FranklinGothic-Book>",
        "metadata": {
            "page": 130
        },
        "id": "b6610d77-ff68-4dd5-9b6c-1c27ece9d759"
    },
    {
        "page_content": "## %AF7 glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=23,font=/PIIBCD+FranklinGothic-Book>\n\n## glyph<c=27,font=/PIIBCD+FranklinGothic-Book>;EBAE;F;A@E\n\n## *3>7 A8 !A;@F -7@FGD7 glyph<c=28,font=/PIIBCD+FranklinGothic-Book>CG;FK @F7D7EF ;@ *3?EG@9 glyph<c=25,font=/PIIBCD+FranklinGothic-Book>;A7B;E\n\nIn April 2022 we completed the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics. Under the terms of this transaction, we received approximately $1.0 billion in cash at closing and expect to receive approximately $1.3 billion in cash to be deferred over two payments of approximately $812.5 million due at the first anniversary and approximately $437.5 million due at the second anniversary of the closing of this transaction.\n\nPrior to the sale, the carrying value of our investment in Samsung Bioepis totaled $581.6 million. For the year ended December 31, 2022, we recognized a pre-tax gain of approximately $1.5 billion related to this transaction, which was recorded in other (income) expense, net in our consolidated statements of income. This pre-tax gain included reclassifications from accumulated other comprehensive income (loss) to net income of approximately $58.9 million in cumulative translation losses, partially offset by approximately $57.0 million in gains resulting from the termination of our net investment hedge.\n\nWe have concluded that the divestment of Samsung Bioepis does not meet the criteria to be reported as discontinued operations in our consolidated financial statements, as our decision to divest this business does not represent a strategic shift that will have a major effect on our operations and financial results.\n\nWe elected the fair value option and measured the payments due to us from Samsung BioLogics at fair value. As of December 31, 2022, the estimated fair values of the first and second payments using risk-adjusted discount rates of 5.7% and 5.9%, respectively, were approximately $798.8 million and $405.4 million, respectively. These payments have been classified as level 3 measurements and are reflected in other current assets and investments and other assets, respectively, in our consolidated balance sheets.\n\nFor the year ended December 31, 2022, we recognized a gain of approximately $10.7 million and a loss of approximately $1.4 million to reflect the changes in fair value related to our first and second payments, respectively. These changes were recorded in other (income) expense, net in our consolidated statements of income.\n\nAs part of this transaction, we are also eligible to receive up to an additional $50.0 million upon the achievement of certain commercial milestones. Our policy for contingent payments of this nature is to recognize the payments in the period that they become realizable, which is generally the same period in which the payments are earned.\n\nIf any payments due to us remain outstanding after the second anniversary of the closing of this transaction, we may elect to receive shares of Samsung BioLogics common stock at a 5.0% discount in lieu of a cash payment for the remaining amount due. Currently, we believe that the likelihood of Samsung BioLogics failing to make timely payments to us for the amounts due is remote.\n\nAdditionally, for the year ended December 31, 2022, we recorded a discrete tax expense of approximately $257.9 million related to this transaction, which is reflected in income tax (benefit) expense in our consolidated statements of income.\n\n## %AF7 glyph<c=17,font=/PIIBCD+FranklinGothic-Book>glyph<c=23,font=/PIIBCD+FranklinGothic-Book> )7EFDG5FGD;@9\n\n## glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book> glyph<c=26,font=/PIIBCD+FranklinGothic-Book>AEF *3H;@9  @;F;3F;H7E\n\nIn December 2021 and May 2022 we announced our plans to implement a series of cost-reduction measures during 2022. These savings are being achieved through a number of initiatives, including reductions to our workforce, the substantial elimination of our commercial ADUHELM infrastructure, the consolidation of certain real estate locations and operating efficiency gains across our selling, general and administrative and research and development functions.\n\nUnder these initiatives, we estimate we will incur total restructuring charges of approximately $131.0 million, primarily related to severance. These amounts were substantially incurred during 2022. As of December 31, 2022, approximately $35.9 million remained in our restructuring reserve and payments are expected to be made through 2026.\n\n## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+*",
        "metadata": {
            "page": 131
        },
        "id": "3f099eca-6284-4648-b98d-f2d87d896c8d"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nFor the year ended December 31, 2022, we recognized approximately $131.1 million of net pre-tax restructuring charges related to our 2022 cost saving initiatives, of which approximately $112.6 million consisted of employee severance costs. These costs were recorded in restructuring charges in our consolidated statements of income. Our restructuring reserve is included in accrued expense and other in our consolidated balance sheets.\n\nIn September 2022 we entered into an agreement to partially terminate a portion of our lease located at 300 Binney Street, Cambridge, MA (300 Binney Street), as well as to reduce the lease term for the majority of the remaining space. This resulted in a gain of approximately $5.3 million, which was recorded within restructuring charges in our consolidated statements of income for the year ended December 31, 2022. For additional information on our 300 Binney Street lease modification, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> 3/A3A , to these consolidated financial statements.\n\nFollowing an evaluation of our current capacity needs, in March 2022 we ceased using a patient services office space in Durham, NC. Our decision to cease use of the facility resulted in the immediate expense of certain leasehold improvements and other assets at this facility. As a result, we recognized approximately $10.4 million of accelerated depreciation expense, which was recorded in restructuring charges in our consolidated statements of income for the year ended December 31, 2022. In May 2022 we entered into a lease assignment agreement whereby we assigned our remaining lease obligations to an external third party. As a result of the lease assignment, we derecognized the related operating lease obligation and right-of-use asset during the second quarter of 2022.\n\nFor the year ended December 31, 2022, we recognized other restructuring costs of approximately $13.2 million, which were recorded in restructuring charges in our consolidated statements of income. Other restructuring costs include items such as facility closure costs, employee non-severance expense, asset write-offs and other costs.\n\nThe following table summarizes the charges and spending related to our 2022 workforce reductions for the year ended December 31, 2022:\n\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book>   | +AF3>   |\n|-----------------------------------------------------------------------------------------------------|---------|\n| Restructuring reserve, December 31, 2021                                                            | $ -     |\n| Expense                                                                                             | 112.6   |\n| Payment                                                                                             | (78.0)  |\n| Foreign currency and other adjustments                                                              | 1.3     |\n| Restructuring reserve, December 31, 2022                                                            | $ 35.9  |",
        "metadata": {
            "page": 132
        },
        "id": "a3f80e60-7e09-4745-ae5a-3e6ea1c0ba58"
    },
    {
        "page_content": "## %AF7 glyph<c=18,font=/PIIBCD+FranklinGothic-Book>glyph<c=23,font=/PIIBCD+FranklinGothic-Book>\n\n)7H7@G7\n\n## 'DA6G5F )7H7@G7\n\nRevenue by product are summarized as follows:\n\n|                                                                                                   | F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n|                                                                                                   | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                                     | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                                     | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                                     | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                                     | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                                     | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                                     | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                                     | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                                     | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                                     |\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | ,@;F76 *F3F7E                                                                                                                                                                                                                                        | )7EF A8 .AD>6                                                                                                                                                                                                                                        | +AF3>                                                                                                                                                                                                                                                | ,@;F76 *F3F7E                                                                                                                                                                                                                                        | )7EF A8 .AD>6                                                                                                                                                                                                                                        | +AF3>                                                                                                                                                                                                                                                | ,@;F76 *F3F7E                                                                                                                                                                                                                                        | )7EF A8 .AD>6                                                                                                                                                                                                                                        | +AF3>                                                                                                                                                                                                                                                |\n| Multiple Sclerosis (MS):                                                                          |                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                      |\n| TECFIDERA                                                                                         | $ 417.7                                                                                                                                                                                                                                              | $1,026.2                                                                                                                                                                                                                                             | $ 1,443.9                                                                                                                                                                                                                                            | $ 680.6                                                                                                                                                                                                                                              | $1,271.3                                                                                                                                                                                                                                             | $ 1,951.9                                                                                                                                                                                                                                            | $2,677.7                                                                                                                                                                                                                                             | $1,163.4                                                                                                                                                                                                                                             | $ 3,841.1                                                                                                                                                                                                                                            |\n| VUMERITY (1)                                                                                      | 521.3                                                                                                                                                                                                                                                | 32.1                                                                                                                                                                                                                                                 | 553.4                                                                                                                                                                                                                                                | 408.9                                                                                                                                                                                                                                                | 1.5                                                                                                                                                                                                                                                  | 410.4                                                                                                                                                                                                                                                | 64.3                                                                                                                                                                                                                                                 | -                                                                                                                                                                                                                                                    | 64.3                                                                                                                                                                                                                                                 |\n| Total Fumarate                                                                                    | 939.0                                                                                                                                                                                                                                                | 1,058.3                                                                                                                                                                                                                                              | 1,997.3                                                                                                                                                                                                                                              | 1,089.5                                                                                                                                                                                                                                              | 1,272.8                                                                                                                                                                                                                                              | 2,362.3                                                                                                                                                                                                                                              | 2,742.0                                                                                                                                                                                                                                              | 1,163.4                                                                                                                                                                                                                                              | 3,905.4                                                                                                                                                                                                                                              |\n| AVONEX                                                                                            | 649.2                                                                                                                                                                                                                                                | 324.3                                                                                                                                                                                                                                                | 973.5                                                                                                                                                                                                                                                | 830.2                                                                                                                                                                                                                                                | 378.5                                                                                                                                                                                                                                                | 1,208.7                                                                                                                                                                                                                                              | 1,083.4                                                                                                                                                                                                                                              | 408.5                                                                                                                                                                                                                                                | 1,491.9                                                                                                                                                                                                                                              |\n| PLEGRIDY                                                                                          | 148.4                                                                                                                                                                                                                                                | 183.5                                                                                                                                                                                                                                                | 331.9                                                                                                                                                                                                                                                | 152.9                                                                                                                                                                                                                                                | 204.5                                                                                                                                                                                                                                                | 357.4                                                                                                                                                                                                                                                | 190.1                                                                                                                                                                                                                                                | 195.5                                                                                                                                                                                                                                                | 385.6                                                                                                                                                                                                                                                |\n| Total Interferon                                                                                  | 797.6                                                                                                                                                                                                                                                | 507.8                                                                                                                                                                                                                                                | 1,305.4                                                                                                                                                                                                                                              | 983.1                                                                                                                                                                                                                                                | 583.0                                                                                                                                                                                                                                                | 1,566.1                                                                                                                                                                                                                                              | 1,273.5                                                                                                                                                                                                                                              | 604.0                                                                                                                                                                                                                                                | 1,877.5                                                                                                                                                                                                                                              |\n| TYSABRI                                                                                           | 1,123.4                                                                                                                                                                                                                                              | 907.5                                                                                                                                                                                                                                                | 2,030.9                                                                                                                                                                                                                                              | 1,142.2                                                                                                                                                                                                                                              | 920.9                                                                                                                                                                                                                                                | 2,063.1                                                                                                                                                                                                                                              | 1,096.8                                                                                                                                                                                                                                              | 849.3                                                                                                                                                                                                                                                | 1,946.1                                                                                                                                                                                                                                              |\n| FAMPYRA                                                                                           | -                                                                                                                                                                                                                                                    | 96.6                                                                                                                                                                                                                                                 | 96.6                                                                                                                                                                                                                                                 | -                                                                                                                                                                                                                                                    | 105.2                                                                                                                                                                                                                                                | 105.2                                                                                                                                                                                                                                                | -                                                                                                                                                                                                                                                    | 103.1                                                                                                                                                                                                                                                | 103.1                                                                                                                                                                                                                                                |\n| Subtotal: MS                                                                                      | 2,860.0                                                                                                                                                                                                                                              | 2,570.2                                                                                                                                                                                                                                              | 5,430.2                                                                                                                                                                                                                                              | 3,214.8                                                                                                                                                                                                                                              | 2,881.9                                                                                                                                                                                                                                              | 6,096.7                                                                                                                                                                                                                                              | 5,112.3                                                                                                                                                                                                                                              | 2,719.8                                                                                                                                                                                                                                              | 7,832.1                                                                                                                                                                                                                                              |\n| Spinal Muscular Atrophy:                                                                          |                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                      |\n| SPINRAZA                                                                                          | 600.2                                                                                                                                                                                                                                                | 1,193.3                                                                                                                                                                                                                                              | 1,793.5                                                                                                                                                                                                                                              | 587.9                                                                                                                                                                                                                                                | 1,317.2                                                                                                                                                                                                                                              | 1,905.1                                                                                                                                                                                                                                              | 787.8                                                                                                                                                                                                                                                | 1,264.3                                                                                                                                                                                                                                              | 2,052.1                                                                                                                                                                                                                                              |\n| Biosimilars:                                                                                      |                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                      |\n| BENEPALI                                                                                          | -                                                                                                                                                                                                                                                    | 441.0                                                                                                                                                                                                                                                | 441.0                                                                                                                                                                                                                                                | -                                                                                                                                                                                                                                                    | 498.3                                                                                                                                                                                                                                                | 498.3                                                                                                                                                                                                                                                | -                                                                                                                                                                                                                                                    | 481.6                                                                                                                                                                                                                                                | 481.6                                                                                                                                                                                                                                                |\n| IMRALDI                                                                                           | -                                                                                                                                                                                                                                                    | 224.5                                                                                                                                                                                                                                                | 224.5                                                                                                                                                                                                                                                | -                                                                                                                                                                                                                                                    | 233.4                                                                                                                                                                                                                                                | 233.4                                                                                                                                                                                                                                                | -                                                                                                                                                                                                                                                    | 216.3                                                                                                                                                                                                                                                | 216.3                                                                                                                                                                                                                                                |\n| FLIXABI                                                                                           | -                                                                                                                                                                                                                                                    | 81.3                                                                                                                                                                                                                                                 | 81.3                                                                                                                                                                                                                                                 | -                                                                                                                                                                                                                                                    | 99.4                                                                                                                                                                                                                                                 | 99.4                                                                                                                                                                                                                                                 | -                                                                                                                                                                                                                                                    | 97.9                                                                                                                                                                                                                                                 | 97.9                                                                                                                                                                                                                                                 |\n| BYOOVIZ (2)                                                                                       | 4.3                                                                                                                                                                                                                                                  | -                                                                                                                                                                                                                                                    | 4.3                                                                                                                                                                                                                                                  | -                                                                                                                                                                                                                                                    | -                                                                                                                                                                                                                                                    | -                                                                                                                                                                                                                                                    | -                                                                                                                                                                                                                                                    | -                                                                                                                                                                                                                                                    | -                                                                                                                                                                                                                                                    |\n| Subtotal: Biosimilars                                                                             | 4.3                                                                                                                                                                                                                                                  | 746.8                                                                                                                                                                                                                                                | 751.1                                                                                                                                                                                                                                                | -                                                                                                                                                                                                                                                    | 831.1                                                                                                                                                                                                                                                | 831.1                                                                                                                                                                                                                                                | -                                                                                                                                                                                                                                                    | 795.8                                                                                                                                                                                                                                                | 795.8                                                                                                                                                                                                                                                |\n| Other:                                                                                            |                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                      |\n| FUMADERM                                                                                          | -                                                                                                                                                                                                                                                    | 8.2                                                                                                                                                                                                                                                  | 8.2                                                                                                                                                                                                                                                  | -                                                                                                                                                                                                                                                    | 11.0                                                                                                                                                                                                                                                 | 11.0                                                                                                                                                                                                                                                 | -                                                                                                                                                                                                                                                    | 12.2                                                                                                                                                                                                                                                 | 12.2                                                                                                                                                                                                                                                 |\n| ADUHELM                                                                                           | 4.8                                                                                                                                                                                                                                                  | -                                                                                                                                                                                                                                                    | 4.8                                                                                                                                                                                                                                                  | 3.0                                                                                                                                                                                                                                                  | -                                                                                                                                                                                                                                                    | 3.0                                                                                                                                                                                                                                                  | -                                                                                                                                                                                                                                                    | -                                                                                                                                                                                                                                                    | -                                                                                                                                                                                                                                                    |\n| Total product revenue                                                                             | $3,469.3                                                                                                                                                                                                                                             | $4,518.5                                                                                                                                                                                                                                             | $ 7,987.8                                                                                                                                                                                                                                            | $3,805.7                                                                                                                                                                                                                                             | $5,041.2                                                                                                                                                                                                                                             | $ 8,846.9                                                                                                                                                                                                                                            | $5,900.1                                                                                                                                                                                                                                             | $4,792.1                                                                                                                                                                                                                                             | $10,692.2                                                                                                                                                                                                                                            |\n\nWe recognized revenue from two wholesalers accounting for 26.8% and 11.1% of gross product revenue in 2022, 28.8% and 10.1% of gross product revenue in 2021 and 30.5% and 15.3% of gross product revenue in 2020, respectively.\n\nAs of December 31, 2022, two wholesale distributors individually accounted for approximately 22.7% and 10.9% of net accounts receivable associated with our product sales, as compared to 21.9% and 10.2% as of December 31, 2021, respectively.\n\n## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>",
        "metadata": {
            "page": 133
        },
        "id": "cdca79fc-1b25-48da-ad85-943909970535"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nAn analysis of the change in reserves for discounts and allowances is summarized as follows:\n\n|                                                                                                   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>;E5AG@FE                                                                                                                                                                                                                                                                                                                       | glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@FD35FG3> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>6<GEF?7@FE                                                                                                                                                                                                                                                              | )7FGD@E                                                                                                                                                                                                                                                                                                                                                                    | +AF3>                                                                                                                                                                                                                                                                                                                                                                      |\n| Beginning balance                                                                                 | $ 137.7                                                                                                                                                                                                                                                                                                                                                                    | $ 759.6                                                                                                                                                                                                                                                                                                                                                                    | $ 38.0                                                                                                                                                                                                                                                                                                                                                                     | $ 935.3                                                                                                                                                                                                                                                                                                                                                                    |\n| Current provisions relating to sales in current year                                              | 666.6                                                                                                                                                                                                                                                                                                                                                                      | 2,715.5                                                                                                                                                                                                                                                                                                                                                                    | 12.3                                                                                                                                                                                                                                                                                                                                                                       | 3,394.4                                                                                                                                                                                                                                                                                                                                                                    |\n| Adjustments relating to prior years                                                               | (2.8)                                                                                                                                                                                                                                                                                                                                                                      | 1.4                                                                                                                                                                                                                                                                                                                                                                        | (7.2)                                                                                                                                                                                                                                                                                                                                                                      | (8.6)                                                                                                                                                                                                                                                                                                                                                                      |\n| Payments/credits relating to sales in current year                                                | (514.9)                                                                                                                                                                                                                                                                                                                                                                    | (2,060.7)                                                                                                                                                                                                                                                                                                                                                                  | (1.2)                                                                                                                                                                                                                                                                                                                                                                      | (2,576.8)                                                                                                                                                                                                                                                                                                                                                                  |\n| Payments/credits relating to sales in prior years                                                 | (132.8)                                                                                                                                                                                                                                                                                                                                                                    | (558.1)                                                                                                                                                                                                                                                                                                                                                                    | (18.4)                                                                                                                                                                                                                                                                                                                                                                     | (709.3)                                                                                                                                                                                                                                                                                                                                                                    |\n| Ending balance                                                                                    | $ 153.8                                                                                                                                                                                                                                                                                                                                                                    | $ 857.7                                                                                                                                                                                                                                                                                                                                                                    | $ 23.5                                                                                                                                                                                                                                                                                                                                                                     | $ 1,035.0                                                                                                                                                                                                                                                                                                                                                                  |\n\n|                                                                                                   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>;E5AG@FE                                                                                                                                                                                                                                                                                                                       | glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@FD35FG3> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>6<GEF?7@FE                                                                                                                                                                                                                                                              | )7FGD@E                                                                                                                                                                                                                                                                                                                                                                    | +AF3>                                                                                                                                                                                                                                                                                                                                                                      |\n| Beginning balance                                                                                 | $ 141.4                                                                                                                                                                                                                                                                                                                                                                    | $ 1,093.0                                                                                                                                                                                                                                                                                                                                                                  | $ 41.6                                                                                                                                                                                                                                                                                                                                                                     | $ 1,276.0                                                                                                                                                                                                                                                                                                                                                                  |\n| Current provisions relating to sales in current year                                              | 736.7                                                                                                                                                                                                                                                                                                                                                                      | 2,948.7                                                                                                                                                                                                                                                                                                                                                                    | 15.2                                                                                                                                                                                                                                                                                                                                                                       | 3,700.6                                                                                                                                                                                                                                                                                                                                                                    |\n| Adjustments relating to prior years                                                               | (4.0)                                                                                                                                                                                                                                                                                                                                                                      | (96.1)                                                                                                                                                                                                                                                                                                                                                                     | (3.3)                                                                                                                                                                                                                                                                                                                                                                      | (103.4)                                                                                                                                                                                                                                                                                                                                                                    |\n| Payments/credits relating to sales in current year                                                | (599.3)                                                                                                                                                                                                                                                                                                                                                                    | (2,283.1)                                                                                                                                                                                                                                                                                                                                                                  | (0.4)                                                                                                                                                                                                                                                                                                                                                                      | (2,882.8)                                                                                                                                                                                                                                                                                                                                                                  |\n| Payments/credits relating to sales in prior years                                                 | (137.1)                                                                                                                                                                                                                                                                                                                                                                    | (902.9)                                                                                                                                                                                                                                                                                                                                                                    | (15.1)                                                                                                                                                                                                                                                                                                                                                                     | (1,055.1)                                                                                                                                                                                                                                                                                                                                                                  |\n| Ending balance                                                                                    | $ 137.7                                                                                                                                                                                                                                                                                                                                                                    | $ 759.6                                                                                                                                                                                                                                                                                                                                                                    | $ 38.0                                                                                                                                                                                                                                                                                                                                                                     | $ 935.3                                                                                                                                                                                                                                                                                                                                                                    |\n\n|                                                                                                   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>;E5AG@FE                                                                                                                                                                                                                                                                                                                       | glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@FD35FG3> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>6<GEF?7@FE                                                                                                                                                                                                                                                              | )7FGD@E                                                                                                                                                                                                                                                                                                                                                                    | +AF3>                                                                                                                                                                                                                                                                                                                                                                      |\n| Beginning balance                                                                                 | $ 131.1                                                                                                                                                                                                                                                                                                                                                                    | $ 1,027.3                                                                                                                                                                                                                                                                                                                                                                  | $ 40.5                                                                                                                                                                                                                                                                                                                                                                     | $ 1,198.9                                                                                                                                                                                                                                                                                                                                                                  |\n| Current provisions relating to sales in current year                                              | 774.7                                                                                                                                                                                                                                                                                                                                                                      | 3,308.8                                                                                                                                                                                                                                                                                                                                                                    | 19.0                                                                                                                                                                                                                                                                                                                                                                       | 4,102.5                                                                                                                                                                                                                                                                                                                                                                    |\n| Adjustments relating to prior years                                                               | (1.0)                                                                                                                                                                                                                                                                                                                                                                      | (54.0)                                                                                                                                                                                                                                                                                                                                                                     | 1.3                                                                                                                                                                                                                                                                                                                                                                        | (53.7)                                                                                                                                                                                                                                                                                                                                                                     |\n| Payments/credits relating to sales in current year                                                | (635.1)                                                                                                                                                                                                                                                                                                                                                                    | (2,426.1)                                                                                                                                                                                                                                                                                                                                                                  | -                                                                                                                                                                                                                                                                                                                                                                          | (3,061.2)                                                                                                                                                                                                                                                                                                                                                                  |\n| Payments/credits relating to sales in prior years                                                 | (128.3)                                                                                                                                                                                                                                                                                                                                                                    | (763.0)                                                                                                                                                                                                                                                                                                                                                                    | (19.2)                                                                                                                                                                                                                                                                                                                                                                     | (910.5)                                                                                                                                                                                                                                                                                                                                                                    |\n| Ending balance                                                                                    | $ 141.4                                                                                                                                                                                                                                                                                                                                                                    | $ 1,093.0                                                                                                                                                                                                                                                                                                                                                                  | $ 41.6                                                                                                                                                                                                                                                                                                                                                                     | $ 1,276.0                                                                                                                                                                                                                                                                                                                                                                  |\n\nThe total reserves above, which are included in our consolidated balance sheets, are summarized as follows:\n\n|                                                                                                   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                           | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                           |\n| Reduction of accounts receivable                                                                  | $ 143.4                                                                                                                                                                                                                                    | $ 133.2                                                                                                                                                                                                                                    |\n| Component of accrued expense and other                                                            | 891.6                                                                                                                                                                                                                                      | 802.1                                                                                                                                                                                                                                      |\n| Total revenue-related reserves                                                                    | $ 1,035.0                                                                                                                                                                                                                                  | $ 935.3                                                                                                                                                                                                                                    |\n\n)7H7@G7 8DA? glyph<c=24,font=/PIIBCD+FranklinGothic-Book>@F;glyph<c=10,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book> +:7D3B7GF;5 'DA9D3?E\n\nRevenue from anti-CD20 therapeutic programs is summarized in the table below. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.\n\n|                                                                                                   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    |\n| Royalty revenue on sales of OCREVUS                                                               | $ 1,136.3                                                                                                                                                                                                                                                                                           | $ 991.7                                                                                                                                                                                                                                                                                             | $ 845.4                                                                                                                                                                                                                                                                                             |\n| Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA                              | 547.0                                                                                                                                                                                                                                                                                               | 647.7                                                                                                                                                                                                                                                                                               | 1,080.2                                                                                                                                                                                                                                                                                             |\n| Other revenue from anti-CD20 therapeutic programs                                                 | 17.2                                                                                                                                                                                                                                                                                                | 19.1                                                                                                                                                                                                                                                                                                | 52.2                                                                                                                                                                                                                                                                                                |\n| Total revenue from anti-CD20 therapeutic programs                                                 | $ 1,700.5                                                                                                                                                                                                                                                                                           | $ 1,658.5                                                                                                                                                                                                                                                                                           | $ 1,977.8                                                                                                                                                                                                                                                                                           |\n\nApproximately 16.7%, 15.1% and 14.7% of our total revenue in 2022, 2021 and 2020, respectively, was derived from our collaboration arrangements with Genentech. For additional information on our collaboration",
        "metadata": {
            "page": 134
        },
        "id": "158e6b6f-28cb-4f73-8fdc-db395dc76650"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\narrangements with Genentech, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>A , to these consolidated financial statements.\n\n## &F:7D )7H7@G7\n\nOther revenue consists of royalty revenue and contract manufacturing and other revenue and is summarized as follows:\n\n|                                                                                                   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    |\n| Contract manufacturing and other revenue                                                          | $ 417.7                                                                                                                                                                                                                                                                                             | $ 427.7                                                                                                                                                                                                                                                                                             | $ 719.1                                                                                                                                                                                                                                                                                             |\n| Royalty revenue                                                                                   | 67.4                                                                                                                                                                                                                                                                                                | 48.6                                                                                                                                                                                                                                                                                                | 55.5                                                                                                                                                                                                                                                                                                |\n| Total other revenue                                                                               | $ 485.1                                                                                                                                                                                                                                                                                             | $ 476.3                                                                                                                                                                                                                                                                                             | $ 774.6                                                                                                                                                                                                                                                                                             |\n\n## glyph<c=16,font=/PIICNA+FranklinGothic-BookItal>0/53\"$5 glyph<c=25,font=/PIICNA+FranklinGothic-BookItal>\"/6'\"$563*/( \"/% glyph<c=27,font=/PIICNA+FranklinGothic-BookItal>5)&3 glyph<c=29,font=/PIICNA+FranklinGothic-BookItal>&7&/6&\n\nContract manufacturing and other revenue primarily reflects amounts earned under contract manufacturing agreements with our strategic customers.\n\nDuring the third quarter of 2019, we amended our agreement with a contract manufacturing customer pursuant to which we licensed certain of our manufacturing-related intellectual property to the customer. In the second quarter of 2020, the customer received regulatory approval for its product that is being manufactured using certain of our manufacturing-related intellectual property. As a result we were entitled to $500.0 million in a series of three payments. The first payment became due upon a regulatory approval of such product and was received during the second quarter of 2020. The second payment became due upon the first anniversary of the regulatory approval and was received during the second quarter of 2021. The third payment became due upon the second anniversary of the regulatory approval and was received during the second quarter of 2022.\n\nContract manufacturing and other revenue for the year ended December 31, 2020, reflects $346.2 million related to the delivery of the license for certain of our manufacturing-related intellectual property under the amended agreement, as discussed above, and the performance of manufacturing product supply services for such customer. We allocated the remaining $153.8 million of the $500.0 million transaction price to the performance of manufacturing product supply services for the customer, which we expect to perform through 2026. The value allocated to the manufacturing services was based on expected demand for supply and the fair value of comparable manufacturing and development services.\n\n## glyph<c=29,font=/PIICNA+FranklinGothic-BookItal>0:\"-5: glyph<c=29,font=/PIICNA+FranklinGothic-BookItal>&7&/6&\n\nRoyalty revenue reflects the royalties we receive from net sales on products related to patents that we have out-licensed, as well as royalty revenue on biosimilar products from our collaboration arrangements with Samsung Bioepis.\n\nFor additional information on our collaboration arrangements with Samsung Bioepis, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>A , to these consolidated financial statements.",
        "metadata": {
            "page": 135
        },
        "id": "3fafcdd2-1864-4817-af9e-8619c97fd209"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\n## %AF7 glyph<c=19,font=/PIIBCD+FranklinGothic-Book>glyph<c=23,font=/PIIBCD+FranklinGothic-Book> @H7@FADK\n\nThe components of inventory are summarized as follows:\n\n|                                                                                                                                                                            | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book>                                                                          | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                           | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                           |\n| Raw materials                                                                                                                                                              | $ 413.2                                                                                                                                                                                                                                    | $ 349.6                                                                                                                                                                                                                                    |\n| Work in process (1)                                                                                                                                                        | 751.9                                                                                                                                                                                                                                      | 814.0                                                                                                                                                                                                                                      |\n| Finished goods                                                                                                                                                             | 200.4                                                                                                                                                                                                                                      | 187.9                                                                                                                                                                                                                                      |\n| Total inventory                                                                                                                                                            | $ 1,365.5                                                                                                                                                                                                                                  | $ 1,351.5                                                                                                                                                                                                                                  |\n| glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>/:/<13 '633B glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>:/AA7471/B7=<glyph<c=20,font=/PIIBDE+FranklinGothic-BookItal> |                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                            |\n| Inventory                                                                                                                                                                  | $ 1,344.4                                                                                                                                                                                                                                  | $ 1,351.5                                                                                                                                                                                                                                  |\n| Investments and other assets                                                                                                                                               | 21.1                                                                                                                                                                                                                                       | -                                                                                                                                                                                                                                          |\n| Total inventory                                                                                                                                                            | $ 1,365.5                                                                                                                                                                                                                                  | $ 1,351.5                                                                                                                                                                                                                                  |\n\nLong-term inventory is included in investments and other assets in our consolidated balance sheets.\n\nInventory amounts written down as a result of excess, obsolescence or unmarketability are charged to cost of sales, and totaled $336.2 million, $167.6 million and $26.6 million for the years ended December 31, 2022, 2021 and 2020, respectively.\n\n## glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><D3<B=@G +@7B3glyph<c=8,font=/PIIBDE+FranklinGothic-BookItal>#44A\n\nIn April 2022 the Centers for Medicare and Medicaid Services (CMS) released the final National Coverage Decision (NCD) for the class of anti-amyloid treatments in Alzheimer's disease, including ADUHELM. The final NCD confirmed coverage with evidence development, in which patients with Medicare can only access treatment if they are part of an approved clinical trial. We expect that this decision will reduce future demand for ADUHELM to a minimal level. During the first quarter of 2022 we wrote-off approximately $275.0 million of inventory related to ADUHELM, as a result of this CMS decision, which was recognized in cost of sales within our consolidated statements of income for the year ended December 31, 2022. We have recognized approximately $136.0 million related to Eisai's 45.0% share of these charges in collaboration profit (loss) sharing within our consolidated statements of income for the year ended December 31, 2022.\n\nDuring the fourth quarter of 2021 we wrote-off approximately $120.0 million of inventory in excess of forecasted demand related to ADUHELM, which was recognized in cost of sales within our consolidated statements of income for the year ended December 31, 2021. We have recognized approximately $59.0 million related to Eisai's 45.0% share of these charges in collaboration profit (loss) sharing within our consolidated statements of income for the year ended December 31, 2021.\n\nAs of December 31, 2022, the carrying value of our ADUHELM inventory was immaterial. As of December 31, 2021, we had approximately $223.0 million of ADUHELM inventory. For additional information please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>A , to these consolidated financial statements.",
        "metadata": {
            "page": 136
        },
        "id": "f62892d7-faa1-4737-9704-12a24111125e"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\n## %AF7 glyph<c=20,font=/PIIBCD+FranklinGothic-Book>glyph<c=23,font=/PIIBCD+FranklinGothic-Book> @F3@9;4>7 glyph<c=24,font=/PIIBCD+FranklinGothic-Book>EE7FE 3@6 glyph<c=30,font=/PIIBCD+FranklinGothic-Book>AA6I;>>\n\n## @F3@9;4>7 glyph<c=24,font=/PIIBCD+FranklinGothic-Book>EE7FE\n\nIntangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:\n\n|                                                                                                   |                                                           | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------------------------------------------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | glyph<c=28,font=/PIIBCD+FranklinGothic-Book>EF;?3F76 #;87 | glyph<c=26,font=/PIIBCD+FranklinGothic-Book>AEF                                                                                                                                                                                                                                                                                                                                                                             | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>55G?G>3F76 glyph<c=24,font=/PIIBCD+FranklinGothic-Book>?ADF;L3F;A@                                                                                                                                                                                                                                                                                                              | %7F                                                                                                                                                                                                                                                                                                                                                                                                                         | glyph<c=26,font=/PIIBCD+FranklinGothic-Book>AEF                                                                                                                                                                                                                                                                                                                                                                             | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>55G?G>3F76 glyph<c=24,font=/PIIBCD+FranklinGothic-Book>?ADF;L3F;A@                                                                                                                                                                                                                                                                                                              | %7F                                                                                                                                                                                                                                                                                                                                                                                                                         |\n| Completed technology                                                                              | 4-28 years                                                | $ 7,415.3                                                                                                                                                                                                                                                                                                                                                                                                                   | $ (5,629.2)                                                                                                                                                                                                                                                                                                                                                                                                                 | $ 1,786.1                                                                                                                                                                                                                                                                                                                                                                                                                   | $ 7,413.1                                                                                                                                                                                                                                                                                                                                                                                                                   | $ (5,388.5)                                                                                                                                                                                                                                                                                                                                                                                                                 | $ 2,024.6                                                                                                                                                                                                                                                                                                                                                                                                                   |\n| In-process research and development                                                               | Indefinite until commercialization                        | -                                                                                                                                                                                                                                                                                                                                                                                                                           | -                                                                                                                                                                                                                                                                                                                                                                                                                           | -                                                                                                                                                                                                                                                                                                                                                                                                                           | 132.7                                                                                                                                                                                                                                                                                                                                                                                                                       | -                                                                                                                                                                                                                                                                                                                                                                                                                           | 132.7                                                                                                                                                                                                                                                                                                                                                                                                                       |\n| Trademarks and trade names                                                                        | Indefinite                                                | 64.0                                                                                                                                                                                                                                                                                                                                                                                                                        | -                                                                                                                                                                                                                                                                                                                                                                                                                           | 64.0                                                                                                                                                                                                                                                                                                                                                                                                                        | 64.0                                                                                                                                                                                                                                                                                                                                                                                                                        | -                                                                                                                                                                                                                                                                                                                                                                                                                           | 64.0                                                                                                                                                                                                                                                                                                                                                                                                                        |\n| Total intangible assets                                                                           |                                                           | $ 7,479.3                                                                                                                                                                                                                                                                                                                                                                                                                   | $ (5,629.2)                                                                                                                                                                                                                                                                                                                                                                                                                 | $ 1,850.1                                                                                                                                                                                                                                                                                                                                                                                                                   | $ 7,609.8                                                                                                                                                                                                                                                                                                                                                                                                                   | $ (5,388.5)                                                                                                                                                                                                                                                                                                                                                                                                                 | $ 2,221.3                                                                                                                                                                                                                                                                                                                                                                                                                   |\n\n## glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>;=@B7H/B7=< /<2 glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>;>/7@;3<BA\n\nAmortization and impairment of acquired intangible assets totaled $365.9 million, $881.3 million and $464.8 million for the years ended December 31, 2022, 2021 and 2020, respectively.\n\nAmortization of acquired intangible assets, excluding impairment charges, totaled $246.3 million, $252.0 million and $255.1 million for the years ended December 31, 2022, 2021 and 2020, respectively. The decrease in amortization of acquired intangible assets, excluding impairment charges, over the three years was primarily duetoa lower rate of amortization for acquired intangible assets.\n\nFor the year ended December 31, 2022, amortization and impairment of acquired intangible assets reflects the impact of a $119.6 million impairment charge related to vixotrigine (BIIB074) for the potential treatment of diabetic painful neuropathy (DPN).\n\nFor the year ended December 31, 2021, amortization and impairment of acquired intangible assets reflects the impact of a $365.0 million impairment charge related to BIIB111 (timrepigene emparvovec), a $220.0 million impairment charge related to BIIB112 (cotoretigene toliparvovec) and a $44.3 million impairment charge related to vixotrigine for the potential treatment of trigeminal neuralgia (TGN).\n\nFor the year ended December 31, 2020, amortization and impairment of acquired intangible assets reflects the impact of a $115.0 million impairment charge related to BIIB111, a $75.4 million impairment charge related to BIIB054 (cinpanemab) and a $19.3 million impairment charge related to one of our other IPR&D intangible assets.\n\n## glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=;>:3B32 (316<=:=5G\n\nCompleted technology primarily relates to our other marketed products and programs acquired through asset acquisitions, licenses and business combinations.\n\n## glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>$&glyph<c=3,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal> &3:/B32 B= glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>CA7<3AA glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=;07</B7=<A\n\nIPR&D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&D balances are adjustments related to foreign currency exchange rate fluctuations. We review amounts capitalized as acquired IPR&D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. The carrying value associated with our IPR&D assets as of December 31, 2021, relates to the IPR&D programs we acquired in connection with our acquisition of Convergence Pharmaceuticals Holdings Ltd. (Convergence). As of December 31, 2022, as a result of our decision to discontinue development of vixotrigine, we recognized an impairment charge reducing the remaining book value to zero.",
        "metadata": {
            "page": 137
        },
        "id": "4c3bc3c4-2ab4-4b1b-aa88-cb1fd9473354"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\n## *7F=B@757<3\n\nIn connection with our acquisition of Convergence, we recognized $424.6 million of acquired IPR&D intangible assets for vixotrigine. In the periods following our acquisition of vixotrigine, there were numerous delays in the initiation of Phase 3 studies for the potential treatment of TGN and for the potential treatment of DPN, another form of neuropathic pain. We engaged with the FDA regarding the design of the potential Phase 3 studies of vixotrigine for the potential treatment of TGN and DPN and performed an additional clinical trial of vixotrigine, which was completed during 2022.\n\nThe performance of this additional clinical trial delayed the initiation of the Phase 3 studies of vixotrigine for the potential treatment of TGN, and, as a result, we recognized an impairment charge of $44.3 million related to vixotrigine for the potential treatment of TGN during the first quarter of 2021.\n\nDuring the fourth quarter of 2022 we discontinued further development of vixotrigine based on regulatory, development and commercialization challenges. For the year ended December 31, 2022, we recognized an impairment charge of approximately $119.6 million related to vixotrigine for the potential treatment of DPN, reducing the remaining book value of this IPR&D intangible asset to zero. We also adjusted the value of our contingent consideration obligations related to this asset resulting in a pre-tax gain of approximately $209.1 million, which was recognized in (gain) loss on fair value remeasurement of contingent consideration within our consolidated statements of income.\n\n## glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal> /<2 glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>\n\nIn connection with our acquisition of Nightstar Therapeutics plc, we recognized $480.0 million and $220.0 million of acquired IPR&D intangible assets for BIIB111 and BIIB112, respectively. During the fourth quarter of 2020 we recognized an impairment charge of $115.0 million related to BIIB111 as a result of third-party manufacturing delays that impacted the timing and increased the costs associated with advancing BIIB111 through Phase 3 development.\n\nDuring the second quarter of 2021 we announced that our Phase 3 STAR study of BIIB111 and our Phase 2/3 XIRIUS study of BIIB112 did not meet their primary endpoints. In the third quarter of 2021 we suspended further development on these programs based on the decision by management as part of its strategic review process. For the year ended December 31, 2021, we recognized an impairment charge of $365.0 million related to BIIB111 and an impairment charge of $220.0 million related to BIIB112, reducing the remaining book values of these IPR&D intangible assets to zero.\n\nIn addition, as a result of our decision to suspend further development of BIIB111 and BIIB112, we recorded charges of approximately $39.1 million during the third quarter of 2021 related to our manufacturing arrangements and other costs that we expect to incur as a result of suspending these programs. These charges were recognized in research and development expense in our consolidated statements of income for the year ended December 31, 2021.\n\n## glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=10,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=15,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=14,font=/PIIBDE+FranklinGothic-BookItal>\n\nIn connection with our acquisition of Biogen International Neuroscience GmbH (BIN), we recognized a $110.9 million acquired IPR&D intangible asset. In February 2021 we announced that we discontinued development of BIIB054 as a potential treatment of Parkinson's disease as our Phase 2 SPARK study did not meet its primary or secondary endpoints. Although we made this determination in February 2021, it was based on conditions that existed as of December 31, 2020. As a result, we recognized an impairment charge of approximately $75.4 million during the fourth quarter of 2020 to reduce the fair value of the related IPR&D intangible asset to zero.\n\nThe IPR&D impairment charges were included in amortization and impairment of acquired intangible assets and the gain resulting from the remeasurement of our contingent consideration obligation was recorded in (gain) loss on fair value remeasurement of contingent consideration in our consolidated statements of income. The fair value of the intangible assets and contingent consideration obligations were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs including estimated revenue, costs and probabilities of success.",
        "metadata": {
            "page": 138
        },
        "id": "3f00d673-745a-4a42-85a5-b38cbc6c168d"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nglyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>AB7;/B32 glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>CBC@3 glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>;=@B7H/B7=< =4 glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><B/<570:3 glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>AA3BA\n\nThe estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:\n\n|   glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>   |\n|-----------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n|                                                                                                2023 | $ 215.0                                                                                                                                                                                                                                                                                                                                                                                                                     |\n|                                                                                                2024 | 195.0                                                                                                                                                                                                                                                                                                                                                                                                                       |\n|                                                                                                2025 | 190.0                                                                                                                                                                                                                                                                                                                                                                                                                       |\n|                                                                                                2026 | 175.0                                                                                                                                                                                                                                                                                                                                                                                                                       |\n|                                                                                                2027 | 165.0                                                                                                                                                                                                                                                                                                                                                                                                                       |\n\n## glyph<c=30,font=/PIIBCD+FranklinGothic-Book>AA6I;>>\n\nThe following table provides a roll forward of the changes in our goodwill balance:\n\n|                                                                                                   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                           | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                           |\n| Goodwill, beginning of year                                                                       | $ 5,761.1                                                                                                                                                                                                                                  | $ 5,762.1                                                                                                                                                                                                                                  |\n| Other                                                                                             | (12.1)                                                                                                                                                                                                                                     | (1.0)                                                                                                                                                                                                                                      |\n| Goodwill, end of year                                                                             | $ 5,749.0                                                                                                                                                                                                                                  | $ 5,761.1                                                                                                                                                                                                                                  |\n\nAs of December 31, 2022, we had no accumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.",
        "metadata": {
            "page": 139
        },
        "id": "4ae9f809-4543-4d97-85f5-d8a1e6c96847"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\n## %AF7 glyph<c=21,font=/PIIBCD+FranklinGothic-Book>glyph<c=23,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book>3;D -3>G7 $73EGD7?7@FE\n\nThe tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:\n\n|                                                                                                       | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book> *;9@;8;53@F   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book> *;9@;8;53@F   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book> *;9@;8;53@F   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book> *;9@;8;53@F   |\n|-------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book>     | +AF3>                                                                                                                                                                                                                                                                                                                                                                                                                                   | (GAF76 'D;57E ;@ glyph<c=24,font=/PIIBCD+FranklinGothic-Book>5F;H7 $3D=7FE glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#7H7> glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=7,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                                                                     | *;9@;8;53@F &F:7D &4E7DH34>7  @BGFE glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#7H7> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=7,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                                                                                                            | ,@A4E7DH34>7  @BGFE glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#7H7> glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=7,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                                                                                                                            |\n| glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>AA3BAglyph<c=20,font=/PIIBDE+FranklinGothic-BookItal> |                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                         |\n| Cash equivalents                                                                                      | $ 2,847.6                                                                                                                                                                                                                                                                                                                                                                                                                               | $ - $                                                                                                                                                                                                                                                                                                                                                                                                                                   | 2,847.6                                                                                                                                                                                                                                                                                                                                                                                                                                 | $ -                                                                                                                                                                                                                                                                                                                                                                                                                                     |\n| Marketable debt securities:                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                         |\n| Corporate debt securities                                                                             | 1,231.6                                                                                                                                                                                                                                                                                                                                                                                                                                 | -                                                                                                                                                                                                                                                                                                                                                                                                                                       | 1,231.6                                                                                                                                                                                                                                                                                                                                                                                                                                 | -                                                                                                                                                                                                                                                                                                                                                                                                                                       |\n| Government securities                                                                                 | 810.3                                                                                                                                                                                                                                                                                                                                                                                                                                   | -                                                                                                                                                                                                                                                                                                                                                                                                                                       | 810.3                                                                                                                                                                                                                                                                                                                                                                                                                                   | -                                                                                                                                                                                                                                                                                                                                                                                                                                       |\n| Mortgage and other asset backed securities                                                            | 137.3                                                                                                                                                                                                                                                                                                                                                                                                                                   | -                                                                                                                                                                                                                                                                                                                                                                                                                                       | 137.3                                                                                                                                                                                                                                                                                                                                                                                                                                   | -                                                                                                                                                                                                                                                                                                                                                                                                                                       |\n| Marketable equity securities                                                                          | 791.1                                                                                                                                                                                                                                                                                                                                                                                                                                   | 791.1                                                                                                                                                                                                                                                                                                                                                                                                                                   | -                                                                                                                                                                                                                                                                                                                                                                                                                                       | -                                                                                                                                                                                                                                                                                                                                                                                                                                       |\n| Other current assets:                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                         |\n| Receivable from Samsung BioLogics (1)                                                                 | 798.8                                                                                                                                                                                                                                                                                                                                                                                                                                   | -                                                                                                                                                                                                                                                                                                                                                                                                                                       | -                                                                                                                                                                                                                                                                                                                                                                                                                                       | 798.8                                                                                                                                                                                                                                                                                                                                                                                                                                   |\n| Other assets:                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                         |\n| Derivative contracts                                                                                  | 63.0                                                                                                                                                                                                                                                                                                                                                                                                                                    | -                                                                                                                                                                                                                                                                                                                                                                                                                                       | 63.0                                                                                                                                                                                                                                                                                                                                                                                                                                    | -                                                                                                                                                                                                                                                                                                                                                                                                                                       |\n| Plan assets for deferred compensation                                                                 | 32.8                                                                                                                                                                                                                                                                                                                                                                                                                                    | -                                                                                                                                                                                                                                                                                                                                                                                                                                       | 32.8                                                                                                                                                                                                                                                                                                                                                                                                                                    | -                                                                                                                                                                                                                                                                                                                                                                                                                                       |\n| Receivable from Samsung BioLogics (1)                                                                 | 405.4                                                                                                                                                                                                                                                                                                                                                                                                                                   | -                                                                                                                                                                                                                                                                                                                                                                                                                                       | -                                                                                                                                                                                                                                                                                                                                                                                                                                       | 405.4                                                                                                                                                                                                                                                                                                                                                                                                                                   |\n| Total                                                                                                 | $ 7,117.9                                                                                                                                                                                                                                                                                                                                                                                                                               | $ 791.1                                                                                                                                                                                                                                                                                                                                                                                                                                 | $ 5,122.6                                                                                                                                                                                                                                                                                                                                                                                                                               | $ 1,204.2                                                                                                                                                                                                                                                                                                                                                                                                                               |\n| 7/07:7B73Aglyph<c=20,font=/PIIBDE+FranklinGothic-BookItal>                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                         |\n| Derivative contracts                                                                                  | $ 26.0                                                                                                                                                                                                                                                                                                                                                                                                                                  | $                                                                                                                                                                                                                                                                                                                                                                                                                                       | - $ 26.0                                                                                                                                                                                                                                                                                                                                                                                                                                | $ -                                                                                                                                                                                                                                                                                                                                                                                                                                     |\n| Total                                                                                                 | $ 26.0                                                                                                                                                                                                                                                                                                                                                                                                                                  | $                                                                                                                                                                                                                                                                                                                                                                                                                                       | - $ 26.0                                                                                                                                                                                                                                                                                                                                                                                                                                | $ -                                                                                                                                                                                                                                                                                                                                                                                                                                     |\n\n|                                                                                                       | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book> *;9@;8;53@F *;9@;8;53@F   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book> *;9@;8;53@F *;9@;8;53@F   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book> *;9@;8;53@F *;9@;8;53@F   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book> *;9@;8;53@F *;9@;8;53@F   |\n|-------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book>     | +AF3>                                                                                                                                                                                                                                                                                                                                                                                                                                               | (GAF76 'D;57E ;@ glyph<c=24,font=/PIIBCD+FranklinGothic-Book>5F;H7 $3D=7FE glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#7H7> glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=7,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                                                                                 | &F:7D &4E7DH34>7  @BGFE glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#7H7> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=7,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                                                                                                                                    | ,@A4E7DH34>7  @BGFE glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#7H7> glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=7,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                                                                                                                                        |\n| glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>AA3BAglyph<c=20,font=/PIIBDE+FranklinGothic-BookItal> |                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                     |\n| Cash equivalents                                                                                      | $ 1,632.2                                                                                                                                                                                                                                                                                                                                                                                                                                           | $ - $                                                                                                                                                                                                                                                                                                                                                                                                                                               | 1,632.2                                                                                                                                                                                                                                                                                                                                                                                                                                             | $ -                                                                                                                                                                                                                                                                                                                                                                                                                                                 |\n| Marketable debt securities:                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                     |\n| Corporate debt securities                                                                             | 1,108.2                                                                                                                                                                                                                                                                                                                                                                                                                                             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 1,108.2                                                                                                                                                                                                                                                                                                                                                                                                                                             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                   |\n| Government securities                                                                                 | 1,192.7                                                                                                                                                                                                                                                                                                                                                                                                                                             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 1,192.7                                                                                                                                                                                                                                                                                                                                                                                                                                             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                   |\n| Mortgage and other asset backed securities                                                            | 132.2                                                                                                                                                                                                                                                                                                                                                                                                                                               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 132.2                                                                                                                                                                                                                                                                                                                                                                                                                                               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                   |\n| Marketable equity securities                                                                          | 1,048.5                                                                                                                                                                                                                                                                                                                                                                                                                                             | 181.7                                                                                                                                                                                                                                                                                                                                                                                                                                               | 866.8                                                                                                                                                                                                                                                                                                                                                                                                                                               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                   |\n| Derivative contracts                                                                                  | 80.9                                                                                                                                                                                                                                                                                                                                                                                                                                                | -                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 80.9                                                                                                                                                                                                                                                                                                                                                                                                                                                | -                                                                                                                                                                                                                                                                                                                                                                                                                                                   |\n| Plan assets for deferred compensation                                                                 | 33.4                                                                                                                                                                                                                                                                                                                                                                                                                                                | -                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 33.4                                                                                                                                                                                                                                                                                                                                                                                                                                                | -                                                                                                                                                                                                                                                                                                                                                                                                                                                   |\n| Total                                                                                                 | $ 5,228.1                                                                                                                                                                                                                                                                                                                                                                                                                                           | $ 181.7                                                                                                                                                                                                                                                                                                                                                                                                                                             | $ 5,046.4                                                                                                                                                                                                                                                                                                                                                                                                                                           | $ -                                                                                                                                                                                                                                                                                                                                                                                                                                                 |\n| 7/07:7B73Aglyph<c=20,font=/PIIBDE+FranklinGothic-BookItal>                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                     |\n| Derivative contracts                                                                                  | $ 10.8                                                                                                                                                                                                                                                                                                                                                                                                                                              | $ - $                                                                                                                                                                                                                                                                                                                                                                                                                                               | 10.8                                                                                                                                                                                                                                                                                                                                                                                                                                                | $ -                                                                                                                                                                                                                                                                                                                                                                                                                                                 |\n| Contingent consideration obligations                                                                  | 209.1                                                                                                                                                                                                                                                                                                                                                                                                                                               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                   | -                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 209.1                                                                                                                                                                                                                                                                                                                                                                                                                                               |\n| Total                                                                                                 | $ 219.9                                                                                                                                                                                                                                                                                                                                                                                                                                             | $ - $                                                                                                                                                                                                                                                                                                                                                                                                                                               | 10.8                                                                                                                                                                                                                                                                                                                                                                                                                                                | $ 209.1                                                                                                                                                                                                                                                                                                                                                                                                                                             |",
        "metadata": {
            "page": 140
        },
        "id": "4d54d67e-594d-4079-b377-0ef48c35f445"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nThe fair value of Level 2 instruments classified as cash equivalents and marketable debt securities was determined through third-party pricing services. In the third quarter of 2022 we elected to early adopt ASU 2022-03 on a prospective basis, which resulted in removing the impact of contractual sale restrictions from the fair value measurement of our remaining Sage common stock subject to certain holding period restrictions. As of December 31, 2022, our entire investment in the common stock of Sage was classified as a Level 1 measurement. Prior to the adoption of this standard, the fair value of Level 2 instruments classified as marketable equity securities represented a portion of our investment in the common stock of Sage and was valued using an option pricing valuation model.\n\nOur investments in the common stock of Sangamo Therapeutics, Inc. (Sangamo) and Denali Therapeutics Inc. (Denali) had holding period restrictions that expired during 2022. As of December 31, 2022, the fair values of our investments in Sangamo and Denali common stock were classified as Level 1 measurements. Prior to the expiration of these holding period restrictions the investments were classified as Level 2 measurements.\n\nAlthough the contractual holding period restrictions on our investments in Denali, Sage and Sangamo have expired, our ability to liquidate these investments may be limited by the size of our interest, the volume of market related activity, our concentrated level of ownership and potential restrictions resulting from our status as a collaborator. Therefore, we may realize significantly less than the current value of such investments.\n\nFor additional information on our investments in Denali, Sangamo and Sage common stock, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>A , to these consolidated financial statements.\n\nThere have been no material impairments of our assets measured and carried at fair value as of December 31, 2022 and 2021. In addition, there have been no changes in valuation techniques as of December 31, 2022 and 2021.\n\nFor a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read the glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>/7@ */:C3 !3/AC@3;3<BA A31B7=< within \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> 'C;;/@G =4 '75<7471/<B glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>11=C<B7<5 $=:7173Aglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> to these consolidated financial statements.\n\n## #7H7> glyph<c=16,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>EE7FE 3@6 #;34;>;F;7E glyph<c=31,font=/PIIBCD+FranklinGothic-Book>7>6 3F glyph<c=29,font=/PIIBCD+FranklinGothic-Book>3;D -3>G7\n\nThe following table presents quantitative information, as of the dates indicated, about the valuation techniques and significant unobservable inputs used in the valuation of our level 3 financial assets and liabilities measured at fair value on a recurring basis:\n\n|                                                                                                            | (G3@F;F3F;H7  @8AD?3F;A@ 34AGF #7H7> glyph<c=16,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book>3;D -3>G7 $73EGD7?7@FE                                                                                                                                                                | (G3@F;F3F;H7  @8AD?3F;A@ 34AGF #7H7> glyph<c=16,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book>3;D -3>G7 $73EGD7?7@FE                             | (G3@F;F3F;H7  @8AD?3F;A@ 34AGF #7H7> glyph<c=16,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book>3;D -3>G7 $73EGD7?7@FE   | (G3@F;F3F;H7  @8AD?3F;A@ 34AGF #7H7> glyph<c=16,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book>3;D -3>G7 $73EGD7?7@FE   | (G3@F;F3F;H7  @8AD?3F;A@ 34AGF #7H7> glyph<c=16,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book>3;D -3>G7 $73EGD7?7@FE                             | (G3@F;F3F;H7  @8AD?3F;A@ 34AGF #7H7> glyph<c=16,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book>3;D -3>G7 $73EGD7?7@FE                                                                                                                                                                | (G3@F;F3F;H7  @8AD?3F;A@ 34AGF #7H7> glyph<c=16,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book>3;D -3>G7 $73EGD7?7@FE                             |\n|------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n|                                                                                                            | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>3;D -3>G7                                                                                                                                                                                                                                                               | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>3;D -3>G7                                                                                                                            |                                                                                                                                                        |                                                                                                                                                        | )3@97                                                                                                                                                                            | .7;9:F76 glyph<c=24,font=/PIIBCD+FranklinGothic-Book>H7D397                                                                                                                                                                                                                                                         | .7;9:F76 glyph<c=24,font=/PIIBCD+FranklinGothic-Book>H7D397                                                                                                                      |\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book>          | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book> glyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=7,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book> | -3>G3F;A@ +75:@;CG7                                                                                                                                    | *;9@;8;53@F ,@A4E7DH34>7  @BGFglyph<c=6,font=/PIIBCD+FranklinGothic-Book>Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book>                                  | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book> glyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=7,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book> |\n| glyph<c=24,font=/PIICNA+FranklinGothic-BookItal>*\"#*-*5*&4glyph<c=13,font=/PIICNA+FranklinGothic-BookItal> |                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                  |                                                                                                                                                        |                                                                                                                                                        |                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                  |\n| Contingent consideration obligations                                                                       | $ - $                                                                                                                                                                                                                                                                                                               | 209.1                                                                                                                                                                            | Discounted cash flow                                                                                                                                   | Discount rate                                                                                                                                          | 1.30%                                                                                                                                                                            | -%                                                                                                                                                                                                                                                                                                                  | 1.30 %                                                                                                                                                                           |\n|                                                                                                            |                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                  |                                                                                                                                                        | Expected timing of achievement of development milestones                                                                                               | 2023 to 2027                                                                                                                                                                     | -                                                                                                                                                                                                                                                                                                                   | -                                                                                                                                                                                |\n\nThe weighted average discount rates were calculated based on the relative fair value of our contingent consideration obligations. In addition, we apply various probabilities of technological and regulatory success to the valuation models to estimate the fair values of our contingent consideration obligations, which ranged from 10.9% to certain probability as of December 31, 2021.\n\nThere were no transfers of assets or liabilities into or out of Level 3 as of December 31, 2022 and 2021.",
        "metadata": {
            "page": 141
        },
        "id": "87dac56c-a7dd-481f-ba32-3a1fdfe7f304"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\n## glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=<B7<53<B glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=<A723@/B7=< #0:75/B7=<A\n\nIn connection with our acquisitions of Convergence and BIN, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which are classified as Level 3 measurements:\n\n|                                                                                                   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                           | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                           |\n| Fair value, beginning of year                                                                     | $ 209.1                                                                                                                                                                                                                                    | $ 259.8                                                                                                                                                                                                                                    |\n| Changes in fair value                                                                             | (209.1)                                                                                                                                                                                                                                    | (50.7)                                                                                                                                                                                                                                     |\n| Fair value, end of year                                                                           | $ - $                                                                                                                                                                                                                                      | 209.1                                                                                                                                                                                                                                      |\n\nAs of December 31, 2021, approximately $209.1 million of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our consolidated balance sheets. Changes in the fair values of our contingent consideration obligations are recorded in (gain) loss on fair value remeasurement of contingent consideration in our consolidated statements of income.\n\nFor the year ended December 31, 2022, the changes in fair value of our contingent consideration obligations were primarily due to the discontinuation of further development efforts related to vixotrigine for the potential treatment of TGN and DPN, resulting in a reduction of our contingent consideration obligations of approximately $195.4 million, and changes in the interest rates used to revalue our contingent consideration liabilities.\n\nFor the year ended December 31, 2021, the changes in fair value of our contingent consideration obligations were primarily due to reductions in the probability of technical and regulatory success and delays in the expected timing of the achievement of certain remaining developmental milestones related to our vixotrigine programs.\n\nThe fair values of the contingent consideration liabilities were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs. For additional information on the valuation techniques and inputs utilized in the valuation of our financial assets and liabilities, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> 'C;;/@G =4 '75<7471/<B glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>11=C<B7<5 $=:7173Aglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> to these consolidated financial statements.\n\n## glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=<D3@53<13 $6/@;/13CB71/:A glyph<c=28,font=/PIIBDE+FranklinGothic-BookItal>=:27<5A 7;7B32\n\nIn connection with our acquisition of Convergence in February 2015 we recorded a contingent consideration obligation of $274.5 million. As of December 31, 2021, the fair value of this contingent consideration obligation was $209.1 million. During the fourth quarter of 2022 we discontinued further development of vixotrigine based on regulatory, development and commercialization challenges. As a result, the fair value of the contingent consideration obligations related to Convergence has been adjusted to zero, resulting in a pre-tax gain of approximately $209.1 million for the year ended December 31, 2022. This pre-tax gain was recorded in (gain) loss on fair value remeasurement of contingent consideration within our consolidated statements of income.\n\n## glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>7=53< glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><B3@</B7=</: \"3C@=A173<13 glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>;0glyph<c=28,font=/PIIBDE+FranklinGothic-BookItal>\n\nIn connection with our acquisition of BIN in December 2010 we recorded a contingent consideration obligation of $81.2 million. We discontinued further development of BIIB054 for the potential treatment of Parkinson's disease based on the results of a Phase 2 study of BIIB054. Additionally, during the third and fourth quarters of 2020 we discontinued other programs related to our acquisition of BIN for which we had immaterial contingent consideration obligations. As a result, the fair value of the contingent consideration obligations related to our acquisition of BIN was adjusted to zero, resulting in a gain of $101.5 million for the year ended December 31, 2020. This pre-tax gain was recorded in (gain) loss on fair value remeasurement of contingent consideration within our consolidated statements of income.\n\n## %A@D75GDD;@9 glyph<c=29,font=/PIIBCD+FranklinGothic-Book>3;D -3>G7 $73EGD7?7@FE\n\nFor the year ended December 31, 2022, we recorded impairment charges of $119.6 million related to vixotrigine. As a result, the remaining book values associated with these programs were reduced to zero. For the year ended December 31, 2021, we recorded impairment charges of $365.0 million related to BIIB111 and $220.0 million related to BIIB112. As a result, the remaining book values associated with these programs were reduced to zero.",
        "metadata": {
            "page": 142
        },
        "id": "44a6a0d3-581e-4e1a-87e3-900c6a281756"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nFor additional information on our impairments for intangible assets, please read \"=B3 glyph<c=17,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><B/<570:3 glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>AA3BA /<2 glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>==2E7:: , to these consolidated financial statements.\n\n## glyph<c=29,font=/PIIBCD+FranklinGothic-Book>;@3@5;3> @EFDG?7@FE %AF glyph<c=26,font=/PIIBCD+FranklinGothic-Book>3DD;76 3F glyph<c=29,font=/PIIBCD+FranklinGothic-Book>3;D -3>G7\n\n## #B63@ glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>7</<17/: glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><AB@C;3<BA\n\nDue to the short-term nature of certain financial instruments, the carrying value reflected in our consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expense and other, approximates fair value.\n\n## glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>30B glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><AB@C;3<BA\n\nThe fair values of our debt instruments, which are Level 2 liabilities, are summarized as follows:\n\n|                                                                                                   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>3;D -3>G7 glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>3;D -3>G7 glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                                                                                 | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                                                                                 |\n| 3.625% Senior Notes due September 15, 2022 (1)                                                    | $ - $                                                                                                                                                                                                                                                                                            | 1,020.0                                                                                                                                                                                                                                                                                          |\n| 4.050% Senior Notes due September 15, 2025                                                        | 1,699.9                                                                                                                                                                                                                                                                                          | 1,895.2                                                                                                                                                                                                                                                                                          |\n| 2.250% Senior Notes due May 1, 2030                                                               | 1,219.0                                                                                                                                                                                                                                                                                          | 1,475.9                                                                                                                                                                                                                                                                                          |\n| 5.200% Senior Notes due September 15, 2045                                                        | 1,033.2                                                                                                                                                                                                                                                                                          | 1,463.0                                                                                                                                                                                                                                                                                          |\n| 3.150% Senior Notes due May 1, 2050                                                               | 989.0                                                                                                                                                                                                                                                                                            | 1,457.7                                                                                                                                                                                                                                                                                          |\n| 3.250% Senior Notes due February 15, 2051                                                         | 469.1                                                                                                                                                                                                                                                                                            | 692.9                                                                                                                                                                                                                                                                                            |\n| Total                                                                                             | $ 5,410.2                                                                                                                                                                                                                                                                                        | $ 8,004.7                                                                                                                                                                                                                                                                                        |\n\nThe fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. The changes in the fair values of our Senior Notes as of December 31, 2022, compared to 2021, are primarily related to increases in U.S. treasury yields used to value our Senior Notes since December 31, 2021. For additional information related to our Senior Notes, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=13,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><230B32<3AA , to these consolidated financial statements.\n\n## %AF7 glyph<c=22,font=/PIIBCD+FranklinGothic-Book>glyph<c=23,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book>;@3@5;3> @EFDG?7@FE\n\nThe following table summarizes our financial assets with maturities of less than three months from the date of purchase included in cash and cash equivalents in our consolidated balance sheets:\n\n|                                                                                                   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                           | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                           |\n| Commercial paper                                                                                  | $ 177.2                                                                                                                                                                                                                                    | $ 247.6                                                                                                                                                                                                                                    |\n| Overnight reverse repurchase agreements                                                           | 59.0                                                                                                                                                                                                                                       | 200.0                                                                                                                                                                                                                                      |\n| Money market funds                                                                                | 2,581.5                                                                                                                                                                                                                                    | 901.6                                                                                                                                                                                                                                      |\n| Short-term debt securities                                                                        | 29.9                                                                                                                                                                                                                                       | 283.0                                                                                                                                                                                                                                      |\n| Total                                                                                             | $ 2,847.6                                                                                                                                                                                                                                  | $ 1,632.2                                                                                                                                                                                                                                  |\n\nThe carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities.",
        "metadata": {
            "page": 143
        },
        "id": "33fcb0cf-84a0-4949-b3cb-48e6be66b9fe"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nOur marketable equity securities gains (losses) are recorded in other (income) expense, net in our consolidated statements of income. The following tables summarize our marketable debt and equity securities, classified as available for sale:\n\n|                                                                                                   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>?ADF;L76 glyph<c=26,font=/PIIBCD+FranklinGothic-Book>AEF                                                                                                                                                                                                                                                                                                                        | glyph<c=30,font=/PIIBCD+FranklinGothic-Book>DAEE ,@D73>;L76 glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@E                                                                                                                                                                                                                                                                                                                | glyph<c=30,font=/PIIBCD+FranklinGothic-Book>DAEE ,@D73>;L76 #AEE7E                                                                                                                                                                                                                                                                                                                                                          | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>3;D -3>G7                                                                                                                                                                                                                                                                                                                                                                       |\n| Marketable debt securities:                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                             |\n| Corporate debt securities:                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                             |\n| Current                                                                                           | $ 936.2                                                                                                                                                                                                                                                                                                                                                                                                                     | $ - $                                                                                                                                                                                                                                                                                                                                                                                                                       | (4.9)                                                                                                                                                                                                                                                                                                                                                                                                                       | $ 931.3                                                                                                                                                                                                                                                                                                                                                                                                                     |\n| Non-current                                                                                       | 305.3                                                                                                                                                                                                                                                                                                                                                                                                                       | 0.1                                                                                                                                                                                                                                                                                                                                                                                                                         | (5.1)                                                                                                                                                                                                                                                                                                                                                                                                                       | 300.3                                                                                                                                                                                                                                                                                                                                                                                                                       |\n| Government securities:                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                             |\n| Current                                                                                           | 547.1                                                                                                                                                                                                                                                                                                                                                                                                                       | 0.1                                                                                                                                                                                                                                                                                                                                                                                                                         | (5.0)                                                                                                                                                                                                                                                                                                                                                                                                                       | 542.2                                                                                                                                                                                                                                                                                                                                                                                                                       |\n| Non-current                                                                                       | 271.4                                                                                                                                                                                                                                                                                                                                                                                                                       | -                                                                                                                                                                                                                                                                                                                                                                                                                           | (3.3)                                                                                                                                                                                                                                                                                                                                                                                                                       | 268.1                                                                                                                                                                                                                                                                                                                                                                                                                       |\n| Mortgage and other asset backed securities:                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                             |\n| Current                                                                                           | -                                                                                                                                                                                                                                                                                                                                                                                                                           | -                                                                                                                                                                                                                                                                                                                                                                                                                           | -                                                                                                                                                                                                                                                                                                                                                                                                                           | -                                                                                                                                                                                                                                                                                                                                                                                                                           |\n| Non-current                                                                                       | 139.1                                                                                                                                                                                                                                                                                                                                                                                                                       | 0.1                                                                                                                                                                                                                                                                                                                                                                                                                         | (1.9)                                                                                                                                                                                                                                                                                                                                                                                                                       | 137.3                                                                                                                                                                                                                                                                                                                                                                                                                       |\n| Total marketable debt securities                                                                  | $ 2,199.1                                                                                                                                                                                                                                                                                                                                                                                                                   | $ 0.3                                                                                                                                                                                                                                                                                                                                                                                                                       | $ (20.2)                                                                                                                                                                                                                                                                                                                                                                                                                    | $ 2,179.2                                                                                                                                                                                                                                                                                                                                                                                                                   |\n| Marketable equity securities:                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                             |\n| Marketable equity securities, current                                                             | $ 1,133.8                                                                                                                                                                                                                                                                                                                                                                                                                   | $                                                                                                                                                                                                                                                                                                                                                                                                                           | - $ (342.7)                                                                                                                                                                                                                                                                                                                                                                                                                 | $ 791.1                                                                                                                                                                                                                                                                                                                                                                                                                     |\n| Total marketable equity securities                                                                | $ 1,133.8                                                                                                                                                                                                                                                                                                                                                                                                                   | $                                                                                                                                                                                                                                                                                                                                                                                                                           | - $ (342.7)                                                                                                                                                                                                                                                                                                                                                                                                                 | $ 791.1                                                                                                                                                                                                                                                                                                                                                                                                                     |\n\n|                                                                                                   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>?ADF;L76 glyph<c=26,font=/PIIBCD+FranklinGothic-Book>AEF                                                                                                                                                                                                                                                                                                                        | glyph<c=30,font=/PIIBCD+FranklinGothic-Book>DAEE ,@D73>;L76 glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@E                                                                                                                                                                                                                                                                                                                | glyph<c=30,font=/PIIBCD+FranklinGothic-Book>DAEE ,@D73>;L76 #AEE7E                                                                                                                                                                                                                                                                                                                                                          | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>3;D -3>G7                                                                                                                                                                                                                                                                                                                                                                       |\n| Marketable debt securities:                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                             |\n| Corporate debt securities:                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                             |\n| Current                                                                                           | $ 723.6                                                                                                                                                                                                                                                                                                                                                                                                                     | $ 0.1                                                                                                                                                                                                                                                                                                                                                                                                                       | $ (0.3)                                                                                                                                                                                                                                                                                                                                                                                                                     | $ 723.4                                                                                                                                                                                                                                                                                                                                                                                                                     |\n| Non-current                                                                                       | 385.4                                                                                                                                                                                                                                                                                                                                                                                                                       | 0.2                                                                                                                                                                                                                                                                                                                                                                                                                         | (0.8)                                                                                                                                                                                                                                                                                                                                                                                                                       | 384.8                                                                                                                                                                                                                                                                                                                                                                                                                       |\n| Government securities:                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                             |\n| Current                                                                                           | 817.0                                                                                                                                                                                                                                                                                                                                                                                                                       | -                                                                                                                                                                                                                                                                                                                                                                                                                           | (0.4)                                                                                                                                                                                                                                                                                                                                                                                                                       | 816.6                                                                                                                                                                                                                                                                                                                                                                                                                       |\n| Non-current                                                                                       | 377.0                                                                                                                                                                                                                                                                                                                                                                                                                       | 0.1                                                                                                                                                                                                                                                                                                                                                                                                                         | (1.0)                                                                                                                                                                                                                                                                                                                                                                                                                       | 376.1                                                                                                                                                                                                                                                                                                                                                                                                                       |\n| Mortgage and other asset backed securities:                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                             |\n| Current                                                                                           | 1.1                                                                                                                                                                                                                                                                                                                                                                                                                         | -                                                                                                                                                                                                                                                                                                                                                                                                                           | -                                                                                                                                                                                                                                                                                                                                                                                                                           | 1.1                                                                                                                                                                                                                                                                                                                                                                                                                         |\n| Non-current                                                                                       | 131.8                                                                                                                                                                                                                                                                                                                                                                                                                       | -                                                                                                                                                                                                                                                                                                                                                                                                                           | (0.7)                                                                                                                                                                                                                                                                                                                                                                                                                       | 131.1                                                                                                                                                                                                                                                                                                                                                                                                                       |\n| Total marketable debt securities                                                                  | $ 2,435.9                                                                                                                                                                                                                                                                                                                                                                                                                   | $ 0.4                                                                                                                                                                                                                                                                                                                                                                                                                       | $ (3.2)                                                                                                                                                                                                                                                                                                                                                                                                                     | $ 2,433.1                                                                                                                                                                                                                                                                                                                                                                                                                   |\n| Marketable equity securities:                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                             |\n| Marketable equity securities, current                                                             | $ 33.9                                                                                                                                                                                                                                                                                                                                                                                                                      | $ 9.9                                                                                                                                                                                                                                                                                                                                                                                                                       | $                                                                                                                                                                                                                                                                                                                                                                                                                           | - $ 43.8                                                                                                                                                                                                                                                                                                                                                                                                                    |\n| Marketable equity securities, non-current                                                         | 1,133.1                                                                                                                                                                                                                                                                                                                                                                                                                     | 151.0                                                                                                                                                                                                                                                                                                                                                                                                                       | (279.4)                                                                                                                                                                                                                                                                                                                                                                                                                     | 1,004.7                                                                                                                                                                                                                                                                                                                                                                                                                     |\n| Total marketable equity securities                                                                | $ 1,167.0                                                                                                                                                                                                                                                                                                                                                                                                                   | $ 160.9                                                                                                                                                                                                                                                                                                                                                                                                                     | $ (279.4)                                                                                                                                                                                                                                                                                                                                                                                                                   | $ 1,048.5                                                                                                                                                                                                                                                                                                                                                                                                                   |",
        "metadata": {
            "page": 144
        },
        "id": "5ac45b6a-ce32-409a-b363-796c165aeb78"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\n*G??3DK A8 glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@FD35FG3> $3FGD;F;7Eglyph<c=23,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>H3;>34>7glyph<c=10,font=/PIIBCD+FranklinGothic-Book>8ADglyph<c=10,font=/PIIBCD+FranklinGothic-Book>*3>7 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>74F *75GD;F;7E\n\nThe estimated fair value and amortized cost of our marketable debt securities classified as available-for-sale by contractual maturity are summarized as follows:\n\n|                                                                                                   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n|                                                                                                   | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                           | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                           | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                           | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                           |\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | glyph<c=28,font=/PIIBCD+FranklinGothic-Book>EF;?3F76 glyph<c=29,font=/PIIBCD+FranklinGothic-Book>3;D -3>G7                                                                                                                                 | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>?ADF;L76 glyph<c=26,font=/PIIBCD+FranklinGothic-Book>AEF                                                                                                                                       | glyph<c=28,font=/PIIBCD+FranklinGothic-Book>EF;?3F76 glyph<c=29,font=/PIIBCD+FranklinGothic-Book>3;D -3>G7                                                                                                                                 | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>?ADF;L76 glyph<c=26,font=/PIIBCD+FranklinGothic-Book>AEF                                                                                                                                       |\n| Due in one year or less                                                                           | $ 1,473.5                                                                                                                                                                                                                                  | $ 1,483.3                                                                                                                                                                                                                                  | $ 1,541.1                                                                                                                                                                                                                                  | $ 1,541.7                                                                                                                                                                                                                                  |\n| Due after one year through five years                                                             | 694.4                                                                                                                                                                                                                                      | 703.7                                                                                                                                                                                                                                      | 868.2                                                                                                                                                                                                                                      | 870.2                                                                                                                                                                                                                                      |\n| Due after five years                                                                              | 11.3                                                                                                                                                                                                                                       | 12.1                                                                                                                                                                                                                                       | 23.8                                                                                                                                                                                                                                       | 24.0                                                                                                                                                                                                                                       |\n| Total marketable debt securities                                                                  | $ 2,179.2                                                                                                                                                                                                                                  | $ 2,199.1                                                                                                                                                                                                                                  | $ 2,433.1                                                                                                                                                                                                                                  | $ 2,435.9                                                                                                                                                                                                                                  |\n\nThe average maturity of our marketable debt securities classified as available-for-sale as of December 31, 2022 and 2021, was approximately 8 months and 10 months, respectively.\n\n## 'DA5776E 8DA? $3D=7F34>7 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>74F *75GD;F;7E\n\nThe proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:\n\n|                                                                                                   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    |\n| Proceeds from maturities and sales                                                                | $ 3,671.0                                                                                                                                                                                                                                                                                           | $ 3,405.4                                                                                                                                                                                                                                                                                           | $ 7,299.4                                                                                                                                                                                                                                                                                           |\n| Realized gains                                                                                    | -                                                                                                                                                                                                                                                                                                   | 0.2                                                                                                                                                                                                                                                                                                 | 17.7                                                                                                                                                                                                                                                                                                |\n| Realized losses                                                                                   | 12.6                                                                                                                                                                                                                                                                                                | 4.0                                                                                                                                                                                                                                                                                                 | 26.0                                                                                                                                                                                                                                                                                                |\n\nRealized losses for the year ended December 31, 2022, 2021 and 2020, primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities.\n\n## *FD3F79;5  @H7EF?7@FE\n\nAs of December 31, 2022, our strategic investment portfolio comprised of investments totaling $846.0 million which are included in investments and other assets in our consolidated balance sheets. As of December 31, 2021, our strategic investment portfolio comprised of investments totaling $1,110.3 million, which are included in other current assets and investments and other assets in our consolidated balance sheets.\n\nOur strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in \"=B3 glyph<c=18,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>/7@ */:C3 !3/AC@3;3<BA , to these consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.\n\nThe decrease in our strategic investment portfolio for the year ended December 31, 2022, was primarily due to a decrease in the fair value of our investments in Denali and Sangamo common stock.\n\nFor additional information on our investments in Denali, Sangamo, Sage and Ionis common stock, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>A , to these consolidated financial statements.\n\n## %AF7 glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=23,font=/PIIBCD+FranklinGothic-Book> glyph<c=27,font=/PIIBCD+FranklinGothic-Book>7D;H3F;H7 @EFDG?7@FE\n\n## glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD7;9@ glyph<c=26,font=/PIIBCD+FranklinGothic-Book>GDD7@5K glyph<c=29,font=/PIIBCD+FranklinGothic-Book>ADI3D6 glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@FD35FE glyph<c=10,font=/PIIBCD+FranklinGothic-Book> glyph<c=31,font=/PIIBCD+FranklinGothic-Book>769;@9 @EFDG?7@FE\n\nDue to the global nature of our operations, portions of our revenue and operating expense are recorded in currencies other than the U.S. dollar. The value of revenue and operating expense measured in U.S. dollars is therefore subject to changes in foreign currency exchange rates. We enter into foreign currency forward contracts and foreign currency options with financial institutions with the primary objective to mitigate the impact of foreign currency exchange rate fluctuations on our international revenue and operating expense.\n\nForeign currency forward contracts and foreign currency options in effect as of December 31, 2022 and 2021, had durations of 1 to 12 months and 1 to 15 months, respectively. These contracts have been designated as cash",
        "metadata": {
            "page": 145
        },
        "id": "2f4a012f-a8dc-4efe-83a0-da5e874114de"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nflow hedges and unrealized gains and losses on the portion of these foreign currency forward contracts and foreign currency options that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the table below). Realized gains and losses of such contracts are recognized in revenue when the sale of product in the currency being hedged is recognized and in operating expense when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income (loss) and fair value changes of excluded portions in the same line item in our consolidated statements of income that have been impacted by the hedged item.\n\nThe notional amount of foreign currency forward contracts and foreign currency options that were entered into to hedge forecasted revenue and operating expense is summarized as follows:\n\n|                                                                                                   | %AF;A@3> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>?AG@F glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | %AF;A@3> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>?AG@F glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                                                                                      | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                                                                                      |\n| Euro                                                                                              | $ 1,495.5                                                                                                                                                                                                                                                                                             | $ 1,828.0                                                                                                                                                                                                                                                                                             |\n| British pound                                                                                     | 162.8                                                                                                                                                                                                                                                                                                 | 166.2                                                                                                                                                                                                                                                                                                 |\n| Japanese yen                                                                                      | -                                                                                                                                                                                                                                                                                                     | 72.7                                                                                                                                                                                                                                                                                                  |\n| Canadian dollar                                                                                   | 57.2                                                                                                                                                                                                                                                                                                  | 59.9                                                                                                                                                                                                                                                                                                  |\n| Total foreign currency forward contracts                                                          | $ 1,715.5                                                                                                                                                                                                                                                                                             | $ 2,126.8                                                                                                                                                                                                                                                                                             |\n\nThe pre-tax portion of the fair value of these foreign currency forward contracts and foreign currency options that were included in accumulated other comprehensive income (loss) in total equity is summarized as follows:\n\n|                                                                                                   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    |\n| Unrealized gains                                                                                  | 29.9                                                                                                                                                                                                                                                                                                | 60.8                                                                                                                                                                                                                                                                                                | -                                                                                                                                                                                                                                                                                                   |\n| Unrealized (losses)                                                                               | (21.3)                                                                                                                                                                                                                                                                                              | (7.0)                                                                                                                                                                                                                                                                                               | (212.5)                                                                                                                                                                                                                                                                                             |\n| Net unrealized gains (losses)                                                                     | 8.6                                                                                                                                                                                                                                                                                                 | 53.8                                                                                                                                                                                                                                                                                                | (212.5)                                                                                                                                                                                                                                                                                             |\n\nWe expect the net unrealized gains of approximately $8.6 million to be settled over the next 12 months, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties' credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of December 31, 2022 and 2021, credit risk did not materially change the fair value of our foreign currency forward contracts.\n\nThe following table summarizes the effect of foreign currency forward contracts designated as hedging instruments in our consolidated statements of income:\n\n## glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>\n\n| %7F glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@Eglyph<c=12,font=/PIIBCD+FranklinGothic-Book>glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book>   | %7F glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@Eglyph<c=12,font=/PIIBCD+FranklinGothic-Book>glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book>   | %7F glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@Eglyph<c=12,font=/PIIBCD+FranklinGothic-Book>glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book>   | %7F glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@Eglyph<c=12,font=/PIIBCD+FranklinGothic-Book>glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book>   | %7F glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@Eglyph<c=12,font=/PIIBCD+FranklinGothic-Book>glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> )75A9@;L76 ;@ &B7D3F;@9  @5A?7 glyph<c=6,font=/PIIBCD+FranklinGothic-Book>;@ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book>   | %7F glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@Eglyph<c=12,font=/PIIBCD+FranklinGothic-Book>glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> )75A9@;L76 ;@ &B7D3F;@9  @5A?7 glyph<c=6,font=/PIIBCD+FranklinGothic-Book>;@ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book>   | %7F glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@Eglyph<c=12,font=/PIIBCD+FranklinGothic-Book>glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> )75A9@;L76 ;@ &B7D3F;@9  @5A?7 glyph<c=6,font=/PIIBCD+FranklinGothic-Book>;@ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book>   | %7F glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@Eglyph<c=12,font=/PIIBCD+FranklinGothic-Book>glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> )75A9@;L76 ;@ &B7D3F;@9  @5A?7 glyph<c=6,font=/PIIBCD+FranklinGothic-Book>;@ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book>   |\n|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| #A53F;A@                                                                                                                                                                                       | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>               | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>               | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>               | #A53F;A@                                                                                                                                                                                                                                                                                                                        | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                |\n| Revenue                                                                                                                                                                                        | $ 201.6                                                                                                                                                                                        | $ (60.0)                                                                                                                                                                                       | $ 18.3                                                                                                                                                                                         | Revenue                                                                                                                                                                                                                                                                                                                         | $ (8.6)                                                                                                                                                                                                                                                                                                                         | $ (8.4)                                                                                                                                                                                                                                                                                                                         | $ (9.9)                                                                                                                                                                                                                                                                                                                         |\n| Operating expense                                                                                                                                                                              | (5.5)                                                                                                                                                                                          | (0.8)                                                                                                                                                                                          | 3.3                                                                                                                                                                                            | Operating expense                                                                                                                                                                                                                                                                                                               | -                                                                                                                                                                                                                                                                                                                               | -                                                                                                                                                                                                                                                                                                                               | -                                                                                                                                                                                                                                                                                                                               |\n\n## @F7D7EF )3F7 glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@FD35FE glyph<c=10,font=/PIIBCD+FranklinGothic-Book> glyph<c=31,font=/PIIBCD+FranklinGothic-Book>769;@9 @EFDG?7@FE\n\nWe have entered into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing.\n\n## glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><B3@3AB &/B3 'E/> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=<B@/1BA\n\nIn connection with the issuance of our 2.90% Senior Notes due September 15, 2020, we entered into interest rate swaps with an aggregate notional amount of $675.0 million, which were originally set to expire on September 15, 2020. The interest rate swap contracts were designated as hedges of the fair value changes in our 2.90% Senior Notes attributable to changes in interest rates. In May 2020 we settled our interest rate swap contracts, in conjunction with our early redemption of our 2.90% Senior Notes, resulting in a gain of approximately $3.3 million, which was recorded as a component of interest expense in our consolidated statements of income during the year ended December 31, 2020.",
        "metadata": {
            "page": 146
        },
        "id": "2e93d126-b93b-4b6b-8569-bfbe6a68da35"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\n%7F  @H7EF?7@F glyph<c=31,font=/PIIBCD+FranklinGothic-Book>7697E glyph<c=10,font=/PIIBCD+FranklinGothic-Book> glyph<c=31,font=/PIIBCD+FranklinGothic-Book>769;@9 @EFDG?7@FE\n\nIn February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately 5.0% to approximately 49.9%. The share purchase transaction was completed in November 2018 and, upon closing, we paid 759.5 billion South Korean won ($676.6 million) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis related to this transaction was exposed to the currency fluctuations in the South Korean won.\n\nIn order to mitigate these currency fluctuations between the U.S. dollar and South Korean won, we entered into foreign currency forward contracts. These contracts were designated as net investment hedges. In April 2022 we completed the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics and closed these foreign currency forward contracts. Upon completing this sale, the cumulative gains on our net investment hedges of $57.0 million were reclassified from accumulated other comprehensive income (loss) and reflected within the total pre-tax gain recognized from the sale, which was recorded in other (income) expense, net in our consolidated statements of income. For additional information on the sale of our equity interest in Samsung Bioepis please read \"=B3 glyph<c=13,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>7A>=A7B7=<A , to these consolidated financial statements.\n\nPrior to the sale of our 49.9% equity interest in Samsung Bioepis, we recognized changes in the spot exchange rate of these foreign currency forward contracts in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of $10.6 million as of December 31, 2021. We excluded fair value changes related to the forward rate from our hedging relationship and amortized the forward points in other (income) expense, net in our consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected net losses of $3.6 million as of December 31, 2021.\n\nThe following table summarizes the effect of our net investment hedges in our consolidated financial statements:\n\n| %7F glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@Eglyph<c=12,font=/PIIBCD+FranklinGothic-Book>glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> )75A9@;L76 ;@ &F:7D glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A?BD7:7@E;H7  @5A?7 glyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>8875F;H7   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> %7F glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@Eglyph<c=12,font=/PIIBCD+FranklinGothic-Book>glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> )75A9@;L76 ;@ &F:7D glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A?BD7:7@E;H7  @5A?7 %7F glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@Eglyph<c=12,font=/PIIBCD+FranklinGothic-Book>glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> )75A9@;L76 ;@ %7F  @5A?7   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> %7F glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@Eglyph<c=12,font=/PIIBCD+FranklinGothic-Book>glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> )75A9@;L76 ;@ &F:7D glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A?BD7:7@E;H7  @5A?7 %7F glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@Eglyph<c=12,font=/PIIBCD+FranklinGothic-Book>glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> )75A9@;L76 ;@ %7F  @5A?7   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> %7F glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@Eglyph<c=12,font=/PIIBCD+FranklinGothic-Book>glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> )75A9@;L76 ;@ &F:7D glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A?BD7:7@E;H7  @5A?7 %7F glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@Eglyph<c=12,font=/PIIBCD+FranklinGothic-Book>glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> )75A9@;L76 ;@ %7F  @5A?7   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> %7F glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@Eglyph<c=12,font=/PIIBCD+FranklinGothic-Book>glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> )75A9@;L76 ;@ &F:7D glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A?BD7:7@E;H7  @5A?7 %7F glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@Eglyph<c=12,font=/PIIBCD+FranklinGothic-Book>glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> )75A9@;L76 ;@ %7F  @5A?7   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> %7F glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@Eglyph<c=12,font=/PIIBCD+FranklinGothic-Book>glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> )75A9@;L76 ;@ &F:7D glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A?BD7:7@E;H7  @5A?7 %7F glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@Eglyph<c=12,font=/PIIBCD+FranklinGothic-Book>glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> )75A9@;L76 ;@ %7F  @5A?7   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> %7F glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@Eglyph<c=12,font=/PIIBCD+FranklinGothic-Book>glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> )75A9@;L76 ;@ &F:7D glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A?BD7:7@E;H7  @5A?7 %7F glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@Eglyph<c=12,font=/PIIBCD+FranklinGothic-Book>glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> )75A9@;L76 ;@ %7F  @5A?7   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> %7F glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@Eglyph<c=12,font=/PIIBCD+FranklinGothic-Book>glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> )75A9@;L76 ;@ &F:7D glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A?BD7:7@E;H7  @5A?7 %7F glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@Eglyph<c=12,font=/PIIBCD+FranklinGothic-Book>glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> )75A9@;L76 ;@ %7F  @5A?7   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> %7F glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@Eglyph<c=12,font=/PIIBCD+FranklinGothic-Book>glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> )75A9@;L76 ;@ &F:7D glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A?BD7:7@E;H7  @5A?7 %7F glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@Eglyph<c=12,font=/PIIBCD+FranklinGothic-Book>glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> )75A9@;L76 ;@ %7F  @5A?7   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> %7F glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@Eglyph<c=12,font=/PIIBCD+FranklinGothic-Book>glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> )75A9@;L76 ;@ &F:7D glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A?BD7:7@E;H7  @5A?7 %7F glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@Eglyph<c=12,font=/PIIBCD+FranklinGothic-Book>glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> )75A9@;L76 ;@ %7F  @5A?7   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> %7F glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@Eglyph<c=12,font=/PIIBCD+FranklinGothic-Book>glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> )75A9@;L76 ;@ &F:7D glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A?BD7:7@E;H7  @5A?7 %7F glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@Eglyph<c=12,font=/PIIBCD+FranklinGothic-Book>glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> )75A9@;L76 ;@ %7F  @5A?7   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> %7F glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@Eglyph<c=12,font=/PIIBCD+FranklinGothic-Book>glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> )75A9@;L76 ;@ &F:7D glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A?BD7:7@E;H7  @5A?7 %7F glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@Eglyph<c=12,font=/PIIBCD+FranklinGothic-Book>glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> )75A9@;L76 ;@ %7F  @5A?7   |\n|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| #A53F;A@                                                                                                                                                                                                                                                                                                                                                                           | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | #A53F;A@                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | #A53F;A@                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |\n| Gains (losses) on net investment hedge (1)                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | $20.4 $ 46.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | $(35.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Gains (losses) on net investment hedge (1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | $(3.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | $(3.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | $ 4.5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Other (income) expense (1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | $(4.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | $(0.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | $ 2.9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |\n\nFor additional information on our collaboration arrangements with Samsung Bioepis, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>A , to these consolidated financial statements.\n\n## glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD7;9@ glyph<c=26,font=/PIIBCD+FranklinGothic-Book>GDD7@5K glyph<c=29,font=/PIIBCD+FranklinGothic-Book>ADI3D6 glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@FD35FE glyph<c=10,font=/PIIBCD+FranklinGothic-Book> &F:7D glyph<c=27,font=/PIIBCD+FranklinGothic-Book>7D;H3F;H7 @EFDG?7@FE\n\nWe also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.\n\nThe aggregate notional amount of these outstanding foreign currency forward contracts was $1,238.8 million and $1,268.0 million as of December 31, 2022 and 2021, respectively. Net losses of $34.7 million, net losses of $43.3 million and net gains of $30.1 million related to these contracts were recorded as a component of other (income) expense, net for the years ended December 31, 2022, 2021 and 2020, respectively.\n\n## *G??3DK A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>7D;H3F;H7 @EFDG?7@FE\n\nWhile certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.",
        "metadata": {
            "page": 147
        },
        "id": "48581be2-770f-4c0f-bb73-280ac2aa64c8"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nThe following table summarizes the fair value and presentation in our consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:\n\n|                                                                                                                                                                                                                                                                                                                                                                                |                                                                   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                                                                                                                              | glyph<c=25,font=/PIIBCD+FranklinGothic-Book>3>3@57 *:77F #A53F;A@ | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                           | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                           |\n| glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>/A6 glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>:=E glyph<c=28,font=/PIIBDE+FranklinGothic-BookItal>3257<5 glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><AB@C;3<BAglyph<c=20,font=/PIIBDE+FranklinGothic-BookItal>                                                                                                      |                                                                   |                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                            |\n| Asset derivative instruments                                                                                                                                                                                                                                                                                                                                                   | Other current assets                                              | 37.9                                                                                                                                                                                                                                       | 66.2                                                                                                                                                                                                                                       |\n|                                                                                                                                                                                                                                                                                                                                                                                | Investments and other assets                                      | -                                                                                                                                                                                                                                          | 5.5                                                                                                                                                                                                                                        |\n| Liability derivative instruments                                                                                                                                                                                                                                                                                                                                               | Accrued expense and other                                         | 18.4                                                                                                                                                                                                                                       | 6.6                                                                                                                                                                                                                                        |\n| \"3B glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><D3AB;3<B glyph<c=28,font=/PIIBDE+FranklinGothic-BookItal>3257<5 glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><AB@C;3<BAglyph<c=20,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=5,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=6,font=/PIIBDE+FranklinGothic-BookItal> |                                                                   |                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                            |\n| Asset derivative instruments                                                                                                                                                                                                                                                                                                                                                   | Other current assets                                              | -                                                                                                                                                                                                                                          | 4.1                                                                                                                                                                                                                                        |\n| #B63@ glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>3@7D/B7D3 glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><AB@C;3<BAglyph<c=20,font=/PIIBDE+FranklinGothic-BookItal>                                                                                                                                                                                                     |                                                                   |                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                            |\n| Asset derivative instruments                                                                                                                                                                                                                                                                                                                                                   | Other current assets                                              | 25.1                                                                                                                                                                                                                                       | 5.1                                                                                                                                                                                                                                        |\n| Liability derivative instruments                                                                                                                                                                                                                                                                                                                                               | Accrued expense and other                                         | 7.6                                                                                                                                                                                                                                        | 4.2                                                                                                                                                                                                                                        |\n\n## %AF7 glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=23,font=/PIIBCD+FranklinGothic-Book> 'DAB7DFKglyph<c=9,font=/PIIBCD+FranklinGothic-Book> '>3@F 3@6 glyph<c=28,font=/PIIBCD+FranklinGothic-Book>CG;B?7@F\n\nProperty, plant and equipment are recorded at historical cost, net of accumulated depreciation. Components of property, plant and equipment, net are summarized as follows:\n\n|                                                                                                   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                           | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                           |\n| Land                                                                                              | $ 202.4                                                                                                                                                                                                                                    | $ 207.5                                                                                                                                                                                                                                    |\n| Buildings                                                                                         | 1,592.9                                                                                                                                                                                                                                    | 1,699.7                                                                                                                                                                                                                                    |\n| Leasehold improvements                                                                            | 107.7                                                                                                                                                                                                                                      | 121.0                                                                                                                                                                                                                                      |\n| Machinery and equipment                                                                           | 1,611.5                                                                                                                                                                                                                                    | 1,585.5                                                                                                                                                                                                                                    |\n| Computer software and hardware                                                                    | 999.9                                                                                                                                                                                                                                      | 971.6                                                                                                                                                                                                                                      |\n| Furniture and fixtures                                                                            | 61.1                                                                                                                                                                                                                                       | 67.4                                                                                                                                                                                                                                       |\n| Construction in progress                                                                          | 888.8                                                                                                                                                                                                                                      | 770.3                                                                                                                                                                                                                                      |\n| Total cost                                                                                        | 5,464.3                                                                                                                                                                                                                                    | 5,423.0                                                                                                                                                                                                                                    |\n| Less: accumulated depreciation                                                                    | (2,165.7)                                                                                                                                                                                                                                  | (2,006.6)                                                                                                                                                                                                                                  |\n| Total property, plant and equipment, net                                                          | $ 3,298.6                                                                                                                                                                                                                                  | $ 3,416.4                                                                                                                                                                                                                                  |\n\nDepreciation expense totaled $272.4 million, $235.3 million and $201.9 million for the years ended December 31, 2022, 2021 and 2020, respectively.\n\nFor the years ended December 31, 2022, 2021 and 2020, we capitalized interest costs related to construction in progress totaling approximately $17.1 million, $36.3 million and $65.2 million, respectively.\n\n## *A>AF:GD@glyph<c=9,font=/PIIBCD+FranklinGothic-Book> *I;FL7D>3@6 $3@G835FGD;@9 glyph<c=29,font=/PIIBCD+FranklinGothic-Book>35;>;FK\n\nIn order to support our future growth and drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. Upon completion, this facility will include 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of December 31, 2022 and 2021, we had approximately $711.1 million and $677.0 million, respectively, capitalized as construction in progress related to this facility. In the second quarter of 2021 a portion of the facility received a Good Manufacturing Practice multi-product license from the Swiss Agency for Therapeutic Products, resulting in approximately $1.2 billion of fixed assets being placed in service during the second quarter of 2021. Solothurn has been approved for the manufacture of ADUHELM and",
        "metadata": {
            "page": 148
        },
        "id": "05e1eacf-1e3f-42e8-9f00-af5f46027f5d"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nLE , EMBI by the FDA. We estimate the second manufacturing suite at the Solothurn facility will be operational by the end of 2023.\n\n## glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=18,font=/PIIBCD+FranklinGothic-Book> glyph<c=25,font=/PIIBCD+FranklinGothic-Book>DA36I3K glyph<c=25,font=/PIIBCD+FranklinGothic-Book>G;>6;@9 *3>7\n\nIn September 2022 we completed the sale of our building and land parcel located at 125 Broadway for an aggregate sales price of approximately $603.0 million, which is inclusive of a $10.8 million tenant allowance. This sale resulted in a pre-tax gain on sale of approximately $503.7 million, net of transaction costs, which is reflected within gain on sale of building in our consolidated statements of income for the year ended December 31, 2022. This transaction included approximately $79.2 million of property, plant and equipment, net, which comprised of approximately $72.6 million for buildings, approximately $1.6 million for land and approximately $5.0 million for machinery and equipment.\n\n## %AF7 glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=23,font=/PIIBCD+FranklinGothic-Book> #73E7E\n\nWe lease real estate, including laboratory and office space, and certain equipment.\n\nOur leases have remaining lease terms ranging from less than one year to eight years. Certain leases include one or more options to renew, exercised at our sole discretion, with renewal terms that can extend the lease term from one year to six years.\n\nIn addition, we sublease certain real estate to third parties. Our sublease portfolio consists of operating leases, with remaining lease terms ranging from two years to six years. Our subleases do not include an option to renew as they are coterminous with our operating leases.\n\nAll of our leases qualify as operating leases. The following table summarizes the presentation in our consolidated balance sheets of our operating leases:\n\n|                                                                                                       |                                                                   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|-------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book>     | glyph<c=25,font=/PIIBCD+FranklinGothic-Book>3>3@57 E:77F >A53F;A@ | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                           | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                           |\n| glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>AA3BAglyph<c=20,font=/PIIBDE+FranklinGothic-BookItal> |                                                                   |                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                            |\n| Operating lease assets                                                                                | Operating lease assets                                            | $ 403.9                                                                                                                                                                                                                                    | $ 375.4                                                                                                                                                                                                                                    |\n| 7/07:7B73A                                                                                            |                                                                   |                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                            |\n| Current operating lease liabilities                                                                   | Accrued expense and other                                         | $ 97.2                                                                                                                                                                                                                                     | $ 89.1                                                                                                                                                                                                                                     |\n| Non-current operating lease liabilities                                                               | Long-term operating lease liabilities                             | 333.0                                                                                                                                                                                                                                      | 330.4                                                                                                                                                                                                                                      |\n| Total operating lease liabilities                                                                     |                                                                   | $ 430.2                                                                                                                                                                                                                                    | $ 419.5                                                                                                                                                                                                                                    |\n\nThe following table summarizes the effect of lease costs in our consolidated statements of income:\n\n|                                                                                                   |                                     | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------------------------------------------------------------------------------------------|-------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | @5A?7 *F3F7?7@F #A53F;A@            | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    |\n| Operating lease cost                                                                              | Research and development            | $ 2.0                                                                                                                                                                                                                                                                                               | $ 3.4                                                                                                                                                                                                                                                                                               | $ 5.2                                                                                                                                                                                                                                                                                               |\n|                                                                                                   | Selling, general and administrative | 95.9                                                                                                                                                                                                                                                                                                | 95.9                                                                                                                                                                                                                                                                                                | 93.1                                                                                                                                                                                                                                                                                                |\n| Variable lease cost                                                                               | Research and development            | 0.4                                                                                                                                                                                                                                                                                                 | 0.8                                                                                                                                                                                                                                                                                                 | 1.1                                                                                                                                                                                                                                                                                                 |\n|                                                                                                   | Selling, general and administrative | 25.4                                                                                                                                                                                                                                                                                                | 25.7                                                                                                                                                                                                                                                                                                | 21.1                                                                                                                                                                                                                                                                                                |\n| Sublease income                                                                                   | Selling, general and administrative | (24.0)                                                                                                                                                                                                                                                                                              | (23.9)                                                                                                                                                                                                                                                                                              | (24.2)                                                                                                                                                                                                                                                                                              |\n|                                                                                                   | Other (income) expense, net         | (4.1)                                                                                                                                                                                                                                                                                               | (4.0)                                                                                                                                                                                                                                                                                               | (3.9)                                                                                                                                                                                                                                                                                               |\n| Net lease cost                                                                                    |                                     | $ 95.6                                                                                                                                                                                                                                                                                              | $ 97.9                                                                                                                                                                                                                                                                                              | $ 92.4                                                                                                                                                                                                                                                                                              |",
        "metadata": {
            "page": 149
        },
        "id": "85439c4c-4d75-4a02-a2c7-65ebbed8a09a"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nVariable lease cost primarily related to operating expense, taxes and insurance associated with our operating leases. As these costs are generally variable in nature, they are not included in the measurement of the operating lease asset and related lease liability.\n\nThe minimum lease payments for the next five years and thereafter is expected to be as follows:\n\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book>   |   glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book> |\n|-----------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| 2023                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                       111   |\n| 2024                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                       107   |\n| 2025                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                        80.5 |\n| 2026                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                        65.7 |\n| 2027                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                        69.5 |\n| Thereafter                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                        36.6 |\n| Total lease payments                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                       470.3 |\n| Less: interest                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                        40.1 |\n| Present value of operating lease liabilities                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                       430.2 |\n\nThe weighted average remaining lease term and weighted average discount rate of our operating leases are as follows:\n\n|                                                | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n|                                                | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                           | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                           |\n| Weighted average remaining lease term in years | 4.64                                                                                                                                                                                                                                       | 5.43                                                                                                                                                                                                                                       |\n| Weighted average discount rate                 | 3.7 %                                                                                                                                                                                                                                      | 2.9 %                                                                                                                                                                                                                                      |\n\nSupplemental disclosure of cash flow information related to our operating leases included in cash flow provided by operating activities in our consolidated statements of cash flow is as follows:\n\n|                                                                                                   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                           | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                           | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                           |\n| Cash paid for amounts included in the measurement of lease liabilities                            | $ 107.4                                                                                                                                                                                                                                    | $ 105.8                                                                                                                                                                                                                                    | $ 100.2                                                                                                                                                                                                                                    |\n| Operating lease assets obtained in exchange for lease obligations                                 | 108.3                                                                                                                                                                                                                                      | 18.1                                                                                                                                                                                                                                       | 59.0                                                                                                                                                                                                                                       |\n\n## glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=18,font=/PIIBCD+FranklinGothic-Book> glyph<c=25,font=/PIIBCD+FranklinGothic-Book>DA36I3K glyph<c=25,font=/PIIBCD+FranklinGothic-Book>G;>6;@9 *3>7 3@6 #73E7435= +D3@E35F;A@\n\nIn connection with the sale of our building at 125 Broadway, we simultaneously leased back the building for a term of approximately 5.5 years, which resulted in the recognition of approximately $168.2 million in new lease liabilities and right-of-use assets recorded within our consolidated balance sheets as of December 31, 2022. The sale and immediate leaseback of this building qualified for sale and leaseback treatment and is classified as an operating lease. For additional information on the sale of our building, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> $@=>3@BGglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> $:/<B /<2 glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>?C7>;3<B , to these consolidated financial statements.\n\n## glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book> glyph<c=25,font=/PIIBCD+FranklinGothic-Book>;@@7K *FD77F #73E7 $A6;8;53F;A@\n\nIn September 2022 we entered into an agreement to partially terminate a portion of our lease located at 300 Binney Street, Cambridge MA, as well as to reduce the lease term for the majority of the remaining space. The agreement was driven by our 2022 efforts to reduce costs by consolidating real estate locations. The transaction was treated as a lease modification as of the effective date and resulted in the derecognition of right of use assets of approximately $47.4 million and lease liabilities of approximately $52.7 million, which resulted in a gain of approximately $5.3 million, which was recorded within restructuring charges in our consolidated statements of income for the year ended December 31, 2022.",
        "metadata": {
            "page": 150
        },
        "id": "748e6418-5fc7-413b-9c45-e3be052c94d6"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\n## %AF7 glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=23,font=/PIIBCD+FranklinGothic-Book> @674F76@7EE\n\nOur indebtedness is summarized as follows:\n\n|                                                                                                                   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|-------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book>                 | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                           | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                           |\n| glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>C@@3<B >=@B7=<glyph<c=20,font=/PIIBDE+FranklinGothic-BookItal>    |                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                            |\n| 3.625% Senior Notes due September 15, 2022 (1)                                                                    | $ - $                                                                                                                                                                                                                                      | 999.1                                                                                                                                                                                                                                      |\n| Current portion of notes payable                                                                                  | $ - $                                                                                                                                                                                                                                      | 999.1                                                                                                                                                                                                                                      |\n| \"=<glyph<c=8,font=/PIIBDE+FranklinGothic-BookItal>1C@@3<B >=@B7=<glyph<c=20,font=/PIIBDE+FranklinGothic-BookItal> |                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                            |\n| 4.050% Senior Notes due September 15, 2025                                                                        | $ 1,744.7                                                                                                                                                                                                                                  | $ 1,742.9                                                                                                                                                                                                                                  |\n| 2.250% Senior Notes due May 1, 2030                                                                               | 1,492.9                                                                                                                                                                                                                                    | 1,492.0                                                                                                                                                                                                                                    |\n| 5.200% Senior Notes due September 15, 2045                                                                        | 1,100.3                                                                                                                                                                                                                                    | 1,099.9                                                                                                                                                                                                                                    |\n| 3.150% Senior Notes due May 1, 2050                                                                               | 1,473.8                                                                                                                                                                                                                                    | 1,473.2                                                                                                                                                                                                                                    |\n| 3.250% Senior Notes due February 15, 2051                                                                         | 469.3                                                                                                                                                                                                                                      | 466.0                                                                                                                                                                                                                                      |\n| Non-current portion of notes payable                                                                              | $ 6,281.0                                                                                                                                                                                                                                  | $ 6,274.0                                                                                                                                                                                                                                  |\n\n## glyph<c=28,font=/PIIBCD+FranklinGothic-Book>J5:3@97 &887D\n\nIn February 2021 we completed our private offer to exchange (Exchange Offer) our tendered 5.200% Senior Notes due September 15, 2045 (2045 Senior Notes) for a new series of 3.250% Senior Notes due February 15, 2051 (2051 Senior Notes) and cash, and an offer to purchase our tendered 2045 Senior Notes for cash.\n\nAn aggregate principal amount of approximately $624.6 million of our 2045 Senior Notes was exchanged for an aggregate principal amount of approximately $700.7 million of our 2051 Senior Notes and aggregate cash payments of approximately $151.8 million. Our Exchange Offer has been accounted for as a debt modification; as such, the cash component has been reflected as additional debt discount and is amortized as an adjustment to interest expense over the term of our 2051 Senior Notes.\n\nIn addition, we redeemed an aggregate principal amount of approximately $8.9 million of our 2045 Senior Notes for aggregate cash payments of approximately $12.1 million, excluding accrued and unpaid interest. The redemption has been accounted for as a debt extinguishment; as such, we recognized a pre-tax charge of $3.2 million upon the extinguishment of such 2045 Senior Notes. This charge, which was recognized in interest expense in other (income) expense, net in our consolidated statements of income for the year ended December 31, 2021, reflects the payment of an early call premium and the write-off of the remaining unamortized original debt issuance costs and discount balances associated with such 2045 Senior Notes.\n\nUpon settlement, we also made aggregate cash payments of approximately $13.8 million to settle all accrued and unpaid interest from the last interest payment date on our 2045 Senior Notes that were exchanged or redeemed. We incurred approximately $6.1 million of costs associated with our Exchange Offer, which was recognized in interest expense in other (income) expense, net in our consolidated statements of income for the year ended December 31, 2021.",
        "metadata": {
            "page": 151
        },
        "id": "7e6b46d8-0ca1-447c-bf26-4c97f0bfb1b1"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+*\n\n## glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book> *7@;AD %AF7E\n\nOn April 30, 2020, we issued senior unsecured notes for an aggregate principal amount of $3.0 billion (2020 Senior Notes), consisting of the following:\n\n- \u00b7 $1.5 billion aggregate principal amount of 2.25% Senior Notes due May 1, 2030, valued at 99.973% of par; and\n- \u00b7 $1.5 billion aggregate principal amount of 3.15% Senior Notes due May 1, 2050, valued at 99.174% of par.\n\nOur 2020 Senior Notes are senior unsecured obligations and may be redeemed at our option at any time at 100.0% of the principal amount plus accrued interest and, until a specified period before maturity, a specified makewhole amount. Our 2020 Senior Notes contain a change-of-control provision that, under certain circumstances, may require us to purchase our 2020 Senior Notes at a price equal to 101.0% of the principal amount plus accrued and unpaid interest to the date of repurchase.\n\nWe incurred approximately $24.4 million of costs associated with this offering, which have been recorded as a reduction to the carrying amount of the debt on our consolidated balance sheet. These costs will be amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. The discounts will be amortized as additional interest expense over the period from issuance through maturity using the effective interest rate method. Interest on our 2020 Senior Notes is payable May 1 and November 1 of each year, commencing November 1, 2020.\n\n## glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=18,font=/PIIBCD+FranklinGothic-Book> *7@;AD %AF7E\n\nThe following is a summary of our currently outstanding senior unsecured notes issued in 2015 (the 2015 Senior Notes), consisting of the following:\n\n- \u00b7 $1.75 billion aggregate principal amount of 4.05% Senior Notes due September 15, 2025, valued at 99.764% of par; and\n- \u00b7 $1.12 billion aggregate principal amount of 5.20% Senior Notes due September 15, 2045, valued at 99.294% of par.\n\nThe original costs associated with this offering of approximately $47.5 million have been recorded as a reduction to the carrying amount of the debt in our consolidated balance sheets. These costs along with the discounts will be amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity.\n\nOur 2015 Senior Notes are senior unsecured obligations and may be redeemed at our option at any time at 100.0% of the principal amount plus accrued interest and a specified make-whole amount. Our 2015 Senior Notes contain a change of control provision that may require us to purchase the notes at a price equal to 101.0% of the principal amount plus accrued and unpaid interest to the date of purchase under certain circumstances.\n\nOn September 15, 2015, we issued $1.5 billion aggregate principal amount of 2.90% Senior Notes due September 15, 2020, at 99.792% of par. Our 2.90% Senior Notes were senior unsecured obligations. In connection with the 2.90% Senior Notes, we entered into interest rate swap contracts where we received a fixed rate and paid a variable rate. In May 2020 we used the net proceeds from the sale of our 2020 Senior Notes to redeem our 2.90% Senior Notes prior to their maturity and recognized a net pre-tax charge of $9.4 million upon the extinguishment of these notes. This charge, which was recognized in interest expense in other (income) expense, net in our consolidated statements of income for the year ended December 31, 2020, reflects the payment of a $12.7 million early call premium and the write off of remaining unamortized original debt issuance costs and discount balances, partially offset by a $3.3 million gain related to the settlement of the associated interest rate swap contracts. For additional information on our interest rate contracts, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=10,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>3@7D/B7D3 glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><AB@C;3<BAglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> to these consolidated financial statements.\n\n## glyph<c=13,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=16,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=15,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=2,font=/PIIBDE+FranklinGothic-BookItal> '3<7=@ \"=B3A 2C3 '3>B3;03@ glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=15,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=10,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>\n\nOn September 15, 2015, we issued $1.0 billion aggregate principal amount of our 3.625% Senior Notes due September 15, 2022, at 99.920% of par. Our 3.625% Senior Notes were senior unsecured obligations. In July 2022 we redeemed our 3.625% Senior Notes prior to their maturity and recognized a net pre-tax charge of approximately $2.4 million upon the extinguishment of these Senior Notes, which primarily reflects the payment of an early call premium as well as the write-off of remaining unamortized original debt issuance costs and discount balances.",
        "metadata": {
            "page": 152
        },
        "id": "df14dbfa-6f63-4fc7-8316-25649d170297"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nThese charges were recognized as interest expense in other (income) expense, net in our consolidated statements of income for the year ended December 31, 2022.\n\n## glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book> glyph<c=26,font=/PIIBCD+FranklinGothic-Book>D76;F glyph<c=29,font=/PIIBCD+FranklinGothic-Book>35;>;FK\n\nIn January 2020 we entered into a $1.0 billion, five-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. This revolving credit facility replaced the revolving credit facility that we entered into in August 2015. As of December 31, 2022, we had no outstanding borrowings and were in compliance with all covenants under this facility.\n\n## glyph<c=27,font=/PIIBCD+FranklinGothic-Book>74F $3FGD;FK\n\nThe total gross payments due under our debt arrangements are as follows:\n\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>   |\n|-----------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| 2023                                                                                                | $ -                                                                                                                                                                                                                                                                                                                                                                                                                         |\n| 2024                                                                                                | -                                                                                                                                                                                                                                                                                                                                                                                                                           |\n| 2025                                                                                                | 1,750.0                                                                                                                                                                                                                                                                                                                                                                                                                     |\n| 2026                                                                                                | -                                                                                                                                                                                                                                                                                                                                                                                                                           |\n| 2027                                                                                                | -                                                                                                                                                                                                                                                                                                                                                                                                                           |\n| 2028 and thereafter                                                                                 | 4,817.3                                                                                                                                                                                                                                                                                                                                                                                                                     |\n| Total debt                                                                                          | $ 6,567.3                                                                                                                                                                                                                                                                                                                                                                                                                   |\n| Less: debt discount and issuance fees                                                               | (286.3)                                                                                                                                                                                                                                                                                                                                                                                                                     |\n| Total long-term debt                                                                                | $ 6,281.0                                                                                                                                                                                                                                                                                                                                                                                                                   |\n\nThe fair value of our debt is disclosed in \"=B3 glyph<c=18,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>/7@ */:C3 !3/AC@3;3<BAglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> to these consolidated financial statements.\n\n|                                                                                                                                           | glyph<c=28,font=/PIIBCD+FranklinGothic-Book>CG;FK   |\n|-------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------|\n| %AF7 glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=17,font=/PIIBCD+FranklinGothic-Book>glyph<c=23,font=/PIIBCD+FranklinGothic-Book> |                                                     |\n\n## 'D787DD76 *FA5=\n\nWe have 8.0 million shares of Preferred Stock authorized, of which 1.75 million shares are authorized as Series A, 1.0 million shares are authorized as Series X junior participating and 5.25 million shares are undesignated. Shares may be issued without a vote or action of shareholders from time to time in classes or series with the designations, powers, preferences and the relative, participating, optional or other special rights of the shares of each such class or series and any qualifications, limitations or restrictions thereon as set forth in the instruments governing such shares. Any such Preferred Stock may rank prior to common stock as to dividend rights, liquidation preference or both, and may have full or limited voting rights and may be convertible into shares of common stock. No shares of Preferred Stock were issued and outstanding during 2022, 2021 and 2020.\n\n## glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A??A@ *FA5=\n\nThe following table describes the number of shares authorized, issued and outstanding of our common stock as of December 31, 2022, 2021 and 2020:\n\n|                                                                                                   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>GF:AD;L76                                                                                                                                                                                                                                                                                                                                                                       | EEG76                                                                                                                                                                                                                                                                                                                                                                                                                       | &GFEF3@6;@9                                                                                                                                                                                                                                                                                                                                                                                                                 | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>GF:AD;L76                                                                                                                                                                                                                                                                                                                                                                       | EEG76                                                                                                                                                                                                                                                                                                                                                                                                                       | &GFEF3@6;@9                                                                                                                                                                                                                                                                                                                                                                                                                 | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>GF:AD;L76                                                                                                                                                                                                                                                                                                                                                                       | EEG76                                                                                                                                                                                                                                                                                                                                                                                                                       | &GFEF3@6;@9                                                                                                                                                                                                                                                                                                                                                                                                                 |\n| Common stock                                                                                      | 1,000.0                                                                                                                                                                                                                                                                                                                                                                                                                     | 167.9                                                                                                                                                                                                                                                                                                                                                                                                                       | 144.0                                                                                                                                                                                                                                                                                                                                                                                                                       | 1,000.0                                                                                                                                                                                                                                                                                                                                                                                                                     | 170.8                                                                                                                                                                                                                                                                                                                                                                                                                       | 147.0                                                                                                                                                                                                                                                                                                                                                                                                                       | 1,000.0                                                                                                                                                                                                                                                                                                                                                                                                                     | 176.2                                                                                                                                                                                                                                                                                                                                                                                                                       | 152.4                                                                                                                                                                                                                                                                                                                                                                                                                       |\n\n## *:3D7 )7BGD5:3E7E\n\nIn October 2020 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (2020 Share Repurchase Program). Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately 3.6 million, 6.0 million and 1.6 million shares of our common stock at a cost of approximately $750.0 million, $1.8 billion and $400.0 million during the years ended December",
        "metadata": {
            "page": 153
        },
        "id": "0b202d98-85df-48b7-9046-0567d942b856"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\n31, 2022, 2021 and 2020, respectively. Approximately $2.1 billion remained available under our 2020 Share Repurchase Program as of December 31, 2022.\n\nIn December 2019 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (December 2019 Share Repurchase Program), which was completed as of September 30, 2020. All shares repurchased under our December 2019 Share Repurchase Program were retired. Under our December 2019 Share Repurchase Program, we repurchased and retired approximately 16.7 million shares of our common stock at a cost of approximately $5.0 billion during the year ended December 31, 2020.\n\nIn March 2019 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (March 2019 Share Repurchase Program), which was completed as of March 31, 2020. All shares repurchased under our March 2019 Share Repurchase Program were retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately 4.1 million shares of our common stock at a cost of approximately $1.3 billion during the year ended December 31, 2020.\n\nIn August 2022 the Inflation Reduction Act of 2022 (the IRA) was signed into law. Among other things, the IRA levies a 1.0% excise tax on net stock repurchases after December 31, 2022. Historically, we have made discretionary share repurchases.\n\nAmounts paid to repurchase shares in excess of their par value are allocated between additional paid-in capital and retained earnings, with payments in excess of our additional paid-in-capital balance recorded as a reduction to retained earnings.\n\n## glyph<c=24,font=/PIIBCD+FranklinGothic-Book>55G?G>3F76 &F:7D glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A?BD7:7@E;H7 @5A?7 glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEEglyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nThe following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:\n\n|                                                                                                   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | ,@D73>;L76 glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@E glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> A@ *75GD;F;7E glyph<c=24,font=/PIIBCD+FranklinGothic-Book>H3;>34>7 8AD *3>7glyph<c=9,font=/PIIBCD+FranklinGothic-Book> %7F A8 +3J                                                                                 | ,@D73>;L76 glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@E glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> A@ glyph<c=26,font=/PIIBCD+FranklinGothic-Book>3E: glyph<c=29,font=/PIIBCD+FranklinGothic-Book>>AI glyph<c=31,font=/PIIBCD+FranklinGothic-Book>7697Eglyph<c=9,font=/PIIBCD+FranklinGothic-Book> %7F A8 +3J        | glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@E glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> A@ %7F  @H7EF?7@F glyph<c=31,font=/PIIBCD+FranklinGothic-Book>7697Eglyph<c=9,font=/PIIBCD+FranklinGothic-Book> %7F A8 +3J glyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=7,font=/PIIBCD+FranklinGothic-Book> | ,@D73>;L76 glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@E glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> A@ '7@E;A@ glyph<c=25,font=/PIIBCD+FranklinGothic-Book>7@78;F &4>;93F;A@glyph<c=9,font=/PIIBCD+FranklinGothic-Book> %7F A8 +3J                                                                                    | glyph<c=26,font=/PIIBCD+FranklinGothic-Book>GDD7@5K +D3@E>3F;A@ glyph<c=24,font=/PIIBCD+FranklinGothic-Book>6<GEF?7@FE                                                                                                                                                                                                                                                     | +AF3>                                                                                                                                                                                                                                                                                                                                                                      |\n| Balance, December 31, 2021                                                                        | $ (2.2)                                                                                                                                                                                                                                                                                                                                                                    | $ 53.8                                                                                                                                                                                                                                                                                                                                                                     | $ 25.5                                                                                                                                                                                                                                                                                                                                                                                                     | $ (44.8)                                                                                                                                                                                                                                                                                                                                                                   | $ (139.0)                                                                                                                                                                                                                                                                                                                                                                  | $ (106.7)                                                                                                                                                                                                                                                                                                                                                                  |\n| Other comprehensive income (loss) before reclassifications                                        | (23.5)                                                                                                                                                                                                                                                                                                                                                                     | 137.3                                                                                                                                                                                                                                                                                                                                                                      | 12.6                                                                                                                                                                                                                                                                                                                                                                                                       | 43.7                                                                                                                                                                                                                                                                                                                                                                       | (83.1)                                                                                                                                                                                                                                                                                                                                                                     | 87.0                                                                                                                                                                                                                                                                                                                                                                       |\n| Amounts reclassified from accumulated other comprehensive income (loss)                           | 10.0                                                                                                                                                                                                                                                                                                                                                                       | (176.0)                                                                                                                                                                                                                                                                                                                                                                    | (38.1)                                                                                                                                                                                                                                                                                                                                                                                                     | -                                                                                                                                                                                                                                                                                                                                                                          | 58.9                                                                                                                                                                                                                                                                                                                                                                       | (145.2)                                                                                                                                                                                                                                                                                                                                                                    |\n| Net current period other comprehensive income (loss)                                              | (13.5)                                                                                                                                                                                                                                                                                                                                                                     | (38.7)                                                                                                                                                                                                                                                                                                                                                                     | (25.5)                                                                                                                                                                                                                                                                                                                                                                                                     | 43.7                                                                                                                                                                                                                                                                                                                                                                       | (24.2)                                                                                                                                                                                                                                                                                                                                                                     | (58.2)                                                                                                                                                                                                                                                                                                                                                                     |\n| Balance, December 31, 2022                                                                        | $ (15.7)                                                                                                                                                                                                                                                                                                                                                                   | $ 15.1                                                                                                                                                                                                                                                                                                                                                                     | $                                                                                                                                                                                                                                                                                                                                                                                                          | - $ (1.1)                                                                                                                                                                                                                                                                                                                                                                  | $ (163.2)                                                                                                                                                                                                                                                                                                                                                                  | $ (164.9)                                                                                                                                                                                                                                                                                                                                                                  |\n\n|                                                                                                   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | ,@D73>;L76 glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@E glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> A@ *75GD;F;7E glyph<c=24,font=/PIIBCD+FranklinGothic-Book>H3;>34>7 8AD *3>7glyph<c=9,font=/PIIBCD+FranklinGothic-Book> %7F A8 +3J                                                                                 | ,@D73>;L76 glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@E glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> A@ glyph<c=26,font=/PIIBCD+FranklinGothic-Book>3E: glyph<c=29,font=/PIIBCD+FranklinGothic-Book>>AI glyph<c=31,font=/PIIBCD+FranklinGothic-Book>7697Eglyph<c=9,font=/PIIBCD+FranklinGothic-Book> %7F A8 +3J        | glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@E glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> A@ %7F  @H7EF?7@F glyph<c=31,font=/PIIBCD+FranklinGothic-Book>7697Eglyph<c=9,font=/PIIBCD+FranklinGothic-Book> %7F A8 +3J                                                                                                    | ,@D73>;L76 glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@E glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> A@ '7@E;A@ glyph<c=25,font=/PIIBCD+FranklinGothic-Book>7@78;F &4>;93F;A@glyph<c=9,font=/PIIBCD+FranklinGothic-Book> %7F A8 +3J                                                                                    | glyph<c=26,font=/PIIBCD+FranklinGothic-Book>GDD7@5K +D3@E>3F;A@ glyph<c=24,font=/PIIBCD+FranklinGothic-Book>6<GEF?7@FE                                                                                                                                                                                                                                                     | +AF3>                                                                                                                                                                                                                                                                                                                                                                      |\n| Balance, December 31, 2020                                                                        | $ 1.4                                                                                                                                                                                                                                                                                                                                                                      | $ (179.0)                                                                                                                                                                                                                                                                                                                                                                  | $ (8.5)                                                                                                                                                                                                                                                                                                                                                                    | $ (66.3)                                                                                                                                                                                                                                                                                                                                                                   | $ (46.6)                                                                                                                                                                                                                                                                                                                                                                   | $ (299.0)                                                                                                                                                                                                                                                                                                                                                                  |\n| Other comprehensive income (loss) before reclassifications                                        | (6.6)                                                                                                                                                                                                                                                                                                                                                                      | 178.2                                                                                                                                                                                                                                                                                                                                                                      | 33.4                                                                                                                                                                                                                                                                                                                                                                       | 21.5                                                                                                                                                                                                                                                                                                                                                                       | (92.4)                                                                                                                                                                                                                                                                                                                                                                     | 134.1                                                                                                                                                                                                                                                                                                                                                                      |\n| Amounts reclassified from accumulated other comprehensive income (loss)                           | 3.0                                                                                                                                                                                                                                                                                                                                                                        | 54.6                                                                                                                                                                                                                                                                                                                                                                       | 0.6                                                                                                                                                                                                                                                                                                                                                                        | -                                                                                                                                                                                                                                                                                                                                                                          | -                                                                                                                                                                                                                                                                                                                                                                          | 58.2                                                                                                                                                                                                                                                                                                                                                                       |\n| Net current period other comprehensive income (loss)                                              | (3.6)                                                                                                                                                                                                                                                                                                                                                                      | 232.8                                                                                                                                                                                                                                                                                                                                                                      | 34.0                                                                                                                                                                                                                                                                                                                                                                       | 21.5                                                                                                                                                                                                                                                                                                                                                                       | (92.4)                                                                                                                                                                                                                                                                                                                                                                     | 192.3                                                                                                                                                                                                                                                                                                                                                                      |\n| Balance, December 31, 2021                                                                        | $ (2.2)                                                                                                                                                                                                                                                                                                                                                                    | $ 53.8                                                                                                                                                                                                                                                                                                                                                                     | $ 25.5                                                                                                                                                                                                                                                                                                                                                                     | $ (44.8)                                                                                                                                                                                                                                                                                                                                                                   | $ (139.0)                                                                                                                                                                                                                                                                                                                                                                  | $ (106.7)                                                                                                                                                                                                                                                                                                                                                                  |",
        "metadata": {
            "page": 154
        },
        "id": "cdf92963-8364-4518-b559-99e1410c05ff"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\n|                                                                                                   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | ,@D73>;L76 glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@E glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> A@ *75GD;F;7E glyph<c=24,font=/PIIBCD+FranklinGothic-Book>H3;>34>7 8AD *3>7glyph<c=9,font=/PIIBCD+FranklinGothic-Book> %7F A8 +3J                                                                                 | ,@D73>;L76 glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@E glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> A@ glyph<c=26,font=/PIIBCD+FranklinGothic-Book>3E: glyph<c=29,font=/PIIBCD+FranklinGothic-Book>>AI glyph<c=31,font=/PIIBCD+FranklinGothic-Book>7697Eglyph<c=9,font=/PIIBCD+FranklinGothic-Book> %7F A8 +3J        | glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@E glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> A@ %7F  @H7EF?7@F glyph<c=31,font=/PIIBCD+FranklinGothic-Book>7697Eglyph<c=9,font=/PIIBCD+FranklinGothic-Book> %7F A8 +3J                                                                                                    | ,@D73>;L76 glyph<c=30,font=/PIIBCD+FranklinGothic-Book>3;@E glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEE7Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> A@ '7@E;A@ glyph<c=25,font=/PIIBCD+FranklinGothic-Book>7@78;F &4>;93F;A@glyph<c=9,font=/PIIBCD+FranklinGothic-Book> %7F A8 +3J                                                                                    | glyph<c=26,font=/PIIBCD+FranklinGothic-Book>GDD7@5K +D3@E>3F;A@ glyph<c=24,font=/PIIBCD+FranklinGothic-Book>6<GEF?7@FE                                                                                                                                                                                                                                                     | +AF3>                                                                                                                                                                                                                                                                                                                                                                      |\n| Balance, December 31, 2019                                                                        | $ 4.2                                                                                                                                                                                                                                                                                                                                                                      | $ 7.8                                                                                                                                                                                                                                                                                                                                                                      | $ 25.1                                                                                                                                                                                                                                                                                                                                                                     | $ (32.8)                                                                                                                                                                                                                                                                                                                                                                   | $ (139.5)                                                                                                                                                                                                                                                                                                                                                                  | $ (135.2)                                                                                                                                                                                                                                                                                                                                                                  |\n| Other comprehensive income (loss) before reclassifications                                        | (9.3)                                                                                                                                                                                                                                                                                                                                                                      | (165.0)                                                                                                                                                                                                                                                                                                                                                                    | (30.7)                                                                                                                                                                                                                                                                                                                                                                     | (33.5)                                                                                                                                                                                                                                                                                                                                                                     | 92.9                                                                                                                                                                                                                                                                                                                                                                       | (145.6)                                                                                                                                                                                                                                                                                                                                                                    |\n| Amounts reclassified from accumulated other comprehensive income (loss)                           | 6.5                                                                                                                                                                                                                                                                                                                                                                        | (21.8)                                                                                                                                                                                                                                                                                                                                                                     | (2.9)                                                                                                                                                                                                                                                                                                                                                                      | -                                                                                                                                                                                                                                                                                                                                                                          | -                                                                                                                                                                                                                                                                                                                                                                          | (18.2)                                                                                                                                                                                                                                                                                                                                                                     |\n| Net current period other comprehensive income (loss)                                              | (2.8)                                                                                                                                                                                                                                                                                                                                                                      | (186.8)                                                                                                                                                                                                                                                                                                                                                                    | (33.6)                                                                                                                                                                                                                                                                                                                                                                     | (33.5)                                                                                                                                                                                                                                                                                                                                                                     | 92.9                                                                                                                                                                                                                                                                                                                                                                       | (163.8)                                                                                                                                                                                                                                                                                                                                                                    |\n| Balance, December 31, 2020                                                                        | $ 1.4                                                                                                                                                                                                                                                                                                                                                                      | $ (179.0)                                                                                                                                                                                                                                                                                                                                                                  | $ (8.5)                                                                                                                                                                                                                                                                                                                                                                    | $ (66.3)                                                                                                                                                                                                                                                                                                                                                                   | $ (46.6)                                                                                                                                                                                                                                                                                                                                                                   | $ (299.0)                                                                                                                                                                                                                                                                                                                                                                  |\n\nThe following table summarizes the amounts reclassified from accumulated other comprehensive income (loss):\n\n|                                                                                                   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>?AG@FE )75>3EE;8;76 8DA? glyph<c=24,font=/PIIBCD+FranklinGothic-Book>55G?G>3F76 &F:7D glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A?BD7:7@E;H7  @5A?7 glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEEglyph<c=7,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>?AG@FE )75>3EE;8;76 8DA? glyph<c=24,font=/PIIBCD+FranklinGothic-Book>55G?G>3F76 &F:7D glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A?BD7:7@E;H7  @5A?7 glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEEglyph<c=7,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>?AG@FE )75>3EE;8;76 8DA? glyph<c=24,font=/PIIBCD+FranklinGothic-Book>55G?G>3F76 &F:7D glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A?BD7:7@E;H7  @5A?7 glyph<c=6,font=/PIIBCD+FranklinGothic-Book>#AEEglyph<c=7,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |                              |\n|---------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                 | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                 | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                                                                                                                                                                                                                                                                 | @5A?7 *F3F7?7@F #A53F;A@     |\n| Gains (losses) on securities available for sale                                                   | $ (12.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | $ (3.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | $ (8.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Other (income) expense       |\n|                                                                                                   | 2.6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 0.8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 1.7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Income tax (benefit) expense |\n| Gains (losses) on cash flow hedges                                                                | 201.6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | (60.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 18.3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Revenue                      |\n|                                                                                                   | (5.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | (0.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 3.3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Operating expense            |\n|                                                                                                   | (0.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 0.2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 0.3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Other (income) expense       |\n|                                                                                                   | (19.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 6.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | (0.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Income tax (benefit) expense |\n| Gains (losses) on net investment hedges (1)                                                       | 38.1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | (0.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 2.9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Other (income) expense       |\n| Currency Translation Adjustments                                                                  | (58.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | - Other (income) expense     |\n| Total reclassifications, net of tax                                                               | $ 145.2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | $ (58.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | $ 18.2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                              |\n\n## %AF7 glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=18,font=/PIIBCD+FranklinGothic-Book>glyph<c=23,font=/PIIBCD+FranklinGothic-Book> glyph<c=28,font=/PIIBCD+FranklinGothic-Book>3D@;@9E B7D *:3D7\n\nBasic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:\n\n|                                                                                                            | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book>          | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    |\n| \"C;3@/B=@glyph<c=20,font=/PIIBDE+FranklinGothic-BookItal>                                                  |                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                     |\n| Net income attributable to Biogen Inc.                                                                     | $ 3,046.9                                                                                                                                                                                                                                                                                           | $ 1,556.1                                                                                                                                                                                                                                                                                           | $ 4,000.6                                                                                                                                                                                                                                                                                           |\n| glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>3<=;7</B=@glyph<c=20,font=/PIIBDE+FranklinGothic-BookItal> |                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                     |\n| Weighted average number of common shares outstanding                                                       | 145.3                                                                                                                                                                                                                                                                                               | 149.1                                                                                                                                                                                                                                                                                               | 160.9                                                                                                                                                                                                                                                                                               |\n| Effect of dilutive securities:                                                                             |                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                     |\n| Time-vested restricted stock units                                                                         | 0.5                                                                                                                                                                                                                                                                                                 | 0.3                                                                                                                                                                                                                                                                                                 | 0.2                                                                                                                                                                                                                                                                                                 |\n| Market stock units                                                                                         | 0.1                                                                                                                                                                                                                                                                                                 | 0.1                                                                                                                                                                                                                                                                                                 | 0.1                                                                                                                                                                                                                                                                                                 |\n| Performance stock units settled in stock                                                                   | 0.1                                                                                                                                                                                                                                                                                                 | 0.1                                                                                                                                                                                                                                                                                                 | 0.1                                                                                                                                                                                                                                                                                                 |\n| Dilutive potential common shares                                                                           | 0.7                                                                                                                                                                                                                                                                                                 | 0.5                                                                                                                                                                                                                                                                                                 | 0.4                                                                                                                                                                                                                                                                                                 |\n| Shares used in calculating diluted earnings per share                                                      | 146.0                                                                                                                                                                                                                                                                                               | 149.6                                                                                                                                                                                                                                                                                               | 161.3                                                                                                                                                                                                                                                                                               |\n\nAmounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.",
        "metadata": {
            "page": 155
        },
        "id": "e8cca879-7c21-4d15-b68a-99a359261c4a"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nEarnings per share for the years ended December 31, 2022, 2021 and 2020, reflects the repurchase of approximately 3.6 million shares, 6.0 million shares and 22.4 million shares of our common stock, respectively, under our share repurchase programs. For additional information on our share repurchase programs, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=14,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>?C7BG , to these consolidated financial statements.\n\n## %AF7 glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=19,font=/PIIBCD+FranklinGothic-Book>glyph<c=23,font=/PIIBCD+FranklinGothic-Book> *:3D7glyph<c=10,font=/PIIBCD+FranklinGothic-Book>glyph<c=25,font=/PIIBCD+FranklinGothic-Book>3E76 '3K?7@FE\n\n## *:3D7glyph<c=10,font=/PIIBCD+FranklinGothic-Book>glyph<c=25,font=/PIIBCD+FranklinGothic-Book>3E76 glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A?B7@E3F;A@ glyph<c=28,font=/PIIBCD+FranklinGothic-Book>JB7@E7\n\nThe following table summarizes share-based compensation expense included in our consolidated statements of income:\n\n|                                                                                                   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    |\n| Research and development                                                                          | $ 98.5                                                                                                                                                                                                                                                                                              | $ 89.3                                                                                                                                                                                                                                                                                              | $ 80.0                                                                                                                                                                                                                                                                                              |\n| Selling, general and administrative                                                               | 175.1                                                                                                                                                                                                                                                                                               | 169.5                                                                                                                                                                                                                                                                                               | 131.3                                                                                                                                                                                                                                                                                               |\n| Subtotal                                                                                          | 273.6                                                                                                                                                                                                                                                                                               | 258.8                                                                                                                                                                                                                                                                                               | 211.3                                                                                                                                                                                                                                                                                               |\n| Capitalized share-based compensation costs                                                        | (9.3)                                                                                                                                                                                                                                                                                               | (8.0)                                                                                                                                                                                                                                                                                               | (6.2)                                                                                                                                                                                                                                                                                               |\n| Share-based compensation expense included in total cost and expense                               | 264.3                                                                                                                                                                                                                                                                                               | 250.8                                                                                                                                                                                                                                                                                               | 205.1                                                                                                                                                                                                                                                                                               |\n| Income tax effect                                                                                 | (49.2)                                                                                                                                                                                                                                                                                              | (46.7)                                                                                                                                                                                                                                                                                              | (33.5)                                                                                                                                                                                                                                                                                              |\n| Share-based compensation expense included in net income attributable to Biogen Inc.               | $ 215.1                                                                                                                                                                                                                                                                                             | $ 204.1                                                                                                                                                                                                                                                                                             | $ 171.6                                                                                                                                                                                                                                                                                             |\n\nThe following table summarizes share-based compensation expense associated with each of our share-based compensation programs:\n\n|                                                                                                   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    |\n| Market stock units                                                                                | $ 13.2                                                                                                                                                                                                                                                                                              | $ 45.6                                                                                                                                                                                                                                                                                              | $ 40.5                                                                                                                                                                                                                                                                                              |\n| Time-vested restricted stock units                                                                | 202.3                                                                                                                                                                                                                                                                                               | 159.8                                                                                                                                                                                                                                                                                               | 142.6                                                                                                                                                                                                                                                                                               |\n| Cash settled performance units                                                                    | -                                                                                                                                                                                                                                                                                                   | -                                                                                                                                                                                                                                                                                                   | (1.7)                                                                                                                                                                                                                                                                                               |\n| Performance units                                                                                 | -                                                                                                                                                                                                                                                                                                   | -                                                                                                                                                                                                                                                                                                   | (0.1)                                                                                                                                                                                                                                                                                               |\n| Performance stock units settled in stock                                                          | 35.0                                                                                                                                                                                                                                                                                                | 23.9                                                                                                                                                                                                                                                                                                | 7.9                                                                                                                                                                                                                                                                                                 |\n| Performance stock units settled in cash                                                           | 10.1                                                                                                                                                                                                                                                                                                | 12.2                                                                                                                                                                                                                                                                                                | 8.6                                                                                                                                                                                                                                                                                                 |\n| Employee stock purchase plan                                                                      | 12.7                                                                                                                                                                                                                                                                                                | 17.3                                                                                                                                                                                                                                                                                                | 13.5                                                                                                                                                                                                                                                                                                |\n| Stock options                                                                                     | 0.3                                                                                                                                                                                                                                                                                                 | -                                                                                                                                                                                                                                                                                                   | -                                                                                                                                                                                                                                                                                                   |\n| Subtotal                                                                                          | 273.6                                                                                                                                                                                                                                                                                               | 258.8                                                                                                                                                                                                                                                                                               | 211.3                                                                                                                                                                                                                                                                                               |\n| Capitalized share-based compensation costs                                                        | (9.3)                                                                                                                                                                                                                                                                                               | (8.0)                                                                                                                                                                                                                                                                                               | (6.2)                                                                                                                                                                                                                                                                                               |\n| Share-based compensation expense included in total cost and expense                               | $ 264.3                                                                                                                                                                                                                                                                                             | $ 250.8                                                                                                                                                                                                                                                                                             | $ 205.1                                                                                                                                                                                                                                                                                             |\n\nAs of December 31, 2022, unrecognized compensation cost related to unvested share-based compensation was approximately $290.5 million, net of estimated forfeitures. We expect to recognize the cost of these unvested awards over a weighted-average period of 2.0 years.\n\n## *:3D7glyph<c=10,font=/PIIBCD+FranklinGothic-Book>glyph<c=25,font=/PIIBCD+FranklinGothic-Book>3E76 glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A?B7@E3F;A@ '>3@E\n\nWe have three share-based compensation plans pursuant to which awards are currently being made: (i) the Biogen Inc. 2006 Non-Employee Directors Equity Plan (2006 Directors Plan); (ii) the Biogen Inc. 2017 Omnibus Equity Plan (2017 Omnibus Equity Plan); and (iii) the Biogen Inc. 2015 Employee Stock Purchase Plan (2015 ESPP).\n\n## glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>7@31B=@A $:/<\n\nIn May 2006 our shareholders approved the 2006 Directors Plan for share-based awards to our directors. Awards granted from the 2006 Directors Plan may include stock options, shares of restricted stock, RSUs, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by",
        "metadata": {
            "page": 156
        },
        "id": "8b247583-8f11-4894-b20c-edaaae451ebe"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\na committee of our Board of Directors, subject to the provisions of the 2006 Directors Plan. We have reserved a total of 1.6 million shares of common stock for issuance under the 2006 Directors Plan. The 2006 Directors Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares reserved under the plan in a 1.5-to-1 ratio. In June 2015 our shareholders approved an amendment to extend the term of the 2006 Directors Plan until June 2025.\n\n## #;<70CA $:/<\n\nIn June 2017 our shareholders approved the 2017 Omnibus Equity Plan for share-based awards to our employees. Awards granted from the 2017 Omnibus Equity Plan may include stock options, shares of restricted stock, RSUs, performance shares, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the 2017 Omnibus Equity Plan. Shares of common stock available for grant under the 2017 Omnibus Equity Plan consist of 8.0 million shares reserved for this purpose, plus shares of common stock that remained available for grant under the Biogen Idec Inc. 2008 Omnibus Equity Plan (2008 Omnibus Equity Plan) as of June 7, 2017, or that could again become available for grant if outstanding awards under the 2008 Omnibus Equity Plan as of June 7, 2017, are cancelled, surrendered or terminated in whole or in part. The 2017 Omnibus Equity Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares available under theplanina1.5-to-1ratio.\n\nWe have not made any awards pursuant to the 2008 Omnibus Equity Plan since our shareholders approved the 2017 Omnibus Equity Plan, and do not intend to make any awards pursuant to the 2008 Omnibus Equity Plan in the future, except that unused shares under the 2008 Omnibus Equity Plan have been carried over for use under the 2017 Omnibus Equity Plan.\n\n## *FA5= &BF;A@E\n\nDuring the year ended December 31, 2022, we granted approximately 81,000 stock options to our Chief Executive Officer (CEO) (2022 CEO Grant) under the 2017 Omnibus Plan with a grant date fair value of $139.10 per option for a total of approximately $11.2 million. The fair values of our stock option grants are estimated as of the date of grant using a Black-Scholes option valuation model. The estimated fair values of the stock options are then expensed over the options' vesting periods. The 2022 CEO Grant is eligible to vest in equal annual installments over a three-year period from the grant date, subject to the CEO's continued employment. The outstanding stock options have a 10-year term and are exercisable at a price per share not less than the fair market value of the underlying common stock on the date of grant.\n\nThe total intrinsic value related to the remaining stock options previously granted in 2010 that were exercised in 2020 totaled $2.9 million.\n\nThe following table summarizes the amount of tax benefit realized for stock options and cash received from the exercise of the remaining stock options previously granted in 2010:\n\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book>   |   glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 K73D 7@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book> |\n|-----------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Tax benefit realized for stock options                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                      2.9 |\n| Cash received from the exercise of stock options                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                      0.7 |\n\n## $3D=7F *FA5= ,@;FE glyph<c=6,font=/PIIBCD+FranklinGothic-Book>$*,Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nMSUs awarded to employees prior to 2014 vested in four equal annual increments beginning on the first anniversary of the grant date. Participants may ultimately earn between zero and 150.0% of the target number of units granted based on actual stock performance.\n\nMSUs awarded to employees in 2014 and thereafter vest in three equal annual increments beginning on the first anniversary of the grant date, and participants may ultimately earn between zero and 200.0% of the target number of units granted based on actual stock performance.\n\nThe vesting of these awards is subject to the respective employee's continued employment. The number of MSUs granted represents the target number of units that are eligible to be earned based on the attainment of certain market-based criteria involving our stock price. The number of MSUs earned is calculated at each annual anniversary from the date of grant over the respective vesting periods, resulting in multiple performance periods.",
        "metadata": {
            "page": 157
        },
        "id": "a8322039-b146-4f05-a1f0-befd9c2e4e77"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nAccordingly, additional MSUs may be issued or currently outstanding MSUs may be cancelled upon final determination of the number of awards earned.\n\nBeginning in 2022 we no longer grant MSUs as part of our long term incentive program and have replaced with granting performance-vested RSUs.\n\nThe following table summarizes our MSU activity:\n\n|                               | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>   |\n|-------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n|                               | *:3D7E                                                                                                                                                                                                                                                                                                                                                                     | .7;9:F76 glyph<c=24,font=/PIIBCD+FranklinGothic-Book>H7D397 glyph<c=30,font=/PIIBCD+FranklinGothic-Book>D3@F glyph<c=27,font=/PIIBCD+FranklinGothic-Book>3F7 glyph<c=29,font=/PIIBCD+FranklinGothic-Book>3;D -3>G7                                                                                                                                                         |\n| Unvested at December 31, 2021 | 257,000                                                                                                                                                                                                                                                                                                                                                                    | $ 372.08                                                                                                                                                                                                                                                                                                                                                                   |\n| Granted                       | -                                                                                                                                                                                                                                                                                                                                                                          | -                                                                                                                                                                                                                                                                                                                                                                          |\n| Vested                        | (87,000)                                                                                                                                                                                                                                                                                                                                                                   | 369.22                                                                                                                                                                                                                                                                                                                                                                     |\n| Forfeited                     | (57,000)                                                                                                                                                                                                                                                                                                                                                                   | 371.24                                                                                                                                                                                                                                                                                                                                                                     |\n| Unvested at December 31, 2022 | 113,000                                                                                                                                                                                                                                                                                                                                                                    | $ 366.52                                                                                                                                                                                                                                                                                                                                                                   |\n\nWe value grants of MSUs using a lattice model with a Monte Carlo simulation. This valuation methodology utilizes several key assumptions, the 30 calendar day average closing stock price on the date of grant for MSUs, expected volatility of our stock price, risk-free rates of return and expected dividend yield.\n\nThe assumptions used in our valuation are summarized as follows:\n\n|                                                   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n|                                                   | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    |\n| Expected dividend yield                           | Oglyph<c=4,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                                                                                                        | -%                                                                                                                                                                                                                                                                                                  |\n| Range of expected stock price volatility          | 54.8% - 61.6%                                                                                                                                                                                                                                                                                       | 37.8% - 44.1%                                                                                                                                                                                                                                                                                       |\n| Range of risk-free interest rates                 | 0.06% - 0.21%                                                                                                                                                                                                                                                                                       | 1.41% - 1.48%                                                                                                                                                                                                                                                                                       |\n| 30 calendar day average stock price on grant date | $262.23 - $360.31                                                                                                                                                                                                                                                                                   | $257.83 - $325.40                                                                                                                                                                                                                                                                                   |\n| Weighted-average per share grant date fair value  | $358.77                                                                                                                                                                                                                                                                                             | $398.61                                                                                                                                                                                                                                                                                             |\n\nThe fair values of MSUs vested in 2022, 2021 and 2020 totaled $18.8 million, $22.5 million and $26.9 million, respectively.\n\n## glyph<c=26,font=/PIIBCD+FranklinGothic-Book>3E: *7FF>76 '7D8AD?3@57 ,@;FE glyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>*',Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nCSPUs awarded to employees vest in three equal annual increments beginning on the first anniversary of the grant date. The vesting of these awards is subject to the respective employee's continued employment with such awards settled in cash. The number of CSPUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December 31 of each year. Participants may ultimately earn between zero and 200.0% of the target number of units granted based on the degree of actual performance metric achievement. Accordingly, additional CSPUs may be issued or currently outstanding CSPUs may be cancelled upon final determination of the number of units earned. CSPUs are classified as liability awards and will be settled in cash based on the 30 calendar day average closing stock price through each vesting date, once the actual vested and earned number of units is known. Since no shares are issued, these awards do not dilute equity. All remaining CSPUs were fully vested as of December 31, 2020.\n\nThe cash paid in settlement of CSPUs vested in 2020 totaled $3.8 million.\n\n## '7D8AD?3@57glyph<c=10,font=/PIIBCD+FranklinGothic-Book>H7EF76 )7EFD;5F76 *FA5= ,@;FE glyph<c=6,font=/PIIBCD+FranklinGothic-Book>',Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nPUs are granted to certain employees in the form of RSUs that may be settled in cash or shares of our common stock at the sole discretion of the Compensation and Management Development Committee of our Board of Directors. These awards are structured and accounted for the same way as the CSPUs, and vest in three equal annual increments beginning on the first anniversary of the grant date. The number of PUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December 31 of each year. Participants may ultimately earn between zero and 200.0% of the target number of units granted based on the degree of actual performance metric achievement. Accordingly, additional PUs may be issued or currently outstanding PUs may be cancelled upon final determination of the number of units earned. PUs settling in cash are based on the 30 calendar",
        "metadata": {
            "page": 158
        },
        "id": "a6726e22-5328-4e13-8032-e31d2e7fba14"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nday average closing stock price through each vesting date once the actual vested and earned number of units is known. All remaining PUs were fully vested as of December 31, 2020.\n\nAll PUs that vested in 2020 were settled in cash totaling $3.4 million.\n\n## '7D8AD?3@57 *FA5= ,@;FE glyph<c=6,font=/PIIBCD+FranklinGothic-Book>'*,Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\n## $')A '3BB:32 7< 'B=19\n\nDuring the first quarter of 2018 we began granting awards for performance-vested RSUs that will settle in stock. PSUs awarded to employees have a three-year performance period and vest on the third anniversary of the grant date. The vesting of these awards is subject to the respective employee's continued employment. The number of PSUs granted represents the target number of units that are eligible to be earned based on the achievement of cumulative three-year performance measures established at the beginning of the performance period, which ends on December 31 of the third year of the performance period.\n\nParticipants may ultimately earn between zero and 200.0% of the target number of PSUs granted based on the degree of achievement of the applicable performance metric. Accordingly, additional PSUs may be issued or currently outstanding PSUs may be cancelled upon final determination of the number of units earned.\n\nBeginning in 2022 we no longer grant MSUs as part of long term incentive program and have replaced with granting PSUs with a performance metric based on a three-year cumulative relative total shareholder return (rTSR) metric. The PSUs will vest on the third anniversary of the date of grant, with the number of PSUs earned based on this cumulative rTSR metric.\n\nThe following table summarizes our PSUs that settle in stock activity:\n\n|                               | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>   |\n|-------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n|                               | *:3D7E                                                                                                                                                                                                                                                                                                                                                                     | .7;9:F76 glyph<c=24,font=/PIIBCD+FranklinGothic-Book>H7D397 glyph<c=30,font=/PIIBCD+FranklinGothic-Book>D3@F glyph<c=27,font=/PIIBCD+FranklinGothic-Book>3F7 glyph<c=29,font=/PIIBCD+FranklinGothic-Book>3;D -3>G7                                                                                                                                                         |\n| Unvested at December 31, 2021 | 196,000                                                                                                                                                                                                                                                                                                                                                                    | $ 289.94                                                                                                                                                                                                                                                                                                                                                                   |\n| Granted (1)                   | 270,000                                                                                                                                                                                                                                                                                                                                                                    | 294.43                                                                                                                                                                                                                                                                                                                                                                     |\n| Vested                        | (44,000)                                                                                                                                                                                                                                                                                                                                                                   | 316.83                                                                                                                                                                                                                                                                                                                                                                     |\n| Forfeited                     | (86,000)                                                                                                                                                                                                                                                                                                                                                                   | 279.09                                                                                                                                                                                                                                                                                                                                                                     |\n| Unvested at December 31, 2022 | 336,000                                                                                                                                                                                                                                                                                                                                                                    | $ 292.95                                                                                                                                                                                                                                                                                                                                                                   |\n\nWe value grants of PSUs using a lattice model with a Monte Carlo simulation. This valuation methodology utilizes several key assumptions, the 30 calendar day average closing stock price on the date of grant for PSUs, expected volatility of our stock price, risk-free rates of return and expected dividend yield.\n\nThe assumptions used in our valuation are summarized as follows:\n\n|                                                   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Expected dividend yield                           | -%                                                                                                                                                                                                                                                                                                                                                                         |\n| Range of expected stock price volatility          | 44.0% - 45.9%                                                                                                                                                                                                                                                                                                                                                              |\n| Range of risk-free interest rates                 | 1.8% - 3.9%                                                                                                                                                                                                                                                                                                                                                                |\n| 30 calendar day average stock price on grant date | $231.31 - $294.86                                                                                                                                                                                                                                                                                                                                                          |\n| Weighted-average per share grant date fair value  | $294.43                                                                                                                                                                                                                                                                                                                                                                    |\n\nThe fair values of PSUs settled in stock that vested in 2022 and 2021 totaled $9.5 million and $15.5 million, respectively\n\n## $')A '3BB:32 7< glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>/A6\n\nDuring the first quarter of 2018 we began granting awards for performance-vested restricted stock units that will settle in cash. PSUs awarded to employees have three performance periods and vest on the third anniversary of the grant date. The vesting of these awards is subject to the respective employee's continued employment. The number of PSUs granted represents the target number of units that are eligible to be earned based on the",
        "metadata": {
            "page": 159
        },
        "id": "6548d855-5894-48ea-a003-5a0605d5926f"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nachievement of three annual performance measures established when the performance objectives are defined, which will be at the beginning of each year and will end on December 31 of such year.\n\nParticipants may ultimately earn between zero and 200.0% of the target number of PSUs granted based on the degree of achievement of the applicable performance metric. Accordingly, additional PSUs may be issued or currently outstanding PSUs may be cancelled upon final determination of the number of units earned. PSUs are classified as liability awards and will be settled in cash based on the 30 calendar day average closing stock price through the vesting date, once the actual vested and earned number of PSUs is determined. Since no shares are issued, these awards do not dilute equity.\n\nBeginning in 2022 we no longer grant this type of PSUs as part of our long term incentive program and have replaced with granting time-vested RSUs.\n\nThe following table summarizes our PSUs that settle in cash activity:\n\n|                               | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book> *:3D7E   |\n|-------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Unvested at December 31, 2021 | 134,000                                                                                                                                                                                                                                                                                                                                                                           |\n| Granted (1)                   | 24,000                                                                                                                                                                                                                                                                                                                                                                            |\n| Vested                        | (49,000)                                                                                                                                                                                                                                                                                                                                                                          |\n| Forfeited                     | (26,000)                                                                                                                                                                                                                                                                                                                                                                          |\n| Unvested at December 31, 2022 | 83,000                                                                                                                                                                                                                                                                                                                                                                            |\n\nThe fair values of PSUs settled in cash that vested in 2022 and 2021 totaled $11.0 million and $9.9 million, respectively.\n\n## +;?7glyph<c=10,font=/PIIBCD+FranklinGothic-Book>-7EF76 )7EFD;5F76 *FA5= ,@;FE glyph<c=6,font=/PIIBCD+FranklinGothic-Book>)*,Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nRSUs awarded to employees generally vest no sooner than one-third per year over three years on the anniversary of the date of grant, or upon the third anniversary of the date of the grant, provided the employee remains continuously employed with us, except as otherwise provided in the plan. Shares of our common stock will be delivered to the employee upon vesting, subject to payment of applicable withholding taxes. RSUs awarded to directors for service on our Board of Directors vest on the first anniversary of the date of grant, provided in each case that the director continues to serve on our Board of Directors through the vesting date. Shares of our common stock will be delivered to the director upon vesting and are not subject to any withholding taxes.\n\nThe following table summarizes our RSU activity:\n\n|                               | *:3D7E    | .7;9:F76 glyph<c=24,font=/PIIBCD+FranklinGothic-Book>H7D397 glyph<c=30,font=/PIIBCD+FranklinGothic-Book>D3@F glyph<c=27,font=/PIIBCD+FranklinGothic-Book>3F7 glyph<c=29,font=/PIIBCD+FranklinGothic-Book>3;D -3>G7   |\n|-------------------------------|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Unvested at December 31, 2021 | 1,202,000 | $ 291.54                                                                                                                                                                                                             |\n| Granted (1)                   | 1,751,000 | 221.28                                                                                                                                                                                                               |\n| Vested                        | (539,000) | 297.72                                                                                                                                                                                                               |\n| Forfeited                     | (468,000) | 244.03                                                                                                                                                                                                               |\n| Unvested at December 31, 2022 | 1,946,000 | $ 237.90                                                                                                                                                                                                             |\n\nRSUs granted in 2021 and 2020 had weighted average grant date fair values of $276.90 and $318.87, respectively.\n\nThe fair values of RSUs vested in 2022, 2021 and 2020 totaled $116.3 million, $132.2 million and $140.5 million, respectively.",
        "metadata": {
            "page": 160
        },
        "id": "b0a927c7-3339-4e5c-b3d7-f2ace72ce1c6"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nglyph<c=28,font=/PIIBCD+FranklinGothic-Book>?B>AK77 *FA5= 'GD5:3E7 '>3@ glyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*''glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nIn June 2015 our shareholders approved the 2015 ESPP. The maximum aggregate number of shares of our common stock that may be purchased under the 2015 ESPP is 6.2 million.\n\nThe following table summarizes our ESPP activity:\n\n|                                                                                                                                                                   |                                                                                                                                                                   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=9,font=/PIIBCD+FranklinGothic-Book> 7J57BF E:3D7 3?AG@FEglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=9,font=/PIIBCD+FranklinGothic-Book> 7J57BF E:3D7 3?AG@FEglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    |\n| Shares issued under the 2015 ESPP                                                                                                                                 | Shares issued under the 2015 ESPP                                                                                                                                 | 241,000                                                                                                                                                                                                                                                                                             | 248,000                                                                                                                                                                                                                                                                                             | 212,000                                                                                                                                                                                                                                                                                             |\n| Cash received under the 2015 ESPP                                                                                                                                 | Cash received under the 2015 ESPP                                                                                                                                 | $ 44.2                                                                                                                                                                                                                                                                                              | $ 54.4                                                                                                                                                                                                                                                                                              | 48.6                                                                                                                                                                                                                                                                                                |\n| %AF7 glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=20,font=/PIIBCD+FranklinGothic-Book>glyph<c=23,font=/PIIBCD+FranklinGothic-Book>                         | @5A?7 +3J7E                                                                                                                                                       |                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                     |\n\n## @5A?7 +3J glyph<c=28,font=/PIIBCD+FranklinGothic-Book>JB7@E7\n\nIncome before income tax expense and the income tax expense consist of the following:\n\n|                                                                                                                                                                                                                                       | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                     | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    |\n| glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><1=;3 034=@3 7<1=;3 B/F glyph<c=5,font=/PIIBDE+FranklinGothic-BookItal>03<347Bglyph<c=6,font=/PIIBDE+FranklinGothic-BookItal> 3F>3<A3glyph<c=20,font=/PIIBDE+FranklinGothic-BookItal> |                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                     |\n| Domestic                                                                                                                                                                                                                              | $ 1,842.0                                                                                                                                                                                                                                                                                           | $ 448.3                                                                                                                                                                                                                                                                                             | $ 3,290.0                                                                                                                                                                                                                                                                                           |\n| Foreign                                                                                                                                                                                                                               | 1,749.8                                                                                                                                                                                                                                                                                             | 1,296.9                                                                                                                                                                                                                                                                                             | 1,757.5                                                                                                                                                                                                                                                                                             |\n| Total income before income tax (benefit) expense                                                                                                                                                                                      | $ 3,591.8                                                                                                                                                                                                                                                                                           | $ 1,745.2                                                                                                                                                                                                                                                                                           | $ 5,047.5                                                                                                                                                                                                                                                                                           |\n| glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><1=;3 B/F glyph<c=5,font=/PIIBDE+FranklinGothic-BookItal>03<347Bglyph<c=6,font=/PIIBDE+FranklinGothic-BookItal> 3F>3<A3glyph<c=20,font=/PIIBDE+FranklinGothic-BookItal>               |                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                     |\n| Current:                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                     |\n| Federal                                                                                                                                                                                                                               | $ 694.5                                                                                                                                                                                                                                                                                             | $ 319.1                                                                                                                                                                                                                                                                                             | $ 647.0                                                                                                                                                                                                                                                                                             |\n| State                                                                                                                                                                                                                                 | 39.0                                                                                                                                                                                                                                                                                                | 23.1                                                                                                                                                                                                                                                                                                | 41.2                                                                                                                                                                                                                                                                                                |\n| Foreign                                                                                                                                                                                                                               | 67.9                                                                                                                                                                                                                                                                                                | 137.1                                                                                                                                                                                                                                                                                               | 155.1                                                                                                                                                                                                                                                                                               |\n| Total current                                                                                                                                                                                                                         | 801.4                                                                                                                                                                                                                                                                                               | 479.3                                                                                                                                                                                                                                                                                               | 843.3                                                                                                                                                                                                                                                                                               |\n| Deferred:                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                     |\n| Federal                                                                                                                                                                                                                               | (328.3)                                                                                                                                                                                                                                                                                             | (242.5)                                                                                                                                                                                                                                                                                             | (1,749.9)                                                                                                                                                                                                                                                                                           |\n| State                                                                                                                                                                                                                                 | 2.5                                                                                                                                                                                                                                                                                                 | (11.9)                                                                                                                                                                                                                                                                                              | (6.8)                                                                                                                                                                                                                                                                                               |\n| Foreign                                                                                                                                                                                                                               | 157.2                                                                                                                                                                                                                                                                                               | (172.4)                                                                                                                                                                                                                                                                                             | 1,905.7                                                                                                                                                                                                                                                                                             |\n| Total deferred                                                                                                                                                                                                                        | (168.6)                                                                                                                                                                                                                                                                                             | (426.8)                                                                                                                                                                                                                                                                                             | 149.0                                                                                                                                                                                                                                                                                               |\n| Total income tax (benefit) expense                                                                                                                                                                                                    | $ 632.8                                                                                                                                                                                                                                                                                             | $ 52.5                                                                                                                                                                                                                                                                                              | $ 992.3                                                                                                                                                                                                                                                                                             |\n\n## (@/<A7B7=< (=:: (/F\n\nThe Tax Cuts and Jobs Act of 2017 eliminated the deferral of U.S. income tax on the historical unrepatriated earnings by imposing the one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings (the Transition Toll Tax). The Transition Toll Tax was assessed on our share of our foreign corporations' accumulated foreign earnings that were not previously taxed. Earnings in the form of cash and cash equivalents were taxed at a rate of 15.5% and all other earnings were taxed at a rate of 8.0%.\n\nAs of December 31, 2022 and 2021, we have accrued income tax liabilities of $558.0 million and $633.0 million, respectively, under the Transition Toll Tax. Of the amounts accrued as of December 31, 2022, approximately $137.8 million is expected to be paid within one year. The Transition Toll Tax will be paid in installments over an eight--year period, which started in 2018, and will not accrue interest.\n\n## ,@D7?;FF76 glyph<c=28,font=/PIIBCD+FranklinGothic-Book>3D@;@9E\n\nAt December 31, 2022, we considered our earnings not to be permanently reinvested outside the U.S. and therefore recorded deferred tax liabilities associated with an estimate of the total withholding taxes expected as a result of our repatriation of earnings. Other than for earnings, we are permanently reinvested for book/tax basis differences of approximately $1.5 billion as of December 31, 2022, primarily arising through the impacts of",
        "metadata": {
            "page": 161
        },
        "id": "5f921c1a-b626-41ce-a231-bc9b4618d288"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\npurchase accounting. These permanently reinvested basis differences could reverse through sales of the foreign subsidiaries, as well as various other events, none of which were considered probable as of December 31, 2022. The residual U.S. tax liability, if these differences reverse, would be between $300.0 million and $400.0 million as of December 31, 2022.\n\n## +glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=29,font=/PIIBCD+FranklinGothic-Book> glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>)glyph<c=24,font=/PIIBCD+FranklinGothic-Book>\n\nMultiple TECFIDERA generic entrants are now in North America, Brazil and certain E.U. countries and have deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA has significantly reduced our TECFIDERA revenue and we expect that TECFIDERA revenue will continue to decline in the future.\n\nAs of December 31, 2020, we assessed the realizability of our deferred tax assets that are dependent on future expected sales of TECFIDERA in the U.S. and reduced the net value of certain deferred tax assets by approximately $1.7 billion and reduced the net value of deferred tax liabilities associated with GILTI and tax credits by approximately $1.6 billion. For the year ended December 31, 2020, the income tax expense associated with these reductions was approximately $90.3 million. We continue to assess the realizability of these deferred tax assets. For the years ended December 31, 2022 and 2021, we recorded increases in these deferred tax assets of approximately $17.4 million and $108.5 million, respectively, and increases in these deferred tax liabilities of approximately $16.7 million and $103.9 million, respectively.\n\n## glyph<c=27,font=/PIIBCD+FranklinGothic-Book>787DD76 +3J glyph<c=24,font=/PIIBCD+FranklinGothic-Book>EE7FE 3@6 #;34;>;F;7E\n\nSignificant components of our deferred tax assets and liabilities are summarized as follows:\n\n|                                                                                                                         | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|-------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book>                       | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                           | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                           |\n| glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>343@@32 B/F /AA3BAglyph<c=20,font=/PIIBDE+FranklinGothic-BookItal>      |                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                            |\n| Tax credits                                                                                                             | $ 112.6                                                                                                                                                                                                                                    | $ 121.0                                                                                                                                                                                                                                    |\n| Inventory, other reserves and accruals                                                                                  | 202.8                                                                                                                                                                                                                                      | 199.4                                                                                                                                                                                                                                      |\n| Intangibles, net                                                                                                        | 1,370.3                                                                                                                                                                                                                                    | 1,477.5                                                                                                                                                                                                                                    |\n| Neurimmune's tax basis in ADUHELM                                                                                       | 470.3                                                                                                                                                                                                                                      | 475.8                                                                                                                                                                                                                                      |\n| IRC Section 174 capitalized research and development                                                                    | 271.8                                                                                                                                                                                                                                      | -                                                                                                                                                                                                                                          |\n| Net operating loss                                                                                                      | 1,845.9                                                                                                                                                                                                                                    | 1,973.0                                                                                                                                                                                                                                    |\n| Share-based compensation                                                                                                | 37.2                                                                                                                                                                                                                                       | 31.7                                                                                                                                                                                                                                       |\n| Other                                                                                                                   | 280.7                                                                                                                                                                                                                                      | 208.8                                                                                                                                                                                                                                      |\n| Valuation allowance                                                                                                     | (2,003.3)                                                                                                                                                                                                                                  | (1,961.3)                                                                                                                                                                                                                                  |\n| Total deferred tax assets                                                                                               | $ 2,588.3                                                                                                                                                                                                                                  | $ 2,525.9                                                                                                                                                                                                                                  |\n| glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>343@@32 B/F :7/07:7B73Aglyph<c=20,font=/PIIBDE+FranklinGothic-BookItal> |                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                            |\n| Purchased intangible assets                                                                                             | $ (76.1)                                                                                                                                                                                                                                   | $ (256.6)                                                                                                                                                                                                                                  |\n| Samsung Bioepis investment installments                                                                                 | (138.0)                                                                                                                                                                                                                                    | -                                                                                                                                                                                                                                          |\n| GILTI                                                                                                                   | (1,002.0)                                                                                                                                                                                                                                  | (1,037.6)                                                                                                                                                                                                                                  |\n| Tax credits                                                                                                             | (228.7)                                                                                                                                                                                                                                    | (260.2)                                                                                                                                                                                                                                    |\n| Depreciation, amortization and other                                                                                    | (251.8)                                                                                                                                                                                                                                    | (250.9)                                                                                                                                                                                                                                    |\n| Total deferred tax liabilities                                                                                          | $ (1,696.6)                                                                                                                                                                                                                                | $ (1,805.3)                                                                                                                                                                                                                                |\n\nThe change in the valuation allowance between December 31, 2022 and 2021, was primarily related to the establishment of a valuation allowance against the deferred tax asset related to Neurimmune SubOne AG's (Neurimmune) tax basis in ADUHELM, as discussed below, and the adjustment of a valuation against certain deferred tax assets, the realization of which is dependent on future sales of TECFIDERA in the U.S., as discussed above.\n\nIn addition to deferred tax assets and liabilities, we have recorded deferred charges related to intra-entity sales of inventory. As of December 31, 2022 and 2021, the total deferred charges were $56.6 million and $39.6 million, respectively.",
        "metadata": {
            "page": 162
        },
        "id": "6f173c46-5d7e-4fd8-9fe7-7435149f55f9"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\n## @8>3F;A@ )76G5F;A@ glyph<c=24,font=/PIIBCD+FranklinGothic-Book>5F\n\nIn August 2022 the IRA was signed into law in the U.S. The IRA introduced new tax provisions, including a 15.0% corporate alternative minimum tax and a 1.0% excise tax on stock repurchases. The provisions of the IRA will be effective for periods after December 31, 2022. The enactment of the IRA did not result in any material adjustments to our income tax provision or net deferred tax assets as of December 31, 2022.\n\n## +3J )3F7\n\nA reconciliation between the U.S. federal statutory tax rate and our effective tax rate is summarized as follows:\n\n|                                 | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n|                                 | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    |\n| Statutory rate                  | 21.0 %                                                                                                                                                                                                                                                                                              | 21.0 %                                                                                                                                                                                                                                                                                              | 21.0 %                                                                                                                                                                                                                                                                                              |\n| State taxes                     | 1.1                                                                                                                                                                                                                                                                                                 | 0.8                                                                                                                                                                                                                                                                                                 | 0.7                                                                                                                                                                                                                                                                                                 |\n| Taxes on foreign earnings       | (4.9)                                                                                                                                                                                                                                                                                               | (10.5)                                                                                                                                                                                                                                                                                              | (3.3)                                                                                                                                                                                                                                                                                               |\n| Tax credits                     | (1.7)                                                                                                                                                                                                                                                                                               | (3.8)                                                                                                                                                                                                                                                                                               | (1.2)                                                                                                                                                                                                                                                                                               |\n| Purchased intangible assets     | 0.3                                                                                                                                                                                                                                                                                                 | (1.6)                                                                                                                                                                                                                                                                                               | 0.7                                                                                                                                                                                                                                                                                                 |\n| TECFIDERA impairment            | -                                                                                                                                                                                                                                                                                                   | -                                                                                                                                                                                                                                                                                                   | 1.8                                                                                                                                                                                                                                                                                                 |\n| GILTI                           | 0.7                                                                                                                                                                                                                                                                                                 | 1.3                                                                                                                                                                                                                                                                                                 | 1.3                                                                                                                                                                                                                                                                                                 |\n| Sale of Samsung Bioepis         | (1.6)                                                                                                                                                                                                                                                                                               | -                                                                                                                                                                                                                                                                                                   | -                                                                                                                                                                                                                                                                                                   |\n| Litigation settlement agreement | 2.6                                                                                                                                                                                                                                                                                                 | -                                                                                                                                                                                                                                                                                                   | -                                                                                                                                                                                                                                                                                                   |\n| Neurimmune tax impacts          | 2.3                                                                                                                                                                                                                                                                                                 | (5.3)                                                                                                                                                                                                                                                                                               | (0.1)                                                                                                                                                                                                                                                                                               |\n| Internal reorganization         | (1.4)                                                                                                                                                                                                                                                                                               | -                                                                                                                                                                                                                                                                                                   | -                                                                                                                                                                                                                                                                                                   |\n| Other                           | (0.8)                                                                                                                                                                                                                                                                                               | 1.1                                                                                                                                                                                                                                                                                                 | (1.2)                                                                                                                                                                                                                                                                                               |\n| Effective tax rate              | 17.6 %                                                                                                                                                                                                                                                                                              | 3.0 %                                                                                                                                                                                                                                                                                               | 19.7 %                                                                                                                                                                                                                                                                                              |\n\n## glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>6/<53A 7< (/F &/B3\n\nFor the year ended December 31, 2022, compared to 2021, the increase in our effective tax rate, excluding the impact of the net Neurimmune deferred tax asset, as discussed below, includes the tax impacts of the litigation settlement agreement and the sale of our building at 125 Broadway. These increases were partially offset by the impact of the current year tax benefits related to an international reorganization to align with global tax developments, the impacts of the sale of our equity interest in Samsung Bioepis and the tax impacts of the decision to discontinue development of vixotrigine. Further in 2021, our effective tax rate benefited from the tax effects of the BIIB111 and BIIB112 impairment charges and the non-cash tax effects of changes in the value of our equity instruments.\n\nFor the year ended December 31, 2021, compared to 2020, the decrease in our effective tax rate, excluding the impact of the Neurimmune deferred tax asset, as discussed below, was primarily due to the change in the territorial mix of our profitability, which included the adverse effect of generic competition for TECFIDERA in the U.S. market, the tax impacts of the BIIB111 and BIIB112 impairment charges and the impact of the non-cash tax effects of changes in the value of our equity investments, where we recorded net unrealized losses in 2021 and net unrealized gains in 2020. Our 2020 effective tax rate also reflected an income tax expense related to the establishment of a valuation allowance against certain deferred tax assets, the realization of which is dependent on future sales of TECFIDERA in the U.S.\n\nFor additional information on the litigation settlement agreement, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=18,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> #B63@ glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=<A=:72/B32 glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>7</<17/: 'B/B3;3<B glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>3B/7: , to these consolidated financial statements.\n\n## \"3C@7;;C<3 glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>343@@32 (/F glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>AA3B\n\nDuring 2021 we recorded a net deferred tax asset in Switzerland of approximately $100.0 million on Neurimmune's tax basis in ADUHELM, the realization of which was dependent on future sales of ADUHELM.\n\nDuring the first quarter of 2022, upon issuance of the final NCD related to ADUHELM, we recorded an increase in a valuation allowance of approximately $85.0 million to reduce the net value of this deferred tax asset to zero.",
        "metadata": {
            "page": 163
        },
        "id": "38801530-27bf-4fcc-bc9f-80f809633f9e"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nThese adjustments to our net deferred tax asset are each recorded with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.\n\nFor additional information on our collaboration arrangement with Neurimmune, please read \"=B3 glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=10,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><D3AB;3<BA 7< */@7/0:3 glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><B3@3AB glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal><B7B73A , to these consolidated financial statements.\n\n## (/F glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>BB@70CB3A\n\nAs of December 31, 2022, we had general business credit carry forwards for U.S. federal income tax purposes of approximately $8.1 million, which begin to expire in 2027. For U.S. state income tax purposes, we had research and investment credit carry forwards of approximately $132.7 million that begin to expire in 2023 and net operating losses of approximately $24.8 million that begin to expire in 2036. For foreign income tax purposes, we had $15.5 billion of federal net operating loss carryforwards that begin to expire in 2027 and $15.4 billion of Swiss cantonal net operating loss carryforwards that begin to expire in 2027.\n\nIn assessing the realizability of our deferred tax assets, we have considered whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. In making this determination, under the applicable financial reporting standards, we are allowed to consider the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies. Based upon the level of historical taxable income and income tax liability and projections for future taxable income over the periods in which the deferred tax assets are utilizable, we believe it is more likely than not that we will realize the net benefits of the deferred tax assets of our wholly owned subsidiaries, net of the recorded valuation allowance. In the event that actual results differ from our estimates or we adjust our estimates in future periods, we may need to adjust or establish a valuation allowance, which could materially impact our consolidated financial position and results of operations.\n\n## glyph<c=24,font=/PIIBCD+FranklinGothic-Book>55AG@F;@9 8AD ,@57DF3;@FK ;@  @5A?7 +3J7E\n\nA reconciliation of the beginning and ending amount of our unrecognized tax benefits is summarized as follows:\n\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>   |\n|-----------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Beginning balance                                                                                   | $ 563.4                                                                                                                                                                            | $ 75.7                                                                                                                                                                             | $ 129.9                                                                                                                                                                            |\n| Additions based on tax positions related to the current period                                      | 36.3                                                                                                                                                                               | 4.2                                                                                                                                                                                | 1.5                                                                                                                                                                                |\n| Additions for tax positions of prior periods                                                        | 23.4                                                                                                                                                                               | 509.9                                                                                                                                                                              | 51.7                                                                                                                                                                               |\n| Reductions for tax positions of prior periods                                                       | (14.9)                                                                                                                                                                             | (18.8)                                                                                                                                                                             | (63.6)                                                                                                                                                                             |\n| Statute expirations                                                                                 | (1.6)                                                                                                                                                                              | (3.2)                                                                                                                                                                              | (7.9)                                                                                                                                                                              |\n| Settlement refund (payment)                                                                         | (0.2)                                                                                                                                                                              | (4.4)                                                                                                                                                                              | (35.9)                                                                                                                                                                             |\n| Ending balance                                                                                      | $ 606.4                                                                                                                                                                            | $ 563.4                                                                                                                                                                            | $ 75.7                                                                                                                                                                             |\n\nDuring the year ended December 31, 2021, we increased our gross unrecognized tax benefits by approximately $455.0 million, related to a deferred tax asset for Swiss tax purposes for Neurimmune's tax basis in ADUHELM. This unrecognized tax benefit was recorded as a reduction to the gross deferred tax asset, resulting in the net deferred tax asset, as discussed above, and not as a separate liability on our consolidated balance sheets. As of December 31, 2022, the unrecognized tax benefit related to Neurimmune was approximately $450.0 million, as a result of changes in exchange rates.\n\nOur 2020 activity reflects the impact of the effective settlement of certain tax matters. We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2017 or state, local or non-U.S. income tax examinations for years before 2013.\n\nThe U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.",
        "metadata": {
            "page": 164
        },
        "id": "0d51bc2e-ed7a-4b06-8d9e-fefff6a32882"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nIncluded in the balance of unrecognized tax benefits as of December 31, 2022, 2021 and 2020, are $134.0 million, $87.5 million and $68.8 million (net of the federal benefit on state issues), respectively, of unrecognized tax benefits that, if recognized, would affect the effective income tax rate in future periods.\n\nWe recognize potential interest and penalties related to unrecognized tax benefits in income tax expense. During the years ended December 31, 2022, 2021 and 2020, we recognized total interest and penalty expense of $0.7 million, $2.7 million and $1.0 million, respectively. We have accrued $25.2 million and $24.8 million for the payment of interest and penalties as of December 31, 2022 and 2021, respectively.\n\nIt is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.\n\nWe estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could decrease by up to approximately $500.0 million, including approximately $450.0 million related to the unrecognized tax benefits related to Neurimmune's tax basis in ADUHELM, as discussed above, in the next 12 months as a result of various audit closures, settlements and expiration of the statute of limitations. Any changes to our gross unrecognized tax benefits related to Neurimmune's tax basis in ADUHELM would result in a zero net impact to net income attributable to Biogen, Inc., as we have recorded a full valuation allowance against the relevant deferred tax assets.\n\n## *GBB>7?7@F3> glyph<c=26,font=/PIIBCD+FranklinGothic-Book>3E: glyph<c=29,font=/PIIBCD+FranklinGothic-Book>>AI @8AD?3F;A@\n\nSupplemental disclosure of cash flow information for the years ended December 31, 2022, 2021 and 2020, is as follows:\n\n|                                                                                                   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    |\n| Cash paid during the year for:                                                                    |                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                     |\n| Interest                                                                                          | $ 262.5                                                                                                                                                                                                                                                                                             | $ 280.8                                                                                                                                                                                                                                                                                             | $ 272.7                                                                                                                                                                                                                                                                                             |\n| Income taxes                                                                                      | 932.9                                                                                                                                                                                                                                                                                               | 247.9                                                                                                                                                                                                                                                                                               | 906.7                                                                                                                                                                                                                                                                                               |\n\n## &F:7D glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @5A?7glyph<c=7,font=/PIIBCD+FranklinGothic-Book> glyph<c=28,font=/PIIBCD+FranklinGothic-Book>JB7@E7glyph<c=9,font=/PIIBCD+FranklinGothic-Book> %7F\n\nComponents of other (income) expense, net, are summarized as follows:\n\n|                                                                                                   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    |\n| Gain on sale of equity interest in Samsung Bioepis (1)                                            | $ (1,505.4)                                                                                                                                                                                                                                                                                         | $                                                                                                                                                                                                                                                                                                   | - $ -                                                                                                                                                                                                                                                                                               |\n| Litigation settlement agreement and settlement fees                                               | 917.0                                                                                                                                                                                                                                                                                               | -                                                                                                                                                                                                                                                                                                   | -                                                                                                                                                                                                                                                                                                   |\n| Interest income                                                                                   | (89.3)                                                                                                                                                                                                                                                                                              | (11.0)                                                                                                                                                                                                                                                                                              | (42.0)                                                                                                                                                                                                                                                                                              |\n| Interest expense                                                                                  | 246.6                                                                                                                                                                                                                                                                                               | 253.6                                                                                                                                                                                                                                                                                               | 222.5                                                                                                                                                                                                                                                                                               |\n| (Gains) losses on investments, net                                                                | 277.3                                                                                                                                                                                                                                                                                               | 824.9                                                                                                                                                                                                                                                                                               | (685.7)                                                                                                                                                                                                                                                                                             |\n| Foreign exchange (gains) losses, net                                                              | 35.5                                                                                                                                                                                                                                                                                                | 22.4                                                                                                                                                                                                                                                                                                | 10.7                                                                                                                                                                                                                                                                                                |\n| Other, net                                                                                        | 10.1                                                                                                                                                                                                                                                                                                | 5.6                                                                                                                                                                                                                                                                                                 | (2.9)                                                                                                                                                                                                                                                                                               |\n| Total other (income) expense, net                                                                 | $ (108.2)                                                                                                                                                                                                                                                                                           | $ 1,095.5                                                                                                                                                                                                                                                                                           | $ (497.4)                                                                                                                                                                                                                                                                                           |\n\nThe (gains) losses on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.",
        "metadata": {
            "page": 165
        },
        "id": "1c17e0c6-b36f-4007-ae18-6ca317185027"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nDuring the second quarter of 2022 we recorded a pre-tax charge of $900.0 million, plus settlement fees and expenses, related to a litigation settlement agreement to resolve a qui tam litigation relating to conduct prior to 2015. This charge is included within other (income) expense, net in our consolidated statements of income for the year ended December 31, 2022.\n\nThe following table summarizes our (gains) losses on investments, net that relates to our equity securities held as of December 31, 2022, 2021 and 2020:\n\n|                                                                                                   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    |\n| Net (gains) losses recognized on equity securities                                                | $ 264.7                                                                                                                                                                                                                                                                                             | $ 821.1                                                                                                                                                                                                                                                                                             | $ (693.9)                                                                                                                                                                                                                                                                                           |\n| Less: Net (gains) losses realized on equity securities                                            | -                                                                                                                                                                                                                                                                                                   | (10.3)                                                                                                                                                                                                                                                                                              | (12.1)                                                                                                                                                                                                                                                                                              |\n| Unrealized (gains) losses recognized on equity securities                                         | $ 264.7                                                                                                                                                                                                                                                                                             | $ 831.4                                                                                                                                                                                                                                                                                             | $ (681.8)                                                                                                                                                                                                                                                                                           |\n\nThe net unrealized losses recognized during the year ended December 31, 2022, primarily reflect a decrease in the aggregate fair value of our investments in Denali and Sangamo common stock of approximately $278.0 million. The net unrealized losses recognized during the year ended December 31, 2021, primarily reflect decreases in the aggregate fair value of our investments in Denali, Sage, Sangamo and Ionis common stock of approximately $819.6 million.\n\n## glyph<c=24,font=/PIIBCD+FranklinGothic-Book>55DG76 glyph<c=28,font=/PIIBCD+FranklinGothic-Book>JB7@E7 3@6 &F:7D\n\nAccrued expense and other consists of the following:\n\n|                                                                                                   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                           | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                           |\n| Revenue-related reserves for discounts and allowances                                             | $ 891.6                                                                                                                                                                                                                                    | $ 802.1                                                                                                                                                                                                                                    |\n| Employee compensation and benefits                                                                | 395.6                                                                                                                                                                                                                                      | 345.1                                                                                                                                                                                                                                      |\n| Collaboration expense                                                                             | 277.9                                                                                                                                                                                                                                      | 324.7                                                                                                                                                                                                                                      |\n| Royalties and licensing fees                                                                      | 209.4                                                                                                                                                                                                                                      | 234.7                                                                                                                                                                                                                                      |\n| Other                                                                                             | 746.9                                                                                                                                                                                                                                      | 828.6                                                                                                                                                                                                                                      |\n| Total accrued expense and other                                                                   | $ 2,521.4                                                                                                                                                                                                                                  | $ 2,535.2                                                                                                                                                                                                                                  |\n\nOther long-term liabilities were $944.2 million and $1,320.5 million as of December 31, 2022 and 2021, respectively, and included accrued income taxes totaling $541.7 million and $664.5 million, respectively.\n\n## %AF7 glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=22,font=/PIIBCD+FranklinGothic-Book>glyph<c=23,font=/PIIBCD+FranklinGothic-Book> glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A>>34AD3F;H7 3@6 &F:7D )7>3F;A@E:;BE\n\nIn connection with our business strategy, we have entered into various collaboration agreements that provide us with rights to develop, produce and market products using certain know-how, technology and patent rights maintained by our collaborative partners. Terms of the various collaboration agreements may require us to make milestone payments upon the achievement of certain product research and development objectives and pay royalties on future sales, if any, of commercial products resulting from the collaboration.\n\nDepending on the collaborative arrangement, we may record funding receivable or payable balances with our collaboration partners, based on the nature of the cost-sharing mechanism and activity within the collaboration. Our significant collaborative arrangements are discussed below.\n\n## glyph<c=30,font=/PIIBCD+FranklinGothic-Book>7@7@F75:glyph<c=9,font=/PIIBCD+FranklinGothic-Book> @5glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=6,font=/PIIBCD+FranklinGothic-Book>)A5:7 glyph<c=30,font=/PIIBCD+FranklinGothic-Book>DAGBglyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nWe have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO (mosunetuzumab), which was granted accelerated approval in the U.S. during the fourth quarter of 2022 for the treatment of relapsed or refractory follicular lymphoma; glofitamab, an investigational bispecific antibody for the potential treatment of non-Hodgkin's lymphoma; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.",
        "metadata": {
            "page": 166
        },
        "id": "8a6997df-145e-44b0-9b40-4c04d6d26435"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nIf we undergo a change in control, as defined in our collaboration agreement, Genentech has the right to present an offer to buy the rights to RITUXAN and we must either accept Genentech's offer or purchase Genentech's rights on the same terms as its offer. Genentech will also be deemed concurrently to have purchased our rights to the remaining products in the collaboration on the terms set forth below.\n\nOur collaboration with Genentech was created through a contractual arrangement and not through a joint venture or other legal entity.\n\n## &glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>(),glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>\"\n\nGenentech and its affiliates are responsible for the worldwide manufacture of RITUXAN as well as all development and commercialization activities as follows:\n\n- I )glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal>'glyph<c=9,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=20,font=/PIIBDE+FranklinGothic-BookItal> We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in the U.S.\n- I glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>/</2/glyph<c=20,font=/PIIBDE+FranklinGothic-BookItal> We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in Canada.\n\n## glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>.-*glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>\n\nThe Roche Group and its sub-licensees maintain sole responsibility for the development, manufacture and commercialization of GAZYVA in the U.S. The level of gross sales of GAZYVA in the U.S. could impact our percentage of the co-promotion profits for RITUXAN and LUNSUMIO, as summarized in the table below.\n\n## #glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>&glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>*)'\n\nPursuant to the terms of our collaboration arrangements with Genentech, we receive a tiered royalty on U.S. net sales from 13.5% and increasing up to 24.0% if annual net sales exceed $900.0 million. There will be a 50.0% reduction to these royalties if a biosimilar to OCREVUS is approved in the U.S.\n\nIn addition, we receive a gross 3.0% royalty on net sales of OCREVUS outside the U.S., with the royalty period lasting 11 years from the first commercial sale of OCREVUS on a country-by-country basis.\n\nThe commercialization of OCREVUS does not impact the percentage of the co-promotion profits we receive for RITUXAN or GAZYVA. Genentech is solely responsible for development and commercialization of OCREVUS and funding future costs. Genentech cannot develop OCREVUS in CLL, non-Hodgkin's lymphoma or rheumatoid arthritis.\n\nOCREVUS royalty revenue is based on our estimates from third-party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenue will be adjusted for in the period in which they become known, which is generally expected to be the following quarter.\n\nIf we undergo a change in control, as defined in our collaboration agreement, Genentech will be deemed to have purchased our rights to OCREVUS in exchange for the continued payment of the current royalties on net sales (as defined in our collaboration agreement and summarized above) in the U.S. only, until the 11 year anniversary of the first commercial sale of OCREVUS in the U.S.\n\n## )\"')!glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal># glyph<c=5,font=/PIIBDE+FranklinGothic-BookItal>;=AC<3BCHC;/0glyph<c=6,font=/PIIBDE+FranklinGothic-BookItal>\n\nIn January 2022 we exercised our option with Genentech to participate in the joint development and commercialization of LUNSUMIO. In connection with this exercise, we recorded a $30.0 million option exercise fee payable to Genentech in December 2021, which was recognized in research and development expense in our consolidated statements of income for the year ended December 31, 2021. We also recorded a charge of approximately $20.0 million to reimburse Genentech for our 30.0% share of the costs incurred in developing this product candidate during 2021, which was recognized in research and development expense in our consolidated statements of income for the year ended December 31, 2021. For the year ended December 31, 2022, we recorded approximately $28.4 million in research and development expense and approximately $13.0 million in sales and marketing expense in our consolidated statements of income related to this collaboration.\n\nUnder our collaboration with Genentech, we were responsible for 30.0% of development costs for LUNSUMIO prior to FDA approval and will be entitled to a tiered share of co-promotion operating profits and losses in the U.S., as summarized in the table below. In addition, we receive low single-digit royalties on sales of LUNSUMIO outside the U.S. In December 2022 LUNSUMIO was granted accelerated approval by the FDA for the treatment of relapsed or refractory follicular lymphoma.",
        "metadata": {
            "page": 167
        },
        "id": "7dea19b7-3fe4-4d28-afdc-51408e8f5e81"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nIf we undergo a change in control, as defined in our collaboration agreement, Genentech will be deemed to have purchased our rights to LUNSUMIO in exchange for 30.0% of the U.S. co-promotion operating profits or losses until the 11 year anniversary of the first commercial sale of LUNSUMIO in the U.S.\n\n## glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>:=47B/;/0\n\nIn December 2022 we entered into an agreement with Genentech related to the commercialization and sharing of economics for glofitamab, a late-stage bispecific antibody in development for B-cell non-Hodgkin's lymphoma and other blood cancers. Under the terms of this agreement, we will have no payment obligations and will receive tiered royalties on potential net sales of glofitamab in the U.S. Genentech will have sole decision-making rights on the commercialization of glofitamab within the U.S and, in the event of approval, we are eligible to receive tiered royalties in the mid-single digit range on potential net sales of glofitamab in the U.S.\n\nIf we undergo a change in control, as defined in our collaboration agreement, Genentech will be deemed to have purchased our rights to Glofitamab in exchange for a mid-single digit royalty on net sales (as defined in our collaboration agreement) in the U.S. only, until the 11 year anniversary of the first commercial sale of the product in the U.S.\n\n## $@=47Bglyph<c=8,font=/PIIBDE+FranklinGothic-BookItal>A6/@7<5 glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>=@;C:/A\n\n## &glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>(),glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>\" /<2  )\"')!glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal># $@=47B '6/@3\n\nOur current pretax co-promotion profit-sharing formula for RITUXAN and LUNSUMIO in the U.S. provides for a 30.0% share on the first $50.0 million of combined co-promotion operating profits earned each calendar year. As a result of the FDA approval of LUNSUMIO our share of the combined annual co-promotion profits for RITUXAN and LUNSUMIO in excess of $50.0 million varies upon the following events, as summarized in the table below:\n\n| After LUNSUMIO Approval until the First Threshold Date     | 37.5 %   |\n|------------------------------------------------------------|----------|\n| After First Threshold Date until the Second Threshold Date | 35.0 %   |\n| After Second Threshold Date                                | 30.0 %   |\n\nFirst Threshold Date means the earlier of (i) the first day of the calendar quarter following the date U.S. gross sales of GAZYVA within any consecutive 12-month period have reached $500.0 million or (ii) the first date in any calendar year in which U.S. gross sales of LUNSUMIO have reached $150.0 million.\n\nSecond Threshold Date means the later of (i) the first date the gross sales in any calendar year in which U.S. gross sales of LUNSUMIO reach $350.0 million and (ii) January 1 of the calendar year following the calendar year in which the First Threshold Date occurs.\n\nOur share of RITUXAN pre-tax profits in the U.S. in excess of $50.0 million for the years ended December 31, 2022, 2021 and 2020, was 37.5%.\n\n## glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>.-*glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal> $@=47B '6/@3\n\nOur current pretax profit-sharing formula for GAZYVA provides for a 35.0% share on the first $50.0 million of operating profits earned each calendar year. Our share of annual co-promotion profits in excess of $50.0 million varies upon the following events, as summarized in the table below:\n\n| Until Second GAZYVA Threshold Date   | 37.5 %   |\n|--------------------------------------|----------|\n| After Second GAZYVA Threshold Date   | 35.0 %   |\n\nSecond GAZYVA Threshold Date means the first day of the calendar quarter following the date U.S. gross sales of GAZYVA within any consecutive 12-month period have reached $500.0 million. The second GAZYVA threshold date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.\n\nOur share of GAZYVA pre-tax profits in excess of $50.0 million for the years ended December 31, 2022, 2021 and 2020, was 37.5%.\n\nIf we undergo a change in control, as defined in our collaboration agreement, Genentech will be deemed to have purchased our rights to GAZYVA in exchange for the continued payment of the compensation payable for GAZYVA under the collaboration arrangement (and set forth above) until the 11 year anniversary of the first commercial sale of GAZYVA in the U.S.",
        "metadata": {
            "page": 168
        },
        "id": "aa01e911-e999-4220-8e26-6348f6dd45a7"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\n## &3D3<C3 4@=; glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal><B7glyph<c=8,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=10,font=/PIIBDE+FranklinGothic-BookItal> (63@/>3CB71 $@=5@/;A\n\n## Revenue from anti-CD20 therapeutic programs is summarized as follows:\n\n|                                                                                                   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    |\n| Royalty revenue on sales of OCREVUS                                                               | $ 1,136.3                                                                                                                                                                                                                                                                                           | $ 991.7                                                                                                                                                                                                                                                                                             | $ 845.4                                                                                                                                                                                                                                                                                             |\n| Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA                              | 547.0                                                                                                                                                                                                                                                                                               | 647.7                                                                                                                                                                                                                                                                                               | 1,080.2                                                                                                                                                                                                                                                                                             |\n| Other revenue from anti-CD20 therapeutic programs                                                 | 17.2                                                                                                                                                                                                                                                                                                | 19.1                                                                                                                                                                                                                                                                                                | 52.2                                                                                                                                                                                                                                                                                                |\n| Total revenue from anti-CD20 therapeutic programs                                                 | $ 1,700.5                                                                                                                                                                                                                                                                                           | $ 1,658.5                                                                                                                                                                                                                                                                                           | $ 1,977.8                                                                                                                                                                                                                                                                                           |\n\nPrior to regulatory approval, we record our share of the expense incurred by the collaboration for the development of anti-CD20 products in research and development expense and pre-commercialization costs within selling, general and administrative expense in our consolidated statements of income. After an anti-CD20 product is approved, we record our share of the development and sales and marketing expense related to that product as a reduction of our share of pre-tax profits in revenue from anti-CD20 therapeutic programs.\n\n## A@;E ':3D?357GF;53>Eglyph<c=9,font=/PIIBCD+FranklinGothic-Book> @5glyph<c=11,font=/PIIBCD+FranklinGothic-Book>\n\n## '$glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>\"&glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>.glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>\n\nIn January 2012 we entered into a collaboration and license agreement with Ionis Pharmaceuticals Inc. (Ionis) pursuant to which we have an exclusive, worldwide license to develop and commercialize SPINRAZA for the treatment of SMA.\n\nUnder our agreement with Ionis, we make royalty payments to Ionis on annual worldwide net sales of SPINRAZA using a tiered royalty rate between 11.0% and 15.0%, which are recognized in cost of sales within our consolidated statements of income. Royalty cost of sales related to sales of SPINRAZA for the years ended December 31, 2022, 2021 and 2020, totaled approximately $243.1 million, $267.1 million and $286.6 million, respectively.\n\n## glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=10,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=18,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>=<7A glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>5@33;3<B\n\nIn June 2018 we entered into a 10-year exclusive collaboration agreement with Ionis to develop novel antisense oligonucleotide (ASO) drug candidates for a broad range of neurological diseases for a total payment of $1.0 billion, consisting of an upfront payment of $375.0 million and the purchase of approximately 11.5 million shares of Ionis common stock at a cost of $625.0 million.\n\nUpon closing, we recorded $50.9 million of the $375.0 million upfront payment as prepaid services in our consolidated balance sheets and recognized the remaining $324.1 million as research and development expense in our consolidated statements of income. The amount recorded as prepaid services represented the value of the employee resources committed to the arrangement to provide research and discovery services over the term of the agreement.\n\nWe have the option to license therapies arising out of this agreement and will be responsible for the development and commercialization of such therapies. We may pay development milestones to Ionis of up to $125.0 million or $270.0 million for each program, depending on the indication plus an annual license fee, as well as royalties on potential net commercial sales.\n\nDuring the years ended December 31, 2022, 2021 and 2020, we incurred milestones of $10.0 million, $22.5 million and $11.3 million, respectively, related to the advancement of neurological targets identified under this agreement, which were recorded as research and development expense in our consolidated statements of income.\n\n## glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=10,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=17,font=/PIIBDE+FranklinGothic-BookItal> '!glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7=< glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>5@33;3<B\n\nIn December 2017 we entered into a collaboration agreement with Ionis to identify new ASO drug candidates for the potential treatment of SMA. Under this agreement, we have the option to license therapies arising out of this collaboration and will be responsible for their development and commercialization of such therapies.\n\nUpon entering into this agreement, we made a $25.0 million upfront payment to Ionis and we may pay Ionis up to $260.0 million in additional development and regulatory milestone payments if new drug candidates advance to marketing approval. Upon commercialization, we may also pay Ionis up to $800.0 million in additional performancebased milestone payments and tiered royalties on potential net sales of such therapies.",
        "metadata": {
            "page": 169
        },
        "id": "13b21cbb-d39c-451e-9531-5218e9c26611"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nIn December 2021 we exercised our option with Ionis and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB115, an investigational ASO in development for SMA. In connection with this option exercise, we made an opt-in payment of $60.0 million to Ionis, which was recorded as research and development expense in our consolidated statements of income for the year ended December 31, 2021.\n\n## glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=10,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=13,font=/PIIBDE+FranklinGothic-BookItal> =<5glyph<c=8,font=/PIIBDE+FranklinGothic-BookItal>B3@; 'B@/B3571 &3A3/@16 glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>5@33;3<B\n\nIn September 2013 we entered into a six-year research collaboration agreement with Ionis under which both companies collaborate to perform discovery level research and subsequent development and commercialization activities of antisense or other therapeutics for the potential treatment of neurological diseases. Under this agreement, Ionis performs research on a set of neurological targets identified within the agreement.\n\nIonis is eligible to receive milestone payments, license fees and royalty payments for all product candidates developed through this collaboration, with the specific amount dependent upon the modality of the product candidate advanced by us under the terms of the agreement.\n\nFor non-ALS antisense product candidates, Ionis is responsible for global development through the completion of a Phase 2 trial and we provide advice on the clinical trial design and regulatory strategy. For ALS antisense product candidates, we are responsible for global development, clinical trial design and regulatory strategy. We have an option to license a product candidate until completion of the Phase 2 trial. If we exercise our option, we will pay Ionis up to a $70.0 million license fee and assume global development, regulatory and commercialization responsibilities. Ionis could receive additional milestone payments upon the achievement of certain regulatory milestones of up to $130.0 million, plus additional amounts related to the cost of clinical trials conducted by Ionis under the collaboration, and royalties on future sales if we successfully develop the product candidate after option exercise.\n\nIn December 2018 we exercised our option with Ionis and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize tofersen (BIIB067), an investigational treatment for ALS with superoxide dismutase 1 (SOD1) mutations. Potential post-licensing milestone payments may include up to $55.0 million and royalties in the low- to mid-teen percentages on potential annual worldwide net sales. We are solely responsible for the costs and expense related to the development, manufacturing and commercialization of tofersen following the option exercise.\n\nDuring the years ending December 31, 2022, 2021 and 2020, we incurred milestones of $17.0 million, $10.0 million and $28.0 million, respectively, related to the advancement of programs under this agreement, which were recorded as research and development expense in our consolidated statements of income.\n\n## glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=10,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>=<7A glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>5@33;3<B\n\nIn December 2012 we entered into an agreement with Ionis for the development and commercialization of up to three gene targets.\n\nUnder this agreement, Ionis is responsible for global development of any product candidate through the completion of a Phase 2 trial and we will provide advice on the clinical trial design and regulatory strategy. We have an option to license the product candidate until completion of the Phase 2 trial. If we exercise our option, we will pay a license fee of up to $70.0 million to Ionis and assume global development, regulatory and commercialization responsibilities. Ionis is eligible to receive up to $130.0 million in additional milestone payments upon the achievement of certain regulatory milestones as well as royalties on future sales if we successfully develop the product candidate after option exercise.\n\nIn December 2019 we exercised our option with Ionis and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB080 (tau ASO), which is currently in Phase 2 development for the potential treatment of Alzheimer's disease. In connection with the option exercise, we made a payment of $45.0 million to Ionis, which was recorded as research and development expense in our consolidated statements of income. Future payments may include additional milestone payments of up to $155.0 million and royalties on future sales in the low- to mid-teens if we successfully develop the product candidate after option exercise.\n\nDuring the year ended December 31, 2022, we incurred a milestone payment of $10.0 million, related to the advancement of BIIB080 under this agreement, which was recorded within research and development expense in our consolidated statements of income.",
        "metadata": {
            "page": 170
        },
        "id": "02328cef-5cac-4dc9-9ac8-448e9360bb03"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\n## glyph<c=28,font=/PIIBCD+FranklinGothic-Book>;E3; glyph<c=26,font=/PIIBCD+FranklinGothic-Book>Aglyph<c=11,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> #F6glyph<c=11,font=/PIIBCD+FranklinGothic-Book>\n\n## glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>%glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>!glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=5,font=/PIIBDE+FranklinGothic-BookItal>:31/<3;/0glyph<c=6,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7=<\n\nWe have a collaboration agreement with Eisai to jointly develop and commercialize LE , EMBI (lecanemab), an anti-amyloid antibody for the potential treatment of Alzheimer's disease (the LE , EMBI Collaboration).\n\nEisai serves as the lead of LE , EMBI development and regulatory submissions globally with both companies cocommercializing and co-promoting the product, and Eisai having final decision-making authority. All costs, including research, development, sales and marketing expense, are shared equally between us and Eisai. Upon LE , EMBI marketing approval, we and Eisai will co-promote LE , EMBI and share profits and losses equally. We currently manufacture LE , EMBI drug substance and drug product and in March 2022 we extended our supply agreement with Eisai related to LE , EMBI from five years to ten years for the manufacture of LE , EMBI drug substance.\n\nThe LE , EMBI Collaboration also provided Eisai with an option to jointly develop and commercialize ADUHELM (aducanumab) (ADUHELM Option), and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). In October 2017 Eisai exercised its ADUHELM Option and we entered into a new collaboration agreement for the joint development and commercialization of ADUHELM (aducanumab) (the ADUHELM Collaboration Agreement).\n\nOn March 14, 2022, we amended our ADUHELM Collaboration Agreement with Eisai. As of the amendment date, we have sole decision making and commercialization rights worldwide on ADUHELM, and beginning January 1, 2023, Eisai receives only a tiered royalty based on net sales of ADUHELM, and no longer participates in sharing ADUHELM's global profits and losses. In March 2022 we also amended the LE , EMBI Collaboration Agreement with Eisai to eliminate the Anti-Tau Option.\n\nIf either company undergoes a change of control, as defined in our LE , EMBI Collaboration Agreement, the nonacquired party may elect to initiate an operational separation, as defined in the LE , EMBI Collaboration Agreement. In the event of an operational separation, we would work with Eisai to effect a timely transition of any development, manufacturing or commercial responsibilities regarding LE , EMBI from us to Eisai. In this scenario, as of six months following the change of control, our ongoing responsibility for LE , EMBI related cost-sharing would be reduced to an amount equal to 80.0% of what we would have owed prior to the operational separation, and all other economic rights would remain unchanged.\n\nIn addition, in the event either company undergoes a change of control in which the acquirer is engaged in commercialization of a competing product, as defined in the LE , EMBI Collaboration Agreement, the non-acquired party may also request that the acquired party cease commercializing the competing product. Should the acquired party elect to continue commercializing the competing product, the non-acquired party may terminate the LE , EMBI Collaboration Agreement. Furthermore, in the event we are the non-acquired party, we may choose either to sell our interest in LE , EMBI to Eisai or purchase Eisai's interest in LE , EMBI, subject to the parameters set forth in the LE , EMBI Collaboration Agreement.\n\nA summary of development and sales and marketing expense related to the LE , EMBI Collaboration is as follows:\n\n|                                                                                                                                                                             | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book>                                                                           | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    |\n| Total development expense incurred by the collaboration related to the advancement of LE , EMBI                                                                             | $ 347.2                                                                                                                                                                                                                                                                                             | $ 323.0                                                                                                                                                                                                                                                                                             | $ 219.3                                                                                                                                                                                                                                                                                             |\n| Biogen's share of the LE , EMBI Collaboration development expense reflected in research and development expense in our consolidated statements of income                    | 173.6                                                                                                                                                                                                                                                                                               | 161.5                                                                                                                                                                                                                                                                                               | 109.6                                                                                                                                                                                                                                                                                               |\n| Total sales and marketing expense incurred by the LE , EMBI Collaboration                                                                                                   | 104.6                                                                                                                                                                                                                                                                                               | 27.2                                                                                                                                                                                                                                                                                                | 9.8                                                                                                                                                                                                                                                                                                 |\n| Biogen's share of the LE , EMBI Collaboration sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income | 52.3                                                                                                                                                                                                                                                                                                | 13.6                                                                                                                                                                                                                                                                                                | 4.9                                                                                                                                                                                                                                                                                                 |\n\n## glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>)glyph<c=28,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal> ! glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7=< glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>5@33;3<B\n\nUnder our initial ADUHELM Collaboration Agreement, we would lead the ongoing development of ADUHELM, and we and Eisai would co-promote ADUHELM with a region-based profit split. Beginning in 2019, Eisai was reimbursing us for 45.0% of development and sales and marketing expense incurred by the collaboration for the advancement of ADUHELM.",
        "metadata": {
            "page": 171
        },
        "id": "bffbaf37-c84c-4fee-aeb0-396875466a7e"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nOn March 14, 2022, we amended our ADUHELM Collaboration Agreement with Eisai. As of the amendment date, we have sole decision making and commercialization rights worldwide on ADUHELM, and beginning January 1, 2023, Eisai receives only a tiered royalty based on net sales of ADUHELM, and no longer participates in sharing ADUHELM's global profits and losses. Eisai's share of development, commercialization and manufacturing expense was limited to $335.0 million for the period from January 1, 2022 to December 31, 2022, which was achieved as of December 31, 2022. Once this limit was achieved, we became responsible for all ADUHELM related costs.\n\nA summary of development expense, sales and marketing expense and milestone payments related to the ADUHELM Collaboration Agreement is as follows:\n\n|                                                                                                                                                                                                                   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book>                                                                                                                 | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    |\n| Total ADUHELM development expense                                                                                                                                                                                 | $ 149.4                                                                                                                                                                                                                                                                                             | $ 183.7                                                                                                                                                                                                                                                                                             | $ 152.0                                                                                                                                                                                                                                                                                             |\n| Biogen's share of the ADUHELM Collaboration development expense reflected in research and development expense in our consolidated statements of income                                                            | 82.2                                                                                                                                                                                                                                                                                                | 101.1                                                                                                                                                                                                                                                                                               | 83.6                                                                                                                                                                                                                                                                                                |\n| Total ADUHELM sales and marketing expense incurred by the ADUHELM Collaboration Agreement                                                                                                                         | 134.2                                                                                                                                                                                                                                                                                               | 562.3                                                                                                                                                                                                                                                                                               | 353.0                                                                                                                                                                                                                                                                                               |\n| Biogen's share of the ADUHELM Collaboration sales and marketing expense reflected in selling, general and administrative expense and collaboration profit (loss) sharing in our consolidated statements of income | 71.5                                                                                                                                                                                                                                                                                                | 301.4                                                                                                                                                                                                                                                                                               | 193.7                                                                                                                                                                                                                                                                                               |\n| Total ADUHELM Collaboration third party milestones                                                                                                                                                                | -                                                                                                                                                                                                                                                                                                   | 100.0                                                                                                                                                                                                                                                                                               | 75.0                                                                                                                                                                                                                                                                                                |\n| Biogen's share of reimbursement from Eisai of ADUHELM milestone payments reflected in collaboration profit (loss) sharing in our consolidated statements of income                                                | -                                                                                                                                                                                                                                                                                                   | 45.0                                                                                                                                                                                                                                                                                                | 33.8                                                                                                                                                                                                                                                                                                |\n\n## glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>)glyph<c=28,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal> ! glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=glyph<c=8,font=/PIIBDE+FranklinGothic-BookItal>>@=;=B7=< $@=47BA /<2  =AA3A\n\nIn the U.S. we recognize revenue on sales of ADUHELM to third parties as a component of product revenue, net in our consolidated statements of income. We also record the related cost of revenue and sales and marketing expense in our consolidated statements of income as these costs are incurred. Payments made to and received from Eisai for its 45.0% share of the co-promotion profits or losses in the U.S. are recognized in collaboration profit (loss) sharing in our consolidated statements of income. For the years ended December 31, 2022 and 2021, we recognized net reductions to our operating expense of approximately $224.7 million and $233.2 million, respectively, to reflect Eisai's 45.0% share of net collaboration losses in the U.S.\n\nFor the year ended December 31, 2021, we recognized a net reduction to our operating expense of $45.0 million to reflect Eisai's 45.0% share of the $100.0 million milestone payment made to Neurimmune related to the launch of ADUHELM in the U.S., which was recorded in collaboration profit (loss) sharing in our consolidated statements of income.\n\nFor the year ended December 31, 2020, we recognized a net reduction to our operating expense of $33.8 million to reflect Eisai's 45.0% share of the $75.0 million milestone payment made to Neurimmune related to the submission of a Biologics License Application (BLA) to the FDA for the approval of ADUHELM, which was recorded in collaboration profit (loss) sharing in our consolidated statements of income.\n\nDuring the fourth quarter of 2021 we recorded approximately $164.0 million of charges associated with the write-off of inventory and purchase commitments in excess of forecasted demand related to ADUHELM. During the first quarter of 2022, as a result of the final NCD, we recorded approximately $275.0 million of charges associated with the write-off of inventory and purchase commitments in excess of forecasted demand related to ADUHELM. Additionally, for the years ended December 31, 2022 and 2021, we recorded approximately $111.0 million and $30.0 million, respectively, of aggregate gross idle capacity charges related to ADUHELM. These charges were recorded in cost of sales within our consolidated statements of income for the years ended December 31, 2022 and 2021.\n\nWe have recognized approximately $197.0 million and $99.0 million related to Eisai's 45.0% share of inventory, idle capacity charges and contractual commitments in collaboration profit (loss) sharing within our consolidated statements of income for the years ended December 31, 2022 and 2021, respectively.\n\nAmounts receivable from Eisai related to the agreements discussed above were approximately $88.0 million and $285.4 million as of December 31, 2022 and 2021, respectively. Amounts payable to Eisai related to the agreements discussed above were approximately $81.2 million and $46.5 million as of December 31, 2022 and 2021, respectively.",
        "metadata": {
            "page": 172
        },
        "id": "aacc7aa1-0a08-483c-a291-57e231d65c9f"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nIn addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.\n\n## ,glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=25,font=/PIIBCD+FranklinGothic-Book>\n\nIn November 2003 we entered into a collaboration agreement with UCB to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of systemic lupus erythematosus and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity.\n\nAll costs incurred for agreed indications, including research, development, sales and marketing expense, are shared equally between us and UCB. If marketing approval is obtained, both companies will co-promote dapirolizumab pegol and share profits and losses equally.\n\nA summary of development expense related to the UCB collaboration agreement is as follows:\n\n|                                                                                                                                                    | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|----------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| (In millions)                                                                                                                                      | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    |\n| Total UCB collaboration development expense                                                                                                        | $ 68.0                                                                                                                                                                                                                                                                                              | $ 84.2                                                                                                                                                                                                                                                                                              | $ 58.3                                                                                                                                                                                                                                                                                              |\n| Biogen's share of the UCB collaboration development expense reflected in research and development expense in our consolidated statements of income | 34.0                                                                                                                                                                                                                                                                                                | 42.1                                                                                                                                                                                                                                                                                                | 29.2                                                                                                                                                                                                                                                                                                |\n\n## glyph<c=24,font=/PIIBCD+FranklinGothic-Book>>=7D?7E\n\nIn November 2017 we entered into an exclusive license and collaboration agreement with Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc (Alkermes), for VUMERITY, a novel fumarate for the treatment of RMS. In October 2019 the FDA approved VUMERITY in the U.S. for the treatment of RMS. During the fourth quarter of 2021 VUMERITY was approved for the treatment of relapsing-remitting MS (RRMS) in the E.U., Switzerland and the United Kingdom (U.K.).\n\nUnder this agreement, we received an exclusive, worldwide license to develop and commercialize VUMERITY and we pay Alkermes royalties of 15.0% on worldwide net commercial sales of VUMERITY, which are recognized in cost of sales within our consolidated statements of income. Royalties payable on net commercial sales of VUMERITY are subject, under certain circumstances, to tiered minimum annual payment requirements for a period of five years following FDA approval. Royalty cost of sales related to sales of VUMERITY for the years ended December 31, 2022, 2021 and 2020, totaled approximately $83.0 million, $61.6 million and $12.9 million, respectively.\n\nAlkermes is eligible to receive royalties in the high-single digits to sub-teen double digits of annual net commercial sales upon successful development and commercialization of new product candidates, other than VUMERITY, developed under the exclusive license from Alkermes.\n\nAlkermes currently supplies both VUMERITY and FAMPYRA to us pursuant to separate supply agreements. In October 2019 we entered into a new supply agreement and amended our license and collaboration agreement with Alkermes for VUMERITY. We have elected to initiate a technology transfer and, following a transition period, to manufacture VUMERITY or have VUMERITY manufactured by a third party we have engaged in exchange for paying an increased royalty rate to Alkermes on any portion of future worldwide net commercial sales of VUMERITY that is manufactured by us or our designee. In October 2022 we entered into a new supply agreement with Alkermes for FAMPYRA. Acorda previously supplied FAMPYRA to us pursuant to a sublicensing arrangement with Alkermes, which was terminated in October 2022 as a result of an arbitration outcome between Acorda and Alkermes.\n\n## glyph<c=24,font=/PIIBCD+FranklinGothic-Book>5AD63 +:7D3B7GF;5Eglyph<c=9,font=/PIIBCD+FranklinGothic-Book> @5glyph<c=11,font=/PIIBCD+FranklinGothic-Book>\n\nIn June 2009 we entered into a collaboration and license agreement with Acorda Therapeutics, Inc. (Acorda) to develop and commercialize products containing fampridine, such as FAMPYRA, in markets outside the U.S. We are responsible for all regulatory activities and the future clinical development of related products in those markets.\n\nUnder this agreement, we pay tiered royalties based on the level of ex-U.S. net sales and we may pay potential milestone payments based on the successful achievement of certain regulatory and commercial milestones, which would be capitalized as intangible assets upon achievement of the milestones and amortized utilizing an economic consumption model. During the third quarter of 2020 we recognized a milestone of $15.0 million, which became due",
        "metadata": {
            "page": 173
        },
        "id": "77fa329b-51fd-4687-ae95-2453fe70abe0"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nupon ex-U.S. net sales reaching $100.0 million over a period of four consecutive quarters, and was capitalized within intangible assets, net in our consolidated balance sheets.\n\nIn connection with the collaboration and license agreement, we also entered into a supply agreement with Acorda for the commercial supply of FAMPYRA. This agreement was a sublicense arrangement of an existing agreement between Acorda and Alkermes Inc., who acquired Elan Drug Technologies, the original party to the license with Acorda. In October 2022 we learned that, as a result of an arbitration filed by Acorda with the American Arbitration Association in July 2020 after Acorda and Alkermes were unable to resolve a dispute over license and supply royalties, Acorda no longer had to pay Alkermes any royalties on net sales for license and supply of FAMPYRA and Acorda was now free to use alternative sources for supply of FAMPYRA. Acorda notified us that as a result of it no longer obtaining FAMPYRA from Alkermes, that we would need to enter into a supply agreement to obtain FAMPYRA directly with Alkermes.\n\nFor the years ending December 31, 2022, 2021 and 2020, total cost of sales related to royalties and commercial supply of FAMPYRA reflected in our consolidated statements of income were approximately $46.1 million, $46.6 million and $44.5 million, respectively.\n\n## *397 +:7D3B7GF;5Eglyph<c=9,font=/PIIBCD+FranklinGothic-Book> @5glyph<c=11,font=/PIIBCD+FranklinGothic-Book>\n\nIn November 2020 we entered into a global collaboration and license agreement with Sage to jointly develop and commercialize zuranolone (BIIB125) for the potential treatment of MDD and PPD and BIIB124 (SAGE-324) for the potential treatment of essential tremor with potential in other neurological conditions such as epilepsy.\n\nIn connection with the closing of this transaction in December 2020 we purchased $650.0 million of Sage common stock, or approximately 6.2 million shares at approximately $104.14 per share, which were initially subject to transfer restrictions. We recorded an asset in investments and other assets in our consolidated balance sheets to reflect the initial fair value of the Sage common stock acquired and a charge of approximately $209.0 million to research and development expense in our consolidated statements of income to reflect the premium paid for the Sage common stock. We also made an upfront payment of $875.0 million that was recorded as research and development expense within our consolidated statements of income for the year ended December 31, 2020.\n\nWe may also pay Sage development and commercial milestone payments that could total up to approximately $1.6 billion if all the specified milestones set forth in this collaboration are achieved. Both companies will share equal responsibility and costs for development as well as profits and losses for commercialization in the U.S. Outside of the U.S., we are responsible for development and commercialization, excluding Japan, Taiwan and South Korea, with respect to zuranolone and may pay Sage potential tiered royalties in the high teens to low twenties. We may pay Sage milestones totaling $225.0 million upon the first commercial sale of zuranolone, for the potential treatment of MDD and PPD, in the U.S.\n\nA summary of development and sales and marketing expense related to this collaboration is as follows:\n\n|                                                                                                                                                                        | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| (In millions)                                                                                                                                                          | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    |\n| Total Sage collaboration development expense                                                                                                                           | $ 173.3                                                                                                                                                                                                                                                                                             | $ 167.7                                                                                                                                                                                                                                                                                             | $ -                                                                                                                                                                                                                                                                                                 |\n| Biogen's share of the Sage collaboration development expense reflected in research and development expense in our consolidated statements of income                    | 86.7                                                                                                                                                                                                                                                                                                | 83.8                                                                                                                                                                                                                                                                                                | -                                                                                                                                                                                                                                                                                                   |\n| Total Sage sales and marketing expense incurred by the collaboration                                                                                                   | 109.9                                                                                                                                                                                                                                                                                               | 36.4                                                                                                                                                                                                                                                                                                | -                                                                                                                                                                                                                                                                                                   |\n| Biogen's share of the Sage collaboration sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income | 55.0                                                                                                                                                                                                                                                                                                | 18.2                                                                                                                                                                                                                                                                                                | -                                                                                                                                                                                                                                                                                                   |",
        "metadata": {
            "page": 174
        },
        "id": "63e7aa42-9a47-4c27-9349-42c9a9bfdd25"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\n## glyph<c=27,font=/PIIBCD+FranklinGothic-Book>7@3>; +:7D3B7GF;5E  @5glyph<c=11,font=/PIIBCD+FranklinGothic-Book>\n\nIn August 2020 we entered into a collaboration and license agreement with Denali to co-develop and cocommercialize Denali's small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson's disease. In addition to the LRRK2 program, we also have an exclusive option to license two preclinical programs from Denali's Transport Vehicle platform, including its Antibody Transport Vehicle (ATV): ATV enabled anti-amyloid beta program and a second program utilizing its Transport Vehicle technology. Further, we have a right of first negotiation on two additional ATV-enabled therapeutics for indications within specific neurodegenerative diseases, should Denali decide to seek a collaboration for such programs.\n\nAs part of this collaboration we purchased $465.0 million of Denali common stock in September 2020, or approximately 13 million shares at approximately $34.94 per share, which were initially subject to transfer restrictions. We recorded an asset in investments and other assets in our consolidated balance sheets to reflect the initial fair value of the Denali common stock acquired and a charge of approximately $41.3 million to research and development expense in our consolidated statements of income to reflect the premium paid for the Denali common stock. We also made an upfront payment of $560.0 million that was recorded as research and development expense within our consolidated statements of income for the year ended December 31, 2020.\n\nWe may also pay Denali development and commercial milestone payments that could total up to approximately $1.1 billion if the milestones related to the LRRK2 program are achieved. Under this collaboration, both companies share responsibility and costs for global development based on specified percentages as well as profits and losses for commercialization in the U.S. and China. Outside the U.S. and China we are responsible for commercialization and may pay Denali potential tiered royalties.\n\nIn October 2022 we and Denali announced the initiation of the Phase 3 LIGHTHOUSE study for BIIB122 (DNL151), a small molecule inhibitor of LRRK2 for the potential treatment of Parkinson's disease.\n\nA summary of development expense related to this collaboration is as follows:\n\n|                                                                                                                                                       | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=29,font=/PIIBCD+FranklinGothic-Book>AD F:7 073DE glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@676 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book>   |\n|-------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| (In millions)                                                                                                                                         | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    | glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>                                                                                                                    |\n| Total Denali collaboration development expense                                                                                                        | $ 75.1                                                                                                                                                                                                                                                                                              | $ 42.5                                                                                                                                                                                                                                                                                              | $ 14.6                                                                                                                                                                                                                                                                                              |\n| Biogen's share of the Denali collaboration development expense reflected in research and development expense in our consolidated statements of income | 43.8                                                                                                                                                                                                                                                                                                | 25.5                                                                                                                                                                                                                                                                                                | 8.8                                                                                                                                                                                                                                                                                                 |\n\n## *3@93?A +:7D3B7GF;5Eglyph<c=9,font=/PIIBCD+FranklinGothic-Book> @5glyph<c=11,font=/PIIBCD+FranklinGothic-Book>\n\nIn February 2020 we entered into a collaboration and license agreement with Sangamo to develop and commercialize ST-501 for tauopathies, including Alzheimer's disease; ST-502 for synucleinopathies, including Parkinson's disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a five-year period. The companies are leveraging Sangamo's proprietary zinc finger protein technology delivered via adeno-associated virus to modulate the expression of key genes involved in neurological diseases.\n\nIn connection with the closing of this transaction in April 2020 we purchased $225.0 million of Sangamo common stock, or approximately 24 million shares at approximately $9.21 per share, which were initially subject to transfer restrictions. We recorded an asset in investments and other assets in our consolidated balance sheets to reflect the initial fair value of the Sangamo common stock acquired and a charge of approximately $83.0 million to research and development expense in our consolidated statements of income to reflect the premium paid for the Sangamo common stock. We also made an upfront payment of $125.0 million that was recorded as research and development expense within our consolidated statements of income for the year ended December 31, 2020.\n\nWe may also pay Sangamo research, development, regulatory and commercial milestone payments that could total up to approximately $2.4 billion if we select all of the targets allowed under this collaboration and all the specified milestones set forth in this collaboration are achieved. Of this amount, up to $80.0 million relates to the selection of targets, $1.9 billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones and $380.0 million relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. In addition, we may pay Sangamo tiered royalties on potential net sales of any products developed under this collaboration in the high single digit to sub-teen percentages.",
        "metadata": {
            "page": 175
        },
        "id": "87db5668-816b-45dc-aae7-65cb91590ea9"
    },
    {
        "page_content": "## BIOGEN INC. AND SUBSIDIARIES\n\n## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (Continued)\n\nA summary of development expense related to this collaboration is as follows:\n\n|                                                                                                                                                        | For the Years Ended December 31,   | For the Years Ended December 31,   | For the Years Ended December 31,   |\n|--------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|------------------------------------|------------------------------------|\n| (In millions)                                                                                                                                          | 2022                               | 2021                               | 2020                               |\n| Total Sangamo collaboration development expense                                                                                                        | $ 19.1                             | $ 22.7                             | $ 10.1                             |\n| Biogen's share of the Sangamo collaboration development expense reflected in research and development expense in our consolidated statements of income | 12.1                               | 14.6                               | 6.4                                |\n\n## InnoCare Pharma Limited\n\nIn July 2021 we entered into a collaboration and license agreement with InnoCare Pharma Limited (InnoCare) for orelabrutinib, an oral small molecule Bruton's tyrosine kinase inhibitor for the potential treatment of MS. Orelabrutinib is currently being studied in a multi-country, placebo-controlled Phase 2 trial in RRMS. Under the terms of this collaboration, we have exclusive rights to orelabrutinib in the field of MS worldwide and certain autoimmune diseases outside of China (including Hong Kong, Macau and Taiwan), while InnoCare retains exclusive worldwide rights to orelabrutinib in the field of oncology and certain autoimmune diseases in China (including Hong Kong, Macau and Taiwan).\n\nIn connection with the closing of this transaction in August 2021 we made an upfront payment of $125.0 million that was recorded as research and development expense within our consolidated statements of income for the year ended December 31, 2021. We may also pay InnoCare up to approximately $812.5 million in potential development milestones and potential commercial payments should this collaboration achieve certain development, commercial milestones and sales thresholds. In addition, we may pay InnoCare tiered royalties on potential net sales of any products developed under this collaboration in the low to high teen percentages.\n\nIn February 2023 we terminated our license and collaboration agreement with InnoCare for orelabrutinib, for the potential treatment of MS.\n\n## Other Research and Discovery Arrangements\n\nThese arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.\n\n## Other\n\nFor the years ended December 31, 2022, 2021 and 2020, we recorded approximately $39.2 million, $89.1 million and $92.1 million, respectively, as research and development expense in our consolidated statements of income related to other research and discovery related arrangements.\n\n## Samsung Bioepis Co., Ltd.\n\n## Joint Venture Agreement\n\nIn February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. Samsung BioLogics contributed 280.5 billion South Korean won (approximately $250.0 million) for an 85.0% ownership interest in Samsung Bioepis and we contributed 49.5 billion South Korean won (approximately $45.0 million) for the remaining 15.0% ownership interest. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately 5.0%, which reflected the effect of previous equity financings in which we did not participate, to approximately 49.9%. The share purchase transaction was completed in November 2018 and, upon closing, we paid 759.5 billion South Korean won ($676.6 million) to Samsung BioLogics.\n\nIn April 2022 we completed the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics. Under the terms of this transaction, we received approximately $1.0 billion in cash at closing and expect to receive approximately $1.3 billion in cash to be deferred over two payments of approximately $812.5 million due at the first anniversary and approximately $437.5 million due at the second anniversary of the closing of this transaction.\n\nAs part of this transaction, we are also eligible to receive up to an additional $50.0 million upon the achievement of certain commercial milestones. Our policy for contingent payments of this nature is to recognize the payments in the period that they become realizable, which is generally the same period in which the payments are earned.",
        "metadata": {
            "page": 176
        },
        "id": "5ab417e7-a2de-432f-8872-f7a144f63a3c"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nPrior to this sale, we recognized our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity became available, which was reflected as equity in (income) loss of investee, net of tax in our consolidated statements of income.\n\nUpon our November 2018 investment, the equity method of accounting required us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These basis differences were being amortized over their economic life, until the completion of the sale in April 2022, as discussed above. The total basis difference was approximately $675.0 million and related to inventory, developed technology, IPR&D and deferred tax balances. The basis differences related to inventory were amortized, net of tax, over their estimated useful lives of 1.5 years, and the basis differences related to developed technology and IPR&D for marketed products were being amortized, net of tax, over their estimated useful lives of 15 years.\n\nFor the year ended December 31, 2022, we recognized net income on our investment of $2.6 million, reflecting our share of Samsung Bioepis' operating profits, net of tax, totaling $17.0 million offset by amortization of basis differences totaling $14.4 million. This amount reflects our share of results prior to the sale of Samsung Bioepis as the results are recognized one quarter in arrears. Following the sale of Samsung Bioepis we no longer recognize gains or losses associated with Samsung Bioepis' results of operations and amortization related to basis differences.\n\nFor the year ended December 31, 2021, we recognized net income on our investment of $34.9 million, reflecting our share of Samsung Bioepis' operating profits, net of tax, totaling $64.6 million offset by amortization of basis differences totaling $29.7 million.\n\nNet income on our investment for the year ended December 31, 2021, reflects a $31.2 million benefit related to the release of a valuation allowance on deferred tax assets associated with Samsung Bioepis. The valuation allowance was released in the second quarter of 2021 based on a consideration of the positive and negative evidence, including the historic earnings of Samsung Bioepis.\n\nAs of December 31, 2021, the carrying value of our investment in Samsung Bioepis totaled 713.3 billion South Korean won ($599.9 million), which is classified as a component of investments and other assets within our consolidated balance sheets. In connection with the sale of Samsung Bioepis, the carrying value of our investment was reduced to zero.\n\nFor additional information on the sale of our equity interest in Samsung Bioepis, please read \"=B3 glyph<c=13,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>7A>=A7B7=<A , to these consolidated financial statements.\n\n## glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=10,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>3D3:=>;3<B /<2 glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=;;3@17/:7H/B7=< glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>5@33;3<B\n\nIn December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, BYOOVIZ (ranibizumab-nuna), a ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us at a pre-specified gross margin of approximately 45.0%.\n\nIn connection with this transaction, we made an upfront payment of $100.0 million to Samsung Bioepis in January 2020, of which $63.0 million was recorded as research and development expense in our consolidated statements of income in 2019 and $37.0 million was recorded as an intangible assets, net in our consolidated balance sheets in 2019.\n\nDuring the third quarter of 2020 we paid Samsung Bioepis a $15.0 million development milestone, which was included in research and development expense in our consolidated statements of income. During the third quarter of 2021 we accrued $15.0 million in milestone payments related to the approval of BYOOVIZ in the U.S., the E.U. and the U.K., that were capitalized within intangible assets, net in our consolidated balance sheets. We may also pay Samsung Bioepis up to approximately $180.0 million in additional development, regulatory and sales-based milestones.\n\nWe also acquired an option to extend the term of our 2013 commercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional five years, subject to payment of an option exercise fee of $60.0 million, and obtained an option to acquire exclusive rights to commercialize these products in China.",
        "metadata": {
            "page": 177
        },
        "id": "bb4f0443-292b-4b85-8b05-a1f8aeaf8f91"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\n## glyph<c=12,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=10,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=13,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=;;3@17/: glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>5@33;3<B\n\nIn December 2013 we entered into an agreement with Samsung Bioepis to commercialize, over a 10-year term, 3 anti-tumor necrosis factor (TNF) biosimilar product candidates in Europe and in the case of BENEPALI, Japan. As discussed above, we have an option to extend this agreement by an additional five years. Under this agreement, we have made upfront and clinical development milestone payments totaling $46.0 million, which were recorded as research and development expense in our consolidated statements of income as the programs they relate to had not achieved regulatory approval. We also agreed to make additional milestone payments of $25.0 million upon regulatory approval in the E.U. for each of the three anti-TNF biosimilar product candidates. IMRALDI, an adalimumab biosimilar referencing HUMIRA, FLIXABI, an infliximab biosimilar referencing REMICADE, and BENEPALI, an etanercept biosimilar referencing ENBREL, received regulatory approval in the E.U. in August 2017, May 2016 and January 2016, respectively, and we capitalized the related milestone payments totaling $75.0 million as intangible assets, net in our consolidated balance sheets.\n\nWe reflect revenue on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenue, net in our consolidated statements of income and record the related cost of revenue and sales and marketing expense in our consolidated statements of income to their respective line items when these costs are incurred. Royalty payments to AbbVie Inc. (AbbVie) on sales of IMRALDI are recognized in cost of sales within our consolidated statements of income.\n\nWe share 50.0% of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our consolidated statements of income. For the years ended December 31, 2022, 2021 and 2020, we recognized net profit-sharing expense of $217.4 million, $285.4 million and $266.5 million, respectively, to reflect Samsung Bioepis' 50.0% sharing of the net collaboration profits.\n\n## #B63@ '3@D713A\n\nSimultaneous with the formation of Samsung Bioepis, we also entered into a license agreement with Samsung Bioepis.\n\nUnder the license agreement, we granted Samsung Bioepis an exclusive license to use, develop, manufacture and commercialize biosimilar products created by Samsung Bioepis using Biogen product-specific technology. In exchange, we receive single digit royalties on biosimilar products developed and commercialized by Samsung Bioepis.\n\nFor the years ended December 31, 2022, 2021 and 2020, we recognized $20.6 million, $20.7 million and $20.9 million, respectively, in royalty revenue under the license agreement, as a component of other revenue in our consolidated statements of income.\n\nAmounts receivable from Samsung Bioepis related to the agreements discussed above were $2.0 million and $4.1 million as of December 31, 2022 and 2021, respectively. Amounts payable to Samsung Bioepis related to the agreements discussed above were $40.5 million and $148.7 million as of December 31, 2022 and 2021, respectively.\n\n## %AF7 glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=23,font=/PIIBCD+FranklinGothic-Book> @H7EF?7@FE ;@ -3D;34>7  @F7D7EF glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@F;F;7E\n\n## glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@EA>;63F76 -3D;34>7  @F7D7EF glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@F;F;7E\n\nOur consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.\n\n## \"3C@7;;C<3 'C0#<3 glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>\n\nWe have a collaboration and license agreement with Neurimmune for the development and commercialization of antibodies for the potential treatment of Alzheimer's disease, including ADUHELM (as amended, the Neurimmune Agreement). We are responsible for the development, manufacturing and commercialization of all collaboration products. The Neurimmune Agreement is effective for the longer of the duration of certain patents relating to a licensed product or 12 years from the first commercial sale of a licensed product.\n\nWe consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity's economic performance and we are required to fund 100.0% of the research and development costs incurred in support of the collaboration. Our royalty rates payable on products developed under the",
        "metadata": {
            "page": 178
        },
        "id": "e36587ec-d5f5-438f-ba5b-4307ea3fef77"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nNeurimmune Agreement, including royalty rates payable on commercial sales of ADUHELM, range from the high single digits to sub-teens.\n\nUnder the terms of the Neurimmune Agreement, we were required to pay Neurimmune a milestone payment of $75.0 million upon the regulatory filing with the FDA for the approval of ADUHELM. During the second quarter of 2020 we paid Neurimmune $75.0 million upon the completed submission of the BLA for the approval of ADUHELM to the FDA, which was recognized as a charge to net income (loss) attributable to noncontrolling interests, net of tax in our consolidated statements of income. In addition, during the second quarter of 2020 we recognized net profitsharing income of $33.8 million to reflect Eisai's 45.0% share of the $75.0 million milestone payment, which was recognized in collaboration profit (loss) sharing in our consolidated statements of income.\n\nIn June 2021 ADUHELM was granted accelerated approval by the FDA. Under the terms of the Neurimmune Agreement, we were required to pay Neurimmune a milestone payment of $100.0 million related to the launch of ADUHELM in the U.S. During the second quarter of 2021 we made this $100.0 million payment, which was recognized as a charge to net income (loss) attributable to noncontrolling interests, net of tax in our consolidated statements of income. In addition, during the second quarter of 2021 we recognized net profit-sharing income of $45.0 million to reflect Eisai's 45.0% share of the $100.0 million milestone payment, which was recognized in collaboration profit (loss) sharing in our consolidated statements of income.\n\nDuring 2021 we recorded a net deferred tax asset in Switzerland of approximately $100.0 million on Neurimmune's tax basis in ADUHELM, the realization of which was dependent on future sales of ADUHELM. During the first quarter of 2022, upon issuance of the final NCD related to ADUHELM, we recorded an increase in a valuation allowance of approximately $85.0 million to reduce the net value of this deferred tax asset to zero. These adjustments to our net deferred tax asset are each recorded with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.\n\nExcluding the impact of the Neurimmune deferred tax asset, the assets and liabilities of Neurimmune are not significant to our consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.\n\nResearch and development costs for which we reimburse Neurimmune are reflected in research and development expense in our consolidated statements of income. During the years ending December 31, 2022, 2021 and 2020, amounts reimbursed were immaterial.\n\nFor additional information on our collaboration arrangements with Eisai, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>A , to these consolidated financial statements.\n\n## ,@5A@EA>;63F76 -3D;34>7  @F7D7EF glyph<c=28,font=/PIIBCD+FranklinGothic-Book>@F;F;7E\n\nWe have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements.\n\nAs of December 31, 2022 and 2021, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled $27.8 million and $24.6 million, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.\n\nWe have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previous contractually required amounts.\n\n## %AF7 glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=23,font=/PIIBCD+FranklinGothic-Book> #;F;93F;A@\n\nWe are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> 'C;;/@G =4 '75<7471/<B glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>11=C<B7<5 $=:7173A , to these consolidated financial statements.",
        "metadata": {
            "page": 179
        },
        "id": "d08c8ee2-60dc-4c8a-b100-c127ea382b72"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nWith respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties' legal theories; and (v) the parties' settlement positions. If an estimate of the possible loss or range of loss can be made at this time, it is included in the potential loss contingency description below.\n\nThe claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third-parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.\n\n## #AEE glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@97@5;7E\n\n## glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>)glyph<c=28,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal> ! '31C@7B73A  7B75/B7=<\n\nWe and certain current and former officers are named as defendants in actions filed by shareholders in November 2020 (the November 2020 Securities Action) and February 2022 (the February 2022 Securities Action) and pending in the U.S. District Court for the District of Massachusetts. The actions allege violations of federal securities laws under 15 U.S.C S 78j(b) and S 78t(a) and 17 C.F.R. S 240.10b-5 and seek declarations of the actions as class actions and monetary relief. In September 2022, the court dismissed the November 2020 Securities Action, and the plaintiff has appealed to the U.S. Court of Appeals for the First Circuit. Our motion to dismiss the February 2022 Securities Action is pending.\n\n## '6/@36=:23@ glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>3@7D/B7D3 glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>1B7=<A\n\nWe and members of the Board of Directors are named as defendants in derivative actions filed by shareholders on February 9 and July 21, 2022, in the U.S. District Court for the District of Massachusetts. The actions allege violations of federal securities laws under 15 U.S.C. S 78n(a) and 17 C.F.R. S 240 14.a-9, breaches of fiduciary duties and waste of corporate assets, and seek declaratory and injunctive relief, monetary relief payable to Biogen, and attorneys' fees and costs payable to the plaintiffs. The court has stayed both cases.\n\n## glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>!&glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal> $/B3<B  7B75/B7=<\n\nIn September 2018 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris and proceedings against Biogen GmbH in the D Q sseldorf Regional Court, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis that Biogen commercializes in Europe, infringes national counterparts of European Patent No. 3 148 510 (the EP '510 Patent). In June 2022 Fresenius Kabi amended both actions to assert claims under European Patent 3 145 488 (the EP ] 488 Patent), which expires in May 2035. No hearing has been set in either action.\n\nIn June 2022 the Technical Boards of Appeal (TBA) of the European Patent Office (EPO) affirmed the revocation of the EP '510 Patent, which resolves all pending infringement claims under the EP '510 Patent. The EPO upheld the validity of the EP '488 Patent in October 2022.\n\nIn June 2020 Fresenius Kabi commenced preliminary injunction proceedings in Denmark's Maritime and Commercial High Court alleging that IMRALDI infringes the Danish counterpart of the EP '488 Patent and a corresponding Danish utility model, DK 2020 00038 Y3. In September 2021 the Court refused Fresenius Kabi's request for a preliminary injunction and Fresenius Kabi has withdrawn its appeal.\n\nIn July 2019 Gedeon Richter Nyrt commenced proceedings for damages and injunctive relief against Biogen GmbH in the D Q sseldorf Regional Court, alleging infringement of the German counterpart of European Patent No. 3 212 667 (the EP '667 Patent), which expires in October 2035. The case has been stayed pending Gedeon Richter's appeal to the TBA of the revocation of the patent. A hearing has been set by the TBA for July 2023.\n\nIn November 2020 Gedeon Richter Nyrt commenced proceedings against Biogen GmbH in the D Q sseldorf Regional Court alleging infringement of a German utility model corresponding to EP '667. The proceeding has been stayed pending the outcome of proceedings that Biogen has filed in the German Patent and Trademark Office to cancel the utility model, and in which a hearing has been set for March 2023.",
        "metadata": {
            "page": 180
        },
        "id": "42547c6e-225a-44f6-a699-58294cd0209d"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\n## glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>7A>CB3 E7B6 glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>=@;3@ glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=<D3@53<13 '6/@36=:23@A\n\nIn 2015 Biogen acquired Convergence, a UK company. In November and December 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, sent us correspondence asserting claims of $200.0 million for alleged breach of the contract under which we acquired Convergence. We dispute the claims.\n\n## glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>&glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>'glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>:/AA glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>1B7=< 7B75/B7=<\n\nIn September 2020 the U.S. District Court for the District of Massachusetts consolidated two cases filed against us in July and August 2020 by participants in the Biogen 401(k) Savings Plan, alleging breach of fiduciary duty under ERISA. Plaintiffs seek a declaration of the action as a class action and monetary and other relief.\n\n## glyph<c=28,font=/PIIBDE+FranklinGothic-BookItal>C;/</ $/B73<B glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>AA7AB/<13 7B75/B7=<\n\nIn September 2021 Humana Inc. (Humana) filed suit against us in the U.S. District Court for the District of Massachusetts, alleging damages related to our providing MS patients with free medications and making charitable contributions to non-profit organizations that assist MS patients. Humana alleges violation of the federal RICO Act and state laws and seeks statutory treble damages, attorneys' fees and costs. We filed a motion to dismiss, which is pending.\n\n## glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>7AB@70CB=@ !/BB3@\n\nIn December 2022 we terminated our distribution agreement with the distributor of products for Biogen in various countries in the Middle East and northern Africa. The former distributor has asserted breach of contract. No suit has been filed.\n\n## &F:7D $3FF7DE\n\n## glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>=D3@<;3<B glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><D3AB75/B7=<A\n\nThe company has received subpoenas from the Securities and Exchange Commission seeking information relating to ADUHELM, including healthcare sites and ADUHELM's approval. In 2021 the U.S. House of Representatives Committees on Oversight and Reform and Energy (House Committees) and the Office of Inspector General (OIG) each announced investigations related to ADUHELM. In December 2022 the House Committees issued a report on their investigation.\n\n## (-'glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>&glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal> $/B3<B !/BB3@A\n\nIn September 2022 we filed an action in the U.S. District Court for the District of Delaware against Sandoz Inc. and Polpharma Biologics S.A. under the Biologics Price Competition and Innovation Act, 42 U.S.C. S 262, seeking a declaratory judgment of patent infringement. No trial date has been set.\n\nIn December 2022 the TBA affirmed the revocation of our European Patent 2 676 967 (the EP '967 Patent), covering pre-treatment testing of patients using natalizumab (TYSABRI).\n\nIn September 2021 Polpharma Biologics S.A., Sandoz AG, Sandoz Limited and Sandoz GmbH filed an action in the English High Court to revoke the U.K. counterpart of the EP ] 967 Patent. No trial date has been set.\n\n## glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal><<C:;3<B $@=13327<5A 7< B63 glyph<c=27,font=/PIIBDE+FranklinGothic-BookItal>3<3@/: glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=C@B =4 B63 glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>C@=>3/< )<7=< @3:/B7<5 B= (glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=26,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=24,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>&glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>\n\nPharmaceutical Works Polpharma SA (Polpharma) and Mylan Ireland Ltd. (Mylan Ireland) each filed actions in the General Court of the European Union (Polpharma in October 2018 and Mylan Ireland in November 2020) to annul the European Medicines Agency's (EMA) decision not to validate their applications to market generic versions of TECFIDERA on the grounds that TECFIDERA benefits from regulatory data protection. On May 5, 2021, the European General Court annulled the EMA's non-validation decision with respect to Polpharma. The European Court of Justice will announce its decision in our appeal of this decision on March 16, 2023. The case brought by Mylan Ireland has been stayed.\n\n## $@=2C1B  7/07:7BG /<2 #B63@  35/: $@=13327<5A\n\nWe are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe",
        "metadata": {
            "page": 181
        },
        "id": "4d5e79b6-fa50-41ae-a460-e0c12d9a478c"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+*\n\nthe ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.\n\n## %AF7 glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=23,font=/PIIBCD+FranklinGothic-Book> glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A??;F?7@FE\n\n3@6 glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@97@5;7E\n\n## )AK3>FK '3K?7@FE\n\n## (-'glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=22,font=/PIIBDE+FranklinGothic-BookItal>&glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>\n\nIn 2013 we acquired from Elan full ownership of all remaining rights to TYSABRI that we did not already own or control. Under the acquisition agreement, we are obligated to make contingent payments to Elan of 18.0% on annual worldwide net commercial sales up to $2.0 billion and 25.0% on annual worldwide net commercial sales that exceed $2.0 billion. Royalty payments to Elan and other third parties are recognized as cost of sales in our consolidated statements of income. Elan was acquired by Perrigo Company plc (Perrigo) in December 2013 and Perrigo subsequently sold its rights to these payments to a third-party effective January 2017.\n\n## '$glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>\"&glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>.glyph<c=21,font=/PIIBDE+FranklinGothic-BookItal>\n\nIn 2016 we exercised our option to develop and commercialize SPINRAZA from Ionis. Under our agreement with Ionis, we make royalty payments to Ionis on annual worldwide net commercial sales of SPINRAZA using a tiered royalty rate between 11.0% and 15.0%, which are recorded as cost of sales in our consolidated statements of income. For additional information on our collaboration arrangements with Ionis, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>A , to these consolidated financial statements.\n\n## *)!glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>&glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal>(-\n\nUnder our agreement with Alkermes, we make royalty payments to Alkermes on worldwide net commercial sales of VUMERITY using a royalty rate of 15.0%, which are recorded as cost of sales in our consolidated statements of income. Royalties payable on net commercial sales of VUMERITY are subject, under certain circumstances, to tiered minimum annual payment requirements for a period of five years following FDA approval. For additional information on our collaboration arrangement with Alkermes, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=19,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=23,font=/PIIBDE+FranklinGothic-BookItal>=::/0=@/B7D3 /<2 #B63@ &3:/B7=<A67>A , to these consolidated financial statements.\n\n## )79G>3FADK 3@6 glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A??7D5;3> $;>7EFA@7 '3K?7@FE\n\nBased on our development plans as of December 31, 2022, we could trigger potential future milestone payments to third parties of up to approximately $9.3 billion, including approximately $2.0 billion in development milestones, approximately $0.5 billion in regulatory milestones and approximately $6.8 billion in commercial milestones, as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones was not considered probable as of December 31, 2022, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory or commercial milestones.\n\nIf certain clinical and commercial milestones are met, we may pay up to $356.2 million in milestones in 2023 under our current agreements. This includes milestones totaling $225.0 million due to Sage upon the first commercial sale of zuranolone, for the potential treatment of MDD and PPD, in the U.S.\n\nDuring the second quarter of 2020 we paid Neurimmune $75.0 million upon the completed submission of the BLA for the approval of ADUHELM to the FDA, which was recognized as a charge to net income (loss) attributable to noncontrolling interests, net of tax in our consolidated statements of income.\n\nIn June 2021 ADUHELM was granted accelerated approval by the FDA. Under the terms of the Neurimmune Agreement, we were required to pay Neurimmune a milestone payment of $100.0 million related to the launch of ADUHELM in the U.S. During the second quarter of 2021 we made this $100.0 million payment, which was recognized as a charge to net income (loss) attributable to noncontrolling interests, net of tax in our consolidated statements of income.",
        "metadata": {
            "page": 182
        },
        "id": "44e5e853-9eda-4ab6-8638-efb9376c11a8"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\n## &F:7D glyph<c=29,font=/PIIBCD+FranklinGothic-Book>G@6;@9 glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A??;F?7@FE\n\nAs of December 31, 2022, we have several ongoing clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to CROs. The contracts with CROs are generally cancellable, with notice, at our option. We recorded accrued expense of approximately $20.4 million in our consolidated balance sheets for expenditures incurred by CROs as of December 31, 2022. We have approximately $929.0 million in cancellable future commitments based on existing CRO contracts as of December 31, 2022.\n\n## +3J )7>3F76 &4>;93F;A@E\n\nWe exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of December 31, 2022, we have approximately $154.6 million of liabilities associated with uncertain tax positions.\n\nAs of December 31, 2022 and 2021, we have accrued income tax liabilities of approximately $558.0 million and $633.0 million, respectively, under the Transition Toll Tax. Of the amounts accrued as of December 31, 2022, approximately $137.8 million is expected to be paid within one year. The Transition Toll Tax will be paid in installments over an eight--year period, which started in 2018, and will not accrue interest. For additional information on the Transition Toll Tax, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=17,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> glyph<c=29,font=/PIIBDE+FranklinGothic-BookItal><1=;3 (/F3A , to these consolidated financial statements.\n\n## %AF7 glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=23,font=/PIIBCD+FranklinGothic-Book> glyph<c=30,font=/PIIBCD+FranklinGothic-Book>G3D3@F77E\n\nAs of December 31, 2022 and 2021, we did not have significant liabilities recorded for guarantees.\n\nWe enter into indemnification provisions under our agreements with other companies in the ordinary course of business, typically with business partners, contractors, clinical sites and customers. Under these provisions, we generally indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of our activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited. However, to date we have not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these agreements is minimal. Accordingly, we have no liabilities recorded for these agreements as of December 31, 2022 and 2021.\n\n## %AF7 glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=17,font=/PIIBCD+FranklinGothic-Book>glyph<c=23,font=/PIIBCD+FranklinGothic-Book> glyph<c=28,font=/PIIBCD+FranklinGothic-Book>?B>AK77 glyph<c=25,font=/PIIBCD+FranklinGothic-Book>7@78;F '>3@E\n\nWe sponsor various retirement and pension plans. Our estimates of liabilities and expense for these plans incorporate a number of assumptions, including expected rates of return on plan assets and interest rates used to discount future benefits.\n\n## glyph<c=17,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=6,font=/PIIBCD+FranklinGothic-Book>=glyph<c=7,font=/PIIBCD+FranklinGothic-Book> *3H;@9E '>3@\n\nWe maintain a 401(k) Savings Plan, which is available to substantially all regular employees in the U.S. over the age of 21. Participants may make voluntary contributions. We make matching contributions according to the 401(k) Savings Plan's matching formula. All matching contributions and participant contributions vest immediately. The 401(k) Savings Plan also holds certain transition contributions on behalf of participants who previously participated in the Biogen, Inc. Retirement Plan. The expense related to our 401(k) Savings Plan primarily consists of our matching contributions.\n\nExpense related to our 401(k) Savings Plan totaled approximately $56.0 million, $58.4 million and $44.3 million for the years ended December 31, 2022, 2021 and 2020, respectively.\n\n## glyph<c=27,font=/PIIBCD+FranklinGothic-Book>787DD76 glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A?B7@E3F;A@ '>3@\n\nWe maintain a non-qualified deferred compensation plan, known as the Supplemental Savings Plan (SSP), which allows a select group of management employees in the U.S. to defer a portion of their compensation. The SSP also provides certain credits to highly compensated U.S. employees that are paid by the company. These credits are known as the Restoration Match. The deferred compensation amounts are accrued when earned. Such deferred compensation is distributable in cash in accordance with the rules of the SSP. Deferred compensation amounts under such plan as of December 31, 2022 and 2021, totaled approximately $131.9 million and $131.4 million, respectively, and are included in other long-term liabilities in our consolidated balance sheets. The SSP also holds certain transition contributions on behalf of participants who previously participated in the Biogen, Inc. Retirement",
        "metadata": {
            "page": 183
        },
        "id": "8e61099f-259c-4387-9bf1-bf4598f7f2a7"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\nPlan. The Restoration Match and participant contributions vest immediately. Distributions to participants can be either in one lump sum payment or annual installments as elected by the participants.\n\n## '7@E;A@ '>3@E\n\nOur retiree benefit plans include defined benefit plans for employees in our affiliates in Switzerland and Germany as well as other insignificant defined benefit plans in certain other countries where we maintain an operating presence.\n\nOur Swiss plan is a government-mandated retirement fund that provides employees with a minimum investment return. The minimum investment return is determined annually by the Swiss government and was 2.00% in 2022 and 1.00% in both 2021 and 2020. Under the Swiss plan, both we and certain of our employees with annual earnings in excess of government determined amounts are required to make contributions into a fund managed by an independent investment fiduciary. Employer contributions must be in an amount at least equal to the employee's contribution. Minimum employee contributions are based on the respective employee's age, salary and gender. As of December 31, 2022 and 2021, the Swiss plan had an unfunded net pension obligation of $49.9 million and $64.1 million, respectively, and plan assets that totaled $193.7 million and $200.1 million, respectively. In 2022, 2021 and 2020 we recognized net expense totaling $20.0 million, $21.5 million and $15.5 million, respectively, related to our Swiss plan, of which $5.3 million, $3.5 million and $2.6 million, respectively, was included in other (income) expense, net in our consolidated statements of income.\n\nThe obligations under the German plans are unfunded and totaled $40.9 million and $68.4 million as of December 31, 2022 and 2021, respectively. Net periodic pension cost related to the German plans totaled $5.9 million, $7.6 million and $6.2 million for the years ended December 31, 2022, 2021 and 2020, respectively, of which $1.8 million, $2.1 million and $2.0 million, respectively, was included in other (income) expense, net in our consolidated statements of income.\n\n## %AF7 glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=18,font=/PIIBCD+FranklinGothic-Book>glyph<c=23,font=/PIIBCD+FranklinGothic-Book>\n\n## *79?7@F  @8AD?3F;A@\n\nWe operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our CEO, as the chief operating decision-maker, manages and allocates resources to the operations of our company on a total company basis. Our research and development organization is responsible for the research and discovery of new product candidates and supports development and registration efforts for potential future products. Our pharmaceutical, operations and technology organization manages the development of the manufacturing processes, clinical trial supply, commercial product supply, distribution, buildings and facilities. Our commercial organization is responsible for U.S. and international development of our commercial products. The company is also supported by corporate staff functions. Managing and allocating resources on a total company basis enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions, therapeutic areas and research and development projects that are in line with our long-term company-wide strategic goals. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.\n\nEnterprise-wide disclosures about product revenue, other revenue and long-lived assets by geographic area are presented below. Revenue is primarily attributed to individual countries based on location of the customer or licensee.",
        "metadata": {
            "page": 184
        },
        "id": "fbe3a944-2d42-4502-b67a-76d6fa83efb4"
    },
    {
        "page_content": "## glyph<c=25,font=/PIIBCD+FranklinGothic-Book> &glyph<c=30,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>% %glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=11,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book> *,glyph<c=25,font=/PIIBCD+FranklinGothic-Book>* glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>) glyph<c=28,font=/PIIBCD+FranklinGothic-Book>*\n\n## %&+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>* +& glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&%*&# glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=24,font=/PIIBCD+FranklinGothic-Book>%glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book># *+glyph<c=24,font=/PIIBCD+FranklinGothic-Book>+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>$glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+* Oglyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>A@F;@G76glyph<c=7,font=/PIIBCD+FranklinGothic-Book>\n\n## glyph<c=30,font=/PIIBCD+FranklinGothic-Book>7A9D3B:;5 @8AD?3F;A@\n\nThe following tables contain certain financial information by geographic area:\n\n|                                                                                                   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | ,glyph<c=11,font=/PIIBCD+FranklinGothic-Book>*glyph<c=11,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                                                                                                                                 | glyph<c=28,font=/PIIBCD+FranklinGothic-Book>GDAB7 glyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=7,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                                       | glyph<c=30,font=/PIIBCD+FranklinGothic-Book>7D?3@K                                                                                                                                                                                                                                                                                                                         | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E;3                                                                                                                                                                                                                                                                                                                            | &F:7D                                                                                                                                                                                                                                                                                                                                                                      | +AF3>                                                                                                                                                                                                                                                                                                                                                                      |\n| Product revenue from external customers                                                           | $ 3,469.3                                                                                                                                                                                                                                                                                                                                                                  | $ 2,401.3                                                                                                                                                                                                                                                                                                                                                                  | $ 926.2                                                                                                                                                                                                                                                                                                                                                                    | $ 672.1                                                                                                                                                                                                                                                                                                                                                                    | $ 518.9                                                                                                                                                                                                                                                                                                                                                                    | $ 7,987.8                                                                                                                                                                                                                                                                                                                                                                  |\n| Revenue from anti-CD20 therapeutic programs                                                       | 1,636.4                                                                                                                                                                                                                                                                                                                                                                    | 0.1                                                                                                                                                                                                                                                                                                                                                                        | -                                                                                                                                                                                                                                                                                                                                                                          | -                                                                                                                                                                                                                                                                                                                                                                          | 64.0                                                                                                                                                                                                                                                                                                                                                                       | 1,700.5                                                                                                                                                                                                                                                                                                                                                                    |\n| Other revenue from external customers                                                             | 425.8                                                                                                                                                                                                                                                                                                                                                                      | 11.7                                                                                                                                                                                                                                                                                                                                                                       | -                                                                                                                                                                                                                                                                                                                                                                          | 47.6                                                                                                                                                                                                                                                                                                                                                                       | -                                                                                                                                                                                                                                                                                                                                                                          | 485.1                                                                                                                                                                                                                                                                                                                                                                      |\n| Long-lived assets                                                                                 | 1,369.4                                                                                                                                                                                                                                                                                                                                                                    | 2,275.8                                                                                                                                                                                                                                                                                                                                                                    | 21.0                                                                                                                                                                                                                                                                                                                                                                       | 13.7                                                                                                                                                                                                                                                                                                                                                                       | 22.6                                                                                                                                                                                                                                                                                                                                                                       | 3,702.5                                                                                                                                                                                                                                                                                                                                                                    |\n\n|                                                                                                   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | ,glyph<c=11,font=/PIIBCD+FranklinGothic-Book>*glyph<c=11,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                                                                                                                                 | glyph<c=28,font=/PIIBCD+FranklinGothic-Book>GDAB7 glyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=7,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                                       | glyph<c=30,font=/PIIBCD+FranklinGothic-Book>7D?3@K                                                                                                                                                                                                                                                                                                                         | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E;3                                                                                                                                                                                                                                                                                                                            | &F:7D                                                                                                                                                                                                                                                                                                                                                                      | +AF3>                                                                                                                                                                                                                                                                                                                                                                      |\n| Product revenue from external customers                                                           | $ 3,805.7                                                                                                                                                                                                                                                                                                                                                                  | $ 2,626.0                                                                                                                                                                                                                                                                                                                                                                  | $ 1,162.4                                                                                                                                                                                                                                                                                                                                                                  | $ 688.0                                                                                                                                                                                                                                                                                                                                                                    | $ 564.8                                                                                                                                                                                                                                                                                                                                                                    | $ 8,846.9                                                                                                                                                                                                                                                                                                                                                                  |\n| Revenue from anti-CD20 therapeutic programs                                                       | 1,596.7                                                                                                                                                                                                                                                                                                                                                                    | -                                                                                                                                                                                                                                                                                                                                                                          | -                                                                                                                                                                                                                                                                                                                                                                          | -                                                                                                                                                                                                                                                                                                                                                                          | 61.8                                                                                                                                                                                                                                                                                                                                                                       | 1,658.5                                                                                                                                                                                                                                                                                                                                                                    |\n| Other revenue from external customers                                                             | 429.9                                                                                                                                                                                                                                                                                                                                                                      | 9.7                                                                                                                                                                                                                                                                                                                                                                        | -                                                                                                                                                                                                                                                                                                                                                                          | 36.7                                                                                                                                                                                                                                                                                                                                                                       | -                                                                                                                                                                                                                                                                                                                                                                          | 476.3                                                                                                                                                                                                                                                                                                                                                                      |\n| Long-lived assets                                                                                 | 1,390.5                                                                                                                                                                                                                                                                                                                                                                    | 2,337.8                                                                                                                                                                                                                                                                                                                                                                    | 25.4                                                                                                                                                                                                                                                                                                                                                                       | 16.4                                                                                                                                                                                                                                                                                                                                                                       | 21.7                                                                                                                                                                                                                                                                                                                                                                       | 3,791.8                                                                                                                                                                                                                                                                                                                                                                    |\n\n|                                                                                                   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>   | glyph<c=27,font=/PIIBCD+FranklinGothic-Book>757?47D glyph<c=16,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=9,font=/PIIBCD+FranklinGothic-Book> glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>glyph<c=15,font=/PIIBCD+FranklinGothic-Book>glyph<c=13,font=/PIIBCD+FranklinGothic-Book>   |\n|---------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| glyph<c=6,font=/PIIBCD+FranklinGothic-Book> @ ?;>>;A@Eglyph<c=7,font=/PIIBCD+FranklinGothic-Book> | ,glyph<c=11,font=/PIIBCD+FranklinGothic-Book>*glyph<c=11,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                                                                                                                                 | glyph<c=28,font=/PIIBCD+FranklinGothic-Book>GDAB7 glyph<c=6,font=/PIIBCD+FranklinGothic-Book>glyph<c=14,font=/PIIBCD+FranklinGothic-Book>glyph<c=7,font=/PIIBCD+FranklinGothic-Book>                                                                                                                                                                                       | glyph<c=30,font=/PIIBCD+FranklinGothic-Book>7D?3@K                                                                                                                                                                                                                                                                                                                         | glyph<c=24,font=/PIIBCD+FranklinGothic-Book>E;3                                                                                                                                                                                                                                                                                                                            | &F:7D                                                                                                                                                                                                                                                                                                                                                                      | +AF3>                                                                                                                                                                                                                                                                                                                                                                      |\n| Product revenue from external customers                                                           | $ 5,900.1                                                                                                                                                                                                                                                                                                                                                                  | $ 2,495.3                                                                                                                                                                                                                                                                                                                                                                  | $ 1,161.1                                                                                                                                                                                                                                                                                                                                                                  | $ 596.7                                                                                                                                                                                                                                                                                                                                                                    | $ 539.0                                                                                                                                                                                                                                                                                                                                                                    | $ 10,692.2                                                                                                                                                                                                                                                                                                                                                                 |\n| Revenue from anti-CD20 therapeutic programs                                                       | 1,897.4                                                                                                                                                                                                                                                                                                                                                                    | 0.1                                                                                                                                                                                                                                                                                                                                                                        | -                                                                                                                                                                                                                                                                                                                                                                          | -                                                                                                                                                                                                                                                                                                                                                                          | 80.3                                                                                                                                                                                                                                                                                                                                                                       | 1,977.8                                                                                                                                                                                                                                                                                                                                                                    |\n| Other revenue from external customers                                                             | 733.6                                                                                                                                                                                                                                                                                                                                                                      | 8.0                                                                                                                                                                                                                                                                                                                                                                        | 0.1                                                                                                                                                                                                                                                                                                                                                                        | 32.9                                                                                                                                                                                                                                                                                                                                                                       | -                                                                                                                                                                                                                                                                                                                                                                          | 774.6                                                                                                                                                                                                                                                                                                                                                                      |\n| Long-lived assets                                                                                 | 1,496.3                                                                                                                                                                                                                                                                                                                                                                    | 2,290.2                                                                                                                                                                                                                                                                                                                                                                    | 31.2                                                                                                                                                                                                                                                                                                                                                                       | 16.2                                                                                                                                                                                                                                                                                                                                                                       | 10.9                                                                                                                                                                                                                                                                                                                                                                       | 3,844.8                                                                                                                                                                                                                                                                                                                                                                    |\n\n## #A@9glyph<c=10,font=/PIIBCD+FranklinGothic-Book>#;H76 glyph<c=24,font=/PIIBCD+FranklinGothic-Book>EE7FE\n\nAs of December 31, 2022, 2021 and 2020, approximately $2,198.5 million, $2,237.0 million and $2,180.6 million, respectively, of our long-lived assets were related to the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland.\n\nFor additional information on our Solothurn manufacturing facility, please read \"=B3 glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=11,font=/PIIBDE+FranklinGothic-BookItal>glyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> $@=>3@BGglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> $:/<B /<2 glyph<c=25,font=/PIIBDE+FranklinGothic-BookItal>?C7>;3<Bglyph<c=7,font=/PIIBDE+FranklinGothic-BookItal> to these consolidated financial statements.",
        "metadata": {
            "page": 185
        },
        "id": "ff3dd8c8-7c7c-413e-b154-c612b4e26371"
    },
    {
        "page_content": "## )glyph<c=28,font=/PIIBCD+FranklinGothic-Book>'&)+ &glyph<c=29,font=/PIIBCD+FranklinGothic-Book> %glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>'glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%glyph<c=27,font=/PIIBCD+FranklinGothic-Book>glyph<c=28,font=/PIIBCD+FranklinGothic-Book>%+ )glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=30,font=/PIIBCD+FranklinGothic-Book> *+glyph<c=28,font=/PIIBCD+FranklinGothic-Book>)glyph<c=28,font=/PIIBCD+FranklinGothic-Book>glyph<c=27,font=/PIIBCD+FranklinGothic-Book> ',glyph<c=25,font=/PIIBCD+FranklinGothic-Book># glyph<c=26,font=/PIIBCD+FranklinGothic-Book> glyph<c=24,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>glyph<c=26,font=/PIIBCD+FranklinGothic-Book>&,%+ %glyph<c=30,font=/PIIBCD+FranklinGothic-Book> glyph<c=29,font=/PIIBCD+FranklinGothic-Book> )$\n\n+A F:7 glyph<c=25,font=/PIIBCD+FranklinGothic-Book>A3D6 A8 glyph<c=27,font=/PIIBCD+FranklinGothic-Book>;D75FADE 3@6 *:3D7:A>67DE A8 glyph<c=25,font=/PIIBCD+FranklinGothic-Book>;A97@ @5glyph<c=11,font=/PIIBCD+FranklinGothic-Book>\n\nglyph<c=27,font=/PIICNA+FranklinGothic-BookItal>1*/*0/4 0/ 5)& glyph<c=19,font=/PIICNA+FranklinGothic-BookItal>*/\"/$*\"glyph<c=30,font=/PIICNA+FranklinGothic-BookItal>5\"5&.&/54 \"/% glyph<c=22,font=/PIICNA+FranklinGothic-BookItal>/5&3/\"glyph<c=16,font=/PIICNA+FranklinGothic-BookItal>0/53007&3 glyph<c=19,font=/PIICNA+FranklinGothic-BookItal>*/\"/$*\"glyph<c=29,font=/PIICNA+FranklinGothic-BookItal>&1035*/(\n\nWe have audited the accompanying consolidated balance sheets of Biogen Inc. and its subsidiaries (the [ Company \\ ) as of December 31, 2022 and 2021, and the related consolidated statements of income, of comprehensive income, of equity and of cash flow for each of the three years in the period ended December 31, 2022, including the related notes (collectively referred to as the [ consolidated financial statements \\ ). We also have audited the Company's internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).\n\nIn our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.\n\n## glyph<c=15,font=/PIICNA+FranklinGothic-BookItal>\"4*4 '03 glyph<c=27,font=/PIICNA+FranklinGothic-BookItal>1*/*0/4\n\nThe Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management's Annual Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company's consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.\n\nWe conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.\n\nOur audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.\n\n## glyph<c=17,font=/PIICNA+FranklinGothic-BookItal>&'*/*5*0/ \"/% glyph<c=24,font=/PIICNA+FranklinGothic-BookItal>*.*5\"5*0/4 0' glyph<c=22,font=/PIICNA+FranklinGothic-BookItal>/5&3/\"glyph<c=16,font=/PIICNA+FranklinGothic-BookItal>0/53007&3 glyph<c=19,font=/PIICNA+FranklinGothic-BookItal>*/\"/$*\"glyph<c=29,font=/PIICNA+FranklinGothic-BookItal>&1035*/(\n\nA company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.",
        "metadata": {
            "page": 186
        },
        "id": "315f62e2-2f37-4042-ba45-652006a44710"
    },
    {
        "page_content": "Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.\n\n## glyph<c=16,font=/PIICNA+FranklinGothic-BookItal>3*5*$\"glyph<c=14,font=/PIICNA+FranklinGothic-BookItal>6%*5 glyph<c=25,font=/PIICNA+FranklinGothic-BookItal>\"55&34\n\nThe critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.\n\n## Reserves for Medicaid and Managed Care Rebates\n\nAs described in Notes 1 and 5 to the consolidated financial statements, the Company recognized revenue from product sales net of reserves, including Medicaid and managed care rebates. Within accrued expense and other, total contractual adjustments amounted to $868.1 million as of December 31, 2022. A portion of this balance includes provisions for Medicaid and managed care rebates in the US. Medicaid rebates relate to the Company's estimated obligations to states under established reimbursement arrangements. The Company's liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid and an estimate of potential claims that will be made for inventory that exists in the distribution channel at period end. Managed care rebates represent the Company's estimated obligations to third-parties, primarily pharmacy benefit managers. These rebates result from performance-based goals, formulary position and price increase limit allowances (price protection). The calculation of the accrual for these rebates is based on an estimate of the coverage patterns and the resulting applicable contractual rebate rate(s) to be earned over a contractual period. Rebate accruals for Medicaid and managed care are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expense and other current liabilities. The Medicaid and managed care estimates reflect historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns.\n\nThe principal considerations for our determination that performing procedures relating to reserves for Medicaid and managed care rebates is a critical audit matter are the significant judgment by management due to the significant measurement uncertainty involved in developing these reserves, as the reserves are based on assumptions developed using historical experience, current contractual requirements, specific known market events and payment patterns, which in turn led to a high degree of auditor judgment, subjectivity, and effort in applying procedures and evaluating audit evidence related to these assumptions.\n\nAddressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to the reserves for Medicaid and managed care rebates, including controls over the assumptions used to estimate these Medicaid and managed care rebate reserves. These procedures also included, among others (i) developing an independent estimate of the Medicaid and managed care rebate reserves by utilizing third-party data related to product demand, data related to price changes, the terms of the specific rebate programs, the historical trend of actual rebate claims paid and consideration of contractual requirement changes and market events; (ii) comparing the independent estimate to management's estimate; and (iii) testing rebate claims paid by the Company, including evaluating the claims for consistency with the contractual terms of the Company's rebate agreements.\n\n/s/PricewaterhouseCoopers LLP Boston, Massachusetts February 15, 2023\n\nWe have served as the Company's auditor since 2003.",
        "metadata": {
            "page": 187
        },
        "id": "c9d1b11e-adf2-4e8b-b039-cd3c412e21aa"
    },
    {
        "page_content": "",
        "metadata": {
            "page": 188
        },
        "id": "5e67de25-7771-44df-bb58-33b5d332a763"
    },
    {
        "page_content": "## Corporate information\n\n## Board of Directors (as of April 21, 2023)\n\n## Stelios Papadopoulos, Ph.D.\n\nChairman, Biogen Inc., Chairman, Exelixis, Inc.; Chairman, Regulus Therapeutics Inc.; Chairman, Eucrates Biomedical Acquisition Corp.\n\n## Alexander J. Denner, Ph.D.\n\nFounding Partner and Chief Investment Of/ficer, Sarissa Capital Management LP\n\n## Caroline D. Dorsa\n\nRetired Executive Vice President and Chief Financial Of/ficer, Public Service Enterprise Group Incorporated\n\n## Maria C. Freire, Ph.D.\n\nRetired President and Executive Director, Foundation for the National Institutes of Health\n\n## William A. Hawkins\n\nRetired Chairman and CEO, Medtronic, Inc.; Senior Advisor, EW Healthcare Partners\n\n## William D. Jones\n\nManaging Member, CityLink LLC\n\n## Jesus Mantas\n\nGlobal Managing Partner for IBM Business Transformation Services\n\n## Richard C. Mulligan, Ph.D.\n\nMallinckrodt Professor of Genetics, Emeritus, Harvard Medical School and Head of SanaX; Vice Chairman, Sana Biotechnology, Inc.\n\n## Eric K. Rowinsky, M.D.\n\nPresident and Executive Chairman, RGenix, Inc.\n\n## Stephen A. Sherwin, M.D.\n\nClinical Professor of Medicine, University of California, San\u00a0Francisco\n\n## Christopher A. Viehbacher\n\nPresident and Chief Executive Of/ficer, Biogen Inc.",
        "metadata": {
            "page": 189
        },
        "id": "ab1f9d69-c53f-46a0-b6b3-396e98938722"
    },
    {
        "page_content": "## Stockholder Information\n\n## Corporate headquarters\n\nBiogen Inc. 225 Binney Street Cambridge, MA 02142 Phone: (617) 679-2000\n\n## SEC Form 10-K\n\nA copy of Biogen's Annual Report on Form 10-K /filed with the U.S. Securities and Exchange Commission is available at sec.gov and upon request to:\n\nInvestor Relations Department Biogen Inc. 225 Binney Street Cambridge, MA 02142 Phone: (781) 464-2442\n\n## Transfer agent\n\nTo keep your contact information current and for stockholder questions regarding lost stock certi/ficates, address changes and changes of ownership or names in which the shares are held, direct inquiries to:\n\nComputershare Phone: (781) 575-2879 Toll Free Phone: (877) 282-1168 computershare.com\n\nBy regular mail: P.O. Box 505000 Louisville, KY 40233-5000\n\nBy overnight delivery:\n\n462 South 4 th Street Suite 1600 Louisville, KY 40202\n\n## ADDITIONAL RESOURCES\n\nAccess and Health Equity: www.biogen.com/responsibility/access-and-health-equity.html Diversity, Equity & Inclusion: www.biogen.com/responsibility/diversity-inclusion.html Environment: www.biogen.com/responsibility/environment.html Global Community Lab: www.biogen.com/responsibility/global-community-lab.html 2022 ESG Report: www.biogen.com/esgreport Reporting & Principles: www.biogen.com/responsibility/reporting-and-principles.html\n\nWe include our website addresses in this report only as inactive textual references and do not intend them to be active links to our website. The contents of our website are not incorporated into this report.\n\n## Independent accountant\n\nPricewaterhouseCoopers LLP 101 Seaport Boulevard Boston, MA 02210\n\n## News releases\n\nAs a service to our stockholders and prospective investors, Biogen's news releases are usually posted within one hour of being issued and are available at no cost at investors.biogen.com.\n\n## Market information\n\nOur common stock trades on the Nasdaq Global Select Market under the symbol 'BIIB.'",
        "metadata": {
            "page": 190
        },
        "id": "a8058c61-d37d-4afe-917c-18818f07ed45"
    },
    {
        "page_content": "",
        "metadata": {
            "page": 191
        },
        "id": "ee1cd218-a0d8-44be-ba6b-5a2c556d2941"
    },
    {
        "page_content": "<!-- image -->\n\n<!-- image -->\n\n<!-- image -->",
        "metadata": {
            "page": 192
        },
        "id": "96eac3a6-be08-4121-9bcb-98990b19cddd"
    }
]